<SEC-DOCUMENT>0001626199-19-000010.txt : 20190318
<SEC-HEADER>0001626199-19-000010.hdr.sgml : 20190318
<ACCEPTANCE-DATETIME>20190318160234
ACCESSION NUMBER:		0001626199-19-000010
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190318
DATE AS OF CHANGE:		20190318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALPINE IMMUNE SCIENCES, INC.
		CENTRAL INDEX KEY:			0001626199
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				208969493
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37449
		FILM NUMBER:		19688209

	BUSINESS ADDRESS:	
		STREET 1:		201 ELLIOTT AVE. WEST, SUITE 230
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
		BUSINESS PHONE:		206-788-4545

	MAIL ADDRESS:	
		STREET 1:		201 ELLIOTT AVE. WEST, SUITE 230
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nivalis Therapeutics, Inc.
		DATE OF NAME CHANGE:	20150211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	N30 Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20141121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>a10k_2018.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1DC2760DEBB7820949C331F4C6B66954"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">FORM 10-K </font></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#9746;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the fiscal year ended </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">OR</font></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Commission File Number&#160;001-37449</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;font-weight:bold;">ALPINE IMMUNE SCIENCES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Exact name of Registrant as specified in its Charter)</font></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">20-8969493</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">201 Elliott Avenue West, Suite 230</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Seattle, WA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">98119</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (206)&#160;788-4545</font></div><div style="line-height:120%;padding-top:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Securities registered pursuant to Section&#160;12(b) of the Act: Common Stock, Par Value $0.001 Per Share; Common stock traded on the NASDAQ stock market</font></div><div style="line-height:120%;padding-top:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Securities registered pursuant to Section&#160;12(g) of the Act: </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">None</font></div><div style="line-height:120%;padding-top:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;&#9744; NO&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-top:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;YES&#160;&#9744;&#160;NO&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-top:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;YES&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font><font style="font-family:inherit;font-size:8pt;">&#160;NO&#160;&#9744;</font></div><div style="line-height:120%;padding-top:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit and post such files).&#160;YES&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font><font style="font-family:inherit;font-size:8pt;">&#160;NO&#160;&#9744;</font></div><div style="line-height:120%;padding-top:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K (&#167;229.405) is not contained herein, and will not be contained, to the best of Registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-top:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:21%;"></td><td style="width:2%;"></td><td style="width:47%;"></td><td style="width:3%;"></td><td style="width:21%;"></td><td style="width:2%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#9744;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#9744;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-accelerated filer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Emerging growth company</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-top:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;YES&#160;&#9744;&#160;NO&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-top:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The NASDAQ Stock Market on June 30, 2018, was approximately </font><font style="font-family:inherit;font-size:8pt;">$33.8 million</font><font style="font-family:inherit;font-size:8pt;">. Shares of common stock held by each executive officer and director and by each other person who may be deemed to be an affiliate of the Registrant, have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.</font></div><div style="line-height:120%;padding-top:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The number of shares of Registrant&#8217;s Common Stock outstanding as of </font><font style="font-family:inherit;font-size:8pt;">March&#160;6, 2019</font><font style="font-family:inherit;font-size:8pt;">&#32;was </font><font style="font-family:inherit;font-size:8pt;">18,561,029</font><font style="font-family:inherit;font-size:8pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s38F105BD43C52899E76031F4C70A3215"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:83%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB8EBF09E08BB6A76CC8831F4C73BF987"><font style="font-family:inherit;font-size:10pt;">Forward-Looking Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB8EBF09E08BB6A76CC8831F4C73BF987">1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0B68FC09A8DACC13651331F4C75EE6D7"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDA1504BF033EF53BA5EE31F4C78F823D"><font style="font-family:inherit;font-size:10pt;">Item&#160;1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDA1504BF033EF53BA5EE31F4C78F823D"><font style="font-family:inherit;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDA1504BF033EF53BA5EE31F4C78F823D">2</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCF7396DCF2D2399BDC0F31F4C7C49CB6"><font style="font-family:inherit;font-size:10pt;">Item&#160;1A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCF7396DCF2D2399BDC0F31F4C7C49CB6"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCF7396DCF2D2399BDC0F31F4C7C49CB6">28</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s935C81A7EC6668764B7031F4C88A4FC0"><font style="font-family:inherit;font-size:10pt;">Item&#160;1B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s935C81A7EC6668764B7031F4C88A4FC0"><font style="font-family:inherit;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s935C81A7EC6668764B7031F4C88A4FC0">61</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s22A5B0351F110C640D9F31F4C8ABC0E2"><font style="font-family:inherit;font-size:10pt;">Item&#160;2.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s22A5B0351F110C640D9F31F4C8ABC0E2"><font style="font-family:inherit;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s22A5B0351F110C640D9F31F4C8ABC0E2">61</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBAC1F24FC4ED060955C431F4C8DCC57F"><font style="font-family:inherit;font-size:10pt;">Item&#160;3.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBAC1F24FC4ED060955C431F4C8DCC57F"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBAC1F24FC4ED060955C431F4C8DCC57F">62</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9602674D1A0534C9B27331F4C8FDBFDD"><font style="font-family:inherit;font-size:10pt;">Item&#160;4.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9602674D1A0534C9B27331F4C8FDBFDD"><font style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9602674D1A0534C9B27331F4C8FDBFDD">62</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD2DE8532CDA14DFDB2D331F4C92F70C9"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;II</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5CFCB697F2EA9464258331F4C9539F03"><font style="font-family:inherit;font-size:10pt;">Item&#160;5.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5CFCB697F2EA9464258331F4C9539F03"><font style="font-family:inherit;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5CFCB697F2EA9464258331F4C9539F03">63</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6BBC58AE1292A6DE2FEF31F4C24A49ED"><font style="font-family:inherit;font-size:10pt;">Item&#160;6.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6BBC58AE1292A6DE2FEF31F4C24A49ED"><font style="font-family:inherit;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6BBC58AE1292A6DE2FEF31F4C24A49ED">63</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s42D9D33AA9E110CE95F631F4C9A472AD"><font style="font-family:inherit;font-size:10pt;">Item&#160;7.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s42D9D33AA9E110CE95F631F4C9A472AD"><font style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s42D9D33AA9E110CE95F631F4C9A472AD">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s499FDCA44A39FFC62E0531F4CB23E60E"><font style="font-family:inherit;font-size:10pt;">Item&#160;7A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s499FDCA44A39FFC62E0531F4CB23E60E"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s499FDCA44A39FFC62E0531F4CB23E60E">75</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDE3F29C3B7A319DAB14B31F4CB452B91"><font style="font-family:inherit;font-size:10pt;">Item&#160;8.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDE3F29C3B7A319DAB14B31F4CB452B91"><font style="font-family:inherit;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDE3F29C3B7A319DAB14B31F4CB452B91">75</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s03C4F44CE8BAD8D3D37731F4CB7846B8"><font style="font-family:inherit;font-size:10pt;">Item&#160;9.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s03C4F44CE8BAD8D3D37731F4CB7846B8"><font style="font-family:inherit;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s03C4F44CE8BAD8D3D37731F4CB7846B8">75</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s028195AA915145B58B6431F4CB99AFDA"><font style="font-family:inherit;font-size:10pt;">Item&#160;9A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s028195AA915145B58B6431F4CB99AFDA"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s028195AA915145B58B6431F4CB99AFDA">75</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9DCA35C28F58F79409A331F4CBCAF017"><font style="font-family:inherit;font-size:10pt;">Item&#160;9B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9DCA35C28F58F79409A331F4CBCAF017"><font style="font-family:inherit;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9DCA35C28F58F79409A331F4CBCAF017">76</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s98853DE633FD10DD92ED31F4CBECB620"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;III</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB29B05D1C416A32893DA31F4CC1E84F4"><font style="font-family:inherit;font-size:10pt;">Item&#160;10.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB29B05D1C416A32893DA31F4CC1E84F4"><font style="font-family:inherit;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB29B05D1C416A32893DA31F4CC1E84F4">77</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFBB01E13F67CBD44B45931F4CC41FFFC"><font style="font-family:inherit;font-size:10pt;">Item&#160;11.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFBB01E13F67CBD44B45931F4CC41FFFC"><font style="font-family:inherit;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFBB01E13F67CBD44B45931F4CC41FFFC">82</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4CF3176FF8651E6C167C31F4CC723E0B"><font style="font-family:inherit;font-size:10pt;">Item&#160;12.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4CF3176FF8651E6C167C31F4CC723E0B"><font style="font-family:inherit;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4CF3176FF8651E6C167C31F4CC723E0B">86</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5D1F7A0CEF73296F6BF731F4CC92B1EC"><font style="font-family:inherit;font-size:10pt;">Item&#160;13.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5D1F7A0CEF73296F6BF731F4CC92B1EC"><font style="font-family:inherit;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5D1F7A0CEF73296F6BF731F4CC92B1EC">89</a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4CDB79B5DD6701A5738331F4CCC50785"><font style="font-family:inherit;font-size:10pt;">Item&#160;14.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4CDB79B5DD6701A5738331F4CCC50785"><font style="font-family:inherit;font-size:10pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4CDB79B5DD6701A5738331F4CCC50785">91</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sB49150E77CDDBB537F3031F4CCE6E94B"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;IV</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s375D784DE95FF69A2DAA31F4CD18EE06"><font style="font-family:inherit;font-size:10pt;">Item&#160;15.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s375D784DE95FF69A2DAA31F4CD18EE06"><font style="font-family:inherit;font-size:10pt;">Exhibits, Financial Statement Schedules</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s375D784DE95FF69A2DAA31F4CD18EE06">92</a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">i</font></div></div><hr style="page-break-after:always"><div><a name="sB8EBF09E08BB6A76CC8831F4C73BF987"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This Annual Report on Form 10-K contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created by those sections. In some cases you can identify these statements by forward-looking words such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; or similar expressions, or the negative or plural of these words or expressions. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other &#8220;forward-looking&#8221; information. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our ability to identify, develop and commercialize additional products or product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our estimates regarding our expenses, revenues, anticipated capital requirements and our needs for additional financing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our ability to obtain funding for our operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">the implementation of our business model and strategic plans for our business and technology;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">the timing of the commencement, progress and receipt of data from any of our preclinical and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">the expected results of any preclinical or clinical trial and the impact on the likelihood or timing of any regulatory approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">the scope of protection we are able to establish and maintain for intellectual property rights covering our technology and product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">the timing or likelihood of regulatory filings and approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">the therapeutic benefits, effectiveness and safety of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">the rate and degree of market acceptance and clinical utility of any future products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our ability to maintain and establish collaborations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our expectations regarding market risk, including interest rate changes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">developments relating to our competitors and our industry; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">our expectations regarding licensing, acquisitions and strategic operations.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-bottom:8px;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this report in </font><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#sCF7396DCF2D2399BDC0F31F4C7C49CB6"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Part I, Item 1A. Risk Factors</font></a><font style="font-family:inherit;font-size:10pt;font-style:italic;">, and elsewhere in this report. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments, except as required by law.</font></div><div style="line-height:120%;padding-left:4px;padding-bottom:8px;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</font></div><div style="line-height:120%;padding-left:4px;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s0B68FC09A8DACC13651331F4C75EE6D7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDA1504BF033EF53BA5EE31F4C78F823D"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Business.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our company is focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory disorders, and other diseases. Our proprietary scientific platform uses a process known as directed evolution to convert native immune system proteins from the Immunoglobulin Super Family, or IgSF, into multi-targeted therapeutics potentially capable of modulating the human immune system.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our lead program is ALPN-101, a dual ICOS and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases. Preclinical data have demonstrated potential efficacy in models of graft versus host disease, or GvHD, arthritis, inflammatory bowel disease, and multiple sclerosis. In January 2019, we initiated dosing in a Phase I healthy volunteer study in Australia. We anticipate presenting data from this study at a conference in 2020 and using the data from this study to begin one or more proof-of-concept Phase II studies in indications such as psoriatic arthritis and GvHD. Our goal is to file an investigational new drug application, or IND, or IND-equivalent in 2019 for a Phase Ib trial of ALPN-101 in GvHD.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our second program is ALPN-202, a dual PD-L1/CTLA-4 antagonist with PD-L1 dependent CD28 costimulation intended for the treatment of cancer. Preclinical data have demonstrated potential efficacy in tumor models with an immune stimulatory profile significantly different than PD-L1 checkpoint antagonism alone. Our goal is to file an IND or IND-equivalent in 2019 for authorization to initiate human clinical trials with ALPN-202.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our scientific platform has also generated immune modulatory proteins with the potential of improving engineered cellular therapies, or ECT, such as chimeric antigen receptor T cells, or CAR-T, T cell receptor-engineered T cells, or TCR-T, and tumor infiltrating lymphocytes, or TILs. In October 2015, we signed a collaboration agreement with Kite Pharma (now a Gilead Company), or Kite, covering two IgSF targets addressable by our platform. Separate from this collaboration, we have developed multifunctional proteins based on other IgSF targets with the potential to improve CAR-T, TCR-T, TILs, and oncolytic virus based therapies.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on these advancements and other preclinical data to date, our scientific platform has proven capable of identifying novel molecules - including single domains capable of modulating multiple targets. These molecules have demonstrated efficacy in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;">&#32;as well as </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;preclinical models. We believe therapeutics generated by our scientific platform have the potential to provide benefit in a broad range of immune system disorders. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Immunology Background</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our therapies are being evaluated for their potential to target immune system disorders, including oncology (cancer), and inflammatory/autoimmune disease. Based on preclinical data generated to date, we believe therapeutics generated by our platform have the potential to provide patient benefit in a broad range of immune system disorders. We have chosen to focus our initial efforts on select therapeutic areas with unmet medical needs in oncology and inflammatory/autoimmune disease.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The human immune system is a complex system evolved to protect the host from external infection and harmful alterations of the body&#8217;s own cells. At the most basic level, this system has evolved to detect antigens. Antigens are essentially anything causing the immune system to try and mount an immune response. Antigens vary from pathogens like a virus, mutated cells like those involved in causing cancer, or even otherwise healthy cells. In special situations such as transplanted organs or cells from a bone marrow transplant, the body sees antigens from these otherwise normal cells as &#8220;non-self&#8221;.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The immune system determines if an antigen is harmful or not, and then acts accordingly&#8212;activating to destroy cells displaying the target antigen or inhibiting the immune system from doing anything if the target antigen is determined not harmful. The immune system has a memory for antigens so it can mount an activating or inhibitory response more quickly if a previously-seen antigen is encountered again.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The basic actors within the immune system are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Antigen presenting cells, or APCs, responsible for gathering antigens and presenting them to the immune system.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">T cells armed to destroy cells the immune system has decided are harmful&#8212;including pathogens, cancer cells, and transplanted cells.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B cells capable of recognizing foreign antigens and secreting antibodies to facilitate removal of the identified antigens.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulatory T cells and suppressive myeloid cells which inhibit the immune system from responding, preventing the immune system from attacking healthy cells.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Importantly, the APCs in the immune system gather antigens to determine whether they are harmful or not. If the antigens are determined harmful by the immune system, cytotoxic (effector) cells are activated to eliminate the harmful cells. If the antigens are determined not harmful by the immune system, regulatory cells inhibit the immune system to ensure no normal healthy cells are eliminated. There are several components and signaling pathways involved in regulating the activation or inhibition of the immune system.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activation and inhibition can be thought of like applying the gas or pressing the brake in an automobile. When viewed through the lens of activation (costimulation) and inhibition, our scientists work to develop therapies seeking to do one of four things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deliver an activating signal (press on the gas) to get a stronger immune response</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Block an inhibitory signal (release the brake) to get a stronger immune response</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deliver an inhibitory signal (press on the brake) to slow down an existing immune response</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Block an activating signal (release the gas) to slow down an existing immune response</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The above can also be expressed in more precise scientific terminology this way:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Agonize a costimulatory receptor to press on the gas</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Antagonize an inhibitory receptor to release the brake</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Agonize an inhibitory receptor to press on the brake</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Antagonize a costimulatory receptor to release the gas</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For cancer, patients need a stronger immune response, so we seek to develop therapies delivering an activating signal, blocking an inhibitory signal, or both. If a patient has an inflammatory/autoimmune disease or has received a transplant, we seek to develop therapies delivering an inhibitory signal, blocking an activating signal, or both.&#160;</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inflammatory/Autoimmune Disease</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inflammatory or autoimmune diseases like arthritis, systemic lupus erythematosus (&#8220;lupus&#8221;), inflammatory myositis (for example, polymyositis and dermatomyositis), Sj&#246;gren&#8217;s syndrome, Type I diabetes, and inflammatory bowel disease are a result of the immune system targeting the body&#8217;s healthy tissues by mistake. There are more than 80 known types of inflammatory/autoimmune diseases, many of which are severely debilitating and/or life threatening. A related condition is when a transplant patient&#8217;s body attacks the newly transplanted organ (host versus graft rejection) or, in the case of stem cell transplants, the newly transplanted cells attack the patient&#8217;s body (graft versus host disease). These are all immune system disorders caused by the immune system having too much activation or too little inhibition. For simplicity, we will refer to autoimmune and inflammatory diseases as simply &#8220;inflammatory diseases&#8221;.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Substantial progress has been made over the last decade in developing disease-modifying therapies to slow or stop disease progression in multiple inflammatory diseases. Inhibitors of the pro-inflammatory cytokine TNF&#945;, as well as approved drugs like abatacept, which blocks T cell costimulation, have led to disease reductions and improvements in quality of life for patients with a variety of inflammatory diseases.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our therapeutic goal in inflammatory disease is to press on the brake by delivering an inhibitory signal or release the gas by blocking an activating signal. We believe one novel aspect of our proprietary scientific platform is the potential ability to create a single protein-based therapeutic capable of doing both. We do not currently have a therapeutic targeting inflammatory disease on the market. However, based upon evidence from preclinical studies to date, we believe our scientific platform has the potential to produce IgSF&#8209;based therapeutics targeting inflammatory diseases.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncology</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancer is broadly defined as normal human cells growing in an uncontrolled fashion and capable of spreading this aberrant activity elsewhere in the body. Cancer can also be seen as a failure of the immune system to recognize transformed, harmful cells. Tumors develop because cancer cells learn to evade the immune system or dampen immune system activity to such a low level the tumor grows despite an otherwise healthy immune system.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Traditional cancer treatments have focused on directly killing tumor cells using toxic chemicals like chemotherapy or other approaches like irradiating cells. The 2010 FDA approval of sipuleucel-T marked a meaningful change in how tumors are treated. Sipuleucel-T represented the FDA&#8217;s first approval of an active cancer immunotherapy. It was designed to help a patient&#8217;s immune system attack prostate cancer cells. Brought to FDA approval by one of the founders of our company, the approval of sipuleucel-T energized the field to focus more closely on how to make use of the immune system to treat cancer.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The subsequent development of therapies targeting &#8220;checkpoint inhibitors&#8221; or pathways responsible for inhibiting an immune response has resulted in several FDA-approved therapeutics. Targeting checkpoint inhibitors, thereby releasing the brake on the immune system, has provided meaningful efficacy for a subset of cancer patients.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The first drug approved in this therapeutic class was ipilimumab, an antibody interfering with inhibitory signals from an IgSF protein called CTLA-4. In 2014, two antibodies blocking the inhibitory IgSF protein PD-1&#8212; pembrolizumab and nivolumab&#8212;were approved in multiple indications, and a third, cemiplimab, was approved in 2018. Antagonists of the IgSF protein PD-L1 have also been approved in multiple indications, including atezolizumab, avelumab, and durvalumab.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to modulators of these IgSF proteins, several other immunotherapies for cancer are either approved or in development including engineered cellular therapies (CAR-T, TCR-T and TILs), cancer vaccines, and oncolytic viruses.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our Scientific Platform</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The human immune system is a complex system evolved to protect humans from external infections and harmful changes of internal cells. The Immunoglobulin Superfamily (abbreviated &#8220;IgSF&#8221;) is the name given to the largest family of adhesion, costimulatory (activating), and inhibitory (blocking) proteins found on the surface of immunological, neurological, and other human cell types. These cell surface and soluble molecules are broadly involved with recognition of antigens, assisting in the formation of the immune synapse, and performing costimulatory, coinhibitory, and cytokine receptor signaling functions. This family includes many well-known targets, such as those seen in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 1</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="fig01.jpg" alt="fig01.jpg" style="height:149px;width:381px;"></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 1</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our scientific approach and platform are based upon IgSF protein units (referred to as &#8220;domains&#8221;). We believe the IgSF protein family is particularly valuable because many IgSF proteins naturally bind multiple binding partners, also referred to as &#8220;counterstructures&#8221;.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IgSF proteins are the principal players in the immune synapse, which is another reason we chose to focus our scientific platform on IgSF proteins. Immune synapses are a temporary, dynamic interaction required for the immune system&#8217;s response to antigens. When the synapse is created between two cells (like an APC and a T cell, or a tumor cell and a T cell), adhesion molecules hold cell membranes in tight formation to enable sufficient antigen presentation and/or receptor signaling. When this exchange works well, the body is adequately defended against a wide range of pathologies, including cancer and infectious diseases. When this exchange malfunctions, harmful cells are not destroyed or normal/healthy cells are mistakenly attacked - eventually resulting in inflammatory diseases. We believe our scientific platform represents a novel approach to targeting the immune system. Our scientists create Variant Ig Domains, or vIgDs through directed evolution, which is an iterative scientific </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">engineering process purposefully conducted to engineer an IgSF protein for a desired therapeutic function. The potential to create therapies capable of working within a formed synapse, forcing a synapse to occur, or preventing a synapse from occurring are important, novel attributes of our scientific platform.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The immune synapse is very small and often exists for just minutes. While intact, cells forming the synapse exchange a wide variety of information. Environmental cues, ligand/receptor expression ratios, and specific receptor orientations come together in a dynamic fashion to determine whether a T cell is going to respond to a given antigen or recognize it as harmless. </font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our scientific platform seeks to engineer native, or so-called &#8220;wild-type&#8221; IgSFs, turning them into therapeutics with potential benefit to patients with cancer or inflammatory diseases. We believe our scientific platform represents a novel approach to targeting the immune system. </font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe the key advantages to our approach are:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential broad applicability since many critical immuno-regulatory proteins are composed of IgSF members;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potentially rapid and precise selection of desired binding properties; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential recovery of affinity-modified proteins biased towards a well-folded, non-aggregated, and stable subset of proteins.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 2</font><font style="font-family:inherit;font-size:10pt;">&#32;shows the process of directed evolution in our scientific platform. Our scientists utilize yeast display protein library strategies to identify variants of wild-type IgSFs with desired binding characteristics via so-called &#8220;affinity maturation&#8221; campaigns. We start with a wild-type IgSF protein and then enter a cycle of library generation and yeast display. Flow cytometry or other methods are used to sort for yeast clones displaying variants with desired binding characteristics. Biologic and biophysical assays of purified proteins assess biological function and manufacturing characteristics. The end product is an optimized vIgD. Additional cycles can be carried out by building next generation libraries from the output of prior libraries to result in further optimization.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;"><img src="fig02.jpg" alt="fig02.jpg" style="height:292px;width:610px;"></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 2</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our scientific platform is generally able to improve upon native IgSF activity regardless of whether natural binding affinity is weak or strong. When starting affinity is very weak, techniques employed by our scientists have accomplished several thousand-fold increases in binding affinity with sometimes as few as two library generation cycles. Even when starting affinity is very high, our scientific platform can still improve binding affinities. The same general strategies can be used when the desired therapeutic profile requires reduced affinity compared to the wild-type IgSF.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe the advantages of our scientific platform allow us to identify new biology. Our lead program, ALPN-101, is an example where a single wild-type ICOSL domain, normally only binding ICOS with any physiological relevance, is engineered as a vIgD able to bind both ICOS and CD28. We have accomplished analogous modifications in other programs directed to disclosed and undisclosed targets, including the disclosed targets in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 3</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:40px;"><img src="fig03.jpg" alt="fig03.jpg" style="height:416px;width:381px;"></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 3</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preclinical animal models, we find our engineered vIgDs can outperform the relevant wild-type IgSF protein and/or other reference molecules when the vIgD differs from the wild-type IgSF by as few as one to three mutations. Based on </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in silico</font><font style="font-family:inherit;font-size:10pt;">&#32;analyses and analogous FDA-approved therapies, we do not believe vIgDs are unusually susceptible to immunogenic effects causing adverse events or loss of drug activity.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our scientific platform is highly productive. A single library run through the directed evolution process can potentially create vIgDs useful in both oncology and inflammatory diseases. While this potential advantage is not universal for every IgSF target, our experience is most of our successful discovery campaigns result in vIgDs applicable to a broad variety of therapeutic protein designs . We believe this is a novel attribute given most other platforms require each molecule to be painstakingly purpose-built for each intended therapeutic area.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe our vIgDs are highly flexible. In many cases, a single affinity-maturation campaign can result in potential multiple domains suitable for use in the formats such as those illustrated in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 4</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;"><img src="fig04.jpg" alt="fig04.jpg" style="height:264px;width:640px;"></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 4</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">vIgD-Fc</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The vIgD-Fc fusion protein is the simplest format. Our lead autoimmune/inflammation program, ALPN-101, and lead oncology program, ALPN&#8209;202, are both examples of vIgD-Fc formats. The engineered vIgD protein is fused to an Fc backbone. Combining vIgDs with antibody Fc domains to make Fc fusion proteins potentially allows for better expression, facilitates purification, and improves pharmacokinetic (dosing) properties. Fc fusion proteins are a standard format in the industry, with examples such as etanercept, abatacept, and belatacept. A vIgD-Fc could potentially be administered intravenously, subcutaneously, topically, or other methods of delivery.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Multifunction vIgD-based Molecule</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple vIgDs can be combined or &#8220;stacked&#8221; together with or without an Fc backbone to create a multifunctional, vIgD-based molecule. With the potential to make use of novel biology discovered using our scientific platform, an Fc fusion with just two domains can potentially affect three, four, or more IgSF targets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">V-mAb</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our V-mAb technology potentially allows targeting a vIgD into the tumor microenvironment with a monoclonal antibody. A V-mAb is a vIgD joined with a monoclonal antibody recognizing a validated target (as depicted in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 4</font><font style="font-family:inherit;font-size:10pt;">). Our V-mAbs use the targeting antibody to localize the vIgD to the tumor micro-environment or target tissue to potentially deliver specific, locally-active immuno-modulation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cell Therapy Enhancement</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our scientific platform has also generated immune modulatory proteins with the potential of improving engineered cellular therapies, such as CAR-Ts, TCR-Ts, or TILs. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration with Kite Pharma, a Gilead Company</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to advancing programs internally, we continue to seek partners who can bring therapeutic area experience, development expertise, commercialization capabilities, and funding allowing us to maximize the potential of vIgDs and our scientific platform. In October 2015, we signed a research and license agreement with Kite, granting Kite an exclusive license to two of our TIP programs for use in Kite&#8217;s ECT programs. Under the terms of the license and research agreement with Kite, we have conducted initial research to deliver two program TIPs with certain pre-defined characteristics, and we are further responsible for conducting a research plan to deliver TIPs to two specified IgSF targets.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We received $5.5 million in up-front cash and are eligible to receive up to $530.0 million in developmental, clinical, and regulatory milestone payments in addition to royalties on any products containing our TIPs. In October 2017, we entered into an amendment with Kite to extend the research term of the Collaboration Agreement. Under the amendment, we are eligible to receive an additional $450,000 research support payment from Kite in two tranches (instead of a single tranche as previously contemplated by the Collaboration Agreement). In June 2018, we recognized the remaining deferred balance and the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">first support payment under the amendment. In October 2018, we entered into another amendment with Kite, which amended portions of the research plan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ALPN-101, a Dual ICOS/CD28 Antagonist for Inflammatory Diseases</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our lead inflammatory disease program, ALPN-101, is comprised of a novel single domain vIgD binding both ICOS and CD28 at higher affinity than wild-type molecules. This vIgD is fused to an effectorless Fc backbone and is intended for the potential treatment of certain inflammatory diseases.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notably, ALPN-101 is not a bispecific antibody construct. A traditional bispecific would be constructed of one domain binding ICOS and one domain binding CD28. Instead, ALPN-101 makes use of a novel single domain protein vIgD engineered by our scientists using our proprietary scientific platform.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inducible T cell Costimulator, or ICOS, is part of the CD28 costimulatory family of molecules, including PD-1, CD28, and CTLA-4. ICOS is related to CD28, but, in contrast, is poorly expressed in na&#239;ve T cells. ICOS is, however, rapidly induced upon T cell activation. It appears to be a dominant costimulatory pathway in at least some effector or pathogenic T cells, such as potentially in the absence of CD28. Elevated levels of ICOS&#8209;expressing T cells have been described in an increasing number of inflammatory diseases, correlating with disease activity. At the same time, inhibition of ICOS is effective in several preclinical inflammatory disease models. The ICOS pathway may therefore represent a major costimulatory pathway, nonredundant with CD28, and highly relevant to inflammatory diseases.</font></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cluster of Differentiation 28 (&#8220;CD28&#8221;) is the dominant costimulatory pathway in na&#239;ve, antigen-inexperienced T cells, and is required for their activation. However, optimal and/or durable development of activated and/or effector T cells often occurs independently of CD28. CD28 expression becomes progressively reduced during longer-term activation in at least some T cell populations, and CD28-negative T cells have been observed in a growing number of inflammatory diseases, often correlated with disease activity. </font></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While CD28 and ICOS both provide costimulatory signals, there is potentially a time-shifted dynamic to their evolved immune functions with CD28 providing initial costimulation and ICOS providing longer-term costimulatory effects. During activation, T cells eventually lose their dependence on CD28. ICOS, however, begins to be upregulated to provide an additional costimulatory signal.</font></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since ALPN-101 addresses potential deficiencies of single pathway blockade via its dual mechanism, we believe it is capable of delivering deeper clinical responses by blocking two key T cell costimulatory pathways with a single therapeutic. This hypothesis is supported by clinical data from CD28-only and ICOS-only therapeutics, both of which demonstrate only partial efficacy. Therapeutic agents directed against the CD28 pathway alone, such as the FDA-approved therapeutic abatacept, have proven only partially effective or ineffective in some inflammatory diseases, and/or induce only partial disease improvement in their approved indications.</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">9</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;While few studies have examined the effect of therapeutic blockade of ICOS in humans, early clinical trial findings with the anti ICOSL monoclonal antibody prezalumab suggest inhibition of the ICOS pathway alone may also be insufficient to achieve complete remission in many inflammatory conditions.</font></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have performed a number of pre-clinical experiments demonstrating ALPN&#8209;101 is active in both </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;models.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Superior Activity in Human Xenograft GvHD Model</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ALPN-101 has been studied in an </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;mouse model of GvHD, a damaging and even potentially fatal inflammatory disease most often brought about during stem cell and/or bone marrow transplant treatments for cancer or other serious diseases. </font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results represented in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 5</font><font style="font-family:inherit;font-size:10pt;">&#32;shows ALPN-101 had superior survival when dosed three times per week for four weeks compared to belatacept (an FDA-approved drug for prevention of renal allograft rejection &#8211; a type of inflammation-related rejection process analogous to GvHD). In fact, 100% of ALPN-101 multi-dose treated animals across three different dose levels survived. Animals given only a single dose of ALPN-101 performed comparably to animals treated with belatacept dosed 3x/week for four weeks, demonstrating the potency and efficacy of ALPN-101 in this disease model.</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><img src="fig05.jpg" alt="fig05.jpg" style="height:264px;width:434px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 5</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arthritis Model</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 6</font><font style="font-family:inherit;font-size:10pt;">&#32;shows data from an </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;collagen-induced arthritis model. This model is designed to test a drug&#8217;s ability to reduce inflammatory signals associated with rheumatoid arthritis, psoriatic arthritis, and other types of inflammatory arthritis conditions. In this experiment, an early molecule in the ALPN-101 program was superior to abatacept, a drug approved by the FDA to treat rheumatoid and psoriatic arthritis, in preventing arthritic inflammation. </font></div><div style="line-height:120%;padding-top:4px;text-align:center;"><img src="fig06.jpg" alt="fig06.jpg" style="height:301px;width:366px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 6</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inflammatory Bowel Disease Model</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inflammatory bowel disease, or IBD, is a disease caused by dysregulation of the immune system characterized by chronic inflammation of the gastrointestinal tract. In an animal model of inflammatory bowel disease, ALPN-101 demonstrated nearly complete control of disease in the subject animals as seen in</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Figure 7</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:4px;text-align:center;"><img src="fig07.jpg" alt="fig07.jpg" style="height:216px;width:386px;"></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 7</font></div><div style="line-height:174%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Multiple Sclerosis Model</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple sclerosis, or MS, is an abnormal response of the body&#8217;s immune system directed against the central nervous system, or CNS. The CNS is made up of the brain, spinal cord and optic nerves. In an animal model of MS, ALPN-101 demonstrated improved disease scores compared to abatacept and superior disease scores against wild-type ICOSL as seen in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 8</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:4px;text-align:center;"><img src="fig08.jpg" alt="fig08.jpg" style="height:250px;width:324px;"></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 8</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of ALPN-101 Program Preclinical Data</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our scientists and collaborators have demonstrated in preclinical studies that ALPN-101:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">improves survival compared to belatacept in an </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;animal GvHD model; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduces disease severity and delays disease onset time relative to control in a pilot </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;arthritis model with activity superior to abatacept, an FDA-approved drug for rheumatoid and psoriatic arthritis; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">demonstrates control of IBD in an animal model of IBD; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">shows improved disease scores in an animal model of MS compared to abatacept.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPN-101 Clinical Plans</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2019, we initiated dosing in a Phase I trial of ALPN-101 in healthy volunteers, referred to as our AIS-A01 trial. This study is designed to evaluate the safety and tolerability of single and multiple ascending intravenous and/or subcutaneous doses of ALPN-101. In addition, pharmacokinetics, pharmacodynamics and exploratory biomarkers are being evaluated to help determine ALPN-101&#8217;s potential for the treatment of inflammatory diseases. The trial is being conducted in Australia. More information is available at www.clinicaltrials.gov (Identifier: NCT03748836). We expect to present data from the AIS-A01 clinical trial at a conference in 2020.</font></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We plan to file an IND or IND-equivalent for a Phase Ib trial of ALPN-101 in GvHD in 2019. GvHD is a damaging and even potentially fatal inflammatory disease most often brought about during stem cell and/or bone marrow transplant treatments for cancer or other serious diseases. With a mortality rate of 75% or more, GvHD is an inflammatory disease which has been particularly challenging for development of new therapies and where there exists a substantial unmet need. Over the last two decades, a multitude of therapies including stem cell transplant, IL-2 antagonists, antithymocyte globulin, anti-CD52, anti-TNF therapies, and others have been studied. While ibrutinib was recently approved for chronic GvHD, as of December 31, 2018 there are no approved therapies for the treatment of acute GvHD and a significant number of chronic GvHD patients did not have durable responses to ibrutinib. </font></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate using the data from the AIS-A01 trial to begin proof-of-concept Phase II studies in inflammatory diseases such as psoriatic arthritis. Psoriatic arthritis is a chronic, inflammatory disease of the joints, typically associated with psoriasis, an itchy, flaky skin condition. Both psoriasis and psoriatic arthritis are inflammatory diseases, meaning that they occur when the body&#8217;s immune system mistakenly attacks healthy tissue, in this case the joints and skin. The faulty immune response causes inflammation that triggers joint pain, stiffness and swelling. The inflammation can affect the entire body and may lead to permanent joint and tissue damage if it is not treated early and aggressively. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ALPN-202, a Dual PD-L1/CTLA-4 Antagonist with PD-L1 Dependent CD28 Costimulation for Oncology</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ALPN-202 is our lead program for immuno-oncology. Our scientists used wild&#8209;type CD80 as the basis for a directed evolution campaign using our proprietary scientific platform. They were able to create a vIgD capable of antagonizing PD-L1 and CTLA-4, while delivering PD-L1 dependent costimulation via CD28. </font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Programmed cell death protein ligand 1, or PD-L1, and its counterstructure, PD-1, are responsible for suppressing immune system responses. Cytotoxic T-lymphocyte Associated protein 4, or CTLA-4, also suppresses immune system responses. Both are IgSFs commonly referred to as checkpoint proteins since they act as inhibitory checks against immune system activation, pressing the brakes on an immune reaction. As noted above, CD28 provides a costimulatory signal necessary for T cell activation and survival. </font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It has long been recognized CD28 is required for T cell activation and CD28 is considered the most important of the costimulatory molecules. The tumor microenvironment often features exhausted T cells suppressed via PD-1/PD-L1 engagement as seen on the left of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 9</font><font style="font-family:inherit;font-size:10pt;">&#32;below. The development of anti PD-1/L1 mAbs have helped relieve one aspect of the exhausted phenotype, but less than 30% of patients typically respond &#8211; likely attributable to the minority of patients who do have sufficient CD28 costimulation as depicted in the center panel of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 9</font><font style="font-family:inherit;font-size:10pt;">. More recent research has, in fact, suggested CD28 costimulation is required for anti PD-1/L1 efficacy, absent which tumors do not respond due to inadequate costimulation as seen in the third panel of</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Figure 9</font><font style="font-family:inherit;font-size:10pt;">. Therefore, there may be a need for a therapeutic providing both checkpoint antagonism and CD28 costimulation.</font></div><div style="line-height:120%;padding-top:4px;text-align:center;"><img src="fig09.jpg" alt="fig09.jpg" style="height:200px;width:682px;"></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 9</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The goal of the ALPN-202 program is to create a therapeutic capable of blocking checkpoint inhibition to take the brakes off the immune system while providing for CD28 costimulation to step on the gas and increase immune system response. We believe ALPN-202 has three modes of activity:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">antagonize PD-L1 to decrease PD-L1&#8217;s ability to inhibit immune response;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">agonize CD28 to increase immune response, but only in the presence of PD&#8209;L1&#8212;a potential mechanism of action we call PD-L1 &#8220;dependent&#8221; activity; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">antagonize CTLA-4 to decrease CTLA-4&#8217;s ability to inhibit immune response.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This triple-action mechanism has been accomplished with a single vIgD domain-based protein. The fact we have engineered a single vIgD to accomplish this, instead of relying on multiple IgSF domains fused together, represents a potentially important scientific advance and emphasizes the potential power of our scientific platform to create novel therapeutics. We are currently studying ALPN-202 using </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;models to better characterize its activity against tumors and performing appropriate enabling work towards our goal of filing an IND or IND-equivalent in the fourth quarter of 2019 for our first ALPN-202 human clinical trial.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In a mouse model where mice were implanted with mouse colon cancer tumors transfected with human PD-L1, ALPN-202 as a monotherapy demonstrated superior tumor control compared to durvalumab, an FDA-approved anti PD-L1 monoclonal antibody (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 10</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:4px;text-align:center;"><img src="fig10.jpg" alt="fig10.jpg" style="height:248px;width:432px;"></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 10</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When tumor-free mice in the ALPN-202 arm of the same experiment were re-challenged with additional tumor, they continued to be tumor free despite no additional doses of ALPN-202. This potentially demonstrates ALPN-202 confers persistent anti-tumor immunity (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 11</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:4px;text-align:center;"><img src="fig11.jpg" alt="fig11.jpg" style="height:253px;width:365px;"></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 11</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In a similar model of human PD-L1 transduced mouse colon cancer, the effects of ALPN-202 or durvalumab on various components of the immune system were compared using a technique called RNA sequencing. This technique generates a display of inflammatory gene signatures where green represents lower or no upregulation of inflammatory genes and red represents higher upregulation of inflammatory genes. For the treatment of cancer, it is thought the more upregulation of the immune system - indicated by higher upregulation of inflammatory genes - potentially results in better outcomes for patients.</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">16</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;As seen in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 12</font><font style="font-family:inherit;font-size:10pt;">&#32;below, ALPN-202 upregulates a broader variety of different inflammatory genes connected with several different types of immune cells compared to durvalumab.</font></div><div style="line-height:120%;padding-top:4px;"><img src="fig12.jpg" alt="fig12.jpg" style="height:208px;width:682px;"></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 12</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">16</sup>&#160;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">e.g. Galon, et. al. Lancet v391 n10135. May 2018, pp 2128-2139</font></div></td></tr></table></div></div><div style="line-height:174%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of ALPN-202 Preclinical Data</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our scientists have demonstrated in preclinical studies that ALPN-202:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">improves survival in a human PD-L1 transduced mouse model of colon cancer compared to the FDA approved anti PD-L1 therapeutic durvalumab; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">creates potentially persistent anti-tumor immunity in the same model, as demonstrated by mice remaining tumor free after rechallenge, even without additional doses of ALPN-202; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">demonstrates a more robust intra-tumor inflammatory signature in the mouse colon cancer model than durvalumab, potentially indicating superior immune system upregulation to fight cancer.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPN-202 Program Clinical Plans</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal is to file an IND or IND-equivalent for authorization to initiate human clinical trials with ALPN-202 in the fourth quarter of 2019. We have not yet determined which cancer indication or indications we will investigate first.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Research Programs</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our ALPN-101 and ALPN-202 programs, we have a number of other research efforts underway to address cancer and inflammatory diseases. We highlight two below: our programs to enhance ECTs and our V-mAb program.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Enhancement of Engineered Cellular Therapies </font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ECTs in the form of CAR-T, engineered TCR-T, and engineered TILS have emerged as therapies with the potential to provide dramatic improvements in outcomes in certain cancer indications. In 2017, two CAR-T therapies were approved by the FDA (Kymriah (Novartis AG), and Yescarta (Kite Pharma, Inc.)). Despite the positive results observed with these and other ECTs in select tumors, there may be an opportunity to enhance efficacy and expand the utility of ECTs in additional indications. </font></div><div style="line-height:120%;padding-top:4px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our cell therapy enhancement programs were created to improve ECTs by increasing T cell proliferation, persistence, and effector functions, including tumor killing. We have approached this by creating vIgD-based TIPs, switch or decoy TIPs, and SIPs (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 13</font><font style="font-family:inherit;font-size:10pt;">). </font></div><div style="line-height:120%;padding-top:4px;text-align:center;"><img src="fig13.jpg" alt="fig13.jpg" style="height:244px;width:537px;"></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 13</font></div><div style="line-height:174%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Examples of such approaches include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TIP: expression of a costimulatory vIgD, such as a CD86 vIgD, on the surface of an ECT to provide additional costimulation in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">cis </font><font style="font-family:inherit;font-size:10pt;">and/or </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">trans;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Decoy TIP: expression of a checkpoint vIgD, such as a PD-1 vIgD, on the surface of an ECT in the absence of the normal inhibitory intracelluar domain, competing with checkpoint ligands in the tumor microenvironment, or TME; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Switch TIP: expression of a checkpoint vIgD, such as a PD-1 vIgD, on the surface of an ECT in association with an activating intracellular domain, turning a checkpoint signal into a T cell-activating signal; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SIP: expression of a secreted checkpoint vIgD, such as a PD-L1 vIgD, by an ECT, competing with checkpoint ligands in the TME</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have observed encouraging </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;">&#32;data with such approaches, where vIgDs enhance the proliferation, cytokine production and cytotoxicity of ECTs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transmembrane vIgD or TIP (Transmembrane Immunomodulatory Protein)</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TIPs are engineered costimulatory ligands expressed on the cell surface of T cells to promote activation and survival of both endogenous and engineered therapeutic cells in the local tumor environment. We have engineered several molecules for use in ECTs, including proprietary CD86 vIgDs. In an </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;">&#32;HPV tumor model, expression of engineered CD86 vIgD TIPs in E6 TCR-engineered T cells resulted in superior HPV-specific tumor responses including T cell proliferation, cytokine production, and cytotoxicity in comparison to TCR-alone and TCR with wild-type CD86 vIgDs (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 14</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:4px;text-align:center;"><img src="fig14.jpg" alt="fig14.jpg" style="height:328px;width:645px;"></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 14</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">V-mAb Program</font></div><div style="line-height:120%;padding-top:4px;text-align:center;"><img src="fig15.jpg" alt="fig15.jpg" style="height:280px;width:498px;"></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 15</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our V-mAb technology potentially allows delivering a vIgD into the tumor microenvironment, or TME, with a monoclonal antibody. A V-mAb is a vIgD joined with a monoclonal antibody, or mAb, recognizing a validated target (as depicted in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 15</font><font style="font-family:inherit;font-size:10pt;">). Additionally, a V-mAb could potentially deliver a checkpoint inhibitor to the TME. Our V-mAbs use the targeting antibody to localize the vIgD to the TME or target tissue to potentially deliver specific, locally-active immuno-modulation.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tumors thrive in environments of immune suppression. Immune cells have often been recruited to the TME, but are not responding correctly. In many cases, the T cells are recognizing antigen in the form of MHC peptide, but this signal is not supported by required costimulatory activity. In these cases, T cells could benefit from tumor or APC expression of costimulatory ligands such as CD80, CD86, or ICOSL. This strategy could potentially invigorate tumor immune responses in a tumor-specific context.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our Strategy</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal is to create modern therapies targeting the immune synapse, using our directed-evolution based scientific platform to treat patients with serious conditions such as cancer and inflammatory diseases. To achieve our goals, we intend to:</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aggressively move our lead inflammation/autoimmune therapeutic ALPN-101 through clinical development for the treatment of inflammatory diseases.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ALPN-101 is an ICOS/CD28 dual antagonist based on the discovery, using our scientific platform, of a single vIgD with increased binding affinity for both ICOS and CD28. ALPN-101 has demonstrated activity in vitro and in vivo in multiple models of inflammatory diseases. In January 2019, we initiated dosing in a Phase I trial of ALPN-101 in healthy volunteers. We anticipate using the data from this study to begin one or more proof-of-concept Phase II studies in inflammatory diseases, such as psoriatic arthritis and GvHD, and expect to present data from the AIS-A01 clinical trial at a conference in 2020.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aggressively move our lead oncology program ALPN-202 to clinical trials.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ALPN-202 is designed to antagonize PD-L1 and CTLA-4, while also providing PD-L1 dependent CD28 agonism. ALPN-202 is thus potentially capable of blocking inhibitory signals from PD-L1 and CTLA-4 while providing CD28 costimulation, thereby removing the brake and pressing the gas on the immune system to treat cancer. The ALPN-202 program is based on the discovery, using directed evolution and our scientific platform, of a single domain capable of interacting with PD-L1, CD28, and CTLA-4. ALPN-202 has demonstrated in vivo activity in mouse models of PD-L1 positive tumors. Our goal is to file an IND or IND-equivalent for authorization to initiate human clinical trials with ALPN-202 in the fourth quarter of 2019.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Maximize the value of our pipeline and platform via partnering activities.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe our scientific platform is highly productive, with affinity maturation campaigns potentially capable of producing dozens of vIgDs with desirable biologic activity. Our discovery efforts to date have resulted in vIgDs with potential uses in cancer and inflammatory diseases. We believe this provides significant opportunity for partnering discussions. Our first such collaboration, with Kite Pharma, a Gilead company, involved two targets for use in ECTs and provided us $5.5 million in cash as well as up to $530.0 million in potential developmental, clinical, and regulatory milestone payments. While difficult to predict the timing of such partnerships or whether we will be successful in our efforts to enter into further collaborations, we are continually in discussions with multiple potential partners ranging from small biotechnology firms to large pharmaceutical companies.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Pipeline</font></div><div style="line-height:120%;padding-top:4px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a diverse pipeline of potentially novel therapies as shown in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 16</font><font style="font-family:inherit;font-size:10pt;">&#32;below. In January 2019, we started the Phase I healthy volunteer trial for ALPN-101 . </font></div><div style="line-height:120%;padding-top:4px;text-align:center;"><img src="fig16.jpg" alt="fig16.jpg" style="height:302px;width:661px;"></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 16</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Manufacturing</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have established in-house non-cGMP recombinant protein generation capabilities enabling our scientific platform, including validation of new scientific discoveries </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">. Having protein production capabilities in-house allows more rapid progression for vIgDs generated by our scientific platform.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, our lead programs have been accomplished through standard protein production and purification methods. As noted above, we believe one advantage of our scientific platform is selection outputs are generally manufacturable. Because the directed evolution process itself requires some level of protein production, campaigns often select for proteins readily expressed with favorable biochemical properties. We produce our vIgDs and vIgD-Fc constructs in mammalian cell lines using both HEK293 and CHO cell expression systems in our in-house protein production processes.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have successfully completed a cGMP manufacturing campaign for ALPN-101 and have produced sufficient quantities of drug product necessary to execute initial human clinical trials. The upstream and downstream manufacturing processes for ALPN-101 use unit operations amenable to further scale-up to support later stage clinical trials and commercial production. GMP scale-up for ALPN-202 is ongoing, and on track to facilitate our goal to file an IND or IND-equivalent for authorization to initiate human clinical trials with ALPN-202 in the fourth quarter of 2019.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not yet manufactured any of our proteins at commercial scale. Abatacept is a wild-type IgSF protein commercially approved for multiple indications with no publicly-reported manufacturing difficulties. Belatacept is an IgSF protein with two mutations, likewise approved in multiple countries. We believe these two examples are potentially similar (in manufacturing terms) to our vIgD-based products.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have chosen U.S.-based contract drug substance and drug product manufacturers for our initial clinical trial supplies of ALPN-101 and ALPN-202. We believe these contract manufacturers&#8217; particular expertise in protein production, analytical development and fill/finish provide us with the capability to meet rapid timelines encompassing the development of production cell-lines to manufacturing of clinical trial quantities of the biopharmaceutical product.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Competition</font></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We participate in the highly competitive sector of biotechnology and pharmaceuticals and in the subsector of immune modulation. This subsector has undergone tremendous technological advancement over the last decade due to advancements in understanding the role of the immune system across multiple therapeutic areas, including oncology and inflammatory disease. While we believe our novel technology platform, discovery programs, knowledge, experience, and scientific resources offer </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, public and private research institutions, and others.</font></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any products we successfully develop and commercialize will face competition from currently approved therapies and new therapies potentially available in the future.</font></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market.</font></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of the companies we compete against may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruitment and retention of qualified scientific and management personnel; recruitment of investigative sites and participants for clinical trials; and the acquisition of technologies complementary to, or necessary for, our programs.</font></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Specifically, our competitors include companies developing therapies with the same target(s) as ALPN-101 in inflammatory diseases and ALPN-202 in oncology as well as companies building novel platforms to generate multi-specific antibody or non-antibody-based targeting proteins.</font></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See the risk factor &#8220;We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to us. If these companies develop technologies or therapeutic candidates more rapidly than we do, or their technologies, including delivery technologies, are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected&#8221; in Part I, Item 1A of this report for more discussion of the effects of competition and competitors on our business.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ICOSL/CD28 Competitors</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The competitors listed below have programs targeting either ICOS or CD28 (or one of their ligands). To our knowledge, there are currently no competitors with a single molecule targeting ICOS and CD28 simultaneously.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an anti-ICOSL/B7RP-1 monoclonal antibody being developed by Amgen, Inc (may be referred to as prezalumab, AMG557 or MEDI5872);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an anti-BAFF, anti-ICOSL bispecific antibody being developed by Amgen, Inc (AMG570/MEDI0700);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an anti-CD28 monoclonal antibody fragment being developed by OSE ImmunoTherapeutics SA (FR104);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an anti-CD28 peptide being developed by AtoxBio, Inc; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an IL-10 - anti CD86 cytokine-scFv fusion protein being developed by Aptevo, Inc (APVO210).</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPN-202 Program Competitors</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are hundreds of clinical trials for immuno-oncology products used as a single agent or in combination. One of the potentially novel attributes of the ALPN-202 program is it combines inhibitory receptor antagonism and activating costimulation with a single molecule interacting with multiple immune targets.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Examples of additional multi-target compounds for immuno-oncology are highlighted below. To our knowledge, there are currently no competitors with a single molecule capable of dual PD-L1/CTLA-4 antagonism and PD-L1 dependent CD28 agonism.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">wild-type CD80-Fc being developed by Five Prime Therapeutics, Inc. (FPT155);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">bifunctional fusion protein composed of monoclonal antibody against PD-L1 fused to the extracellular domain of human transforming growth factor-&#223;, or TGF-&#223;, receptor II being developed by EMD Serono, Inc and GSK plc (M7824);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">bifunctional fusion protein composed of PD-1 and OX40L developed by Shattuck Labs, Inc. (SL-279252);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">bispecific fusion protein targeting 4-1BB and PD-L1 being developed by Pieris Pharmaceuticals, Inc. (PRS-344);</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">bispecific monoclonal antibody being developed by Xencor, Inc. including XmAb20717 targeting CTLA-4 and PD-1, XmAb22841 targeting CTLA-4 and LAG-3, and XmAb23104 targeting PD-1 and ICOS;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">bispecific constructs called &#8220;DARTs&#8221; being developed by Macrogenics Inc., including MGD013 targeting PD-1 and LAG-3 and MGD019 targeting PD-1 and CTLA-4;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">bispecific monoclonal antibody being developed by Tesaro, Inc., targeting PD-1 and LAG-3;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">small molecule antagonists being developed by Aurigene Ltd and Curis, Inc., including CA-170 targeting PD-L1 and VISTA and CA-327 targeting PD-L1 and TIM-3;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FS118, a bispecific monoclonal antibody targeting PD-L1 and LAG-3 being developed by F-star Biotechnology, Ltd.; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">various combinations of separate anti PD-1/L1 and anti-CTLA-4 monoclonal antibodies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">various combinations of separate anti-PD-1/L1 and costimulatory monoclonal antibodies such as OX-40, 4-1BB, and others.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Novel Platform Competitors</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multifunctional therapeutic protein platforms potentially competitive with our platform include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amgen, Inc. (BiTE&#174;): fusion proteins consisting of two single-chain variable fragments to link T-cells to tumors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Macrogenics Inc. (DART&#174;): Dual-Affinity Re-Targeting and Trident technology platforms bind multiple targets with a single molecule; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Xencor Inc. (XmAb Bispecific): Optimized Fc domains for improved potency, half-life and stability;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zymeworks Inc. (Azymetric&#8482;): Proprietary amino acid modifications to facilitate interaction of distinct heavy chains;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pieris Pharmaceuticals, Inc. (Anticalin&#174;): Engineered proteins derived from natural lipocalins found in blood plasma; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compass Therapeutics LLC (Targeted Immunomodulation&#8482;, StitchMabs&#8482;): Antibody discovery targeting the tumor-immune synapse;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Harpoon Therapeutics Inc.: TriTac&#8482; (Tri-specific T cell Activating Construct) contain CD3 binding domain, half-life extension domain and antigen-binding domain;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shattuck Labs, Inc.: Agonist Redirected Antibody platform claimed to bind tumor-necrosis factor, or TNF, and checkpoint targets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ablynx NV (Nanobody&#174;), purchased by Sanofi Pharma, Inc.: Platform technology of single-domain, heavy-chain antibody fragments derived from camelidae (e.g., camels and llamas);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regeneron, Inc.: VEGF Trap and VelociSuite&#174; antibody technology platforms; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Five Prime Therapeutics, Inc: Proprietary protein library and rapid protein production and testing platform.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our scientific platform and substantially all our intellectual property have been developed internally. </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">As of </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">, our patent portfolio</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">consists</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">of over</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;pending</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">patent</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">applications.</font><font style="font-family:inherit;font-size:10pt;">&#32;Our initial patent application is directed to our scientific platform itself. Our second patent application is directed to the TIP program. We filed subsequent patent applications directed to our SIP program as well as to various target domains under development. To date, some of these applications have published but none have yet matured into granted patents. Each of these patent applications is solely owned by us. As we continue the development of our scientific platform and target vIgDs, we intend to continue pursuing intellectual property protection for these technologies.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have in-licensed some intellectual property and trade secret materials on a non-exclusive basis. To date, such non-exclusive in-licenses are solely related to commercially-available cell lines involved in the manufacture of our vIgD programs. To date, no other intellectual property related to our scientific platform has been in-licensed.&#160;&#160;We have out-licensed two programs under our TIP technology to Kite on an exclusive basis. No other out-licenses have been made.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we do not believe our technology infringes any intellectual property rights owned by third parties, we are aware of one or more patents and patent applications that may relate to our technology. Third parties may assert claims against us alleging infringement of their intellectual property rights regardless of whether their allegations have merit. Allegations of infringement could harm our reputation, may result in the expenditure of significant resources to defend and resolve such allegations, and could require us to pay monetary damages if we are found to have infringed any third-party intellectual property rights.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements on the clinical development, manufacture, marketing, and distribution of therapeutic candidates. These agencies and other federal, state, and local entities regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, and export and import of therapeutic candidates and products.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the U.S., the FDA regulates drugs, medical devices, and biologic products under the Federal Food, Drug, and Cosmetic Act, or FFDCA, its implementing regulations and other laws, including, in the case of biologics, the Public Health Service Act. Our potential therapeutic candidates and products will be subject to regulation by the FDA as biologics. Biologics require the submission of a Biologics License Application, or BLA, and approval by the FDA before being marketed in the U.S. None of our therapeutic candidates have been approved by the FDA for marketing in the U.S., and we currently have no BLAs pending. If we fail to comply with applicable FDA or other requirements at any time during the product development process, clinical testing, the approval process, or after approval, we may become subject to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, or criminal prosecution. Any FDA enforcement action could have a material adverse effect on us. The process required by the FDA before biologic therapeutic candidates may be marketed in the U.S. generally involves the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">completion of extensive preclinical laboratory tests, preclinical animal studies, and formulation studies all performed in accordance with the FDA&#8217;s current good laboratory practice, or cGLP, regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">submission to the FDA of an IND application which must become effective before human clinical trials in the U.S. may begin;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug candidate for each proposed indication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">submission to the FDA of a BLA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP regulations; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA review and approval of the BLA prior to any commercial marketing, sale, or shipment of the therapeutic product.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain any approvals for our therapeutic candidates will be granted on a timely basis, if at all.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once a therapeutic candidate is identified for development, it enters the preclinical testing stage. Preclinical studies include laboratory evaluations of protein chemistry, formulation, and stability, as well as studies to evaluate toxicity in animals. The results of the preclinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application. Currently, the IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND may result in the FDA not allowing the clinical trials to commence or not allowing the clinical trials to commence on the terms originally specified in the IND. A separate submission to an existing IND must also be made for each successive clinical trial conducted during drug development, and the FDA must grant permission, either explicitly or implicitly by not objecting, before each clinical trial can begin. We have commenced only one clinical trial for any of our current therapeutic candidates, the AIS-A01 dosing study of ALPN-101 in healthy volunteers beginning in January 2019.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials involve the administration of the therapeutic candidate to human subjects under the supervision of qualified investigators. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be used. Each protocol must be submitted to the FDA as part of the IND. For each medical center proposing to conduct a clinical trial, an institutional review board, or IRB, must also review and approve a plan for any clinical trial before it can begin at that center and the IRB must monitor the clinical trial until it is completed. The FDA, an IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding the subjects are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive Good Clinical Practice requirements, including the requirements for informed consent.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All clinical research performed in the U.S. in support of a BLA must be authorized in advance by the FDA under the IND regulations and procedures described above. However, a sponsor who wishes to conduct a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA so long as the clinical trial is conducted in compliance with an international guideline for the ethical conduct of clinical research known as the Declaration of Helsinki and/or the laws and regulations of the country or countries in which the clinical trial is performed, whichever provides the greater protection to the participants in the clinical trial.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trials</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of BLA submission and approval, clinical trials are typically conducted in three sequential phases, which may overlap or be combined.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase I clinical trials are initially conducted in a limited population of subjects to test the therapeutic candidate for safety, dose tolerance, absorption, metabolism, distribution, and excretion in healthy humans or, on occasion, in patients with severe problems or life-threatening diseases to gain an early indication of its effectiveness.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase II clinical trials are generally conducted in a limited patient population to evaluate preliminary efficacy of the therapeutic candidate for specific targeted indications in patients with the disease or condition under study, evaluate dosage tolerance and appropriate dosage, determine a dosage schedule, and identify possible adverse effects and safety risks.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase III clinical trials are commonly definitive efficacy studies of the experimental medication. Phase III trials are typically conducted when Phase II clinical trials demonstrate a dose range of the therapeutic candidate is effective and has an acceptable safety profile. Phase III clinical trials are generally undertaken with large numbers of patients, such as groups of several hundred to several thousand, to provide substantial evidence of clinical efficacy and to further test for safety in an expanded patient population at multiple, geographically-dispersed clinical trial sites.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In some cases, the FDA may condition approval of a BLA on the sponsor&#8217;s agreement to conduct additional post-approval clinical trials to further assess the biologic&#8217;s safety and effectiveness after BLA approval. Such post-approval clinical trials are typically referred to as Phase IV clinical trials.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concurrent with clinical trials, companies usually complete additional animal trials and must also develop additional information about the chemistry and physical characteristics of the biologic and finalize a process for manufacturing the biologic in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the therapeutic candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final biologic product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate the therapeutic candidate does not undergo unacceptable deterioration over its shelf life.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Biologics License Applications</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of preclinical studies and of the clinical trials, together with other detailed information, including extensive manufacturing information and information on the chemistry, pharmacology, clinical pharmacology, and the clinical effects of the biologic, are submitted to the FDA in the form of a BLA requesting approval to market the biologic for one or more specified indications. The FDA reviews a BLA to determine, among other things, whether a biologic is safe, pure, and potent and whether the facility in which the biological product is manufactured, processed, packed, or held meets standards designed to assure the biological product continues to be safe, pure, and potent.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once a BLA has been accepted for filing, by law the FDA will review the application and respond to the applicant, but the review process may be significantly delayed by FDA&#8217;s requests for additional information or clarification. Under the Prescription Drug User Fee Act, the FDA evaluates a standard original BLA submission within the first 60 days of its receipt to determine if it is sufficiently complete to conduct a full review, and the FDA has a goal of responding to the submission within ten months of the 60-day filing date, but this timeframe is often extended. The FDA may refer the application to an advisory committee for review, evaluation, and/or recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. The FDA may deny approval of a BLA if the applicable statutory and regulatory criteria are not satisfied, or for any reason, or it may require additional clinical data. Even if such data are submitted, the FDA may ultimately decide the BLA does not satisfy the criteria for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret data. Once the FDA approves a BLA, or supplement thereto, the FDA may withdraw the approval if ongoing regulatory requirements are not met or if safety problems are identified after the biologic reaches the market. Where a withdrawal may not be appropriate, the FDA still may seize existing inventory of such biologic or require a recall of any biologic already on the market. In addition, the FDA may require testing, including Phase IV clinical trials and surveillance programs to monitor the effect of approved biologics which have been commercialized. The FDA has the authority to prevent or limit further marketing of a biologic based on the results of these post-marketing programs.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A sponsor may also seek approval of its therapeutic candidates under programs designed to accelerate FDA review and approval of BLAs. For instance, a sponsor may seek FDA designation of a therapeutic candidate as a &#8220;fast track product.&#8221; Fast track products are those products intended for the treatment of a serious or life-threatening disease or condition and which demonstrate the potential to address unmet medical needs for such diseases or conditions. If fast track designation is obtained, the FDA may initiate review of sections of a BLA before the application is complete. This &#8220;rolling review&#8221; is available if the applicant provides, and the FDA approves, a schedule for the remaining information. In some cases, a fast track product may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments, under the FDA&#8217;s accelerated approval program. Approvals of this kind typically include requirements for appropriate post-approval confirmatory clinical trials to validate the surrogate endpoint or otherwise confirm the effect of the clinical endpoint.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the Food and Drug Administration Safety and Innovation Act, or FDASIA, which was enacted and signed into law in 2012, established a new category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be subject to accelerated approval. A sponsor may seek FDA designation of a drug candidate as a &#8220;breakthrough therapy&#8221; if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Therapeutic candidates may also be eligible for &#8220;priority review,&#8221; or review within a six-month timeframe from the 60-day filing date, if a sponsor provides sufficient clinical data demonstrating its therapeutic candidate provides a significant improvement compared to marketed products. Even if a therapeutic candidate qualifies for one or more of these programs, the FDA may later decide the therapeutic candidate no longer meets the conditions for qualification or that the period for FDA review or approval will be lengthened. When appropriate, we intend to seek fast track designation and/or accelerated approval for our biologics. We cannot predict whether any of our therapeutic candidates will obtain a fast track and/or accelerated approval designation and, if so, whether such designation will be maintained or rescinded by FDA, or the ultimate impact, if any, of the fast track or the accelerated approval process on the timing or likelihood of FDA approval of any of our proposed biologics.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biologics may be marketed only for the FDA approved indications and in accordance with the provisions of the approved labeling. Further, if there are any modifications to the biologic, including changes in indications, labeling, or manufacturing processes, equipment, or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require us to develop additional data or conduct additional preclinical studies and clinical trials.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before approving an application, the FDA will inspect the facility or the facilities at which the biologic product is manufactured and will not approve the product unless cGMP compliance is satisfactory. The FDA may also inspect the sites at which the clinical trials were conducted to assess their compliance and will not approve the biologic unless compliance with Good Clinical Practice requirements is satisfactory.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The testing and approval processes require substantial time, effort, and financial resources, and each may take several years to complete. The FDA may not grant approval on a timely basis, or at all. Even if we believe a clinical trial has demonstrated safety and efficacy of one of our therapeutic candidates for the treatment of a disease, the results may not be satisfactory to the FDA. Preclinical and clinical data may be interpreted by the FDA in different ways, which could delay, limit, or prevent regulatory approval. We may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental approvals which could delay or preclude us from marketing our therapeutic candidates. The FDA may limit the indications for use or place other conditions on any approvals restricting the commercial application of the products. After approval, certain changes to the approved biologic, such as adding new indications, change in personnel, manufacturing changes, or additional labeling claims, are subject to further FDA review and approval. Depending on the nature of the change proposed, a BLA supplement which may require additional studies to evaluate the effect of such change on the identity, strength, quality, purity, or potency of the product as they may relate to the safety or effectiveness of the product&#8212;must be filed and approved before the change may be implemented. As with new BLAs, the review process for BLA supplements may be delayed by the FDA through requests for additional information or clarification.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe any of our therapeutic products approved as a biological product under a BLA might qualify for a 12-year period of exclusivity currently permitted by the Biologics Price Competition and Innovation Act, or BPCIA. Specifically, the BPCIA established an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be submitted by an applicant until four years after the date the reference product was first licensed and cannot be approved by the FDA until 12 years after the original branded product was first licensed under a BLA. There is a risk the U.S. Congress could amend the BPCIA to significantly shorten this exclusivity period or the FDA will not consider our therapeutic candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. The BPCIA is complex and is only beginning to be interpreted and implemented by the FDA and the courts. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when any such processes may be fully adopted by the FDA, any such processes operating to limit the scope or length of exclusivity afforded by the BPCIA could have a material adverse effect on the future commercial prospects for our biological products. In addition, foreign regulatory authorities may also provide for exclusivity periods for approved biological products or for abbreviated pathways for follow on biological products. For example, biological products in Europe may be eligible for a 10-year period of exclusivity.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to therapeutic candidates intended to treat a rare disease or condition, which is generally a disease or condition affecting fewer than 200,000 individuals in the U.S. or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation the cost of developing and making available in the U.S. a therapeutic candidate for this type of disease or condition will be recovered from sales in the U.S. for that therapeutic candidate. Orphan drug designation must be requested before submitting a marketing application for the therapeutic for that particular rare disease or condition. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The FDA may revoke orphan drug designation, and if it does, it will publicize the drug is no longer designated as an orphan drug. If a therapeutic candidate with orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the therapeutic candidate is entitled to orphan product exclusivity, which means the FDA may not approve any other applications to market the same therapeutic candidate for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same therapeutic candidate as defined by the FDA or if our therapeutic candidate is determined to be contained within the competitor&#8217;s therapeutic candidate for the same indication or disease.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Best Pharmaceuticals for Children Act, certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor submits information requested in writing by the FDA, referred to as a &#8220;Written Request,&#8221; relating to the use of the active moiety of the therapeutic candidate in children. The FDA may not issue a Written Request for studies on unapproved or approved indications where it determines information relating to the use of a therapeutic candidate in a pediatric population, or part of the pediatric population, may not produce health benefits in that population. In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric studies for most therapeutic candidates and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs, BLAs and supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must assess the safety and effectiveness of the therapeutic candidate for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">which the therapeutic candidate is safe and effective. The sponsor or the FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding the drug or biologic is ready for approval for use in adults before pediatric studies are complete or additional safety or effectiveness data needs to be collected before the pediatric studies begin. The FDA must send a noncompliance letter to any sponsor that fails to submit the required assessment, keep a deferral current, or fails to submit a request for approval of a pediatric formulation.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Regulatory Requirements</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any biologics manufactured or distributed by us or our collaborators pursuant to FDA approvals would be subject to continuing regulation by the FDA, including recordkeeping requirements and reporting of adverse experiences associated with the product. Manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements upon us and third-party manufacturers. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. Our company cannot be certain it or its present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements. If our company or its present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may halt our clinical trials, require us to recall a drug from distribution, or withdraw approval of the BLA for the therapeutic product.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. A company can make only those claims relating to safety and efficacy approved by the FDA. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe legally available biologics for uses not described in the product&#8217;s labeling and different from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers&#8217; communications regarding off-label use.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Healthcare Reform</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2010, Congress passed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, which we refer to as the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry, and impose additional policy reforms. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes, and fraud and abuse, impacting existing government healthcare programs and resulting in the development of new programs, including Medicare payment for performance initiatives, and improvements to the physician quality reporting system and feedback program. The Affordable Care Act also does, among other things, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases pharmaceutical manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate on most branded prescription drugs, and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed care plans.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expands the 340B Drug Pricing Program to require discounts for &#8220;covered outpatient drugs&#8221; sold to certain children&#8217;s hospitals, critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospital.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Requires pharmaceutical companies to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly referred to as the &#8220;Donut Hole.&#8221;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Requires pharmaceutical companies to pay an annual non-tax-deductible fee to the federal government based on each company&#8217;s market share of prior year total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs, and Department of Defense.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Establishes the Patient-Centered Outcomes Research Institute to identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The research conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Establishes The Center for Medicare and Medicaid Innovation within the Centers for Medicare and Medicaid Services, or CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation from 2011 to 2019.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, legislation is drafted, introduced, and passed in Congress that could significantly change the statutory provisions governing the sale, marketing, coverage, and reimbursement of products regulated by the CMS or other government agencies. In addition to new legislation, CMS regulations and policies are often revised or interpreted by the agency in ways significantly affecting our business and our products.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In particular, we expect the Administration and Congress will continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the U.S. healthcare reform legislation. Since taking office, President Trump has continued to support the repeal of all or portions of the ACA. President Trump has also issued an executive order in which he stated it is his Administration&#8217;s policy to seek the repeal of the ACA and directed executive departments and federal agencies to waive, defer, grant exemptions from, or delay the implementation of the provisions of the ACA to the maximum extent permitted by law. There is still uncertainty with respect to the impact President Trump&#8217;s Administration and Congress may have, if any, and any changes will likely take time to unfold. Such reforms could have an adverse effect on anticipated revenues from therapeutic candidates we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop therapeutic candidates. However, we cannot predict the ultimate content, timing, or effect of any healthcare reform legislation or the impact of potential legislation on our company.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, political, economic, and regulatory influences are subjecting the health care industry in the U.S. to fundamental change. Initiatives to reduce the federal budget and debt and to reform health care coverage are increasing cost-containment efforts. We anticipate federal agencies, Congress, state legislatures, and the private sector will continue to review and assess alternative health care benefits, controls on health care spending, and other fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit coverage for, or the amounts federal and state governments will pay for, health care products and services, which could also result in reduced demand for our products or additional pricing pressures, and limit or eliminate our spending on development projects and affect our ultimate profitability.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Third-Party Payor Coverage and Reimbursement</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the U.S., sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities such as Medicare, Medicaid, TRICARE, and the Veterans Administration, managed care providers, private health insurers and other organizations.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Medicaid Drug Rebate Program, which is part of the federal Medicaid program, a program for financially needy patients, among others, requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order for a pharmaceutical product to receive federal reimbursement under Medicare Part B, part of the federal Medicare program covering outpatient items and services for the aged and disabled, and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program, a federal program requiring manufacturers to provide discounts to certain safety-net providers. The required 340B discount on a given product is calculated based upon certain Medicaid Drug Rebate Program metrics reported by the manufacturer.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list or formulary which might not include all of the FDA-approved products for a particular indication. Also, third-party payors may refuse to include a particular branded product on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. However, under Medicare Part D - Medicare&#8217;s outpatient prescription drug benefit - there are protections in place to ensure coverage and reimbursement for oncology products and all Part D prescription drug plans are required to cover substantially all anti-cancer agents. Furthermore, a payor&#8217;s decision to provide coverage for a product does not imply an adequate reimbursement rate will be available. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product approved for sale, we may need to pursue compendia listings or conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of any products, in addition to the costs required to obtain regulatory approvals. Our drug candidates may not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover an approved product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Healthcare Laws and Regulations</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we obtain regulatory approval of our products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing strategies. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws affecting our ability to operate include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal health care program, such as the Medicare and Medicaid programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payors that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provisions of HIPAA,&#160;prohibiting knowingly and willfully executing a scheme to defraud any health care benefit program and making false statements relating to health care matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security, and transmission of individually identifiable health information;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal transparency laws, including the federal Physician Payment Sunshine Act, which was part of the Affordable Care Act, requiring manufacturers of certain drugs and biologics to track and disclose payments and other transfers of value they make to U.S. physicians and teaching hospitals, as well as physician ownership and investment interests in the manufacturer, which information is subsequently made publicly available in a searchable format on a CMS website; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state transparency reporting and compliance laws, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The ACA broadened the reach of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute and the applicable criminal healthcare fraud statutes contained within 42 U.S.C. &#167; 1320a-7b. Pursuant to the statutory amendment, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the ACA provides the government may assert a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act or the civil monetary penalties statute. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had 48 employees, of which 37 are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Facilities</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We lease a facility containing our research and development, laboratory, and office space, which consists of approximately 11,158 square feet located at 201 Elliott Avenue West, Seattle, Washington. In January 2018, we entered into a lease amendment for approximately 6,184 square feet of additional office and laboratory space adjacent to our existing leased premises in Seattle, Washington. The lease expires on December 31, 2019 and has two options to extend the lease term with each option enabling us to extend the lease term by twelve months. In March 2019, we entered into a lease for 27,164 square feet of office and laboratory space located at 188 East Blaine Street, Seattle, Washington which we expect to occupy prior to the expiration of our current lease. See Part I, Item 2</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:10pt;">of this report for more details on the terms of the lease. We believe that our existing facilities and the facilities we intend to occupy prior to the expiration of our current lease are adequate to meet our business requirements for the near-term and that additional space will be available on commercially reasonable terms, if required.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate Information</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 24, 2017, Alpine Immune Sciences, Inc., or Private Alpine, completed its business combination with Nivalis Therapeutics, Inc., a publicly held company. In connection with the merger, Nivalis Therapeutics, Inc. changed its name to Alpine Immune Sciences, Inc. For additional information regarding this business combination, see </font><a style="font-family:inherit;font-size:10pt;" href="#sD825573C793AF4AC779431F4B0E6A7BD"><font style="font-family:inherit;font-size:10pt;">Note 3</font></a><font style="font-family:inherit;font-size:10pt;">&#32;to our consolidated financial statements contained elsewhere in this Annual Report on Form 10-K. Nivalis Therapeutics, Inc. was incorporated in Delaware in March 2007.&#160;&#160;Alpine Immune Sciences, Inc. (prior to its business combination with Nivalis Therapeutics, Inc.) was incorporated in Delaware on December 30, 2014.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal executive office is located at 201 Elliott Avenue West, Suite 230, Seattle WA, 98119. Our telephone number is (206) 788-4545. Our website is www.alpineimmunesciences.com. Information contained in, or that can be accessed through, our website is not a part of, and is not incorporated into, this report.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">This Annual Report on Form 10-K includes our trademarks and registered trademarks, including &#8220;vIgD&#8221;, &#8220;Transmembrane Immunomodulatory Protein&#8221; (&#8220;TIP&#8221;), and &#8220;Secreted Immunomodulatory Protein&#8221; (&#8220;SIP&#8221;). Each other trademark, trade name or service mark appearing in this Annual Report on Form 10-K belongs to its holder. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><a name="sCF7396DCF2D2399BDC0F31F4C7C49CB6"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A. Risk Factors</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;">You should carefully consider the following risk factors, in addition to the other information contained in this Annual Report on Form 10-K, including </font><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s42D9D33AA9E110CE95F631F4C9A472AD"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;">&#32;included in Part II, Item 7, and our </font><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s8D1084986631244E2E7A31F4CDBC717F"><font style="font-family:inherit;font-size:10pt;font-style:italic;">consolidated financial statements and related notes</font></a><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;">. If any of the events described in the following risk factors and the risks described elsewhere in this report occurs, our business, operating results and financial condition could be seriously harmed. This report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this report.</font></div><div><a name="sDA8E57CBC1D0668564DE31F4C7E27CA9"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-weight:bold;">Risks Related to Our Financial Position, Capital Needs and Business</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We will need to raise substantial additional funds to advance development of our therapeutic candidates, and we cannot guarantee we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We will need to raise substantial additional funds to expand our development, regulatory, manufacturing, marketing, and sales capabilities or contract with other organizations to provide these capabilities to us. We have used substantial funds to develop our therapeutic candidates and will require significant funds to conduct further research and development, preclinical testing, and clinical trials of our therapeutic candidates, to seek regulatory approvals for our therapeutic candidates, and to manufacture and market products, if any are approved for commercial sale. As of </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">, we had </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">$52.3 million</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;in cash and cash equivalents and short-term investments. Based on our current operating plan, we believe our available cash and cash equivalents, will be sufficient to fund our planned level of operations for at least the next 12 months. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with successful development of our therapeutic candidates are highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. To execute our business plan, we will need, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to obtain the human and financial resources necessary to develop, test, obtain regulatory approval for, manufacture, and market our therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to build and maintain a strong intellectual property portfolio and avoid infringing intellectual property of third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to establish and maintain successful licenses, collaborations, and alliances;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to satisfy the requirements of clinical trial protocols, including patient enrollment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to establish and demonstrate the clinical efficacy and safety of our therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to obtain regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to manage our spending as costs and expenses increase due to preclinical studies, clinical trials, regulatory approvals, manufacturing scale-up, and commercialization;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to obtain additional capital to support and expand our operations; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to market our products </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">to achieve</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">acceptance</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">and use by the</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">medical</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">community</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">in general.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">If we are unable to obtain necessary funding on a timely basis or on acceptable terms, we may have to delay, reduce, or terminate our research and development programs, preclinical studies, or clinical trials, if any, limit strategic opportunities, or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others requiring us to relinquish rights to some of our technologies or therapeutic candidates we would otherwise pursue on our own. We do not expect to realize revenue from product sales, or royalties in the foreseeable future, if at all. Our revenue sources are, and will remain, extremely limited unless and until our therapeutic candidates are clinically tested, approved for commercialization, and successfully marketed.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">To date, we have financed our operations primarily through the sale of equity securities and payments received under our license and research agreement with Kite. We will be required to seek additional funding in the future and intend to do so through a combination of public or private equity offerings, debt financings, credit and loan facilities, research collaborations, and license agreements. Our ability to raise additional funds from these or other sources will depend on financial, economic, and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">If we raise additional funds by issuing equity securities, our stockholders will suffer dilution, and the terms of any financing may adversely affect the rights of our stockholders. For example, in January 2019, we issued in a private placement 4,706,700 shares of common stock and warrants to purchase an additional 1,835,610 shares of common stock for gross proceeds of approximately $25.3 million. We also have an Equity Distribution Agreement in place with Piper Jaffray to sell up to $50.0 million of our common stock, from time to time, through an &#8220;at the market&#8221; equity offering program under which Piper Jaffray acts as sales agent. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of a liquidation or insolvency, debt holders would be repaid before holders of equity securities receive any distribution of corporate assets. Our failure to raise capital or enter into such other arrangements within a reasonable timeframe would have a negative impact on our financial condition, and we may have to delay, reduce, or terminate our research and development programs, preclinical or clinical trials, or undergo reductions in our workforce or other corporate restructuring activities.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We are an early stage biopharmaceutical company with a history of losses, we expect to continue to incur significant losses for the foreseeable future, we may never achieve or maintain profitability, and we have a limited operating history that may make it difficult for investors to evaluate the potential success of our business.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We are a clinical-stage immunotherapy company, with a limited operating history, focused on developing treatments for autoimmune/inflammatory diseases and cancer. Since inception, we have devoted our resources to developing novel protein-based immunotherapies using our proprietary scientific platform technology, which produces variant Ig domains or vIgDs. We have had significant operating losses since inception. For </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">2018</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">, our net loss was </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">$36.5 million</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">. Substantially all of our losses have resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations. Our technologies and therapeutic candidates are in early stages of development, and we are subject to the risks of failure inherent in the development of therapeutic candidates based on novel technologies.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We have historically generated revenue primarily from the receipt of research funding and upfront payments under our license and research agreement with Kite. We have not generated, and do not expect to generate, any revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials, and the regulatory approval process for therapeutic candidates. The amount of future losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, our or our existing collaborators, or any future collaborators, successfully developing therapeutic candidates, obtaining regulatory approvals to market and commercialize therapeutic candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third party alternatives for any approved product, and raising sufficient funds to finance business activities. If we or our existing collaborators, or any future collaborators, are unable to develop and commercialize one or more of our therapeutic candidates or if sales revenue from any therapeutic candidate receiving approval is insufficient, we will not achieve profitability, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We plan to develop novel protein-based immunotherapies using our proprietary vIgD technology for the treatment of cancer and autoimmune/inflammatory diseases. The potential to create therapies capable of working within and/or modulating an immune synapse, forcing a synapse to occur, or preventing a synapse from occurring is an important, novel attribute of our vIgDs. However, the scientific research forming the basis of our efforts to develop therapeutic candidates based on our platform is relatively new. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on vIgDs is both preliminary and limited.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Relatively few therapeutic candidates based on immunoglobulin superfamily, or IgSF, domains have been tested in animals or humans, and a number of clinical trials conducted by other companies using IgSF domains technologies have not been successful. We may discover the therapeutic candidates developed using our scientific platform do not possess certain properties required for the therapeutic candidate to be effective, such as the ability to remain stable or active in the human body for the period of time required for the therapeutic candidate to reach the target tissue and/or cell. We currently have only limited data, and no conclusive evidence, to suggest we can introduce these necessary therapeutic properties into vIgD-based therapeutic candidates. We may spend substantial funds attempting to introduce these properties and may never succeed in doing so. In addition, vIgDs may demonstrate different chemical and pharmacological properties in human subjects or patients than they do in laboratory studies. Even if our programs, such as the ALPN-101 program, have successful results in animal studies, they may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective, or harmful ways. For example, in the context of immunotherapies, in a Phase I </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">clinical trial of TeGenero AG&#8217;s product candidate TGN1412, healthy volunteer subjects receiving the product candidate experienced a systemic inflammatory response resulting in renal and pulmonary failure requiring interventions such as dialysis and critical care support. Following this experience, regulatory agencies now ask for evaluation of immunomodulatory antibodies with a number of </font><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;assays with human cells. While we are currently performing </font><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;proof of concept studies for several of our vIgDs preclinically, and safety studies clinically for ALPN-101, the risk profile in humans has yet to be fully assessed. Undesirable side effects that may be caused by our therapeutic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete clinical trials or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. As a result, we may never succeed in developing a marketable therapeutic, we may not become profitable, and the value of our common stock will decline.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Further, we believe that the FDA has no prior experience with vIgDs and no regulatory authority has granted approval to any person or entity, including our company, to market and commercialize therapeutics using vIgDs, which may increase the complexity, uncertainty, and length of the regulatory approval process for our therapeutic candidates. Our company and our current collaborators, or any future collaborators, may never receive approval to market and commercialize any therapeutic candidate. Even if our company or a collaborator obtains regulatory approval, the approval may be for disease indications or patient populations not as broad as we intended or desired or may require labeling, including significant use or distribution restrictions or safety warnings. Our company or a collaborator may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If therapeutic candidates we develop using our scientific platform prove to be ineffective, unsafe, or commercially unviable, our entire platform and pipeline would have little, if any, value, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">The market may not be receptive to our therapeutic products based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of therapeutic products.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Even if approval is obtained for a therapeutic candidate, we may not generate or sustain revenue from sales of the therapeutic product due to factors such as whether the therapeutic product can be sold at a competitive price and otherwise accepted in the market. Therefore, any revenue from sales of the therapeutic product may not offset the costs of development. The therapeutic candidates we are developing are based on new technologies and therapeutic approaches. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors, may not adopt a treatment based on our therapeutic products, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable coverage or reimbursement for, any therapeutic products developed by our company, our existing collaborator, or any future collaborators. Market acceptance of our therapeutic products will depend on, among other factors:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing of our receipt of any marketing and commercialization approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the terms of any approvals and the countries in which approvals are obtained;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the safety and efficacy of our therapeutic products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the prevalence and severity of any adverse side effects associated with our therapeutic products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the prevalence and severity of any adverse side effects associated with therapeutics of the same type or class as our therapeutic products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">relative convenience and ease of administration of our therapeutic products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the willingness of patients to accept any new methods of administration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the success of our physician education programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of adequate government and third-party payor coverage and reimbursement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the pricing of our products, particularly as compared to alternative treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to compliantly market and sell our products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">availability of alternative effective treatments for the disease indications our therapeutic products are intended to treat and the relative risks, benefits, and costs of those treatments.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">With our focus on engineering wild-type IgSFs proteins, these risks may increase to the extent this field becomes more competitive or less favored in the commercial marketplace. Additional risks apply in relation to any disease indications we pursue which are classified as rare diseases and allow for orphan drug designation by regulatory agencies in major commercial markets, such as the United States, European Union, and Japan. Because of the small patient population for a rare disease, if pricing is not approved or accepted in the market at an appropriate level for an approved therapeutic product with orphan drug designation, such drug may not generate enough revenue to offset costs of development, manufacturing, marketing, and commercialization despite any benefits received from the orphan drug designation, such as market exclusivity, assistance in clinical trial design, or a reduction in user fees or tax credits related to development expense. Market size is also a variable in disease indications classified as rare. Our estimates regarding potential market size for any rare indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a therapeutic product, which could result in significant changes in our business plan and have a material adverse effect on our business, financial condition, results of operations, and prospects.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">If a therapeutic product with orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the therapeutic product is entitled to orphan product exclusivity, which means the FDA may not approve any other applications to market the same therapeutic product for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic products for seven years if a competitor obtains approval of the same therapeutic product as defined by the FDA or if our therapeutic product is determined to be within the same class as the competitor&#8217;s therapeutic product for the same indication or disease.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">As in the United States, we may apply for designation of a therapeutic product as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. Sponsors of orphan drugs in the European Union can enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show its therapeutic product is safer, more effective, or otherwise clinically superior to the orphan-designated therapeutic product. The respective orphan designation and exclusivity frameworks in the United States and in the European Union are subject to change, and any such changes may affect our ability to obtain EU or U.S. orphan designations in the future.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. </font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We have no products on the market and all of our therapeutic candidates are in early stages of development. Our ability to achieve and sustain profitability depends on obtaining regulatory approval and Institutional Review Board, or IRB, approval to conduct clinical trials at particular sites, obtaining regulatory approvals to market our therapeutic candidates and successfully commercializing our therapeutic candidates, either alone or with third parties, such as our collaborator Kite. Before obtaining regulatory approval for the commercial distribution of our therapeutic candidates, we or a collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our therapeutic candidates. Preclinical testing and clinical trials are expensive, difficult to design and implement, can take many years to complete, and are uncertain as to outcome. For example, in January 2019, we enrolled our first subjects in a Phase I healthy volunteer trial of ALPN-101. We are also working to advance our lead oncology program ALPN-202 for the treatment of cancer and preclinical development activities continue as planned, with the goal of filing an IND or IND-equivalent in the fourth quarter of 2019. Even with the significant investment of time and funding to advance ALPN-101 and ALPN-202, we cannot guarantee that our clinical and pre-clinical development efforts will be successful or that any of our product candidates will advance to human clinical trials. The start or end of a clinical study is often delayed or halted due to delays in or failure to obtain regulatory approval to commence the study, delays in or failure to reach agreement on acceptable terms with prospective contract research organizations or clinical trial sites, delays in or failure to obtain IRB approval at each site, changing regulatory requirements, manufacturing challenges, clinical sites or contract research organizations deviating from the trial protocol or failing to comply with regulatory requirements or meet contractual obligations, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparative therapeutic or required prior therapy, clinical outcomes, failure of patients to complete the trial or return for post-treatment follow-up, or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times, or termination of a clinical trial. Clinical trials of a new therapeutic candidate require the enrollment of a sufficient number of patients, which may include patients who are suffering from the disease the therapeutic candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites, and the availability of effective treatments or competing academic and other clinical trials for the relevant disease.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">A therapeutic candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for therapeutic candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care, and other variables. The novelty of our platform may mean our failure rates are higher than historical norms. The results from preclinical testing or early clinical trials of a therapeutic candidate may not predict the outcome of later phase clinical trials of the therapeutic candidate, particularly in immuno-oncology and autoimmune/inflammatory disorders. To date, we have not conducted any clinical trials of our therapeutic candidates in patients with active disease. However, we will have to conduct trials in our proposed indications to verify the results obtained to date in our preclinical studies and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether Phase 1, Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our therapeutic candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We, the FDA, an IRB, an independent ethics committee, or other applicable regulatory authorities may suspend clinical trials of a therapeutic candidate at any time for various reasons, including a belief that subjects participating in such trials are being exposed to unacceptable health risks or adverse side effects. Similarly, an IRB or ethics committee may suspend a clinical trial at a particular trial site. We may not have the financial resources to continue development of, or to enter into collaborations for, a therapeutic candidate if we experience any problems or other unforeseen events delaying or preventing clinical development or regulatory approval of, or our ability to commercialize, therapeutic candidates, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">negative or inconclusive results from our clinical trials, or the clinical trials of others for therapeutic candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using therapeutics similar to our therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">serious drug-related side effects experienced in the past by individuals using therapeutics similar to our therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in submitting Investigational New Drug, or IND, applications or clinical trial applications, or comparable foreign applications, or delays or failure in obtaining the necessary approvals from regulators or IRBs to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conditions imposed by the FDA or comparable foreign authorities, such as the European Medicines Agency, or EMA, regarding the scope or design of our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in enrolling research subjects in clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">high drop-out rates of research subjects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inadequate supply or quality of therapeutic candidate or therapeutic candidate components, or materials or other supplies necessary for the conduct of our clinical trials, including those owned, manufactured, or provided by companies other than ours;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">greater than anticipated clinical trial costs, including the cost of any approved drugs used in combination with our therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">poor effectiveness of our therapeutic candidates during clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays and changes in regulatory requirements, policies, and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">varying interpretations of data by the FDA and similar foreign regulatory agencies.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier pre-clinical and clinical trials may not be predictive of future clinical trial results.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of pre-clinical trials and early clinical trials of our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">product candidates may not be predictive of the results of larger, later-stage controlled clinical trials. Product candidates showing promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical trials. In January 2019, we dosed the first subjects with ALPN-101 in a Phase I trial enrolling healthy volunteers. We have conducted no clinical trials to date with ALPN-202 and have not dosed ALPN-101 in patients with active inflammatory disease. We will have to conduct trials in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether Phase 1, Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our therapeutic candidates.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Additionally, disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down multiple times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">To date, our revenue has been primarily derived from our license and research agreement with Kite, and we are dependent on Kite for the successful development of therapeutic candidates in the collaboration.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In October 2015, we entered into an exclusive, worldwide license and research agreement with Kite to research, develop, and commercialize engineered autologous T cell therapies incorporating two targets from our technology.&#160;Pursuant to the license and research agreement, we will be potentially eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">$530.0 million</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;in total milestone payments upon the successful completion of research, clinical, and regulatory milestones. We will also potentially be eligible to receive a low single-digit percentage royalty for sales on a licensed product-by-licensed product and country-by-country basis.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Continued success of our collaboration with Kite, and our realization of the milestone and royalty payments under the agreement, depends upon the efforts of Kite. Kite has sole discretion in determining and directing the efforts and resources, including the ability to discontinue all efforts and resources, it applies to the development and, if approval is obtained, commercialization and marketing of the therapeutic candidates covered by the collaboration. Kite may not be effective in obtaining approvals for the therapeutic candidates developed under the collaboration arrangement or marketing or arranging for necessary supply, manufacturing, or distribution relationships for any approved products. Kite may change its strategic focus or pursue alternative technologies in a manner resulting in reduced, delayed, or no revenue to us. Kite has a variety of marketed products and its own corporate objectives and strategies may not be consistent with our best interests. If Kite fails to develop, obtain regulatory approval for, or ultimately commercialize any therapeutic candidate under the collaboration or if Kite terminates the collaboration, our business, financial condition, results of operations, and prospects could be materially and adversely affected. In addition, any dispute or litigation proceedings we may have with Kite in the future could delay development programs, create uncertainty as to ownership of intellectual property rights, distract management from other business activities and generate substantial expense.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">If we are unable to secure intellectual property rights to programs covered under the license and research agreement, Kite may terminate the agreement and our business, financial condition, results of operations, and prospects could be materially and adversely affected. In addition, any dispute or litigation proceedings we may have with Kite related to intellectual property rights or other aspects of the agreement or the relationship could delay development programs, create uncertainty as to ownership of intellectual property rights, may distract management from other business activities and generate substantial expense.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In October 2017, Kite was acquired by Gilead Pharma, Inc., or Gilead. While the research term of the collaboration was extended after the closing of the acquisition, there is no guarantee Gilead will place the same emphasis on the collaboration or wish to continue the collaboration. If either of these occurs, our business, financial condition, results of operations, stock price, and prospects could be materially and adversely affected.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">If third parties on which we depend to conduct our clinical or preclinical studies, or any future clinical trials, do not perform as expected, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development program could be delayed, which may result in materially adverse effects on our business, financial condition, results of operations, and prospects.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We rely, in part, on third party clinical investigators, contract research organizations, or CROs, clinical data management organizations, and consultants to design, conduct, supervise, and monitor clinical trials and preclinical studies of our therapeutic candidates and may do the same for future clinical trials. Because we rely on third parties to conduct preclinical studies or clinical trials, we have less control over the timing, quality, compliance, and other aspects of preclinical studies and clinical trials than we would if we conducted all preclinical studies and clinical trials on our own. These investigators, CROs, and consultants are not our employees and we have limited control over the amount of time and resources they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw their time and resources away from our programs. The third parties with which we contract might not be diligent, careful, compliant, or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. Further, if any of our relationships with third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their expected duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials, or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial and with legal, regulatory and scientific standards. The FDA and certain foreign regulatory authorities, such as the EMA, require preclinical studies to be conducted in accordance with applicable Good Laboratory Practices, or GLPs, and clinical trials to be conducted in accordance with applicable FDA regulations and Good Clinical Practices, or GCPs, including requirements for conducting, recording, and reporting the results of preclinical studies and clinical trials to assure data and reported results are credible and accurate and the rights, integrity, and confidentiality of clinical trial participants are protected. Our reliance on third parties we do not control does not relieve us of these responsibilities and requirements. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under current good manufacturing practice, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Any such event could have a material adverse effect on our business, financial condition, results of operations, and prospects.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In addition, switching or adding additional CROs involves additional cost and requires management time and focus. There is also a natural transition period when a new CRO commences work. As a result, delays may occur, which could materially impact our ability to meet our desired clinical development timelines. There can be no assurance that we will not encounter such challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Because we rely on third party manufacturing and supply partners, our supply of clinical trial materials may become limited or interrupted or may not be of satisfactory quantity or quality, and our dependence on these third parties may impair the advancement of our research and development programs.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We have established in-house recombinant protein generation capabilities for producing sufficient protein materials to enable a portion of our current preclinical studies. We rely on third party supply and manufacturing partners to supply the materials, components, and manufacturing services for a portion of preclinical studies and also rely on such third parties for all our clinical trial drug supplies. We do not own manufacturing facilities or supply sources for such components and materials for clinical trial supplies and our current manufacturing facilities are insufficient to supply such components and materials for all of our preclinical studies. Certain raw materials necessary for the manufacture of our therapeutic products, such as cell lines, are available from a single or limited number of source suppliers on a purchase order basis. There can be no assurance our supply of research and development, preclinical study, and clinical trial drugs and other materials will not be limited, interrupted, restricted in certain geographic regions, of satisfactory quality or quantity, or continue to be available at acceptable prices. In particular, any replacement of our therapeutic substance manufacturer could require significant effort and expertise and could result in significant delay of our preclinical or clinical activities because there may be a limited number of qualified replacements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The manufacturing process for a therapeutic candidate is subject to FDA and foreign regulatory authority review, and the facilities used by our contract manufacturers to manufacture our therapeutic candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our marketing application(s) to the FDA. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with cGMP regulations or other regulatory standards. In the event any of our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing, or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may experience shortages resulting in delayed shipments, supply constraints, and/or stock-outs of our products, be forced to manufacture the materials alone, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our therapeutic candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual and intellectual property restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist. These factors may increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our therapeutic candidates. If we are required to change manufacturers for any reason, we will be required to verify the new manufacturer maintains facilities and procedures complying with quality standards and with all applicable regulations. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop therapeutic candidates in a timely manner, within budget, or at all.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We expect to continue to rely on third party manufacturers if we receive regulatory approval for any therapeutic candidate. To the extent we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for therapeutic candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our therapeutic candidates successfully. Our, or a third party&#8217;s, failure to execute on our manufacturing requirements could adversely affect our business in a number of ways, including as a result of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an inability to initiate or continue preclinical studies or clinical trials of therapeutic candidates under development;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delay in submitting regulatory applications, or receiving regulatory approvals, for therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the loss of the cooperation of a collaborator;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">subjecting manufacturing facilities of our therapeutic candidates to additional inspections by regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requirements to cease distribution or to recall batches of our therapeutic candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the event of approval to market and commercialize a therapeutic candidate, an inability to meet commercial demands for our products.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize therapeutic candidates, impact our cash position, increase our expenses, and present significant distractions to our management.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">From time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases, and out- or in-licensing of therapeutic candidates or technologies. In particular, in addition to our current arrangements with Kite, we intend to evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or pharmaceutical companies. The competition for collaborative partners is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on suboptimal terms for us, and we may be unable to maintain any new or existing collaboration if, for example, development or approval of a therapeutic candidate is delayed, sales of an approved therapeutic product do not meet expectations, or the collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">These transactions would entail numerous operational and financial risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exposure to unknown liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired therapeutic candidates, or technologies;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">higher than expected collaboration, acquisition, or integration costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">write-downs of assets or goodwill, or incurring impairment charges or increased amortization expenses; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business or impairment of relationships with key suppliers, manufacturers, or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Accordingly, although there can be no assurance we will undertake or successfully complete any transactions of the nature described above, any transactions we do complete may be subject to the foregoing or other risks and have a material adverse effect on our business, results of operations, financial condition, and prospects. Conversely, any failure to enter any collaboration or other strategic transaction beneficial to us could delay the development and potential commercialization of our therapeutic candidates and have a negative impact on the competitiveness of any therapeutic candidate reaching market.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to us. If these companies develop technologies or therapeutic candidates more rapidly than we do, or their technologies, including delivery technologies, are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We participate in the highly competitive sector of biotechnology and pharmaceuticals and in the subsector of immune modulation. This subsector has undergone tremendous technological advancement over the last decade due to advancements in understanding the role of the immune system across multiple therapeutic areas, including oncology and autoimmune/inflammatory disease. While we believe our novel technology platform, discovery programs, knowledge, experience, and scientific resources offer competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, public and private research institutions, and others.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any products we successfully develop and commercialize will face competition from currently approved therapies and new therapies potentially available in the future.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of the companies we compete against may have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Specifically, our competitors include companies developing therapies with the same target(s) as ALPN-101 and ALPN-202 as well as companies building novel platforms to generate multi-specific antibody or non-antibody-based targeting proteins. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ICOSL/CD28 Competitors</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The competitors listed below have programs targeting either ICOS or CD28 (or one of their ligands). To our knowledge, there are currently no competitors with a single molecule targeting ICOS and CD28 simultaneously.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an anti-ICOSL/B7RP-1 monoclonal antibody being developed by Amgen, Inc. (may be referred to as prezalumab, AMG557 or MEDI5872);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an anti-BAFF, anti-ICOSL bispecific antibody being developed by Amgen, Inc. (AMG570/MEDI0700);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an anti-CD28 monoclonal antibody fragment being developed by OSE ImmunoTherapeutics SA (FR104); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an anti-CD28 peptide being developed by AtoxBio, Inc.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an IL-10 - anti-CD86 cytokine-scFv fusion protein being developed by Aptevo, Inc. (APVO210)</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPN-202 Program Competitors</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are numerous clinical trials for immuno-oncology products used as a single agent or in combination. One of the potentially novel attributes of the ALPN-202 program is it combines inhibitory receptor antagonism and activating costimulation with a single molecule interacting with multiple immune targets.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Examples of additional multi-target compounds for immuno-oncology are highlighted below. To our knowledge, there are currently no competitors with a single molecule capable of dual PD-L1/CTLA-4 antagonism and PD-L1-dependent CD28 agonism.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">wild-type CD80-Fc being developed by Five Prime Therapeutics, Inc. (FPT155);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">bifunctional fusion protein composed of monoclonal antibody against programmed death ligand 1 (&#8220;PD-L1&#8221;) fused to the extracellular domain of human transforming growth factor&#8211;&#946; (&#8220;TGF-&#946;&#8221;) receptor II being developed by EMD Serono, Inc and GSK plc (M7824);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">bifunctional fusion protein composed of PD-1 and OX40L developed by Shattuck Labs, Inc. (SL-279252);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">bispecific fusion protein targeting 4-1BB and PD-L1 being developed by Pieris Pharmaceuticals, Inc. (PRS-344);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">bispecific monoclonal antibodies being developed by Xencor, Inc. including XmAb20717 targeting CTLA-4 and PD-1, XmAb22841 targeting CTLA-4 and LAG-3, and XmAb23104 targeting PD-1 and ICOS;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">bispecific constructs called &#8220;DARTs&#8221; being developed by Macrogenics, Inc., including MGD013 targeting PD-1 and LAG-3 and MGD019 targeting PD-1 and CTLA-4;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">bispecific monoclonal antibody being developed by Tesaro, Inc., targeting PD-1 and LAG-3;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">small molecule antagonists being developed by Aurigene Ltd and Curis, Inc., including CA-170 targeting PD-L1 and VISTA and CA-327 targeting PD-L1 and TIM-3;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FS118, a bispecific monoclonal antibody targeting PD-L1 and LAG-3 being developed by F-star Biotechnology, Ltd.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">various combinations of separate anti PD-1/L1 and anti-CTLA-4 monoclonal antibodies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">various combinations of separate anti PD-1/L1 and costimulatory monoclonal antibodies such as OX-40, 4-1BB, and others.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Novel Platform Competitors</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multifunctional therapeutic protein platforms potentially competitive with our platform include:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amgen, Inc. (BiTE&#174;): fusion proteins consisting of two single-chain variable fragments to link T-cells to tumors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Macrogenics, Inc. (DART&#174;): Dual-Affinity Re-Targeting and Trident technology platforms bind multiple targets with a single molecule;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Xencor, Inc. (XmAb Bispecific): Optimized Fc domains for improved potency, half-life and stability;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zymeworks, Inc. (Azymetric&#8482;): Proprietary amino acid modifications to facilitate interaction of distinct heavy chains;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pieris Pharmaceuticals, Inc. (Anticalin&#174;): Engineered proteins derived from natural lipocalins found in blood plasma;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compass Therapeutics, LLC (Targeted Immunomodulation&#8482;, StitchMabs&#8482;)): Antibody discovery targeting the tumor-immune synapse;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Harpoon Therapeutics, Inc.: TriTAC&#8482; (Tri-specific T cell Activating Construct) contain CD3 binding domain, half-life extension domain, and antigen-binding domain;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shattuck Labs, Inc.: Agonist Redirected Antibody platform claimed to bind tumor-necrosis factor (&#8220;TNF&#8221;) and checkpoint targets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ablynx NV (Nanobody&#174;), purchased by Sanofi Pharma, Inc.: Platform technology of single-domain, heavy-chain antibody fragments derived from camelidae (e.g., camels and llamas);</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regeneron, Inc.: VEGF Trap and VelociSuite&#174; antibody technology platforms; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Five Prime Therapeutics, Inc.: Proprietary protein library and rapid protein production and testing platform.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Additionally, there are a number of other therapies for autoimmune/inflammatory diseases or cancer approved or in development that are also competitive with our lead program and other programs in development. Many of the other therapies include other types of immunotherapies with different targets than our programs. Other potentially competitive therapies work in ways distinct from our development programs.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales, and supply resources or experience than we have. If we successfully obtain approval for any therapeutic candidate, we will face competition based on many different factors, including safety and effectiveness, ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, timing and scope of regulatory approvals, availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage, and patent position of our products. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive, or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our therapeutic candidates. Competitors could also recruit our employees, which could negatively impact our ability to execute our business plan.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our success largely depends on the continued service of key management and other specialized personnel, including Mitchell H. Gold, M.D., our Executive Chairman and Chief Executive Officer, Mark J. Litton, Ph.D., our President and Chief Operating Officer, Stanford Peng, M.D., Ph.D., our Executive Vice President of Research and Development and Chief Medical Officer, and Paul Rickey, our Senior Vice President and Chief Financial Officer.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and materially harm our business, financial condition, results of operations, and prospects. The relationships our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our therapeutic candidates and technologies, and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical, and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation, and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities, and other organizations, including significant competition in the Seattle employment market.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">As our therapeutic candidates advance into clinical trials, we may experience difficulties in managing our growth and expanding our operations.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We have limited experience in therapeutic development and very limited experience with clinical trials of therapeutic candidates. As our therapeutic candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development, regulatory, and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers, and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial, and management controls, reporting systems, and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">If any of our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we may be unable to successfully commercialize any such future products.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We currently have no sales, marketing, or distribution capabilities or experience. If any of our therapeutic candidates are approved, we will need to develop internal sales, marketing, and distribution capabilities to commercialize such products, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">which may be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market our products directly, we will need to commit significant financial, legal, and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration, and compliance capabilities. If we rely on third parties with such capabilities to market our approved products, or decide to co-promote products with collaborators, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance we will be able to enter into such arrangements on acceptable, compliant terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and there can be no assurance such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved therapeutic. If we are not successful in commercializing any therapeutic approved in the future, either on our own or through third parties, our business, financial condition, results of operations, and prospects could be materially and adversely affected.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our company, our therapeutic candidates, our suppliers, and our contract manufacturers, distributors, and contract testing laboratories are subject to extensive regulation by governmental authorities in the European Union, the United States, and other countries, with regulations differing from country to country.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Even if we receive marketing and commercialization approval of a therapeutic candidate, we and our third-party service providers will be subject to continuing regulatory requirements, including a broad array of regulations related to establishment registration and product listing, manufacturing processes, risk management measures, quality and pharmacovigilance systems, post-approval clinical studies, labeling and packaging, advertising and promotional activities, record keeping, distribution, adverse event reporting, import and export of pharmaceutical products, pricing, sales, and marketing, and fraud and abuse requirements. </font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We are required to submit safety and other post market information and reports, and are subject to continuing regulatory review, including in relation to adverse patient experiences with the product and clinical results reported after a product is made commercially available, both in the United States and in any foreign jurisdiction in which we seek regulatory approval. The FDA and certain foreign regulatory authorities, such as the EMA, have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The FDA also has the authority to require a Risk Evaluation and Mitigation Strategies, or REMS, plan either before or after approval, which may impose further requirements or restrictions on the distribution or use of an approved therapeutic. The EMA now routinely requires risk management plans, or RMPs, as part of the marketing authorization application process, and such plans must be continually modified and updated throughout the lifetime of the product as new information becomes available. In addition, the relevant governmental authority of any EU member state can request an RMP whenever there is a concern about the risk/ benefit balance of the product.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The manufacturers and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturers or facilities, including withdrawal of the product from the market. If we rely on third-party manufacturers, we will have limited control over compliance with applicable rules and regulations by such manufacturers.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">If we or our collaborators, manufacturers, or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, we may be subject to, among other things, fines, warning and untitled letters, clinical holds, a requirement to conduct additional clinical trials, delay or refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension, refusal to renew or withdrawal of regulatory approval, product recalls, seizures, or administrative detention of products, refusal to permit the import or export of products, operating restrictions, inability to participate in government programs including Medicare and Medicaid, and total or partial suspension of production or distribution, injunction, restitution, disgorgement, debarment, civil penalties, and criminal prosecution.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Imposed price controls may adversely affect our future profitability.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In most countries, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic, and regulatory developments may further complicate pricing and reimbursement negotiations, and pricing negotiations may continue after reimbursement has been obtained.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or our collaborators may be required to conduct a clinical trial or other studies comparing the cost-effectiveness of our therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations, or prospects could be adversely affected.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our business entails a significant risk of product liability and our inability to obtain sufficient insurance coverage could harm our business, financial condition, results of operations, or prospects.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing, and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an investigation by certain regulatory authorities, such as FDA or foreign regulatory authorities, of the safety and effectiveness of our products, our manufacturing processes and facilities, or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used, or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients, and a decline in our valuation. We currently have product liability insurance we believe is appropriate for our stage of development and may need to obtain higher levels of product liability insurance prior to marketing any therapeutic candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims with a potentially material adverse effect on our business.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include, but is not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intentional failures to comply with FDA or U.S. health care laws and regulations, or applicable laws, regulations, guidance, or codes of conduct set by foreign governmental authorities or self-regulatory industry organizations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a provision of inaccurate information to any governmental authorities such as FDA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">noncompliance with manufacturing standards we may establish;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">noncompliance with federal and state healthcare fraud and abuse laws and regulations; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a failure to report financial information or data accurately or a failure to disclose unauthorized activities to us.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws, regulations, guidance and codes of conduct intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws, regulations, guidance statements, and codes of conduct may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive program, health care professional, and other business arrangements.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions, including debarment or disqualification of those employees from participation in FDA regulated activities and serious harm to our reputation. This could include violations of provisions of the U.S. federal Health Insurance Portability and Accountability Act, or HIPAA, as amended by the Health Information Technology for </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Economic and Clinical Health Act, or HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending such actions or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines, exclusion from government programs, or other sanctions.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which may be expensive and restrict how we conduct business.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our third-party manufacturers&#8217; activities and our own activities involve the controlled storage, use and disposal of hazardous and flammable materials, including the components of our pharmaceutical product candidates, test samples and reagents, biological materials and other hazardous compounds. We and our manufacturers are subject to federal, state, local, and foreign laws and regulations governing the use, generation, manufacture, storage, handling, and disposal of these hazardous materials. Although we believe our safety procedures for handling and disposing of these materials and waste products comply with the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental injury or contamination from the use, storage, handling, or disposal of hazardous materials. In the event of an accident, state, or federal or other applicable authorities may curtail our use of these materials and/or interrupt our business operations. In addition, if an accident or environmental discharge occurs, or if we discover contamination caused by prior operations, including by prior owners and operators of properties we acquire, we could be liable for cleanup obligations, damages, and fines. If such unexpected costs are substantial, this could significantly harm our financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our technology.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The Animal Welfare Act, or AWA, is the federal law covering the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations governing the humane handling, care, treatment, and transportation of certain animals by producers and users of research animals, most notably relating to personnel, facilities, sanitation, cage size and feeding, watering, and shipping conditions. Third parties with whom we contract are subject to registration, inspections, and reporting requirements under the AWA. Furthermore, some states have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our information technology systems could face serious disruptions adversely affecting our business.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines, and connection to the Internet, face the risk of systemic failure potentially disruptive to our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions in our collaborations with our partners and delays in our research and development work.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our current operations are concentrated in one location and any events affecting this location may have material adverse consequences.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our current operations are located in facilities situated in Seattle. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, power outage, telecommunication failure, or other natural or manmade accidents or incidents resulting in our company being unable to fully utilize the facilities, may have a material adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates, or interruption of our business operations. As part of our risk management policy, we maintain insurance coverage at levels we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you the amounts of insurance will be sufficient to satisfy any damages and losses or that the insurance covers all risks. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">business interruption may have a material adverse effect on our business, financial position, results of operations, and prospects.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">The investment of our cash, cash equivalents, and fixed income in marketable securities is subject to risks which may cause losses and affect the liquidity of these investments.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">As of </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">, we had </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">$52.3 million</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;in cash and cash equivalents, and short-term investments. We expect to invest our excess cash in marketable securities. These investments are subject to general credit, liquidity, market and interest rate risks, including potential future impacts similar to the impact of U.S. sub-prime mortgage defaults previously affecting various sectors of the financial markets and which caused credit and liquidity issues. We may realize losses in the fair value of these investments, an inability to access cash in these investments for a potentially meaningful period, or a complete loss of these investments, which would have a negative effect on our financial statements.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Changes in accounting rules and regulations, or interpretations thereof, could result in unfavorable accounting charges or require us to change our compensation policies.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Accounting methods and policies for biopharmaceutical companies, including policies governing revenue recognition, research and development and related expenses, and accounting for stock-based compensation, are subject to review, interpretation, and guidance from our auditors and relevant accounting authorities, including the SEC. Changes to accounting methods or policies, or interpretations thereof, may require us to reclassify, restate, or otherwise change or revise our financial statements.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our net operating loss carryforwards and certain other tax attributes are likely subject to limitations. </font></div><div style="line-height:120%;padding-top:8px;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In </font><font style="font-family:inherit;font-size:10pt;">general,</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">a corporation</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">that</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">undergoes</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">an &#8220;ownership</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">change&#8221;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">is</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">subject</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">to limitations</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">on its</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">ability</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">to utilize</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">its</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">pre-change</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">net</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">operating</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">loss carryforwards, or NOLs, to offset</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">future</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">taxable</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">income.</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">In general,</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">an ownership</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">change</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">occurs</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">if</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">the</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">aggregate</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">stock</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">ownership</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">of certain</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">stockholders,</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">generally</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">stockholders beneficially</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">owning five</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">percent</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">or more</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">of a corporation&#8217;s</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">common</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">stock,</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">applying</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">certain</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">look-through</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">and aggregation</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">rules,</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">increases</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">by more</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">than</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">50 percentage</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">points</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">over</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">such stockholders&#8217;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">lowest</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">percentage ownership</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">during</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">the</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">testing</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">period,</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">generally</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">years.</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Nivalis</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">may</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">have experienced</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">ownership</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">changes</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">in the</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">past</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">and may</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">experience</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">ownership</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">changes</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">in the</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">future. In addition,</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">the</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">closing</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">of the</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">merger</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;of Nivalis and Alpine in 2017 </font><font style="font-family:inherit;font-size:10pt;">likely</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">resulted</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">in an ownership</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">change</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">for</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Nivalis. It is likely that, due to the method by which limitations on the utilization of NOL carryforwards are calculated, we</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">will</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">not be able</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">to utilize any of Nivalis&#8217; net</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">operating</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">loss</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">carryforwards</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">and certain other</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">tax</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">attributes.</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">It</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">is</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">also</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">possible</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">that</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Alpine&#8217;s</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">net</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">operating</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">loss</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">carryforwards</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">and certain</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">other tax</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">attributes</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">may</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">be subject</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">to limitation</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">as a result</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">of ownership</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">changes</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">in the</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">past</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">and/or</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">the</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">closing</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">of the</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">merger.</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Consequently,</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">even if</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">we</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">achieve</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">profitability,</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">we</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">may</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">not be able</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">to utilize</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">a material</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">portion of</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Alpine&#8217;s,</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">or any of Nivalis&#8217;,</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">net</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">operating</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">loss</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">carryforwards</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">and certain other</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">tax</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">attributes,</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">which could</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">have a material</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">adverse</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">effect</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">on cash</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">flow and results</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;</font><font style="font-family:inherit;font-size:10pt;">of operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Provisions of our debt instruments may restrict our ability to pursue our business strategies.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our term loan agreement requires us, and any debt financing we may obtain in the future may require us, to comply with </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">various</font><font style="font-family:inherit;font-size:10pt;">&#32;covenants that limit our ability to, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">dispose of assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">complete mergers or acquisitions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incur indebtedness;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">encumber assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pay dividends or make other distributions to holders of our capital stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">make specified investments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">engage in any new line or business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">engagement in certain </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">transactions</font><font style="font-family:inherit;font-size:10pt;">&#32;with our affiliates.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">These restrictions could inhibit our ability to pursue our business strategies.&#160;&#160;If we default under our term loan agreement, and such event of default is not cured or waived, the lenders could terminate commitments to lend and cause all amounts outstanding with respect to the debt to be due and payable immediately, which in turn could result in cross defaults under other debt instruments. Our assets and cash flow may not be sufficient to fully repay borrowings under our outstanding </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">debt instruments if some or all of these instruments are accelerated upon a default. We may incur additional indebtedness in the future. The debt instruments governing such indebtedness could contain provisions that are as, or more, restrictive than our existing debt instruments. If we are unable to repay, refinance or restructure our indebtedness when payment is due, the lenders could proceed against the collateral granted to them to secure such indebtedness or force us into bankruptcy or liquidation.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our business may be affected by litigation and government investigations.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We may from time to time receive inquiries and subpoenas and other types of information requests from government authorities and others and we may become subject to claims and other actions related to our business activities. While the ultimate outcome of investigations, inquiries, information requests, and legal proceedings is difficult to predict, defense of litigation claims can be expensive, time-consuming and distracting, and adverse resolutions or settlements of those matters may result in, among other things, modification of our business practices, costs, and significant payments, any of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We believe our development programs and platform have a particular mechanism of action, but this mechanism of action has not been proven conclusively.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our scientific platform is novel, and the underlying science is not exhaustively understood nor conclusively proven. In particular, the interaction of vIgDs with the immune synapse, the ability of vIgDs to slow, stop, restart, or accelerate immune responses, and the ability of vIgD domains to interact with multiple counterstructures is still largely theoretical. Graphical representations of proposed mechanisms of action of our therapies, the size, actual or relative, of our therapeutics, and how our therapeutics might interface with other cells within the human body, inside the immune synapse, or inside the disease and/or the tumor microenvironment are similarly theoretical and not yet conclusively proven. The lack of a proven mechanism of action may adversely affect our ability to raise sufficient capital, complete preclinical studies, adequately manufacture drug product, obtain regulatory clearance for clinical trials, gain marketing approval, or conclude collaborations, or interfere with our ability to market our product to patients and physicians or achieve reimbursement from payors.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Any inability to present our data in scientific journals or at scientific conferences could adversely impact our business and stock price.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We may from time to time submit data related to our research and development activities in peer-reviewed scientific publications or apply to present data related to our research and development activities at scientific or other conferences. We have no control over whether these submissions or applications are accepted. Even if accepted for a conference, we have no control over whether presentations at scientific conferences will be accepted for oral presentation, poster presentation, or abstract publication only. Even when accepted for publication, we have no control over the timing of the release of the publication. Rejection by publications, delays in publication, rejection for presentation, or a less-preferred format for a presentation may adversely impact our stock price, ability to raise capital, and business.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our business may be affected by adverse scientific publications or editorial or discussant opinions.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We may from time to time publish data related to our research and development activities in peer-reviewed scientific publications or present data related to our research and development activities at scientific or other conferences. Editorials or discussants unrelated to us may provide opinions on our presented data unfavorable to us. In addition, scientific publications or presentations may be made which are critical of our science or research or the field of immunotherapy in general. This may adversely affect our ability to raise necessary capital, complete clinical and preclinical studies, adequately manufacture drug product, obtain regulatory clearance for clinical trials, or approval for marketing, or interfere with our ability to market our product to patients and physicians or achieve reimbursement from payors.</font></div><div><a name="s250E31CBBEFC2561A9C831F4C8038480"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">If we are not able to obtain and enforce patent protection for our technology, including therapeutic candidates, therapeutic products, and platform technology, development of our therapeutic candidates and platform, and commercialization of our therapeutic products may be materially and adversely affected.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our technology, including platform and therapeutic candidates and products, methods used to manufacture our therapeutic candidates and products, and methods for treating patients using our therapeutic candidates and products, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights, and to operate without infringing upon the proprietary rights of others. As </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">of </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">, our patent portfolio consists of over </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;pending patent applications. We may not be able to apply for patents on certain aspects of our technology, including therapeutic candidates and products, in a timely fashion or at all. Any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing therapeutics and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, any of our issued or granted patents will not later be found to be invalid or unenforceable, or any issued or granted patents will include claims sufficiently broad to cover our technology, including therapeutic candidates and products, or to provide meaningful protection from our competitors. Moreover, the patent position of pharmaceutical and biotechnology companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent our current and future technology, including therapeutic candidates and products, are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely impact our competitive position in the market.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and pharmaceutical patents. As such, we do not know the degree of future protection we will have on our technology, including therapeutic candidates and products. While we will endeavor to try to protect our technology, including therapeutic candidates and products, with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive, and sometimes unpredictable, and we can provide no assurances our technology, including therapeutic candidates and products, will be adequately protected in the future against unauthorized uses or competing claims by third parties.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In addition, recent and future changes to the patent laws and to the rules of the USPTO or other foreign patent offices may have a significant impact on our ability to protect our technology, including therapeutic candidates and products, and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act enacted in 2011 involves significant changes in patent legislation. In addition, we cannot assure that court rulings or interpretations of any court decision will not adversely impact our patents or patent applications. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, there also may be uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the USPTO, or made in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification, or derivation action in court or before patent offices or similar proceedings before or after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the pending, allowed or granted claims thus attacked or may lose the allowed or granted claims altogether. Our patent risks include that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">others may, or may be able to, make, use, offer to sell, or sell compounds that are the same as or similar to our therapeutic candidates and products but that are not covered by the claims of the patents we own or license;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or our licensors, collaborators, or any future collaborators may not be the first to file patent applications covering certain aspects of our technology, including therapeutic candidates and products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">others may independently develop similar or alternative technology or duplicate any of our technology without infringing our intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a third party may challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable, or that a third party is infringing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a third party may challenge our patents in various patent offices and, if challenged, we may be compelled to limit the scope of our pending allowed or granted claims or lose the allowed or granted claims altogether;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any issued patents we own or have licensed may not provide us with any competitive advantages, or may be challenged by third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not develop additional proprietary technologies that are patentable;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the patents of others could harm our business; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our competitors could conduct research and development activities in countries where we do not or will not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in major commercial markets where we do not or will not have enforceable patent rights.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We may license patent rights from third-party owners or licensees. If such owners or licensees do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be materially and adversely affected.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We may rely upon intellectual property rights licensed from third parties to protect our technology, including platform technology and therapeutic candidates and products. To date, we have in-licensed some intellectual property on a non-exclusive basis relating to commercially-available cell lines involved in the manufacture of our vIgD programs; however, we may also license additional third-party intellectual property in the future, to protect our technology, including intellectual property relating to our platform technology and therapeutic candidates and products. Our success will depend in part on the ability of our licensors to obtain, maintain, and enforce patent protection for our licensed intellectual property, in particular those patents to which we have secured exclusive rights. Our licensors may elect not to prosecute, or may be unsuccessful in prosecuting, any patent applications licensed to us. Even if patents issue or are granted, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies infringing these patents, or may pursue litigation less aggressively than we would. Further, any licenses we enter into may be non-exclusive and we may not be able to obtain exclusive rights, which would potentially allow third parties to develop competing products or technology. Without protection for, or exclusive right to, any intellectual property we may license, other companies might be able to offer substantially identical or similar product for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we may sublicense any rights we have under third-party licenses to current or future collaborators or any future strategic partners. Any impairment of these sublicensed rights could result in reduced revenue under or result in termination of an agreement by one or more of our collaborators or any future strategic partners.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We may be unable to protect our patent intellectual property rights throughout the world.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Obtaining a valid and enforceable issued or granted patent covering our technology, including therapeutic candidates and products, in the United States and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors may use our technology, including therapeutic candidates and products, to develop their own products, and further, may commercialize such products in those jurisdictions and export otherwise infringing products to territories where we have not obtained patent protection. In certain instances, a competitor may be able to export otherwise infringing products in territories where we will obtain patent protection. In jurisdictions outside the United States where we will obtain patent protection, it may be more difficult to enforce a patent as compared to the United States. Competitor products may compete with our future products in jurisdictions where we do not or will not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly relating to biopharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or marketing of competing products in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We generally file a provisional patent application first (a priority filing) at the United States Patent and Trademark Office, or USPTO. An international application under the Patent Cooperation Treaty, or PCT, is usually filed within twelve months after the priority filing, at times with a United States filing. Based on the PCT filing, national and regional patent applications may be filed in various international jurisdictions, such as in Europe, Japan, Australia, Canada, and the United States. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before they are granted. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that, depending on the country, various scopes of patent protection may be granted on the same therapeutic candidate, product, or technology. The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We or our licensors, collaborators, or any future strategic partners may become subject to third party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development of our therapeutic candidates and commercialization of our therapeutic products, or put our patents and other proprietary rights at risk.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We or our licensors, licensees, collaborators, or any future strategic partners may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. We are generally obligated under our license or collaboration agreements to indemnify and hold harmless our licensors, licensees, or collaborators for damages arising from intellectual property infringement by us. If we or our licensors, licensees, collaborators, or any future strategic partners are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our licensors, licensees, collaborators, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to or from us. If we fail to obtain a required license, we or our licensee or collaborator, or any future licensee or collaborator, may be unable to effectively market therapeutic products based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Although we do not believe our technology infringes the intellectual property rights of others, we are aware of one or more patents or patent applications that may relate to our technology, and third parties may assert against our claims alleging infringement of their intellectual property rights regardless of whether their claims have merit. Infringement claims could harm our reputation, may result in the expenditure of significant resources to defend and resolve such claims, and could require us to pay monetary damages if we are found to have infringed the intellectual property rights of others.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">If we were to initiate legal proceedings against a third party to enforce a patent covering our technology, including therapeutic candidates and products, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, patent ineligibility, lack of novelty, lack of written description, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology, including therapeutic candidates and products. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology, including therapeutic candidates and products, if competitors design around our protected technology, including therapeutic candidates and products, without legally infringing our patents or other intellectual property rights.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">It is also possible we have failed to identify relevant third-party patents or applications. For example, patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our technology, including therapeutic candidates and products, could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our technology, including therapeutic candidates and products. Third party intellectual property rights holders may also actively bring infringement claims against us. We cannot guarantee we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable, and time-consuming litigation and may be prevented from, or experience substantial delays in, marketing our technology, including therapeutic candidates and products. If </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing our technology, including a therapeutic product, held to be infringing. We might, if possible, also be forced to redesign therapeutic candidates or products so we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources we would otherwise be able to devote to our business.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">If we fail to comply with our obligations under any license, collaboration, or other agreements, we may be required to pay damages and could lose intellectual property rights necessary for developing and protecting our technology, including our platform technology, therapeutic candidates, and therapeutic products, or we could lose certain rights to grant sublicenses, either of which could have a material adverse effect on our results of operations and business prospects. </font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture, and sell or offer to sell products covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on future sales of licensed products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in therapeutic products we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize therapeutic products, we may be unable to achieve or maintain profitability.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In addition to seeking patent protection for certain aspects of our technology, including platform technology and therapeutic candidates and products, we also consider trade secrets, including confidential and unpatented know-how, important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants obligating them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. We also cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We are also subject both in the United States and outside the United States to various regulatory schemes regarding requests for the information we provide to regulatory authorities, which may include, in whole or in part, trade secrets or confidential commercial information. While we are likely to be notified in advance of any disclosure of such information and would likely object to such disclosure, there can be no assurance our challenge to the request would be successful.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We may be in the future subject to claims we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages, may be prohibited from using some of our research and development and may lose valuable intellectual property rights or personnel.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Many of our employees were previously employed at universities or biotechnology or pharmaceutical companies, including our current and potential competitors. We may receive correspondence from other companies alleging the improper use or disclosure, and have received, and may in the future receive, correspondence from other companies regarding the use or disclosure, by certain of our employees who have previously been employed elsewhere in our industry, including with our competitors, of their former employer&#8217;s trade secrets or other proprietary information. Responding to these allegations can be costly and disruptive to our business, even when the allegations are without merit, and can be a distraction to management. We may be subject to claims in the future that our employees have, or we have, inadvertently or otherwise used or disclosed trade </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending current or future claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, personnel, or the ability to use some of our research and development. A loss of intellectual property, key research personnel, or their work product could hamper our ability to commercialize, or prevent us from commercializing, our therapeutic candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be materially and adversely affected.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. Any trademark litigation could be expensive. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business may be materially and adversely affected.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Third parties may independently develop similar or superior technology.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">There can be no assurance others will not independently develop, or have not already developed, similar or more advanced technologies than our technology or that others will not design around, or have not already designed around, aspects of our technology or our trade secrets developed therefrom. If third parties develop technology similar or superior to our technology, or they successfully design around our current or future technology, our competitive position, business prospects, and results of operations could be materially and adversely affected.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Breaches of our internal computer systems, or those of our contractors, vendors, or consultants, may place our patents or proprietary rights at risk.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The loss of clinical or preclinical data or data from any future clinical trial involving our technology, including therapeutic candidates and products, could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, theft or other exposure of data may interfere with our ability to protect our intellectual property, including trade secrets, and other information critical to our operations. We have experienced in the past, and may experience in the future, unauthorized intrusions into our internal computer systems, including portions of our internal computer systems storing information related to our platform technology, therapeutic candidates and products, and we can provide no assurances that certain sensitive and proprietary information relating to one or more of our therapeutic candidates or products has not been, or will not in the future be, compromised. Although we have invested significant resources to enhance the security of our computer systems, there can be no assurances we will not experience additional unauthorized intrusions into our computer systems, or those of our CROs, vendors, contractors, and consultants, that we will successfully detect future unauthorized intrusions in a timely manner, or that future unauthorized intrusions will not result in material adverse effects on our financial condition, reputation, or business prospects. Payments related to the elimination of ransomware may materially affect our financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Certain data breaches must also be reported to affected individuals and the government, and in some cases to the media, under provisions of HIPAA, as amended by HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive, and financial penalties may also apply.</font></div><div><a name="s6B406E12EF951411235D31F4C835FD7D"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-weight:bold;">Risks Related to Government Regulation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize our therapeutic candidates.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our therapeutic candidates are subject to extensive governmental regulations relating to, among other things, research, development, testing, manufacture, quality control, approval, labeling, packaging, promotion, storage, record-keeping, advertising, distribution, sampling, pricing, sales and marketing, safety, post-approval monitoring and reporting, and export and import of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be completed successfully in the United States and in many foreign jurisdictions before a new therapeutic can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain, and subject to unanticipated delays. We have not obtained regulatory approval for any therapeutic candidates, and it is possible none of the therapeutic candidates we may develop will obtain the regulatory approvals necessary for us or our collaborators to begin selling them.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA as well as foreign regulatory authorities, such as the EMA. The time required to obtain FDA and foreign regulatory approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity, and novelty of the therapeutic candidate, and at the substantial discretion of the regulatory authorities. The standards the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, who could delay, limit, or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, future legislation or administrative action, or from changes in the policy of FDA or foreign regulatory authorities during the period of product development, clinical trials, and regulatory review by the FDA or foreign regulatory authorities. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign, regulations, guidance, or interpretations will be changed, or what the impact of such changes, if any, may be.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Because the therapeutic candidates we are developing may represent a new class of therapeutics, we are not aware of any definitive policies, practices, or guidelines that the FDA or its foreign counterparts have yet established in relation to these drugs. While we believe the therapeutic candidates we are currently developing are regulated as new biological products under the Public Health Service Act, or PHSA, the FDA could decide to regulate them or other products we may develop as drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA. The lack of policies, practices, or guidelines may hinder or slow review by the FDA or foreign regulatory authorities of any regulatory filings we may submit. Moreover, the FDA or foreign regulatory authorities may respond to these submissions by defining requirements we may not have anticipated. Such responses could lead to significant delays in the clinical development of our therapeutic candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our therapeutic candidates could fail to receive regulatory approval for many reasons, including the following: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a therapeutic candidate is safe and effective for its proposed indication; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be unable to demonstrate that a therapeutic candidate&#8217;s clinical and other benefits outweigh its safety risks; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from pre-clinical studies or clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the data collected from clinical trials of our therapeutic candidates may not be sufficient to support the submission of a Biologics License Application, or BLA, or other submission or to obtain regulatory approval in the United States, the European Union or elsewhere;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular therapeutic candidate for which we are seeking approval. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process, and in determining when or whether regulatory approval will be obtained for any of our therapeutic candidates. Even if we believe the data collected from preclinical and clinical trials of our therapeutic candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved uses for which we may market the product or in the product labeling or be subject to other restrictions. Regulatory authorities also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic. In addition, the FDA has the authority to require a REMS plan as part of the approval of a BLA or New Drug Application, or NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria, and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the therapeutic and affect coverage and reimbursement by third-party payors.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing, marketing authorization, pricing, and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and vice versa.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">If we fail to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for certain of our products, our competitors may sell products to treat the same conditions and our revenue may be reduced.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a therapeutic product with orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the therapeutic product is entitled to orphan product exclusivity, which means the FDA may not approve any other applications to market the same therapeutic product for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">As in the United States, we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. In the European Union, the EMA&#8217;s Committee for Orphan Medicinal Products, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. Sponsors of orphan drugs in the European Union can enjoy economic and marketing benefits, including reduction of fees or fee waivers and up to ten years of market exclusivity for the approved indication unless another applicant can show its therapeutic product is safer, more effective, or otherwise clinically superior to the orphan-designated therapeutic product. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We plan to seek orphan drug designation from the FDA and the EMA for certain of our product candidates. However, we may never receive such designation. Even if we are able to obtain orphan designation, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, regulatory authorities may subsequently approve the same drug with the same active moiety for the same condition if they conclude that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a product candidate nor gives the product candidate any advantage in the regulatory review or approval process. In addition, orphan drug exclusivity could block the approval of one of our therapeutic candidates, if a competitor obtains approval of the same therapeutic product as defined by the FDA before we do, or if our therapeutic candidate is determined to be within the same class as the competitor&#8217;s therapeutic product for the same indication or disease.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The respective orphan designation and exclusivity frameworks in the United States and in the European Union are subject to change, and any such changes may affect our ability to obtain EU or U.S. orphan designations in the future.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">If we or our existing or future collaborators, manufacturers, or service providers fail to comply with healthcare laws and regulations, we or such other parties could be subject to enforcement actions, which could adversely affect our ability to develop, market, and sell our therapeutics and may harm our reputation.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Although we do not currently have any products on the market, once we begin commercializing our therapeutic candidates, if approved, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal, state, and foreign governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians, and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud, abuse, and other healthcare laws and regulations constraining the business or financial arrangements and relationships through which we market, sell, and distribute the therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering, or providing remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the U.S. federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, false or fraudulent claims for payment or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government. In addition, the government may assert a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state all-payor fraud laws, which impose criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HIPAA, HITECH, and their implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates performing certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Physician Payment Sunshine Act and its implementing regulations, also referred to as &#8220;Open Payments,&#8221; issued under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or ACA, and any subsequent amending legislation or executive actions, which require manufacturers of pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, and Children&#8217;s Health Insurance Programs to report to the Department of Health and Human Services all consulting fees, travel reimbursements, research grants, and other payments, transfers of value or gifts made to physicians and teaching hospitals with limited exceptions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">analogous state laws and regulations, such as, state anti-kickback and false claims laws potentially applicable to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Ensuring our future business arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement, or other government programs, including Medicare and Medicaid, any of which could adversely affect our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause our company to incur significant legal expenses and could </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time, and resources.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">If we or our current or future collaborators, manufacturers, or service providers fail to comply with applicable federal, state, or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market, and sell our therapeutics successfully and could harm our reputation and lead to reduced acceptance of our therapeutics by the market. These enforcement actions include, among others:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse regulatory inspection findings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warning or untitled letters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">voluntary product recalls with public notification or medical product safety alerts to healthcare professionals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on, or prohibitions against, marketing our therapeutics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on, or prohibitions against, importation or exportation of our therapeutics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspension of review or refusal to approve pending applications or supplements to approved applications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exclusion from participation in government-funded healthcare programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exclusion from eligibility for the award of government contracts for our therapeutics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA debarment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspension or withdrawal of therapeutic approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">seizures or administrative detention of therapeutics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injunctions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restitution, disgorgement of profits, or civil and criminal penalties and fines.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of our therapeutic candidates.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The policies of the FDA or similar regulatory authorities may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and biologics and spur innovation, but it is still being implemented and its ultimate implementation is unclear. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, our therapeutic candidates may not obtain or maintain regulatory approval, and we may not achieve or sustain profitability, which would adversely affect our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry.&#160; Namely, the Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications.&#160;It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority.&#160; If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Any therapeutics we develop may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives, thereby harming our business.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The regulations governing marketing approvals, pricing, coverage, and reimbursement for new drugs and biologics vary widely from country to country. Many countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently in the early stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result, we might obtain regulatory approval </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">for a product in a particular country but then be subject to price regulations delaying our commercial launch of the product and negatively impacting the revenues we are able to generate from the sale of the product in that country.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our ability to commercialize any therapeutics successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. However, there may be significant delays in obtaining coverage for newly-approved therapeutics. Moreover, eligibility for coverage does not necessarily signify a therapeutic will be reimbursed in all cases or at a rate covering our costs, including research, development, manufacture, sale, and distribution costs. Also, interim payments for new therapeutics, if applicable, may be insufficient to cover our costs and may not be made permanent. Thus, even if we succeed in bringing one or more therapeutics to the market, these products may not be considered cost-effective, and the amount reimbursed for any of them may be insufficient to allow us to sell them on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness, coverage prospects, potential compendia listings, or the likely level or method of reimbursement, if covered. It is equally difficult for us to predict how Medicare coverage and reimbursement policies will be applied to our products in the future, and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement rates. These coverage policies and limitations may rely, in part, on compendia listings for approved therapeutics. Our inability to promptly obtain relevant compendia listings, coverage, and adequate reimbursement from both government-funded and private payors for new therapeutics we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our financial condition.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We believe the efforts of governments and third-party payors to contain or reduce the cost of healthcare, and legislative and regulatory proposals to broaden the availability of healthcare, will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical companies. A number of legislative and regulatory changes in the healthcare system in the United States and other major healthcare markets have been proposed, and such efforts have expanded substantially in recent years. These developments could, directly or indirectly, affect our ability to sell our products, if approved, at a favorable price. In addition, third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking greater upfront discounts, additional rebates, and other concessions to reduce the prices for therapeutics. If the price we are able to charge for any therapeutics we develop, or the reimbursement provided for such products, is inadequate, our return on investment could be adversely affected.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Pursuant to health reform legislation and related initiatives, the Centers for Medicare and Medicaid Services, or CMS, are working with various healthcare providers to develop, refine, and implement Accountable Care Organizations, or ACOs, and other innovative models of care for Medicare and Medicaid beneficiaries, including the Bundled Payments for Care Improvement Initiative, the Comprehensive Primary Care Initiative, the Duals Demonstration, and other models. The continued development and expansion of ACOs and other innovative models of care will have an uncertain impact on any future reimbursement we may receive for approved therapeutics administered by such organizations.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In addition, in recent years, the U.S. Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures. For example, as a result of the Budget Control Act of 2011 and the Bipartisan Budget Act of 2015, an annual 2% reduction to Medicare payments that took effect in 2013 has been extended through 2025. These across-the-board spending cuts could adversely affect our future revenues, earnings, and cash flows.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">From time to time, legislation is drafted, introduced, and passed in Congress that could significantly change the statutory provisions governing coverage, reimbursement, and marketing of products regulated by CMS or other government agencies. In addition to new legislation, CMS coverage and reimbursement policies are often revised or interpreted in ways that may significantly affect our business and our products. In particular, we expect the Administration and Congress will seek to modify, repeal, or otherwise invalidate all, or certain provisions of, U.S. healthcare legislation. A number of additional executive orders have been issued affecting, or potentially affecting, the ACA and other aspects of the healthcare market in the United States. There is a high degree of uncertainty with respect to the impact President Trump&#8217;s Administration and Congress may have, and any changes will likely take time to unfold. Such reforms could have an adverse effect on anticipated revenues from therapeutic candidates we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop therapeutic candidates. However, we cannot predict the ultimate content, timing, or effect of any healthcare reform legislation or executive orders or the impact of potential legislation and executive orders on us.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">The healthcare industry is heavily regulated in the U.S. at the federal, state, and local levels, and our failure to comply with applicable requirements may subject us to penalties and negatively affect our financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">As a healthcare company, our operations, clinical trial activities, and interactions with healthcare providers will be subject to extensive regulation in the United States, particularly if we receive FDA approval for any of our products in the future. For example, if we receive FDA approval for a therapeutic for which reimbursement is available under a federal healthcare program, it would be subject to a variety of federal laws and regulations, including those prohibiting the filing of false or improper claims for payment by federal healthcare programs, prohibiting unlawful inducements for the referral of business reimbursable by federal healthcare programs, and requiring disclosure of certain payments or other transfers of value made to U.S.-licensed physicians and teaching hospitals. We are not able to predict how government authorities will interpret these laws. They may challenge our practices and activities under one or more of these laws. If our past or present operations are found to be in violation of any of these laws, we could be subject to civil and criminal penalties, which could hurt our business, operations, and financial condition.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Similarly, some state laws prohibit, among other offenses, knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors, or falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for items or services under a health care benefit program. We may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the privacy and security of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers with respect to such information. Additionally, many states have enacted similar laws imposing more stringent requirements on entities like us. Failure to comply with applicable laws and regulations could result in substantial penalties and adversely affect our financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our ability to obtain services, reimbursement, or funding from the federal government may be impacted by possible reductions in federal spending.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The U.S. federal budget remains in flux and could, among other things, cut Medicare payments to providers. The Medicare program is frequently mentioned as a target for spending cuts. The full impact on our business of any future cuts in Medicare or other programs is uncertain. In addition, we cannot predict any impact President Trump&#8217;s administration and Congress may have on the federal budget. If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve drug research and development, manufacturing, and marketing activities, which may delay our ability to develop, market, and sell any therapeutics we may develop.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">If any of our therapeutic candidates receives marketing approval and we or others later identify undesirable side effects caused by the therapeutic product, our ability to market and derive revenue from the therapeutic products could be compromised.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In the event any of our therapeutic candidates receive regulatory approval and we or others identify undesirable side effects, adverse events, or other problems caused by one of our therapeutics, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may withdraw their approval of the product and require us to take the product off the market or seize the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may need to recall the therapeutic or change the way the therapeutic is administered to patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional restrictions may be imposed on the marketing and promotion of the particular therapeutic or the manufacturing processes for the therapeutic or any component thereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not be able to secure or maintain adequate coverage and reimbursement for our proprietary therapeutic products from government (including U.S. federal health care programs) and private payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may lose or see adverse alterations to compendia listings or treatment protocols specified by accountable care organizations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be subject to fines, restitution, or disgorgement of profits or revenues, injunctions, or the imposition of civil penalties or criminal prosecution;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning, or equivalent, or a contraindication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require us to implement a REMS plan, or to conduct post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we could be sued and held liable for harm caused to patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the therapeutic may become less competitive; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our therapeutic candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The Patient Protection and Affordable Care Act, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We believe that any of our therapeutic candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our therapeutic candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Significant developments stemming from the United Kingdom&#8217;s recent referendum on membership in the European Union could have a material adverse effect on us.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In June 2016, the United Kingdom held a referendum and voted in favor of leaving the European Union, and in March 2017, the government of the United Kingdom formally initiated the withdrawal process. This has created political and economic uncertainty, particularly in the United Kingdom and the European Union, and this uncertainty may last for years. Any business we conduct, now and in the future, in the United Kingdom, the European Union, and worldwide could be affected during this period of uncertainty, and perhaps longer, by the impact of the United Kingdom&#8217;s referendum. There are many ways in which our business could be affected, only some of which we can identify as of the date of this filing.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The decision of the United Kingdom to withdraw from the European Union has caused and, along with events that could occur in the future as a consequence of the United Kingdom&#8217;s withdrawal, may continue to cause significant volatility in global financial markets, including in global currency and debt markets. This volatility could cause a slowdown in economic activity in the United Kingdom, Europe, or globally, which could adversely affect our operating results and growth prospects. In addition, our business could be negatively affected by new trade agreements or data transfer agreements between the United Kingdom and other countries, including the United States, and by the possible imposition of trade or other regulatory barriers in the United Kingdom.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">It is currently unknown how regulations affecting clinical trials, the approval of our future products, and the sale of these products will be affected by this referendum either in the United Kingdom or elsewhere in Europe.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">These possible negative impacts, and others resulting from the United Kingdom&#8217;s actual or threatened withdrawal from the EU, may adversely affect our operating results and growth prospects.</font></div><div><a name="s0462FD2B96718B716CA031F4C8573895"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-weight:bold;">Risks Related to Ownership of Our Common Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our stock price may be volatile, and an active, liquid, and orderly trading market may not develop for our common stock. As a result, stockholders may not be able to resell shares at or above their purchase price.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Although our common stock is listed on Nasdaq, an active trading market for our common stock may not develop or, if it develops, may not be sustained. The lack of an active market may impair the ability of our stockholders to sell their shares at the time they wish to sell them or at a price that they consider reasonable, which may reduce the fair market value of their shares. Further, an inactive market may also impair our ability to raise capital by selling our common stock should we determine additional funding is required.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The market price of our common stock could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology, and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain regulatory approvals for product candidates, and delays or failures to obtain such approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the failure of any of our product candidates, if approved, to achieve commercial success;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">issues in manufacturing our approved products, if any, or product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the results of current, and any future, preclinical or clinical trials of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the entry into, or termination of, key agreements, including key licensing, collaboration or acquisition agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the initiation or material developments in, or conclusion of, litigation to enforce or defend any of our intellectual property rights or defend against the intellectual property rights of others;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">announcements by commercial partners or competitors of new commercial products, clinical progress (or the lack thereof), significant contracts, commercial relationships, or capital commitments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse publicity relating to our markets, including with respect to other products and potential products in such markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse publicity about our company, employees, therapeutic candidates, and/or therapeutic products in the media or on social media;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the introduction of technological innovations or new therapies competing with our potential products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the loss of key employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in estimates or recommendations by securities analysts, if any, who cover our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general and industry-specific economic conditions potentially affecting our research and development expenditures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the structure of health care payment systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated serious safety concerns related to the use of any of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to meet or exceed financial and development projections we may provide to the public;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to meet or exceed the financial and development projections of the investment community;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the perception of the pharmaceutical industry by the public, legislators, regulators, and the investment community;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse regulatory decisions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">commencement of, or our involvement in, litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales of our common stock by us or our stockholders in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">trading volume of our common stock;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">period-to-period fluctuations in our financial results; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the other factors described in this &#8220;Risk Factors&#8221; section.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies or the biotechnology sector. These broad market fluctuations may also adversely affect the trading price of our common stock.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our business and reputation.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our officers and directors, and their respective affiliates, have a controlling influence over our business affairs and may make business decisions with which stockholders disagree and which may adversely affect the value of their investment.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our executive officers and directors together with their respective affiliates, beneficially own approximately </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">75%</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;of our common stock as of January 31, 2019. As a result, if some of these persons or entities act together, they will have the ability to exercise significant influence over matters submitted to the stockholders for approval, including the election of directors, amendments to the certificate of incorporation and bylaws and the approval of any strategic transaction requiring the approval of the stockholders. These actions may be taken even if they are opposed by other stockholders. This concentration of ownership may also have the effect of delaying or preventing a change of control of our company or discouraging others from making tender offers for our shares, which could prevent our stockholders from receiving a premium for their shares. Some of these persons or entities who make up our principal stockholders may have interests different from other stockholders. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Future sales, or the perception of future sales, of a substantial amount of our common stock could depress the trading price of our common stock.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our stock price could decline as a result of sales of a large number of shares of our common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">For example, in connection with our January 2019 private placement, we entered into a registration rights agreement with the private placement investors that requires us to prepare and file a registration statement on the date on which we file this Annual Report on Form 10-K. Once declared effective by the SEC, this registration statement will permit the resale by the private placement investors of approximately </font><font style="font-family:inherit;font-size:10pt;">4.7 million</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;shares of our common stock as well as approximately </font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;shares of common stock issuable upon the exercise of warrants issued in the private placement. In addition, the shares subject to outstanding options and warrants, of which options and warrants to purchase 887,134 shares and 17,153 shares, respectively, were exercisable as of </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">, and the shares reserved for future issuance under our equity incentive plans will become available for sale immediately upon the exercise of such options. </font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We also register the offer and sale of all shares of common stock that we may issue under our equity incentive plans. Once we register the offer and sale of shares for the holders of registration rights and option holders, they can be freely sold in the public market upon issuance, subject to any related lock-up agreements or applicable securities laws.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In addition, in the future, we may issue additional shares of common stock or other equity or debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such future issuance, including any issuances pursuant to our &#8220;at the market&#8221; equity offering program, could result in substantial dilution to our existing stockholders and could cause our stock price to decline.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We will have broad discretion over the use of the proceeds to us from our financing activities and may apply the proceeds to uses that do not improve our operating results or the value of your securities.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We will have broad discretion to use any net proceeds from our January 2019 private placement, as well as any net proceeds to us from our &#8220;at the market&#8221; equity offering program put in place in June 2018, and investors will be relying solely on the judgment of our board of directors and management regarding the application of these proceeds. Although we expect to use the net proceeds from our January 2019 private placement and our &#8220;at the market&#8221; equity offering program for general corporate purposes and to advance the development of our product candidates, we have not allocated these net proceeds for </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">specific purposes. Investors will not have the opportunity, as part of their investment decision, to assess whether the proceeds are being used appropriately. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">The JOBS Act allows us to postpone the date by which we must comply with certain laws and regulations intended to protect investors and to reduce the amount of information we provide in our reports filed with the SEC. We cannot be certain if this reduced disclosure will make our common stock less attractive to investors.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The JOBS Act is intended to reduce the regulatory burden on &#8220;emerging growth companies.&#8221; As defined in the JOBS Act, we qualify as an &#8220;emerging growth company&#8221; and could remain an &#8220;emerging growth company&#8221; until as late as December 31, 2020. For so long as we are an &#8220;emerging growth company,&#8221; we will, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not be required to comply with the auditor attestation requirements of Section 404(b) of Sarbanes-Oxley;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not be required to hold a nonbinding advisory stockholder vote on executive compensation pursuant to Section 14A of the Securities Exchange Act of 1934, as amended, or the Exchange Act;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not be required to seek stockholder approval of any golden parachute payments not previously approved pursuant to Section 14A of the Exchange Act;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be exempt from any rule adopted by the Public Company Accounting Oversight Board, requiring mandatory audit firm rotation or a supplemental auditor discussion and analysis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be subject to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We have previously decided to opt out of an extended transition period under the JOBS Act that permits an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Our decision is irrevocable. As a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other companies.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Furthermore, if we take advantage of some or all of the reduced disclosure requirements above, investors may find our common stock less attractive, which may result in a less active trading market for our common stock and greater stock price volatility.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of The Nasdaq Stock Market LLC. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K filing for that year, as required by Section 404 of the Sarbanes-Oxley Act.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. An internal control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the internal control system&#8217;s objectives will be met. Because of the inherent limitations in all internal control systems, no evaluation of internal controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all internal control issues and instances of fraud will be detected.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our common stock could decline and we could be subject to sanctions or investigations by The Nasdaq Stock Market LLC, the SEC, or other regulatory authorities.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our disclosure controls and procedures are designed to reasonably ensure that information required to be disclosed by us in reports we file or submits under the Exchange Act is accumulated and communicated to management and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">disclosure controls and procedures as well as internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are and will be met. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We will continue to incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We will incur significant legal, accounting, and other expenses associated with public company reporting requirements. We will also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as new rules implemented by the SEC and The Nasdaq Stock Market LLC. Although the JOBS Act may for a limited period of time somewhat lessen the cost of complying with these additional regulatory and other requirements, we nonetheless expect that these rules and regulations will increase our legal and financial compliance costs and to make some activities more time-consuming and costlier. For example, our management team consists in part of the executive officers of Alpine prior to the merger, some of whom may not have previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations. These rules and regulations may also make it difficult and expensive for us to obtain directors and officer&#8217;s liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers of our company, which may adversely affect investor confidence in us and could cause our business or stock price to suffer.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware or Washington law could discourage, delay or prevent a change in control of our company, limit attempts by our stockholders to replace or remove our current management and may affect the trading price of our common stock.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our corporate documents contain provisions that may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our stock. Among other things, our certificate of incorporation and bylaws:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">stagger the terms of our board of directors and require 66 and 2/3% stockholder voting to remove directors, who may only be removed for cause;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide that the authorized number of directors may be changed only by resolution of the board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">authorize our board of directors to issue &#8220;blank check&#8221; preferred stock and to determine the rights and preferences of those shares, which may be senior to our common stock, without prior stockholder approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish advance notice requirements for nominating directors and proposing matters to be voted on by stockholders at stockholders&#8217; meetings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">prohibit our stockholders from calling a special meeting and prohibit stockholders from acting by written consent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require 66 and 2/3% stockholder voting to effect certain amendments to our certificate of incorporation and bylaws; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three years following the date on which the stockholder became an &#8220;interested&#8221; stockholder. Likewise, because our principal executive offices are located in Washington, the anti-takeover provisions of the Washington Business Corporation Act may apply to us under certain circumstances now or in the future. These provisions prohibit a &#8220;target corporation&#8221; from engaging in any of a broad range of business combinations with any stockholder constituting an &#8220;acquiring person&#8221; for a period of five years following the date on which the stockholder became an &#8220;acquiring person.&#8221; These provisions could discourage, delay or prevent a transaction involving a change in control </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">of our company. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and cause us to take other corporate actions our stockholders desire.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of available cash.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our amended and restated certificate of incorporation provides that we will indemnify our directors to the fullest extent permitted by Delaware law.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In addition, as permitted by Section 145 of the DGCL, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may, in our discretion, indemnify other employees and agents in those circumstances where indemnification is permitted by applicable law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we will not be obligated pursuant to our amended and restated bylaws to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless the proceeding was authorized in the specific case by our board of directors or such indemnification is required to be made pursuant to our amended and restated bylaws.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to our directors or officers</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">As a result, if we are required to indemnify one or more of our directors or officers, it may reduce our available funds to satisfy successful third-party claims against us, may reduce the amount of available cash and may have a material adverse effect on our business and financial condition.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our common stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation. This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We do not expect to pay any dividends on our common stock for the foreseeable future.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">We currently expect to retain all future earnings, if any, for future operations and expansion, and have no current plans to pay any cash dividends to holders of our common stock for the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that our board of directors may deem relevant. As a result, stockholders may not receive any return on an investment in our common stock unless stockholders sell our common stock for a price greater than that which they paid for it.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our common stock or discontinue existing research coverage, and such lack of research coverage may adversely affect the market price of our common stock. We do not have any control over the analysts, or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">Nasdaq may delist our common stock from its exchange, which could limit investors&#8217; ability to make transactions in our securities and subject us to additional trading restrictions.</font></div><div style="line-height:120%;padding-top:8px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Our common shares are listed on Nasdaq under the trading symbol &#8220;ALPN.&#8221; Our securities may fail to meet the continued listing requirements to be listed on Nasdaq. If Nasdaq delists our common shares from trading on its exchange, we could face significant material adverse consequences, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significant impairment of the liquidity for our common stock, which may substantially decrease the market price of our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a limited availability of market quotations for our securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a determination that our common stock qualifies as a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere to more stringent rules and possibly resulting in a reduced level of trading activity in the secondary trading market for our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a limited amount of news and analyst coverage for our company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a decreased ability </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">to issue additional securities or obtain additional financing in the future.</font></div></td></tr></table><div><a name="s935C81A7EC6668764B7031F4C88A4FC0"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1B. Unresolved Staff Comments.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s22A5B0351F110C640D9F31F4C8ABC0E2"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Properties.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We lease a facility containing our research and development, laboratory, and office space, which consists of approximately 17,342 square feet located at 201 Elliott Avenue West, Seattle, Washington. </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">The lease expires on December 31, 2019 and has two options to extend the lease term with each option enabling us to extend the lease term by twelve months.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2019, we entered into a lease with ARE-Seattle No. 28, LLC, or the Landlord, for </font><font style="font-family:inherit;font-size:10pt;">27,164</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet of office and laboratory space located at 188 East Blaine Street, Seattle, Washington. The term of the lease is </font><font style="font-family:inherit;font-size:10pt;">10.8 years</font><font style="font-family:inherit;font-size:10pt;">&#32;with one option to extend the term by </font><font style="font-family:inherit;font-size:10pt;">5.0 years</font><font style="font-family:inherit;font-size:10pt;">. The target &#8220;Commencement Date&#8221; is May 1, 2019 and shall be the date that Landlord delivers the premises to us in substantially complete condition. The &#8220;Rent Commencement Date&#8221; shall be the date that is nine months after the Commencement Date. The annual base rent due under the lease is approximately </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first year and will increase by </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;each year thereafter. We will not be required to pay base rent from the Rent Commencement Date </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">through the last day of the ninth month following the Rent Commencement Date. We will receive a maximum tenant improvement allowance of </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;">, which is included in our base rent, and a maximum additional tenant improvement allowance of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, which will result in additional rent amortized over the term of the lease at an annual rate of </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">. The lease also requires us to pay additional amounts for operating and maintenance expenses. In connection with the lease, we provided a&#160;</font><font style="font-family:inherit;font-size:10pt;">$254,000</font><font style="font-family:inherit;font-size:10pt;">&#160;letter of credit as a security deposit. </font></div><div><a name="sBAC1F24FC4ED060955C431F4C8DCC57F"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Legal Proceedings.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not engaged in any material legal proceedings. From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. We believe that there are no claims or actions pending against us currently, the ultimate disposition of which would have a material adverse effect on our consolidated results of operation, financial condition or cash flows.</font></div><div><a name="s9602674D1A0534C9B27331F4C8FDBFDD"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Mine Safety Disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><a name="sD2DE8532CDA14DFDB2D331F4C92F70C9"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div><a name="s5CFCB697F2EA9464258331F4C9539F03"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Market Information</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From June 17, 2015 through July 24, 2017, our common stock was traded under the symbol &#8220;NVLS.&#8221; On July 24, 2017, in connection with the business combination of Nivalis Therapeutics, Inc. and Alpine Immune Sciences, Inc., we completed a 1-for-4 reverse stock split. Commencing on July 25, 2017, our common stock began trading on The NASDAQ Global Market under the symbol &#8220;ALPN.&#8221; As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;6, 2019</font><font style="font-family:inherit;font-size:10pt;">, we have approximately 29 stockholders of record for our common stock, which excludes stockholders whose shares were held in nominee or street name accounts through brokers.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings for use in the operation of our business and do not intend to declare or pay any cash dividends in the foreseeable future. Any further determination to pay dividends on our capital stock will be at the discretion of our board of directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors considers relevant.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Performance Graph</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a &#8220;smaller reporting company,&#8221; as defined by Rule 12b-2 of the Exchange Act, and pursuant to Instruction 6 to Item 201(e) of Regulation S-K we are not required to provide the stock performance graph.</font></div><div><a name="s6BBC58AE1292A6DE2FEF31F4C24A49ED"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6. Selected Financial Data.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a &#8220;smaller reporting company,&#8221; as defined by Rule 12b-2 of the Exchange Act, and pursuant to Item 301(c) of Regulation S-K we are not required to provide selected financial data.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><a name="s42D9D33AA9E110CE95F631F4C9A472AD"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our </font><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s8D1084986631244E2E7A31F4CDBC717F"><font style="font-family:inherit;font-size:10pt;font-style:italic;">consolidated financial statements and the related notes</font></a><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;appearing elsewhere in this Annual Report on Form 10-K. In addition to historical information, some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business, future financial performance, expense levels and liquidity sources, includes forward-looking statements that involve risks and uncertainties. You should read </font><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#sCF7396DCF2D2399BDC0F31F4C7C49CB6"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk Factors</font></a><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;in Part I, Item 1A of this report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a clinical-stage immunotherapy company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory disorders, and other diseases. Our proprietary scientific platform uses a process known as directed evolution to  convert native immune system proteins from the Immunoglobulin Super Family, or IgSF, into multi-targeted therapeutics potentially capable of modulating the human immune system.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal is to create modern therapies targeting the immune synapse, using our directed-evolution based scientific platform to treat patients with serious conditions such as cancer and inflammatory diseases. To achieve our goal, we intend to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">move our lead inflammation/autoimmune therapeutic ALPN-101 through clinical development for the treatment of inflammatory diseases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">move our lead oncology program ALPN-202 to clinical trials; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maximize the value of our pipeline and platform via partnering activities.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operations to date have been limited to business planning, raising capital, developing our platform technology, identifying potential immunotherapy candidates, and other research and development activities. To date, we have financed operations primarily through private placements of common stock and convertible preferred stock, funds received from a license and research agreement, debt financing and assets acquired upon the close of our merger with Nivalis Therapeutics Inc., or Nivalis. We do not have any products approved for sale and have not generated any product sales. Since inception and through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, excluding amounts borrowed through debt financing, we have raised an aggregate of $98.9 million to fund operations, of which </font><font style="font-family:inherit;font-size:10pt;">$49.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was from the sale of convertible preferred stock, </font><font style="font-family:inherit;font-size:10pt;">$5.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was through a license and research agreement, and </font><font style="font-family:inherit;font-size:10pt;">$44.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents, and marketable securities acquired through the merger with Nivalis. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents, and short-term investments totaling </font><font style="font-family:inherit;font-size:10pt;">$52.3 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our net loss was </font><font style="font-family:inherit;font-size:10pt;">$36.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. We expect to continue incurring significant expenses and operating losses for at least the next several years as we:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">initiate and complete clinical trials for product candidates, including ALPN-101, a dual ICOS/CD28 antagonist program targeting autoimmune/inflammatory disorders and ALPN-202, a CD80 vIgD-Fc, or multi PD-1 inhibitor and CD28 costimulatory vIgD targeting cancer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">contract to manufacture and perform additional process development for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue research and development efforts to build our pipeline beyond the current product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maintain, expand, and protect our intellectual property portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">hire additional clinical, quality control, scientific, and management personnel; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">add operational and financial personnel to support our product development efforts and operational capabilities applicable to operating as a public company.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not expect to generate product revenue unless and until we successfully complete development of, obtain marketing approval for and commercialize our product candidates, either alone or in collaboration with third parties. We expect these activities will take a number of years and our success in these efforts is subject to significant uncertainty. Accordingly, we will need to raise additional capital prior to the regulatory approval and commercialization of any of our product candidates. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our operating activities through public equity or debt financings, collaborations or licenses, capital lease transactions, or other available financing transactions. However, additional capital may not be available on reasonable terms, if at all, and if we raise additional funds through the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">issuance of additional equity or debt securities, it could result in dilution to our existing stockholders and increased fixed payment obligations.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Developments</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2019, we entered into a securities purchase agreement, or the Purchase Agreement, with a select group of institutional investors, pursuant to which we, in a private placement, sold </font><font style="font-family:inherit;font-size:10pt;">$25.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of units, or the Units, for a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$5.37</font><font style="font-family:inherit;font-size:10pt;">&#32;per Unit. Each Unit consists of one share of our common stock and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.39</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. Pursuant to the terms of the Purchase Agreement, we issued approximately </font><font style="font-family:inherit;font-size:10pt;">4.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock and warrants to purchase an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. The warrants have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$12.74</font><font style="font-family:inherit;font-size:10pt;">&#32;and have a term of </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2019, we entered into a lease with Landlord for </font><font style="font-family:inherit;font-size:10pt;">27,164</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet of office and laboratory space located at 188 East Blaine Street, Seattle, Washington. The term of the lease is </font><font style="font-family:inherit;font-size:10pt;">10.8 years</font><font style="font-family:inherit;font-size:10pt;">&#32;with one option to extend the term by </font><font style="font-family:inherit;font-size:10pt;">5.0 years</font><font style="font-family:inherit;font-size:10pt;">. The target &#8220;Commencement Date&#8221; is May 1, 2019 and shall be the date that Landlord delivers the premises to us in substantially complete condition. The &#8220;Rent Commencement Date&#8221; shall be the date that is nine months after the Commencement Date. The annual base rent due under the lease is </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first year and will increase by </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;each year thereafter. We will not be required to pay base rent from the Rent Commencement Date through the last day of the ninth month following the Rent Commencement Date. We will receive a maximum tenant improvement allowance of of </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;">, which is included in our base rent, and a maximum additional tenant improvement allowance of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, which will result in additional rent amortized over the term of the lease at an annual rate of </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">. The lease also requires us to pay additional amounts for operating and maintenance expenses. In connection with the lease, we provided a&#160;</font><font style="font-family:inherit;font-size:10pt;">$254,000</font><font style="font-family:inherit;font-size:10pt;">&#160;letter of credit as a security deposit. </font></div><div><a name="sE093BAA0AC7102E08D7B31F4C9D61ACE"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Overview</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration Revenue</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration and Licensing Revenue</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We derive our collaboration revenue primarily from our License and Research Agreement (the &#8220;Collaboration Agreement&#8221;), with Kite. In October 2015, we entered into the Collaboration Agreement providing Kite with access to two transmembrane immunomodulatory protein, or TIP, programs for use in Kite&#8217;s engineered cellular therapy programs. We received $5.5 million in upfront cash and are eligible to receive up to $530.0 million upon successful achievement of pre-specified research, clinical, and regulatory milestones in addition to royalties on any products containing our TIPs. On October 20, 2017, we entered into an amendment, or the &#8220;Amendment, with Kite to extend the research term of the Collaboration Agreement. Under the Amendment, an additional $450,000 research support payment from Kite was split into two tranches (instead of a single tranche as previously contemplated by the Collaboration Agreement). In June 2018, we recognized the remaining deferred balance and the first support payment of $150,000 under the Amendment. In October 2018, we entered into another amendment with Kite, which amended portions of the research plan.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have recognized a total of </font><font style="font-family:inherit;font-size:10pt;">$5.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in revenue from inception through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the Collaboration Agreement. We may generate revenue in the future from milestone payments made pursuant to the Collaboration Agreement, or from payments from future license or collaboration agreements, product sales, or government contracts and grants. We expect any revenue we generate will fluctuate from quarter to quarter.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We focus our resources on research and development activities, including the conduct of preclinical studies and product development and expense such costs as they are incurred. Our research and development expenses consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">employee-related expenses, including salaries, benefits, taxes, travel, and stock-based compensation expense for personnel in research and development functions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expenses related to process development and production of product candidates paid to contract manufacturing organizations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs associated with preclinical activities and regulatory operations, including the cost of acquiring, developing, and manufacturing research material; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical trials and activities related to regulatory filings for our product candidates</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">allocation of facilities, depreciation, and amortization of laboratory equipment and other expenses.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incurred </font><font style="font-family:inherit;font-size:10pt;">$29.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$10.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in research and development expenses for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. We plan to increase our research and development activities for the foreseeable future as we continue to develop our platform and product candidates.</font></div><div style="line-height:120%;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The successful development of our platform and product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing, or costs of the efforts necessary to finish developing any of our product candidates or the period in which material net cash, if any, from these product candidates may commence. This is due to the numerous risks and uncertainties associated with developing therapeutics, including the uncertainty of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope, rate of progress, expense, and results of clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope, rate of progress, and expense of process development and manufacturing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">preclinical and other research activities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing of regulatory approvals.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses consist primarily of salaries and related costs for employees in executive, business development, finance, and administrative functions. Other significant general and administrative expenses include professional fees for accounting and legal services, expenses associated with obtaining and maintaining patents and other intellectual property, and allocation of facilities costs.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect general and administrative expenses will increase as we expand infrastructure and support operating as a public company. These increases will include increased costs for director and officer liability insurance, costs related to the hiring of additional personnel, and increased fees for directors, outside consultants, lawyers, and accountants. We expect to incur significant costs to comply with corporate governance, internal controls, and similar requirements applicable to public companies.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss on Sale of Intangible Asset</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on sale of intangible asset relates solely to the sale of the GSNOR asset to Laurel in June 2018. For additional information regarding the sale of the GSNOR asset, see </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Note 8</font><font style="font-family:inherit;font-size:10pt;">&#32;to our consolidated financial statements contained elsewhere in this Annual Report on Form 10-K. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bargain Purchase Gain</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As Alpine was the accounting acquirer in the merger agreement with Nivalis Therapeutics, Inc., we allocated the purchase price to the acquired tangible and intangible assets and assumed liabilities of Nivalis based on their estimated fair values as of the acquisition date. The excess of the estimated fair values of net assets acquired over the acquisition consideration paid was recorded as a bargain purchase gain in the consolidated statements of operations and comprehensive income (loss). The determination of the fair values of the assets acquired and liabilities assumed requires significant judgment, including third party valuation estimates relating to the value of the acquired in-process research and development asset, or IPR&amp;D.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense consists of accrued interest and the amortization of the debt discount associated with our $5.0 million term loan.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest and Other Income</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income consists of interest earned on our cash, cash equivalents, and short-term investments.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Tax Benefit (Expense)</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit for 2018 relates to the sale of our in-process research and development, or IPR&amp;D. Income tax benefit for 2017 relates to the deferred tax liability recorded in connection with the acquisition of our IPR&amp;D, which had a financial reporting basis of $1.5 million and a tax basis of zero. The federal taxable income in 2016 is due to the acceleration of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our deferred revenue balance under Rev. Proc. 2004-34. Consequently, we have recorded current federal and state income tax payable for the year ended December&#160;31, 2016.</font></div><div><a name="sDC368CC8A60B92D22F1A31F4C1C842E7"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of Years Ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our results of operations for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Decrease)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,362</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,079</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,283</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on sale of intangible asset</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,535</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,705</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,830</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bargain purchase gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,601</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,601</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">754</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,983</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,487</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,783</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,704</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Revenue</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;in revenue was primarily attributable to the timing of revenue recognized under our Collaboration Agreement with Kite, the recognition of the first research support payment under the Amendment, and the adoption of ASC 606. Under the terms of the Collaboration Agreement, we received upfront payments of $5.5 million, which were initially recorded as deferred revenue and recognized over the period of the research term, which was completed during the first half of 2018. During 2018, the expected research term was extended pursuant to the Amendment and we recognized the first research support payment under the amended agreement. The adoption of ASC 606 resulted in&#160;$0.2 million&#160;in higher revenue for the 2018 period, as compared to what would have been recorded under previous accounting guidance.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$18.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;in research and development expenses was primarily attributable to an increase of $9.2 million in contract manufacturing and process development of our product candidates, an increase of $5.3 million in direct research activities, an increase of $2.7 million in personnel-related expenses as a result of growth in headcount to support ongoing discovery and development programs, an increase of $0.6 million in stock-based compensation, and an increase of $0.5 million in allocated overhead and facilities.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;in general and administrative expenses was primarily attributable to a $1.6 million increase in personnel-related expenses related to an increase in administrative headcount, an increase of $0.9 million in stock-based compensation, and a $0.5 million increase in insurance and facility costs to support the growth and expansion of our business. Offsetting this increase was a $0.7 million decrease in professional and legal services, which relates primarily to lower merger-related costs, partially offset by higher costs to support operating as a public company for a full year in 2018.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss on Sale of Intangible Asset</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on sale of intangible asset relates solely to the sale of the GSNOR asset to Laurel in June 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Bargain Purchase Gain</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The bargain purchase gain relates solely to the excess of the estimated fair values of net assets acquired over the acquisition consideration paid for Nivalis.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Expense</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense relates primarily to interest paid on our term loan with Silicon Valley Bank, which we drew down in June 2017, and the related non-cash interest expense associated with the amortization of the debt discount. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest and Other Income</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in interest and other income relates primarily to more interest earned on our short-term investments as we maintained a higher average investment balance during the 2018 period. </font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of Years Ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our results of operations for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Decrease)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,079</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,149</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,930</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,705</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,138</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,567</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,974</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,188</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,786</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bargain purchase gain</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,983</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,166</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,817</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,783</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,232</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,551</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Revenue</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;in revenues was primarily attributable to the timing of revenue recognized under our Collaboration Agreement with Kite.&#160;Under the terms of the Collaboration Agreement, we received upfront payments of $5.5 million, which were initially recorded as deferred revenue and expensed over the period of the research term. During the current period, the expected research term was extended pursuant to the Amendment.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$7.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;in research and development expenses was primarily attributable to an increase of $3.9 million in direct research, contract manufacturing, and process development activities to support ALPN-101, an increase of $3.1 million in personnel-related expenses as a result of growth in headcount to support ongoing discovery and development programs, and an increase of $0.6 million in allocated overhead and facilities.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;in general and administrative expenses was primarily attributable to a $2.8 million increase in professional and legal service fees to support the merger and operating as a public company, a $2.0 million increase in personnel-related expenses primarily related to an increase in administrative headcount, and a $0.1 million increase in insurance and facility costs to support the growth and expansion of our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Bargain Purchase Gain</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The bargain purchase gain relates solely to the excess of the estimated fair values of net assets acquired over the acquisition consideration paid for Nivalis.</font></div><div><a name="s764B7EF3188BD2E6444031F4CA297128"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents, and short-term investments totaling </font><font style="font-family:inherit;font-size:10pt;">$52.3 million</font><font style="font-family:inherit;font-size:10pt;">. Excluding amounts borrowed through debt financing, we have raised an aggregate of $98.9 million to fund operations, of which </font><font style="font-family:inherit;font-size:10pt;">$49.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was from the sale of convertible preferred stock, </font><font style="font-family:inherit;font-size:10pt;">$5.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was through a license and research agreement, and </font><font style="font-family:inherit;font-size:10pt;">$44.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents, and marketable securities acquired through the merger with Nivalis.  In June, 2017, we drew down a term loan of $5.0 million. In addition to our existing cash, cash equivalents, and marketable securities, we are eligible to receive research and development funding and to earn milestone and other contingent payments for the achievement of defined collaboration objectives and certain development and regulatory milestones and royalty payments under the Collaboration Agreement. Our ability to earn these milestone and contingent payments and the timing of achieving these milestones is primarily dependent upon the outcome of Kite&#8217;s research and development activities and is uncertain.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred operating losses since inception. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we continue our research and preclinical and clinical development of our product candidates; expand the scope of our current studies for our product candidates; initiate additional preclinical, clinical or other studies for our product candidates, including under any collaboration agreements; change or add additional manufacturers or suppliers; seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical studies; seek to identify, evaluate and validate additional product candidates; acquire or in-license other product candidates and technologies; maintain, protect and expand our intellectual property portfolio; attract and retain skilled personnel; and experience any delays or encounter issues with any of the above.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Until such time as we can generate substantial product revenue, if ever, we expect to finance our cash needs through a combination of equity or debt financings and collaboration agreements. Except for any obligations of our collaborator to make milestone payments under our agreement with them, we do not have any committed external sources of capital. To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through collaboration agreements in the future, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our future capital requirements are difficult to forecast and will depend on many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number and characteristics of the future product candidates we pursue either from our internal research efforts or through acquiring or in-licensing other product candidates or technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope, progress, results and costs of independently researching and developing any of our future product candidates, including conducting preclinical research and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether our existing collaboration generates substantial milestone payments and, ultimately, royalties on future approved products for us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing of, and the costs involved in, obtaining regulatory approvals for any future product candidates we develop independently;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of future commercialization activities, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of manufacturing our future product candidates and products, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to maintain our existing collaboration and to establish new collaborations, licensing or other arrangements and the financial terms of such arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs of preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing, receipt and amount of sales of, or royalties on, our current or future collaborators&#8217; product candidates, and our future products, if any.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our existing cash, cash equivalents and marketable securities as of the date of this report will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing drug candidates in preclinical and clinical studies is costly, and the timing of progress in these studies remains uncertain.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financing Agreements</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2019, we entered into a Purchase Agreement with a limited number of accredited investors, pursuant to which we, in a private placement, sold </font><font style="font-family:inherit;font-size:10pt;">$25.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;Units for a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$5.37</font><font style="font-family:inherit;font-size:10pt;">&#32;per Unit. Each Unit consists of one share of our common stock and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.39</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. Pursuant to the terms of the Purchase Agreement, we issued approximately </font><font style="font-family:inherit;font-size:10pt;">4.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock and warrants to purchase an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. The warrants have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$12.74</font><font style="font-family:inherit;font-size:10pt;">&#32;and have a term of </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to execution and delivery of the merger agreement with Nivalis Therapeutics, Inc. certain holders of our Series&#160;A-1 convertible preferred stock purchased shares of our Series A-1 convertible preferred stock. In March 2017, we issued and sold 707,330 shares of Series A convertible preferred stock and received a total of $4.0 million. In April 2017, we issued and sold 2,947,211&#160;shares of our Series&#160;A-1 convertible preferred stock for an aggregate of $16.7&#160;million in net proceeds. In addition, contemporaneously with the close of the Merger, certain existing stockholders of Alpine purchased 1,335,118 additional shares of Alpine&#8217;s capital stock for an aggregate of $17.0 million in net proceeds.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, we entered into an equity distribution agreement, or the Equity Distribution Agreement, with Piper Jaffray &amp; Co., or Piper Jaffray, pursuant to which we may sell shares of our common stock through an &#8220;at the market&#8221; equity offering program for up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">, in gross cash proceeds. Piper Jaffray will be entitled to compensation for its services of up to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the gross sales price per share of all shares sold through Piper Jaffray under the Equity Distribution Agreement. The Equity Distribution Agreement may be terminated by us upon written notice to Piper Jaffray for any reason, or by Piper Jaffray upon written notice to us for any reason, or at any time under certain circumstances, including but not limited to if we experience a material adverse change.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Equity Distribution Agreement, we will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. We have no obligation to sell any shares under the Equity Distribution Agreement and may at any time suspend solicitation and offers under the Equity Distribution Agreement. The shares will be issued pursuant to our effective shelf registration statement on Form S-3 (File No.&#160;333-212404), declared effective by the SEC on July&#160;14, 2016. We filed a prospectus supplement, or the Prospectus Supplement, dated June 11, 2018, with the SEC in connection with the offer and sale of the shares pursuant to the Equity Distribution Agreement. The Prospectus Supplement relates to the offering of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in shares of our common stock and we will be required to file an additional prospectus supplement in the event we seek to offer more than </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in shares of our common stock in accordance with the Equity Distribution Agreement. As </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we have made no sales under the Equity Distribution Agreement. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Long-Term Financing</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016, we entered into a term loan agreement with Silicon Valley Bank pursuant to which up to $5.0 million could be borrowed. On June 30, 2017, we drew down a term loan of $5.0 million pursuant to the agreement. The loan&#8217;s interest-only period expired on July 1, 2018, at which point we began making thirty consecutive equal monthly payments of principal (each in an amount that will fully amortize the loan), plus accrued interest. Interest accrues at a floating per annum rate equal to the lender&#8217;s prime rate minus 1.75%. As a condition to the loan, we agreed to pay a final payment fee of 7.5%, or $375,000, upon repayment of the loan. The final payment fee was recorded in long-term debt with an offsetting reduction in long-term debt and was accounted for as a debt discount.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the loan agreement we have pledged substantially all of our assets, excluding intellectual property, as collateral.&#160;The obligations under the loan agreement are subject to acceleration upon the occurrence of specified events of default, including a material adverse change in our business, operations or financial or other condition. The term loan agreement contains customary conditions to borrowings, events of default and negative covenants, including covenants that could limit our ability to, among other things, incur additional indebtedness, liens or other encumbrances, make dividends or other distributions; buy, sell or transfer assets; engage in any new line of business; and enter into certain transactions with affiliates. We were in compliance with our covenants as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of our cash flows (in thousands):&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,416</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,572</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,797</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,118</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,803</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(782</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by financing activities</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(991</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,688</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,975</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net cash used in operating activities</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">:</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities was </font><font style="font-family:inherit;font-size:10pt;">$28.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and consisted primarily of our net loss of&#160;</font><font style="font-family:inherit;font-size:10pt;">$36.5 million</font><font style="font-family:inherit;font-size:10pt;">. This was offset by increases of $5.0 million in our net operating assets and liabilities and $3.1 million in our net non-cash adjustments, which primarily relates to the loss on the sale of our intangible asset, stock-based compensation, the write-off of our deferred tax liability, depreciation and amortization.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities was </font><font style="font-family:inherit;font-size:10pt;">$16.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and consisted primarily of our net loss of </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and bargain purchase gain of $6.6 million. We also had a $3.2 million decrease in our net operating assets and liabilities, partially offset by a $1.0 million increase in our net non-cash adjustments.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities was </font><font style="font-family:inherit;font-size:10pt;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and consisted primarily of our net loss of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and our net decrease in operating assets and liabilities of $2.7 million. This was partially offset by $0.1 million in non-cash adjustments, which primarily include stock-based compensation and depreciation expense. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net cash provided by (used in) investing activities</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">:</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from investing activities primarily reflect cash used to purchase short-term investments and proceeds from the maturities of short-term investments, thus causing a shift between our cash and cash equivalents and short-term investment balances. We manage our cash usage with respect to our total cash, cash equivalents and short-term investments. </font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by investing activities was </font><font style="font-family:inherit;font-size:10pt;">$32.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and consisted primarily of purchases and maturities of short-term investments in U.S. Treasury securities, commercial paper, and corporate debt securities as well as the purchases of property and equipment, primarily lab equipment, to support our research and development efforts. </font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities was </font><font style="font-family:inherit;font-size:10pt;">$29.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and consisted primarily of the net purchases and sales of short-term investments, and purchases of property and equipment to build out our laboratory, partially offset by consideration acquired in the merger.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities was </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and primarily related to the purchase of property and equipment to build out our laboratory at our Seattle facility. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net cash (used in) provided by financing activities</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">:</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in financing activities was </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and consisted of principal payments on our debt, partially offset by the proceeds from stock option exercises. </font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities was </font><font style="font-family:inherit;font-size:10pt;">$42.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and consisted primarily of $37.7 million in proceeds from the sale of preferred stock and $5.0 million from the advance of a long-term loan.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities was </font><font style="font-family:inherit;font-size:10pt;">$11.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and consisted primarily of the sale of preferred stock.</font></div><div><a name="s3A5A254CED1B14BBA6B631F4C1CB9042"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations and Contingent Liabilities</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a &#8220;smaller reporting company,&#8221; as defined by Rule 12b-2 of the Exchange Act, we are not required to provide additional information on our contractual obligations and contingent liabilities pursuant to Item 303 of Regulation S-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><a name="s2F76AFC38B4343B1CACB31F4CA9ECAF6"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</font></div><div><a name="s7531F0DA3FFEA1387CBF31F4CAD283DC"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">JOBS Act</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 5, 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</font></div><div><a name="s7962734D6ADE43E7277731F4CAF12B70"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenues and expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While our significant accounting policies are more fully described in </font><a style="font-family:inherit;font-size:10pt;" href="#sFE10AB00D18A281B653831F4AFFB388C"><font style="font-family:inherit;font-size:10pt;">Note&#160;2</font></a><font style="font-family:inherit;font-size:10pt;">&#32;to our consolidated financial statements, we believe that the following accounting policies are the most critical to fully understanding and evaluating our financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate accruals for professional services and research and development expenses. This process involves reviewing contracts and vendor agreements and communicating with applicable personnel to identify services that have been performed on our behalf. We estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We estimate accrued liabilities as of each balance sheet date based on known facts and circumstances.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, we have not experienced any significant adjustments to our estimates.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition (effective January 1, 2018)</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our steps for recognizing revenue consist of;&#160;(1) identifying the contract,&#160;(2) identifying the performance obligations as either distinct or bundled goods and services,&#160;(3) determining the transaction price associated with each performance obligation for which we expect to be entitled in exchange for transferring such goods and services,&#160;(4) allocating the transaction price to the performance obligations in the contract and&#160;(5) recognizing revenue upon satisfaction of performance obligations.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our collaboration agreements principally contain multiple performance obligations, which may include (1)&#160;grants of, or options to obtain, intellectual property licenses; (2)&#160;research and development services; and/or (3)&#160;manufacturing or supply services. Payments typically received under these arrangements include one or more of the following: non-refundable upfront license fees, option exercise fees, payment for research and/or development efforts, amounts due upon the achievement of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">specified objectives, and/or royalties on future product sales. Our revenue is primarily derived from our License and Research Agreement, or the Collaboration Agreement, with Kite. See further discussion of the Collaboration Agreement in Note 12. </font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We allocate revenue to each performance obligation based on its relative stand-alone selling price. We generally determine stand-alone selling prices at the inception of the contract based on our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the accompanying </font><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">&#32;and recognized as revenue when the related revenue recognition criteria are met. We recognize revenue under the Collaboration Agreement based on employee hours contributed to each performance obligation.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Collaboration Agreement provides for non-refundable milestone payments. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to us for such milestone (1)&#160;is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance; (2)&#160;relates solely to our past performance; and (3)&#160;is reasonable relative to all of the other deliverables and payments within the arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial, and other risks that must be overcome to achieve the milestone, the level of effort and investment required to achieve the milestone and whether any portion of the milestone consideration is related to future performance or deliverables.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We review the contributed employee hours for each performance obligation under the Collaboration Agreement and adjust the revenue recognized to reflect changes in assumptions relating to the estimated satisfaction of the performance obligation. We could accelerate revenue recognition in the event of early termination of programs or if our expectations change. Alternatively, we could decelerate revenue recognition if programs are extended or delayed. While such changes to our estimates have no impact on our reported cash flows, the timing of revenue recorded in future periods could be materially impacted.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 2 included in our Annual Report on </font><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-10k_20171231.htm"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Form 10-K for the year ended December 31, 2017</font></a><font style="font-family:inherit;font-size:10pt;">&#32;for more discussion regarding the accounting policies that governed revenue recognition prior to January 1, 2018.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for all stock-based compensation granted to employees and&#160;non-employees&#160;using a fair value method. Stock-based compensation awarded to employees and&#160;non-employees&#160;is measured at the grant date fair value for stock option grants. Stock-based compensation to employees is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis. Stock-based compensation awarded to&#160;non-employees&#160;is revalued over its vesting period using a Black-Sholes option pricing model. We recognize forfeiture of awards as they occur rather than estimating the expected forfeiture rate.</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the Black-Scholes option pricing model to estimate the fair value of stock option grants. The Black-Scholes option pricing model relies on a number of key assumptions to calculate estimated fair value, including the risk-free interest rate, expected life, expected volatility, and expected dividend yield. For risk-free interest rate, we use the zero-coupon U.S. Treasury instruments security rate with a term equal to the expected life of the option. We use the &#8220;simplified method&#8221; for options to determine the expected term of stock option granted to employees. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. For expected volatility, we analyzed the stock price volatility of companies at a similar stage of development to estimate expected volatility of our stock price. Our assumed dividend yield of zero as we have never paid cash dividends and have no present intention to pay cash dividends.</font></div><div style="line-height:120%;padding-top:16px;text-indent:44px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If factors change and we employ different assumptions for estimating stock-based compensation expense in future periods, or if we decide to use a different valuation model, the stock-based compensation expense we recognize in future periods may differ significantly from what we have recorded in the current period and could materially affect our financial statements.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No.&#160;2016-02, Leases. ASU 2016-02 requires a lessee to separate the lease components from the non-lease components in a contract and recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of-use asset representing its right to use the underlying asset for the lease term. It also aligns lease accounting for lessors with the revenue recognition guidance in ASU 2014-09. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years, and is to be applied at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU 2018-11, related to another transition method in lease accounting. If elected, the transition method allows entities to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We plan to adopt ASU 2016-02 on January 1, 2019 and intend to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of the accumulated deficit in the period of adoption as permitted under ASU 2018-11. Based on our leases in place on January 1, 2019 and considering the practical expedients, we expect the adoption of the new standard will not have a material effect on our consolidated statements of operations, will result in a gross-up on our consolidated balance sheets of less than </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;relating to our office and laboratory leases, and will have no effect on our consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU No.&#160;2018-07, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. Upon transition, nonemployee awards will be required to be measured at fair value as of the adoption date with a cumulative-effect adjustment recognized in retained earnings as of the beginning of the annual period of adoption. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity&#8217;s adoption date of ASC 606. We are evaluating the effect the standard will have on our financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In&#160;August 2018,&#160;the FASB issued ASU&#160;No.&#160;2018-13,&#160;Fair Value Measurement. ASU&#160;2018-13&#160;modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted for any eliminated or modified disclosures. We are evaluating the effect of adopting this new accounting guidance to determine the impact it may have on our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU&#160;No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606. This ASU clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. This ASU is effective for public companies for annual reporting periods and interim periods within those annual periods beginning after December 15, 2019. We are currently evaluating the effect, if any, that ASU 2018-18 will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09, Revenue from Contracts with Customers, as amended, which we refer to as new revenue standard or ASC 606, which amends the guidance for revenue recognition to replace numerous industry specific requirements. ASC 606 implements a five-step process for customer contract revenue recognition focusing on transfer of control, as opposed to transfer of risk and rewards. ASC 606 also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include ensuring the time value of money is considered in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. ASC 606 is effective for reporting periods beginning after December&#160;15, 2017. On January 1, 2018, we adopted the new accounting standard and all of the related amendments using the modified retrospective method. We recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of our accumulated deficit. The cumulative effect of the changes related to the adoption of the new revenue standard and increased our beginning balances in accumulated deficit and deferred revenue by $203,000 within our </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. For further discussion of the impact of the adoption of ASC 606 see </font><a style="font-family:inherit;font-size:10pt;" href="#sFE10AB00D18A281B653831F4AFFB388C"><font style="font-family:inherit;font-size:10pt;">Note 2 </font></a><font style="font-family:inherit;font-size:10pt;">in the notes to our consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Statement of Cash Flows</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15 which provides new guidance on the classification of certain cash receipts and payments in the statement of cash flows. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We adopted this new standard effective January 1, 2018. The adoption of this standard did not impact our financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09 to provide clarity and reduce both diversity in practice and cost and complexity when applying the guidance in Compensation - Stock Compensation (&#8220;Topic 718&#8221;) about a change to the terms and conditions of a share-based payment award. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this update are effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted and applied prospectively to modifications occurring on or after the adoption date. We adopted this this standard effective January 1, 2018. The adoption of this standard did not have an impact on our financial statements.&#160;For the year ended December 31, 2018, there were no modifications to the terms or conditions of a share-based payment award.</font></div><div><a name="s499FDCA44A39FFC62E0531F4CB23E60E"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a &#8220;smaller reporting company,&#8221; as defined by Rule 12b-2 of the Exchange Act, and pursuant to Item 305 of Regulation S-K we are not required to provide quantitative and qualitative disclosures about market risk.</font></div><div><a name="sDE3F29C3B7A319DAB14B31F4CB452B91"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8. Financial Statements and Supplementary Data.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For information regarding our financial statements and supplementary data, please refer to the </font><a style="font-family:inherit;font-size:10pt;" href="#sF1E61FAA64CAD25219FB31F4CEEB5BB1"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></a><font style="font-family:inherit;font-size:10pt;">&#32;included elsewhere in this report.</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a &#8220;smaller reporting company,&#8221; as defined by Rule 12b-2 of the Exchange Act and pursuant to Article 8, Regulation X and Item 302 of Regulation S-K, we are permitted to provide scaled Item 8 disclosure.</font></div><div><a name="s03C4F44CE8BAD8D3D37731F4CB7846B8"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s028195AA915145B58B6431F4CB99AFDA"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9A. Controls and Procedures.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act, means controls and other </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">procedures</font><font style="font-family:inherit;font-size:10pt;">&#32;of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-weight:bold;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) and Rule 15d-15(f) of the Exchange Act. Our internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute, assurances. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Our management assessed the effectiveness of our internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, Internal Control-Integrated Framework (2013). Based on our assessment using those criteria, our management has concluded that, as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, our internal control over financial reporting was effective.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-weight:bold;">Changes in Internal Control Over Financial Reporting</font></div><div style="line-height:120%;padding-top:16px;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No significant changes in our internal control over financial reporting occurred during the fiscal quarter ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><a name="s9DCA35C28F58F79409A331F4CBCAF017"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9B. Other Information.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2019, we entered into a lease with the Landlord for 27,164 square feet of office and laboratory space located at 188 East Blaine Street, Seattle, Washington. The term of the lease is 10.8 years with one option to extend the term by 5.0 years. The target &#8220;Commencement Date&#8221; is May 1, 2019 and shall be the date that Landlord delivers the premises to us in substantially complete condition. The &#8220;Rent Commencement Date&#8221; shall be the date that is nine months after the Commencement Date. The annual base rent due under the lease is $1.7 million for the first year and will increase by 3.0% each year thereafter. We will not be required to pay base rent from the Rent Commencement Date through the last day of the ninth month following the Rent Commencement Date. We will receive a maximum tenant improvement allowance of $5.4 million, which is included in our base rent, and a maximum additional tenant improvement allowance of $1.8 million, which will result in additional rent amortized over the term of the lease at an annual rate of 8.0%. The lease also requires us to pay additional amounts for operating and maintenance expenses. In connection with the lease, we provided a&#160;$254,000&#160;letter of credit as a security deposit. The foregoing description of the March 2019 lease is only a summary of its material terms, does not purport to be complete and is qualified in its entirety by reference to the March 2019 lease. A copy of the March 2019 lease will be filed as an exhibit to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019. </font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><a name="s98853DE633FD10DD92ED31F4CBECB620"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div><a name="sB29B05D1C416A32893DA31F4CC1E84F4"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 10. Directors, Executive Officers and Corporate Governance.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Executive Officers and Directors</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the names, ages and positions of our executive officers and directors as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;6, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Age</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Position</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Executive Officers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mitchell H. Gold, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Chairman and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Litton, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Operating Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stanford Peng, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President of Research and Development and Chief Medical Officer</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paul Rickey</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Robert Conway</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Min Cui, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paul Sekhri</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Peter Thompson, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James Topper, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jay Venkatesan, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Christopher Peetz</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Executive Officers</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mitchell H. Gold, M.D.</font><font style="font-family:inherit;font-size:10pt;">&#160;has served as our executive chairman, chief executive officer and a member of our board of directors since the completion of the merger of Nivalis and Alpine in July 2017 and previously served as Alpine&#8217;s chief executive officer since June 2016 and as Alpine&#8217;s executive chairman and member of Alpine&#8217;s board of directors since January 2015. Prior to co-founding Alpine, Dr.&#160;Gold was Chairman and Founder of Alpine Biosciences, a privately-held biotech company, from 2012 to 2014. From 2001 to 2012, Dr.&#160;Gold served in a variety of roles with Dendreon Corporation (which was acquired by Valeant Pharmaceuticals International, Inc. through an asset purchase agreement), including President, Chief Executive Officer, and Chairman of the board of directors. Earlier in his career, Dr.&#160;Gold served as Vice President of Business Development at Data Critical from 2000 to 2001. From 1995 to 2000, Dr.&#160;Gold was President and Chief Executive Officer of Elixis Corporation. Dr.&#160;Gold is currently a Managing Partner at Alpine BioVentures. Dr.&#160;Gold holds an M.D. from Rush Medical College of Rush University Medical Center and a B.S. in Biology from the University of Wisconsin. We believe that Dr.&#160;Gold possesses specific attributes that qualify him to serve as a member of our board of directors, including more than 20 years of experience in senior executive management roles with both early stage and public biopharmaceutical companies.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mark Litton, Ph.D.</font><font style="font-family:inherit;font-size:10pt;">&#32;has served as our president and chief operating officer since August 2018. Dr. Litton previously served as the chief business officer, treasurer and secretary from 2004 to 2018 of Alder BioPharmaceuticals, Inc., a publicly-traded biopharmaceutical company&#160;co-founded&#160;by Dr.&#160;Litton in 2004. From 1999 to 2004, Dr.&#160;Litton served as vice president of business development for Celltech Group, where he was responsible for securing, commercializing and partnering numerous novel discoveries and therapeutic programs. In 1999, Dr.&#160;Litton joined Celltech Group as an employee of Chiroscience Group plc and was later promoted to vice president of business development after Chiroscience&#8217;s merger with Celltech Group in 1999. From 1997 to 1999, Dr.&#160;Litton served as the manager of business development for Ribozyme Pharmaceuticals Inc., currently Sirna Therapeutics, Inc., a biopharmaceutical company and wholly-owned subsidiary of Alnylam Pharmaceuticals, Inc., where he helped form relationships with Eli Lilly and Company, Roche Bioscience and GlaxoWellcome plc, currently GlaxoSmithKline plc, a biopharmaceutical company. From 1991 to 1994, Dr.&#160;Litton served as a research associate for DNAX Research Institute, a research facility of Schering-Plough, now Merck&#160;&amp; Co., a publicly-traded pharmaceutical company. Dr.&#160;Litton holds a Ph.D. in Immunology from Stockholm University, an M.B.A. from Santa Clara University and a B.S. in Biochemistry from the University of California, Santa Cruz.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stanford Peng</font><font style="font-family:inherit;font-size:10pt;">&#32;has as served as our executive vice president of research and development and chief medical officer since the completion of the merger of Nivalis and Alpine in July 2017 and previously served as Alpine&#8217;s chief medical officer from </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 2016 to February 2017 and as Alpine&#8217;s executive vice president of research and development and chief medical officer since February 2017. Prior to joining Alpine, Dr.&#160;Peng was chief medical officer and head of clinical development at Stemcentrx, providing strategic oversight of the company&#8217;s clinical and translational programs from 2015 to 2016. Previously, Dr.&#160;Peng was executive medical director at Seattle Genetics where he developed multiple programs for antibody-drug conjugates from 2014 to 2015. Earlier in his career, he directed translational research and auto-immune related clinical trials as head of the Rheumatology Clinical Research Unit at the Benaroya Research Institute from 2009 to 2014 and served as senior director, clinical research and exploratory development at Roche from 2005 to 2008. Between 2009 and 2014, Dr.&#160;Peng also served as member physician at Virginia Mason Medical Center. Dr.&#160;Peng served as an assistant professor at the Washington University School of Medicine from 2002 to 2005. From 2008 to 2009, Dr.&#160;Peng served as senior director at ARYx Therapeutics, Inc. (Nasdaq: ARYX). Dr.&#160;Peng received an M.D. and Ph.D. in biology from the Yale University School of Medicine and a B.A. in music and B.S. in biological sciences from Stanford University.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paul Rickey</font><font style="font-family:inherit;font-size:10pt;">&#32;has served as our senior vice president and chief financial officer since the completion of the merger of Nivalis and Alpine in July 2017 and previously served as Alpine&#8217;s senior vice president and chief financial officer since April 2017. Mr.&#160;Rickey served as chief financial officer of Sound Pharmaceuticals, overseeing finance, accounting and human resources. Before joining Sound Pharmaceuticals in 2016, Mr.&#160;Rickey was vice president of finance and administration of Immune Design Corp., (Nasdaq: IMDZ) a publicly traded biotechnology company, where he helped complete the company&#8217;s private offerings, initial public offering, and follow-on financing, and also oversaw the corporate development, accounting and human resource functions. Before joining Immune Design in 2009, Mr.&#160;Rickey was corporate controller of Northstar Neuroscience, a publicly-traded medical device company, where he managed the company&#8217;s finance and accounting groups following Northstar&#8217;s initial public offering. Prior to his role at Northstar Neuroscience, Mr.&#160;Rickey was the accounting manager for Mobliss, Inc., a mobile technology company that was sold to Index Corp., of Japan. Mr.&#160;Rickey started his finance career at Ernst&#160;&amp; Young LLP. Mr.&#160;Rickey graduated from the University of Washington with a B.A. and Masters in Professional Accounting and is a certified public accountant, inactive.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Directors</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Robert Conway</font><font style="font-family:inherit;font-size:10pt;">&#32;has served as a member of our board of directors since April 2015. From 1999 to 2012, Mr. Conway served as the chief executive officer and member of the board of directors of Array BioPharma (Nasdaq: ARRY), a publicly traded biopharmaceutical company. Prior to joining Array, Mr. Conway was the chief operating officer and executive vice president of Hill Top Research, from 1996 to 1999. From 1979 until 1996, Mr.&#160;Conway held various executive positions for Corning Inc. (NYSE: GLW), including corporate vice president and general manager of Corning Hazleton, a contract research organization. Since 2013, Mr.&#160;Conway has served on the board of directors of ARCA BioPharma (Nasdaq: ABIO), a publicly traded biopharmaceutical company, and was elected Chairman in June 2014. From 2004 to 2013, Mr.&#160;Conway served on the boards of directors of PRA International (Nasdaq: PRAH), which was a public company for a portion of his tenure there, and Bracket Corp., a private company. Mr.&#160;Conway has also served on the boards of directors of Bracket, Inc. and ClinOne, Inc., private clinical technology companies, since March 2017 and November 2018, respectively. In addition, Mr.&#160;Conway is a member of the strategic advisory committee of Genstar Capital. Mr.&#160;Conway received a B.S. in accounting from Marquette University in 1976. We believe that Mr.&#160;Conway&#8217;s experience and expertise in the pharmaceutical industry, pharmaceutical development and clinical trials, and corporate finance, governance, accounting and public company compliance give him the qualifications and skills to serve on our board of directors.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Min Cui</font><font style="font-family:inherit;font-size:10pt;">&#32;has served as a member of our board of directors since January 2019. Dr. Cui has served as managing director of Decheng Capital, an investment firm focused on life sciences companies, since he founded the firm in 2011. Prior to founding Decheng, Dr. Cui was an investment partner at Bay City Capital, an international life science venture capital firm in San Francisco. Dr. Cui was previously director of strategic investment for the Southern Research Institute, a not-for-profit research organization. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals, where he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui has served as a member of the board of directors of ARMO BioSciences, Inc., a publicly-traded immuno-oncology company acquired by Eli Lilly and Company in May 2018, from August 2017 to May 2018, and also currently serves on the boards of directors of several private companies. Dr. Cui holds a Ph.D. in Cancer Biology from Stanford University and a BS and MS in Molecular Biology from Peking University. We believe that Dr.&#160;Cui&#8217;s venture capital and management experience in the pharmaceuticals industry provides him with the qualifications and skills necessary to serve as a member of our board of directors. Dr. Cui was appointed to the Board pursuant to the terms of the Purchase Agreement.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Christopher Peetz</font><font style="font-family:inherit;font-size:10pt;">&#32;has served as a member of our board of directors since April 2018. Mr.&#160;Peetz has been the president of Mirium Pharmaceuticals, Inc. since November 2018. He has also served as the chief executive officer of Flashlight Therapeutics, Inc. and an entrepreneur-in-residence at Frazier Healthcare Partners since May 2017. He served as chief financial </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">officer and head of corporate development at Tobira Therapeutics, Inc., a publicly-traded biotechnology company acquired by Allergan plc in November 2016, from May 2014 to December 2016. Prior to joining Tobira Therapeutics, Mr.&#160;Peetz served as vice president, finance&#160;&amp; corporate development of Jennerex Biotherapeutics, a private biopharmaceutical company. Prior to Jennerex, Mr.&#160;Peetz held various positions at Onyx Pharmaceuticals, Inc. (now Amgen), including oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles. Prior to Onyx, Mr.&#160;Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. Mr.&#160;Peetz received an MBA from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis. We believe Mr.&#160;Peetz&#8217; experience in senior management positions in both business and finance and his experience supporting various corporate and financing transactions provide him with the qualifications and skills to serve on our board of directors.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paul Sekhri</font><font style="font-family:inherit;font-size:10pt;">&#32;has served as a member of our board of directors since February 2016. Mr.&#160;Sekhri is the president and chief executive officer of eGenesis, Inc., a private life sciences company. Before Mr. Sekhri joined eGenesis, he was the president and chief executive officer of Lycera Corp., a private biopharmaceutical company from February 2015 through January 2019. Prior to this position, he served as senior vice president, integrated care for Sanofi from April 2014 through January 2015, and as group executive vice president, global business development and chief strategy officer for Teva Pharmaceutical Industries, Ltd. from March 2013 to March 2014. Prior to joining Teva, Mr.&#160;Sekhri spent five years from January 2009 to February 2013, as operating partner and head of the biotechnology operating group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004 to 2009 Mr.&#160;Sekhri was founder, president, and chief executive officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr.&#160;Sekhri was president and chief business officer of ARIAD Pharmaceuticals, Inc. Previously, Mr.&#160;Sekhri spent four years at Novartis, as senior vice president, and head of global search and evaluation, business development and licensing for Novartis Pharma AG.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr.&#160;Sekhri has been a director on more than 24 private and public company boards, and is currently a member of the board of directors of Veeva Systems Inc. Mr.&#160;Sekhri is also the chairman of the board of Pharming N.V., Petra Pharma, Inc., Topas Therapeutics GmbH, and Compugen Ltd. Additionally, he serves on several non-profit boards including the BioExec Institute, Inc., the TB Alliance, Young Concert Artists, Inc., The English Concert in America (TECA), and the Caramoor Center for Music and the Arts. Mr.&#160;Sekhri also served as a member of the board of trustees of Carnegie Hall from 2010 to 2012, where he is now an active member of their Patrons Council. We believe that Mr.&#160;Sekhri&#8217;s extensive experience in operational and strategic drug development and his outstanding reputation and expertise in the biomedical community give him the qualifications and skills to serve as a director on our board of directors.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Peter Thompson, M.D.</font><font style="font-family:inherit;font-size:10pt;">&#160;has served as a member of our board of directors since the completion of the merger of Nivalis and Alpine in July 2017 and previously served as a member of the board of directors of Alpine since June 2016. Dr.&#160;Thompson currently serves as a private equity partner for OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he has also served as venture partner since joining in September 2010. Dr.&#160;Thompson is a co-founder of and has served as a member of the board of directors of Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) since December 2014. Dr.&#160;Thompson also served as a director of Adaptimmune Therapeutics plc (Nasdaq: ADAP), a biopharmaceutical company, from 2014 until July 2018 and also currently serves on the boards of directors of several private companies. Dr.&#160;Thompson is a board-certified internist and oncologist and has served as Affiliate Professor of Neurosurgery at the University of Washington since 2010. Dr.&#160;Thompson co-founded and served as the chief executive officer of Trubion Pharmaceuticals, Inc., a biopharmaceutical company, from 2002 to 2009. Dr.&#160;Thompson previously held executive positions at Chiron Corporation and Becton Dickinson and served on the faculty of the National Cancer Institute following his medical staff fellowship there. Dr.&#160;Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School. We believe that Dr.&#160;Thompson&#8217;s venture capital and management experience in the pharmaceuticals industry provides him with the qualifications and skills necessary to serve as a member of our board of directors.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">James N. Topper, M.D., Ph.D.</font><font style="font-family:inherit;font-size:10pt;">&#160;has served as a member of our board of directors since the completion of the merger of Nivalis and Alpine in July 2017 and previously served as a member of the board of directors of Alpine since June 2016. Dr.&#160;Topper has been a partner with Frazier Healthcare Partners since August 2003, serving as general partner since 2005. Before joining Frazier Healthcare Partners, Dr.&#160;Topper served as head of the cardiovascular research and development division of Millennium Pharmaceuticals, Inc. and ran Millennium San Francisco (formerly COR Therapeutics, Inc.) from 2002 to 2003. Before the merger of COR and Millennium in 2002, Dr.&#160;Topper served as the vice president of biology at COR from 1999 to 2002. Dr.&#160;Topper currently serves as a member of the board of directors of AnaptysBio, Inc. (Nasdaq: ANAB), Allena Pharmaceuticals (Nasdaq: ALNA), Aptinyx, Inc. (Nasdaq: APTX) and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) and has served on numerous other boards of directors, including Sierra Oncology, Inc. (formerly ProNai) (Nasdaq: SRRA), Amicus Therapeutics, Inc. (Nasdaq: FOLD), Portola Pharmaceuticals, Inc. (Nasdaq: PTLA), and La Jolla Pharmaceutical Company (Nasdaq: LJPC). Dr.&#160;Topper received his M.D. and Ph.D. in biophysics from Stanford University and his B.S. in biology from the University of Michigan. We believe that Dr.&#160;Topper&#8217;s experience overseeing Frazier Healthcare Partners&#8217; investments in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">biotechnology, his experience in senior management positions, and his significant knowledge of industry, medical and scientific matters, provide Dr.&#160;Topper with the qualifications and skills to serve on our board of directors.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Jay Venkatesan, M.D.</font><font style="font-family:inherit;font-size:10pt;">&#160;has served as a member of our board of directors since the completion of the merger of Nivalis and Alpine in July 2017, served as our president from July 2017 to August 2018 and previously served as Alpine&#8217;s chief executive officer from November 2015 to June 2016 and Alpine&#8217;s president in June 2016. Dr.&#160;Venkatesan also served as a member of Alpine&#8217;s board of directors since November 2015. Since May 2018, Dr. Venkatesan has served as chief executive officer and a member of the board of directors of Angion Biomedica, Inc., a private pharmaceutical company. Prior to joining Alpine, Dr.&#160;Venkatesan was the executive vice president and general manager of Oncothyreon, Inc. (now Cascadian Therapeutics) from August 2014 to May 2015 following Oncothyreon&#8217;s acquisition of Alpine Biosciences, where he served as co-founder and chief executive officer. Previously, Dr.&#160;Venkatesan was the founder, portfolio manager, and managing director of Ayer Capital Management, a global healthcare equity fund from 2008 to 2013. Prior to that, he was a director at Brookside Capital Partners from 2002 to 2007. Earlier in his career, Dr.&#160;Venkatesan was involved in healthcare investing at Partricof&#160;&amp; Co. Ventures from 1995 to 1996 and consulting at McKinsey&#160;&amp; Company from 1993 to 1995. Dr.&#160;Venkatesan is currently a managing partner at Alpine BioVentures. In addition, Dr.&#160;Venkatesan currently serves on the board of directors of Transplant Genomics, CellBioTherapy, and Exicure Therapeutics. Dr.&#160;Venkatesan received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania, and a B.A. in Chemistry from Williams College. We believe that Dr.&#160;Venkatesan possesses specific attributes that qualify him to serve as a member of our board of directors, including his experience on the boards of and in management positions with biopharmaceutical companies, including publicly-traded companies.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section 16(a) Beneficial Ownership Reporting Compliance</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section&#160;16(a) of the Securities Exchange Act of 1934, as amended, requires our directors and executive officers, and persons who own more than ten percent of a registered class of our equity securities, to file reports of ownership of, and transactions in, our securities with the Securities and Exchange Commission, or SEC, and Nasdaq. Such directors, executive officers, and ten percent stockholders are also required to furnish us with copies of all Section&#160;16(a) forms that they file.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SEC regulations require us to identify in this proxy statement anyone who filed a required report late during the most recent year. Based solely on a review of the copies of such forms received by us, or written representations from certain reporting persons, we believe that during 2018, our directors, executive officers, and 10% stockholders complied with all Section&#160;16(a) filing requirements applicable to them.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Code of Business Conduct and Ethics</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to the highest standards of integrity and ethics in the way we conduct our business. Our board of directors has adopted a Code of Business Conduct and Ethics, which applies to all of our employees, officers and directors, including our chief executive officer, chief financial officer, and other executive and senior financial officers. Our code of conduct establishes our policies and expectations with respect to a wide range of business conduct, including preparation and maintenance of financial and accounting information, compliance with laws and conflicts of interest. In accordance with our code of conduct, each of our employees, officers and directors is required to report suspected or actual violations to the extent permitted by law. In addition, our board of directors has adopted separate policies and procedures concerning the receipt and investigation of complaints relating to accounting, internal accounting controls or auditing matters, which are administered by our audit committee. Our Code of Business Conduct and Ethics is posted on the Corporate Governance portion of our website at https://ir.alpineimmunesciences.com/governance. We will post amendments to our Code of Business Conduct or waivers of our Code of Business Conduct for directors and executive officers on the same website.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Audit Committee</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The responsibilities of the audit committee include, but are not limited to, the following:</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">meeting with our independent auditors, our management team and such other personnel as it deems appropriate to conduct and assist with certain audit committee functions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">overseeing our accounting and financial reporting processes and audits of its financial statements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">deciding whether to appoint, retain or terminate our independent auditors, including the sole authority to approve all audit engagement fees and terms and to pre-approve all audit and permitted non-audit and tax services to be provided by the independent auditors;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reviewing and discussing with management and our independent auditors the financial statements of Alpine Immune Sciences, Inc, including certain disclosures, addressing any issues encountered in the course of the audit work, and evaluating the performance of our independent auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discussing with management our earnings press releases, financial information and any earnings guidance provided to analysts and ratings agencies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discussing with Alpine Immune Sciences and the internal auditors (if any) our disclosure controls, internal accounting and financial controls and accounting policies and practices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discussing with management any outsourcing of the internal audit function (if any), including selection of vendor, fees paid and areas to be audited;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establishing procedures for the receipt, retention and treatment of complaints received by us regarding certain accounting or audit matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establishing policies governing the hiring by us of any current or former employee of our independent auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reviewing our compliance with applicable laws and regulations and to review and oversee our policies and procedures designed to promote and monitor regulatory compliance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining assurance from the independent auditors that the audit of the financial statements was conducted in a manner consistent with Section&#160;10A of the Exchange Act;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reviewing, approving and overseeing transactions between us and any related person and any other potential conflict of interest situation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">administering our Whistleblower and Non-Retaliation Policy and responding to and resolving related complaints or concerns;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">overseeing portions of our Code of Business Conduct and Ethics as designated by our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">providing our board of directors with the results of its monitoring and recommendations derived from its responsibilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reviewing and approving our investment policy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">providing the independent and internal auditors with access to the board of directors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">producing the report required to be prepared for inclusion in our annual proxy statement.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since April&#160;2018 the audit committee has been composed of three directors: Messrs. Conway (chairman), Peetz and Sekhri. From the completion of the merger of Nivalis and Alpine in July&#160;2017 until April&#160;2018 the committee was composed of three directors: Messrs. Conway (chairman) and Sekhri and Dr.&#160;Topper. Our board of directors has determined that Mr.&#160;Conway is an &#8220;audit committee financial expert&#8221; as defined in the SEC rules and made a qualitative assessment of Mr.&#160;Conway&#8217;s level of knowledge and experience based on several factors, including his prior experience, business acumen and independence. Our board of directors has concluded that the composition of the audit committee meets the requirements for independence under the rules and regulations of Nasdaq and the SEC.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The audit committee met four times during 2018. The audit committee also meets periodically with our outside auditors without management present, at such times as it deems appropriate. Our board of directors has adopted a written charter for the audit committee in compliance with the applicable rules of the SEC and the Nasdaq listing standards and which is available on our website at https://ir.alpineimmunesciences.com/governance.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><a name="sFBB01E13F67CBD44B45931F4CC41FFFC"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 11. Executive Compensation.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary Compensation Table</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information regarding the compensation of our named executive officers:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name and Principal Position</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Salary&#160;($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Awards</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">($)(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nonequity</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Incentive Plan</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Compensation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">($)(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">All Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Compensation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">($)(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total ($)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:2pt;"><font style="font-family:inherit;font-size:2pt;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mitchell H. Gold, M.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:2pt;"><font style="font-family:inherit;font-size:2pt;">&#160;</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">512,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,045,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Chairman and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:2pt;"><font style="font-family:inherit;font-size:2pt;">&#160;</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,056,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="font-size:2pt;"><font style="font-family:inherit;font-size:2pt;">&#160;</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;&#160;&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,359,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Litton, Ph.D. (5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,365</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">768,812</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,100</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">984,977</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Operating Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stanford Peng, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,036,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President of Research and Development and Chief Medical Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">546,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts shown in this column do not reflect dollar amounts actually received by our NEOs. Instead, these amounts reflect the aggregate grant date fair value of the stock options granted, computed in accordance with the provisions of FASB ASC Topic 718. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Represents cash bonuses earned under our 2018 performance bonus plan, paid in 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Represents parking expenses for Drs. Gold and Litton.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Excludes $37,000 paid in 2017, pursuant to the terms of a deferred salary arrangement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Litton commenced employment with us on August 6, 2018. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Represents the probable value of $108,497 for Dr. Litton&#8217;s August 6, 2018 performance-based option award. The maximum value of such award is $216,993.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Executive Employment Arrangements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into amended and restated executive employment agreements with each of Drs. Gold and Peng effective January 1, 2018 and an executive employment agreement with Dr. Litton on August 6, 2018. Pursuant to these agreements, the annual base salaries for Drs. Gold, Litton and Peng were $400,000, $410,000 and $400,000, respectively. In February 2019, the compensation committee approved adjusted salaries for Drs. Gold, Litton and Peng of $485,000, $415,000 and $425,000, respectively. Additionally, Drs. Gold, Litton and Peng are eligible to earn cash bonuses of up to 50%, 40% and 35%, respectively, of their base salary. The actual amount of such bonuses is tied to the achievement of various objectives for each year. Dr.&#160;Gold&#8217;s bonus is based solely on achievement of corporate objectives. The bonuses for Drs.&#160;Peng and Litton are based on 75% corporate objectives and 25% individual objectives. These agreements also provide for certain severance benefits upon the termination of employment or a change in control of the company pursuant to our Change in Control and Severance Policy, or the Severance Policy.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Severance Policy, if we terminate the employment of any of Dr.&#160;Gold, Dr. Litton or Dr.&#160;Peng, each an Eligible Employee, other than for cause, death or disability, or the Eligible Employee resigns for good reason on or within 12 months following a change of control, then, subject to the Eligible Employee signing and not revoking a separation agreement and release of claims and continuing to adhere to the Eligible Employee&#8217;s non-competition, non-disclosure and invention assignment agreement, such Eligible Employee will be eligible to receive the following severance benefits, less applicable tax withholdings:</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A lump-sum payment totaling 100% (or, in case of Dr.&#160;Gold, 150%) of the Eligible Employee&#8217;s applicable annual base salary.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A lump-sum payment equal to (1) 100% of the Eligible Employee&#8217;s applicable target annual bonus plus (2)&#160;a payment equal to the Eligible Employee&#8217;s pro-rated applicable target annual bonus.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% of the Eligible Employee&#8217;s then-outstanding and unvested time-based equity awards will become vested and exercisable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment or reimbursement of continued health coverage for the Eligible Employee and the Eligible Employee&#8217;s dependents under COBRA for a period of up to 12 months (or, in Dr.&#160;Gold&#8217;s case, 18 months).</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, under the Severance Policy, if the Company terminates an Eligible Employee&#8217;s employment other than for cause, death or disability or such Eligible Employee resigns for good reason at any time other than during the period lasting from the date of a change of control or within 12 months thereafter, then, subject to the Severance Conditions, such Eligible Employee will be eligible to receive the following severance benefits, less applicable tax withholdings:</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Continued payments totaling 75% (or, in Dr.&#160;Gold&#8217;s case, 100%) of the Eligible Employee&#8217;s applicable annual base salary over a period of 9 months (or in Dr.&#160;Gold&#8217;s case, 12 months).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% of the Eligible Employee&#8217;s then-outstanding and unvested time-based equity awards granted prior to the closing of the merger by and between Alpine Immune Sciences, Inc. and Nivalis Therapeutics, Inc. that would have otherwise vested during the 12-month period following the date of the Eligible Employee&#8217;s termination, and 0% in all other cases.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment or reimbursement of continued health coverage for the Eligible Employee and the Eligible Employee&#8217;s dependents under COBRA for a period of up to 9 months (or, in Dr.&#160;Gold&#8217;s case, 12 months).</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mitchell H. Gold</font><font style="font-family:inherit;font-size:10pt;">. Alpine entered into an employment agreement with Dr.&#160;Gold in March 2017, which pre-dated the merger of Nivalis and Alpine. The agreement had no specific term and constituted at-will employment. Effective January 2017, Dr.&#160;Gold&#8217;s annual base salary was $300,000. Pursuant to the terms of the agreement, Dr.&#160;Gold was subject to certain confidentiality obligations and was obligated to sign and comply with an agreement relating to proprietary information and inventions. During his employment, Dr.&#160;Gold was eligible to participate in our applicable benefit plans and was eligible for paid vacation and sick leave, with levels determined by our board of directors, all upon the same terms as offered to other senior executives. Effective January 2018, we entered into an amended and restated executive employment agreement with Dr.&#160;Gold on the terms and conditions described above.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mark Litton</font><font style="font-family:inherit;font-size:10pt;">. We entered into an employment agreement with Dr. Litton in August 2018 on the terms and conditions described above. Dr. Litton was also granted an initial stock option grant of 150,000 shares and an additional stock option grant of 50,000 shares which vests upon satisfaction of certain performance goals determined by the board of directors or the compensation committee of the board of directors. Pursuant to the terms of the agreement, Dr.&#160;Litton is subject to certain confidentiality obligations and was obligated to sign and comply with an agreement relating to proprietary information and inventions. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stanford Peng</font><font style="font-family:inherit;font-size:10pt;">. Alpine entered into an employment agreement with Dr.&#160;Peng in August 2016. The agreement had no specific term and constituted at-will employment. Effective January 2017, Dr.&#160;Peng&#8217;s annual base salary was $375,000. Pursuant to the terms of the agreement, Dr.&#160;Peng was subject to certain confidentiality obligations and is obligated to sign and comply with an agreement relating to proprietary information and inventions. Effective January 2018, we entered into an amended and restated executive employment agreement with Dr.&#160;Peng on the terms and conditions described above.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding Equity Awards at Year-End</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information regarding the equity awards outstanding at December&#160;31, 2018 held by each of our NEOs.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option Awards</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Vesting</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Commencement</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unexercised</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options (#)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unexercised</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options (#)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unexercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price&#160;($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mitchell H. Gold</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">01/16/2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/16/2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/15/2025</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">01/20/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">03/14/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,051</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,573</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">03/13/2027</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">01/20/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">04/12/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">04/11/2027</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">01/02/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">01/02/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">01/01/2028</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Litton</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">08/06/2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">08/06/2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">08/05/2028</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">08/06/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">08/06/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">08/05/2028</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stanford Peng</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">09/06/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">09/22/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">09/21/2026</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">09/06/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">03/14/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,971</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,296</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">03/13/2027</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">01/02/2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">01/02/2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">01/01/2028</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">09/28/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">09/28/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">09/27/2028</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One-half of the shares shall vest on May&#160;16, 2016, and 1/32</font><font style="font-family:inherit;font-size:9pt;">nd</font><font style="font-family:inherit;font-size:10pt;">&#32;of the remaining shares shall vest on each monthly anniversary thereafter, such that 100% of the shares shall be fully vested and exercisable as of the 4-year anniversary of January&#160;16, 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/4</font><font style="font-family:inherit;font-size:9pt;">th</font><font style="font-family:inherit;font-size:10pt;">&#32;of the shares will vest on the one-year anniversary of the vesting commencement date, and 1/36</font><font style="font-family:inherit;font-size:9pt;">th</font><font style="font-family:inherit;font-size:10pt;">&#32;of the remaining shares shall vest on each monthly anniversary thereafter, such that 100% of the shares shall be vested and exercisable as of the four-year anniversary of the vesting commencement date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The shares underlying the Option vest in two equal tranches upon satisfaction of certain performance goals determined by the board of directors or the compensation committee of the board of directors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/2 of the shares subject to the option become vested and exercisable on October 1, 2020 and the balance of the shares subject to the option become vested and exercisable on October 1, 2022, subject to continued service through each such date.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">401(k) Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have adopted the WTIA 401(k) Multiple Employer Plan, maintained by Washington Technology Industry Association, which is a defined contribution retirement plan, in which all Alpine employees providing at least 20 hours of service a week are eligible to participate. This plan provides our eligible employees with an opportunity to save for retirement on a tax advantaged basis, and participants are able to defer a portion of their eligible compensation. All participants&#8217; interests in their deferrals are 100% vested when contributed. The 401(k) plan permits us to make matching contributions and profit-sharing contributions to eligible participants. We have not provided a discretionary company match to employee contributions during the periods presented. Pre-tax contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. The 401(k) plan is intended to qualify under Sections&#160;401(a) and 501(a) of the Internal Revenue Code. As a tax-qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) plan and all contributions are deductible by us when made.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director Compensation</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Director Compensation Policy</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, our board of directors approved a director compensation policy for our non-employee directors that became effective following our initial public offering and which was subsequently amended in March 2018. For purposes of the policy, the board of directors classified each director into one of the two following categories: (1)&#160;an &#8220;employee director,&#8221; is a director who is employed by us; and (2)&#160;a &#8220;non-employee director,&#8221; is a director who is not an employee director. Only non-employee directors will receive compensation under the director compensation policy. Non-employee directors will receive compensation in the form of equity and cash under the director compensation policy, as described below. We believe our non-employee director compensation program provides reasonable compensation to our non-employee directors that is appropriately aligned with our peers and is commensurate with the services and contributions of our non-employee directors.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-employee directors receive an initial stock option grant to purchase shares of our common stock upon appointment or election to the board of directors. Pursuant to the March 2018 amendments to the policy, the size of the initial stock option grant is 7,650 shares. Non-employee directors also receive on an annual basis, an additional stock option grant to purchase 7,650 shares. These annual grants occur on the first trading day in January of each year. All options are expected to have an exercise price equal to the closing price of our common stock as reported by Nasdaq on the date of grant subject to vesting in 36 equal monthly installments over a three-year period from the grant date for initial option grants, or in 12 equal monthly installments over a 12-month period from the grant date for annual stock option grants, subject to further evaluation by the compensation committee. On a change in control, all outstanding, unvested options held by non-employee directors are expected to vest in full.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each non-employee director is eligible to receive the following cash annual retainer, which will be paid quarterly in arrears on a prorated basis.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual retainer for board membership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual retainer for board chairperson</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual retainer for audit committee chairperson</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual retainer for audit committee member</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual retainer for compensation committee chairperson</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual retainer for compensation committee member</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual retainer for nominating and corporate governance committee chairperson</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual retainer for nominating and corporate governance committee member</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Director Compensation Table</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows for the fiscal year ended December&#160;31, 2018 certain information with respect to the compensation of our non-employee directors who served on our board of directors during any part of 2018.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fees&#160;Earned</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">or paid in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash ($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option Awards ($)(1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total&#160;($)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Robert Conway(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Peter Thompson, M.D.(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,619</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,119</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James N. Topper, M.D., Ph.D.(4)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paul Sekhri(5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,619</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,869</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Christopher Peetz(6)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,553</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jay Venkatesan, M.D.(7)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,320</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,396</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts shown in this column do not reflect dollar amounts actually received by our non-employee directors. Instead, these amounts reflect the aggregate grant date fair value of the stock options granted, computed in accordance with the provisions of FASB ASC Topic 718.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2018, Mr. Conway held outstanding options to purchase 15,505 shares of common stock. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, Dr. Thompson held outstanding options to purchase 7,650 shares of common stock.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, Dr. Topper held outstanding options to purchase 7,650 shares of common stock.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, Mr. Sekhri held outstanding options to purchase 13,593 shares of commons stock. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, Mr. Peetz held outstanding options to purchase 7,650 shares of common stock. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, Dr. Venkatesan held outstanding options to purchase 115,063 shares of common stock. Dr. Venkatesan served as our president until August 2018 and did not receive or earn any fees during that time.  The amount shown in the &#8220;Fees Earned or paid in Cash ($)&#8221; column excludes cash compensation paid to Dr. Venkatesan in 2018 while Dr. Venkatesan was serving as our president. The amount shown in the &#8220;Option Awards&#8221; column includes the aggregate grant date fair value of the stock options granted while Dr. Venkatesan was serving as our president. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><a name="s4CF3176FF8651E6C167C31F4CC723E0B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plans</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information as of December&#160;31, 2018, with respect to the shares of our common stock that may be issued under existing equity compensation plans:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">C</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities&#160;to&#160;be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issued Upon</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Available for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Future</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issuance&#160;Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Compensation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Plans</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Excluding</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reflected in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Column A) (1)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation plans approved by</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">security holders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated 2015 Stock Plan, as amended, or the 2015 Stock&#160;Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,421,724</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015 Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">530,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018 Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">496,530</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation plans not approved by security holders (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,522,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">541,741</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Represents the number of securities remaining available for future issuance under the 2015 Equity Incentive Plan, the 2015 Stock Plan, the 2018 Equity Incentive Plan and the Employee Stock Purchase Plan. The number of shares available for issuance under the 2018 Equity Incentive Plan is subject to an annual increase on the first day of each year equal to the lesser of (a) 1,500,000 shares or (b) 5% of the total number of shares of common stock outstanding on December&#160;31 of the preceding calendar year or (c)&#160;a lesser number of shares of common stock approved by the board of directors prior to January 1 of a given year.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Represents 150,000 shares of our common stock subject to the Stand-Alone Inducement Stock Option Grant for Mark Litton. This stock option was not approved by security holders pursuant to an exemption permitted under the rules of The Nasdaq Stock Market LLC. </font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Stockholders</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of January 31, 2019 for:</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">each person who we know beneficially owns more than 5% of our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">each of our directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">each of our NEOs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all of our directors and executive officers as a group.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The percentage of beneficial ownership shown in the table is based upon 18,560,905 shares outstanding as of January 31, 2019.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of common stock that they beneficially own, subject to applicable community property laws.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In computing the number of shares beneficially owned by a person and the percentage ownership of that person, we take into account shares of common stock issuable pursuant to stock options, warrants and restricted stock units that may be exercised or that are scheduled to vest on or before the 60th day after January 31, 2019. These shares are deemed to be outstanding and beneficially owned by the person holding those options, warrants or restricted stock units for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as otherwise noted below, the address for each person or entity listed in the table is c/o Alpine Immune Sciences, Inc., 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beneficially Owned</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name of Beneficial Owner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5% Stockholders:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alpine Immunosciences, L.P.(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,069,222</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OrbiMed Private Investments VI, LP(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,816,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Decheng Capital China Life Sciences USD Fund III, L.P.(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,846,387</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Frazier Life Sciences VIII, L.P.(4)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,716,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Entities affiliated with BVF Partners L.P.(5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,201,718</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Directors and Executive Officers:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mitchell H. Gold(6)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,428,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Litton(7)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stanford Peng(8)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jay Venkatesan(9)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,214,435</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Peter Thompson(10)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,825,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James N. Topper(11)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,725,626</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Robert Conway(12)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paul Sekhri(13)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,868</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Christopher Peetz (14)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Min Cui(15)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,846,812</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All current directors and executive officers as a group</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11 persons)(16)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,239,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:25.390625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:23%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(*)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less than one percent.</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">According to a Schedule 13D filed on January 23, 2019 with the Securities and Exchange Commission, Alpine BioVentures, GP, LLC, Mitchell H. Gold and Jay Venkatesan may be deemed to beneficially own 4,069,222 shares which are held by Alpine Immunosciences, L.P., including 74,441 shares issuable upon the exercise of warrants, which are exercisable within 60 days of January 31, 2019. Alpine BioVentures GP, LLC is the general partner of Alpine Immunosciences, L.P. Dr.&#160;Gold and Dr.&#160;Venkatesan are the Managing Partners of Alpine BioVentures GP, LLC. Dr.&#160;Gold and Dr.&#160;Venkatesan are also limited partners of Alpine Immunosciences, L.P. By virtue of such relationships, Dr.&#160;Gold and Dr.&#160;Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine Immunosciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. Each of Dr.&#160;Gold and Dr.&#160;Venkatesan disclaims beneficial ownership of the shares held by Alpine Immunosciences, L.P., except to the extent of his pecuniary interest therein, if any. The address for Alpine Immunosciences, L.P. is 600 Stewart Street, Suite 1503, Seattle Washington 98101.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">According to a Schedule 13D filed on January&#160;23, 2019 with the Securities and Exchange Commission, OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC may be deemed to beneficially own 3,816,206 shares which are held by OrbiMed Private Investments VI, LP, including 145,251 shares issuable upon the exercise of warrants, which are exercisable within 60 days of January 31, 2019. OrbiMed Capital GP VI LLC (&#8220;GP VI&#8221;) is the general partner of OrbiMed Private Investments VI, LP. OrbiMed Advisors LLC (&#8220;OrbiMed Advisors&#8221;) is the managing member of GP VI. Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein share voting and investment power over the shares held by OrbiMed Private Investments VI, LP and as a result may be deemed to have beneficial ownership of such shares. Dr.&#160;Thompson, an employee of OrbiMed Advisors, may be deemed to have beneficial ownership of such shares. Each of GP VI, OrbiMed Advisors, Carl L. Gordon, Sven H. Borho, Jonathan T. Silverstein and Dr.&#160;Thompson disclaims beneficial ownership of the shares held by OrbiMed Private Investments VI, LP, except to the extent of its or his </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:40px;text-align:left;"><font style="font-family:inherit;font-size:10pt;">pecuniary interest therein, if any. The address for OrbiMed Private Investments VI, LP is 601 Lexington Avenue, 54th Floor, New York, New York 10022.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Decheng Capital Management III (Cayman), LLC (&#8220;Decheng Capital Management&#8221;) and Min Cui may be deemed to beneficially own 3,846,387 shares which are held by Decheng Capital China Life Sciences USD Fund III, L.P. (&#8220;Decheng&#8221;), including 680,652 shares issuable upon the exercise of a warrant that is exercisable within 60 days of January 31, 2019. Until approval of our stockholders is obtained, the warrants are not exercisable to the extent necessary to ensure that, following any such proposed exercise, the total number of shares of common stock then beneficially owned by such holder and its affiliates would not exceed 4.99%, or 19.99% for Decheng (the &#8220;Beneficial Ownership Limitation&#8221;). Excludes 553,984 shares subject to the warrant that is not exercisable within 60 days of January 31, 2019 due to the Beneficial Ownership Limitation, based on the number of shares outstanding as of January 31, 2019. Decheng Capital Management is the general partner of Decheng. Dr. Cui is the sole manager of Decheng Capital Management and may be deemed to have voting and investment power with respect to the shares held by Decheng and as a result may be deemed to have beneficial ownership of such shares. The address for Decheng is 3000 Sand Hill Road, Building 2, Suite 110, Menlo Park, California 94025.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">According to a Schedule 13D filed on January 23, 2019 with the Securities and Exchange Commission, FHM Life Sciences VIII, L.P., FHM Life Sciences VIII, L.L.C., James Topper and Patrick J. Heron may be deemed to beneficially own 2,716,701 shares which are held by Frazier Life Sciences VIII, L.P., including 145,251 shares issuable upon the exercise of warrants that are exercisable within 60 days of January 31, 2019. FHM Life Sciences VIII, LP is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, LLC is the general partner of FHM Life Sciences VIII, LP. Dr.&#160;Topper and Patrick J. Heron are the sole members of FHM Life Sciences VIII, LLC and therefore share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P. Dr.&#160;Topper and Mr.&#160;Heron disclaim beneficial ownership of the shares held by Frazier Life Sciences VIII, L.P. except to the extent of their pecuniary interests in such shares, if any. The address for Frazier Life Sciences VIII, L.P. is 601 Union Street, Suite 3200, Seattle, Washington 98101.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(5) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">According to a Schedule 13G filed on January 28, 2019 with the Securities and Exchange Commission, (i) Biotechnology Value Fund, L.P. (&#8220;BVF&#8221;) may be deemed to beneficially own 584,078 shares, (ii) Biotechnology Value Fund II, L.P. (&#8220;BVF2&#8221;) may be deemed to beneficially own 460,853 shares, and (iii) Biotechnology Value Trading Fund OS LP (&#8220;Trading Fund OS&#8221;) may be deemed to beneficially own 84,524 shares. BVF Partners OS Ltd. (&#8220;Partners OS&#8221;), as the general partner of Trading Fund OS, may be deemed to beneficially own the 84,524 shares held by Trading Fund OS. BVF Partners L.P. (&#8220;BVF Partners&#8221;), as the general partner of BVF, BVF2, the investment manager of Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 1,201,718 shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and a certain BVF Partners managed account (&#8220;Partners Managed Account&#8221;), including 72,263 shares held in the Partners Managed Account. BVF Inc., as the general partner of BVF Partners, may be deemed to beneficially own the 1,201,718 shares beneficially owned by BVF Partners. Mr. Mark N. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 1,201,718 shares beneficially owned by BVF Inc. Excludes 217,875 shares subject to warrants held by BVF, BVF2 and Trading Fund OS that are not exercisable within 60 days of January 31, 2019 due to the Beneficial Ownership Limitation, based on the number of shares outstanding as of January 31, 2019. The address of each of BVF Inc., Partners, BVF, BVF2, Trading Fund OS, Partners OS and Mr. Lampert is 1 Sansome Street, 30th Floor, San Francisco, California 94104, USA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consists of (i) 11,292 shares of our common stock held directly by Dr.&#160;Gold, (ii) 347,671 shares of our common stock issuable upon the exercise of options within 60 days of January 31, 2019, (iii) 3,994,781 shares of our common stock held directly by Alpine Immunosciences, L.P and (iv) 74,441 shares of our common stock issuable upon the exercise of warrants held by Alpine Immunosciences, L.P. which are exercisable within 60 days of January 31, 2019. Please see footnote 1 regarding Dr.&#160;Gold&#8217;s voting and investment power over the shares held by Alpine Immunosciences, L.P. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(7) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consists of 25,000 shares of our common stock issuable upon the exercise of options within 60 days of January 31, 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consist of 143,197 shares of our common stock issuable upon the exercise of options within 60 days of January 31, 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(9)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consists of (i) 21,739 shares of our common stock held directly by Dr.&#160;Venkatesan, (ii) 37,266 shares of our common stock held in trust for the benefit of Dr.&#160;Venkatesan&#8217;s children, (iii) 86,208 shares of our common stock issuable upon the exercise of options within 60 days of January 31, 2019, (iv) 3,994,781 shares of our common stock held directly by Alpine Immunosciences, L.P., and (v) 74,441 shares of our common stock issuable upon the exercise of warrants held by Alpine Immunosciences, L.P. which are exercisable within 60 days of January 31, 2019. Please see footnote 1 regarding Dr.&#160;Venkatesan&#8217;s voting and investment power over the shares held by Alpine Immunosciences, L.P.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(10)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consists of (i) 8,925 shares of our common stock issuable upon the exercise of options within 60 days of January 31, 2019, (ii) 3,670,955 shares of our common stock held directly by OrbiMed Private Investments VI, LP and (iii) 145,251 shares of our common stock issuable upon the exercise of warrants held by OrbiMed Private Investments VI, LP which are exercisable within 60 days of January 31, 2019. Please see footnote 2 regarding Dr.&#160;Thompson&#8217;s voting and investment power over the shares held by OrbiMed Private Investments VI, LP.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:42px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11) Consists of (i) 8,925 shares of our common stock issuable upon the exercise of options within 60 days of January 31, 2019, (ii) 2,571,450 shares of our common stock held directly by Frazier Life Sciences VIII, L.P. and (iii) 145,251 shares of our common stock issuable upon the exercise of warrants held by Frazier Life Sciences VIII, L.P. which are exercisable within 60 days of January 31, 2019. Please see footnote 4 regarding Dr.&#160;Topper&#8217;s voting and investment power over the shares held by Frazier Life Sciences VIII, L.P.</font></div><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:42px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12) Consists of 15,000 shares of our common stock held directly by Mr.&#160;Conway and 16,780 shares of our common stock issuable upon exercise of options within 60 days of January 31, 2019.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(13)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consist of 14,868 shares of our common stock issuable upon the exercise of options within 60 days of January 31, 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(14)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consist of 3,612 shares of our common stock issuable upon the exercise of options within 60 days of January 31, 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(15)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consists of (i) 425 shares of our common stock issuable upon the exercise of options within 60 days of January 31, 2019, (ii) 3,165,735 shares of our common stock held directly by Decheng Capital China Life Sciences USD Fund III, L.P. and (iii) 680,652 shares of our common stock issuable upon the exercise of warrants held by Decheng Capital China Life Sciences USD Fund III, L.P. which are exercisable within 60 days of January 31, 2019. Please see footnote 3 regarding Dr.&#160;Cui&#8217;s voting and investment power over the shares held by Decheng Capital China Life Sciences USD Fund III, L.P.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(16)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes only current directors and executive officers serving in such capacity as of January 31, 2019. Includes 706,005 shares of our common stock issuable upon the exercise of options within 60 days of January 31, 2019.</font></div></td></tr></table><div><a name="s5D1F7A0CEF73296F6BF731F4CC92B1EC"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 13. Certain Relationships and Related Transactions, and Director Independence.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transaction Policy</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors has adopted a written policy governing the review and approval of related party transactions. The audit committee of our board of directors has the primary responsibility for reviewing and approving or disapproving related party transactions, as designated in the audit committee charter. In addition, our Code of Business Conduct and Ethics requires that each of our employees and directors inform his or her superior or the chairman of the audit committee, respectively, of any material transaction or relationship that comes to his or her attention that could reasonably be expected to create a conflict of interest. Further, at least annually, each director and executive officer will complete a detailed questionnaire that asks questions about any business relationship that may give rise to a conflict of interest and all transactions in which we are involved and in which an executive officer, a director or a related person has a direct or indirect material interest.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Affiliations with Principal Stockholders</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Gold is an executive officer, and Dr. Venkatesan was an executive officer until August 2018. Each of Drs. Venkatesan and Gold is also a member of our board of directors and, in their individual capacities, a limited partner of Alpine Immunosciences, L.P., Delaware limited partnership, which is a holder of more than 5% of our outstanding capital stock. In addition, each of Drs. Venkatesan and Gold, in their individual capacities, is a Managing Partner of Alpine BioVentures, GP, LLC, a Delaware limited liability company, which is the general partner of Alpine Immunosciences, L.P.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr.&#160;James&#160;N. Topper is a member of our board of directors and, in his individual capacity, is a managing member of FHM Life Sciences VIII, LLC, a Delaware limited liability company. FHM Life Sciences VIII, LLC is the general partner of FHM Life Sciences VIII, LP, a Delaware limited partnership. FHM Life Sciences VIII, LP is the general partner of Frazier Life Sciences VIII, L.P., a Delaware limited partnership, which is a holder of more than 5% of our outstanding capital stock.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr.&#160;Peetz is a member of our board of directors and, in his individual capacity, is an Entrepreneur-in-Residence at Frazier Healthcare Partners, which is an affiliate of Frazier Life Sciences VIII, L.P.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr.&#160;Peter Thompson is a member of our board of directors and, in his individual capacity, is an employee of OrbiMed Advisors LLC. OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP VI LLC. OrbiMed Capital GP VI LLC is the general partner of OrbiMed Private Investments VI, LP, which is a holder of more than 5% of our outstanding capital stock.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Min Cui is a member of our board of directors and, in his individual capacity, is the manager of Decheng Capital Management III (Cayman), LLC, which in turn is the general partner of Decheng Capital China Life Sciences USD Fund III, L.P. Decheng Capital China Life Sciences USD Fund III, L.P. is a holder of more than 5% of our outstanding capital stock. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Indemnification Agreements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into indemnification agreements with each of our directors and with each of our executive officers. Pursuant to the indemnification agreements, we have agreed to indemnify and hold harmless these directors and officers to the fullest extent permitted by applicable law. The agreements generally cover expenses that a director or officer incurs or amounts that a director or officer becomes obligated to pay because of any proceeding to which he or she is made or threatened to be made a party or participant by reason of his or her service as a current or former director, officer, employee or agent of Alpine Immune Sciences. The agreements also provide for the advancement of expenses to the directors and executive officers subject to specified conditions. There are certain exceptions to our obligation to indemnify the directors and officers, including any intentional misconduct or act where the director or officer did not in good faith believe he or she was acting in our best interests, with respect to &#8220;short-swing&#8221; profit claims under Section&#160;16(b) of the 1934 Act and, with certain exceptions, with respect to proceedings that he or she initiates. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Private Placement</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 15, 2019, we entered into a securities purchase agreement in connection with the sale and issuance of 4,706,700 units for $5.37 per unit representing (i) 4,706,700 shares of our common stock and (ii)&#160;warrants to purchase an additional 1,835,610 shares of common stock for $12.74 per share, with each unit consisting of one share of common stock and a warrant to purchase 0.39 of a share of common stock. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the purchases on January 18, 2019 of our securities by our 5% stockholders:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name of Purchaser</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares of Common Stock Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares of Common Stock Subject to Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Purchase Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alpine Immunosciences, L.P.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,024,998.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OrbiMed Private Investments VI, LP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">372,439</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145,251</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,999,997.43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Frazier Life Sciences VIII, L.P.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">372,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145,251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,999,997.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also entered into a registration rights agreement requiring us to register the resale of the shares of common stock issued and issuable upon the exercise of warrants. We are required to prepare and file a registration statement with the Securities and Exchange Commission on the date on which we file this Annual Report on Form&#160;10-K&#160;for the year ended December&#160;31, 2018, and in any event no later than March&#160;18, 2019, which we refer to as the Filing Deadline, and to use commercially reasonable efforts to have the registration statement declared effective within 25 days of the Filing Deadline if there is no review by the SEC, and within 90 days of the Filing Deadline in the event of such review.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Indebtedness of Directors and Officers</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None of our current or former directors or executive officers is indebted to us, nor are any of these individuals indebted to another entity which indebtedness is the subject of a guarantee, support agreement, letter of credit or other similar arrangement or understanding provided by us.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Transactions</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have granted stock options to our NEOs, other executive officers and our directors.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director Independence</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors has undertaken a review of its composition, the composition of its committees and the independence of current directors and considered whether any such director has a material relationship with us that could compromise his ability to exercise independent judgment in carrying out his responsibilities. Based upon information requested from and provided by each current director concerning his background, employment and affiliations, including family relationships, the board of directors has determined that (1)&#160;none of our current directors except for Drs. Gold and Venkatesan, has a relationship which would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is an &#8220;independent director&#8221; as defined under the rules of the Nasdaq. The board of directors also determined that Messrs. Conway (chairman), Sekhri and Peetz, who comprise our audit committee, Drs. Topper (chairman) and Thompson and Mr.&#160;Sekhri, who comprise our compensation committee, and Dr.&#160;Thompson (chairman) and Messrs. Conway and Sekhri, who comprise our nominating and corporate governance committee, satisfy the independence standards for those committees established by applicable SEC rules and the rules of Nasdaq.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></div><hr style="page-break-after:always"><div><a name="s4CDB79B5DD6701A5738331F4CCC50785"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 14. Principal Accounting Fees and Services.</font></div><div style="line-height:120%;padding-top:8px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents fees for professional audit services and other services rendered to our company by EY for the years ended December&#160;31, 2018 and 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fee Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit fees(1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">494,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit-related fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">494,210</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit fees consist of fees for professional services provided in connection with the audit of our annual consolidated financial statements, review of our quarterly consolidated financial statements, procedures for comfort letters, consents and assistance with and review of documents filed with the SEC.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Services Rendered to Private Alpine</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents fees for the year ended December 31, 2017 for professional audit services and other services rendered to Alpine by EY prior to the merger of Nivalis and Alpine in 2017.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:82%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fee Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit fees(1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit-related fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377,050</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit fees consist of fees for professional services provided in connection with the audit of our annual consolidated financial statements, review of our quarterly consolidated financial statements, procedures for comfort letters, consents and assistance with and review of documents filed with the SEC.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Auditor Independence</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, there were no other professional services provided by EY that would have required the audit committee to consider their compatibility with maintaining the independence of EY.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Audit Committee Policy on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to its charter, the audit committee must review and approve, in advance, the scope and plans for the audits and the audit fees and approve in advance (or, where permitted under the rules and regulations of the SEC, subsequently) all non-audit services to be performed by the independent auditor that are not otherwise prohibited by law and any associated fees. All fees paid to EY for 2018 were pre-approved by our audit committee and all fees paid to EY for 2017 were pre-approved by our audit committee or board of directors. The audit committee may delegate to one or more members of the committee the authority to pre-approve audit and permissible non-audit services, as long as this pre-approval is presented to the full committee at scheduled meetings.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></div><hr style="page-break-after:always"><div><a name="sB49150E77CDDBB537F3031F4CCE6E94B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div><div><a name="s375D784DE95FF69A2DAA31F4CD18EE06"></a></div><div style="line-height:120%;padding-top:16px;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 15. Exhibits, Financial Statement Schedules.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements, schedules and exhibits filed as a part of this Annual Report on Form 10-K are as follows:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:79px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:55px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial statements &#8211; The financial statements included in Item 8 are filed as part of this Annual Report on Form 10-K.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:79px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:55px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial Statement Schedules &#8211; All schedules have been omitted because they are not applicable or required, or the information required to be set forth therein is included in the </font><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s8D1084986631244E2E7A31F4CDBC717F"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">consolidated financial statements or notes thereto</font></a><font style="font-family:inherit;font-size:10pt;">&#32;included in Item 8 of this Annual Report on Form 10-K.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:79px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:55px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibits &#8211; The exhibits required to be filed as part of this report are listed in the Exhibit List attached hereto and are incorporated herein by reference.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO EXHIBITS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Incorporated by Reference</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">File No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Filing Date</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000110465917024204/a17-11472_1ex2d1.htm"><font style="font-family:inherit;font-size:10pt;">Agreement and Plan of Merger, dated as of April 18, 2017, by and among Nivalis Therapeutics, Inc., Nautilus Merger Sub, Inc. and Alpine Immune Sciences, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 18, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex31_207.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Certificate of Incorporation of the Registrant, as amended</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000104746915004723/a2224618zex-3_4.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Bylaws of the Registrant</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-204127</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 13, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex41_205.htm"><font style="font-family:inherit;font-size:10pt;">Form of Common Stock Certificate of the Registrant</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000104746915004723/a2224618zex-4_2.htm"><font style="font-family:inherit;font-size:10pt;">Second Amended and Restated Warrant to Purchase Common Stock, dated February 18, 2011, issued to Horizon Credit I LLC</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-204127</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 13, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000104746915004723/a2224618zex-4_3.htm"><font style="font-family:inherit;font-size:10pt;">Second Amended and Restated Warrant to Purchase Common Stock, dated February 18, 2011, issued to Horizon Credit II LLC</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-204127</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 13, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000104746915004723/a2224618zex-4_4.htm"><font style="font-family:inherit;font-size:10pt;">Second Amended and Restated Investor Rights Agreement, dated November 18, 2014</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-204127</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 13, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex45_206.htm"><font style="font-family:inherit;font-size:10pt;">Warrant to Purchase Shares, dated December 16, 2016, by and between Alpine Immune Sciences, Inc. and Silicon Valley Bank</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex46_203.htm"><font style="font-family:inherit;font-size:10pt;">Form of Warrant to Purchase Shares of Common Stock issued to certain service providers on April 12, 2017 pursuant to the Amended and Restated 2015 Stock Plan, as amended</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000110465915047582/a15-14497_1ex4d4.htm"><font style="font-family:inherit;font-size:10pt;">Nivalis Therapeutics, Inc. 2015 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-205220</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 25, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000110465915047582/a15-14497_1ex4d5.htm"><font style="font-family:inherit;font-size:10pt;">Form of Notice of Stock Option Grant and Stock Option Agreement for Employees under the Nivalis Therapeutics, Inc. 2015 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-205220</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 25, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000110465915047582/a15-14497_1ex4d6.htm"><font style="font-family:inherit;font-size:10pt;">Form of Notice of Stock Option Grant and Stock Option Agreement for Non-Employee Directors under the Nivalis Therapeutics, Inc. 2015 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-205220</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 25, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000104746915004723/a2224618zex-10_2.htm"><font style="font-family:inherit;font-size:10pt;">N30 Pharmaceuticals, Inc. 2012 Stock Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-204127</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 13, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000104746915004723/a2224618zex-10_3.htm"><font style="font-family:inherit;font-size:10pt;">Form of Stock Option Agreement pursuant to N30 Pharmaceuticals, Inc. 2012 Stock Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-204127</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 13, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000110465915047582/a15-14497_1ex4d7.htm"><font style="font-family:inherit;font-size:10pt;">Nivalis Therapeutics, Inc. Employee Stock Purchase Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-205220</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 25, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000104746915004723/a2224618zex-10_18.htm"><font style="font-family:inherit;font-size:10pt;">Form of Indemnification Agreement entered into by and between the Registrant and its directors and officers</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-204127</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 13, 2015</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Incorporated by Reference</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">File No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Filing Date</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex1026_216.htm"><font style="font-family:inherit;font-size:10pt;">Loan and Security Agreement, dated December 16, 2016, by and among Alpine Immune Sciences, Inc. and Silicon Valley Bank</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619918000004/alpn-ex104_20180331.htm"><font style="font-family:inherit;font-size:10pt;">Non-Employee Director Compensation Guidelines</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 14, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.10#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312517317234/d480657dex101.htm"><font style="font-family:inherit;font-size:10pt;">License and Research Agreement by and between Alpine Immune Sciences, Inc. and Kite Pharma, Inc., effective as of October 26, 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 24, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312517317234/d480657dex102.htm"><font style="font-family:inherit;font-size:10pt;">License and Research Agreement Amendment No. 1 by and between AIS Operating Co., Inc. and Kite Pharma, Inc., effective as of October 20, 2017</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 24, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.12#+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="alpn-ex1012_20181231.htm"><font style="font-family:inherit;font-size:10pt;">License and Research Agreement Amendment No. 2 by and between AIS Operating Co., Inc. and Kite Pharma, Inc., effective as of October 17, 2018</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.13*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312517366252/d505987dex101.htm"><font style="font-family:inherit;font-size:10pt;">Change of Control and Severance Policy</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 11, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.14*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex1032_211.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated as of March 14, 2017, by and between the Registrant and Mitchell H. Gold, M.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.15*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex1033_212.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated as of January 1, 2018, by and between the Registrant and Mitchell H. Gold, M.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.33</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.16*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex1034_213.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated as of April 1, 2017, by and between the Registrant and Paul Rickey</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.34</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.17*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex1035_214.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated as of January 1, 2018, by and between the Registrant and Paul Rickey</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.18*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex1036_215.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated as of August 14, 2016, by and between the Registrant and Stanford Peng, M.D., Ph.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.36</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.19*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex1037_2544.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated as of January 1, 2018 , by and between the Registrant and Stanford Peng, M.D., Ph.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.37</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.20*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312517281903/d453065dex41.htm"><font style="font-family:inherit;font-size:10pt;">Alpine Immune Sciences, Inc. (now known as AIS Operating Co., Inc.) Amended and Restated 2015 Stock Plan, as amended</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-8 POS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-218134</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 11, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.21*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312517281903/d453065dex42.htm"><font style="font-family:inherit;font-size:10pt;">Form of Option Agreement under the Alpine Immune Sciences, Inc. (now known as AIS Operating Co., Inc.) Amended and Restated 2015 Stock Plan, as amended</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-8 POS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-218134</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 11, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312518189404/d600116dex11.htm"><font style="font-family:inherit;font-size:10pt;">Equity Distribution Agreement, dated as of June 11, 2018, between Alpine Immune Sciences, Inc. and Piper Jaffray &amp; Co.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 11, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.23*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312518192903/d605617dex101.htm"><font style="font-family:inherit;font-size:10pt;">Alpine Immune Sciences, Inc. 2018 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 14, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.24*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312518192903/d605617dex102.htm"><font style="font-family:inherit;font-size:10pt;">Form of Stock Option Agreement under the 2018 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 14, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.25*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312518238992/d603285dex101.htm"><font style="font-family:inherit;font-size:10pt;">Form of Stand-Alone Inducement Stock Option Grant between Alpine Immune Sciences, Inc. and Mark Litton</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 6, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.26*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312518238992/d603285dex102.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, by and between the Registrant and Mark Litton</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 6, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312519010606/d673408dex101.htm"><font style="font-family:inherit;font-size:10pt;">Securities Purchase Agreement, dated January 15, 2019, by and among the Company and the Purchasers</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 16, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312519010606/d673408dex102.htm"><font style="font-family:inherit;font-size:10pt;">Registration Rights Agreement, dated January 15, 2019, by and among the Company and the Purchasers</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 16, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex211_2624.htm"><font style="font-family:inherit;font-size:10pt;">List of subsidiaries of the Registrant</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-37449</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Incorporated by Reference</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">File No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Filing Date</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.1+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="alpn-ex231_20181231.htm"><font style="font-family:inherit;font-size:10pt;">Consent of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="alpn-ex311_20181231.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer Required Under Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="alpn-ex312_20181231.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer Required Under Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="alpn-ex321_20181231.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.2+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="alpn-ex322_20181231.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicates a management contract or a compensatory plan, contract or arrangement.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All schedules and exhibits to the Merger Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Portions of this exhibit have been omitted pursuant to a request for confidential treatment and the omitted portions have been filed separately with the Securities and Exchange Commission.&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></div><hr style="page-break-after:always"><div><a name="sF0D1B1407DB03D1AD9FA31F4CDAEED71"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:43%;"></td><td style="width:6%;"></td><td style="width:7%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCIENCES, INC.</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 18, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mitchell Gold</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mitchell Gold</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Chairman and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCIENCES, INC.</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 18, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paul Rickey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paul Rickey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">POWER OF ATTORNEY</font></div><div style="line-height:120%;text-indent:78px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mitchell Gold and Paul Rickey, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file, any and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their and his or her substitute or substitutes, may lawfully do or cause to be done by virtue thereof.</font></div><div style="line-height:120%;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:3%;"></td><td style="width:41%;"></td><td style="width:3%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mitchell Gold</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Chairman and Chief Executive Officer (Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;18, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mitchell Gold</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paul Rickey</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer (Principal Accounting and Financial Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;18, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Paul Rickey</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Peter Thomson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;18, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Peter Thompson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">James N. Topper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;18, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">James N. Topper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Jay Venkatesan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;18, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Jay Venkatesan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Robert Conway</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;18, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Robert Conway</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Peter Sekhri</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;18, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Peter Sekhri</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/&#160;Christopher Peetz</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;18, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Christopher Peetz</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/&#160;Xiangmin Cui</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 18, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Xiangmin Cui</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></div><hr style="page-break-after:always"><div><a name="s8D1084986631244E2E7A31F4CDBC717F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:91%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC6B4CDB56B413FBE9BF731F4CDC870C4"><font style="font-family:inherit;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC6B4CDB56B413FBE9BF731F4CDC870C4">F-2</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3">F-3</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A">F-4</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6412026BA036090DC7DC31F4AD2B0998"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6412026BA036090DC7DC31F4AD2B0998">F-5</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s91A811FC546906E06D5C31F4AEE988B8"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s91A811FC546906E06D5C31F4AEE988B8">F-6</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF1E61FAA64CAD25219FB31F4CEEB5BB1"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF1E61FAA64CAD25219FB31F4CEEB5BB1">F-7</a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-1</font></div></div><hr style="page-break-after:always"><div><a name="sC6B4CDB56B413FBE9BF731F4CDC870C4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Stockholders and the Board of Directors of Alpine Immune Sciences, Inc.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on the Financial Statements</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Alpine Immune Sciences, Inc. as of December 31, 2018 and 2017, the related consolidated statements of operations and comprehensive income (loss), convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2018, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018, in conformity with U.S. generally accepted accounting principles.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.&#160;&#160;</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have served as the Company&#8217;s auditor since 2015.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Seattle, Washington</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 18, 2019</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-2</font></div></div><hr style="page-break-after:always"><div><a name="s5586C0A9B3D54801F78C31F4AB9529B3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCIENCES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:76%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,592</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,240</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,242</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,308</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,545</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,548</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,196</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,089</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,453</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities, convertible preferred stock, and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,716</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,277</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,048</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,127</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,895</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, long-term portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,282</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and contingencies</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock, $0.001 par value per share; 10,000,000 shares authorized at December 31, 2018 and 2017; zero shares issued and outstanding at December 31, 2018 and 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.001 par value per share; 200,000,000 shares authorized at December 31, 2018 and 2017; 13,904,672 shares issued and 13,854,205 shares outstanding at December 31, 2018; 13,881,645 shares issued and 13,831,178 shares outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Treasury stock, at cost; 50,467 shares at December 31, 2018 and 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,664</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,346</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,074</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,917</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities, convertible preferred stock, and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-3</font></div></div><hr style="page-break-after:always"><div><a name="s03C62274E02E2844700331F4AC9CCF8A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCIENCES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,362</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,079</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,149</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on sale of intangible asset</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,535</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,705</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,138</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bargain purchase gain</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,853</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,983</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,166</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,487</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,783</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,232</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) on investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,441</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,842</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,232</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares used to compute basic and diluted net loss per share attributable to common stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,849,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,481,665</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564,816</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-4</font></div></div><hr style="page-break-after:always"><div><a name="s6412026BA036090DC7DC31F4AD2B0998"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCIENCES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENT OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="38"></td></tr><tr><td style="width:15%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Convertible</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Treasury</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Paid-in Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Other Comprehensive Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Stockholders&#8217; Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,212,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">496,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of convertible preferred stock, net of issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,099,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,925</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">111,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">77</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">77</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,311,770</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,535</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">608,701</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">144</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,601</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,457</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of Series A-1 convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,989,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">37,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Conversion of convertible preferred stock to common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(9,301,433</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(49,201</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,301,433</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">49,200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">49,201</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common stock acquired in business combination</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,914,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Adjustment of par value from $0.0001 per share to $0.001 per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Conversion of warrant liability to equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of stock options and common stock</font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">57,453</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Repurchase of common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(50,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">838</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">838</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized loss on investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7,783</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7,783</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,831,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">88,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(9,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">78,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cumulative effect of changes related to adoption of new revenue standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(203</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(203</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized gain on investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(36,487</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(36,487</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,854,205</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50,467</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">90,664</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(46,074</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">44,591</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-5</font></div></div><hr style="page-break-after:always"><div><a name="s91A811FC546906E06D5C31F4AEE988B8"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCIENCES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,487</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,783</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,232</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on sale of intangible asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,203</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bargain purchase gain</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">241</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of premium/discount on investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation and warrant expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">838</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,193</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(480</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,731</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,572</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,797</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing activities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from sale of intangible asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase of short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(72,863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(88,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,226</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from the sale of short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents acquired in connection with merger</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,130</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,118</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,803</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(782</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing activities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from sale of preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repayment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of stock options and common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(991</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,688</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,975</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase (decrease) in cash and cash equivalents and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,711</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,687</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,396</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents and restricted cash, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,819</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents and restricted cash, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,819</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental Information</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock exchanged for common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,201</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount in connection with issuance of debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclass of preferred stock warrant liability to equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-6</font></div></div><hr style="page-break-after:always"><div><a name="sF1E61FAA64CAD25219FB31F4CEEB5BB1"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div><a name="sD31BE121D5B120F8794C31F4AFBEEF04"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. Description of Business</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alpine Immune Sciences, Inc. (the &#8220;Company&#8221;, &#8220;Alpine&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, or &#8220;our&#8221;), together with its consolidated subsidiaries, is focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory disorders, and other diseases. Our proprietary scientific platform uses a process known as directed evolution, or an iterative scientific engineering process purposefully conducted to &#8220;evolve&#8221; a protein to create multi-targeted therapeutics potentially capable of modulating the human immune system. In our&#160;pre-clinical&#160;animal studies, our platform has proven capable of identifying novel molecules, including single domains capable of modulating multiple targets. We were incorporated under the laws of the State of Delaware and are headquartered in Seattle, Washington.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Merger and Subscription Agreement</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April&#160;18, 2017, we entered into a merger agreement with Nivalis Therapeutics, Inc. (&#8220;Nivalis&#8221;), a public biotechnology company, and one of its wholly-owned subsidiaries pursuant to which, the subsidiary merged with and into Alpine, with Alpine continuing as a wholly owned subsidiary of Nivalis and the surviving corporation of the merger (the &#8220;Merger Agreement&#8221;). Nivalis Therapeutics, Inc. was incorporated in Delaware in March 2007.&#160;Alpine Immune Sciences, Inc. (prior to its business combination with Nivalis Therapeutics, Inc.) was incorporated in Delaware on December 30, 2014.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. At the closing of the merger, each outstanding share of our capital stock (common stock and preferred stock) was converted into the right to receive shares of Nivalis common stock (subject to the payment of cash in lieu of fractional shares and after giving effect to a 1:4 reverse stock split of Nivalis common stock) such that, immediately following the effective time of the merger, preexisting Nivalis stockholders, optionholders, and warrantholders owned, or held rights to acquire, approximately </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the fully-diluted common stock of Nivalis, which changed its name to &#8220;Alpine Immune Sciences, Inc.&#8221; following the completion of the merger and Alpine&#8217;s preexisting stockholders, optionholders, and warrantholders owned, or held rights to acquire approximately </font><font style="font-family:inherit;font-size:10pt;">74%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the fully-diluted common stock of Nivalis. The issuance of the shares to our pre-existing stockholders was registered under the Securities Act of 1933, as amended, pursuant to a registration statement on Form S-4 (No. 333-218134) (the &#8220;Registration Statement&#8221;) declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on June 6, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contemporaneously with the execution and delivery of the Merger Agreement, certain of our pre-existing stockholders entered into a subscription agreement with us pursuant to which such stockholders purchased, immediately prior to the closing of the merger, </font><font style="font-family:inherit;font-size:10pt;">1,335,118</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our capital stock at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$12.74</font><font style="font-family:inherit;font-size:10pt;">&#32;per share for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$17.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The merger and the subscription described above were consummated on </font><font style="font-family:inherit;font-size:10pt;">July&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="sFE10AB00D18A281B653831F4AFFB388C"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC and generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates inherent in the preparation of the accompanying consolidated financial statements include accruals for clinical trial activities and other accruals, and the estimated fair value of equity-based awards. We base our estimates and assumptions on historical experience when available and on various factors we believe to be reasonable under the circumstances. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include the financial position and results of operations of Alpine and our wholly owned operating company and subsidiaries, AIS Operating Co., Inc., and Alpine Immune Sciences Australia PTY LTD. On </font><font style="font-family:inherit;font-size:10pt;">July&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">, we closed the merger on the terms described in more detail in </font><a style="font-family:inherit;font-size:10pt;" href="#sD31BE121D5B120F8794C31F4AFBEEF04"><font style="font-family:inherit;font-size:10pt;">Note 1</font></a><font style="font-family:inherit;font-size:10pt;">. In connection with the merger, Nivalis effected a&#160;1:4&#160;reverse stock split of its common stock. Upon the closing of the merger, (1)&#160;a wholly-owned subsidiary of Nivalis merged with and into Alpine, with Alpine (renamed as &#8220;AIS Operating Co., Inc.&#8221;) remaining as the surviving entity; and (2)&#160;Nivalis was renamed as &#8220;Alpine Immune Sciences, Inc.&#8221;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCINECES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segments</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate as&#160;</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#160;operating segment and use cash flow as the primary measure to manage our business.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted cash</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consider all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking and interest-bearing accounts, and highly liquid money market funds.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash represents cash drawn on a line of credit used to establish collateral to support the security deposit on our operating lease to rent office and laboratory space in Seattle, Washington.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Periodically, we maintain deposits in financial institutions in excess of government insured limits. We believe we are not exposed to significant credit risk as our deposits, which are held at financial institutions, are high credit quality securities such as money market funds, U.S. Treasury securities, and commercial paper. To date, we have not realized any losses on these deposits.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our short-term investments include funds invested in highly liquid money market funds, U.S. Treasury securities, commercial paper, and corporate debt securities with a final maturity of each security of less than one year. All investments are classified as available-for-sale securities and are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses excluded from earnings and reported in other comprehensive income (loss). Purchase premiums and discounts are recognized as interest income using the interest method over the terms of the securities. Realized gains and losses and declines in fair value deemed to be other than temporary are reflected in the </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">&#32;using the specific-identification method.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;years, while leasehold improvements are amortized over the shorter of their estimated useful lives or the related lease term. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Maintenance and repairs are expensed as incurred. Major improvements are capitalized as additions to property and equipment.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Asset</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intangible asset is our indefinite-life S-nitrosoglutathione reductase (&#8220;GSNOR&#8221;) inhibitor in-process research and development asset (&#8220;IPR&amp;D&#8221;) acquired from Nivalis. The IPR&amp;D represents the processes, expertise, and technology employed in the development of GSNOR inhibitors and Nivalis&#8217; lead product candidate, cavosonstat. The IPR&amp;D represents the estimated fair value as of the acquisition date of substantive&#160;in-process&#160;projects that have not reached technological feasibility. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-lived Assets</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate our long-lived tangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If the carrying value exceeds the undiscounted future cash flows estimated to result from the use and eventual disposition of the asset, we write down the asset to its estimated fair value. Impairment is assessed by comparing the undiscounted cash flows expected to be generated by the asset to its carrying value. We did not record any impairments in the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate accruals for professional services and research and development expenses. This process involves reviewing contracts and vendor agreements and communicating with applicable personnel to identify services that have been performed on our behalf. We estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We estimate accrued liabilities as of each balance sheet date based on known facts and circumstances.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCINECES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, we have not experienced any significant adjustments to our estimates.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases and Deferred Rent</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into lease agreements for office and laboratory space. These leases are classified as operating leases. Rent payments, rent-free periods and rent increases are recognized as rent expense on a straight-line basis over the lease term. The difference between rent expense recognized and rental payments is recorded as deferred rent in the accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We granted common stock warrants to certain&#160;non-employee&#160;professional advisers. We account for our warrants at fair value, with changes in fair value recognized in operating expenses. Common stock warrants are initially recorded at their issuance date fair value and are subsequently remeasured at each balance sheet date. These warrants are valued using the Black-Scholes option pricing model based on the estimated market value of the underlying common stock at the valuation measurement dates, the remaining contractual term of the warrant, risk-free interest rates, expected dividends, and expected volatility of the price of the underlying common stock.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative Financial Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate all of our financial instruments, including issued&#160;stock purchase warrants, to determine if such instruments are derivatives or contain&#160;features qualifying as embedded derivatives.&#160;For derivative financial instruments accounted for as liabilities, the derivative instrument&#160;is initially recorded at its fair value and is then re-valued at each reporting date, with changes in&#160;the fair value reported in the </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">. We use the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. We do not use derivative instruments to hedge exposures to cash flow, market, or&#160;foreign currency risks.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition (effective January 1, 2018)</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our steps for recognizing revenue consist of;&#160;(1) identifying the contract,&#160;(2) identifying the performance obligations as either distinct or bundled goods and services,&#160;(3) determining the transaction price associated with each performance obligation for which we expect to be entitled in exchange for transferring such goods and services,&#160;(4) allocating the transaction price to the performance obligations in the contract and&#160;(5) recognizing revenue upon satisfaction of performance obligations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our collaboration agreements principally contain multiple performance obligations, which may include (1)&#160;grants of, or options to obtain, intellectual property licenses; (2)&#160;research and development services; and/or (3) manufacturing or supply services. Payments typically received under these arrangements include one or more of the following: non-refundable upfront license fees, option exercise fees, payment for research and/or development efforts, amounts due upon the achievement of specified objectives, and/or royalties on future product sales. Our revenue is primarily derived from our License and Research Agreement (the &#8220;Collaboration Agreement&#8221;) with Kite Pharma, a Gilead company (&#8220;Kite&#8221;). See further discussion of the Collaboration Agreement in </font><a style="font-family:inherit;font-size:10pt;" href="#s8A49DD14B58EDD54C86131F4B9EFCB92"><font style="font-family:inherit;font-size:10pt;">Note 12</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We allocate revenue to each performance obligation based on its relative stand-alone selling price. We generally determine stand-alone selling prices at the inception of the contract based on our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">&#32;and recognized as revenue when the related revenue recognition criteria are met. We recognize revenue under the Collaboration Agreement based on employee hours contributed to each performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Collaboration Agreement provides for non-refundable milestone payments. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to us for such milestone (1)&#160;is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance; (2)&#160;relates solely to our past performance; and (3)&#160;is reasonable relative to all of the other deliverables and payments within the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCINECES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial, and other risks that must be overcome to achieve the milestone, the level of effort and investment required to achieve the milestone and whether any portion of the milestone consideration is related to future performance or deliverables.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We review the contributed employee hours for each performance obligation under the Collaboration Agreement and adjust the revenue recognized to reflect changes in assumptions relating to the estimated satisfaction of the performance obligation. We could accelerate revenue recognition in the event of early termination of programs or if our expectations change. Alternatively, we could decelerate revenue recognition if programs are extended or delayed. While such changes to our estimates have no impact on our reported cash flows, the timing of revenue recorded in future periods could be materially impacted.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 2 included in our Annual Report on </font><a style="font-family:inherit;font-size:10pt;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-10k_20171231.htm"><font style="font-family:inherit;font-size:10pt;">Form 10-K for the year ended December 31, 2017</font></a><font style="font-family:inherit;font-size:10pt;">&#32;for more discussion regarding the accounting policies that governed revenue recognition prior to January 1, 2018.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred. Research and development costs include personnel costs, clinical trials, external contract research and development expenses, raw materials, drug product manufacturing costs and allocated overhead &#8211; including depreciation, rent and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for all stock-based compensation granted to employees and&#160;non-employees&#160;using a fair value method. Stock-based compensation awarded to employees and&#160;non-employees&#160;is measured at the grant date fair value for stock option grants. We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. Stock-based compensation to employees is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis. Stock-based compensation awarded to&#160;non-employees&#160;is revalued over its vesting period using a Black-Scholes option pricing model. For performance-based awards where the vesting of the options may be accelerated upon the achievement of certain milestones, vesting and the related stock-based compensation is recognized as an expense when it is probable the milestone will be met. We recognize forfeiture of awards as they occur rather than estimating the expected forfeiture rate.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When awards are modified, we compare the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the consolidated financial statement and tax bases of assets and liabilities at the applicable enacted tax rates. We will establish a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefits or that future deductibility is uncertain.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize the tax benefit from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax position is measured based on the largest benefit that has a greater than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;likelihood of being realized upon ultimate settlement. We recognize interest and penalties related to income tax matters in income tax expense if incurred. In December 2017, the SEC issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118 to address the application of GAAP in situations in which a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Cuts and Jobs Act (the &#8220;Tax Reform Act&#8221;) which was signed into law on December 22, 2017. In March 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-05, which amended ASC 740 to incorporate the requirements of SAB 118. We recognized the provisional tax impacts of the Tax Reform Act in the fourth quarter of 2017. Our federal tax loss and research and development credit carryforwards have been updated from the amounts previously provisionally disclosed to reflect a change in position with respect to our 2017 federal research and development credit. The update is a result of additional time spent on modeling the potential use of our tax attributes, as impacted by the Tax Reform Act. Otherwise, during the year ended December 31, 2018, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCINECES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we did not receive any additional information regarding these provisional calculations, except as disclosed in </font><a style="font-family:inherit;font-size:10pt;" href="#s2FF5B04E48A0D29197CD31F4BBF8E887"><font style="font-family:inherit;font-size:10pt;">Note 14, Income Taxes</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) is comprised of net loss and certain changes in equity excluded from net loss. For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, other comprehensive loss consisted of unrealized losses on our short-term investments. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;difference between comprehensive loss and net loss for the year ended December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU&#160;No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606. This ASU clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. This ASU is effective for public companies for annual reporting periods and interim periods within those annual periods beginning after December 15, 2019. We are currently evaluating the effect, if any, that ASU 2018-18 will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In&#160;August 2018,&#160;the FASB issued ASU&#160;No.&#160;2018-13,&#160;Fair Value Measurement. ASU&#160;2018-13&#160;modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted for any eliminated or modified disclosures. We are evaluating the effect of adopting this new accounting guidance to determine the impact it may have on our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU No.&#160;2018-07, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. Upon transition, nonemployee awards will be required to be measured at fair value as of the adoption date with a cumulative-effect adjustment recognized in retained earnings as of the beginning of the annual period of adoption. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity&#8217;s adoption date of ASC 606. We are evaluating the effect the standard will have on our financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No.&#160;2016-02, Leases. ASU 2016-02 requires a lessee to separate the lease components from the non-lease components in a contract and recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. It also aligns lease accounting for lessors with the revenue recognition guidance in ASU 2014-09. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years, and is to be applied at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU 2018-11, related to another transition method in lease accounting. If elected, the transition method allows entities to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We plan to adopt ASU 2016-02 on January 1, 2019 and intend to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of the accumulated deficit in the period of adoption as permitted under ASU 2018-11. Based on our leases in place on January 1, 2019 and considering the practical expedients, we expect the adoption of the new standard will not have a material effect on our consolidated statements of operations, will result in a gross-up on our consolidated balance sheets of less than </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;relating to our office and laboratory leases, and will have no effect on our consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09, Revenue from Contracts with Customers, as amended (&#8220;new revenue standard&#8221; or &#8220;ASC 606&#8221;), which amends the guidance for revenue recognition to replace numerous industry specific requirements. ASC 606 implements a five-step process for customer contract revenue recognition focusing on transfer of control, as opposed to transfer of risk and rewards. ASC 606 also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include ensuring the time value of money is considered in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. ASC 606 is effective for reporting periods beginning after December&#160;15, 2017. On January 1, 2018, we adopted the new accounting standard and all of the related amendments using the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCINECES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">modified retrospective method. We recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of our accumulated deficit. The cumulative effect of the changes related to the adoption of the new revenue standard increased our beginning balances in accumulated deficit and deferred revenue by </font><font style="font-family:inherit;font-size:10pt;">$203,000</font><font style="font-family:inherit;font-size:10pt;">&#32;within our </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Collaboration Agreement with Kite is the only contract that was impacted by the adoption of the new revenue standard. Prior to the adoption of the new revenue standard, we recognized revenue under the Collaboration Agreement based upon the estimated performance periods related to the non-refundable upfront payments we received from Kite. Under the new standard, we recognize revenue based on employee hours contributed to each performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated financial statements as of and for the year ended December 31, 2018 is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance without Adoption of ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,074</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,277</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,487</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Statement of Cash Flows</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15 which provides new guidance on the classification of certain cash receipts and payments in the statement of cash flows. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We adopted this new standard effective January 1, 2018. The adoption of this standard did not impact our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09 to provide clarity and reduce both diversity in practice and cost and complexity when applying the guidance in Compensation - Stock Compensation (&#8220;Topic 718&#8221;) about a change to the terms and conditions of a share-based payment award. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this update are effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted and applied prospectively to modifications occurring on or after the adoption date. We adopted this this standard effective January 1, 2018. The adoption of this standard did not have an impact on our financial statements.&#160;For the year ended December 31, 2018, there were no modifications to the terms or conditions of a share-based payment award.</font></div><div><a name="sD825573C793AF4AC779431F4B0E6A7BD"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. Business Combination</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">July&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">, we closed the merger on the terms described in more detail in </font><a style="font-family:inherit;font-size:10pt;" href="#sD31BE121D5B120F8794C31F4AFBEEF04"><font style="font-family:inherit;font-size:10pt;">Note 1</font></a><font style="font-family:inherit;font-size:10pt;">. In connection with the merger, Nivalis effected a </font><font style="font-family:inherit;font-size:10pt;">1:4 reverse stock split</font><font style="font-family:inherit;font-size:10pt;">&#32;of its common stock. Upon the closing of the merger, (1) a wholly-owned subsidiary of Nivalis merged with and into Alpine, with Alpine (renamed as &#8220;AIS Operating Co., Inc.&#8221;) remaining as the surviving entity; and (2) Nivalis was renamed as &#8220;Alpine Immune Sciences, Inc.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Merger Agreement, Nivalis issued shares of its common stock to Alpine&#8217;s stockholders, at an exchange rate of </font><font style="font-family:inherit;font-size:10pt;">0.4969</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Nivalis common stock, after taking into account the 1:4 reverse stock split, for each share of Alpine&#8217;s common stock and preferred stock outstanding immediately prior to the merger. The exchange rate was determined through arms-length negotiations between Nivalis and Alpine. Nivalis also assumed all of the stock options outstanding under Alpine&#8217;s Amended and Restated 2015 Stock Plan, as amended (the &#8220;Alpine Plan&#8221;), and stock warrants for Alpine&#8217;s capital stock outstanding immediately prior to the merger, with such stock options and warrants henceforth representing the right to purchase a number of shares of the Nivalis common stock equal to </font><font style="font-family:inherit;font-size:10pt;">0.4969</font><font style="font-family:inherit;font-size:10pt;">&#32;multiplied by the number of shares of Alpine&#8217;s common stock or preferred stock previously represented by such options and warrants. Nivalis also assumed the Alpine Plan. Immediately after the merger, there were </font><font style="font-family:inherit;font-size:10pt;">13,881,645</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock outstanding. Immediately after the merger, Alpine&#8217;s former </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">stockholders, warrantholders, and optionholders owned, or held rights to acquire, approximately </font><font style="font-family:inherit;font-size:10pt;">74%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the fully-diluted common stock of Nivalis, which for these purposes is defined as the outstanding common stock of Nivalis, plus &#8220;in the money&#8221; options and warrants to purchase shares of Nivalis&#8217; common stock, assuming all &#8220;in the money&#8221; options and warrants of Nivalis outstanding immediately prior to the merger are exercised on a cashless basis immediately prior to the closing of the merger, with Nivalis&#8217; stockholders, optionholders, and warrantholders immediately prior to the merger owning, or holding rights to acquire, approximately </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the fully diluted common stock of Nivalis. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The issuance of shares of Nivalis&#8217; common stock to our pre-existing stockholders was registered with the SEC pursuant to the Registration Statement. Immediately prior to the merger, we issued and sold an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$17.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of shares of our capital stock to certain existing stockholders. For accounting purposes, our historical financial statements were not adjusted to reflect the merger, other than adjustments to the capital structure to reflect the historical capital structure of Nivalis. No other adjustments to our historical assets and liabilities were made as a result of the merger.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the operating assets and liabilities of Nivalis, we also acquired Nivalis&#8217; tax attributes, which primarily consisted of net operating losses which begin to expire in 2032. Our ability to utilize the tax attributes of Nivalis may be limited under Section 382 of the U.S. Internal Revenue Service and as such, have been reserved. We recorded a deferred tax liability related to future tax benefits arising from IPR&amp;D acquired in the Merger. The combined organization is focusing on the development and commercialization of our innovative immunotherapies. Following the merger, the increased cash resources and increased access to capital of the combined organization will help to support the clinical development of our products.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consideration Transferred</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the consideration transferred was based on the most reliable measure, which was determined to be the market price of Nivalis shares of common stock as of the acquisition date. The fair value of the consideration transferred consisted of the following (in thousands except share and per share amounts):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Nivalis common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,914,058</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per share fair value of Nivalis common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Nivalis stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">421,992</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average per share fair value of Nivalis stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of consideration (in 000&#8217;s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,103</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Merger Agreement, unvested Nivalis stock options immediately vested as of the closing of the business combination and were adjusted to give effect to the recapitalization.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Price Allocation</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As Alpine was the accounting acquirer in the merger, we allocated the purchase price to the acquired tangible and intangible assets and assumed liabilities of Nivalis based on their estimated fair values as of the acquisition date. The excess of the estimated fair values of net assets acquired over the acquisition consideration paid was recorded as a bargain purchase gain in the </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">. The determination of the fair values of the assets acquired and liabilities assumed requires significant judgment, including third party valuation estimates relating to the value of the acquired IPR&amp;D. The allocation of the purchase consideration to the assets acquired and liabilities assumed in our financial statements was finalized as of December 31, 2017.&#160;&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The final allocation of the purchase consideration is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,130</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,952</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,453</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,614</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(401</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(910</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bargain purchase gain</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,601</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,103</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We relied on significant Level 3 unobservable inputs to estimate the fair value of our acquired IPR&amp;D using management&#8217;s estimate of future royalties and expected earnings of the assets after taking into account an estimate of future expenses necessary to bring the products to completion. These projected cash flows were then discounted to their present values using a discount rate of </font><font style="font-family:inherit;font-size:10pt;">17%</font><font style="font-family:inherit;font-size:10pt;">, which was considered commensurate with the risks and stages of development of the IPR&amp;D.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The bargain purchase gain resulted from expenses incurred by Nivalis between the time the purchase price was negotiated and the close of the transaction, and changes in the Nivalis stock price during that period as the exchange ratio was fixed when the purchase price was negotiated.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognized acquisition-related costs of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December 31, 2017. These costs are included within general and administrative expense in our </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pro Forma Financial Information</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following pro forma consolidated results of net loss for the year ended December 31, 2017 assume the business combination was completed as of January 1, 2017 (in thousands, except per share amounts):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,731</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,327</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.32</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of the pro forma disclosures above, the primary adjustments for the year ended December 31, 2017 includes the elimination of acquisition related costs and acceleration of stock compensation expense upon the change in control.</font></div><div><a name="sBEFEF0ECDB1F5BE49D1431F4B246E295"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Net Loss Per Share</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we considered our convertible preferred stock to be participating securities, and we computed net loss per share attributable to common stockholders using the two-class method required for participating securities. All participating securities are excluded from basic weighted-average common shares outstanding. In accordance with the two-class method, earnings allocated to these participating securities, which include participation rights in undistributed earnings, are subtracted from net income to determine total undistributed earnings to be allocated to common stockholders. Net loss is not allocated to participating securities as there is no contractual obligation to share in net losses. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net loss per share for the year ended December 31, 2017 includes the conversion of </font><font style="font-family:inherit;font-size:10pt;">9,301,433</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our convertible preferred stock into common stock, and </font><font style="font-family:inherit;font-size:10pt;">3,914,058</font><font style="font-family:inherit;font-size:10pt;">&#32;shares acquired in connection with the merger.&#160;&#160;The significant number of shares issued has affected the year-over-year comparability of our net loss per share calculations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share attributable to common stockholders calculation because their effect would have been antidilutive. Diluted net loss per share, therefore, does not differ from basic net loss per share for the periods presented:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,311,770</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,422</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,611,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,739</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,533,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,636,119</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,844,931</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sF422965E889EE9E2DC6931F4B2EAECAE"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. Cash Equivalents and Short-Term Investments</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amortized cost and fair value of our cash equivalents and short-term investments are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized<br>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br>unrealized<br>gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br>unrealized<br>losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair market<br>value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,405</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,405</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury bills</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,966</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,964</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities and commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,331</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair market</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,680</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,680</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury bills</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,909</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,888</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities and commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,979</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All short-term investments held as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were classified as available-for-sale securities and had contractual maturities of less than </font><font style="font-family:inherit;font-size:10pt;">one year</font><font style="font-family:inherit;font-size:10pt;">. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;realized gains and losses on these securities for the periods presented. </font></div><div><a name="sC1F3665DBAB46B60C33F31F4B3D6DEE8"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, receivables, accounts payable and accrued liabilities, which are recorded at invoiced amount or cost, approximate fair value based on the short-term nature of these financial instruments. Fair value is defined as the exchange price received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, is as follows:</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:inherit;font-size:10pt;">: Quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2</font><font style="font-family:inherit;font-size:10pt;">: Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, quoted prices in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:inherit;font-size:10pt;">: Unobservable inputs supported by little or no market activity and significant to the fair value of the assets or liabilities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, cash of </font><font style="font-family:inherit;font-size:10pt;">$614,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, is excluded from the fair value table below. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets:</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,405</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,405</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury bills</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,964</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,964</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities and commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets:</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,680</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,680</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury bills</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,888</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,888</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities and commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,568</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,352</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Level 2 assets consist of commercial paper and corporate debt securities. We review trading activity and pricing for our available-for-sale securities as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.</font></div><div><a name="s75090E3B4892D16194C231F4B907F14A"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7. Property and Equipment</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following (in thousands):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,506</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General equipment and furniture</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,895</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,400</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(699</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(311</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,196</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,089</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense was </font><font style="font-family:inherit;font-size:10pt;">$388,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$241,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$69,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div><a name="s0562a9ed9f4b40deb669d407c0a2c72f"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8. Loss on Sale of Intangible Asset</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, we entered into an Option License Agreement (&#8220;Option Agreement&#8221;) with Laurel Venture Capital Ltd. (&#8220;Laurel&#8221;), which granted Laurel a limited license to evaluate the indefinite-life GSNOR inhibitor IPR&amp;D asset acquired as part of the merger with Nivalis in 2017. The IPR&amp;D represents the processes, expertise, and technology employed in the development of GSNOR inhibitors and Nivalis&#8217; lead product candidate, cavosonstat. Under the Option Agreement, we received an upfront non-refundable payment of&#160;</font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;">, which was recognized as revenue in our accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, we entered into an Asset Purchase Agreement (&#8220;Purchase Agreement&#8221;) with Laurel and completed the sale of global rights to the GSNOR asset. As consideration under the Purchase Agreement, we received a non-refundable closing payment of&#160;</font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;">, which was accounted for as a purchase of our intangible asset. We are also eligible to receive an additional payment of approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$425,000</font><font style="font-family:inherit;font-size:10pt;">&#160;on the one-year anniversary of the sale completion date. In addition, we are eligible to receive milestone payments of up to&#160;</font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">, in the aggregate upon satisfaction by Laurel of certain regulatory approval milestones. We will also be eligible to receive royalty payments equal to a low single-digit percentage rate of worldwide net sales of any approved products. If Laurel transfers any part of the rights to the GSNOR assets within 12 months </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the sale completion date, we will be eligible to receive one-fourth of any cash payments made to Laurel by a transferee within 18 months of the sale completion date and such transferee will remain obligated with respect to Laurel&#8217;s milestone and royalty obligations to us.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the sale of the GSNOR assets, we derecognized the full carrying value of the intangible asset of&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#160;on our accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">&#32;and recognized a loss on the sale of the intangible asset of&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#160;on the accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="sF177D2DCFA2F9DE311F931F4B94ADC98"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. Additional Consolidated Balance Sheets Information</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets consists of the following (in thousands):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid insurance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,242</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities and other current liabilities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal and professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,277</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sED7F10289A3B0DB32D9431F4B96613FF"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10. Long-term Debt</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain a long-term financing arrangement with Silicon Valley Bank. On June 30, 2017, we drew down a term loan of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">. The loan had an interest-only period that expired on </font><font style="font-family:inherit;font-size:10pt;">July&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">, at which point we became obligated to make </font><font style="font-family:inherit;font-size:10pt;">thirty</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive equal monthly payments of principal (each in an amount that will fully amortize the loan), plus accrued interest. Interest accrues at a floating per annum rate equal to the lender&#8217;s prime rate minus </font><font style="font-family:inherit;font-size:10pt;">1.75%</font><font style="font-family:inherit;font-size:10pt;">. As a condition to the loan, we agreed to pay a final payment fee of </font><font style="font-family:inherit;font-size:10pt;">7.5%</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">$375,000</font><font style="font-family:inherit;font-size:10pt;">, upon repayment of the loan. The final payment fee was recorded in long-term debt with an offsetting reduction in long-term debt and was accounted for as a debt discount.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the loan agreement we have pledged substantially all of our assets, excluding intellectual property, as collateral.&#160;The obligations under the loan agreement are subject to acceleration upon the occurrence of specified events of default, including a material adverse change in our business, operations, financial, or other condition. We assessed the likelihood of the lender accelerating payment of the loan due to a material adverse change in our business, operations, financial, or other condition as remote. As such, as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the classification of the loan is split between current and noncurrent based on the timing of payment obligations. The term loan agreement contains customary conditions to borrowings, events of default and negative covenants, including covenants that could limit our ability to, among other things, incur additional indebtedness, liens or other encumbrances; make dividends or other distributions; buy, sell or transfer assets; engage in any new line of business; and enter into certain transactions with affiliates. We were in compliance with our covenants as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also, in connection with the drawdown of the loan, we granted Silicon Valley Bank </font><font style="font-family:inherit;font-size:10pt;">7,069</font><font style="font-family:inherit;font-size:10pt;">&#32;Series A</font><font style="font-family:inherit;font-size:10pt;">-1</font><font style="font-family:inherit;font-size:10pt;">&#32;Preferred Stock warrants at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$12.38</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. The fair value of the warrants on the date of issuance was </font><font style="font-family:inherit;font-size:10pt;">$53,000</font><font style="font-family:inherit;font-size:10pt;">, determined using the Black-Scholes option-pricing model, and was recorded as a discount to the note and as a warrant liability on the accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">. In connection with the merger and conversion of all outstanding Series A-1 preferred stock, the warrants became exercisable for </font><font style="font-family:inherit;font-size:10pt;">7,069</font><font style="font-family:inherit;font-size:10pt;">&#32;fully vested shares of our common stock. As a result of the change in the underlying shares, the warrants were equity-classified beginning on </font><font style="font-family:inherit;font-size:10pt;">July&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The debt discount is being amortized to interest expense using the effective interest method over the repayment term of the initial loan amount. Non-cash interest expense associated with the amortization of the discount was </font><font style="font-family:inherit;font-size:10pt;">$169,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$87,000</font><font style="font-family:inherit;font-size:10pt;">, for years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The unamortized discount was </font><font style="font-family:inherit;font-size:10pt;">$172,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future principal payments as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;under our loan based on contractual maturities are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year Ending December 31, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future principal payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sDE02C9E1F2B423FE169231F4B9B0F92E"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Lease</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we entered into a non-cancelable operating lease to rent office and laboratory space in Seattle, Washington. In April 2016, we amended the agreement to lease additional premises adjacent to our existing leased premises. Under our lease agreements, we lease approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">11,158</font><font style="font-family:inherit;font-size:10pt;">&#160;square feet of office and laboratory space with an annual base rent of </font><font style="font-family:inherit;font-size:10pt;">$566,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in the first year, which will increase by </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;">&#32;each year thereafter. The leases expire on </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and has </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;options to extend the lease term with each option enabling us to extend the lease term by </font><font style="font-family:inherit;font-size:10pt;">twelve months</font><font style="font-family:inherit;font-size:10pt;">. As required by the terms of the lease, in May 2017, we entered into a line of credit to establish collateral to support the security deposit in an amount of </font><font style="font-family:inherit;font-size:10pt;">$132,000</font><font style="font-family:inherit;font-size:10pt;">. This is recorded as restricted cash in the accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2018, we entered into a lease amendment for approximately </font><font style="font-family:inherit;font-size:10pt;">6,184</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet of additional office and laboratory space adjacent to our existing leased premises in Seattle, Washington. The lease expires on December&#160;31, 2019 and has </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;options to extend the lease term with each option enabling us to extend the lease term by </font><font style="font-family:inherit;font-size:10pt;">twelve months</font><font style="font-family:inherit;font-size:10pt;">. The annual base rent due under the lease is </font><font style="font-family:inherit;font-size:10pt;">$295,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first year and will increase by </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;each year thereafter. We recognize rent expense on a straight-line basis over the lease period and accrue for rent expense incurred but not paid. The lease also requires us to pay additional amounts for operating and maintenance expenses. Rent expense was </font><font style="font-family:inherit;font-size:10pt;">$811,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$529,000</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">$267,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease payments for&#160;our non-cancelable&#160;operating leases at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Minimum Lease Payments</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">930</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">949</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2019, we entered into a lease with ARE-Seattle No. 28, LLC (the &#8220;Landlord&#8221;) for </font><font style="font-family:inherit;font-size:10pt;">27,164</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet of office and laboratory space located at 188 East Blaine Street, Seattle, Washington. The term of the lease is </font><font style="font-family:inherit;font-size:10pt;">10.8 years</font><font style="font-family:inherit;font-size:10pt;">&#32;with </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;option to extend the term by </font><font style="font-family:inherit;font-size:10pt;">5.0 years</font><font style="font-family:inherit;font-size:10pt;">. The target &#8220;Commencement Date&#8221; is May 1, 2019 and shall be the date that Landlord delivers the premises to us in substantially complete condition. The &#8220;Rent Commencement Date&#8221; shall be the date that is nine months after the Commencement Date. The annual base rent due under the lease is </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first year and will increase by </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;each year thereafter. We will not be required to pay base rent from the Rent Commencement Date through the last day of the ninth month following the Rent Commencement Date. We will receive a maximum tenant improvement allowance of </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;">, which is included in our base rent, and a maximum additional tenant improvement allowance of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, which will result in additional rent amortized over the term of the lease at an annual rate of </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">. The lease also requires us to pay additional amounts for operating and maintenance expenses. In connection with the lease, we provided a&#160;</font><font style="font-family:inherit;font-size:10pt;">$254,000</font><font style="font-family:inherit;font-size:10pt;">&#160;letter of credit as a security deposit. Rent payments under our lease with ARE are not included in the table above.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-18</font></div></div><hr style="page-break-after:always"><div><a name="s8A49DD14B58EDD54C86131F4B9EFCB92"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. Collaboration and License Agreement</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, we entered into a Collaboration Agreement with Kite to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. Under our agreement, we are to perform certain research services and grant to Kite an exclusive license to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;programs from our transmembrane immunomodulatory protein (&#8220;TIP&#8221;) technology, which Kite is planning to further engineer into chimeric antigen receptor (&#8220;CAR&#8221;) and T cell receptor (&#8220;TCR&#8221;) product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Collaboration Agreement, in 2015, Kite made upfront payments to us of </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;">, which were initially recorded as deferred revenue. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we are also eligible to receive milestone payments based upon the successful achievement of pre-specified research, clinical, and regulatory milestones totaling up to </font><font style="font-family:inherit;font-size:10pt;">$530.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;plus royalty payments on product sales, if any. Kite will receive an exclusive, worldwide license to research, develop, and commercialize engineered autologous T cell therapies incorporating </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;programs coming from our platform.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, we entered into an amendment with Kite to extend the research term of the Collaboration Agreement. Under the amended agreement, we became eligible to receive an additional </font><font style="font-family:inherit;font-size:10pt;">$450,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in research support payments from Kite in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;tranches. In June 2018, we recognized one of the research support payments under the amended agreement. In October 2018, we entered into another amendment with Kite, which amended portions of the research plan. We have recorded revenue of </font><font style="font-family:inherit;font-size:10pt;">$630,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, under the Collaboration and Licensing Agreement. In the second quarter of 2018, based on the completion of our research and development efforts in connection with the performance period, we recognized the remaining balance in deferred revenue on our accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As further discussed in </font><a style="font-family:inherit;font-size:10pt;" href="#sFE10AB00D18A281B653831F4AFFB388C"><font style="font-family:inherit;font-size:10pt;">Note 2</font></a><font style="font-family:inherit;font-size:10pt;">, on January 1, 2018, we adopted the new revenue standard using the modified retrospective method. Prior to the adoption of the new revenue standard, we recognized revenue under the Collaboration Agreement based upon the estimated performance periods related to the non-refundable upfront payments we received from Kite. Under the new standard, we recognize revenue based on employee hours contributed to each performance obligation. We recognized </font><font style="font-family:inherit;font-size:10pt;">$203,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in higher revenue for the year ended December 31, 2018, as compared to what would have been recorded under previous accounting guidance.</font></div><div><a name="s30476031FB479B69EF9A31F4BAFE7846"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13. Stockholders&#8217; Deficit </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the closing of the merger in 2017, all outstanding shares of our convertible preferred stock converted into </font><font style="font-family:inherit;font-size:10pt;">9,301,433</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we did not have any convertible preferred stock outstanding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had </font><font style="font-family:inherit;font-size:10pt;">13,854,205</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">13,831,178</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. Shares of common stock reserved for future issuance were as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares to be issued upon exercise of outstanding stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,850</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,611,996</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares to be issued upon conversion of common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for future stock grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">496,530</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">576,722</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares to be issued under employee stock purchase plan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,211</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,211</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares of common stock reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,075,714</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,258,052</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, we repurchased </font><font style="font-family:inherit;font-size:10pt;">50,467</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of unvested common stock issued to one of our former employees for the original purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.002</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Securities Offerings</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, we entered into a sales agreement (the &#8220;Cowen Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;) to sell shares of our common stock having aggregate sales proceeds of up to </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;">, from time to time, through an &#8220;at the market&#8221; equity offering program under which Cowen acted as our sales agent. In June 2018, we and Cowen agreed to terminate the Cowen Sales Agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, we entered into an equity distribution agreement, (&#8220;Equity Distribution Agreement&#8221;), with Piper Jaffray &amp; Co., (&#8220;Piper Jaffray&#8221;), pursuant to which we may sell shares of our common stock through an &#8220;at the market&#8221; equity offering </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">program for up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">, in gross cash proceeds. Piper Jaffray will be entitled to compensation for its services of up to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the gross sales price per share of all shares sold through Piper Jaffray under the Equity Distribution Agreement. The Equity Distribution Agreement may be terminated by us upon written notice to Piper Jaffray for any reason or by Piper Jaffray upon written notice to us for any reason or at any time under certain circumstances, including but not limited to if we experience a material adverse change.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Equity Distribution Agreement, we will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. We have no obligation to sell any shares under the Equity Distribution Agreement and may at any time suspend solicitation and offers under the Equity Distribution Agreement. The shares will be issued pursuant to our effective shelf registration statement on Form S-3 (File No.&#160;333-212404), declared effective by the SEC on July&#160;14, 2016. We filed a prospectus supplement (the &#8220;Prospectus Supplement&#8221;), dated June 11, 2018, with the SEC in connection with the offer and sale of the shares pursuant to the Equity Distribution Agreement. The Prospectus Supplement relates to the offering of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in shares of our common stock and we will be required to file an additional prospectus supplement in the event we seek to offer more than </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in shares of our common stock in accordance with the Equity Distribution Agreement. As </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we have made no sales under the Equity Distribution Agreement. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2019, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with a limited number of accredited investors, pursuant to which we, in a private placement (the &#8220;Private Placement&#8221;), sold </font><font style="font-family:inherit;font-size:10pt;">$25.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;units (the &#8220;Units&#8221;) for a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$5.37</font><font style="font-family:inherit;font-size:10pt;">&#32;per Unit. Each Unit consists of one share of our common stock and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.39</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. Pursuant to the terms of the Purchase Agreement, we issued </font><font style="font-family:inherit;font-size:10pt;">4,706,700</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock and warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,835,610</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. The warrants have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$12.74</font><font style="font-family:inherit;font-size:10pt;">&#32;and have a term of </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The securities being sold in the Private Placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. We have agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable in connection with the Private Placement and upon exercise of the warrants.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred legal, accounting and other direct costs related to our efforts to raise capital. These costs have been capitalized as deferred financing costs and are included within prepaid expenses and other current assets in our accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">. These costs are deferred until completion of an offering, at which time they will be reclassified to additional paid-in capital as a reduction of the proceeds. As </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we have incurred </font><font style="font-family:inherit;font-size:10pt;">$477,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of deferred financing costs. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:12px;padding-left:0px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued warrants in connection with the drawdown of our SVB loan, and to certain non-employee professional advisers. We also assumed warrants in connection with the merger. No additional warrants were issued or exercised during the year ended December 31, 2018. A summary of our warrant activity is presented below:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contract</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.62</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,153</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.76</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Incentive Plans</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, our board of directors adopted, and in June 2018 our stockholders approved, the 2018 Equity Incentive Plan (&#8220;2018 Plan&#8221;) under which </font><font style="font-family:inherit;font-size:10pt;">901,530</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of our common stock were initially reserved for issuance, and we ceased granting stock awards under the Nivalis Therapeutics, Inc. 2015 Equity Incentive Plan (the &#8220;2015 EIP&#8221;) and the Amended and Restated 2015 Stock Plan (the &#8220;2015 Plan&#8221;), collectively, the &#8220;Legacy Plans&#8221;. All shares of common stock subject to awards under the Legacy Plans that expire or terminate without having been exercised in full, or are forfeited to or repurchased by the company, will be added to the 2018 Plan up to a maximum of </font><font style="font-family:inherit;font-size:10pt;">1,972,784</font><font style="font-family:inherit;font-size:10pt;">&#32;shares.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, our 2018 Plan provides for an annual increase in the number of shares reserved for insurance under our 2018 Plan equal to the lesser of (1) </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the number of shares of common stock outstanding as of the last day of the preceding calendar year and (2) </font><font style="font-family:inherit;font-size:10pt;">1,500,000</font><font style="font-family:inherit;font-size:10pt;">. However, our board of directors may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for such year will be a lesser number of shares. On January 1, 2019, a total of </font><font style="font-family:inherit;font-size:10pt;">692,710</font><font style="font-family:inherit;font-size:10pt;">&#32;additional shares were automatically added to the shares authorized under the 2018 Plan.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018 our board of directors approved an &#8220;inducement&#8221; option grant, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules, to purchase </font><font style="font-family:inherit;font-size:10pt;">150,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock to our President and Chief Operating Officer. The option grant was exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof as a transaction by an issuer not involving a public offering. The options granted vest within </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#32;years, subject to continued employment, and expire </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">&#32;years after the date of grant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, in connection with the merger, we assumed Nivalis&#8217; Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) and the 2015 EIP. Upon assumption of the ESPP, there were </font><font style="font-family:inherit;font-size:10pt;">45,211</font><font style="font-family:inherit;font-size:10pt;">&#32;shares available for issuance under the ESPP. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we have not activated the ESPP. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options granted under our equity plans generally vest within </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#32;years and vested options are exercisable from the grant date until </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">&#32;after the date of grant. Vesting of certain employee options may be accelerated in the event of a change in control of the Company. We grant stock options to employees with exercise prices equal to the fair value of our common stock on the date of grant. The term of incentive stock options may not exceed </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">&#32;from the date of grant. We utilize newly issued shares to satisfy option exercises.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, a total of </font><font style="font-family:inherit;font-size:10pt;">3,061,084</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock were authorized for issuance under our 2018 Plan, 2015 Plan and 2015 EIP, and </font><font style="font-family:inherit;font-size:10pt;">496,530</font><font style="font-family:inherit;font-size:10pt;">&#32;shares were available for future grants under our 2018 Plan. A summary of stock option activity under our plans is presented below:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contract</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,611,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">936,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,869</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.01</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest after December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,484,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">887,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$6.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of unrecognized stock-based compensation expense related to nonvested stock options that is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.9 years</font><font style="font-family:inherit;font-size:10pt;">. The aggregate intrinsic value of stock options exercised during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$214,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$18,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$22,000</font><font style="font-family:inherit;font-size:10pt;">. The total fair value of shares vested during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$139,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$70,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes option pricing model requires us to make certain estimates and assumptions, including assumptions related to the expected price volatility of our stock, the period during which the options will be outstanding, the rate of return on risk-free investments, and the expected dividend yield of our stock. The fair values of stock options granted to employees were </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">calculated using the following assumptions:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:56%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average estimated fair value at grant</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$5.43</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.69</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.42</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.27% - 3.07%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.90% - 2.26%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.14% - 2.24%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term of options (in years) (2)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50 &#8211; 7.00</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.69 &#8211; 6.32</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.22 &#8211; 7.00</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected stock price volatility (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70% - 77%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72% - 83%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72% - 79%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield (4)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that had terms consistent with the expected term of our stock option grants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We used the &#8220;simplified method&#8221; for options to determine the expected term of stock option granted to employees, since we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited time our shares have been publicly traded. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility is a measure of the amount by which a financial variable, such as share price, has fluctuated or is expected to fluctuate during a period. We analyzed the stock price volatility of companies at a similar stage of development to estimate expected volatility of our stock price.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each non-employee stock option is estimated at the date of grant using the Black-Scholes option pricing model is are remeasured over the vesting term, as earned. Assumptions used in valuing non-employee stock options are generally consistent with those used for employee stock options, with the exception that the expected term is over the contractual life of the option.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is classified in the </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">&#32;as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">890</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,385</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-Employee:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">838</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016 we extended the vesting period of </font><font style="font-family:inherit;font-size:10pt;">567,500</font><font style="font-family:inherit;font-size:10pt;">&#32;unvested share options held by </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;employees. As a result of this modification, we recognized additional compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$4,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December&#160;31, 2016.</font></div><div><a name="s2FF5B04E48A0D29197CD31F4BBF8E887"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14. Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the U.S. government enacted the Tax Act. The Tax Act incorporates broad and complex changes to the U.S. tax code. The main provision of the Tax Act that is applicable to us is the reduction of a maximum federal tax rate of 35% to a flat tax rate of 21%, effective January 1, 2018. We incorporated the change in federal tax rates in our annual tax provision for the annual period ended December 31, 2017. Additionally, SAB 118 was issued to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. December 22, 2018 marked the end of the measurement period for purposes of SAB 118. We have completed and recorded the adjustments necessary under SAB 118 related to the Tax Act. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our income (loss) before taxes is derived from domestic (United States) sources. The provision for income taxes is composed of the following (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. - Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. - State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. - Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(204</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. - State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(204</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total income tax benefit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(366</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes (net of federal benefit)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.8</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permanent differences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal research and development credit</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Benefit of a lower tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-deductible merger costs</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17.6</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bargain purchase gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax rate change</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recorded tax benefits of </font><font style="font-family:inherit;font-size:10pt;">$366,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and of </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended December 31, 2018 and 2017, respectively, which represent effective tax rates of </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended December 31, 2018 and 2017, respectively. The difference between the U.S. federal statutory tax rates of </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;">&#32;and our effective tax rate in all periods is primarily due to a full valuation allowance related to our deferred tax assets, the generation and consumption of federal R&amp;D tax credits, as well as a refund of state taxes from a carryback of the 2018 net operating loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table represents the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significant components of our deferred tax assets and liabilities for the periods presented (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,546</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,475</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset basis</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,774</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,722</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets, net of valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed asset basis</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset basis</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets and liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the merger with Nivalis, we identified </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of acquired IPR&amp;D. IPR&amp;D acquired in a business combination is an indefinite-lived intangible asset until the completion or abandonment of the associated R&amp;D efforts. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2017, future reversal of the deferred tax liability resulting from IPR&amp;D costs could not be scheduled for tax purposes and therefore could not be considered as a source of future taxable income. A deferred tax liability of </font><font style="font-family:inherit;font-size:10pt;">$305,000</font><font style="font-family:inherit;font-size:10pt;">&#32;was recorded in 2017 as a result of the acquired IPR&amp;D having a financial reporting basis of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and a tax basis of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">. In the year ended December 31, 2018, we sold the IPR&amp;D and reversed the deferred tax liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A valuation allowance is provided for deferred tax assets where the recoverability of the assets is uncertain. The determination to provide a valuation allowance is dependent upon the assessment of whether it is more likely than not that sufficient taxable income will be generated to utilize the deferred tax assets. Based on the weight of the available evidence, which includes our historical operating losses, uncertainty of future taxable income, and the accumulated deficit, we provided a full valuation allowance against our deferred tax assets. The valuation allowance increased by </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended December 31, 2018 and December 31, 2017, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have net operating loss carryforwards as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal (before January 1, 2018)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,094</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,784</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal (after January 1, 2018)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,417</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,756</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state net operating loss carryforwards created before January 1, 2018 begin to expire in 2037. Federal net operating loss carryforwards created after January 1, 2018 carryforward indefinitely. The State net operating loss carryforwards begin to expire in 2038. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have net research and development tax credit carryforwards as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal research and development tax credit carryforwards begin to expire in 2035.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current tax laws impose substantial restrictions on the utilization of R&amp;D credit and net operating loss carryforwards in the event of an ownership change, as defined by the Internal Revenue Code Section 382 and 383. Such an event may limit our ability to utilize net operating losses and R&amp;D tax credit carryforwards. Under Internal Revenue Code Section 382 and 383, the 2017 merger with Nivalis is likely considered an ownership change with respect to the potential limitation of the Nivalis federal tax credits and net operating losses. As such, it is likely that any future utilization of Nivalis federal tax credits and net operating losses is substantially limited. Therefore, as of December 31, 2018, all Nivalis tax credit and net operating loss carryforwards have been reduced to </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for uncertainty in income taxes in accordance with ASC 740. Tax positions are evaluated in a two-step process, whereby we first determine whether it is more likely than not that a tax position will be sustained upon examination by the tax authority, including resolutions of any related appeals or litigation processes, based on technical merit. If a tax position meets the more-likely-than-not recognition threshold it is then measured to determine the amount of benefit to recognize in the financial statements. The tax position is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarized the activity related to unrecognized tax benefits (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized benefits &#8211; beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross increases (decreases) &#8211; prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross increases &#8211; current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized benefit &#8211; end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">469</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the unrecognized tax benefits as of December 31, 2018 are accounted for as a reduction in our deferred tax assets. Due to our valuation allowance, none of the </font><font style="font-family:inherit;font-size:10pt;">$469,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of unrecognized tax benefits would affect our effective tax rate, if recognized. We do not believe it is reasonably possible that our unrecognized tax benefits will significantly change in the next twelve months.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize interest and penalties related to unrecognized tax benefits as income tax expense. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;accrued interest or penalties related to unrecognized tax benefits for 2018 and 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not expect any significant change in our unrecognized tax benefits during the next twelve months.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our material income tax jurisdictions are the United States (federal), and California (state). We are subject to audit for tax years 2012 and forward for federal purposes, and 2015 and forward for California.</font></div><div><a name="s18AF2305328B0AB2DF7B31F4BC812CCA"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15. Related Party Transactions</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2019, in connection with our Purchase Agreement we sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">935,753</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock and issued warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">364,943</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock for gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to certain of our </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;stockholders. See </font><a style="font-family:inherit;font-size:10pt;" href="#s5D1F7A0CEF73296F6BF731F4CC92B1EC"><font style="font-family:inherit;font-size:10pt;">Part III, Item 13 of this Form 10-K</font></a><font style="font-family:inherit;font-size:10pt;">&#32;for additional information. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a shared services agreement with Alpine BioVentures GP, LLC, pursuant to which we incurred costs of </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$17,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. We had an accrual of </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the shared services agreement at December&#160;31, 2016, which was paid in April 2017. </font></div><div><a name="s89A6C71E1E97EC30E26E31F4BC9D5596"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16. 401(k) Retirement Plan</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have adopted a 401(k) plan. All employees are eligible to participate, provided they meet the requirements of the plan. To date, we have not matched employee contributions to the plan.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-25</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>2
<FILENAME>alpn-ex1012_20181231.htm
<DESCRIPTION>EXHIBIT 10.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBB01D232165E4DD68799832323F04E0D"></a></div><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit 10.12</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LICENSE AND RESEARCH AGREEMENT AMENDMENT NO. 2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This License and Research Agreement Amendment No. 2 (this &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment No. 2</font><font style="font-family:inherit;font-size:11pt;">&#8221;) is made effective as of October 17, 2018 (the &#8220;Amendment Effective Date&#8221;) by and between </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">AIS Operating Co., Inc.</font><font style="font-family:inherit;font-size:11pt;">, f/k/a Alpine Immune Sciences, Inc., a Delaware corporation (&#8220;Alpine&#8221;), and </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Kite Pharma, Inc.</font><font style="font-family:inherit;font-size:11pt;">, a Delaware corporation (&#8220;Kite&#8221;), with reference to the following facts:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WHEREAS: </font><font style="font-family:inherit;font-size:11pt;">Alpine and Kite entered into that certain License and Research Agreement, effective as of October 26, 2015, as amended by Amendment No. 1 (defined below) (collectively, the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;), pursuant to which, among other things, Alpine agreed to perform certain research services and further agreed to grant Kite certain licenses under technology and intellectual property rights controlled by Alpine and, in exchange for such services and licenses, Kite agreed to pay certain research support and license fees to Alpine, all as further described in the Agreement;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WHEREAS: </font><font style="font-family:inherit;font-size:11pt;">Alpine and Kite entered into that certain License and Research Agreement Amendment No. 1, effective as of October 20, 2017 (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment No. 1</font><font style="font-family:inherit;font-size:11pt;">&#8221;), pursuant to which, among other things, the Parties extended the Research Term (</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 1.67</font><font style="font-family:inherit;font-size:11pt;">) and updated the Research Plan (</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit 4.1(b)</font><font style="font-family:inherit;font-size:11pt;">);</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WHEREAS: </font><font style="font-family:inherit;font-size:11pt;">Alpine and Kite now desire to enter into this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment No. 2</font><font style="font-family:inherit;font-size:11pt;">&#32;to memorialize the automatic extension of the Research Term, and to clarify the confirmation of POC under the Research Plan.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMENDMENT</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NOW, THEREFORE</font><font style="font-family:inherit;font-size:11pt;">, in consideration of the foregoing and the agreements set forth below, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Alpine and Kite (each a &#8220;Party&#8221; and together the &#8220;Parties&#8221;) hereby agree as follows: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The recitals set forth above constitute an integral part of this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment No. 2</font><font style="font-family:inherit;font-size:11pt;">&#32;and are incorporated herein by reference with the same force and effect as if set forth herein as agreements of the Parties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Effective as of the Amendment Effective Date, the Parties mutually acknowledge and agree that the </font><font style="font-family:inherit;font-size:11pt;">[****]</font><font style="font-family:inherit;font-size:11pt;">&#32;Alpine has initiated under the Research Plan triggers the automatic extension of the Research Term (as set forth in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 1.67(b)</font><font style="font-family:inherit;font-size:11pt;">) for an additional period of </font><font style="font-family:inherit;font-size:11pt;">[****]</font><font style="font-family:inherit;font-size:11pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Effective as of the Amendment Effective Date, the Parties wish to clarify the criteria for validation of POC, and hereby agree to delete the following sections of the Research Plan (</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit 4.1(b)</font><font style="font-family:inherit;font-size:11pt;">):</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[****]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">and to replace these sections with the POC demonstration criteria set forth in  </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Schedule 2</font><font style="font-family:inherit;font-size:11pt;">.  Further, for the avoidance of doubt, the Parties acknowledge and agree that any demonstration of POC under the Research Plan shall be confirmed and agreed to by Kite, in Kite&#8217;s sole discretion.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Except as modified herein, all of the provisions of the Agreement shall remain unchanged and in full force and effect. Capitalized terms used in this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment No. 2</font><font style="font-family:inherit;font-size:11pt;">&#32;and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">This </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment No. 2</font><font style="font-family:inherit;font-size:11pt;">&#32;may be executed in counterparts, each of which shall be an original, but all of which together shall be deemed to constitute one (1) instrument. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Signature Page Follows</font><font style="font-family:inherit;font-size:11pt;">]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:inherit;font-size:11pt;">, this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment No. 2</font><font style="font-family:inherit;font-size:11pt;">&#32;is hereby executed as of the Amendment Effective Date. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;ALPINE:&#8221;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;KITE:&#8221;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AIS OPERATING CO., INC.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;KITE PHARMA, INC.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;F/K/A ALPINE IMMUNE SCIENCES, INC.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#32;/s/Paul Rickey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#32;/s/Peter Emtage&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;Paul Rickey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;Name: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;Peter Emtage&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#32;Chief Financial Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;Title: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#32;Senior Vice President&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:137%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;text-decoration:underline;">SCHEDULE 2</font></div><div style="line-height:135%;padding-top:17px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[****]</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1. </font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:100%;text-align:justify;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[****] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.</font></div><div style="line-height:120%;"><hr></div><div style="line-height:100%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>alpn-ex231_20181231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD915A15B0DBC0B7688835DD4E970EBF5"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 23.1</font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consent to the incorporation by reference in the following Registration Statements: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:0%;"></td><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">(1)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-3 No. 333-212404) of Nivalis Therapeutics, Inc.,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">(2)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-205220) pertaining to the 2012 Stock Incentive Plan of N30 Pharmaceuticals, Inc., 2015 Equity Incentive Plan of Nivalis Therapeutics, Inc. and Employee Stock Purchase Plan of Nivalis Therapeutics, Inc.,</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">(3)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-211197) pertaining to the Employment Inducement Awards of Nivalis Therapeutics, Inc.,</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">(4)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Post-Effective Amendment No. 1 on Form S-8 to Form S-4 No. 333-218134) pertaining to the Amended and Restated 2015 Stock Plan of Alpine Immune Sciences, Inc.,</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">(5)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-223965) pertaining to the Amended and Restated 2015 Stock Plan, as amended, and the 2015 Equity Incentive Plan of Alpine Immune Sciences, Inc.,</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">(6)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-225792) pertaining to the 2018 Equity Incentive Plan of Alpine Immune Sciences, Inc.,</font><font style="font-family:inherit;font-size:10pt;color:#333333;">&#160;&#160;&#160;&#160;&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of our report dated March&#160;18, 2019, with respect to the consolidated financial statements of Alpine Immune Sciences, Inc., included in this Annual Report (Form 10-K) of Alpine Immune Sciences, Inc. for the year ended December&#160;31, 2018. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Seattle, Washington</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 18, 2019</font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>alpn-ex311_20181231.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCD6CA6909017DD49B42731F4C43A5C8A"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Mitchell Gold, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Alpine Immune Sciences, Inc.;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 18, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;Mitchell Gold</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mitchell Gold</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Chairman and Chief Executive Officer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>alpn-ex312_20181231.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4756A35C8B4692B315D731F4C4C18630"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Paul Rickey, certify that:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Alpine Immune Sciences, Inc.;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 18, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;Paul Rickey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paul Rickey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Accounting Officer and Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>alpn-ex321_20181231.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF8A1893460650EF0E97A31F4C5696CFE"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCIENCES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Annual Report of Alpine Immune Sciences, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Mitchell Gold, Executive Chairman and Chief Executive Officer </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 18, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;Mitchell Gold</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mitchell Gold</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Chairman and Chief Executive Officer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:120%;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Alpine Immune Sciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>alpn-ex322_20181231.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE3C2CCFB5331101B127831F4C60F3E59"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.2</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALPINE IMMUNE SCIENCES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Annual Report of Alpine Immune Sciences, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Paul Rickey, Senior Vice President and Chief Financial Officer </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Accounting Officer and Principal Financial Officer)</font><font style="font-family:inherit;font-size:10pt;">, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 18, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;Paul Rickey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paul Rickey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Accounting Officer and Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:120%;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Alpine Immune Sciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>alpn-20181231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:acb084b4bf854698b9a3957b2387456e,x:11a1dcf28c684ad78eaae50550139087-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:alpn="http://www.alpineimmunesciences.com/20181231" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="alpn-20181231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Mar06">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Jul24">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul24">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-24</xbrli:startDate>
			<xbrli:endDate>2017-07-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alpn:NivalisTherapeuticsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-24</xbrli:startDate>
			<xbrli:endDate>2017-07-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul24_dei_LegalEntityAxis_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alpn:AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-24</xbrli:startDate>
			<xbrli:endDate>2017-07-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul23toJul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alpn:NivalisTherapeuticsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-23</xbrli:startDate>
			<xbrli:endDate>2017-07-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_LeaseArrangementTypeAxis_alpn_OfficeAndLaboratoryLeasesMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alpn:OfficeAndLaboratoryLeasesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alpn:NivalisTherapeuticsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alpn:NivalisTherapeuticsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alpn:NivalisTherapeuticsIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alpn:AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-24</xbrli:startDate>
			<xbrli:endDate>2017-07-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Jul25">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-25</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_dei_LegalEntityAxis_alpn_NivalisTherapeuticsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alpn:NivalisTherapeuticsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_alpn_GeneralEquipmentAndFurnitureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alpn:GeneralEquipmentAndFurnitureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_alpn_GeneralEquipmentAndFurnitureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alpn:GeneralEquipmentAndFurnitureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Jun01-Jun30_dei_LegalEntityAxis_alpn_LaurelVentureCapitalLtd.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_alpn_GSNORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alpn:LaurelVentureCapitalLtd.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">alpn:GSNORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_dei_LegalEntityAxis_alpn_LaurelVentureCapitalLtd.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_alpn_GSNORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alpn:LaurelVentureCapitalLtd.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">alpn:GSNORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_dei_LegalEntityAxis_alpn_LaurelVentureCapitalLtd.Member_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_alpn_GSNORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alpn:LaurelVentureCapitalLtd.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">alpn:GSNORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1_dei_LegalEntityAxis_alpn_LaurelVentureCapitalLtd.Member_us-gaap_DebtInstrumentAxis_alpn_TermSheetMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_alpn_GSNORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alpn:LaurelVentureCapitalLtd.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alpn:TermSheetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">alpn:GSNORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q2Jun01-Jun30_dei_LegalEntityAxis_alpn_LaurelVentureCapitalLtd.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_alpn_GSNORMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alpn:LaurelVentureCapitalLtd.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">alpn:GSNORMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun30_us-gaap_DebtInstrumentAxis_alpn_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alpn:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-30</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun30_us-gaap_DebtInstrumentAxis_alpn_TermLoanMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alpn:TermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-30</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_alpn_SeriesAOnePreferredStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:SeriesAOnePreferredStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_DebtInstrumentAxis_alpn_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alpn:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Jul24_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-30</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar01-Mar18_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-01</xbrli:startDate>
			<xbrli:endDate>2019-03-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Mar18_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan1toJan31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Mar18_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2May31_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Oct31_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alpn:KiteMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementProductAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CounterpartyNameAxis_alpn_KiteMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alpn:KiteMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementProductAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Oct1-Oct31_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alpn:KiteMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementProductAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alpn:KiteMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementProductAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alpn:KiteMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementProductAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alpn:KiteMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementProductAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Oct31_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alpn:KiteMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementProductAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alpn:KiteMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementProductAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-08-01</xbrli:startDate>
			<xbrli:endDate>2018-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May1toMay31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-01</xbrli:startDate>
			<xbrli:endDate>2016-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PlanNameAxis_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alpn:StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul01-Jul31_dei_LegalEntityAxis_alpn_CowenandCompanyLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alpn:CowenandCompanyLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Jun01-Jun30_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_alpn_TwoThousandAndEighteenPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alpn:TwoThousandAndEighteenPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Jun01-Jun30_dei_LegalEntityAxis_alpn_PiperJaffrayCo.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alpn:PiperJaffrayCo.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3Aug31_us-gaap_PlanNameAxis_alpn_InducementGrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alpn:InducementGrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Jun01-Jun30_us-gaap_PlanNameAxis_alpn_TwoThousandAndEighteenPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alpn:TwoThousandAndEighteenPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2June11">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-11</xbrli:startDate>
			<xbrli:endDate>2018-06-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_AwardTypeAxis_alpn_CommonStockInitialReservesMember_us-gaap_PlanNameAxis_alpn_TwoThousandAndEighteenPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alpn:CommonStockInitialReservesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alpn:TwoThousandAndEighteenPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec1toDec31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PlanNameAxis_alpn_StockPlan2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alpn:StockPlan2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Jan01_us-gaap_PlanNameAxis_alpn_TwoThousandAndEighteenPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alpn:TwoThousandAndEighteenPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_AwardTypeAxis_alpn_LegacyPlanCancellationsMember_us-gaap_PlanNameAxis_alpn_TwoThousandAndEighteenPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alpn:LegacyPlanCancellationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alpn:TwoThousandAndEighteenPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Jul31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_alpn_IncentiveStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alpn:IncentiveStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_EmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">alpn:EmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_NonEmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">alpn:NonEmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_EmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">alpn:EmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_EmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">alpn:EmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_EmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">alpn:EmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_NonEmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">alpn:NonEmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_EmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">alpn:EmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_NonEmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">alpn:NonEmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_NonEmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">alpn:NonEmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_NonEmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">alpn:NonEmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_EmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">alpn:EmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_NonEmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">alpn:NonEmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alpn:SharesToBeIssuedUponConversionOfCommonStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alpn:SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alpn:SharesToBeIssuedUponConversionOfCommonStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alpn:SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alpn:SharesToBeIssuedUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alpn:SharesToBeIssuedUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_alpn_SharesAvailableForFutureStockGrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alpn:SharesAvailableForFutureStockGrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_alpn_SharesAvailableForFutureStockGrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alpn:SharesAvailableForFutureStockGrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alpn:NivalisTherapeuticsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alpn:NivalisTherapeuticsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_alpn_BeforeJanuary12018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">alpn:BeforeJanuary12018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_alpn_AfterJanuary12018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">alpn:AfterJanuary12018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_alpn_BeforeJanuary12018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">alpn:BeforeJanuary12018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_alpn_AlpineBioVenturesGPLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alpn:AlpineBioVenturesGPLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_alpn_AlpineBioVenturesGPLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alpn:AlpineBioVenturesGPLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_alpn_AlpineBioVenturesGPLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alpn:AlpineBioVenturesGPLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_alpn_AlpineBioVenturesGPLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alpn:AlpineBioVenturesGPLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="employee">
		<xbrli:measure>alpn:employee</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="payment">
		<xbrli:measure>alpn:payment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="program">
		<xbrli:measure>alpn:program</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="term">
		<xbrli:measure>alpn:term</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>alpn:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<alpn:AccruedResearchAndDevelopmentCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-CC1DD146DDD7A9F0FA91CCCC1039D754" unitRef="usd">197000</alpn:AccruedResearchAndDevelopmentCurrent>
	<alpn:AccruedResearchAndDevelopmentCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-A135BEAD8563715DD90D323762615689" unitRef="usd">2457000</alpn:AccruedResearchAndDevelopmentCurrent>
	<alpn:AdditionalCompensationExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E1AB99A7F94FEAC35E5532376243790C" unitRef="usd">4000</alpn:AdditionalCompensationExpense>
	<alpn:AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease contextRef="I2018Q1Jan31" decimals="0" id="Fact-2E56B323164CC41EEAC977EC11EB8F78" unitRef="sqft">6184</alpn:AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease>
	<alpn:AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease contextRef="I2018Q1Mar18_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-462E9BB9F8C165B167BB4F15DF938505" unitRef="sqft">27164</alpn:AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease>
	<alpn:AdjustmentOfParValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E82CA53006B632415B87323762253112" unitRef="usd">0</alpn:AdjustmentOfParValue>
	<alpn:AdjustmentOfParValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-26CF09BF5280DD100BCF3237621BA10F" unitRef="usd">-13000</alpn:AdjustmentOfParValue>
	<alpn:AdjustmentOfParValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-16A63872D1043B3890633237622FFEFF" unitRef="usd">13000</alpn:AdjustmentOfParValue>
	<alpn:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9260DFF9CF0D9D15F9B7323762397672" unitRef="usd">52000</alpn:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity>
	<alpn:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-156217F5D4E1E8344C19323762251540" unitRef="usd">52000</alpn:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity>
	<alpn:AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived contextRef="D2018Q2Jun01-Jun30_dei_LegalEntityAxis_alpn_LaurelVentureCapitalLtd.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_alpn_GSNORMember" decimals="-5" id="Fact-8A4340134BE5B7D8846E4ED9CF55644F" unitRef="usd">20000000</alpn:AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived>
	<alpn:AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived contextRef="D2019Q2Jun01-Jun30_dei_LegalEntityAxis_alpn_LaurelVentureCapitalLtd.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_alpn_GSNORMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="-3" id="Fact-E155783C9B5B4D03E32C4ED8DC88B001" unitRef="usd">425000</alpn:AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived>
	<alpn:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="2" id="Fact-44D8910649512AD3963432376239C0B6" unitRef="usdPerShare">-1.32</alpn:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
	<alpn:BusinessCombinationCommonStockIssuedExchangeRate contextRef="D2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember" decimals="4" id="Fact-3400A0E97BDC54DC272073B3A61EDFF6" unitRef="number">0.4969</alpn:BusinessCombinationCommonStockIssuedExchangeRate>
	<alpn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-711A0E417FCBFDA1811432376211817C" unitRef="usd">401000</alpn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities>
	<alpn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="INF" id="Fact-BFB5A26D628E6D0AE93B32376261AA0F" unitRef="usd">0</alpn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis>
	<alpn:CashFlowProjectionsDiscountRate contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="2" id="Fact-948805AF25D50B0D44963237624DF6D4" unitRef="number">0.17</alpn:CashFlowProjectionsDiscountRate>
	<alpn:ClassofWarrantorRightWeightedAverageExercisePriceOutstanding contextRef="FI2017Q4" decimals="2" id="Fact-9769AD4E5072E57671044F815E1FE821" unitRef="usdPerShare">24.86</alpn:ClassofWarrantorRightWeightedAverageExercisePriceOutstanding>
	<alpn:ClassofWarrantorRightWeightedAverageExercisePriceOutstanding contextRef="FI2018Q4" decimals="2" id="Fact-6AB7B12C203916DF86694F815DF8F74D" unitRef="usdPerShare">24.86</alpn:ClassofWarrantorRightWeightedAverageExercisePriceOutstanding>
	<alpn:ClassofWarrantorRightWeightedAveragePriceExercisable contextRef="FI2018Q4" decimals="2" id="Fact-EB7D17D331A303B91D364F815DE75A1A" unitRef="usdPerShare">32.92</alpn:ClassofWarrantorRightWeightedAveragePriceExercisable>
	<alpn:ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding contextRef="FD2017Q4YTD" id="Fact-75ABA0E658970B0A772C4F85F412C3FB">P6Y7M13D</alpn:ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding>
	<alpn:ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding contextRef="FD2018Q4YTD" id="Fact-7E7C9A6140BEA60A1EB34F85F40CCFC7">P5Y7M13D</alpn:ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding>
	<alpn:DebtInstrumentFinalPaymentPercentage contextRef="D2017Q2Jun30_us-gaap_DebtInstrumentAxis_alpn_TermLoanMember" decimals="INF" id="Fact-622FA5946890544CC3F53237622FFCA4" unitRef="number">0.075</alpn:DebtInstrumentFinalPaymentPercentage>
	<alpn:DebtInstrumentNumberOfEqualMonthlyPayment contextRef="D2017Q2Jun30" decimals="INF" id="Fact-2899DF1E9CB638921D863237622F3600" unitRef="payment">30</alpn:DebtInstrumentNumberOfEqualMonthlyPayment>
	<alpn:DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets contextRef="FI2017Q4" decimals="-3" id="Fact-FE9F0DE5754BCC5602B4323762613869" unitRef="usd">0</alpn:DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets>
	<alpn:DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets contextRef="FI2018Q4" decimals="-3" id="Fact-F45E3A126726B175F8EECD68167C86FB" unitRef="usd">54000</alpn:DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets>
	<alpn:DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets contextRef="FI2017Q4" decimals="-3" id="Fact-A4D91EFF66D20F47B489CD684F376F4E" unitRef="usd">247000</alpn:DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets>
	<alpn:DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets contextRef="FI2018Q4" decimals="-3" id="Fact-189DE473B096F86034F032376211002B" unitRef="usd">0</alpn:DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets>
	<alpn:EffectiveIncomeTaxRateReconciliationBargainPurchaseGain contextRef="FD2017Q4YTD" decimals="3" id="Fact-A24DE838AE403D92401DCD6574EB4D15" unitRef="number">0.289</alpn:EffectiveIncomeTaxRateReconciliationBargainPurchaseGain>
	<alpn:EffectiveIncomeTaxRateReconciliationBargainPurchaseGain contextRef="FD2018Q4YTD" decimals="3" id="Fact-E96046D0499F6ADA272A323762251785" unitRef="number">0.000</alpn:EffectiveIncomeTaxRateReconciliationBargainPurchaseGain>
	<alpn:EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate contextRef="FD2017Q4YTD" decimals="3" id="Fact-06D3598C4FFE4EEC2F3B32376243A8E2" unitRef="number">0.002</alpn:EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate>
	<alpn:EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate contextRef="FD2018Q4YTD" decimals="3" id="Fact-FF94ECFD290C7C1E9A563237624DF411" unitRef="number">-0.001</alpn:EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate>
	<alpn:EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts contextRef="FD2017Q4YTD" decimals="3" id="Fact-022D706381CDFB7705F5CD6573A6280C" unitRef="number">-0.176</alpn:EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts>
	<alpn:EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts contextRef="FD2018Q4YTD" decimals="3" id="Fact-DFFA62837F6F74DDDE3D3237624380AC" unitRef="number">0.000</alpn:EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts>
	<alpn:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="FD2017Q4YTD" decimals="3" id="Fact-77788CBEE109ACD8A53F323762259F56" unitRef="number">0.001</alpn:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
	<alpn:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="FD2018Q4YTD" decimals="3" id="Fact-53F74559F35317A287D93237621B328F" unitRef="number">0.000</alpn:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
	<alpn:EligibleToReceiveAdditionalResearchSupportPayment contextRef="I2017Q4Oct31_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember" decimals="-3" id="Fact-E187E87418F6BF15C4315125D98755BB" unitRef="usd">450000</alpn:EligibleToReceiveAdditionalResearchSupportPayment>
	<alpn:ExerciseOfStockOptionsAndCommonStockWarrants contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DE35BB6CCC2AC50375C73237622F8740" unitRef="usd">22000</alpn:ExerciseOfStockOptionsAndCommonStockWarrants>
	<alpn:ExerciseOfStockOptionsAndCommonStockWarrants contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B46B5E5C449CDDF9E4B53237622FC72A" unitRef="usd">22000</alpn:ExerciseOfStockOptionsAndCommonStockWarrants>
	<alpn:ExerciseOfStockOptionsAndCommonStockWarrantsShare contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-09922B3C14C975CD96A8323762395360" unitRef="shares">57453</alpn:ExerciseOfStockOptionsAndCommonStockWarrantsShare>
	<alpn:ExtendedVestingPeriodOfNumberOfUnvestedShareOptions contextRef="D2016Q2May1toMay31" decimals="INF" id="Fact-BB9AEF47C01CAF6DFCB33237624D5EF8" unitRef="shares">567500</alpn:ExtendedVestingPeriodOfNumberOfUnvestedShareOptions>
	<alpn:IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E08C53759D45F9B6E957CC6421BC6AAC" unitRef="usd">146000</alpn:IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities>
	<alpn:IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2FF09DDE3F1CD965215F5125D97B6B35" unitRef="usd">-33000</alpn:IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities>
	<alpn:IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9314BA8AE9D23B5B0BB05125D979DA05" unitRef="usd">-28000</alpn:IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities>
	<alpn:IntangibleAssetsAmountDerecognizedUponSale contextRef="FI2018Q2_dei_LegalEntityAxis_alpn_LaurelVentureCapitalLtd.Member_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_alpn_GSNORMember" decimals="-5" id="Fact-3C4C514AF333AF98A63E4EDA7B383718" unitRef="usd">1500000</alpn:IntangibleAssetsAmountDerecognizedUponSale>
	<alpn:IssuanceOfDebtDiscount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2CD2812B28B0A9580B44CC642B7551DD" unitRef="usd">0</alpn:IssuanceOfDebtDiscount>
	<alpn:IssuanceOfDebtDiscount contextRef="FD2017Q4YTD" decimals="-3" id="Fact-40A1D8B3DB9D9463E9285125D980A7DE" unitRef="usd">428000</alpn:IssuanceOfDebtDiscount>
	<alpn:IssuanceOfDebtDiscount contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B6FDD211174CDFC523965125D96CC3B4" unitRef="usd">0</alpn:IssuanceOfDebtDiscount>
	<alpn:MaximumAmountOfCommonStockEligibleToBeSold contextRef="D2016Q3Jul01-Jul31_dei_LegalEntityAxis_alpn_CowenandCompanyLLCMember" decimals="-5" id="Fact-45B0C4877225090C2FF34F2F519E1FB7" unitRef="usd">30000000</alpn:MaximumAmountOfCommonStockEligibleToBeSold>
	<alpn:MaximumAmountOfCommonStockEligibleToBeSold contextRef="D2018Q2Jun01-Jun30_dei_LegalEntityAxis_alpn_PiperJaffrayCo.Member" decimals="-5" id="Fact-450E24F40062E281EB3F4F2F51A1AB36" unitRef="usd">50000000</alpn:MaximumAmountOfCommonStockEligibleToBeSold>
	<alpn:MaximumAmountOfCommonStockEligibleToBeSold contextRef="D2018Q2June11" decimals="-5" id="Fact-303E4926B3C79CDDFD654F312EC67996" unitRef="usd">14500000</alpn:MaximumAmountOfCommonStockEligibleToBeSold>
	<alpn:MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement contextRef="FD2018Q4YTD" decimals="INF" id="Fact-BC37AEB7EC161A6305583237622F03FB" unitRef="number">0.50</alpn:MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement>
	<alpn:NumberOfEmployees contextRef="D2016Q2May1toMay31" decimals="INF" id="Fact-C9DA40CDDADAB00B8E8A3237624329A4" unitRef="employee">5</alpn:NumberOfEmployees>
	<alpn:NumberOfOptionsToExtendTermLease contextRef="FI2016Q4" decimals="INF" id="Fact-B3643FF6A9F667831EF2323762615D55" unitRef="term">2</alpn:NumberOfOptionsToExtendTermLease>
	<alpn:NumberOfOptionsToExtendTermLease contextRef="I2018Q1Jan31" decimals="INF" id="Fact-82418F2C829D477565FF915A40A8B484" unitRef="term">2</alpn:NumberOfOptionsToExtendTermLease>
	<alpn:NumberOfOptionsToExtendTermLease contextRef="I2018Q1Mar18_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-4F43A3320954835995AC4F18EF29F9CD" unitRef="term">1</alpn:NumberOfOptionsToExtendTermLease>
	<alpn:NumberOfProgramsFromLicenseTechnology contextRef="D2015Q4Oct1-Oct31_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember" decimals="INF" id="Fact-86BFBC999BC41F5CDFB33237621B1583" unitRef="program">2</alpn:NumberOfProgramsFromLicenseTechnology>
	<alpn:NumberOfTranches contextRef="D2017Q4_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember" decimals="INF" id="Fact-9D9C53F63FFE3A5C9B57915CED5DACE8" unitRef="program">2</alpn:NumberOfTranches>
	<alpn:NumberOfWarrantsAvailableTobeExercised contextRef="FI2018Q4" decimals="INF" id="Fact-591E73F2A960C7FAFCDB4F80E935DF22" unitRef="shares">17153</alpn:NumberOfWarrantsAvailableTobeExercised>
	<alpn:OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate contextRef="D2019Q1Mar01-Mar18_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="3" id="Fact-9E219A2C205E80714B654F1E76D97D3A" unitRef="number">0.080</alpn:OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate>
	<alpn:OperatingLeaseAnnualBaseRentIncreasingPercentage contextRef="FI2016Q4" decimals="2" id="Fact-5CE011735734A86BD5023237624315CD" unitRef="number">0.03</alpn:OperatingLeaseAnnualBaseRentIncreasingPercentage>
	<alpn:OperatingLeaseAnnualBaseRentIncreasingPercentage contextRef="I2018Q1Jan31" decimals="3" id="Fact-B9C9F64C554476D1DED977EE1F357BDD" unitRef="number">0.030</alpn:OperatingLeaseAnnualBaseRentIncreasingPercentage>
	<alpn:OperatingLeaseAnnualBaseRentIncreasingPercentage contextRef="I2018Q1Mar18_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="3" id="Fact-2FA689B312EB83894F184F17FEA130BF" unitRef="number">0.030</alpn:OperatingLeaseAnnualBaseRentIncreasingPercentage>
	<alpn:OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation contextRef="D2017Q3Jul24_dei_LegalEntityAxis_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember" decimals="2" id="Fact-F085232106A4717DD37B323762614845" unitRef="number">0.74</alpn:OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation>
	<alpn:OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation contextRef="D2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="2" id="Fact-1CEC834764787BD0BD1C3237626125D4" unitRef="number">0.26</alpn:OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation>
	<alpn:OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation contextRef="D2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember" decimals="2" id="Fact-73EB9D10FC929AD64EFF3237624D4D72" unitRef="number">0.74</alpn:OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation>
	<alpn:PaymentsForProceedsFromAdditionalTenantAllowance contextRef="D2019Q1Mar01-Mar18_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-E99DA6B637A5F701DC674F1CBFA1AFF9" unitRef="usd">-1800000</alpn:PaymentsForProceedsFromAdditionalTenantAllowance>
	<alpn:PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable contextRef="FI2018Q4_srt_CounterpartyNameAxis_alpn_KiteMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember" decimals="-5" id="Fact-EF3C501B1772FA12296F5125D95192CC" unitRef="usd">530000000</alpn:PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable>
	<alpn:PrepaidResearchAndDevelopment contextRef="FI2017Q4" decimals="-3" id="Fact-92E7EBE49FB08F64E7CB4F03A07C1A0D" unitRef="usd">791000</alpn:PrepaidResearchAndDevelopment>
	<alpn:PrepaidResearchAndDevelopment contextRef="FI2018Q4" decimals="-3" id="Fact-98686D722006B51FF6D84F03A08F72E1" unitRef="usd">83000</alpn:PrepaidResearchAndDevelopment>
	<alpn:PurchaseAgreementAggregatePurchasePricePerUnit contextRef="D2019Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-894D35154F1A1B22CF7B565621B52FA9" unitRef="usdPerShare">5.37</alpn:PurchaseAgreementAggregatePurchasePricePerUnit>
	<alpn:PurchaseAgreementRatioOfCommonStockToWarrants contextRef="D2019Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-7B29EC8F644411F003FE4F3771557A99" unitRef="shares">0.39</alpn:PurchaseAgreementRatioOfCommonStockToWarrants>
	<alpn:PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock contextRef="D2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-6F149551A930FE7515924FC7F9C8746F" unitRef="shares">364943</alpn:PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock>
	<alpn:ReclassificationOfPreferredStockWarrantLiabilityToEquity contextRef="FD2016Q4YTD" decimals="-3" id="Fact-84E2BCDA29CCD005A15FCC642C81D1C9" unitRef="usd">0</alpn:ReclassificationOfPreferredStockWarrantLiabilityToEquity>
	<alpn:ReclassificationOfPreferredStockWarrantLiabilityToEquity contextRef="FD2017Q4YTD" decimals="-3" id="Fact-290806A4687FF4CB5E165125D974D511" unitRef="usd">52000</alpn:ReclassificationOfPreferredStockWarrantLiabilityToEquity>
	<alpn:ReclassificationOfPreferredStockWarrantLiabilityToEquity contextRef="FD2018Q4YTD" decimals="-3" id="Fact-7D35C596D6E07CE03B715125D97E151F" unitRef="usd">0</alpn:ReclassificationOfPreferredStockWarrantLiabilityToEquity>
	<alpn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices contextRef="D2018Q2Jun01-Jun30_dei_LegalEntityAxis_alpn_PiperJaffrayCo.Member" decimals="3" id="Fact-C5F3A73D372F1A36926F4F3095018DD1" unitRef="number">0.030</alpn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices>
	<alpn:SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent contextRef="D2018Q2Jun01-Jun30_us-gaap_PlanNameAxis_alpn_TwoThousandAndEighteenPlanMember" decimals="2" id="Fact-019BB82BA61DDB7452A34F7220D85524" unitRef="number">0.05</alpn:SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent>
	<alpn:SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease contextRef="FI2016Q4" decimals="INF" id="Fact-08F59A0AB684BAF886213237624DD13A" unitRef="sqft">11158</alpn:SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease>
	<alpn:StockAcquiredDuringPeriodSharesInBusinessCombination contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-AE4284AAFC37FEB828BC3237621B3BA1" unitRef="shares">3914058</alpn:StockAcquiredDuringPeriodSharesInBusinessCombination>
	<alpn:StockAcquiredDuringPeriodValueInBusinessCombination contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CDBB6D6267A460C7CEEB3237622F69F3" unitRef="usd">38103000</alpn:StockAcquiredDuringPeriodValueInBusinessCombination>
	<alpn:StockAcquiredDuringPeriodValueInBusinessCombination contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7A93158B0FB3E6E75986323762394533" unitRef="usd">38103000</alpn:StockAcquiredDuringPeriodValueInBusinessCombination>
	<alpn:TaxCreditAndNetOperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="INF" id="Fact-3A4AB0B8F6FA843399CD3237624D060C" unitRef="usd">0</alpn:TaxCreditAndNetOperatingLossCarryforwards>
	<alpn:TemporaryEquitySharesConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-8DF81EA93092DB81F4D832376239DBF6" unitRef="shares">9301433</alpn:TemporaryEquitySharesConversionOfConvertibleSecurities>
	<alpn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-F16EEAE10FEFC59821B832376239AC92" unitRef="shares">3099334</alpn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
	<alpn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-7CCDE58F0948EF2D60CF3237622F2523" unitRef="shares">4989663</alpn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
	<alpn:TemporaryEquityValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-78BB0C13AD8D70332DC03237622F0821" unitRef="usd">49201000</alpn:TemporaryEquityValueConversionOfConvertibleSecurities>
	<alpn:WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable contextRef="FD2018Q4YTD" id="Fact-9A7A38EE695A1B7DC4C24F85F41BF8BF">P5Y9M4D</alpn:WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable>
	<dei:AmendmentFlag contextRef="FD2018Q4YTD" id="Fact-49F9FB273F0340CDE87D323762615BD3">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2018Q4YTD" id="Fact-CD3802AEB7E5576C16243237622FBAAF">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2018Q4YTD" id="Fact-4F6B18DBD42D7ADA204A323762614822">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2018Q4YTD" id="Fact-A4B24AFEE0A7F17FA5A9323762571B51">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2018Q4YTD" id="Fact-2A2422D9E0F3BBC8BB523237622F63C2">2018-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2018Q4YTD" id="Fact-6E4B83852108D61EF70132376257C6C2">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2018Q4YTD" id="Fact-39A42DB9D86EF47185A03237622FA0BF">0001626199</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2019Q1Mar06" decimals="INF" id="Fact-4213AD2377FC3B86DAE33237622FE431" unitRef="shares">18561029</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2018Q4YTD" id="Fact-54AB424F8C8F556E8E903237627558BE">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2018Q4YTD" id="Fact-D41CD71DEB2596DEAD5ECC33BB732D7F">true</dei:EntityEmergingGrowthCompany>
	<dei:EntityExTransitionPeriod contextRef="FD2018Q4YTD" id="Fact-D921FDA6DA4DCFDF3515CC33E3F3AB1A">true</dei:EntityExTransitionPeriod>
	<dei:EntityFilerCategory contextRef="FD2018Q4YTD" id="Fact-8ABA1FA96A68B6D6F2AB32376257DB87">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2018Q2" decimals="-5" id="Fact-52C4D7F00C22EAF20D4F323762393EFE" unitRef="usd">33800000</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2018Q4YTD" id="Fact-0417EF64ED1773C5EB93323762575418">Alpine Immune Sciences, Inc.</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2018Q4YTD" id="Fact-8DF3BAAC21760EC1CF73CC3432330F7C">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="FD2018Q4YTD" id="Fact-3F7562D81DD3C55DB412CC340846BD51">true</dei:EntitySmallBusiness>
	<dei:EntityVoluntaryFilers contextRef="FD2018Q4YTD" id="Fact-D6C599F2042D6E4C5E533237626B55FE">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2018Q4YTD" id="Fact-F530FB396B743E1B7DAC323762570093">No</dei:EntityWellKnownSeasonedIssuer>
	<dei:TradingSymbol contextRef="FD2018Q4YTD" id="Fact-A6FD3C23249D2ABC42D932376261CDC4">ALPN</dei:TradingSymbol>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-7F90E7855FB875C1BE845125D96588C8" unitRef="usd">193000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-FAE5F913A3638EA3ACCA5125D969BC87" unitRef="usd">1716000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-021FEDD6F26E8DC6F0F1CC641A587BDE" unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-21F7CA0817F805365C855125D97E1379" unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2018Q4YTD" decimals="-3" id="Fact-68795791C210497AFD275125D97C9C01" unitRef="usd">669000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-7BC71BF38790E63749645125D9691789" unitRef="usd">382000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-66A9AC0F0AE290BF2B315125D96FCCAD" unitRef="usd">4277000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-6A91548E62F5F92AC81E32376211DC15" unitRef="usd">112000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-D6B2F19DD5EC75B40BD5323762619134" unitRef="usd">646000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-973A3E26581DF28EA211323762255154" unitRef="usd">311000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-54EB7EF2E5E4430831EA3237622520A6" unitRef="usd">699000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4" decimals="-3" id="Fact-223516B42A7F69F72E035125D97625DF" unitRef="usd">-59000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="-3" id="Fact-D7667BF8A7A7C6A173A85125D966E32C" unitRef="usd">-13000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AcquisitionCosts contextRef="FD2017Q4YTD" decimals="-5" id="Fact-58FD686DB840B8AC84903237624D078C" unitRef="usd">1500000</us-gaap:AcquisitionCosts>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2017Q4" decimals="-3" id="Fact-F879CC11552182E5303A5125D969C75D" unitRef="usd">88346000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2018Q4" decimals="-3" id="Fact-99A2237C46C54BB519905125D96664A3" unitRef="usd">90664000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A5DD878806C17BF034B73237622F5BF1" unitRef="usd">77000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9F6C8C69FD6DA2D2495C32376225096A" unitRef="usd">77000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DA5892851F715E3F056632376239F089" unitRef="usd">838000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C0A5D5FDDC83602A651D3237622FBA48" unitRef="usd">838000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q4YTD" decimals="-3" id="Fact-99A282E4664DE81F65844EA51E41ED9E" unitRef="usd">2309000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-75E3FEE9BD412040A5444EA4EE0FD942" unitRef="usd">2309000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2BDD17E5C1753AEE5D1C3237626B7D67" unitRef="usd">77000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_EmployeesMember" decimals="-3" id="Fact-58B73135A7F605DC703B3237626BD7E7" unitRef="usd">53000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_NonEmployeesMember" decimals="-3" id="Fact-93015A5446CE533CA1AA3237626B8916" unitRef="usd">5000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_EmployeesMember" decimals="-3" id="Fact-E6DB507A2C1FADEEAC43CD4AB87B678D" unitRef="usd">14000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_NonEmployeesMember" decimals="-3" id="Fact-ABD5E9418BB5C65C744232376211DB14" unitRef="usd">5000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0C4A65B203F9248B0F683237626B15EF" unitRef="usd">838000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_EmployeesMember" decimals="-3" id="Fact-99B5587BCA464777A0953237626B3271" unitRef="usd">588000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_NonEmployeesMember" decimals="-3" id="Fact-874843938F80746DE8633237626B00FD" unitRef="usd">15000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_EmployeesMember" decimals="-3" id="Fact-6BA9D54ACD87CEF69D2A323762112746" unitRef="usd">183000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_NonEmployeesMember" decimals="-3" id="Fact-93DEAB3DBB4F8B8D50543237626B2585" unitRef="usd">52000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B348922859E6E5083B283237626B9F64" unitRef="usd">2309000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_EmployeesMember" decimals="-3" id="Fact-6BAAB48A38777A0844A53237626B7675" unitRef="usd">1385000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_NonEmployeesMember" decimals="-3" id="Fact-2F568DB689F1CA48C78A3237626B6FE0" unitRef="usd">18000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_EmployeesMember" decimals="-3" id="Fact-529DACE97E150AFD58473237626189AD" unitRef="usd">890000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TitleOfIndividualAxis_alpn_NonEmployeesMember" decimals="-3" id="Fact-1D781F18424AEA48A5163237627528EB" unitRef="usd">16000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4246A12BBA6FC01709F23237622FCC63" unitRef="usd">87000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2018Q4YTD" decimals="-3" id="Fact-2155EF49AB53884A0759CCCF0DC03333" unitRef="usd">169000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD" decimals="0" id="Fact-A4FB839E9F76266A2E2C32376239784F" unitRef="shares">4844931</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-0A8ABAA138F23AF885663237623966BE" unitRef="shares">4311770</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-56F6B87A6D7A0FEDD64232376239A5AB" unitRef="shares">520739</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-C423A5D60E7107EF057C323762398CB9" unitRef="shares">12422</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD" decimals="0" id="Fact-B7A407818AF6F0CBF3B132376239C91E" unitRef="shares">1636119</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-2B54A3C0A4E6BDE72C6432376239D81C" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-EBF536535BD9EE287CEF32376239F12B" unitRef="shares">1611996</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-743851F22978D703643832376239632B" unitRef="shares">24123</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD" decimals="0" id="Fact-AFEE1FBEB3D71C32E5B732376239D229" unitRef="shares">2533973</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-A6482E20573752207D6BCCA0A20A5F28" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-3A0D31481543DC1DA9B0323762395CE5" unitRef="shares">2509850</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-EF1EBB5B778F618B557E3237623913DC" unitRef="shares">24123</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-976BCFC93900D4EA1A045125D9713B67" unitRef="usd">85222000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="-3" id="Fact-E15AF6836C87026497EC5125D972355B" unitRef="usd">54873000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-19D9B230486AA1781E7E5125D973D5C6" unitRef="usd">82548000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-ACA5E807A973813FB74D5125D96E352B" unitRef="usd">53545000</us-gaap:AssetsCurrent>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4" decimals="-3" id="Fact-6E5A78FF306C1608E3CDCCA464E17CD8" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-B6EB99E66A545772FC20CCA464E8F548" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-32EF5C83F6B8246101BED2956C7063C1" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-86B05608314B7E6899D9CCA464F06F9C" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4" decimals="-3" id="Fact-9BB03CD9B2732A02F818CCAC9B353A61" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-D0B440F3336B26E84ABECCAC9364EFEA" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-D5C877496E72AC258437D295053A3600" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-3079F1445BF3E0794D38CCAC8B07A517" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4" decimals="-3" id="Fact-7D065B42641DA84DBB5432376275554B" unitRef="usd">59000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-A31CC4880C8C9EC968383237626B11ED" unitRef="usd">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-1D373B3052B9E607B8F5D2956E12921A" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-243F0D35E2A5BECAE2F63237626B8F30" unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4" decimals="-3" id="Fact-B65566004FE4FBCE858FCCAC9C5D5E3B" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-3EE5AA13E435EF54EFC5CCAC968A8FA0" unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-2ED750C563733C0C7032D295068E57C8" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-54EE4E5A137198B0935CCCAC8DEFE824" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4" decimals="-3" id="Fact-FA1F7F0B6655C5CB80183237626B4551" unitRef="usd">78979000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-94DA839C998CC020EFFA323762756D08" unitRef="usd">53390000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-1A6F7CC32921F43563633237626BE656" unitRef="usd">5680000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-73A7A5E59E0F6C0504213237626B8520" unitRef="usd">19909000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4" decimals="-3" id="Fact-55A6B0BE7BA9A1DF86ECCCAC99FC9456" unitRef="usd">51702000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-40F434859E723D7B071DCCAC91108F39" unitRef="usd">31331000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-470E122720BE2199968FCCAC81834BFE" unitRef="usd">6405000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-8D95125260FE8D008D2ACCAC897D5B9E" unitRef="usd">13966000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4" decimals="-3" id="Fact-A23921A4F205B4282F9B3237626B735C" unitRef="usd">78920000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-1A2BBEB93BC272558AD832376257B13B" unitRef="usd">25568000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-91F499DDDB2424C594A5CCBC3C6C1F62" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-28DFC9E44EC9BBE8639C323762570697" unitRef="usd">5680000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember" decimals="-3" id="Fact-4E02F40653C7F5B770823237625759F4" unitRef="usd">19888000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-8224BF9D1D687878AC313237624D8EE2" unitRef="usd">53352000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-79EBCBE7B4646F5154CE323762573EF1" unitRef="usd">53352000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-9F8E56F847957A5DCBD2CCBC11DEFFF5" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember" decimals="-3" id="Fact-D8152FD1CDA46E2ED622CCBC13D89195" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-D5732F278AABB88190AECCBC16F91425" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-EF37E6087D00B88CB7B5CCBC3F1064D2" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-5E66C44D8DFB13EEAB44CCBC13348A82" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember" decimals="-3" id="Fact-A5679A299350F40065F0CCBC1511CEFD" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-BC52390E012410E97A033237626B0A17" unitRef="usd">53352000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-7E8485FBA0447824C0D43237626B354D" unitRef="usd">5680000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember" decimals="-3" id="Fact-1955EE418B6267FB82E532376257DBC6" unitRef="usd">19888000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-3B82C916E2065FD39BDF32376211D5FF" unitRef="usd">19888000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4" decimals="-3" id="Fact-2E7C9113817388FE7DECCCAC9DAD0C79" unitRef="usd">51689000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-9755626711A3608B3849CCC04A5F03A6" unitRef="usd">20369000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-E93C019A5F9BE7D713CCCCC02FFD0240" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-FE04063C719499477083CCC000074EE0" unitRef="usd">6405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember" decimals="-3" id="Fact-706EC6099CCEEB15A6ABCCC0156D48AA" unitRef="usd">13964000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-5335B88C904B2BA9276CCCC04E8C47ED" unitRef="usd">31320000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-111CDB5B46329D0D667FCCC03611918A" unitRef="usd">31320000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-30268B4FDBAAE846D3A3CCC0056BBD2C" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember" decimals="-3" id="Fact-73BA9DA702D2F653DEDCCCC01B78C1F6" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-CE6023076FFBF58DC71BCCC05539EF83" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-8DD3942D1BC1873836B5CCC041330AB2" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-C998134BAD98D4169482CCC00C939AA6" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember" decimals="-3" id="Fact-A05E0B9E5A37258436F5CCC026583723" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_alpn_CorporateDebtSecuritiesAndCommercialPaperMember" decimals="-3" id="Fact-400192C746081C6A5175CCAC983A88FD" unitRef="usd">31320000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-85A0FC3E5EF111A74A9DCCAC8892DB16" unitRef="usd">6405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember" decimals="-3" id="Fact-1A894368F5DDAC82FA57CCC02C6BBF65" unitRef="usd">13964000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-3800DA91F579BB397939CCAC8F4B6CF5" unitRef="usd">13964000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-8B7D75321DC9FB086D605125D9709C50" unitRef="usd">73240000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-CE6D0FA63D795904FB485125D968232F" unitRef="usd">41592000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="FD2017Q4YTD_dei_LegalEntityAxis_alpn_NivalisTherapeuticsIncMember" decimals="INF" id="Fact-3CEE4B98BADB5A4422C83237625774A5" unitRef="shares">3914058</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
	<us-gaap:BusinessAcquisitionSharePrice contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="INF" id="Fact-A0D594FA0EA95E642F0D32376257A2F1" unitRef="usdPerShare">9.60</us-gaap:BusinessAcquisitionSharePrice>
	<us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-2B0EF8EC3116EBDC3C6D32376239C641" unitRef="usd">-18327000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
	<us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-941A3840E75CE98CE7A032376243CA55" unitRef="usd">1731000</us-gaap:BusinessAcquisitionsProFormaRevenue>
	<us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount contextRef="D2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-A3BDA67072D53B59738732376275859C" unitRef="usd">6601000</us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount>
	<us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-75DC09917FAC33685A70CC4498621B93" unitRef="usd">0</us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount>
	<us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3916B2275899C4051CE75125D95CC6E3" unitRef="usd">6601000</us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount>
	<us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount contextRef="FD2018Q4YTD" decimals="-3" id="Fact-12D53470F096E9C3DA985125D955445F" unitRef="usd">0</us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-BF45BA07D20377837FBD323762118EE9" unitRef="usd">38103000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-91B5A2ACFCDC5406E01032376275436F" unitRef="usd">45614000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-F3669BFAD4AB6B7E5CC432376275AE87" unitRef="usd">31130000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-740EF2C9169BAE83A8A7323762115EAC" unitRef="usd">12952000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-3871F16D47BFCE53C76432376275BD30" unitRef="usd">79000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-5B5ED7B4A8E11146C85832376257D54F" unitRef="usd">305000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-10FD3AB0301D8148B5A632376211FDA6" unitRef="usd">509000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-5" id="Fact-8D577445E3E127231006CD563EC80FF5" unitRef="usd">1500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-25E197183CCCB9B476C332376211BB1F" unitRef="usd">1453000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-5" id="Fact-C93BD5AC42B2FCC01DED32376257A5DA" unitRef="usd">1500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="-3" id="Fact-441322B2441FB466A6A33237624DB027" unitRef="usd">910000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
	<us-gaap:Cash contextRef="FI2017Q4" decimals="-5" id="Fact-20467A33AE135C1332AF323762572C40" unitRef="usd">2300000</us-gaap:Cash>
	<us-gaap:Cash contextRef="FI2018Q4" decimals="-3" id="Fact-E355EF930ADA64917602CCB1443B83F4" unitRef="usd">614000</us-gaap:Cash>
	<us-gaap:CashAcquiredFromAcquisition contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9DC24EC07CB55A912427CC6425E58D35" unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAcquiredFromAcquisition contextRef="FD2017Q4YTD" decimals="-3" id="Fact-014951D7C768F8373C755125D979CC17" unitRef="usd">31130000</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAcquiredFromAcquisition contextRef="FD2018Q4YTD" decimals="-3" id="Fact-61EB694B76640CDE41145125D970D7DF" unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-E1933163374365BD53815125D97AA86F" unitRef="usd">8000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-50911CE6060B9BC1C6955125D974DDF3" unitRef="usd">10711000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2015Q4" decimals="-3" id="Fact-6D634D7755FA5F26E90FCC6429FBD793" unitRef="usd">5423000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2016Q4" decimals="-3" id="Fact-FD94D1229C604033BE895125D9668031" unitRef="usd">11819000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="-3" id="Fact-2899AF910A3B756FFA5F5125D96E8F8C" unitRef="usd">8132000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4" decimals="-3" id="Fact-C0F7C027735B5B2616395125D9803D15" unitRef="usd">10843000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2016Q4YTD" decimals="-3" id="Fact-944748C6C8A31F938AA9CC63538EE397" unitRef="usd">6396000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E52662F947E265D5ACBC5125D98180B8" unitRef="usd">-3687000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2018Q4YTD" decimals="-3" id="Fact-2788C1E7F00B98BCEDD95125D96BCB29" unitRef="usd">2711000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_alpn_SeriesAOnePreferredStockWarrantsMember" decimals="2" id="Fact-DEC5093AEB0B9B25FD063237622F9571" unitRef="usdPerShare">12.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2019Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-2A499FD62E57B96F3FE856663C504858" unitRef="usdPerShare">12.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_alpn_SeriesAOnePreferredStockWarrantsMember" decimals="INF" id="Fact-7157841CEA26712720C4323762396C5A" unitRef="shares">7069</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q3Jul24_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9C88480F5DBB22CA7DD63237622FC93D" unitRef="shares">7069</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2019Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-AFDAC055098C304250344F3944CD434E" unitRef="shares">1835610</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-505A718E78C5CAF525D24F80E911C4C5" unitRef="shares">24123</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-D6823DFFACD3890353604F80E93BF603" unitRef="shares">24123</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-18B2278968B7C2A280AB3237622513AF" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-051BBA718FC2DC2E42DE323762618A9A" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4" decimals="INF" id="Fact-18EAAB5B34E2C9DC8EA73237622F1914" unitRef="shares">2258052</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4_us-gaap_AwardTypeAxis_alpn_SharesAvailableForFutureStockGrantsMember" decimals="INF" id="Fact-767939DC5659D3F3971B3237622F2A1C" unitRef="shares">576722</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4_us-gaap_AwardTypeAxis_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-47A20889560E984D9A1ACD43A1006631" unitRef="shares">45211</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4_us-gaap_AwardTypeAxis_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember" decimals="INF" id="Fact-CB8107218171727C0F863237622FE158" unitRef="shares">24123</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4_us-gaap_AwardTypeAxis_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember" decimals="INF" id="Fact-8D6B896587853053B871323762392735" unitRef="shares">1611996</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q4" decimals="INF" id="Fact-80AF770C5D453BDEEE3E3237622F933B" unitRef="shares">3075714</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q4_us-gaap_AwardTypeAxis_alpn_SharesAvailableForFutureStockGrantsMember" decimals="INF" id="Fact-2884FD9782134FA41F723237622FCB25" unitRef="shares">496530</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q4_us-gaap_AwardTypeAxis_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-861EE3A37B5D0573551E3237622F80C8" unitRef="shares">45211</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q4_us-gaap_AwardTypeAxis_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember" decimals="INF" id="Fact-12C19CB4F5434BA59B42323762393433" unitRef="shares">24123</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q4_us-gaap_AwardTypeAxis_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember" decimals="INF" id="Fact-6A6F2CA18A3B5AE1C2B03237622F6108" unitRef="shares">2509850</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q4_us-gaap_PlanNameAxis_alpn_StockPlan2018Member" decimals="INF" id="Fact-86D44D2536405E4A05DE32376243E102" unitRef="shares">496530</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2017Q3Jul31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-36B872E11A1404F048FA3237621148A8" unitRef="shares">45211</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-38FF0420C12E4B6EE6AC82E6FD435CB0" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-3152568461EAEB84927E323762573401" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-873C1D6A5ADF3B17193832376257EE27" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-031CA8EF6423926F56713237626144D2" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-BF590637C994F6C5145432376257345C" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-4D57061DF43F45B449DA32376257BDFB" unitRef="shares">13881645</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-5E5436333AD8E2D38A46323762576F14" unitRef="shares">13904672</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-18252607FA9DB058C197323762617F30" unitRef="shares">13831178</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-D45D4E9E2FDEAC915B5532376257CEEE" unitRef="shares">13854205</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="INF" id="Fact-CABF72E0A452E8FED83C32376257184E" unitRef="shares">3914058</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q3Jul25" decimals="INF" id="Fact-E9A1E0CC6B9157DF969F3237624D6C8B" unitRef="shares">13881645</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValueOutstanding contextRef="FI2017Q4" decimals="-3" id="Fact-6D6E0749BB771F678B485125D96B47DD" unitRef="usd">14000</us-gaap:CommonStockValueOutstanding>
	<us-gaap:CommonStockValueOutstanding contextRef="FI2018Q4" decimals="-3" id="Fact-C2F8142B574D385AA0475125D96F180B" unitRef="usd">14000</us-gaap:CommonStockValueOutstanding>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-44B016C72FB0DC41878DCC43F2CA50CF" unitRef="usd">-1232000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8301378D94084EFC51BD5125D9861D80" unitRef="usd">-7842000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E77937BF6D0504ADF62E5125D9841569" unitRef="usd">-36441000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ContractWithCustomerLiability contextRef="I2015Q4Oct31_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember" decimals="-5" id="Fact-3AE0EB8FB71DE41735615125D953D486" unitRef="usd">5500000</us-gaap:ContractWithCustomerLiability>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-6FD520942CE2DD692C3D5125D96AEC75" unitRef="usd">277000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-181D2ED24456139A3C875125D9687604" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-85EAAA9E9FF8F385A8684EBB967A2743" unitRef="usd">203000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-488B45231A4F0EF5C2A65125D9501EAD" unitRef="usd">203000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3FA3E254BBC7EA628D76CC642B0D3B8E" unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D640296C29ED0A37FEB35125D9690803" unitRef="usd">49201000</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6DE26921CB0913506E9A5125D97A8090" unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="FI2017Q4" decimals="INF" id="Fact-522FF79B55EE80D3311E323762578CAE" unitRef="shares">9301433</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2017Q3Jul24_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-AAE270087736B15D449632376261DCC7" unitRef="shares">9301433</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-73169AF6EB515C436C224EA38153A454" unitRef="usd">-203000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3B6148F3CDBADF5FAC9432376275697A" unitRef="usd">4000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-2460D4DAF9FAFC57740B3237627505E6" unitRef="usd">-61000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DF92A41005F2950279D3323762610907" unitRef="usd">-1000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E17660094EC2BB4A931932376275FFB1" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D03D6EA615E8B339C4EC3237627519C5" unitRef="usd">5000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A6476F514C3E6929A1CB32376261618B" unitRef="usd">-61000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2017Q2Jun30_us-gaap_DebtInstrumentAxis_alpn_TermLoanMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="INF" id="Fact-26A818F6B060FE951AD13237622FEE1B" unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_alpn_TermLoanMember" decimals="INF" id="Fact-7F497214DC10B934E47D3237622F6171" unitRef="usd">375000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2018Q4" decimals="-3" id="Fact-BB9EBC8AAC8E9F8FAD843237622FD1C3" unitRef="usd">172000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtSecuritiesAvailableForSaleGainLoss contextRef="FD2017Q4YTD" decimals="INF" id="Fact-323E20BF50CBB0CECE3A0F71D902B797" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleGainLoss contextRef="FD2018Q4YTD" decimals="INF" id="Fact-B6ABE22468F18237DBCD32376275599F" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4FD1874643F4C8618F7DCD63E39B97A9" unitRef="usd">-204000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-22B8CABF777EC3CBD84F323762611D9F" unitRef="usd">-305000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0C6AC15D0DB6B37152B2CD63E4B6B423" unitRef="usd">-204000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
	<us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1B94BC79C804F69418D43237626126F5" unitRef="usd">-305000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-65AFC2BE10B20719B22ACC641BE552EA" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BA9BAEF6BFB69E50E8AC5125D97CC58B" unitRef="usd">-204000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-839C4917F7C494AF3BED5125D978BC0C" unitRef="usd">-305000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-9C740B1C991CEAF6982532376211342B" unitRef="usd">420000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-A556FC9523C3A21325633237621BCBAE" unitRef="usd">190000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2017Q4" decimals="-3" id="Fact-0E2E37676F6CEC81E24D5125D968F7AC" unitRef="usd">305000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2018Q4" decimals="-3" id="Fact-3001DF830BC52F48AC3A5125D975025C" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredOfferingCosts contextRef="FI2017Q4" decimals="-3" id="Fact-F9A473E83F3F74F3B0F24F04EB75B186" unitRef="usd">0</us-gaap:DeferredOfferingCosts>
	<us-gaap:DeferredOfferingCosts contextRef="FI2018Q4" decimals="-3" id="Fact-14490D29A05EFBA885534F04EB6FA7CA" unitRef="usd">477000</us-gaap:DeferredOfferingCosts>
	<us-gaap:DeferredRentCreditCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-99AAB1C8BC5FEE03D5CB5125D96BEDE3" unitRef="usd">48000</us-gaap:DeferredRentCreditCurrent>
	<us-gaap:DeferredRentCreditCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-D69EEBE3831A2E42D98E5125D974D0FA" unitRef="usd">86000</us-gaap:DeferredRentCreditCurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-0963363C716B66E2B6575125D96DCD43" unitRef="usd">66000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-D8469D556178E30A127B5125D96D6A7C" unitRef="usd">0</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4DD88779B1C3983204BACD6153AE7605" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-36F4C48B548028567045CD61539A7DD5" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2017Q4" decimals="-3" id="Fact-2E60FFCE8C24F354DF013237626BD51B" unitRef="usd">58000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2018Q4" decimals="-3" id="Fact-5AA5CC726AA313B6A41D32376257EE1F" unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2017Q4" decimals="-3" id="Fact-7097F95D570CE0777AE93237626B88AA" unitRef="usd">3837000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2018Q4" decimals="-3" id="Fact-BA497CF8921AB1330FA7323762110E29" unitRef="usd">13964000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2017Q4" decimals="-3" id="Fact-B1A4A18292D8D7A4298B323762579E11" unitRef="usd">115000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2018Q4" decimals="-3" id="Fact-DA75C96201533C65F2C0323762573FAF" unitRef="usd">190000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2017Q4" decimals="-3" id="Fact-73334FEB0497F6D86A0ACD67B068F4BF" unitRef="usd">2475000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2018Q4" decimals="-3" id="Fact-67EEC63F6E9A19108CD132376211CE03" unitRef="usd">10546000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2017Q4" decimals="-3" id="Fact-EF99A58EC42AB8749BB2CD67E7C877E6" unitRef="usd">12000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2018Q4" decimals="-3" id="Fact-6A2DCFA4F0424681938132376211CE14" unitRef="usd">3000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2017Q4" decimals="-3" id="Fact-25F6FE913BD2A79C1F90323762614074" unitRef="usd">458000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-3" id="Fact-B706DD8A93E1EFF7996C3237624DE149" unitRef="usd">458000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2018Q4" decimals="-3" id="Fact-366252E0442C56BB99B932376261B385" unitRef="usd">1958000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-3" id="Fact-6EDEEF68045551886DAC32376257FA52" unitRef="usd">2456000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2017Q4" decimals="-3" id="Fact-29A91E1F92C93A255180323762618287" unitRef="usd">810000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2018Q4" decimals="-3" id="Fact-B0D76E7278DACFFDE5C132376257FFDD" unitRef="usd">1382000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="FI2017Q4" decimals="-3" id="Fact-621853C9A75605679F1C3237626BE03F" unitRef="usd">24000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="FI2018Q4" decimals="-3" id="Fact-0A742D971CD739F61C3F32376261F78D" unitRef="usd">21000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-3" id="Fact-855266BDDE989137AD2F32376261615F" unitRef="usd">3722000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2018Q4" decimals="-3" id="Fact-ACDB1FF61A5879C3BDBD3237626108DF" unitRef="usd">13774000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-936B44A8E06E2F1C00DACD6850E1C64C" unitRef="usd">305000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-62C1F6F931603EBC28763237626B0150" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="FI2017Q4" decimals="-3" id="Fact-D8FF6426CDE8AF93B7D93237626B74FF" unitRef="usd">63000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
	<us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="FI2018Q4" decimals="-3" id="Fact-49460097AB5CCBACE6C732376261AA04" unitRef="usd">91000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
	<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-1473C836151FAC66641E323762571F0E" unitRef="usd">110000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-A3B49DD2767C7DDF3CAA3237624DBCAB" unitRef="usd">99000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
	<us-gaap:Depreciation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0A99A9316D9E35774541CC63537A07FE" unitRef="usd">69000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0E879653FA971FF19E795125D9689C8B" unitRef="usd">241000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8AB44C34047A7FC42F985125D972E5D4" unitRef="usd">388000</us-gaap:Depreciation>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_alpn_SeriesAOnePreferredStockWarrantsMember" decimals="-3" id="Fact-82A4E596040B8B1F63973237622F91B0" unitRef="usd">53000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DueToRelatedPartiesCurrent contextRef="FI2016Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_alpn_AlpineBioVenturesGPLLCMember" decimals="-3" id="Fact-34375FC86AB23F350DEB3237622F7297" unitRef="usd">5000</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-C23185C7B17C6DC42AA0CC43F2C07D6B" unitRef="usdPerShare">-2.18</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-1BB83F58C936986AF6CB5125D94DC3C0" unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q4YTD" decimals="2" id="Fact-951870E37D5B3EEEEE205125D9564E54" unitRef="usdPerShare">-2.63</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q4YTD" decimals="3" id="Fact-7C6491AF5E55FC61685E3237624D5ED4" unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2018Q4YTD" decimals="3" id="Fact-11577CE27E2F813E13DE3237624DBEE2" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="INF" id="Fact-69C61C2132005E49B1A23237624339A8" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q4YTD" decimals="INF" id="Fact-71C0EF3589A04DA3CAB23237622F1F63" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2017Q4YTD" decimals="3" id="Fact-B9CBE6A4E0364F86A2183237621BE334" unitRef="number">-0.194</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2018Q4YTD" decimals="3" id="Fact-5161EE52C0D9AFE6155A3237623940EE" unitRef="number">-0.273</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="3" id="Fact-142B9B1B6FCA6D74A448CD6575FE23DE" unitRef="number">-0.247</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2018Q4YTD" decimals="3" id="Fact-E64FC9DA8E1F9D6BF0E73237624DA1EE" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="FD2017Q4YTD" decimals="3" id="Fact-F5BD7522D7BD2BF146C33237622F170D" unitRef="number">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="FD2018Q4YTD" decimals="3" id="Fact-B9AEBCEAAF73587E810C3237624328B2" unitRef="number">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
	<us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="FD2017Q4YTD" decimals="3" id="Fact-7FDBE7D63FD6A553DB2B32376225EE8B" unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
	<us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="FD2018Q4YTD" decimals="3" id="Fact-21957EAF62ED296AF8A23237621BE970" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="3" id="Fact-81F20E598A5C4E60EAD93237624DBBDF" unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2018Q4YTD" decimals="3" id="Fact-32A200635BE1211D05FD3237621B3D07" unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-157B1375E7B5763ECA3F4F07A197FF6B" unitRef="usd">4000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-8F8809E42394F4E9595B4F07A17E30F9" unitRef="usd">1009000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-6049CA0F8CBE1319E72A32376211EBA5">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-5A7916BE6E8B7A11F916323762250246" unitRef="usd">6500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
	<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7DB8F67F8369D56C1D1C4EA2018183C7" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
	<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DC73CBC5F04BCBED14B95125D95D77B8" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
	<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="FD2018Q4YTD" decimals="-3" id="Fact-62496D5008A9D5D84D385125D9838B88" unitRef="usd">-1203000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
	<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="FD2018Q4YTD_dei_LegalEntityAxis_alpn_LaurelVentureCapitalLtd.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_alpn_GSNORMember" decimals="-5" id="Fact-C0E08319FD5F4E59088E4EDC1505273B" unitRef="usd">-1200000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-776920E77D0FE87DD892CC43F2C04AD6" unitRef="usd">1149000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-243AE4624D6DEB3CB88C5125D95F8D6F" unitRef="usd">6079000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C61C6FE605EEA5D0103F5125D9809F52" unitRef="usd">8362000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D17E70CAFB100A84B0D53237622FE4CD" unitRef="usd">-1232000</us-gaap:IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple>
	<us-gaap:IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-2F9133EB3701EF8CEC8F323762252ECD" unitRef="usd">-1232000</us-gaap:IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple>
	<us-gaap:IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9D968C0B716DD18152B232376225071C" unitRef="usd">-7783000</us-gaap:IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple>
	<us-gaap:IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-36F77C6CB226B58459183237622FA039" unitRef="usd">-7783000</us-gaap:IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple>
	<us-gaap:IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple contextRef="FD2018Q4YTD" decimals="-3" id="Fact-FFD83494276A62B122C34EA65D37B311" unitRef="usd">-36487000</us-gaap:IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple>
	<us-gaap:IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-DDF98D90C5F1339477A04EA65A833CB0" unitRef="usd">-36487000</us-gaap:IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E4D25A22C1C8B2AF27FDCC43F2B65422" unitRef="usd">-1166000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="-3" id="Fact-67B8AC1A6F3C85A941B05125D95891B8" unitRef="usd">-7983000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q4YTD" decimals="-3" id="Fact-EF1D1708B345C98D243C5125D95CB5F4" unitRef="usd">-36853000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F7616A4F3349C2E1C85BCC449B23D40C" unitRef="usd">66000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3B87F139424D09F767E55125D959A847" unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5C1AA675453F923EDD1B5125D9554604" unitRef="usd">-366000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxesPaid contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6A7FCC6981C87D82B472CC642BE2B30A" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="FD2017Q4YTD" decimals="-3" id="Fact-445510E440A02D6210EE5125D959E856" unitRef="usd">76000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A1DEFD154FEB338E3AE25125D95AA568" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F9DED5EA78727EEB8670CC6353668E1C" unitRef="usd">80000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-46C9D95E035CB22C7DFE5125D981F7E9" unitRef="usd">66000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E9D8A692F86440231EDA5125D978AF83" unitRef="usd">1523000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-55D024191D18D90DD279CC6353846D42" unitRef="usd">39000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B9FF41E7AA995805F0585125D9658DD4" unitRef="usd">-259000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C8FF7287C0C37BF5A2155125D97826F6" unitRef="usd">3895000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1F910A496365B93F01C0CC63537A00C8" unitRef="usd">-2950000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="FD2017Q4YTD" decimals="-3" id="Fact-239E7088BE1E066CDCF25125D97D3585" unitRef="usd">-1731000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="FD2018Q4YTD" decimals="-3" id="Fact-69577DB23A2FD32035555125D96E0534" unitRef="usd">-480000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-44E7A1D7BA9D0F35C8AECC6353847729" unitRef="usd">26000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AF2FEB9BA2CAEAA932305125D97E016A" unitRef="usd">1193000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8BDDF8BAB8950E05B4DF5125D9653816" unitRef="usd">-66000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2017Q4" decimals="-3" id="Fact-534644E23378D3CD0B545125D96CE644" unitRef="usd">1453000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2018Q4" decimals="-3" id="Fact-3E2147C114F8195D13C95125D976CA7D" unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:InterestAndOtherIncome contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3955CFDCA136EA91828ACC43F2AC5C98" unitRef="usd">22000</us-gaap:InterestAndOtherIncome>
	<us-gaap:InterestAndOtherIncome contextRef="FD2017Q4YTD" decimals="-3" id="Fact-959093FA669671596FC15125D95F68B1" unitRef="usd">542000</us-gaap:InterestAndOtherIncome>
	<us-gaap:InterestAndOtherIncome contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B4954B40881284D314A45125D97FE2BA" unitRef="usd">1296000</us-gaap:InterestAndOtherIncome>
	<us-gaap:InterestExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F4E59B5458D35BFE2D16CC449940C01E" unitRef="usd">0</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-32305600A704854445C55125D956974A" unitRef="usd">152000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D00377CA161382636C395125D9846B67" unitRef="usd">319000</us-gaap:InterestExpense>
	<us-gaap:InterestPaidNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F0297CBF4548AAC66637CC642C27F4F8" unitRef="usd">0</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CC42B45DCBC06BD9BC8C5125D9693E1B" unitRef="usd">53000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0942299F198050EC67105125D967DC3F" unitRef="usd">149000</us-gaap:InterestPaidNet>
	<us-gaap:LessorOperatingLeaseRenewalTerm contextRef="FI2016Q4" id="Fact-E23281E3987EDDB9F2BB32376261D5CF">P12M</us-gaap:LessorOperatingLeaseRenewalTerm>
	<us-gaap:LessorOperatingLeaseRenewalTerm contextRef="I2018Q1Jan31" id="Fact-C57C6CD216F42759E7B977EEC8EA9178">P12M</us-gaap:LessorOperatingLeaseRenewalTerm>
	<us-gaap:LessorOperatingLeaseRenewalTerm contextRef="I2018Q1Mar18_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-2F1A3A7DCF627FE300084F17128FD830">P5Y0M0D</us-gaap:LessorOperatingLeaseRenewalTerm>
	<us-gaap:LessorOperatingLeaseTermOfContract contextRef="I2018Q1Mar18_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-B93B1A245A98CBB3DF784F16004E04E7">P10Y9M18D</us-gaap:LessorOperatingLeaseTermOfContract>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-3AE889125B51135141C35125D974026A" unitRef="usd">6305000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="-3" id="Fact-143CAEBA80290FA340375125D966E6D4" unitRef="usd">10282000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-45CBED546D4239425CC95125D978DFBF" unitRef="usd">85222000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-6B953862F049D3736D6F5125D96ADAF9" unitRef="usd">54873000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-4B5275A6EDBB0A910BC85125D979B9E1" unitRef="usd">1895000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-BC0E56D6E5C980A007D45125D9786854" unitRef="usd">8127000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LongTermDebt contextRef="FI2018Q4" decimals="-3" id="Fact-BF503682C688C6966FBA736B9289C574" unitRef="usd">4000000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3C6BB580CAB9846CF4425125D9794454" unitRef="usd">995000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-B461268A78D92657AA9F5125D96D5E3B" unitRef="usd">2048000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="FI2018Q4" decimals="-3" id="Fact-EA4B61C56EFEF80D0210736A7F7FD889" unitRef="usd">2000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2018Q4" decimals="-3" id="Fact-59ADF2FF59CEDF46ED51736B51830A05" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2018Q4" decimals="-3" id="Fact-2303FF4A2E6BFF72D00F736B246818FF" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2018Q4" decimals="-3" id="Fact-7628BF2616054B108B0A736AEE2448FD" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2018Q4" decimals="-3" id="Fact-E5FC8CF4BB5D0D03E4F5736ABA5D8EBD" unitRef="usd">2000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-A0A7A446451D4F246B215125D976D844" unitRef="usd">4039000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-541C7F612A49A7B859F35125D96E37E9" unitRef="usd">2155000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="I2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-1A139BF3D2B2AAFB6C704FCA9CD56587" unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7DEC067848D049DAAF5CCC6353844F84" unitRef="usd">10975000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-32759B161E60876FE8E45125D9681AA1" unitRef="usd">42688000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-44395B8C045E79F2ACC15125D96DF462" unitRef="usd">-991000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-92CC39F146568C63262ECC635370B13F" unitRef="usd">-782000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5C170F157C35A847AC975125D97CCB29" unitRef="usd">-29803000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1DE1BE9BAD60BBA9AE345125D975B23D" unitRef="usd">32118000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FD845B67895909B00816CC63538E8106" unitRef="usd">-3797000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7E2FD7530C008B61A9D95125D971C6C2" unitRef="usd">-16572000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-DDE1D51D9B1074CE1EC05125D9817E42" unitRef="usd">-28416000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CB77BF74B2135EDB35B9CC43F2CA281F" unitRef="usd">-1232000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2A4B6007EBFAB39DA1D45125D9516ACA" unitRef="usd">-7783000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD" decimals="-3" id="Fact-ECD9AE46CFAC54FBDF425125D95EB6E4" unitRef="usd">-36487000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-01E70193C9FB438DFB5D4EC5043D252A" unitRef="usd">-203000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-1ED45C9B5215791177F64EC50444A876" unitRef="usd">-36690000</us-gaap:NetIncomeLoss>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2018Q4YTD" decimals="INF" id="Fact-6963F7F02E4C70279D0432376211EA41" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CD8258F665984A98CC47CC43F2A2F02F" unitRef="usd">4138000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B3042749DC7185FC9D015125D95AB587" unitRef="usd">16705000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0AEEDED339DA61F3FDEB5125D986CDD0" unitRef="usd">38535000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-795AF0689AD657227157CC43F2B61683" unitRef="usd">-1188000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-199B0EB7F8B35C4A37735125D95D272A" unitRef="usd">-14974000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q4YTD" decimals="-3" id="Fact-87E1EED56EE252935DAE5125D9883624" unitRef="usd">-37830000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeaseLiability contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_LeaseArrangementTypeAxis_alpn_OfficeAndLaboratoryLeasesMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="-5" id="Fact-1162F2C3350A25107C7891702F9DD236" unitRef="usd">1000000</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_LeaseArrangementTypeAxis_alpn_OfficeAndLaboratoryLeasesMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="-5" id="Fact-D949CE0246D4C37098424EB2F57C7512" unitRef="usd">1000000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2018Q4" decimals="-3" id="Fact-543400C479264174075E3237622FACB0" unitRef="usd">949000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-917C2BBEA79E45FF9E3E323762390684" unitRef="usd">930000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2018Q4" decimals="-3" id="Fact-46E628C55157A132D08ACCE147491EC2" unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2018Q4" decimals="-3" id="Fact-2FA20E40BC6EEE143E20CCE109C74A88" unitRef="usd">1000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2018Q4" decimals="-3" id="Fact-81388D7ABF405AE831EDCCE0C865D2CB" unitRef="usd">9000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2018Q4" decimals="-3" id="Fact-2721AF367AEAD67288CA3237622FDB6E" unitRef="usd">9000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="D2018Q1Jan1toJan31" decimals="-3" id="Fact-2C36CD0905E11FF7AB4177ECA0AAA4CD" unitRef="usd">295000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="D2019Q1Mar01-Mar18_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-BAB372DF220E345E1FCE4F17C608EC78" unitRef="usd">1700000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D7681E59476CF9938FA63237624DA33C" unitRef="usd">566000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-30A6D3CF78262561F63A3237626B967A" unitRef="usd">267000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C7884BC09C834C0FB4AF32376261631F" unitRef="usd">529000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D41ABD5FB80471F00B6D32376261AC90" unitRef="usd">811000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_alpn_BeforeJanuary12018Member" decimals="-3" id="Fact-7F25739D9E4F39DC98B6CD69D56A9001" unitRef="usd">11784000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-3" id="Fact-7AADB434D12043DE1C5B77E1D96B2ADA" unitRef="usd">0</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_alpn_AfterJanuary12018Member" decimals="-3" id="Fact-9C2387CEDD9B2EC3A2334FB94B4AC6FF" unitRef="usd">33417000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_alpn_BeforeJanuary12018Member" decimals="-3" id="Fact-CC55785A7D99F93CF7C932376261AA04" unitRef="usd">11094000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-3" id="Fact-1A07B9E6241CA6E675704FB97A7AA0FB" unitRef="usd">16756000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-08F369851199360E5F3F3237624DA803" unitRef="usd">69000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-4F2CFC1453039E7FD47F32376261B857" unitRef="usd">165000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D6D6FCAFE479CB016617CC449CF265D5" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-98854F6576BE604F46825125D95B5D79" unitRef="usd">-59000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-3B7A4022AFA1AFCCA8D23237622FD87F" unitRef="usd">-59000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-DC9C3654132B2CFBCD855125D94D6C49" unitRef="usd">46000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-B7B220C66D1247BF4EDF4EA556DDA48F" unitRef="usd">46000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherPrepaidExpenseCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-EFC172E8DEF3601DBB4F4F03698AA65A" unitRef="usd">91000</us-gaap:OtherPrepaidExpenseCurrent>
	<us-gaap:OtherPrepaidExpenseCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-A17422521AFB6508E7CD4F03699A48EA" unitRef="usd">145000</us-gaap:OtherPrepaidExpenseCurrent>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-0AF3E79F8ED091A230334F03B6347B8D" unitRef="usd">128000</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-ACA92324EEE125B5C51B4F03B624F20B" unitRef="usd">237000</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:PaidInKindInterest contextRef="FD2016Q4YTD" decimals="-3" id="Fact-06DCEAEBDCA5B75F7915CC641B03FF08" unitRef="usd">0</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D971FC7F3BA781F0C6875125D96AD486" unitRef="usd">87000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0ACDB926514E0F5B63815125D96F98EF" unitRef="usd">169000</us-gaap:PaidInKindInterest>
	<us-gaap:PaymentsForProceedsFromTenantAllowance contextRef="D2019Q1Mar01-Mar18_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-9B34946C8FD5E6E522904F1B098E8201" unitRef="usd">-5400000</us-gaap:PaymentsForProceedsFromTenantAllowance>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4A0A3064D6B7CD29F3B3CC6423E8C6DC" unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0E2FE5C9905742DA36995125D965C9FE" unitRef="usd">88307000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-28068E97C318BBC9842C5125D980A8D2" unitRef="usd">72863000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-23EBF8F3C0533BDAD355CC63538EBBDF" unitRef="usd">782000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D9439030E1AB3D04D8EE5125D96FB4F1" unitRef="usd">586000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q4YTD" decimals="-3" id="Fact-06697F69F79D8455DA665125D9693003" unitRef="usd">495000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-CA93D0AD7CB895B9582A5125D96E83FB" unitRef="usd">1308000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-55A7AB03AFA0E39375BA5125D977EDF2" unitRef="usd">1242000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidInsurance contextRef="FI2017Q4" decimals="-3" id="Fact-837C91A34438E21C8AE54F0351B6C07F" unitRef="usd">298000</us-gaap:PrepaidInsurance>
	<us-gaap:PrepaidInsurance contextRef="FI2018Q4" decimals="-3" id="Fact-92CE361D37C40586CB584F0351CC645D" unitRef="usd">300000</us-gaap:PrepaidInsurance>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="D2017Q3Jul24" decimals="-5" id="Fact-8547008762DE2F1429FA323762617A54" unitRef="usd">17000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EA68C79D687B7B8BDCD9CC63537ADB83" unitRef="usd">10925000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2090A430E28A6DB6DB665125D965DD7B" unitRef="usd">37666000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="FD2018Q4YTD" decimals="-3" id="Fact-47D095561CC82747664A5125D9652C87" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="D2017Q2Jun30_us-gaap_DebtInstrumentAxis_alpn_TermLoanMember" decimals="-5" id="Fact-3C7FC9019C5E6811B1163237622F5EB0" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B744AD6FBECA156CDDF8CC6428020692" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-673029DC79F6393432B15125D976B304" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-258B195952BD6250B0ED5125D9706615" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="D2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-6A95322EEA808258BB604FC9A64F838E" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
	<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="D2019Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-58A92D404E19551E59074F3409CFE608" unitRef="usd">25300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AAFC79A544D724A77A70CC64244EEFDF" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6DC950909F7D155C078D5125D96A827D" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5B5D56E3A96D5AC5C9115125D982C054" unitRef="usd">105226000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-30B568A50DE228251E06CC64254DC6F8" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-67FE78C3F7987549C5E95125D96F112B" unitRef="usd">27960000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F9F5F521C24C4315F3CC5125D97221FC" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
	<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="D2018Q2Jun01-Jun30_dei_LegalEntityAxis_alpn_LaurelVentureCapitalLtd.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_alpn_GSNORMember" decimals="-3" id="Fact-2660030480152FB86C994ED813226BA0" unitRef="usd">250000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
	<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D92E9009DA350DA55724CC6423871F0E" unitRef="usd">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
	<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0E8F121BBA1AE4DAF8DC5125D9711070" unitRef="usd">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
	<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="FD2018Q4YTD" decimals="-3" id="Fact-861514DE74EB7A9EB9E15125D9714D8C" unitRef="usd">250000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-69606766C98A9D2742C8CC64293487D7" unitRef="usd">50000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0F185C21123EED9C96625125D971C112" unitRef="usd">22000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2018Q4YTD" decimals="-3" id="Fact-FF95456255CCE5754C735125D9794433" unitRef="usd">9000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4" decimals="-3" id="Fact-F0B6B1F33DCC2041AC4032376225AEF6" unitRef="usd">1400000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_alpn_GeneralEquipmentAndFurnitureMember" decimals="-3" id="Fact-6E188F9103B80AB363953237622550B7" unitRef="usd">110000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-4E168B717AA389BDC2EA32376225CB96" unitRef="usd">82000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-59603A403E37299BBC8E32376225AEAA" unitRef="usd">1161000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-7BDB474316FDE2A74C0C3237622F8381" unitRef="usd">47000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4" decimals="-3" id="Fact-CABDFCA7B798981FB86C3237622FDC16" unitRef="usd">1895000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_alpn_GeneralEquipmentAndFurnitureMember" decimals="-3" id="Fact-88798B24A090ED3F20043237622F0CA3" unitRef="usd">158000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-AFA5FEE326D9F1C4E3863237622F223D" unitRef="usd">103000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-C1296CCCE3DE85DB6CB23237622FCC22" unitRef="usd">1506000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-4271153CFB8F89FED2453237622F63C6" unitRef="usd">128000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-3" id="Fact-9F0309B208018148B9165125D976EDCF" unitRef="usd">1089000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="-3" id="Fact-A62F2DFC8576CA65B5A35125D96D9971" unitRef="usd">1196000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-CEA97FFDF646A77233243237621BEAD7">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-B87EE60492C36BC924AC3237621BF3BF">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2016Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_alpn_AlpineBioVenturesGPLLCMember" decimals="-3" id="Fact-4E27B88C8FF2CC1A1ECD3237622F9EEC" unitRef="usd">17000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_alpn_AlpineBioVenturesGPLLCMember" decimals="-3" id="Fact-C702223761CEEFC31033323762258EFF" unitRef="usd">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_alpn_AlpineBioVenturesGPLLCMember" decimals="-3" id="Fact-EFE12BA8DC21F3BB0B1A3237621BB20F" unitRef="usd">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-31652B1FEF5A60C9EB164FF2A4D4D45B" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-652120426F54989BC0455125D96C41AD" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E0BE87EF73DF7343B79F5125D97C7E80" unitRef="usd">1000000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4FE5BED40F4607BFC9B9CC43F2CACD06" unitRef="usd">2989000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-51244E95809DA63FA8B85125D95348CD" unitRef="usd">10626000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E662D61EE26EB58500505125D95024A1" unitRef="usd">28970000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCashNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-00B8A6823F908F85FE655125D9711323" unitRef="usd">132000</us-gaap:RestrictedCashNoncurrent>
	<us-gaap:RestrictedCashNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-AF78ADE5FB3A3A5BC1705125D96F0B15" unitRef="usd">132000</us-gaap:RestrictedCashNoncurrent>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-5239BB4BAD55C22BA6375125D9730021" unitRef="usd">-9384000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-3" id="Fact-73541481B23973D86C3B5125D972D00D" unitRef="usd">-46074000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-9F87EA54B238FCDEA0D04EC33298BB9F" unitRef="usd">-203000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-21F00FF4CD2941F766914EC3326C3FF4" unitRef="usd">-46277000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-8CE455742681A160C9E14EB9B9ACC553" unitRef="usd">-203000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q1_dei_LegalEntityAxis_alpn_LaurelVentureCapitalLtd.Member_us-gaap_DebtInstrumentAxis_alpn_TermSheetMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_alpn_GSNORMember" decimals="-3" id="Fact-C00A946DBC873413EE124ED699E6C529" unitRef="usd">75000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-343646843ABD601EF37FCC43F2C05329" unitRef="usd">2950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2016Q4YTD_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember" decimals="-5" id="Fact-E80FC19C25382153BC653237624DE5E0" unitRef="usd">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EE03C022EDFB5D969ADD5125D955C870" unitRef="usd">1731000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember" decimals="-5" id="Fact-5F8498068276EC56E0163237621B1EA6" unitRef="usd">1700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C3C9D57F84848AECE97E5125D94EB284" unitRef="usd">705000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_alpn_KiteMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember" decimals="-3" id="Fact-69B8E5DCD96862A822823237621102C7" unitRef="usd">630000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-7D3125BE1B976FC497B04EC36A0D57F9" unitRef="usd">-203000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-D959FE6087EE888B5FB14EC36A1DBAD1" unitRef="usd">502000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:SecurityDeposit contextRef="I2017Q2May31_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="-3" id="Fact-727DF27F28E6C72C553932376261EA27" unitRef="usd">132000</us-gaap:SecurityDeposit>
	<us-gaap:SecurityDeposit contextRef="I2018Q1Mar18_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-3A3F4DEF5847E6BDF8F94F21F8DB3F35" unitRef="usd">254000</us-gaap:SecurityDeposit>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D8074399525EFE2DA7A8CC63538E46AC" unitRef="usd">77000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0C76E48CD1E5D634F5915125D969928B" unitRef="usd">838000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-11FC1FF5F1699E4CCB265125D97E4C5A" unitRef="usd">2309000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2018Q3" id="Fact-B7C604B037E70146EF289182796E085C">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2018Q4YTD" id="Fact-360E6DBED796F3934E2032376239117D">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD" decimals="3" id="Fact-D45D7F9E921D19775471CD48C1BCA651" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q4YTD" decimals="3" id="Fact-1BFC7D68E67627A09EF3CD48C1B2B765" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q4YTD" decimals="3" id="Fact-266C567FAB8C91376542CD48C1A14E22" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2016Q4YTD" decimals="2" id="Fact-528B8CF85235AB8CF2B13237622FDBA7" unitRef="number">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2017Q4YTD" decimals="2" id="Fact-B697DF136E1BB195C09C3237621BFC46" unitRef="number">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2018Q4YTD" decimals="2" id="Fact-094DEE6064958A954EB23237621B5BAE" unitRef="number">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2016Q4YTD" decimals="2" id="Fact-FF9E132000F91C33E9B432376275300C" unitRef="number">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2017Q4YTD" decimals="2" id="Fact-EF7E510478E2AD662E0B323762119014" unitRef="number">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2018Q4YTD" decimals="2" id="Fact-33F404FCA4E7FD4EC5D83237622535B8" unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2016Q4YTD" decimals="4" id="Fact-5CD6060E61E8406B833E3237621B33F5" unitRef="number">0.0224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2017Q4YTD" decimals="4" id="Fact-4BD5D534643CD85778F4323762115871" unitRef="number">0.0226</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2018Q4YTD" decimals="4" id="Fact-AED81CFA34E73327CEBC32376211A654" unitRef="number">0.0307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2016Q4YTD" decimals="4" id="Fact-D8F59734514097491C10323762251535" unitRef="number">0.0114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2017Q4YTD" decimals="4" id="Fact-62AD7746ED16CD26BCB63237621161C7" unitRef="number">0.0190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2018Q4YTD" decimals="4" id="Fact-CFD4D833C71FE4FE6D0832376211A4DC" unitRef="number">0.0227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2018Q2Jun01-Jun30_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_alpn_TwoThousandAndEighteenPlanMember" decimals="INF" id="Fact-8BE693E78A1560682DF24F72C1FE7667" unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2019Q1Jan01_us-gaap_PlanNameAxis_alpn_TwoThousandAndEighteenPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-62D4C8B98F56E14386D84F7429ACE213" unitRef="shares">692710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2018Q2_us-gaap_AwardTypeAxis_alpn_CommonStockInitialReservesMember_us-gaap_PlanNameAxis_alpn_TwoThousandAndEighteenPlanMember" decimals="INF" id="Fact-18F2526ED001716E7C384F7036256908" unitRef="shares">901530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2018Q2_us-gaap_AwardTypeAxis_alpn_LegacyPlanCancellationsMember_us-gaap_PlanNameAxis_alpn_TwoThousandAndEighteenPlanMember" decimals="INF" id="Fact-2BD252C73F2207A53B214F712F0B5488" unitRef="shares">1972784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2018Q4_us-gaap_PlanNameAxis_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member" decimals="INF" id="Fact-7CA88A756DE6DF065F53323762113D15" unitRef="shares">3061084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2018Q3Aug31_us-gaap_PlanNameAxis_alpn_InducementGrantMember" decimals="INF" id="Fact-2801A425522D317694C04F7579F11689" unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-F062742E612B9FAFC09732376239A616" unitRef="shares">887134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-5B32CFC90C2F2055260A3237622F4FBA" unitRef="usdPerShare">4.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-1D53C8DE25EB0171482D4F7A359E6218" unitRef="usd">22000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-56F17EFC6F7EC35C97684F7A171D43E0" unitRef="usd">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-BA4C1A529B3E82B5A037323762430BF4" unitRef="usd">214000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-F2AE891BD38A3136B32ECD71E76203E0" unitRef="shares">15869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-5D2BA22085BD556A42D5CD71EB1209F3" unitRef="usdPerShare">10.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-D05E487513D74733AC62CD71D8361583" unitRef="shares">936750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD" decimals="2" id="Fact-017E26AD3BBCAD1050983237621B2BB1" unitRef="usdPerShare">0.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD" decimals="2" id="Fact-7758AF61846B87DA9B073237621B10D3" unitRef="usdPerShare">4.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD" decimals="2" id="Fact-99ACBA74FECD496519993237621BB8CC" unitRef="usdPerShare">5.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-BE09CE1CDB83976D053032376239665B" unitRef="shares">1611996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-6D10D4B7C8A2614FB975CD71EDF86C74" unitRef="shares">2509850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="INF" id="Fact-06A10A84FEF8FD31A24232376257C73C" unitRef="shares">421992</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-E41F4A602A8A539615263237621BD776" unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-8D7E02F84EE0921743E3CD71F19A1256" unitRef="usdPerShare">5.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="I2017Q3Jul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="2" id="Fact-62CADA39B84F9B3C21A33237625764D5" unitRef="usdPerShare">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-0F625EA7D26AFD5C221232376239BC48" unitRef="usd">1535000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-C7B9C0C32CBBEAC94DB5323762435B5A" unitRef="usd">2548000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-937A895094C1749F1CA53237621B35F8" unitRef="shares">2484850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-F071C5F3720F438532813237621BE190" unitRef="usdPerShare">5.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-86F09C2DC5733D181539CD71E477A269" unitRef="usdPerShare">0.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-5C643DBFBFBD8722DE86CD71DC80073E" unitRef="usdPerShare">8.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-AB12C3BAD88F1ECBF81432376239CAF5" unitRef="usd" xsi:nil="true" />
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-33F74895995EAF91CBD2CD759CEE46C8" unitRef="usd">2548000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="D2018Q3" id="Fact-C632D92B25042BE9BF7C9182CC511F2C">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2018Q4YTD" id="Fact-FF53285B41AA926F27AF32376211EF26">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_alpn_IncentiveStockOptionMember" id="Fact-FFB85F31765FB61A899B32376275A344">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-82462DD329560955DA6A3237621B1AEB">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-646F0B87BFC097489DDC32376211BB39">P5Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-328C8209BBE86A2CAB7B3237622523A3">P6Y3M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-A99D9BA75D0CF2992DA832376211AA4D">P5Y8M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-16E34714CDE5D57C74A032376275D9A4">P7Y0M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-9DCFB3F5748FFE53FFDF3237621B0782">P5Y6M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-32F13D909667270903A7323762396A4C">P6Y7M27D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-D66469B8E68117A4562C323762434290" xsi:nil="true" />
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-1AF8F703A982AAD0E501CD756A2431F6">P8Y1M11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-6E7D541CD086CBFA26313237621B44CB">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-3C5D3CACE22CCCBFBB8B4F7A8CBA3C12" unitRef="usd">70000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-5E4AC630EDA1C22D69EF4F7A7F4A0BC2" unitRef="usd">139000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-38548CBFB471A1CDFB3A3237621B72EA" unitRef="usd">1800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-22055D908B6BEDF399E73237621B858A" unitRef="shares">496900</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-208F19350AE61E12061FCC5252B0A92E" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-B7523B8FD6733131D62C323762394341" unitRef="shares">608701</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-8E2FCF6B808E0391B9E0CC522D0B19A9" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-380B304684D94E4C236832376239F92F" unitRef="shares">13831178</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-514CC509D12AF7F1EF003237623992FA" unitRef="shares">50467</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-96AABD9E0EABC1083FC44EA696B30DC8" unitRef="shares">13854205</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-D473CF8F2ABCA509DEA64EA69B98EC29" unitRef="shares">50467</us-gaap:SharesIssued>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-26157E1BFE6327BA8BB03237621B1023" unitRef="shares">9301433</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-E94D21DB725474CC3CB54FC3DE5EA85F" unitRef="shares">935753</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2019Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-6A91A35089B6B91896AD4F35017FD6F3" unitRef="shares">4706700</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D50B70E7D5BBCB9CEF5732376239EFDE" unitRef="shares">111801</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-F220A72F7B68FC4C2D9BCD71DFB23B9F" unitRef="shares">23027</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F89F7C4465BBEE823B554EA5D43208BF" unitRef="shares">23027</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-FB317D8DCB6C07B2182A3237622FBE0F" unitRef="usd">49201000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C4B595433B56C04348A73237622F65B0" unitRef="usd">49200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-0588C10F87E43E2E717032376239D8B5" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CB0C8240B4055FB627E83237621B8732" unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-16B0A32FBF5FCE9BAD5A32376225E1E4" unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q4YTD" decimals="-3" id="Fact-72EAD4BBFE286CBE12D54EA627902539" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-2E889B093F60A6D8DBF14EA60200E83A" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-A2433437797E471B178B5125D9672547" unitRef="usd">78917000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-3AD29FD257EBB6CD41865125D970D89C" unitRef="usd">44591000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4" decimals="-3" id="Fact-F116176D1D9F2E46817D32376239B78C" unitRef="usd">-352000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-F8352912AF6FB7775A1ACC5307D9203D" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D289475B30BBBB5D0CF83237622F55E6" unitRef="usd">17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-31252FBC0A9CE62A3914CC52ABD457B2" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D0344BD7A056010CF6423237622FBBE3" unitRef="usd">-369000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-3BF87568DE812AD09789CC5147186CAC" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4" decimals="-3" id="Fact-75C65F78A1283438969932376225AE26" unitRef="usd">-1457000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-78C462D67D127F5D7C43CC53249B7E53" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-65EBFF3B9AA4A33A14B73237622FF969" unitRef="usd">144000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-41580A2EC0ACC78D7CE4CC52CA43F8A4" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-CDAC17FAC15BB74C137132376239285A" unitRef="usd">-1601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-8DC8CAC3784877E3D21FCC519AC38833" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4" decimals="-3" id="Fact-4F40B3B4E0A2FD9FE8BE3237621BD840" unitRef="usd">78917000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-C70A4D68256FC107AA7B3237623923C0" unitRef="usd">-59000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FB1631600C9BB710EDB5323762250108" unitRef="usd">88346000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-90157B9321B1F9FB99D23237623926D6" unitRef="usd">14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-4E629DEF80C8151C3323323762392683" unitRef="usd">-9384000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-90B25730256D925187FCCC51C66AD91E" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4" decimals="-3" id="Fact-2B38C28602A5476A0AA34EA6A7F074E0" unitRef="usd">44591000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-9FAAADAFF8AB2413028C4EA6A302000C" unitRef="usd">-13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-DD4A974693A19F20D6D74EA6A094A662" unitRef="usd">90664000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-93B395E491E6660DFE354EA6996BD13D" unitRef="usd">14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-A72B38DCCCFD591FAD5F4EA6A5523929" unitRef="usd">-46074000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-8BCCB4DFBF855378BBC64EA69E2EC650" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2017Q3Jul23toJul24_us-gaap_BusinessAcquisitionAxis_alpn_NivalisTherapeuticsIncMember" decimals="2" id="Fact-46F5FC513133D49E24373237621178F4" unitRef="number">0.25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-972950217F1D662DDBEF3237622FA96C" unitRef="usd">610000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-5B051A33D5C46280DCB23237621B28FC" unitRef="usd">11535000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4" decimals="-3" id="Fact-EBAE70ED27099208F47D5125D9790636" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-9722E6EB01C8419A64A8CC5095961C49" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2018Q4" decimals="-3" id="Fact-399B3FC2BB38F53CA5615125D967C3AC" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-F9B3B8EC1DD19AB1A0D34EA69418B009" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-1ABD5462AEAC43DE003D323762579214" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-59C394780DDDAB499A443237625751D6" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="I2017Q3Jul24" decimals="INF" id="Fact-F7933384E24195DF007F32376261E743" unitRef="usdPerShare">12.74</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-159A23BA268A83DE03453237625716E8" unitRef="shares">10000000</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-11419E49F40E2840E075323762618097" unitRef="shares">10000000</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-AEA35DEDAB87FAFE1D4F32376257D306" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-24D969B93F4BE55613B2323762572A8A" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="I2017Q3Jul24" decimals="INF" id="Fact-726569FE873E890BFEE632376261BE22" unitRef="shares">1335118</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-0AD25FA6CF30A1A9F3383237622F7F28" unitRef="shares">1212436</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-419E9BFBE61AF38497E23237622F9F8F" unitRef="shares">4311770</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-91FD6390A5CAB16A7DBE32376261C516" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-D64B437EAA567D16097FCC50930210E4" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-263BBB876F35662FF30C323762573BD6" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-1930A9CE2D81EB253D674EA6914794D0" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5E6D23FB26C930E0B2F832376239DD86" unitRef="usd">0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-5ADA87E2AB87696F77D9323762397E9F" unitRef="usd">10925000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8B9034172A5FEB91B118CC5413963831" unitRef="usd">0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-BC27523822CDFB75094332376239F00B" unitRef="usd">37666000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TreasuryStockAcquiredAverageCostPerShare contextRef="D2017Q4Dec1toDec31" decimals="3" id="Fact-C1A28B6C9796BEE84EF032376239C9BC" unitRef="usdPerShare">0.002</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
	<us-gaap:TreasuryStockCommonShares contextRef="FI2017Q4" decimals="INF" id="Fact-905ACFBE52E32316721B323762576847" unitRef="shares">50467</us-gaap:TreasuryStockCommonShares>
	<us-gaap:TreasuryStockCommonShares contextRef="FI2018Q4" decimals="INF" id="Fact-08EF5F765CED5FBEB981323762577C92" unitRef="shares">50467</us-gaap:TreasuryStockCommonShares>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F565004AE9A019A9A1383237621BAD5E" unitRef="shares">50467</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-5A68DA8A3131440B44823237622F892C" unitRef="shares">50467</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-7751D81B6DE5622E2D875125D970A76E" unitRef="usd">0</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-78390E5754CA21AFC6855125D9673A52" unitRef="usd">0</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD" decimals="-3" id="Fact-77AA669C59A0F9CA5147CC55545BC39F" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-3" id="Fact-7FB12FE8FD494B9B12623237623990D5" unitRef="usd">34000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4" decimals="-3" id="Fact-6F8F87BDFDAAE4FBD0FA3237624D4B72" unitRef="usd">114000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2018Q4" decimals="-3" id="Fact-93A139098A350D6AFA4A32376257377B" unitRef="usd">469000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-764C8B9A3E6EDD9C0525323762392F62" unitRef="usd">4000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="FI2017Q4" decimals="INF" id="Fact-2A47B7F13C0C805F81503237624305C6" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="FI2018Q4" decimals="INF" id="Fact-0EC73E0C36D1188170B5323762577D65" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-84A6B1561C9E94F409DF3237624DCDCC" unitRef="usd">84000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3B46CF0E52DD2920858C32376243723D" unitRef="usd">296000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2018Q4YTD" decimals="-3" id="Fact-26B431B2E2131F0B7CDA323762432078" unitRef="usd">59000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2017Q4YTD" decimals="-5" id="Fact-04B2A4341998185E3AFE3237624DB81F" unitRef="usd">2900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2018Q4YTD" decimals="-5" id="Fact-4F2779B729EFCC708782323762617AE4" unitRef="usd">10000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="I2019Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-4AF2A763A4A597B2363573AE9EEED18A">P5Y0M0D</us-gaap:WarrantsAndRightsOutstandingTerm>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q4YTD" decimals="0" id="Fact-C69DF96B5C3B5D45FD0ACC43F2CA4036" unitRef="shares">564816</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q4YTD" decimals="0" id="Fact-7C7CC85B09CE4DBA1D9D5125D94F5545" unitRef="shares">6481665</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q4YTD" decimals="0" id="Fact-10B555F3C8328CADA9025125D95113A6" unitRef="shares">13849470</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<alpn:AccruedLiabilitiesPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-47F640CC08A1681A3FE83237621B47CA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accrued Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As part of the process of preparing our consolidated financial statements, we are required to estimate accruals for professional services and research and development expenses. This process involves reviewing contracts and vendor agreements and communicating with applicable personnel to identify services that have been performed on our behalf. We estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We estimate accrued liabilities as of each balance sheet date based on known facts and circumstances.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, we have not experienced any significant adjustments to our estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</alpn:AccruedLiabilitiesPolicyPolicyTextBlock>
	<alpn:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-FD4A86B0B016A6986B6132376225DA7B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC and generally accepted accounting principles in the United States of America (&amp;#8220;GAAP&amp;#8221;). The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates inherent in the preparation of the accompanying consolidated financial statements include accruals for clinical trial activities and other accruals, and the estimated fair value of equity-based awards. We base our estimates and assumptions on historical experience when available and on various factors we believe to be reasonable under the circumstances. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</alpn:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock>
	<alpn:CommonStockWarrantsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-3725867C3B8C68ACD08E3237621B0290">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We granted common stock warrants to certain&amp;#160;non-employee&amp;#160;professional advisers. We account for our warrants at fair value, with changes in fair value recognized in operating expenses. Common stock warrants are initially recorded at their issuance date fair value and are subsequently remeasured at each balance sheet date. These warrants are valued using the Black-Scholes option pricing model based on the estimated market value of the underlying common stock at the valuation measurement dates, the remaining contractual term of the warrant, risk-free interest rates, expected dividends, and expected volatility of the price of the underlying common stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</alpn:CommonStockWarrantsPolicyTextBlock>
	<us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="FD2018Q4YTD" id="Fact-7C20052B113B7B12C64132376243CBE3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following pro forma consolidated results of net loss for the year ended December 31, 2017 assume the business combination was completed as of January 1, 2017 (in thousands, except per share amounts):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pro forma revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,731&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pro forma net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pro forma basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-46F44AC8F1A904637DFB3237624D91C4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Business Combination&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;July&amp;#160;24, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we closed the merger on the terms described in more detail in &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#sD31BE121D5B120F8794C31F4AFBEEF04"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 1&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In connection with the merger, Nivalis effected a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1:4 reverse stock split&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of its common stock. Upon the closing of the merger, (1) a wholly-owned subsidiary of Nivalis merged with and into Alpine, with Alpine (renamed as &amp;#8220;AIS Operating Co., Inc.&amp;#8221;) remaining as the surviving entity; and (2) Nivalis was renamed as &amp;#8220;Alpine Immune Sciences, Inc.&amp;#8221;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the Merger Agreement, Nivalis issued shares of its common stock to Alpine&amp;#8217;s stockholders, at an exchange rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.4969&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Nivalis common stock, after taking into account the 1:4 reverse stock split, for each share of Alpine&amp;#8217;s common stock and preferred stock outstanding immediately prior to the merger. The exchange rate was determined through arms-length negotiations between Nivalis and Alpine. Nivalis also assumed all of the stock options outstanding under Alpine&amp;#8217;s Amended and Restated 2015 Stock Plan, as amended (the &amp;#8220;Alpine Plan&amp;#8221;), and stock warrants for Alpine&amp;#8217;s capital stock outstanding immediately prior to the merger, with such stock options and warrants henceforth representing the right to purchase a number of shares of the Nivalis common stock equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.4969&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; multiplied by the number of shares of Alpine&amp;#8217;s common stock or preferred stock previously represented by such options and warrants. Nivalis also assumed the Alpine Plan. Immediately after the merger, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,881,645&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock outstanding. Immediately after the merger, Alpine&amp;#8217;s former stockholders, warrantholders, and optionholders owned, or held rights to acquire, approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;74%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the fully-diluted common stock of Nivalis, which for these purposes is defined as the outstanding common stock of Nivalis, plus &amp;#8220;in the money&amp;#8221; options and warrants to purchase shares of Nivalis&amp;#8217; common stock, assuming all &amp;#8220;in the money&amp;#8221; options and warrants of Nivalis outstanding immediately prior to the merger are exercised on a cashless basis immediately prior to the closing of the merger, with Nivalis&amp;#8217; stockholders, optionholders, and warrantholders immediately prior to the merger owning, or holding rights to acquire, approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the fully diluted common stock of Nivalis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The issuance of shares of Nivalis&amp;#8217; common stock to our pre-existing stockholders was registered with the SEC pursuant to the Registration Statement. Immediately prior to the merger, we issued and sold an aggregate of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$17.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of shares of our capital stock to certain existing stockholders. For accounting purposes, our historical financial statements were not adjusted to reflect the merger, other than adjustments to the capital structure to reflect the historical capital structure of Nivalis. No other adjustments to our historical assets and liabilities were made as a result of the merger.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition to the operating assets and liabilities of Nivalis, we also acquired Nivalis&amp;#8217; tax attributes, which primarily consisted of net operating losses which begin to expire in 2032. Our ability to utilize the tax attributes of Nivalis may be limited under Section 382 of the U.S. Internal Revenue Service and as such, have been reserved. We recorded a deferred tax liability related to future tax benefits arising from IPR&amp;amp;D acquired in the Merger. The combined organization is focusing on the development and commercialization of our innovative immunotherapies. Following the merger, the increased cash resources and increased access to capital of the combined organization will help to support the clinical development of our products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Consideration Transferred&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of the consideration transferred was based on the most reliable measure, which was determined to be the market price of Nivalis shares of common stock as of the acquisition date. The fair value of the consideration transferred consisted of the following (in thousands except share and per share amounts):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding Nivalis common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,914,058&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Per share fair value of Nivalis common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding Nivalis stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;421,992&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average per share fair value of Nivalis stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total fair value of consideration (in 000&amp;#8217;s)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the Merger Agreement, unvested Nivalis stock options immediately vested as of the closing of the business combination and were adjusted to give effect to the recapitalization.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Purchase Price Allocation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As Alpine was the accounting acquirer in the merger, we allocated the purchase price to the acquired tangible and intangible assets and assumed liabilities of Nivalis based on their estimated fair values as of the acquisition date. The excess of the estimated fair values of net assets acquired over the acquisition consideration paid was recorded as a bargain purchase gain in the &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The determination of the fair values of the assets acquired and liabilities assumed requires significant judgment, including third party valuation estimates relating to the value of the acquired IPR&amp;amp;D. The allocation of the purchase consideration to the assets acquired and liabilities assumed in our financial statements was finalized as of December 31, 2017.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The final allocation of the purchase consideration is as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,130&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,952&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,614&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities assumed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(910&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Bargain purchase gain&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We relied on significant Level 3 unobservable inputs to estimate the fair value of our acquired IPR&amp;amp;D using management&amp;#8217;s estimate of future royalties and expected earnings of the assets after taking into account an estimate of future expenses necessary to bring the products to completion. These projected cash flows were then discounted to their present values using a discount rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which was considered commensurate with the risks and stages of development of the IPR&amp;amp;D.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The bargain purchase gain resulted from expenses incurred by Nivalis between the time the purchase price was negotiated and the close of the transaction, and changes in the Nivalis stock price during that period as the exchange ratio was fixed when the purchase price was negotiated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recognized acquisition-related costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the year ended December 31, 2017. These costs are included within general and administrative expense in our &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Pro Forma Financial Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following pro forma consolidated results of net loss for the year ended December 31, 2017 assume the business combination was completed as of January 1, 2017 (in thousands, except per share amounts):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pro forma revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,731&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pro forma net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pro forma basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For purposes of the pro forma disclosures above, the primary adjustments for the year ended December 31, 2017 includes the elimination of acquisition related costs and acceleration of stock compensation expense upon the change in control.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-77FE8CA3B7C8E5DE31153237624DB1E2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of the consideration transferred consisted of the following (in thousands except share and per share amounts):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding Nivalis common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,914,058&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Per share fair value of Nivalis common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding Nivalis stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;421,992&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average per share fair value of Nivalis stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total fair value of consideration (in 000&amp;#8217;s)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock>
	<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="FD2018Q4YTD" id="Fact-836685634A4E73A7B31A32376225781C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents and Restricted cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We consider all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking and interest-bearing accounts, and highly liquid money market funds.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted cash represents cash drawn on a line of credit used to establish collateral to support the security deposit on our operating lease to rent office and laboratory space in Seattle, Washington.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
	<us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock contextRef="FD2018Q4YTD" id="Fact-D7CAD17EB30A535EDC43323762119823">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cash Equivalents and Short-Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The amortized cost and fair value of our cash equivalents and short-term investments are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br clear="none"/&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br clear="none"/&gt;unrealized&lt;br clear="none"/&gt;gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br clear="none"/&gt;unrealized&lt;br clear="none"/&gt;losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair market&lt;br clear="none"/&gt;value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury bills&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities and commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,702&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,689&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair market&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury bills&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,909&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities and commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,920&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All short-term investments held as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were classified as available-for-sale securities and had contractual maturities of less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one year&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; realized gains and losses on these securities for the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-A0F695DDBAD9751C03A332376211178E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaboration and License Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2015, we entered into a Collaboration Agreement with Kite to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. Under our agreement, we are to perform certain research services and grant to Kite an exclusive license to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; programs from our transmembrane immunomodulatory protein (&amp;#8220;TIP&amp;#8221;) technology, which Kite is planning to further engineer into chimeric antigen receptor (&amp;#8220;CAR&amp;#8221;) and T cell receptor (&amp;#8220;TCR&amp;#8221;) product candidates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the Collaboration Agreement, in 2015, Kite made upfront payments to us of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which were initially recorded as deferred revenue. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we are also eligible to receive milestone payments based upon the successful achievement of pre-specified research, clinical, and regulatory milestones totaling up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$530.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; plus royalty payments on product sales, if any. Kite will receive an exclusive, worldwide license to research, develop, and commercialize engineered autologous T cell therapies incorporating &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; programs coming from our platform.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2017, we entered into an amendment with Kite to extend the research term of the Collaboration Agreement. Under the amended agreement, we became eligible to receive an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$450,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in research support payments from Kite in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; tranches. In June 2018, we recognized one of the research support payments under the amended agreement. In October 2018, we entered into another amendment with Kite, which amended portions of the research plan. We have recorded revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$630,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, under the Collaboration and Licensing Agreement. In the second quarter of 2018, based on the completion of our research and development efforts in connection with the performance period, we recognized the remaining balance in deferred revenue on our accompanying &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As further discussed in &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#sFE10AB00D18A281B653831F4AFFB388C"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 2&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, on January 1, 2018, we adopted the new revenue standard using the modified retrospective method. Prior to the adoption of the new revenue standard, we recognized revenue under the Collaboration Agreement based upon the estimated performance periods related to the non-refundable upfront payments we received from Kite. Under the new standard, we recognize revenue based on employee hours contributed to each performance obligation. We recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$203,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in higher revenue for the year ended December 31, 2018, as compared to what would have been recorded under previous accounting guidance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-775AB63179A75A86C7D6323762612A63">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Operating Lease&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2016, we entered into a non-cancelable operating lease to rent office and laboratory space in Seattle, Washington. In April 2016, we amended the agreement to lease additional premises adjacent to our existing leased premises. Under our lease agreements, we lease approximately&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,158&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;square feet of office and laboratory space with an annual base rent of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$566,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the first year, which will increase by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; each year thereafter. The leases expire on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options to extend the lease term with each option enabling us to extend the lease term by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;twelve months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As required by the terms of the lease, in May 2017, we entered into a line of credit to establish collateral to support the security deposit in an amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$132,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This is recorded as restricted cash in the accompanying &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2018, we entered into a lease amendment for approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,184&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet of additional office and laboratory space adjacent to our existing leased premises in Seattle, Washington. The lease expires on December&amp;#160;31, 2019 and has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options to extend the lease term with each option enabling us to extend the lease term by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;twelve months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The annual base rent due under the lease is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$295,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the first year and will increase by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; each year thereafter. We recognize rent expense on a straight-line basis over the lease period and accrue for rent expense incurred but not paid. The lease also requires us to pay additional amounts for operating and maintenance expenses. Rent expense was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$811,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$529,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;and&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$267,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments for&amp;#160;our non-cancelable&amp;#160;operating leases at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Minimum Lease Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;930&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2019, we entered into a lease with ARE-Seattle No. 28, LLC (the &amp;#8220;Landlord&amp;#8221;) for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,164&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet of office and laboratory space located at 188 East Blaine Street, Seattle, Washington. The term of the lease is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.8 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; option to extend the term by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.0 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The target &amp;#8220;Commencement Date&amp;#8221; is May 1, 2019 and shall be the date that Landlord delivers the premises to us in substantially complete condition. The &amp;#8220;Rent Commencement Date&amp;#8221; shall be the date that is nine months after the Commencement Date. The annual base rent due under the lease is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the first year and will increase by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; each year thereafter. We will not be required to pay base rent from the Rent Commencement Date through the last day of the ninth month following the Rent Commencement Date. We will receive a maximum tenant improvement allowance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is included in our base rent, and a maximum additional tenant improvement allowance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which will result in additional rent amortized over the term of the lease at an annual rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The lease also requires us to pay additional amounts for operating and maintenance expenses. In connection with the lease, we provided a&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$254,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;letter of credit as a security deposit. Rent payments under our lease with ARE are not included in the table above.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-EC48B3AB77E9D7ECAE4C3237621B639A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Comprehensive income (loss) is comprised of net loss and certain changes in equity excluded from net loss. For the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, other comprehensive loss consisted of unrealized losses on our short-term investments. There was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; difference between comprehensive loss and net loss for the year ended December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2018Q4YTD" id="Fact-5575111952A0FBCADBFE3237621BC5F3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Periodically, we maintain deposits in financial institutions in excess of government insured limits. We believe we are not exposed to significant credit risk as our deposits, which are held at financial institutions, are high credit quality securities such as money market funds, U.S. Treasury securities, and commercial paper. To date, we have not realized any losses on these deposits.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-CDDC3BBCB160665722A632376225382C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our consolidated financial statements include the financial position and results of operations of Alpine and our wholly owned operating company and subsidiaries, AIS Operating Co., Inc., and Alpine Immune Sciences Australia PTY LTD. On &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;July&amp;#160;24, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we closed the merger on the terms described in more detail in &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#sD31BE121D5B120F8794C31F4AFBEEF04"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 1&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In connection with the merger, Nivalis effected a&amp;#160;1:4&amp;#160;reverse stock split of its common stock. Upon the closing of the merger, (1)&amp;#160;a wholly-owned subsidiary of Nivalis merged with and into Alpine, with Alpine (renamed as &amp;#8220;AIS Operating Co., Inc.&amp;#8221;) remaining as the surviving entity; and (2)&amp;#160;Nivalis was renamed as &amp;#8220;Alpine Immune Sciences, Inc.&amp;#8221;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-37CDFED9A6D8BA7EE3573237622FC3FB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Long-term Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We maintain a long-term financing arrangement with Silicon Valley Bank. On June 30, 2017, we drew down a term loan of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The loan had an interest-only period that expired on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;July&amp;#160;1, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, at which point we became obligated to make &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;thirty&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive equal monthly payments of principal (each in an amount that will fully amortize the loan), plus accrued interest. Interest accrues at a floating per annum rate equal to the lender&amp;#8217;s prime rate minus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As a condition to the loan, we agreed to pay a final payment fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$375,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, upon repayment of the loan. The final payment fee was recorded in long-term debt with an offsetting reduction in long-term debt and was accounted for as a debt discount.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the loan agreement we have pledged substantially all of our assets, excluding intellectual property, as collateral.&amp;#160;The obligations under the loan agreement are subject to acceleration upon the occurrence of specified events of default, including a material adverse change in our business, operations, financial, or other condition. We assessed the likelihood of the lender accelerating payment of the loan due to a material adverse change in our business, operations, financial, or other condition as remote. As such, as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the classification of the loan is split between current and noncurrent based on the timing of payment obligations. The term loan agreement contains customary conditions to borrowings, events of default and negative covenants, including covenants that could limit our ability to, among other things, incur additional indebtedness, liens or other encumbrances; make dividends or other distributions; buy, sell or transfer assets; engage in any new line of business; and enter into certain transactions with affiliates. We were in compliance with our covenants as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Also, in connection with the drawdown of the loan, we granted Silicon Valley Bank &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,069&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Series A&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Preferred Stock warrants at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.38&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. The fair value of the warrants on the date of issuance was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$53,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, determined using the Black-Scholes option-pricing model, and was recorded as a discount to the note and as a warrant liability on the accompanying &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In connection with the merger and conversion of all outstanding Series A-1 preferred stock, the warrants became exercisable for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,069&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; fully vested shares of our common stock. As a result of the change in the underlying shares, the warrants were equity-classified beginning on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;July&amp;#160;24, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The debt discount is being amortized to interest expense using the effective interest method over the repayment term of the initial loan amount. Non-cash interest expense associated with the amortization of the discount was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$169,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$87,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, for years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The unamortized discount was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$172,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future principal payments as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under our loan based on contractual maturities are as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year Ending December 31, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total future principal payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="FD2018Q4YTD" id="Fact-109F67269D5A73C4935E323762751F8E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The amortized cost and fair value of our cash equivalents and short-term investments are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br clear="none"/&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br clear="none"/&gt;unrealized&lt;br clear="none"/&gt;gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br clear="none"/&gt;unrealized&lt;br clear="none"/&gt;losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair market&lt;br clear="none"/&gt;value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury bills&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities and commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,702&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,689&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair market&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury bills&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,909&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities and commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,920&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
	<us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-8DAB5455914B7CA2B0F24F10A9F6A92C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other current assets consists of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred financing costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid insurance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;791&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;237&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
	<us-gaap:DerivativesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-1C04DF75C4BD610CC06D3237621B36AB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Derivative Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We evaluate all of our financial instruments, including issued&amp;#160;stock purchase warrants, to determine if such instruments are derivatives or contain&amp;#160;features qualifying as embedded derivatives.&amp;#160;For derivative financial instruments accounted for as liabilities, the derivative instrument&amp;#160;is initially recorded at its fair value and is then re-valued at each reporting date, with changes in&amp;#160;the fair value reported in the &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We use the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. We do not use derivative instruments to hedge exposures to cash flow, market, or&amp;#160;foreign currency risks.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-7E119CA18B509BB0EC5832376257F694">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2016, we considered our convertible preferred stock to be participating securities, and we computed net loss per share attributable to common stockholders using the two-class method required for participating securities. All participating securities are excluded from basic weighted-average common shares outstanding. In accordance with the two-class method, earnings allocated to these participating securities, which include participation rights in undistributed earnings, are subtracted from net income to determine total undistributed earnings to be allocated to common stockholders. Net loss is not allocated to participating securities as there is no contractual obligation to share in net losses. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2018Q4YTD" id="Fact-F63548322DD4508B6D9A32376257EBFD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2016, we considered our convertible preferred stock to be participating securities, and we computed net loss per share attributable to common stockholders using the two-class method required for participating securities. All participating securities are excluded from basic weighted-average common shares outstanding. In accordance with the two-class method, earnings allocated to these participating securities, which include participation rights in undistributed earnings, are subtracted from net income to determine total undistributed earnings to be allocated to common stockholders. Net loss is not allocated to participating securities as there is no contractual obligation to share in net losses. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The net loss per share for the year ended December 31, 2017 includes the conversion of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,301,433&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our convertible preferred stock into common stock, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,914,058&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares acquired in connection with the merger.&amp;#160;&amp;#160;The significant number of shares issued has affected the year-over-year comparability of our net loss per share calculations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share attributable to common stockholders calculation because their effect would have been antidilutive. Diluted net loss per share, therefore, does not differ from basic net loss per share for the periods presented:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,311,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,422&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,509,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,611,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;520,739&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,533,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,636,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,844,931&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="FD2018Q4YTD" id="Fact-3C18D9A32320C6D886DB32376257256D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury bills&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities and commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,369&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,689&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury bills&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities and commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,568&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,920&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2018Q4YTD" id="Fact-EEEDEB052D56B1CBF9AB32376257AF35">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents, receivables, accounts payable and accrued liabilities, which are recorded at invoiced amount or cost, approximate fair value based on the short-term nature of these financial instruments. Fair value is defined as the exchange price received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;: Quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level 2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;: Observable inputs other than Level&amp;#160;1 prices, such as quoted prices for similar assets or liabilities, quoted prices in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;: Unobservable inputs supported by little or no market activity and significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, cash of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$614,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, is excluded from the fair value table below. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury bills&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities and commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,369&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,689&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury bills&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities and commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,568&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,920&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our Level 2 assets consist of commercial paper and corporate debt securities. We review trading activity and pricing for our available-for-sale securities as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-0FF8BAFFA6AC408F28DA3237625700CC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents, receivables, accounts payable and accrued liabilities, which are recorded at invoiced amount or cost, approximate fair value based on the short-term nature of these financial instruments. Fair value is defined as the exchange price received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;: Quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level 2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;: Observable inputs other than Level&amp;#160;1 prices, such as quoted prices for similar assets or liabilities, quoted prices in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;: Unobservable inputs supported by little or no market activity and significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy contextRef="FD2018Q4YTD" id="Fact-1030F1E4567E2AB2DC993237621B5C96">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Intangible Asset&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our intangible asset is our indefinite-life S-nitrosoglutathione reductase (&amp;#8220;GSNOR&amp;#8221;) inhibitor in-process research and development asset (&amp;#8220;IPR&amp;amp;D&amp;#8221;) acquired from Nivalis. The IPR&amp;amp;D represents the processes, expertise, and technology employed in the development of GSNOR inhibitors and Nivalis&amp;#8217; lead product candidate, cavosonstat. The IPR&amp;amp;D represents the estimated fair value as of the acquisition date of substantive&amp;#160;in-process&amp;#160;projects that have not reached technological feasibility. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-12A8326A40703A5942F7323762250FF3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We evaluate our long-lived tangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If the carrying value exceeds the undiscounted future cash flows estimated to result from the use and eventual disposition of the asset, we write down the asset to its estimated fair value. Impairment is assessed by comparing the undiscounted cash flows expected to be generated by the asset to its carrying value. We did not record any impairments in the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-83E6715A3AB98A359CC83237624D725B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2017, the U.S. government enacted the Tax Act. The Tax Act incorporates broad and complex changes to the U.S. tax code. The main provision of the Tax Act that is applicable to us is the reduction of a maximum federal tax rate of 35% to a flat tax rate of 21%, effective January 1, 2018. We incorporated the change in federal tax rates in our annual tax provision for the annual period ended December 31, 2017. Additionally, SAB 118 was issued to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. December 22, 2018 marked the end of the measurement period for purposes of SAB 118. We have completed and recorded the adjustments necessary under SAB 118 related to the Tax Act. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our income (loss) before taxes is derived from domestic (United States) sources. The provision for income taxes is composed of the following (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. - Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. - State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. - Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. - State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total income tax benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effect of:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State taxes (net of federal benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Permanent differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal research and development credit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Benefit of a lower tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-deductible merger costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Bargain purchase gain&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Tax rate change&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(24.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective income tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recorded tax benefits of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$366,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended December 31, 2018 and 2017, respectively, which represent effective tax rates of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended December 31, 2018 and 2017, respectively. The difference between the U.S. federal statutory tax rates of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and our effective tax rate in all periods is primarily due to a full valuation allowance related to our deferred tax assets, the generation and consumption of federal R&amp;amp;D tax credits, as well as a refund of state taxes from a carryback of the 2018 net operating loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table represents the significant components of our deferred tax assets and liabilities for the periods presented (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,475&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible asset basis&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;810&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,774&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets, net of valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed asset basis&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible asset basis&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax assets and liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As part of the merger with Nivalis, we identified &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of acquired IPR&amp;amp;D. IPR&amp;amp;D acquired in a business combination is an indefinite-lived intangible asset until the completion or abandonment of the associated R&amp;amp;D efforts. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2017, future reversal of the deferred tax liability resulting from IPR&amp;amp;D costs could not be scheduled for tax purposes and therefore could not be considered as a source of future taxable income. A deferred tax liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$305,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was recorded in 2017 as a result of the acquired IPR&amp;amp;D having a financial reporting basis of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and a tax basis of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In the year ended December 31, 2018, we sold the IPR&amp;amp;D and reversed the deferred tax liability. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A valuation allowance is provided for deferred tax assets where the recoverability of the assets is uncertain. The determination to provide a valuation allowance is dependent upon the assessment of whether it is more likely than not that sufficient taxable income will be generated to utilize the deferred tax assets. Based on the weight of the available evidence, which includes our historical operating losses, uncertainty of future taxable income, and the accumulated deficit, we provided a full valuation allowance against our deferred tax assets. The valuation allowance increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended December 31, 2018 and December 31, 2017, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have net operating loss carryforwards as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal (before January 1, 2018)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,094&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,784&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal (after January 1, 2018)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal and state net operating loss carryforwards created before January 1, 2018 begin to expire in 2037. Federal net operating loss carryforwards created after January 1, 2018 carryforward indefinitely. The State net operating loss carryforwards begin to expire in 2038. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have net research and development tax credit carryforwards as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal research and development tax credit carryforwards begin to expire in 2035.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current tax laws impose substantial restrictions on the utilization of R&amp;amp;D credit and net operating loss carryforwards in the event of an ownership change, as defined by the Internal Revenue Code Section 382 and 383. Such an event may limit our ability to utilize net operating losses and R&amp;amp;D tax credit carryforwards. Under Internal Revenue Code Section 382 and 383, the 2017 merger with Nivalis is likely considered an ownership change with respect to the potential limitation of the Nivalis federal tax credits and net operating losses. As such, it is likely that any future utilization of Nivalis federal tax credits and net operating losses is substantially limited. Therefore, as of December 31, 2018, all Nivalis tax credit and net operating loss carryforwards have been reduced to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We account for uncertainty in income taxes in accordance with ASC 740. Tax positions are evaluated in a two-step process, whereby we first determine whether it is more likely than not that a tax position will be sustained upon examination by the tax authority, including resolutions of any related appeals or litigation processes, based on technical merit. If a tax position meets the more-likely-than-not recognition threshold it is then measured to determine the amount of benefit to recognize in the financial statements. The tax position is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarized the activity related to unrecognized tax benefits (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrecognized benefits &amp;#8211; beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross increases (decreases) &amp;#8211; prior year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross increases &amp;#8211; current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrecognized benefit &amp;#8211; end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;469&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All of the unrecognized tax benefits as of December 31, 2018 are accounted for as a reduction in our deferred tax assets. Due to our valuation allowance, none of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$469,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of unrecognized tax benefits would affect our effective tax rate, if recognized. We do not believe it is reasonably possible that our unrecognized tax benefits will significantly change in the next twelve months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recognize interest and penalties related to unrecognized tax benefits as income tax expense. There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; accrued interest or penalties related to unrecognized tax benefits for 2018 and 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We do not expect any significant change in our unrecognized tax benefits during the next twelve months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our material income tax jurisdictions are the United States (federal), and California (state). We are subject to audit for tax years 2012 and forward for federal purposes, and 2015 and forward for California.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-BD8646905BF06AE3E8BE3237621B93E5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the consolidated financial statement and tax bases of assets and liabilities at the applicable enacted tax rates. We will establish a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefits or that future deductibility is uncertain.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recognize the tax benefit from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax position is measured based on the largest benefit that has a greater than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; likelihood of being realized upon ultimate settlement. We recognize interest and penalties related to income tax matters in income tax expense if incurred. In December 2017, the SEC issued Staff Accounting Bulletin (&amp;#8220;SAB&amp;#8221;) 118 to address the application of GAAP in situations in which a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Cuts and Jobs Act (the &amp;#8220;Tax Reform Act&amp;#8221;) which was signed into law on December 22, 2017. In March 2018, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2018-05, which amended ASC 740 to incorporate the requirements of SAB 118. We recognized the provisional tax impacts of the Tax Reform Act in the fourth quarter of 2017. Our federal tax loss and research and development credit carryforwards have been updated from the amounts previously provisionally disclosed to reflect a change in position with respect to our 2017 federal research and development credit. The update is a result of additional time spent on modeling the potential use of our tax attributes, as impacted by the Tax Reform Act. Otherwise, during the year ended December 31, 2018, we did not receive any additional information regarding these provisional calculations, except as disclosed in &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s2FF5B04E48A0D29197CD31F4BBF8E887"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 14, Income Taxes&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-8EDEFF4888BDA138B6884ED16633BDEB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss on Sale of Intangible Asset&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2018, we entered into an Option License Agreement (&amp;#8220;Option Agreement&amp;#8221;) with Laurel Venture Capital Ltd. (&amp;#8220;Laurel&amp;#8221;), which granted Laurel a limited license to evaluate the indefinite-life GSNOR inhibitor IPR&amp;amp;D asset acquired as part of the merger with Nivalis in 2017. The IPR&amp;amp;D represents the processes, expertise, and technology employed in the development of GSNOR inhibitors and Nivalis&amp;#8217; lead product candidate, cavosonstat. Under the Option Agreement, we received an upfront non-refundable payment of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which was recognized as revenue in our accompanying &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2018, we entered into an Asset Purchase Agreement (&amp;#8220;Purchase Agreement&amp;#8221;) with Laurel and completed the sale of global rights to the GSNOR asset. As consideration under the Purchase Agreement, we received a non-refundable closing payment of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$250,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which was accounted for as a purchase of our intangible asset. We are also eligible to receive an additional payment of approximately&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$425,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;on the one-year anniversary of the sale completion date. In addition, we are eligible to receive milestone payments of up to&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, in the aggregate upon satisfaction by Laurel of certain regulatory approval milestones. We will also be eligible to receive royalty payments equal to a low single-digit percentage rate of worldwide net sales of any approved products. If Laurel transfers any part of the rights to the GSNOR assets within 12 months of the sale completion date, we will be eligible to receive one-fourth of any cash payments made to Laurel by a transferee within 18 months of the sale completion date and such transferee will remain obligated with respect to Laurel&amp;#8217;s milestone and royalty obligations to us.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon the sale of the GSNOR assets, we derecognized the full carrying value of the intangible asset of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;on our accompanying &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and recognized a loss on the sale of the intangible asset of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;on the accompanying &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
	<us-gaap:LesseeLeasesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-B8395CA6A6A6B3FDCB553237621B0015">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases and Deferred Rent&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have entered into lease agreements for office and laboratory space. These leases are classified as operating leases. Rent payments, rent-free periods and rent increases are recognized as rent expense on a straight-line basis over the lease term. The difference between rent expense recognized and rental payments is recorded as deferred rent in the accompanying &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
	<us-gaap:MarketableSecuritiesPolicy contextRef="FD2018Q4YTD" id="Fact-F50B35E51FF9E01D24EC323762252B2D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Short-Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our short-term investments include funds invested in highly liquid money market funds, U.S. Treasury securities, commercial paper, and corporate debt securities with a final maturity of each security of less than one year. All investments are classified as available-for-sale securities and are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses excluded from earnings and reported in other comprehensive income (loss). Purchase premiums and discounts are recognized as interest income using the interest method over the terms of the securities. Realized gains and losses and declines in fair value deemed to be other than temporary are reflected in the &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; using the specific-identification method.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-70AAAEAC02AE4E15C10E3237621BC6D5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the FASB issued ASU&amp;#160;No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606. This ASU clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. This ASU is effective for public companies for annual reporting periods and interim periods within those annual periods beginning after December 15, 2019. We are currently evaluating the effect, if any, that ASU 2018-18 will have on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In&amp;#160;August 2018,&amp;#160;the FASB issued ASU&amp;#160;No.&amp;#160;2018-13,&amp;#160;Fair Value Measurement. ASU&amp;#160;2018-13&amp;#160;modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted for any eliminated or modified disclosures. We are evaluating the effect of adopting this new accounting guidance to determine the impact it may have on our financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2018, the FASB issued ASU No.&amp;#160;2018-07, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. Upon transition, nonemployee awards will be required to be measured at fair value as of the adoption date with a cumulative-effect adjustment recognized in retained earnings as of the beginning of the annual period of adoption. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity&amp;#8217;s adoption date of ASC 606. We are evaluating the effect the standard will have on our financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No.&amp;#160;2016-02, Leases. ASU 2016-02 requires a lessee to separate the lease components from the non-lease components in a contract and recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. It also aligns lease accounting for lessors with the revenue recognition guidance in ASU 2014-09. ASU 2016-02 is effective for fiscal years beginning after December&amp;#160;15, 2018, including interim periods within those fiscal years, and is to be applied at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU 2018-11, related to another transition method in lease accounting. If elected, the transition method allows entities to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We plan to adopt ASU 2016-02 on January 1, 2019 and intend to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of the accumulated deficit in the period of adoption as permitted under ASU 2018-11. Based on our leases in place on January 1, 2019 and considering the practical expedients, we expect the adoption of the new standard will not have a material effect on our consolidated statements of operations, will result in a gross-up on our consolidated balance sheets of less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; relating to our office and laboratory leases, and will have no effect on our consolidated statements of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No.&amp;#160;2014-09, Revenue from Contracts with Customers, as amended (&amp;#8220;new revenue standard&amp;#8221; or &amp;#8220;ASC 606&amp;#8221;), which amends the guidance for revenue recognition to replace numerous industry specific requirements. ASC 606 implements a five-step process for customer contract revenue recognition focusing on transfer of control, as opposed to transfer of risk and rewards. ASC 606 also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include ensuring the time value of money is considered in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. ASC 606 is effective for reporting periods beginning after December&amp;#160;15, 2017. On January 1, 2018, we adopted the new accounting standard and all of the related amendments using the modified retrospective method. We recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of our accumulated deficit. The cumulative effect of the changes related to the adoption of the new revenue standard increased our beginning balances in accumulated deficit and deferred revenue by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$203,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; within our &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our Collaboration Agreement with Kite is the only contract that was impacted by the adoption of the new revenue standard. Prior to the adoption of the new revenue standard, we recognized revenue under the Collaboration Agreement based upon the estimated performance periods related to the non-refundable upfront payments we received from Kite. Under the new standard, we recognize revenue based on employee hours contributed to each performance obligation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated financial statements as of and for the year ended December 31, 2018 is as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As Reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance without Adoption of ASC 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stockholders&amp;#8217; equity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accumulated deficit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(46,074&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(46,277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collaboration revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;705&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,487&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Statement of Cash Flows&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the FASB issued ASU No. 2016-15 which provides new guidance on the classification of certain cash receipts and payments in the statement of cash flows. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We adopted this new standard effective January 1, 2018. The adoption of this standard did not impact our financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2017, the FASB issued ASU No. 2017-09 to provide clarity and reduce both diversity in practice and cost and complexity when applying the guidance in Compensation - Stock Compensation (&amp;#8220;Topic 718&amp;#8221;) about a change to the terms and conditions of a share-based payment award. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this update are effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted and applied prospectively to modifications occurring on or after the adoption date. We adopted this this standard effective January 1, 2018. The adoption of this standard did not have an impact on our financial statements.&amp;#160;For the year ended December 31, 2018, there were no modifications to the terms or conditions of a share-based payment award.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-FA7D89154BE4B325C43F323762610625">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Alpine Immune Sciences, Inc. (the &amp;#8220;Company&amp;#8221;, &amp;#8220;Alpine&amp;#8221;, &amp;#8220;we&amp;#8221;, &amp;#8220;us&amp;#8221;, or &amp;#8220;our&amp;#8221;), together with its consolidated subsidiaries, is focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory disorders, and other diseases. Our proprietary scientific platform uses a process known as directed evolution, or an iterative scientific engineering process purposefully conducted to &amp;#8220;evolve&amp;#8221; a protein to create multi-targeted therapeutics potentially capable of modulating the human immune system. In our&amp;#160;pre-clinical&amp;#160;animal studies, our platform has proven capable of identifying novel molecules, including single domains capable of modulating multiple targets. We were incorporated under the laws of the State of Delaware and are headquartered in Seattle, Washington.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Reverse Merger and Subscription Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On April&amp;#160;18, 2017, we entered into a merger agreement with Nivalis Therapeutics, Inc. (&amp;#8220;Nivalis&amp;#8221;), a public biotechnology company, and one of its wholly-owned subsidiaries pursuant to which, the subsidiary merged with and into Alpine, with Alpine continuing as a wholly owned subsidiary of Nivalis and the surviving corporation of the merger (the &amp;#8220;Merger Agreement&amp;#8221;). Nivalis Therapeutics, Inc. was incorporated in Delaware in March 2007.&amp;#160;Alpine Immune Sciences, Inc. (prior to its business combination with Nivalis Therapeutics, Inc.) was incorporated in Delaware on December 30, 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section&amp;#160;368(a) of the Internal Revenue Code of 1986, as amended. At the closing of the merger, each outstanding share of our capital stock (common stock and preferred stock) was converted into the right to receive shares of Nivalis common stock (subject to the payment of cash in lieu of fractional shares and after giving effect to a 1:4 reverse stock split of Nivalis common stock) such that, immediately following the effective time of the merger, preexisting Nivalis stockholders, optionholders, and warrantholders owned, or held rights to acquire, approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the fully-diluted common stock of Nivalis, which changed its name to &amp;#8220;Alpine Immune Sciences, Inc.&amp;#8221; following the completion of the merger and Alpine&amp;#8217;s preexisting stockholders, optionholders, and warrantholders owned, or held rights to acquire approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;74%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the fully-diluted common stock of Nivalis. The issuance of the shares to our pre-existing stockholders was registered under the Securities Act of 1933, as amended, pursuant to a registration statement on Form S-4 (No. 333-218134) (the &amp;#8220;Registration Statement&amp;#8221;) declared effective by the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) on June 6, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contemporaneously with the execution and delivery of the Merger Agreement, certain of our pre-existing stockholders entered into a subscription agreement with us pursuant to which such stockholders purchased, immediately prior to the closing of the merger, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,335,118&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our capital stock at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.74&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share for an aggregate purchase price of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$17.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The merger and the subscription described above were consummated on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;July&amp;#160;24, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-9DD1DD70829FF74B7E653237626164EF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;401(k) Retirement Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have adopted a 401(k) plan. All employees are eligible to participate, provided they meet the requirements of the plan. To date, we have not matched employee contributions to the plan.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-5C72263D867F7BC086FD3237622F747B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,506&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General equipment and furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;158&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, at cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(311&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,196&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,089&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$388,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$241,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$69,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-D9C244621D436BA1F2A23237621B5E4A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, while leasehold improvements are amortized over the shorter of their estimated useful lives or the related lease term. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Maintenance and repairs are expensed as incurred. Major improvements are capitalized as additions to property and equipment.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2018Q4YTD" id="Fact-3FD1591F35390EE45344323762614B5E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,506&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General equipment and furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;158&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, at cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(311&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,196&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,089&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-38A1BC16B46FC9F1B45A3237622FE6AC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2019, in connection with our Purchase Agreement we sold an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;935,753&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock and issued warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;364,943&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock for gross proceeds of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to certain of our &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; stockholders. See &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5D1F7A0CEF73296F6BF731F4CC92B1EC"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Part III, Item 13 of this Form 10-K&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for additional information. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have a shared services agreement with Alpine BioVentures GP, LLC, pursuant to which we incurred costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$17,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. We had an accrual of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to the shared services agreement at December&amp;#160;31, 2016, which was paid in April 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2018Q4YTD" id="Fact-E86D6879A9D7E3766AE43237621BA8EC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development costs are expensed as incurred. Research and development costs include personnel costs, clinical trials, external contract research and development expenses, raw materials, drug product manufacturing costs and allocated overhead &amp;#8211; including depreciation, rent and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-6A38769313077F02AAD03237621B265C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition (effective January 1, 2018)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our steps for recognizing revenue consist of;&amp;#160;(1) identifying the contract,&amp;#160;(2) identifying the performance obligations as either distinct or bundled goods and services,&amp;#160;(3) determining the transaction price associated with each performance obligation for which we expect to be entitled in exchange for transferring such goods and services,&amp;#160;(4) allocating the transaction price to the performance obligations in the contract and&amp;#160;(5) recognizing revenue upon satisfaction of performance obligations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our collaboration agreements principally contain multiple performance obligations, which may include (1)&amp;#160;grants of, or options to obtain, intellectual property licenses; (2)&amp;#160;research and development services; and/or (3) manufacturing or supply services. Payments typically received under these arrangements include one or more of the following: non-refundable upfront license fees, option exercise fees, payment for research and/or development efforts, amounts due upon the achievement of specified objectives, and/or royalties on future product sales. Our revenue is primarily derived from our License and Research Agreement (the &amp;#8220;Collaboration Agreement&amp;#8221;) with Kite Pharma, a Gilead company (&amp;#8220;Kite&amp;#8221;). See further discussion of the Collaboration Agreement in &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s8A49DD14B58EDD54C86131F4B9EFCB92"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 12&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We allocate revenue to each performance obligation based on its relative stand-alone selling price. We generally determine stand-alone selling prices at the inception of the contract based on our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the accompanying &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and recognized as revenue when the related revenue recognition criteria are met. We recognize revenue under the Collaboration Agreement based on employee hours contributed to each performance obligation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Collaboration Agreement provides for non-refundable milestone payments. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to us for such milestone (1)&amp;#160;is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance; (2)&amp;#160;relates solely to our past performance; and (3)&amp;#160;is reasonable relative to all of the other deliverables and payments within the arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial, and other risks that must be overcome to achieve the milestone, the level of effort and investment required to achieve the milestone and whether any portion of the milestone consideration is related to future performance or deliverables.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We review the contributed employee hours for each performance obligation under the Collaboration Agreement and adjust the revenue recognized to reflect changes in assumptions relating to the estimated satisfaction of the performance obligation. We could accelerate revenue recognition in the event of early termination of programs or if our expectations change. Alternatively, we could decelerate revenue recognition if programs are extended or delayed. While such changes to our estimates have no impact on our reported cash flows, the timing of revenue recorded in future periods could be materially impacted.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-7DB14B428569C82CE4993237622F4D17">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities and other current liabilities consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development services&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employee compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,009&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Legal and professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2018Q4YTD" id="Fact-265555CCB87C434A8ED73237625791F9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share attributable to common stockholders calculation because their effect would have been antidilutive. Diluted net loss per share, therefore, does not differ from basic net loss per share for the periods presented:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,311,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,422&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,509,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,611,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;520,739&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,533,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,636,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,844,931&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2018Q4YTD" id="Fact-3B8A584FE8AC6F9872CD323762617B17">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The provision for income taxes is composed of the following (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. - Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. - State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. - Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. - State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total income tax benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-A95508498801DC3CEF7A3237625717E5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table represents the significant components of our deferred tax assets and liabilities for the periods presented (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,475&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible asset basis&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;810&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,774&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets, net of valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed asset basis&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible asset basis&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax assets and liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2018Q4YTD" id="Fact-979BB8E54C4B19FB0FC43237624DB6D8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effect of:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State taxes (net of federal benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Permanent differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal research and development credit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Benefit of a lower tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-deductible merger costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Bargain purchase gain&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Tax rate change&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(24.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective income tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2018Q4YTD" id="Fact-4B3626FE98E2F346C51C3237624355B4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense is classified in the &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employee:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,385&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-Employee:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-41A2983A240C540ADE64323762615BE1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments for&amp;#160;our non-cancelable&amp;#160;operating leases at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Minimum Lease Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;930&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2018Q4YTD" id="Fact-05EAA8DD93905658BA51736903881310">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future principal payments as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under our loan based on contractual maturities are as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year Ending December 31, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total future principal payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="FD2018Q4YTD" id="Fact-9EB3A31ECFEEEE2352F84EC1BAA4419A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated financial statements as of and for the year ended December 31, 2018 is as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As Reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance without Adoption of ASC 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stockholders&amp;#8217; equity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accumulated deficit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(46,074&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(46,277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collaboration revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;705&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,487&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
	<us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="FD2018Q4YTD" id="Fact-13F5285A60B3408999473237624DBF1B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The final allocation of the purchase consideration is as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,130&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,952&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,614&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities assumed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(910&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Bargain purchase gain&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-AFEBE153B299086EC40E32376239DB31">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of stock option activity under our plans is presented below:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contract&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,611,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;936,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited/Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,509,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest after December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,484,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;887,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-8BA197771015F97D02FB323762435922">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair values of stock options granted to employees were calculated using the following assumptions:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average estimated fair value at grant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.27% - 3.07%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.90% - 2.26%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.14% - 2.24%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term of options (in years) (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.50 &amp;#8211; 7.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.69 &amp;#8211; 6.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.22 &amp;#8211; 7.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected stock price volatility (3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70% - 77%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72% - 83%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72% - 79%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield (4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:46px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:22px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that had terms consistent with the expected term of our stock option grants.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:46px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:22px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We used the &amp;#8220;simplified method&amp;#8221; for options to determine the expected term of stock option granted to employees, since we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited time our shares have been publicly traded. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:46px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:22px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility is a measure of the amount by which a financial variable, such as share price, has fluctuated or is expected to fluctuate during a period. We analyzed the stock price volatility of companies at a similar stage of development to estimate expected volatility of our stock price.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:46px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:22px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfStockByClassTextBlock contextRef="FD2018Q4YTD" id="Fact-2C7B4A658A737BE4C7713237621B8FA4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares of common stock reserved for future issuance were as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares to be issued upon exercise of outstanding stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,509,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,611,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares to be issued upon conversion of common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares available for future stock grants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;496,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;576,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares to be issued under employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares of common stock reserved for future issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,075,714&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,258,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
	<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="FD2018Q4YTD" id="Fact-EA56A18B868FC707C1D24F7ECA06BF4E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;padding-left:0px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of our warrant activity is presented below:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contract&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,153&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-8B4C15EFBB7BC9545C21323762257B68">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We operate as&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;operating segment and use cash flow as the primary measure to manage our business.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2018Q4YTD" id="Fact-0A9C14DFB35C8420DF0B32376225735E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We account for all stock-based compensation granted to employees and&amp;#160;non-employees&amp;#160;using a fair value method. Stock-based compensation awarded to employees and&amp;#160;non-employees&amp;#160;is measured at the grant date fair value for stock option grants. We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. Stock-based compensation to employees is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis. Stock-based compensation awarded to&amp;#160;non-employees&amp;#160;is revalued over its vesting period using a Black-Scholes option pricing model. For performance-based awards where the vesting of the options may be accelerated upon the achievement of certain milestones, vesting and the related stock-based compensation is recognized as an expense when it is probable the milestone will be met. We recognize forfeiture of awards as they occur rather than estimating the expected forfeiture rate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;When awards are modified, we compare the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2018Q4YTD" id="Fact-7D6121303DEDED4FF4A93237621B079F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC and generally accepted accounting principles in the United States of America (&amp;#8220;GAAP&amp;#8221;). The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates inherent in the preparation of the accompanying consolidated financial statements include accruals for clinical trial activities and other accruals, and the estimated fair value of equity-based awards. We base our estimates and assumptions on historical experience when available and on various factors we believe to be reasonable under the circumstances. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our consolidated financial statements include the financial position and results of operations of Alpine and our wholly owned operating company and subsidiaries, AIS Operating Co., Inc., and Alpine Immune Sciences Australia PTY LTD. On &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;July&amp;#160;24, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we closed the merger on the terms described in more detail in &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#sD31BE121D5B120F8794C31F4AFBEEF04"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 1&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In connection with the merger, Nivalis effected a&amp;#160;1:4&amp;#160;reverse stock split of its common stock. Upon the closing of the merger, (1)&amp;#160;a wholly-owned subsidiary of Nivalis merged with and into Alpine, with Alpine (renamed as &amp;#8220;AIS Operating Co., Inc.&amp;#8221;) remaining as the surviving entity; and (2)&amp;#160;Nivalis was renamed as &amp;#8220;Alpine Immune Sciences, Inc.&amp;#8221;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We operate as&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;operating segment and use cash flow as the primary measure to manage our business.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents and Restricted cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We consider all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking and interest-bearing accounts, and highly liquid money market funds.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted cash represents cash drawn on a line of credit used to establish collateral to support the security deposit on our operating lease to rent office and laboratory space in Seattle, Washington.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Periodically, we maintain deposits in financial institutions in excess of government insured limits. We believe we are not exposed to significant credit risk as our deposits, which are held at financial institutions, are high credit quality securities such as money market funds, U.S. Treasury securities, and commercial paper. To date, we have not realized any losses on these deposits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Short-Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our short-term investments include funds invested in highly liquid money market funds, U.S. Treasury securities, commercial paper, and corporate debt securities with a final maturity of each security of less than one year. All investments are classified as available-for-sale securities and are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses excluded from earnings and reported in other comprehensive income (loss). Purchase premiums and discounts are recognized as interest income using the interest method over the terms of the securities. Realized gains and losses and declines in fair value deemed to be other than temporary are reflected in the &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; using the specific-identification method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, while leasehold improvements are amortized over the shorter of their estimated useful lives or the related lease term. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Maintenance and repairs are expensed as incurred. Major improvements are capitalized as additions to property and equipment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Intangible Asset&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our intangible asset is our indefinite-life S-nitrosoglutathione reductase (&amp;#8220;GSNOR&amp;#8221;) inhibitor in-process research and development asset (&amp;#8220;IPR&amp;amp;D&amp;#8221;) acquired from Nivalis. The IPR&amp;amp;D represents the processes, expertise, and technology employed in the development of GSNOR inhibitors and Nivalis&amp;#8217; lead product candidate, cavosonstat. The IPR&amp;amp;D represents the estimated fair value as of the acquisition date of substantive&amp;#160;in-process&amp;#160;projects that have not reached technological feasibility. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We evaluate our long-lived tangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If the carrying value exceeds the undiscounted future cash flows estimated to result from the use and eventual disposition of the asset, we write down the asset to its estimated fair value. Impairment is assessed by comparing the undiscounted cash flows expected to be generated by the asset to its carrying value. We did not record any impairments in the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accrued Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As part of the process of preparing our consolidated financial statements, we are required to estimate accruals for professional services and research and development expenses. This process involves reviewing contracts and vendor agreements and communicating with applicable personnel to identify services that have been performed on our behalf. We estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We estimate accrued liabilities as of each balance sheet date based on known facts and circumstances.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, we have not experienced any significant adjustments to our estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases and Deferred Rent&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have entered into lease agreements for office and laboratory space. These leases are classified as operating leases. Rent payments, rent-free periods and rent increases are recognized as rent expense on a straight-line basis over the lease term. The difference between rent expense recognized and rental payments is recorded as deferred rent in the accompanying &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We granted common stock warrants to certain&amp;#160;non-employee&amp;#160;professional advisers. We account for our warrants at fair value, with changes in fair value recognized in operating expenses. Common stock warrants are initially recorded at their issuance date fair value and are subsequently remeasured at each balance sheet date. These warrants are valued using the Black-Scholes option pricing model based on the estimated market value of the underlying common stock at the valuation measurement dates, the remaining contractual term of the warrant, risk-free interest rates, expected dividends, and expected volatility of the price of the underlying common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Derivative Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We evaluate all of our financial instruments, including issued&amp;#160;stock purchase warrants, to determine if such instruments are derivatives or contain&amp;#160;features qualifying as embedded derivatives.&amp;#160;For derivative financial instruments accounted for as liabilities, the derivative instrument&amp;#160;is initially recorded at its fair value and is then re-valued at each reporting date, with changes in&amp;#160;the fair value reported in the &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We use the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. We do not use derivative instruments to hedge exposures to cash flow, market, or&amp;#160;foreign currency risks.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition (effective January 1, 2018)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our steps for recognizing revenue consist of;&amp;#160;(1) identifying the contract,&amp;#160;(2) identifying the performance obligations as either distinct or bundled goods and services,&amp;#160;(3) determining the transaction price associated with each performance obligation for which we expect to be entitled in exchange for transferring such goods and services,&amp;#160;(4) allocating the transaction price to the performance obligations in the contract and&amp;#160;(5) recognizing revenue upon satisfaction of performance obligations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our collaboration agreements principally contain multiple performance obligations, which may include (1)&amp;#160;grants of, or options to obtain, intellectual property licenses; (2)&amp;#160;research and development services; and/or (3) manufacturing or supply services. Payments typically received under these arrangements include one or more of the following: non-refundable upfront license fees, option exercise fees, payment for research and/or development efforts, amounts due upon the achievement of specified objectives, and/or royalties on future product sales. Our revenue is primarily derived from our License and Research Agreement (the &amp;#8220;Collaboration Agreement&amp;#8221;) with Kite Pharma, a Gilead company (&amp;#8220;Kite&amp;#8221;). See further discussion of the Collaboration Agreement in &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s8A49DD14B58EDD54C86131F4B9EFCB92"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 12&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We allocate revenue to each performance obligation based on its relative stand-alone selling price. We generally determine stand-alone selling prices at the inception of the contract based on our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the accompanying &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and recognized as revenue when the related revenue recognition criteria are met. We recognize revenue under the Collaboration Agreement based on employee hours contributed to each performance obligation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Collaboration Agreement provides for non-refundable milestone payments. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to us for such milestone (1)&amp;#160;is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance; (2)&amp;#160;relates solely to our past performance; and (3)&amp;#160;is reasonable relative to all of the other deliverables and payments within the arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial, and other risks that must be overcome to achieve the milestone, the level of effort and investment required to achieve the milestone and whether any portion of the milestone consideration is related to future performance or deliverables.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We review the contributed employee hours for each performance obligation under the Collaboration Agreement and adjust the revenue recognized to reflect changes in assumptions relating to the estimated satisfaction of the performance obligation. We could accelerate revenue recognition in the event of early termination of programs or if our expectations change. Alternatively, we could decelerate revenue recognition if programs are extended or delayed. While such changes to our estimates have no impact on our reported cash flows, the timing of revenue recorded in future periods could be materially impacted.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;See Note 2 included in our Annual Report on &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-10k_20171231.htm"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Form 10-K for the year ended December 31, 2017&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for more discussion regarding the accounting policies that governed revenue recognition prior to January 1, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development costs are expensed as incurred. Research and development costs include personnel costs, clinical trials, external contract research and development expenses, raw materials, drug product manufacturing costs and allocated overhead &amp;#8211; including depreciation, rent and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We account for all stock-based compensation granted to employees and&amp;#160;non-employees&amp;#160;using a fair value method. Stock-based compensation awarded to employees and&amp;#160;non-employees&amp;#160;is measured at the grant date fair value for stock option grants. We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. Stock-based compensation to employees is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis. Stock-based compensation awarded to&amp;#160;non-employees&amp;#160;is revalued over its vesting period using a Black-Scholes option pricing model. For performance-based awards where the vesting of the options may be accelerated upon the achievement of certain milestones, vesting and the related stock-based compensation is recognized as an expense when it is probable the milestone will be met. We recognize forfeiture of awards as they occur rather than estimating the expected forfeiture rate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;When awards are modified, we compare the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the consolidated financial statement and tax bases of assets and liabilities at the applicable enacted tax rates. We will establish a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefits or that future deductibility is uncertain.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recognize the tax benefit from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax position is measured based on the largest benefit that has a greater than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; likelihood of being realized upon ultimate settlement. We recognize interest and penalties related to income tax matters in income tax expense if incurred. In December 2017, the SEC issued Staff Accounting Bulletin (&amp;#8220;SAB&amp;#8221;) 118 to address the application of GAAP in situations in which a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Cuts and Jobs Act (the &amp;#8220;Tax Reform Act&amp;#8221;) which was signed into law on December 22, 2017. In March 2018, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2018-05, which amended ASC 740 to incorporate the requirements of SAB 118. We recognized the provisional tax impacts of the Tax Reform Act in the fourth quarter of 2017. Our federal tax loss and research and development credit carryforwards have been updated from the amounts previously provisionally disclosed to reflect a change in position with respect to our 2017 federal research and development credit. The update is a result of additional time spent on modeling the potential use of our tax attributes, as impacted by the Tax Reform Act. Otherwise, during the year ended December 31, 2018, we did not receive any additional information regarding these provisional calculations, except as disclosed in &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s2FF5B04E48A0D29197CD31F4BBF8E887"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 14, Income Taxes&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Comprehensive income (loss) is comprised of net loss and certain changes in equity excluded from net loss. For the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, other comprehensive loss consisted of unrealized losses on our short-term investments. There was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; difference between comprehensive loss and net loss for the year ended December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the FASB issued ASU&amp;#160;No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606. This ASU clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. This ASU is effective for public companies for annual reporting periods and interim periods within those annual periods beginning after December 15, 2019. We are currently evaluating the effect, if any, that ASU 2018-18 will have on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In&amp;#160;August 2018,&amp;#160;the FASB issued ASU&amp;#160;No.&amp;#160;2018-13,&amp;#160;Fair Value Measurement. ASU&amp;#160;2018-13&amp;#160;modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted for any eliminated or modified disclosures. We are evaluating the effect of adopting this new accounting guidance to determine the impact it may have on our financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2018, the FASB issued ASU No.&amp;#160;2018-07, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. Upon transition, nonemployee awards will be required to be measured at fair value as of the adoption date with a cumulative-effect adjustment recognized in retained earnings as of the beginning of the annual period of adoption. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity&amp;#8217;s adoption date of ASC 606. We are evaluating the effect the standard will have on our financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No.&amp;#160;2016-02, Leases. ASU 2016-02 requires a lessee to separate the lease components from the non-lease components in a contract and recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. It also aligns lease accounting for lessors with the revenue recognition guidance in ASU 2014-09. ASU 2016-02 is effective for fiscal years beginning after December&amp;#160;15, 2018, including interim periods within those fiscal years, and is to be applied at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU 2018-11, related to another transition method in lease accounting. If elected, the transition method allows entities to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We plan to adopt ASU 2016-02 on January 1, 2019 and intend to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of the accumulated deficit in the period of adoption as permitted under ASU 2018-11. Based on our leases in place on January 1, 2019 and considering the practical expedients, we expect the adoption of the new standard will not have a material effect on our consolidated statements of operations, will result in a gross-up on our consolidated balance sheets of less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; relating to our office and laboratory leases, and will have no effect on our consolidated statements of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No.&amp;#160;2014-09, Revenue from Contracts with Customers, as amended (&amp;#8220;new revenue standard&amp;#8221; or &amp;#8220;ASC 606&amp;#8221;), which amends the guidance for revenue recognition to replace numerous industry specific requirements. ASC 606 implements a five-step process for customer contract revenue recognition focusing on transfer of control, as opposed to transfer of risk and rewards. ASC 606 also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include ensuring the time value of money is considered in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. ASC 606 is effective for reporting periods beginning after December&amp;#160;15, 2017. On January 1, 2018, we adopted the new accounting standard and all of the related amendments using the modified retrospective method. We recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of our accumulated deficit. The cumulative effect of the changes related to the adoption of the new revenue standard increased our beginning balances in accumulated deficit and deferred revenue by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$203,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; within our &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our Collaboration Agreement with Kite is the only contract that was impacted by the adoption of the new revenue standard. Prior to the adoption of the new revenue standard, we recognized revenue under the Collaboration Agreement based upon the estimated performance periods related to the non-refundable upfront payments we received from Kite. Under the new standard, we recognize revenue based on employee hours contributed to each performance obligation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated financial statements as of and for the year ended December 31, 2018 is as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As Reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance without Adoption of ASC 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stockholders&amp;#8217; equity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accumulated deficit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(46,074&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(46,277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collaboration revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;705&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,487&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Statement of Cash Flows&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the FASB issued ASU No. 2016-15 which provides new guidance on the classification of certain cash receipts and payments in the statement of cash flows. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We adopted this new standard effective January 1, 2018. The adoption of this standard did not impact our financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2017, the FASB issued ASU No. 2017-09 to provide clarity and reduce both diversity in practice and cost and complexity when applying the guidance in Compensation - Stock Compensation (&amp;#8220;Topic 718&amp;#8221;) about a change to the terms and conditions of a share-based payment award. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this update are effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted and applied prospectively to modifications occurring on or after the adoption date. We adopted this this standard effective January 1, 2018. The adoption of this standard did not have an impact on our financial statements.&amp;#160;For the year ended December 31, 2018, there were no modifications to the terms or conditions of a share-based payment award.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-04158E2EB61A94C111B83237624D2A06">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stockholders&amp;#8217; Deficit &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon the closing of the merger in 2017, all outstanding shares of our convertible preferred stock converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,301,433&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we did not have any convertible preferred stock outstanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,854,205&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,831,178&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock outstanding as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Shares of common stock reserved for future issuance were as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares to be issued upon exercise of outstanding stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,509,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,611,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares to be issued upon conversion of common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares available for future stock grants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;496,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;576,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares to be issued under employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares of common stock reserved for future issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,075,714&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,258,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2017, we repurchased &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,467&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of unvested common stock issued to one of our former employees for the original purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.002&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Securities Offerings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2016, we entered into a sales agreement (the &amp;#8220;Cowen Sales Agreement&amp;#8221;) with Cowen and Company, LLC (&amp;#8220;Cowen&amp;#8221;) to sell shares of our common stock having aggregate sales proceeds of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, from time to time, through an &amp;#8220;at the market&amp;#8221; equity offering program under which Cowen acted as our sales agent. In June 2018, we and Cowen agreed to terminate the Cowen Sales Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2018, we entered into an equity distribution agreement, (&amp;#8220;Equity Distribution Agreement&amp;#8221;), with Piper Jaffray &amp;amp; Co., (&amp;#8220;Piper Jaffray&amp;#8221;), pursuant to which we may sell shares of our common stock through an &amp;#8220;at the market&amp;#8221; equity offering program for up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, in gross cash proceeds. Piper Jaffray will be entitled to compensation for its services of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the gross sales price per share of all shares sold through Piper Jaffray under the Equity Distribution Agreement. The Equity Distribution Agreement may be terminated by us upon written notice to Piper Jaffray for any reason or by Piper Jaffray upon written notice to us for any reason or at any time under certain circumstances, including but not limited to if we experience a material adverse change.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Equity Distribution Agreement, we will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. We have no obligation to sell any shares under the Equity Distribution Agreement and may at any time suspend solicitation and offers under the Equity Distribution Agreement. The shares will be issued pursuant to our effective shelf registration statement on Form S-3 (File No.&amp;#160;333-212404), declared effective by the SEC on July&amp;#160;14, 2016. We filed a prospectus supplement (the &amp;#8220;Prospectus Supplement&amp;#8221;), dated June 11, 2018, with the SEC in connection with the offer and sale of the shares pursuant to the Equity Distribution Agreement. The Prospectus Supplement relates to the offering of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in shares of our common stock and we will be required to file an additional prospectus supplement in the event we seek to offer more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in shares of our common stock in accordance with the Equity Distribution Agreement. As &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have made no sales under the Equity Distribution Agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2019, we entered into a securities purchase agreement (the &amp;#8220;Purchase Agreement&amp;#8221;) with a limited number of accredited investors, pursuant to which we, in a private placement (the &amp;#8220;Private Placement&amp;#8221;), sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units (the &amp;#8220;Units&amp;#8221;) for a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.37&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per Unit. Each Unit consists of one share of our common stock and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.39&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. Pursuant to the terms of the Purchase Agreement, we issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,706,700&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock and warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,835,610&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. The warrants have an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.74&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and have a term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The securities being sold in the Private Placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. We have agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable in connection with the Private Placement and upon exercise of the warrants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have incurred legal, accounting and other direct costs related to our efforts to raise capital. These costs have been capitalized as deferred financing costs and are included within prepaid expenses and other current assets in our accompanying &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Balance Sheets&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. These costs are deferred until completion of an offering, at which time they will be reclassified to additional paid-in capital as a reduction of the proceeds. As &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have incurred &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$477,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of deferred financing costs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;padding-left:0px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have issued warrants in connection with the drawdown of our SVB loan, and to certain non-employee professional advisers. We also assumed warrants in connection with the merger. No additional warrants were issued or exercised during the year ended December 31, 2018. A summary of our warrant activity is presented below:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contract&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,153&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity Incentive Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2018, our board of directors adopted, and in June 2018 our stockholders approved, the 2018 Equity Incentive Plan (&amp;#8220;2018 Plan&amp;#8221;) under which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;901,530&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;shares of our common stock were initially reserved for issuance, and we ceased granting stock awards under the Nivalis Therapeutics, Inc. 2015 Equity Incentive Plan (the &amp;#8220;2015 EIP&amp;#8221;) and the Amended and Restated 2015 Stock Plan (the &amp;#8220;2015 Plan&amp;#8221;), collectively, the &amp;#8220;Legacy Plans&amp;#8221;. All shares of common stock subject to awards under the Legacy Plans that expire or terminate without having been exercised in full, or are forfeited to or repurchased by the company, will be added to the 2018 Plan up to a maximum of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,972,784&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additionally, our 2018 Plan provides for an annual increase in the number of shares reserved for insurance under our 2018 Plan equal to the lesser of (1) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the number of shares of common stock outstanding as of the last day of the preceding calendar year and (2) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. However, our board of directors may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for such year will be a lesser number of shares. On January 1, 2019, a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;692,710&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; additional shares were automatically added to the shares authorized under the 2018 Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2018 our board of directors approved an &amp;#8220;inducement&amp;#8221; option grant, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules, to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;150,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock to our President and Chief Operating Officer. The option grant was exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof as a transaction by an issuer not involving a public offering. The options granted vest within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, subject to continued employment, and expire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years after the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2017, in connection with the merger, we assumed Nivalis&amp;#8217; Employee Stock Purchase Plan (the &amp;#8220;ESPP&amp;#8221;) and the 2015 EIP. Upon assumption of the ESPP, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,211&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares available for issuance under the ESPP. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have not activated the ESPP. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options granted under our equity plans generally vest within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years and vested options are exercisable from the grant date until &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; after the date of grant. Vesting of certain employee options may be accelerated in the event of a change in control of the Company. We grant stock options to employees with exercise prices equal to the fair value of our common stock on the date of grant. The term of incentive stock options may not exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the date of grant. We utilize newly issued shares to satisfy option exercises.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2018, a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,061,084&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock were authorized for issuance under our 2018 Plan, 2015 Plan and 2015 EIP, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;496,530&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares were available for future grants under our 2018 Plan. A summary of stock option activity under our plans is presented below:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contract&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,611,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;936,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited/Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,509,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest after December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,484,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;887,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of unrecognized stock-based compensation expense related to nonvested stock options that is expected to be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.9 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The aggregate intrinsic value of stock options exercised during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$214,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$18,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$22,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The total fair value of shares vested during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$139,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$70,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes option pricing model requires us to make certain estimates and assumptions, including assumptions related to the expected price volatility of our stock, the period during which the options will be outstanding, the rate of return on risk-free investments, and the expected dividend yield of our stock. The fair values of stock options granted to employees were calculated using the following assumptions:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average estimated fair value at grant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.27% - 3.07%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.90% - 2.26%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.14% - 2.24%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term of options (in years) (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.50 &amp;#8211; 7.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.69 &amp;#8211; 6.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.22 &amp;#8211; 7.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected stock price volatility (3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70% - 77%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72% - 83%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72% - 79%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield (4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:46px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:22px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that had terms consistent with the expected term of our stock option grants.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:46px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:22px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We used the &amp;#8220;simplified method&amp;#8221; for options to determine the expected term of stock option granted to employees, since we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited time our shares have been publicly traded. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:46px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:22px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility is a measure of the amount by which a financial variable, such as share price, has fluctuated or is expected to fluctuate during a period. We analyzed the stock price volatility of companies at a similar stage of development to estimate expected volatility of our stock price.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:46px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:22px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of each non-employee stock option is estimated at the date of grant using the Black-Scholes option pricing model is are remeasured over the vesting term, as earned. Assumptions used in valuing non-employee stock options are generally consistent with those used for employee stock options, with the exception that the expected term is over the contractual life of the option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense is classified in the &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated Statements of Operations and Comprehensive Income (Loss)&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employee:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,385&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-Employee:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2016 we extended the vesting period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;567,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unvested share options held by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; employees. As a result of this modification, we recognized additional compensation expense of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the year ended December&amp;#160;31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="FD2018Q4YTD" id="Fact-52AF47DBAB3AF65B4D4E32376257C11E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarized the activity related to unrecognized tax benefits (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrecognized benefits &amp;#8211; beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross increases (decreases) &amp;#8211; prior year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross increases &amp;#8211; current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrecognized benefit &amp;#8211; end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;469&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
	<us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="FD2018Q4YTD" id="Fact-1C4752D32431D9DC6148323762437AA0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have net operating loss carryforwards as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal (before January 1, 2018)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,094&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,784&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal (after January 1, 2018)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
	<us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock contextRef="FD2018Q4YTD" id="Fact-86B2E3A0A8B5E26C385F32376257F062">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have net research and development tax credit carryforwards as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="FD2018Q4YTD" id="Fact-D2F5F2C4FF57F4260B5C4F102D9A35E0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Additional Consolidated Balance Sheets Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other current assets consists of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred financing costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid insurance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;791&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;237&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities and other current liabilities consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development services&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employee compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,009&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Legal and professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>alpn-20181231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.alpineimmunesciences.com/20181231" xmlns:alpn="http://www.alpineimmunesciences.com/20181231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alpn-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alpn-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alpn-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alpn-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="A401KRetirementPlan" roleURI="http://www.alpineimmunesciences.com/role/A401KRetirementPlan">
        <link:definition>2116100 - Disclosure - 401(k) Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalConsolidatedBalanceSheetsInformation" roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformation">
        <link:definition>2109100 - Disclosure - Additional Consolidated Balance Sheets Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalConsolidatedBalanceSheetsInformationAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails">
        <link:definition>2409403 - Disclosure - Additional Consolidated Balance Sheets Information - Accrued Liabilities and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalConsolidatedBalanceSheetsInformationPrepaidExpenseAndOtherCurrentAssetsDetails" roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationPrepaidExpenseAndOtherCurrentAssetsDetails">
        <link:definition>2409402 - Disclosure - Additional Consolidated Balance Sheets Information - Prepaid Expense and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalConsolidatedBalanceSheetsInformationTables" roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationTables">
        <link:definition>2309301 - Disclosure - Additional Consolidated Balance Sheets Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombination" roleURI="http://www.alpineimmunesciences.com/role/BusinessCombination">
        <link:definition>2103100 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationAdditionalInformationDetails" roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationAdditionalInformationDetails">
        <link:definition>2403402 - Disclosure - Business Combination - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationScheduleOfAdjustedAllocationOfPurchaseConsiderationDetails" roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfAdjustedAllocationOfPurchaseConsiderationDetails">
        <link:definition>2403404 - Disclosure - Business Combination - Schedule of Adjusted Allocation of Purchase Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationScheduleOfFairValueOfConsiderationTransferredDetails" roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfFairValueOfConsiderationTransferredDetails">
        <link:definition>2403403 - Disclosure - Business Combination - Schedule of Fair Value of Consideration Transferred (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationScheduleOfProFormaFinancialInformationDetails" roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfProFormaFinancialInformationDetails">
        <link:definition>2403405 - Disclosure - Business Combination - Schedule of Pro Forma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationTables" roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationTables">
        <link:definition>2303301 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsAndShortTermInvestments" roleURI="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestments">
        <link:definition>2105100 - Disclosure - Cash Equivalents and Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsAndShortTermInvestmentsDetails" roleURI="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsDetails">
        <link:definition>2405402 - Disclosure - Cash Equivalents and Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsAndShortTermInvestmentsTables" roleURI="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsTables">
        <link:definition>2305301 - Disclosure - Cash Equivalents and Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndLicenseAgreement" roleURI="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreement">
        <link:definition>2112100 - Disclosure - Collaboration and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndLicenseAgreementDetails" roleURI="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreementDetails">
        <link:definition>2412401 - Disclosure - Collaboration and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingencies">
        <link:definition>2111100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>2411402 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForNonCancelableOperatingLeasesDetails" roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForNonCancelableOperatingLeasesDetails">
        <link:definition>2411403 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments for Non-cancelable Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2311301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>1003000 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>1003001 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusiness" roleURI="http://www.alpineimmunesciences.com/role/DescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessDetails" roleURI="http://www.alpineimmunesciences.com/role/DescriptionOfBusinessDetails">
        <link:definition>2401401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.alpineimmunesciences.com/role/DocumentAndEntityInformation">
        <link:definition>0002000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurements">
        <link:definition>2106100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2406403 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurementsTables">
        <link:definition>2306301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxes">
        <link:definition>2114100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2414402 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2414405 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails">
        <link:definition>2414408 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetails" roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetails">
        <link:definition>2414404 - Disclosure - Income Taxes - Summary of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryOfNetOperatingLossCarryforwardsDetails" roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfNetOperatingLossCarryforwardsDetails">
        <link:definition>2414406 - Disclosure - Income Taxes - Summary of Net Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails">
        <link:definition>2414403 - Disclosure - Income Taxes - Summary of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryTaxCreditCarryforwardsDetails" roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryTaxCreditCarryforwardsDetails">
        <link:definition>2414407 - Disclosure - Income Taxes - Summary Tax Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesTables">
        <link:definition>2314301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.alpineimmunesciences.com/role/LongTermDebt">
        <link:definition>2110100 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNarrativeDetails" roleURI="http://www.alpineimmunesciences.com/role/LongTermDebtNarrativeDetails">
        <link:definition>2410402 - Disclosure - Long-term Debt  - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" roleURI="http://www.alpineimmunesciences.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails">
        <link:definition>2410403 - Disclosure - Long-term Debt - Schedule of Maturities of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.alpineimmunesciences.com/role/LongTermDebtTables">
        <link:definition>2310301 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossOnSaleOfIntangibleAssets" roleURI="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssets">
        <link:definition>2108100 - Disclosure - Loss on Sale of Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossOnSaleOfIntangibleAssetsDetails" roleURI="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssetsDetails">
        <link:definition>2408401 - Disclosure - Loss on Sale of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShare">
        <link:definition>2104100 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAdditionalInformationDetails" roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShareAdditionalInformationDetails">
        <link:definition>2404402 - Disclosure - Net Loss Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails">
        <link:definition>2404403 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShareTables">
        <link:definition>2304301 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.alpineimmunesciences.com/role/PropertyAndEquipment">
        <link:definition>2107100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails" roleURI="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentDetails">
        <link:definition>2407402 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentTables">
        <link:definition>2307301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.alpineimmunesciences.com/role/RelatedPartyTransactions">
        <link:definition>2115100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.alpineimmunesciences.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2415401 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficit" roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficit">
        <link:definition>2113100 - Disclosure - Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitAdditionalInformationDetails" roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitAdditionalInformationDetails">
        <link:definition>2413402 - Disclosure - Stockholders' Deficit - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>2413403 - Disclosure - Stockholders' Deficit - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockBasedCompensationExpenseDetails">
        <link:definition>2413407 - Disclosure - Stockholders' Deficit - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitScheduleOfStockOptionAssumptionsDetails" roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockOptionAssumptionsDetails">
        <link:definition>2413406 - Disclosure - Stockholders' Deficit - Schedule of Stock Option Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitScheduleOfWarrantsDetails" roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfWarrantsDetails">
        <link:definition>2413404 - Disclosure - Stockholders' Deficit - Schedule of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitTables" roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitTables">
        <link:definition>2313301 - Disclosure - Stockholders' Deficit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeflicitSummaryOfOptionActivityDetails" roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeflicitSummaryOfOptionActivityDetails">
        <link:definition>2413405 - Disclosure - Stockholders' Deflicit - Summary of Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies  - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesScheduleOfNewAccountingPronouncementsDetails" roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNewAccountingPronouncementsDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Schedule of New Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember" name="AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_AccruedLiabilitiesPolicyPolicyTextBlock" name="AccruedLiabilitiesPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="alpn_AdditionalCompensationExpense" name="AdditionalCompensationExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease" name="AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element id="alpn_AdjustmentOfParValue" name="AdjustmentOfParValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity" name="AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_AfterJanuary12018Member" name="AfterJanuary12018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_AlpineBioVenturesGPLLCMember" name="AlpineBioVenturesGPLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived" name="AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" name="BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_BeforeJanuary12018Member" name="BeforeJanuary12018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" name="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_BusinessCombinationCommonStockIssuedExchangeRate" name="BusinessCombinationCommonStockIssuedExchangeRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="alpn_CashFlowProjectionsDiscountRate" name="CashFlowProjectionsDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding" name="ClassofWarrantorRightWeightedAverageExercisePriceOutstanding" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="alpn_ClassofWarrantorRightWeightedAveragePriceExercisable" name="ClassofWarrantorRightWeightedAveragePriceExercisable" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding" name="ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_CommonStockInitialReservesMember" name="CommonStockInitialReservesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_CommonStockWarrantsPolicyTextBlock" name="CommonStockWarrantsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_CorporateDebtSecuritiesAndCommercialPaperMember" name="CorporateDebtSecuritiesAndCommercialPaperMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_CowenandCompanyLLCMember" name="CowenandCompanyLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_DebtInstrumentFinalPaymentPercentage" name="DebtInstrumentFinalPaymentPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_DebtInstrumentNumberOfEqualMonthlyPayment" name="DebtInstrumentNumberOfEqualMonthlyPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets" name="DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets" name="DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="alpn_DescriptionOfBusinessLineItems" name="DescriptionOfBusinessLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_DescriptionOfBusinessTable" name="DescriptionOfBusinessTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain" name="EffectiveIncomeTaxRateReconciliationBargainPurchaseGain" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate" name="EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts" name="EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_EligibleToReceiveAdditionalResearchSupportPayment" name="EligibleToReceiveAdditionalResearchSupportPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="alpn_EmployeesMember" name="EmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_ExerciseOfStockOptionsAndCommonStockWarrants" name="ExerciseOfStockOptionsAndCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare" name="ExerciseOfStockOptionsAndCommonStockWarrantsShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions" name="ExtendedVestingPeriodOfNumberOfUnvestedShareOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_GSNORMember" name="GSNORMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_GeneralEquipmentAndFurnitureMember" name="GeneralEquipmentAndFurnitureMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_IncentiveStockOptionMember" name="IncentiveStockOptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_IncomeTaxesLineItems" name="IncomeTaxesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_IncomeTaxesTable" name="IncomeTaxesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities" name="IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_InducementGrantMember" name="InducementGrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_IntangibleAssetsAmountDerecognizedUponSale" name="IntangibleAssetsAmountDerecognizedUponSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alpn_IssuanceOfDebtDiscount" name="IssuanceOfDebtDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_KiteMember" name="KiteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_LaurelVentureCapitalLtd.Member" name="LaurelVentureCapitalLtd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_LegacyPlanCancellationsMember" name="LegacyPlanCancellationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_MaximumAmountOfCommonStockEligibleToBeSold" name="MaximumAmountOfCommonStockEligibleToBeSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement" name="MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_NivalisTherapeuticsIncMember" name="NivalisTherapeuticsIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_NonEmployeesMember" name="NonEmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_NumberOfEmployees" name="NumberOfEmployees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_NumberOfOptionsToExtendTermLease" name="NumberOfOptionsToExtendTermLease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="alpn_NumberOfProgramsFromLicenseTechnology" name="NumberOfProgramsFromLicenseTechnology" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_NumberOfTranches" name="NumberOfTranches" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_NumberOfWarrantsAvailableTobeExercised" name="NumberOfWarrantsAvailableTobeExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="alpn_OfficeAndLaboratoryLeasesMember" name="OfficeAndLaboratoryLeasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate" name="OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage" name="OperatingLeaseAnnualBaseRentIncreasingPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation" name="OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_PaymentsForProceedsFromAdditionalTenantAllowance" name="PaymentsForProceedsFromAdditionalTenantAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_PiperJaffrayCo.Member" name="PiperJaffrayCo.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable" name="PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alpn_PrepaidResearchAndDevelopment" name="PrepaidResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alpn_PurchaseAgreementAggregatePurchasePricePerUnit" name="PurchaseAgreementAggregatePurchasePricePerUnit" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_PurchaseAgreementRatioOfCommonStockToWarrants" name="PurchaseAgreementRatioOfCommonStockToWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock" name="PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity" name="ReclassificationOfPreferredStockWarrantLiabilityToEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_SeriesAOnePreferredStockWarrantsMember" name="SeriesAOnePreferredStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_SharesAvailableForFutureStockGrantsMember" name="SharesAvailableForFutureStockGrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember" name="SharesToBeIssuedUnderEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember" name="SharesToBeIssuedUponConversionOfCommonStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember" name="SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease" name="SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element id="alpn_StockAcquiredDuringPeriodSharesInBusinessCombination" name="StockAcquiredDuringPeriodSharesInBusinessCombination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_StockAcquiredDuringPeriodValueInBusinessCombination" name="StockAcquiredDuringPeriodValueInBusinessCombination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_StockPlan2018Member" name="StockPlan2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member" name="StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_TaxCreditAndNetOperatingLossCarryforwards" name="TaxCreditAndNetOperatingLossCarryforwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alpn_TemporaryEquitySharesConversionOfConvertibleSecurities" name="TemporaryEquitySharesConversionOfConvertibleSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_TemporaryEquityValueConversionOfConvertibleSecurities" name="TemporaryEquityValueConversionOfConvertibleSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_TermLoanMember" name="TermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_TermSheetMember" name="TermSheetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alpn_TwoThousandAndEighteenPlanMember" name="TwoThousandAndEighteenPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable" name="WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>alpn-20181231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/A401KRetirementPlan" xlink:href="alpn-20181231.xsd#A401KRetirementPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformation" xlink:href="alpn-20181231.xsd#AdditionalConsolidatedBalanceSheetsInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" xlink:href="alpn-20181231.xsd#AdditionalConsolidatedBalanceSheetsInformationAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:href="alpn-20181231.xsd#AdditionalConsolidatedBalanceSheetsInformationPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationTables" xlink:href="alpn-20181231.xsd#AdditionalConsolidatedBalanceSheetsInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombination" xlink:href="alpn-20181231.xsd#BusinessCombination" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#BusinessCombinationAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfAdjustedAllocationOfPurchaseConsiderationDetails" xlink:href="alpn-20181231.xsd#BusinessCombinationScheduleOfAdjustedAllocationOfPurchaseConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfFairValueOfConsiderationTransferredDetails" xlink:href="alpn-20181231.xsd#BusinessCombinationScheduleOfFairValueOfConsiderationTransferredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfProFormaFinancialInformationDetails" xlink:href="alpn-20181231.xsd#BusinessCombinationScheduleOfProFormaFinancialInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationTables" xlink:href="alpn-20181231.xsd#BusinessCombinationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestments" xlink:href="alpn-20181231.xsd#CashEquivalentsAndShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsDetails" xlink:href="alpn-20181231.xsd#CashEquivalentsAndShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:href="alpn-20181231.xsd#CashEquivalentsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreement" xlink:href="alpn-20181231.xsd#CollaborationAndLicenseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreementDetails" xlink:href="alpn-20181231.xsd#CollaborationAndLicenseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingencies" xlink:href="alpn-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForNonCancelableOperatingLeasesDetails" xlink:href="alpn-20181231.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForNonCancelableOperatingLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesTables" xlink:href="alpn-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheets" xlink:href="alpn-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="alpn-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="alpn-20181231.xsd#ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="alpn-20181231.xsd#ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="alpn-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="alpn-20181231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/DescriptionOfBusiness" xlink:href="alpn-20181231.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/DescriptionOfBusinessDetails" xlink:href="alpn-20181231.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/DocumentAndEntityInformation" xlink:href="alpn-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurements" xlink:href="alpn-20181231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alpn-20181231.xsd#FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurementsTables" xlink:href="alpn-20181231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxes" xlink:href="alpn-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfNetOperatingLossCarryforwardsDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryOfNetOperatingLossCarryforwardsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryTaxCreditCarryforwardsDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryTaxCreditCarryforwardsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesTables" xlink:href="alpn-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LongTermDebt" xlink:href="alpn-20181231.xsd#LongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LongTermDebtNarrativeDetails" xlink:href="alpn-20181231.xsd#LongTermDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" xlink:href="alpn-20181231.xsd#LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LongTermDebtTables" xlink:href="alpn-20181231.xsd#LongTermDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssets" xlink:href="alpn-20181231.xsd#LossOnSaleOfIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssetsDetails" xlink:href="alpn-20181231.xsd#LossOnSaleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShare" xlink:href="alpn-20181231.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShareAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#NetLossPerShareAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:href="alpn-20181231.xsd#NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShareTables" xlink:href="alpn-20181231.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/PropertyAndEquipment" xlink:href="alpn-20181231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentDetails" xlink:href="alpn-20181231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentTables" xlink:href="alpn-20181231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/RelatedPartyTransactions" xlink:href="alpn-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/RelatedPartyTransactionsDetails" xlink:href="alpn-20181231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficit" xlink:href="alpn-20181231.xsd#StockholdersDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockBasedCompensationExpenseDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockOptionAssumptionsDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitScheduleOfStockOptionAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfWarrantsDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitScheduleOfWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitTables" xlink:href="alpn-20181231.xsd#StockholdersDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeflicitSummaryOfOptionActivityDetails" xlink:href="alpn-20181231.xsd#StockholdersDeflicitSummaryOfOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNewAccountingPronouncementsDetails" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfNewAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/A401KRetirementPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_alpn_AccruedResearchAndDevelopmentCurrent_162f41a7-7162-98d0-378c-32376fd61994" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_alpn_AccruedResearchAndDevelopmentCurrent_162f41a7-7162-98d0-378c-32376fd61994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PrepaidResearchAndDevelopment" xlink:label="loc_alpn_PrepaidResearchAndDevelopment_addd5b81-1da3-048d-4938-32377008634d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:to="loc_alpn_PrepaidResearchAndDevelopment_addd5b81-1da3-048d-4938-32377008634d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_9288e0b2-8aad-49d6-163c-6e82e46379e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:to="loc_us-gaap_PrepaidInsurance_9288e0b2-8aad-49d6-163c-6e82e46379e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_f8bba565-b2b1-7745-e5f2-79c3ddd7f45e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_f8bba565-b2b1-7745-e5f2-79c3ddd7f45e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_dbfa1e75-5ca7-c18e-328b-85edddaeec4f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_dbfa1e75-5ca7-c18e-328b-85edddaeec4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_ecb162d0-1bdc-ec68-aa55-3a334ba35df9" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:to="loc_us-gaap_DeferredOfferingCosts_ecb162d0-1bdc-ec68-aa55-3a334ba35df9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombination" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfAdjustedAllocationOfPurchaseConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:label="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_76c25149-3b1e-15d2-3f92-32376ffe8696" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:to="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_76c25149-3b1e-15d2-3f92-32376ffe8696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_49b08da0-3c0d-5e6e-be00-f4ff19b686d5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_49b08da0-3c0d-5e6e-be00-f4ff19b686d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2fb474b5-5859-9678-205e-8aa88ca40daa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_395f9bb0-2492-f247-ce6b-39e67453292c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2fb474b5-5859-9678-205e-8aa88ca40daa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_395f9bb0-2492-f247-ce6b-39e67453292c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_a7dcce4d-e983-e5c1-78ec-c3acb68aab2d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2fb474b5-5859-9678-205e-8aa88ca40daa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_a7dcce4d-e983-e5c1-78ec-c3acb68aab2d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8ce68675-8129-3ab4-cbd9-33127f150e28" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2fb474b5-5859-9678-205e-8aa88ca40daa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8ce68675-8129-3ab4-cbd9-33127f150e28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_517e5230-eae7-c049-ebae-ce057eabc626" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2fb474b5-5859-9678-205e-8aa88ca40daa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_517e5230-eae7-c049-ebae-ce057eabc626" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfFairValueOfConsiderationTransferredDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfProFormaFinancialInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreementDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForNonCancelableOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_fe404cae-7fcc-3489-844f-4d90e9776180" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_fe404cae-7fcc-3489-844f-4d90e9776180" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5b651b24-1278-4eab-c840-7002c6d68546" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5b651b24-1278-4eab-c840-7002c6d68546" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_0c57e6e5-1856-148a-c665-8f26e53c3400" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_0c57e6e5-1856-148a-c665-8f26e53c3400" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99bd5160-e32a-dcfc-e4fd-38dda5d465b0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99bd5160-e32a-dcfc-e4fd-38dda5d465b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_fc15327b-efa3-66ee-074e-4b65565be4b8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_fc15327b-efa3-66ee-074e-4b65565be4b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0d8925ae-714a-26e4-aa69-2d9eac65a5c6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_LongTermDebtCurrent_0d8925ae-714a-26e4-aa69-2d9eac65a5c6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1beea529-7ff9-f264-77a3-b82530469f83" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1beea529-7ff9-f264-77a3-b82530469f83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_2c8b0baf-771b-c301-80d6-9e2df7367293" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_2c8b0baf-771b-c301-80d6-9e2df7367293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_812aff88-265a-55f7-439e-e51eedec6492" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_812aff88-265a-55f7-439e-e51eedec6492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_55fda19b-3ba6-61b5-220d-6f7ed397180a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValueOutstanding_55fda19b-3ba6-61b5-220d-6f7ed397180a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:label="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_e582104e-a88b-b3c8-d9f9-978afa604352" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_e582104e-a88b-b3c8-d9f9-978afa604352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_38b416a4-4707-fba3-1084-9b8a37fd745a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_Depreciation_38b416a4-4707-fba3-1084-9b8a37fd745a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_74538844-e2fb-8444-e093-2ede9444fc66" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_PaidInKindInterest_74538844-e2fb-8444-e093-2ede9444fc66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d3f88de-7d0f-fe63-f176-2a8af9ecbcbd" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d3f88de-7d0f-fe63-f176-2a8af9ecbcbd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities" xlink:label="loc_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_aa4f3397-1294-f510-2cc3-32376fc280bc" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_aa4f3397-1294-f510-2cc3-32376fc280bc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_e1b9e941-2978-dcca-50c7-6a96c5d3f21e" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_e1b9e941-2978-dcca-50c7-6a96c5d3f21e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3832d5-e2fd-470b-5e04-ece38e7ab02d" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3832d5-e2fd-470b-5e04-ece38e7ab02d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_cdd179b1-7a8c-39c5-167f-e92b549591e0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_cdd179b1-7a8c-39c5-167f-e92b549591e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a6cca43-79c5-34f3-6172-5859b13486b1" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a6cca43-79c5-34f3-6172-5859b13486b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c4aa0718-f1b7-8481-8382-216f94e41c89" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c4aa0718-f1b7-8481-8382-216f94e41c89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_33cd5d62-efc5-7725-6424-7800a10af341" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_33cd5d62-efc5-7725-6424-7800a10af341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_cccd0209-1cd8-b603-e355-33e3ccd4e542" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_cccd0209-1cd8-b603-e355-33e3ccd4e542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7c2a31aa-de85-3d78-fe3c-7d70dce934c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7c2a31aa-de85-3d78-fe3c-7d70dce934c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_60ab1096-bf53-5d61-76bd-431fe857fc03" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_60ab1096-bf53-5d61-76bd-431fe857fc03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_e1b9e941-2978-dcca-50c7-6a96c5d3f21e" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_e1b9e941-2978-dcca-50c7-6a96c5d3f21e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:label="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_e582104e-a88b-b3c8-d9f9-978afa604352" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_e582104e-a88b-b3c8-d9f9-978afa604352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_92946da7-0b74-45fc-67f0-5fab8668dd69" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_InterestAndOtherIncome_92946da7-0b74-45fc-67f0-5fab8668dd69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6df44786-4260-4fa4-e123-591abd5e882d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6df44786-4260-4fa4-e123-591abd5e882d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/DescriptionOfBusinessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_8d3f7f58-e2d6-8ff0-86f5-8d249c7b8257" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_8d3f7f58-e2d6-8ff0-86f5-8d249c7b8257" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets" xlink:label="loc_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_a337d6cc-1380-2222-c60a-32377012c2c6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_a337d6cc-1380-2222-c60a-32377012c2c6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_0e2dc226-85ed-d782-cf37-e83741c371ce" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_0e2dc226-85ed-d782-cf37-e83741c371ce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_ed0fcf32-bd00-072a-6e92-10a0ac8015fc" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_ed0fcf32-bd00-072a-6e92-10a0ac8015fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_187bb760-9cde-c4af-d9e1-306e7a6330eb" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_187bb760-9cde-c4af-d9e1-306e7a6330eb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0cc13c2f-6b23-b741-4f28-07325c7e7169" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0cc13c2f-6b23-b741-4f28-07325c7e7169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_bf91fc79-ffa7-5391-a432-8fad97ca53a5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_bf91fc79-ffa7-5391-a432-8fad97ca53a5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4ed01819-014a-ce74-957e-ddc9b0c1d62e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4ed01819-014a-ce74-957e-ddc9b0c1d62e" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets" xlink:label="loc_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_c380dd68-8383-a9ca-7715-323770127395" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:to="loc_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_c380dd68-8383-a9ca-7715-323770127395" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="loc_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_60583ff5-7519-0747-698e-32376fd60f4a" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_60583ff5-7519-0747-698e-32376fd60f4a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_48e0835c-c850-4d13-3096-958714c66dc4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_48e0835c-c850-4d13-3096-958714c66dc4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_082942cb-e31f-ff03-a943-7f4739f70da9" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_082942cb-e31f-ff03-a943-7f4739f70da9" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate" xlink:label="loc_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_7e960763-71ea-93ae-789e-32376fd626ec" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_7e960763-71ea-93ae-789e-32376fd626ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_8e08d6c7-adb5-6628-1188-bc862e7830ff" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_8e08d6c7-adb5-6628-1188-bc862e7830ff" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts" xlink:label="loc_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_efaf7ca7-5bee-bce5-9667-323770804935" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_efaf7ca7-5bee-bce5-9667-323770804935" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain" xlink:label="loc_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_3c5f50aa-0d04-ad40-8778-323770084c70" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_3c5f50aa-0d04-ad40-8778-323770084c70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7ffe16d1-cedd-985f-c95d-65ae6fa8d756" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7ffe16d1-cedd-985f-c95d-65ae6fa8d756" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfNetOperatingLossCarryforwardsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_ad2d4e96-2647-8ea3-2864-1ff612aaa3ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_ad2d4e96-2647-8ea3-2864-1ff612aaa3ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_ad2d4e96-2647-8ea3-2864-1ff612aaa3ec" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_ad2d4e96-2647-8ea3-2864-1ff612aaa3ec" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_f894fd64-a6d8-819b-5246-1e588680be7f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_f894fd64-a6d8-819b-5246-1e588680be7f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_f894fd64-a6d8-819b-5246-1e588680be7f" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_f894fd64-a6d8-819b-5246-1e588680be7f" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryTaxCreditCarryforwardsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/LongTermDebt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/LongTermDebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5cb3949c-1d57-8f66-f002-a3389de7aec0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5cb3949c-1d57-8f66-f002-a3389de7aec0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_53634569-cdf7-3d1b-42b0-596cb4175c67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_53634569-cdf7-3d1b-42b0-596cb4175c67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c4573bf7-1f66-8dfe-59b9-b6903f55406f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c4573bf7-1f66-8dfe-59b9-b6903f55406f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e00da32d-ed06-bb21-8b28-7e7ede769972" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e00da32d-ed06-bb21-8b28-7e7ede769972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_89018c92-f86f-28e7-853c-438f4a34e1f6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_89018c92-f86f-28e7-853c-438f4a34e1f6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/LongTermDebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/NetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/NetLossPerShareAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockOptionAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeflicitSummaryOfOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNewAccountingPronouncementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>alpn-20181231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/A401KRetirementPlan" xlink:href="alpn-20181231.xsd#A401KRetirementPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformation" xlink:href="alpn-20181231.xsd#AdditionalConsolidatedBalanceSheetsInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" xlink:href="alpn-20181231.xsd#AdditionalConsolidatedBalanceSheetsInformationAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:href="alpn-20181231.xsd#AdditionalConsolidatedBalanceSheetsInformationPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationTables" xlink:href="alpn-20181231.xsd#AdditionalConsolidatedBalanceSheetsInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombination" xlink:href="alpn-20181231.xsd#BusinessCombination" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#BusinessCombinationAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfAdjustedAllocationOfPurchaseConsiderationDetails" xlink:href="alpn-20181231.xsd#BusinessCombinationScheduleOfAdjustedAllocationOfPurchaseConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfFairValueOfConsiderationTransferredDetails" xlink:href="alpn-20181231.xsd#BusinessCombinationScheduleOfFairValueOfConsiderationTransferredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfProFormaFinancialInformationDetails" xlink:href="alpn-20181231.xsd#BusinessCombinationScheduleOfProFormaFinancialInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationTables" xlink:href="alpn-20181231.xsd#BusinessCombinationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestments" xlink:href="alpn-20181231.xsd#CashEquivalentsAndShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsDetails" xlink:href="alpn-20181231.xsd#CashEquivalentsAndShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:href="alpn-20181231.xsd#CashEquivalentsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreement" xlink:href="alpn-20181231.xsd#CollaborationAndLicenseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreementDetails" xlink:href="alpn-20181231.xsd#CollaborationAndLicenseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingencies" xlink:href="alpn-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForNonCancelableOperatingLeasesDetails" xlink:href="alpn-20181231.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForNonCancelableOperatingLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesTables" xlink:href="alpn-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheets" xlink:href="alpn-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="alpn-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="alpn-20181231.xsd#ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="alpn-20181231.xsd#ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="alpn-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="alpn-20181231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/DescriptionOfBusiness" xlink:href="alpn-20181231.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/DescriptionOfBusinessDetails" xlink:href="alpn-20181231.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/DocumentAndEntityInformation" xlink:href="alpn-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurements" xlink:href="alpn-20181231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alpn-20181231.xsd#FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurementsTables" xlink:href="alpn-20181231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxes" xlink:href="alpn-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfNetOperatingLossCarryforwardsDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryOfNetOperatingLossCarryforwardsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryTaxCreditCarryforwardsDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryTaxCreditCarryforwardsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesTables" xlink:href="alpn-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LongTermDebt" xlink:href="alpn-20181231.xsd#LongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LongTermDebtNarrativeDetails" xlink:href="alpn-20181231.xsd#LongTermDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" xlink:href="alpn-20181231.xsd#LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LongTermDebtTables" xlink:href="alpn-20181231.xsd#LongTermDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssets" xlink:href="alpn-20181231.xsd#LossOnSaleOfIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssetsDetails" xlink:href="alpn-20181231.xsd#LossOnSaleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShare" xlink:href="alpn-20181231.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShareAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#NetLossPerShareAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:href="alpn-20181231.xsd#NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShareTables" xlink:href="alpn-20181231.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/PropertyAndEquipment" xlink:href="alpn-20181231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentDetails" xlink:href="alpn-20181231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentTables" xlink:href="alpn-20181231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/RelatedPartyTransactions" xlink:href="alpn-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/RelatedPartyTransactionsDetails" xlink:href="alpn-20181231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficit" xlink:href="alpn-20181231.xsd#StockholdersDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockBasedCompensationExpenseDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockOptionAssumptionsDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitScheduleOfStockOptionAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfWarrantsDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitScheduleOfWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitTables" xlink:href="alpn-20181231.xsd#StockholdersDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeflicitSummaryOfOptionActivityDetails" xlink:href="alpn-20181231.xsd#StockholdersDeflicitSummaryOfOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNewAccountingPronouncementsDetails" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfNewAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/A401KRetirementPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombination" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE1E07D48D1DD6223B1E73AD7B32D291" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE1E07D48D1DD6223B1E73AD7B32D291" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_082D46668BC5C2A102AF73AD7B32B8CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE1E07D48D1DD6223B1E73AD7B32D291" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_082D46668BC5C2A102AF73AD7B32B8CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6E3490A4436AEDDEF7373AD7B32FE5B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_082D46668BC5C2A102AF73AD7B32B8CC" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6E3490A4436AEDDEF7373AD7B32FE5B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6E3490A4436AEDDEF7373AD7B32FE5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_082D46668BC5C2A102AF73AD7B32B8CC" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6E3490A4436AEDDEF7373AD7B32FE5B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_5FF177204FD2049ABFA173AD7B321234" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6E3490A4436AEDDEF7373AD7B32FE5B" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_5FF177204FD2049ABFA173AD7B321234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9D5AF7DBA6AE80E3167E73AD7B32735E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE1E07D48D1DD6223B1E73AD7B32D291" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9D5AF7DBA6AE80E3167E73AD7B32735E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_5F046201C69B97A3E2DB73AD7B32E563_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9D5AF7DBA6AE80E3167E73AD7B32735E" xlink:to="loc_us-gaap_RelatedPartyDomain_5F046201C69B97A3E2DB73AD7B32E563_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_5F046201C69B97A3E2DB73AD7B32E563" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9D5AF7DBA6AE80E3167E73AD7B32735E" xlink:to="loc_us-gaap_RelatedPartyDomain_5F046201C69B97A3E2DB73AD7B32E563" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember" xlink:label="loc_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_38637403936ED2A94CB273AD7B322479" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5F046201C69B97A3E2DB73AD7B32E563" xlink:to="loc_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_38637403936ED2A94CB273AD7B322479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_AEF3999A611C29940CDE73AD7B3CD28E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_AEF3999A611C29940CDE73AD7B3CD28E" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessCombinationCommonStockIssuedExchangeRate" xlink:label="loc_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0F64C0A0C78C7F11BC2873AD7B3C92D9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0F64C0A0C78C7F11BC2873AD7B3C92D9" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation" xlink:label="loc_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_A3B8A74B252539C52CB873AD7B3CFA02" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_A3B8A74B252539C52CB873AD7B3CFA02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_D9149C52CE4DA1E00D0873AD7B3C4BE2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_D9149C52CE4DA1E00D0873AD7B3C4BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:label="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_C3B02A0FC32A6B9A02DF73AD7B3C4BD8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_C3B02A0FC32A6B9A02DF73AD7B3C4BD8" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CashFlowProjectionsDiscountRate" xlink:label="loc_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquisitionCosts" xlink:label="loc_us-gaap_AcquisitionCosts_EDB994EF50B555B0297C73AD7B3C1840" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_us-gaap_AcquisitionCosts_EDB994EF50B555B0297C73AD7B3C1840" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfAdjustedAllocationOfPurchaseConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_FACA2E490BFC1109A31BCC99B062E939" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E8F87F4E1CDD632100E0CC99B0612C44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_FACA2E490BFC1109A31BCC99B062E939" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E8F87F4E1CDD632100E0CC99B0612C44" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FBE78D15F74AB89CEF13CC99B061504F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E8F87F4E1CDD632100E0CC99B0612C44" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_FBE78D15F74AB89CEF13CC99B061504F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2F8DB0A56F77DCD9BE6BCC99B061D08B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FBE78D15F74AB89CEF13CC99B061504F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2F8DB0A56F77DCD9BE6BCC99B061D08B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2F8DB0A56F77DCD9BE6BCC99B061D08B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FBE78D15F74AB89CEF13CC99B061504F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2F8DB0A56F77DCD9BE6BCC99B061D08B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_41916FA10A8D8ADB9832CC99B0619541" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2F8DB0A56F77DCD9BE6BCC99B061D08B" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_41916FA10A8D8ADB9832CC99B0619541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_FACA2E490BFC1109A31BCC99B062E939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1E1294DB675B0D8D8003CC99B062A4F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1E1294DB675B0D8D8003CC99B062A4F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_771F2D7972E101876F98CC99B06241FA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_771F2D7972E101876F98CC99B06241FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_726BD8548DCE854C1F39CC99B0630966" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_726BD8548DCE854C1F39CC99B0630966" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_E32077F3433D63552492CC99B0637702" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_E32077F3433D63552492CC99B0637702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_375984B869DD0E526559CC99B06316DD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_375984B869DD0E526559CC99B06316DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_FACA2E490BFC1109A31BCC99B062E939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:label="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:to="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_B26D1F1DD83EC9D68276CC99B064307A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_B26D1F1DD83EC9D68276CC99B064307A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F2B4EB43B4C515394A08CC99B0646776" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F2B4EB43B4C515394A08CC99B0646776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:label="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_4E7E2CCACD664EA61B0CCC99B06465B1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_FACA2E490BFC1109A31BCC99B062E939" xlink:to="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_4E7E2CCACD664EA61B0CCC99B06465B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E62CABC7F7CAA28312BBCC99B065E7D6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_FACA2E490BFC1109A31BCC99B062E939" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E62CABC7F7CAA28312BBCC99B065E7D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfFairValueOfConsiderationTransferredDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DB3BA2FC0195435E05F54EC065E6B70E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DB3BA2FC0195435E05F54EC065E6B70E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_477983D1525D8F6CD2134EC065E62DCF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DB3BA2FC0195435E05F54EC065E6B70E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_477983D1525D8F6CD2134EC065E62DCF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_477983D1525D8F6CD2134EC065E62DCF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DB3BA2FC0195435E05F54EC065E6B70E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_477983D1525D8F6CD2134EC065E62DCF" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_F8C7C25F8048C16EC00E4EC065E7868A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_477983D1525D8F6CD2134EC065E62DCF" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_F8C7C25F8048C16EC00E4EC065E7868A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_E6F1A40A7480300C6AA44EC065E73BA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_E6F1A40A7480300C6AA44EC065E73BA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_12A162A063FD58D0BD6D4EC065E79AEF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_12A162A063FD58D0BD6D4EC065E79AEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A7EE53E73E1F0E55BD594EC065E88C2F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A7EE53E73E1F0E55BD594EC065E88C2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D0793311915BD31E4C354EC065E87437" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D0793311915BD31E4C354EC065E87437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2036DCAE9ABD9547EFBC4EC065E8B0DC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2036DCAE9ABD9547EFBC4EC065E8B0DC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8ECCD7BA9B58C1E46A56CC2FE89EA142" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C3D1E58384BC45AE200ECC2FE89C0486" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ECCD7BA9B58C1E46A56CC2FE89EA142" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C3D1E58384BC45AE200ECC2FE89C0486" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_593BCCAED552E3437AFBCC2FE89D6701" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C3D1E58384BC45AE200ECC2FE89C0486" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_593BCCAED552E3437AFBCC2FE89D6701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0B209F49637238CE6F16CC2FE89DA4A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_593BCCAED552E3437AFBCC2FE89D6701" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0B209F49637238CE6F16CC2FE89DA4A7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0B209F49637238CE6F16CC2FE89DA4A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_593BCCAED552E3437AFBCC2FE89D6701" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0B209F49637238CE6F16CC2FE89DA4A7" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_4B6800D9A7D496AAE2EECC9B618FC3B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0B209F49637238CE6F16CC2FE89DA4A7" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_4B6800D9A7D496AAE2EECC9B618FC3B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_B02EEC3D1E100DA97CF0CC2FE89E33B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ECCD7BA9B58C1E46A56CC2FE89EA142" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_B02EEC3D1E100DA97CF0CC2FE89E33B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90AD500E6AEA4EC3D32ECC2FE89ECBE9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ECCD7BA9B58C1E46A56CC2FE89EA142" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90AD500E6AEA4EC3D32ECC2FE89ECBE9" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="loc_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ECCD7BA9B58C1E46A56CC2FE89EA142" xlink:to="loc_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10" xlink:to="loc_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_205AD37CCE8386F00F820F55124A83B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_205AD37CCE8386F00F820F55124A83B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_721B3AE1D97F06C101DC0F55124ACE8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_721B3AE1D97F06C101DC0F55124ACE8A" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CorporateDebtSecuritiesAndCommercialPaperMember" xlink:label="loc_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:to="loc_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83A1C67B7ECDBB50D6A00F55124B23EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83A1C67B7ECDBB50D6A00F55124B23EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E4C7253851CBB693A7910F55124B2BAF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E4C7253851CBB693A7910F55124B2BAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BFA39D132679160E82F10F55124B4FF9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BFA39D132679160E82F10F55124B4FF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_AAC9AC1C2E0E5F6AA3470F55124B3094" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_AAC9AC1C2E0E5F6AA3470F55124B3094" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreement" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_28AE265FFD59E01C135C91B703C8BFA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:to="loc_srt_RangeAxis_28AE265FFD59E01C135C91B703C8BFA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_97D1FC898196C57C813E91B703C88B25_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_28AE265FFD59E01C135C91B703C8BFA3" xlink:to="loc_srt_RangeMember_97D1FC898196C57C813E91B703C88B25_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_97D1FC898196C57C813E91B703C88B25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_28AE265FFD59E01C135C91B703C8BFA3" xlink:to="loc_srt_RangeMember_97D1FC898196C57C813E91B703C88B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_594A9B05E3CFF729FE5E91B703C86610" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_97D1FC898196C57C813E91B703C88B25" xlink:to="loc_srt_MaximumMember_594A9B05E3CFF729FE5E91B703C86610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A437CD79F6784B24F1F091B703C90860" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A437CD79F6784B24F1F091B703C90860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_33462FD939EB95B69B4D91B703C9A931_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A437CD79F6784B24F1F091B703C90860" xlink:to="loc_us-gaap_TypeOfAdoptionMember_33462FD939EB95B69B4D91B703C9A931_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_33462FD939EB95B69B4D91B703C9A931" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A437CD79F6784B24F1F091B703C90860" xlink:to="loc_us-gaap_TypeOfAdoptionMember_33462FD939EB95B69B4D91B703C9A931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_EA80A008F5C72EE5D0C191B703CAF268" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_33462FD939EB95B69B4D91B703C9A931" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_EA80A008F5C72EE5D0C191B703CAF268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_FFA23D98E3B63798238591B703CA0015" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_FFA23D98E3B63798238591B703CA0015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_AF147E842C672C36B13691B703CA4E54_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_FFA23D98E3B63798238591B703CA0015" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_AF147E842C672C36B13691B703CA4E54_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_AF147E842C672C36B13691B703CA4E54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_FFA23D98E3B63798238591B703CA0015" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_AF147E842C672C36B13691B703CA4E54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8B14A0D0335012A43E3D91B703CB8095" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_AF147E842C672C36B13691B703CA4E54" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8B14A0D0335012A43E3D91B703CB8095" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:to="loc_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_KiteMember" xlink:label="loc_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4" xlink:to="loc_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementProductAgreementMember" xlink:label="loc_us-gaap_CollaborativeArrangementProductAgreementMember_1C36F4AAC823DD6FD37091B703CCC0C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0" xlink:to="loc_us-gaap_CollaborativeArrangementProductAgreementMember_1C36F4AAC823DD6FD37091B703CCC0C7" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfProgramsFromLicenseTechnology" xlink:label="loc_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_781B718183CF4C27483F91B703CD25A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_us-gaap_ContractWithCustomerLiability_781B718183CF4C27483F91B703CD25A9" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable" xlink:label="loc_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EligibleToReceiveAdditionalResearchSupportPayment" xlink:label="loc_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfTranches" xlink:label="loc_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C74C6831BB9DD1ABA2FC91B703D3DD06" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C74C6831BB9DD1ABA2FC91B703D3DD06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2085C10BC6910814EC2591B703D31FAD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2085C10BC6910814EC2591B703D31FAD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5616DF45C08752DCF6CE9141DB8701E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4" xlink:to="loc_us-gaap_SubsequentEventMember_5616DF45C08752DCF6CE9141DB8701E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_B84046BAC48D676C04E49141DB8700AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725" xlink:to="loc_us-gaap_LineOfCreditMember_B84046BAC48D676C04E49141DB8700AD" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease" xlink:label="loc_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_97F33CE9E2585B9495159141DB871347" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_97F33CE9E2585B9495159141DB871347" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage" xlink:label="loc_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfOptionsToExtendTermLease" xlink:label="loc_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LessorOperatingLeaseRenewalTerm_3820A976C20967610BD59141DB87E83C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_LessorOperatingLeaseRenewalTerm_3820A976C20967610BD59141DB87E83C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_9A2621F0AFF8568463179141DB87E878" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_SecurityDeposit_9A2621F0AFF8568463179141DB87E878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_A14A72055FF57CCCC8049141DB87E714" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_A14A72055FF57CCCC8049141DB87E714" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease" xlink:label="loc_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_11BD32A4915E4DAD4BB59141DB8776D0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_11BD32A4915E4DAD4BB59141DB8776D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_2B2D7C6BA1A71969C07B9141DB877124" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_2B2D7C6BA1A71969C07B9141DB877124" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PaymentsForProceedsFromAdditionalTenantAllowance" xlink:label="loc_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate" xlink:label="loc_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForNonCancelableOperatingLeasesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738" xlink:to="loc_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232" xlink:to="loc_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232" xlink:to="loc_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_CC7B2F3726C663FAC3F491D70C57C866" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_CC7B2F3726C663FAC3F491D70C57C866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8CBD8C4E7BE94E390AAE91D70C5A8625" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8CBD8C4E7BE94E390AAE91D70C5A8625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8CBD8C4E7BE94E390AAE91D70C5A8625" xlink:to="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8CBD8C4E7BE94E390AAE91D70C5A8625" xlink:to="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_55A0E525CF30C2B195C191D70C5A9E9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:to="loc_us-gaap_CommonStockMember_55A0E525CF30C2B195C191D70C5A9E9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_AEDB25F7076DCBD8F55291D70C5BD3FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:to="loc_us-gaap_TreasuryStockMember_AEDB25F7076DCBD8F55291D70C5BD3FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7C376D5290F9B9B1F6A291D70C5BC329" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7C376D5290F9B9B1F6A291D70C5BC329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7D984F562243C800F84791D70C5BF103" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7D984F562243C800F84791D70C5BF103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_FC39EE026DF83D73686B91D70C5B99E8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:to="loc_us-gaap_RetainedEarningsMember_FC39EE026DF83D73686B91D70C5B99E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_250A5731570D2A7FC46191D70C5C047B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_250A5731570D2A7FC46191D70C5C047B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3C164EF385209EB1422E91D70C5CDA4B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3C164EF385209EB1422E91D70C5CDA4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_1FDD5C0C5B4B4FBBE1EB91D70C5C939B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_SharesIssued_1FDD5C0C5B4B4FBBE1EB91D70C5C939B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0E975F3E8D3DE388478B91D70C5C564B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0E975F3E8D3DE388478B91D70C5C564B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FF17279218E2C5F18AD691D70C5D703B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FF17279218E2C5F18AD691D70C5D703B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_95EC692A2A513AED3A8D91D70C5D9A56" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_95EC692A2A513AED3A8D91D70C5D9A56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6D2E885B0A4A3C2F4AF91D70C5D996A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6D2E885B0A4A3C2F4AF91D70C5D996A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11F33BA3797DC31E440891D70C5D76C6" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11F33BA3797DC31E440891D70C5D76C6" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:label="loc_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:label="loc_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28CE5D0CC5F8047E935491D70C5E5EAF" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28CE5D0CC5F8047E935491D70C5E5EAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42BEFC49AE9A73F3F5E991D70C5EC858" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42BEFC49AE9A73F3F5E991D70C5EC858" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_StockAcquiredDuringPeriodSharesInBusinessCombination" xlink:label="loc_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_StockAcquiredDuringPeriodValueInBusinessCombination" xlink:label="loc_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AdjustmentOfParValue" xlink:label="loc_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity" xlink:label="loc_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare" xlink:label="loc_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ExerciseOfStockOptionsAndCommonStockWarrants" xlink:label="loc_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_D6EB640157A5BAA5D7AD91D70C5F87F5" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_D6EB640157A5BAA5D7AD91D70C5F87F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6FF598B5D47B2C5A51B291D70C5FCF83" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6FF598B5D47B2C5A51B291D70C5FCF83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_DFA4C5A114AE1A8A7D2F91D70C60D420" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_DFA4C5A114AE1A8A7D2F91D70C60D420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_996B55D49A5AD6A5A70291D70C600D90" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_996B55D49A5AD6A5A70291D70C600D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple" xlink:label="loc_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple_E099CDB14B8151FA3FAB91D70C6089BD" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple_E099CDB14B8151FA3FAB91D70C6089BD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/DescriptionOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DescriptionOfBusinessLineItems" xlink:label="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DescriptionOfBusinessTable" xlink:label="loc_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:to="loc_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_274FE7D47322D03CBFEC0F55134AEB48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_274FE7D47322D03CBFEC0F55134AEB48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E165D957B83AB39087140F55134A0081_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_274FE7D47322D03CBFEC0F55134AEB48" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E165D957B83AB39087140F55134A0081_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E165D957B83AB39087140F55134A0081" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_274FE7D47322D03CBFEC0F55134AEB48" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E165D957B83AB39087140F55134A0081" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_07D10072D7D350286B670F55134A72B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E165D957B83AB39087140F55134A0081" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_07D10072D7D350286B670F55134A72B5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_03250104F8E97B294AA80F55134B5357" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:to="loc_dei_LegalEntityAxis_03250104F8E97B294AA80F55134B5357" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_73336379C7ADE5F5A0C60F55134B000F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_03250104F8E97B294AA80F55134B5357" xlink:to="loc_dei_EntityDomain_73336379C7ADE5F5A0C60F55134B000F_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_73336379C7ADE5F5A0C60F55134B000F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_03250104F8E97B294AA80F55134B5357" xlink:to="loc_dei_EntityDomain_73336379C7ADE5F5A0C60F55134B000F" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember" xlink:label="loc_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_73336379C7ADE5F5A0C60F55134B000F" xlink:to="loc_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D1ABE635C696BC9C39100F55134BCA83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D1ABE635C696BC9C39100F55134BCA83" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation" xlink:label="loc_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:to="loc_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_C22DC8D223D230EA49820F55134CAE7B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_C22DC8D223D230EA49820F55134CAE7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_09496BED1AA8BEE1BED40F551351E3E7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_09496BED1AA8BEE1BED40F551351E3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3C3ECF886781516412EE0F551351D3E3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3C3ECF886781516412EE0F551351D3E3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_DE7FEAC78151DA20931CD2933EA0652B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_DE7FEAC78151DA20931CD2933EA0652B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9E5FA92EC4086431EF04D2933EA065A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9E5FA92EC4086431EF04D2933EA065A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_11B5299D0CD0B99EB98ED2933EA08063" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_11B5299D0CD0B99EB98ED2933EA08063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E75B6E8F92AA56B2F0C5D296C2D241F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E75B6E8F92AA56B2F0C5D296C2D241F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B7E4ADD2D534FBE61449D296C2DCFF5A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E75B6E8F92AA56B2F0C5D296C2D241F5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B7E4ADD2D534FBE61449D296C2DCFF5A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B7E4ADD2D534FBE61449D296C2DCFF5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E75B6E8F92AA56B2F0C5D296C2D241F5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B7E4ADD2D534FBE61449D296C2DCFF5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C95C0704EC25F3E7CBBDD2974362A145" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B7E4ADD2D534FBE61449D296C2DCFF5A" xlink:to="loc_us-gaap_MoneyMarketFundsMember_C95C0704EC25F3E7CBBDD2974362A145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_00F8A419DEE1D2C6BEAED29743DADE40" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B7E4ADD2D534FBE61449D296C2DCFF5A" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_00F8A419DEE1D2C6BEAED29743DADE40" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CorporateDebtSecuritiesAndCommercialPaperMember" xlink:label="loc_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_43A7786400F9EC31B5C2D297445233C8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B7E4ADD2D534FBE61449D296C2DCFF5A" xlink:to="loc_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_43A7786400F9EC31B5C2D297445233C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7693574841B115498973D2933EA0174E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7693574841B115498973D2933EA0174E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesLineItems" xlink:label="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesTable" xlink:label="loc_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2B445E1C49D0ACD400954FB2E91E3C78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2B445E1C49D0ACD400954FB2E91E3C78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_90FD89D79BDDEDF2726A4FB2E91E28D8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_90FD89D79BDDEDF2726A4FB2E91E28D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_D52BA9CF30521AFDCBB04FB2E91E614C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_D52BA9CF30521AFDCBB04FB2E91E614C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent_6351B8B904EA8DA5B1AC4FB2E91E2A8E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent_6351B8B904EA8DA5B1AC4FB2E91E2A8E" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis" xlink:label="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5202224DEDEB73FBF6FE4FB2E91E5066" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5202224DEDEB73FBF6FE4FB2E91E5066" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TaxCreditAndNetOperatingLossCarryforwards" xlink:label="loc_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_785DA3103FDFD27C5C544FB2E91F8186" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_785DA3103FDFD27C5C544FB2E91F8186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_22C412B12ECD5E49FDE64FB2E91F32A4" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_22C412B12ECD5E49FDE64FB2E91F32A4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfNetOperatingLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesLineItems" xlink:label="loc_alpn_IncomeTaxesLineItems_F9A47129ACEC214A61174FB2E8CF050F" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesTable" xlink:label="loc_alpn_IncomeTaxesTable_9E6F92A156A8AB1954A04FB2E8CE192D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alpn_IncomeTaxesLineItems_F9A47129ACEC214A61174FB2E8CF050F" xlink:to="loc_alpn_IncomeTaxesTable_9E6F92A156A8AB1954A04FB2E8CE192D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alpn_IncomeTaxesTable_9E6F92A156A8AB1954A04FB2E8CE192D" xlink:to="loc_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE" xlink:to="loc_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE" xlink:to="loc_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BeforeJanuary12018Member" xlink:label="loc_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:to="loc_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AfterJanuary12018Member" xlink:label="loc_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:to="loc_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alpn_IncomeTaxesTable_9E6F92A156A8AB1954A04FB2E8CE192D" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_80D3DFAEE466C2B6F86F4FB2E8CFEE20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:to="loc_us-gaap_DomesticCountryMember_80D3DFAEE466C2B6F86F4FB2E8CFEE20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_B1401C6BA0036E0A88624FB9FD5B7D99" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_B1401C6BA0036E0A88624FB9FD5B7D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6BBB6DE8163C80BBDDA54FB2E8CF8DFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_IncomeTaxesLineItems_F9A47129ACEC214A61174FB2E8CF050F" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6BBB6DE8163C80BBDDA54FB2E8CF8DFE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryTaxCreditCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesLineItems" xlink:label="loc_alpn_IncomeTaxesLineItems_EACFA3A5C29E415DB95D8272BD0C5377" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesTable" xlink:label="loc_alpn_IncomeTaxesTable_F37267D99C81E0A7CC738272BD0B1087" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alpn_IncomeTaxesLineItems_EACFA3A5C29E415DB95D8272BD0C5377" xlink:to="loc_alpn_IncomeTaxesTable_F37267D99C81E0A7CC738272BD0B1087" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_45068F5FFF88575A15AD8272BD0B2EF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alpn_IncomeTaxesTable_F37267D99C81E0A7CC738272BD0B1087" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_45068F5FFF88575A15AD8272BD0B2EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_28CAEB420B353D0E7C6D8272BD0C3064_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_45068F5FFF88575A15AD8272BD0B2EF7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_28CAEB420B353D0E7C6D8272BD0C3064_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_28CAEB420B353D0E7C6D8272BD0C3064" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_45068F5FFF88575A15AD8272BD0B2EF7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_28CAEB420B353D0E7C6D8272BD0C3064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1AA6E586FB0BBA1F16B58272BD0C05D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_28CAEB420B353D0E7C6D8272BD0C3064" xlink:to="loc_us-gaap_DomesticCountryMember_1AA6E586FB0BBA1F16B58272BD0C05D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_75AE400F9508B51118D98272BD0CBD56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_IncomeTaxesLineItems_EACFA3A5C29E415DB95D8272BD0C5377" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_75AE400F9508B51118D98272BD0CBD56" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/LongTermDebt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:to="loc_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0376E3679D62647857A87819D845CFEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E" xlink:to="loc_us-gaap_DebtInstrumentAxis_0376E3679D62647857A87819D845CFEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F2F6D5B71AE3B52CCEF67819D845E0EB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0376E3679D62647857A87819D845CFEE" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F2F6D5B71AE3B52CCEF67819D845E0EB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F2F6D5B71AE3B52CCEF67819D845E0EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0376E3679D62647857A87819D845CFEE" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F2F6D5B71AE3B52CCEF67819D845E0EB" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TermLoanMember" xlink:label="loc_alpn_TermLoanMember_D6AD1A323B8CCFB97A137819D845BA7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F2F6D5B71AE3B52CCEF67819D845E0EB" xlink:to="loc_alpn_TermLoanMember_D6AD1A323B8CCFB97A137819D845BA7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_8C599E6330A1A00ABB5C7819D8463176" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E" xlink:to="loc_us-gaap_VariableRateAxis_8C599E6330A1A00ABB5C7819D8463176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_0E7D4CF125A2701A9EFA7819D8466F66_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_8C599E6330A1A00ABB5C7819D8463176" xlink:to="loc_us-gaap_VariableRateDomain_0E7D4CF125A2701A9EFA7819D8466F66_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_0E7D4CF125A2701A9EFA7819D8466F66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_8C599E6330A1A00ABB5C7819D8463176" xlink:to="loc_us-gaap_VariableRateDomain_0E7D4CF125A2701A9EFA7819D8466F66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_9773922AECD793A16B397819D846AFEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0E7D4CF125A2701A9EFA7819D8466F66" xlink:to="loc_us-gaap_PrimeRateMember_9773922AECD793A16B397819D846AFEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_E96B1B253A8223570E277819D84CBAC4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_E96B1B253A8223570E277819D84CBAC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_A6CCE150A5E15A0A44DE7819D84CF61C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_E96B1B253A8223570E277819D84CBAC4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_A6CCE150A5E15A0A44DE7819D84CF61C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_A6CCE150A5E15A0A44DE7819D84CF61C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_E96B1B253A8223570E277819D84CBAC4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_A6CCE150A5E15A0A44DE7819D84CF61C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SeriesAOnePreferredStockWarrantsMember" xlink:label="loc_alpn_SeriesAOnePreferredStockWarrantsMember_6BB9BF5A65166515C3027819D84D62E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A6CCE150A5E15A0A44DE7819D84CF61C" xlink:to="loc_alpn_SeriesAOnePreferredStockWarrantsMember_6BB9BF5A65166515C3027819D84D62E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_FEAB232B48FDACE1B2A27819D84D0F53" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_FEAB232B48FDACE1B2A27819D84D0F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DB3C1405F7B07F24ECFF7819D84D23FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_FEAB232B48FDACE1B2A27819D84D0F53" xlink:to="loc_us-gaap_EquityComponentDomain_DB3C1405F7B07F24ECFF7819D84D23FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DB3C1405F7B07F24ECFF7819D84D23FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_FEAB232B48FDACE1B2A27819D84D0F53" xlink:to="loc_us-gaap_EquityComponentDomain_DB3C1405F7B07F24ECFF7819D84D23FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EB41E5BD1A163A2BB88A7819D84E6AA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DB3C1405F7B07F24ECFF7819D84D23FF" xlink:to="loc_us-gaap_CommonStockMember_EB41E5BD1A163A2BB88A7819D84E6AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_95ADDBB14D5A705502F27819D84E33DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_95ADDBB14D5A705502F27819D84E33DA" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DebtInstrumentNumberOfEqualMonthlyPayment" xlink:label="loc_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_8E3FB559145003C5F1897819D84E30C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:to="loc_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_8E3FB559145003C5F1897819D84E30C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5288150DA6E84AA9C86F7819D84F8B11" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5288150DA6E84AA9C86F7819D84F8B11" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DebtInstrumentFinalPaymentPercentage" xlink:label="loc_alpn_DebtInstrumentFinalPaymentPercentage_225713C883A61281A9B07819D84F9368" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:to="loc_alpn_DebtInstrumentFinalPaymentPercentage_225713C883A61281A9B07819D84F9368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_85E9AE100E9EAC887A6F7819D84F85F3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_85E9AE100E9EAC887A6F7819D84F85F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF2DDECA977FF1B0970C7819D84F9BB1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF2DDECA977FF1B0970C7819D84F9BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_603C4A36053DBDF747F17819D84F9354" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_603C4A36053DBDF747F17819D84F9354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_D41B7CC3E007560A68807819D84F489D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_D41B7CC3E007560A68807819D84F489D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6033FCAF609B792813F87819D8506A11" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6033FCAF609B792813F87819D8506A11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_C3D6FFD08767D027305C7819D850A2CC" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_C3D6FFD08767D027305C7819D850A2CC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/LongTermDebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_32B9845996523BDE5E554EDB9CFB40B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_32B9845996523BDE5E554EDB9CFB40B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:to="loc_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_013368E292CE94F7F89B4ED97FB69677" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D" xlink:to="loc_us-gaap_ScenarioForecastMember_013368E292CE94F7F89B4ED97FB69677" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:to="loc_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966" xlink:to="loc_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966" xlink:to="loc_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_LaurelVentureCapitalLtd.Member" xlink:label="loc_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F" xlink:to="loc_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_GSNORMember" xlink:label="loc_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B" xlink:to="loc_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8540A616556342340F814ED6CCDC9DA6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:to="loc_us-gaap_DebtInstrumentAxis_8540A616556342340F814ED6CCDC9DA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B196B6093A7166F64D0C4ED6CCDD16C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8540A616556342340F814ED6CCDC9DA6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B196B6093A7166F64D0C4ED6CCDD16C5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B196B6093A7166F64D0C4ED6CCDD16C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8540A616556342340F814ED6CCDC9DA6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B196B6093A7166F64D0C4ED6CCDD16C5" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TermSheetMember" xlink:label="loc_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B196B6093A7166F64D0C4ED6CCDD16C5" xlink:to="loc_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F90B57177FBF83B152714ED699D60BAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F90B57177FBF83B152714ED699D60BAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_B670E4DAFB455A47EE5F4ED81310F4DC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_B670E4DAFB455A47EE5F4ED81310F4DC" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived" xlink:label="loc_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:to="loc_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IntangibleAssetsAmountDerecognizedUponSale" xlink:label="loc_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:to="loc_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_73074696DE05BC227D254EDC14F52334" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_73074696DE05BC227D254EDC14F52334" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/NetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/NetLossPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5EDEA08F4C883694EE1C0F7945C40F7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE" xlink:to="loc_dei_LegalEntityAxis_5EDEA08F4C883694EE1C0F7945C40F7D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_17F281160E41F3249FD30F7945CEF73D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5EDEA08F4C883694EE1C0F7945C40F7D" xlink:to="loc_dei_EntityDomain_17F281160E41F3249FD30F7945CEF73D_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_17F281160E41F3249FD30F7945CEF73D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5EDEA08F4C883694EE1C0F7945C40F7D" xlink:to="loc_dei_EntityDomain_17F281160E41F3249FD30F7945CEF73D" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_0578A46062E64EFA91C50F7962CB2A17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_17F281160E41F3249FD30F7945CEF73D" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_0578A46062E64EFA91C50F7962CB2A17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1F75B45C4091303684790F551275A0A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1F75B45C4091303684790F551275A0A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_E3111864862C3F50F69B0F55127A22F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_E3111864862C3F50F69B0F55127A22F3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1C5FC82198032A69D4D691664FCB4404" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1C5FC82198032A69D4D691664FCB4404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_DC5014C70D7B8E94E63691664FCCEBD7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:to="loc_us-gaap_WarrantMember_DC5014C70D7B8E94E63691664FCCEBD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2B8B25A320C4A3DAD0E491664FCC624F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2B8B25A320C4A3DAD0E491664FCC624F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9E2C4E58331E4F421E4C91664FCC0F3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9E2C4E58331E4F421E4C91664FCC0F3E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_9BDD30011129562648A8CC2FE848D522" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:to="loc_us-gaap_EquipmentMember_9BDD30011129562648A8CC2FE848D522" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_GeneralEquipmentAndFurnitureMember" xlink:label="loc_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:to="loc_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_B7F35B02833756E9C0FECC2FE8480A82" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:to="loc_us-gaap_ComputerEquipmentMember_B7F35B02833756E9C0FECC2FE8480A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_16564395A9019343FF83CC2FE848CF5B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_16564395A9019343FF83CC2FE848CF5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4F826DD8D950CD203A9BCC2FE8482FD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4F826DD8D950CD203A9BCC2FE8482FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5D1D58C1ED2C7946F3ADCC2FE849F993" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5D1D58C1ED2C7946F3ADCC2FE849F993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C063110B236622C8CFE7CC2FE84927DF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_C063110B236622C8CFE7CC2FE84927DF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_50CFE42545F3134E8B3F91664D6B7F70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_50CFE42545F3134E8B3F91664D6B7F70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2B2C8B4FFB6629EAC3A691664D6B780A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_50CFE42545F3134E8B3F91664D6B7F70" xlink:to="loc_us-gaap_EquityComponentDomain_2B2C8B4FFB6629EAC3A691664D6B780A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2B2C8B4FFB6629EAC3A691664D6B780A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_50CFE42545F3134E8B3F91664D6B7F70" xlink:to="loc_us-gaap_EquityComponentDomain_2B2C8B4FFB6629EAC3A691664D6B780A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CAF70E41F4934EC90B2791664D6B6AE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2B2C8B4FFB6629EAC3A691664D6B780A" xlink:to="loc_us-gaap_CommonStockMember_CAF70E41F4934EC90B2791664D6B6AE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_A7BFAF1C6A5F2650B94691664D6C8C05" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_A7BFAF1C6A5F2650B94691664D6C8C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_FB0A643E0B19FB43011E91664D6C947C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_A7BFAF1C6A5F2650B94691664D6C8C05" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_FB0A643E0B19FB43011E91664D6C947C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_FB0A643E0B19FB43011E91664D6C947C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_A7BFAF1C6A5F2650B94691664D6C8C05" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_FB0A643E0B19FB43011E91664D6C947C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_9D72F34B3E25ABC8E00891664D6C4BE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_FB0A643E0B19FB43011E91664D6C947C" xlink:to="loc_us-gaap_SubsequentEventMember_9D72F34B3E25ABC8E00891664D6C4BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72" xlink:to="loc_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72" xlink:to="loc_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AlpineBioVenturesGPLLCMember" xlink:label="loc_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610" xlink:to="loc_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4E786A7BE12D8989D7CE91664D738515" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4E786A7BE12D8989D7CE91664D738515" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock" xlink:label="loc_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_A2B3E99618B441856FD191664D73D5CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_A2B3E99618B441856FD191664D73D5CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18BFCB9DC1B7D5B08C5491664D73176D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18BFCB9DC1B7D5B08C5491664D73176D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_04D0A9204EC372273C3B91664D730A51" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_04D0A9204EC372273C3B91664D730A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_1CD5345A4A55B6E65EBC91664D74165C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_1CD5345A4A55B6E65EBC91664D74165C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficit" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_912E1134A450D0C9FE6C91B71FD4A06E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_912E1134A450D0C9FE6C91B71FD4A06E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_294DED175E1D1DE2FD6991B71FD5C577_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_912E1134A450D0C9FE6C91B71FD4A06E" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_294DED175E1D1DE2FD6991B71FD5C577_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_294DED175E1D1DE2FD6991B71FD5C577" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_912E1134A450D0C9FE6C91B71FD4A06E" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_294DED175E1D1DE2FD6991B71FD5C577" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_590847B26FBDD945570491B71FD5EA58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_294DED175E1D1DE2FD6991B71FD5C577" xlink:to="loc_us-gaap_SubsequentEventMember_590847B26FBDD945570491B71FD5EA58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A" xlink:to="loc_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A" xlink:to="loc_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_44F4AA06C529D4DF4D5691B71FD6214B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448" xlink:to="loc_srt_MaximumMember_44F4AA06C529D4DF4D5691B71FD6214B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_24D2B92168C29F6577B491B71FD66432" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_dei_LegalEntityAxis_24D2B92168C29F6577B491B71FD66432" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9EE8928A152A7C09F49391B71FD6886A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_24D2B92168C29F6577B491B71FD66432" xlink:to="loc_dei_EntityDomain_9EE8928A152A7C09F49391B71FD6886A_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9EE8928A152A7C09F49391B71FD6886A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_24D2B92168C29F6577B491B71FD66432" xlink:to="loc_dei_EntityDomain_9EE8928A152A7C09F49391B71FD6886A" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CowenandCompanyLLCMember" xlink:label="loc_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9EE8928A152A7C09F49391B71FD6886A" xlink:to="loc_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PiperJaffrayCo.Member" xlink:label="loc_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9EE8928A152A7C09F49391B71FD6886A" xlink:to="loc_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_5B3EC5131AE3CFB46F3D91B71FD7D982" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6" xlink:to="loc_us-gaap_EmployeeStockMember_5B3EC5131AE3CFB46F3D91B71FD7D982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_AAE28EC554D692FCD46691B71FD7239B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_AAE28EC554D692FCD46691B71FD7239B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3ECD24067729E7D53BF891B71FD730C6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AAE28EC554D692FCD46691B71FD7239B" xlink:to="loc_us-gaap_EquityComponentDomain_3ECD24067729E7D53BF891B71FD730C6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3ECD24067729E7D53BF891B71FD730C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AAE28EC554D692FCD46691B71FD7239B" xlink:to="loc_us-gaap_EquityComponentDomain_3ECD24067729E7D53BF891B71FD730C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_110130DC6DAD5A3635EE91B71FD872FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3ECD24067729E7D53BF891B71FD730C6" xlink:to="loc_us-gaap_CommonStockMember_110130DC6DAD5A3635EE91B71FD872FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9" xlink:to="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9" xlink:to="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TwoThousandAndEighteenPlanMember" xlink:label="loc_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:to="loc_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_InducementGrantMember" xlink:label="loc_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:to="loc_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncentiveStockOptionMember" xlink:label="loc_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:to="loc_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member" xlink:label="loc_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:to="loc_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_StockPlan2018Member" xlink:label="loc_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:to="loc_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CommonStockInitialReservesMember" xlink:label="loc_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:to="loc_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_LegacyPlanCancellationsMember" xlink:label="loc_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:to="loc_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_DECEA53175C154B7D17B91B71FDA1A29" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:to="loc_us-gaap_EmployeeStockOptionMember_DECEA53175C154B7D17B91B71FDA1A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_62106B3770B79A8A64A991B71FDB29BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_62106B3770B79A8A64A991B71FDB29BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_E25B4F3C127D9A1999AC91B71FDBF210" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_E25B4F3C127D9A1999AC91B71FDBF210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_429C6B05EF776ECC537C91B71FDBB470" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_TreasuryStockCommonShares_429C6B05EF776ECC537C91B71FDBB470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_42B52E0F6D308D2888AF91B71FDB6687" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_42B52E0F6D308D2888AF91B71FDB6687" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_MaximumAmountOfCommonStockEligibleToBeSold" xlink:label="loc_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices" xlink:label="loc_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_C4552B97464818896F3191B71FDCF273" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_C4552B97464818896F3191B71FDCF273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_BA8CE2FCA27553F66B1C91B71FDC8B24" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_BA8CE2FCA27553F66B1C91B71FDC8B24" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PurchaseAgreementRatioOfCommonStockToWarrants" xlink:label="loc_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PurchaseAgreementAggregatePurchasePricePerUnit" xlink:label="loc_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5C77DFE6EE32A471FD7E91B71FDC97F3" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5C77DFE6EE32A471FD7E91B71FDC97F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_11C48B48F077648994A291B71FDD4F9C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_11C48B48F077648994A291B71FDD4F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_E60F6FEDB9365E64C4A491B97FBCE256" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_E60F6FEDB9365E64C4A491B97FBCE256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_EF8421748ABED4388C7E91B71FDD032C" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_DeferredOfferingCosts_EF8421748ABED4388C7E91B71FDD032C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14CD82C8CC25D08F582091B71FDD59CC" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14CD82C8CC25D08F582091B71FDD59CC" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent" xlink:label="loc_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_E04BA13CCA3F0F27613091B71FDDCFB7" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_E04BA13CCA3F0F27613091B71FDDCFB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1E369B725C5F5F46911191B71FDE7C5B" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1E369B725C5F5F46911191B71FDE7C5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38651EC26A6BFE6057C291B71FDEE6B0" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38651EC26A6BFE6057C291B71FDEE6B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_02133D8A6A33DA370F7E91B71FDE03E0" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_02133D8A6A33DA370F7E91B71FDE03E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_12EF3BFDE3D02A921FE891B71FDE7784" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_12EF3BFDE3D02A921FE891B71FDE7784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35475648EF2A7191082091B71FDED7C7" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35475648EF2A7191082091B71FDED7C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_06F6A3CAF47D584A698091B71FDFB9D9" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_06F6A3CAF47D584A698091B71FDFB9D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7C0B62C4B053B448615091B71FDF86E6" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7C0B62C4B053B448615091B71FDF86E6" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions" xlink:label="loc_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfEmployees" xlink:label="loc_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AdditionalCompensationExpense" xlink:label="loc_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2BCCF002A0271F77702473692A4A58BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0E098147AB21DF6AE11873692A4873F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2BCCF002A0271F77702473692A4A58BB" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0E098147AB21DF6AE11873692A4873F8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B35758117BF613899BAA73692A484953" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0E098147AB21DF6AE11873692A4873F8" xlink:to="loc_us-gaap_AwardTypeAxis_B35758117BF613899BAA73692A484953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_B35758117BF613899BAA73692A484953" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_B35758117BF613899BAA73692A484953" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember" xlink:label="loc_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37" xlink:to="loc_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember" xlink:label="loc_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37" xlink:to="loc_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharesAvailableForFutureStockGrantsMember" xlink:label="loc_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37" xlink:to="loc_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember" xlink:label="loc_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37" xlink:to="loc_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E91E7D56EA8291326F2973692A4A608A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2BCCF002A0271F77702473692A4A58BB" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E91E7D56EA8291326F2973692A4A608A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1028C031FE437501BB50CD390B42B345" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6B7B11404E643966AEEBCD390B405C4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1028C031FE437501BB50CD390B42B345" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6B7B11404E643966AEEBCD390B405C4C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_FEA149E7E03FAE7637AECD390B40DEA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6B7B11404E643966AEEBCD390B405C4C" xlink:to="loc_us-gaap_TitleOfIndividualAxis_FEA149E7E03FAE7637AECD390B40DEA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_FEA149E7E03FAE7637AECD390B40DEA4" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_FEA149E7E03FAE7637AECD390B40DEA4" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EmployeesMember" xlink:label="loc_alpn_EmployeesMember_35EDED410FF17FF58E80CD390B414E47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0" xlink:to="loc_alpn_EmployeesMember_35EDED410FF17FF58E80CD390B414E47" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NonEmployeesMember" xlink:label="loc_alpn_NonEmployeesMember_7794E748D31A06A64C3BCD390B41E6AA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0" xlink:to="loc_alpn_NonEmployeesMember_7794E748D31A06A64C3BCD390B41E6AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_BA88EC05523CE4BBC80BCD390B415BFD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6B7B11404E643966AEEBCD390B405C4C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_BA88EC05523CE4BBC80BCD390B415BFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_BA88EC05523CE4BBC80BCD390B415BFD" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_BA88EC05523CE4BBC80BCD390B415BFD" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_872BAF454674A23108A5CD390B416B3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_872BAF454674A23108A5CD390B416B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_727F99D1B735ACEB4852CD390B427008" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_727F99D1B735ACEB4852CD390B427008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF9AF0230C188037027BCD390B423D19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1028C031FE437501BB50CD390B42B345" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF9AF0230C188037027BCD390B423D19" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockOptionAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ECF1319A59B5154CDBD091664E1CD28E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ECF1319A59B5154CDBD091664E1CD28E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_043E6FF78921078323FA91664E1C4A7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ECF1319A59B5154CDBD091664E1CD28E" xlink:to="loc_srt_RangeAxis_043E6FF78921078323FA91664E1C4A7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_120178A284A85BCC6AEE91664E1CB3FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_043E6FF78921078323FA91664E1C4A7B" xlink:to="loc_srt_RangeMember_120178A284A85BCC6AEE91664E1CB3FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_120178A284A85BCC6AEE91664E1CB3FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_043E6FF78921078323FA91664E1C4A7B" xlink:to="loc_srt_RangeMember_120178A284A85BCC6AEE91664E1CB3FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_520C13B49BC8C691B81691664E1D13D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_120178A284A85BCC6AEE91664E1CB3FE" xlink:to="loc_srt_MinimumMember_520C13B49BC8C691B81691664E1D13D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_17A316AE560028A57CC391664E1D3A69" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_120178A284A85BCC6AEE91664E1CB3FE" xlink:to="loc_srt_MaximumMember_17A316AE560028A57CC391664E1D3A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9C943BFB53ED62F313A791664E1DE6CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9C943BFB53ED62F313A791664E1DE6CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D0263B1F1212ABEF2FB791664E1E14B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D0263B1F1212ABEF2FB791664E1E14B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_945437C6F2ABECF4939591664E1E7D8E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_945437C6F2ABECF4939591664E1E7D8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8278ADB8AF859FD67CE991664E1E7C1B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8278ADB8AF859FD67CE991664E1E7C1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E0BCF806AD09912948BD91664E1E81B0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E0BCF806AD09912948BD91664E1E81B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_406098AA8625F4D1D75891664E1E4FD1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_406098AA8625F4D1D75891664E1E4FD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D16D2462C73C179FC2391664E1E85B2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D16D2462C73C179FC2391664E1E85B2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfWarrantsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeflicitSummaryOfOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_ACE0D88688E6ED85852D7DC9C363A51D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4" xlink:to="loc_us-gaap_AwardTypeAxis_ACE0D88688E6ED85852D7DC9C363A51D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CFEF8884BA020652FC897DC9C3634F11_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ACE0D88688E6ED85852D7DC9C363A51D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CFEF8884BA020652FC897DC9C3634F11_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CFEF8884BA020652FC897DC9C3634F11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ACE0D88688E6ED85852D7DC9C363A51D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CFEF8884BA020652FC897DC9C3634F11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9A3B3443BC35B15ABF4A7DC9C3642E5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CFEF8884BA020652FC897DC9C3634F11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9A3B3443BC35B15ABF4A7DC9C3642E5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98BA121E0329FC99CC697DC9C3672FCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98BA121E0329FC99CC697DC9C3672FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2F7DC63CB65667549D0E7DC9C36705DF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2F7DC63CB65667549D0E7DC9C36705DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5008A4651646DBAD584D7DC9C3674A64" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5008A4651646DBAD584D7DC9C3674A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_933C403E501D2FAE7ACE7DC9C367A177" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_933C403E501D2FAE7ACE7DC9C367A177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8B3337D475C1A4843CAC7DC9C368BB37" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8B3337D475C1A4843CAC7DC9C368BB37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3B2D836AF339FAEE17537DC9C3680B09" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3B2D836AF339FAEE17537DC9C3680B09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16E701095D5A5CD65C937DC9C368D667" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16E701095D5A5CD65C937DC9C368D667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_117F7E964091C0E8B44B7DC9C3692E98" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_117F7E964091C0E8B44B7DC9C3692E98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_BC26ED7D0C0123CB4B8A7DC9C369A6F0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_BC26ED7D0C0123CB4B8A7DC9C369A6F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D6E0C195FF8ECB471A957DC9C3698BE5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D6E0C195FF8ECB471A957DC9C3698BE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_FD868577B9D2E4CB983F7DC9C3690DE6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_FD868577B9D2E4CB983F7DC9C3690DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9E788034A11C6DCCB9E07DC9C369959B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9E788034A11C6DCCB9E07DC9C369959B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D0C23A746FCAA2058D627DC9C36AF201" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D0C23A746FCAA2058D627DC9C36AF201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_C93DD1442DB08AC913007DC9C36A84DA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_C93DD1442DB08AC913007DC9C36A84DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BCF4E027B8A61237960B7DC9C36A01F3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BCF4E027B8A61237960B7DC9C36A01F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_68A9F66BC0AFC318C9457DC9C36DF42E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_68A9F66BC0AFC318C9457DC9C36DF42E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_E56B64C004E5A5DB18D87DC9C77D3E2F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_E56B64C004E5A5DB18D87DC9C77D3E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2DB096A580B940904E517DCBBEBBFD9D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2DB096A580B940904E517DCBBEBBFD9D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SignificantAccountingPoliciesTable" xlink:label="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E59261C80F0BB992CAA4916650692D2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E59261C80F0BB992CAA4916650692D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OfficeAndLaboratoryLeasesMember" xlink:label="loc_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF" xlink:to="loc_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_29724EA822D41D77785C9166506A0924" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_us-gaap_StatementScenarioAxis_29724EA822D41D77785C9166506A0924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_A7BCBA0C8273150D9C8D9166506A1582_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_29724EA822D41D77785C9166506A0924" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_A7BCBA0C8273150D9C8D9166506A1582_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_A7BCBA0C8273150D9C8D9166506A1582" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_29724EA822D41D77785C9166506A0924" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_A7BCBA0C8273150D9C8D9166506A1582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_6CD83A669D1FE529CE9A9166506A16F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_A7BCBA0C8273150D9C8D9166506A1582" xlink:to="loc_us-gaap_ScenarioForecastMember_6CD83A669D1FE529CE9A9166506A16F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996" xlink:to="loc_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996" xlink:to="loc_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_9A7D019D6BA00820F3ED9166506B6F63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_9A7D019D6BA00820F3ED9166506B6F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_8133D1FEA8A4F4930E5D9166506B97CF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_8133D1FEA8A4F4930E5D9166506B97CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_410B6E8BE3A2E18BEF1F9166506CA92D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_410B6E8BE3A2E18BEF1F9166506CA92D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7A2C8EE20C23225DEA8E9166506C9761_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_410B6E8BE3A2E18BEF1F9166506CA92D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7A2C8EE20C23225DEA8E9166506C9761_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7A2C8EE20C23225DEA8E9166506C9761" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_410B6E8BE3A2E18BEF1F9166506CA92D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7A2C8EE20C23225DEA8E9166506C9761" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_AAEE9550EACA6C1120B091665071A32E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7A2C8EE20C23225DEA8E9166506C9761" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_AAEE9550EACA6C1120B091665071A32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F71ECEE04DE39A45858691665071D487" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_srt_RangeAxis_F71ECEE04DE39A45858691665071D487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_E1838F64F49AA9171A2291665071C3CE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_F71ECEE04DE39A45858691665071D487" xlink:to="loc_srt_RangeMember_E1838F64F49AA9171A2291665071C3CE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_E1838F64F49AA9171A2291665071C3CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_F71ECEE04DE39A45858691665071D487" xlink:to="loc_srt_RangeMember_E1838F64F49AA9171A2291665071C3CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C2852600991722C486E091665072E3BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_E1838F64F49AA9171A2291665071C3CE" xlink:to="loc_srt_MinimumMember_C2852600991722C486E091665072E3BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_F5801A0FFAC97243A14A91665072D016" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_E1838F64F49AA9171A2291665071C3CE" xlink:to="loc_srt_MaximumMember_F5801A0FFAC97243A14A91665072D016" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_65448CBDF42E0E2DE1A491665072A88E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_65448CBDF42E0E2DE1A491665072A88E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_D8544E8150127584C2F9916650738115" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_D8544E8150127584C2F9916650738115" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_207DCE5788D71AC5457191665073529E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_207DCE5788D71AC5457191665073529E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B29A9D177940B5B1DCFF91665073E0CC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B29A9D177940B5B1DCFF91665073E0CC" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement" xlink:label="loc_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_C1F25FC23170605965B79170E122D4E7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_C1F25FC23170605965B79170E122D4E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_029CB5E404A1166F22F7917089FB6861" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_OperatingLeaseLiability_029CB5E404A1166F22F7917089FB6861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4CB31D0872035168ED4391665074F6D3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4CB31D0872035168ED4391665074F6D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_429F39E7D949D1E2354A916650741843" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_429F39E7D949D1E2354A916650741843" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNewAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_C28F96A535072153BBD9730636D49874" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_C28F96A535072153BBD9730636D49874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_55C9772034B8FED100F3730636D46CBC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_C28F96A535072153BBD9730636D49874" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_55C9772034B8FED100F3730636D46CBC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_55C9772034B8FED100F3730636D46CBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_C28F96A535072153BBD9730636D49874" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_55C9772034B8FED100F3730636D46CBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E0E9086A59F8090BBDBE730636D55DB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_55C9772034B8FED100F3730636D46CBC" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E0E9086A59F8090BBDBE730636D55DB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_539B9297298AE154FED2730636D5960B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_55C9772034B8FED100F3730636D46CBC" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_539B9297298AE154FED2730636D5960B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AE83082E141BA4B352E1730636D5390C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AE83082E141BA4B352E1730636D5390C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_EB3212203B03E44732F3730636DAC236_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AE83082E141BA4B352E1730636D5390C" xlink:to="loc_us-gaap_TypeOfAdoptionMember_EB3212203B03E44732F3730636DAC236_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_EB3212203B03E44732F3730636DAC236" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AE83082E141BA4B352E1730636D5390C" xlink:to="loc_us-gaap_TypeOfAdoptionMember_EB3212203B03E44732F3730636DAC236" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_829763A31D1B51C53745730636DBF395" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_EB3212203B03E44732F3730636DAC236" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_829763A31D1B51C53745730636DBF395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0BB55DA7518FEB8195CA730636DC0631" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:to="loc_us-gaap_StockholdersEquityNoteAbstract_0BB55DA7518FEB8195CA730636DC0631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DB556D353662D3E328F7730636DC3CA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0BB55DA7518FEB8195CA730636DC0631" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DB556D353662D3E328F7730636DC3CA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:to="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B0836BA5B3FCE09ED329730636DC55B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B0836BA5B3FCE09ED329730636DC55B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E1F6C8183CD7171B9D7F730636DD7095" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:to="loc_us-gaap_NetIncomeLoss_E1F6C8183CD7171B9D7F730636DD7095" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>alpn-20181231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_D7C4746F40C3C97882194EC065B2A708_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_D7C4746F40C3C97882194EC065B2A708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D7C4746F40C3C97882194EC065B2A708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D7C4746F40C3C97882194EC065B2A708" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_D7C4746F40C3C97882194EC065B2A708" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_032F4ACAB977539282FF4EC065B28CFC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_032F4ACAB977539282FF4EC065B28CFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_032F4ACAB977539282FF4EC065B28CFC_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_032F4ACAB977539282FF4EC065B28CFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_032F4ACAB977539282FF4EC065B28CFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_032F4ACAB977539282FF4EC065B28CFC" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_032F4ACAB977539282FF4EC065B28CFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_459ECFC244D99678F01F91664E4741F0_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_459ECFC244D99678F01F91664E4741F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_459ECFC244D99678F01F91664E4741F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_459ECFC244D99678F01F91664E4741F0" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_459ECFC244D99678F01F91664E4741F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_EDA44F2A78AAE19705B991664E47FF16_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_EDA44F2A78AAE19705B991664E47FF16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_EDA44F2A78AAE19705B991664E47FF16_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_EDA44F2A78AAE19705B991664E47FF16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_EDA44F2A78AAE19705B991664E47FF16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_EDA44F2A78AAE19705B991664E47FF16" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_EDA44F2A78AAE19705B991664E47FF16" xlink:type="arc" />
    <link:label id="lab_alpn_NumberOfWarrantsAvailableTobeExercised_3B54EAE49CE6F7C9704D9175D2BCA1CF_terseLabel_en-US" xlink:label="lab_alpn_NumberOfWarrantsAvailableTobeExercised_3B54EAE49CE6F7C9704D9175D2BCA1CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable (in shares)</link:label>
    <link:label id="lab_alpn_NumberOfWarrantsAvailableTobeExercised_3B54EAE49CE6F7C9704D9175D2BCA1CF_label_en-US" xlink:label="lab_alpn_NumberOfWarrantsAvailableTobeExercised_3B54EAE49CE6F7C9704D9175D2BCA1CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Available To be Exercised</link:label>
    <link:label id="lab_alpn_NumberOfWarrantsAvailableTobeExercised_3B54EAE49CE6F7C9704D9175D2BCA1CF_documentation_en-US" xlink:label="lab_alpn_NumberOfWarrantsAvailableTobeExercised_3B54EAE49CE6F7C9704D9175D2BCA1CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants Available To be Exercised</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfWarrantsAvailableTobeExercised" xlink:label="loc_alpn_NumberOfWarrantsAvailableTobeExercised_3B54EAE49CE6F7C9704D9175D2BCA1CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_NumberOfWarrantsAvailableTobeExercised_3B54EAE49CE6F7C9704D9175D2BCA1CF" xlink:to="lab_alpn_NumberOfWarrantsAvailableTobeExercised_3B54EAE49CE6F7C9704D9175D2BCA1CF" xlink:type="arc" />
    <link:label id="lab_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding_D04984A033FBB0A2584491664E472E27_verboseLabel_en-US" xlink:label="lab_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding_D04984A033FBB0A2584491664E472E27" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average, exercise price (in dollars per share)</link:label>
    <link:label id="lab_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding_D04984A033FBB0A2584491664E472E27_label_en-US" xlink:label="lab_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding_D04984A033FBB0A2584491664E472E27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Weighted-Average Exercise Price Outstanding</link:label>
    <link:label id="lab_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding_D04984A033FBB0A2584491664E472E27_documentation_en-US" xlink:label="lab_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding_D04984A033FBB0A2584491664E472E27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Weighted Average-Exercise Price Outstanding</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding" xlink:label="loc_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding_D04984A033FBB0A2584491664E472E27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding_D04984A033FBB0A2584491664E472E27" xlink:to="lab_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding_D04984A033FBB0A2584491664E472E27" xlink:type="arc" />
    <link:label id="lab_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable_765B1B1ED4FD289E3A1991664E48B673_terseLabel_en-US" xlink:label="lab_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable_765B1B1ED4FD289E3A1991664E48B673" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average, exercisable (in dollars per share)</link:label>
    <link:label id="lab_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable_765B1B1ED4FD289E3A1991664E48B673_label_en-US" xlink:label="lab_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable_765B1B1ED4FD289E3A1991664E48B673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Weighted-Average Price Exercisable</link:label>
    <link:label id="lab_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable_765B1B1ED4FD289E3A1991664E48B673_documentation_en-US" xlink:label="lab_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable_765B1B1ED4FD289E3A1991664E48B673" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Weighted-Average Price Exercisable</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ClassofWarrantorRightWeightedAveragePriceExercisable" xlink:label="loc_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable_765B1B1ED4FD289E3A1991664E48B673" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable_765B1B1ED4FD289E3A1991664E48B673" xlink:to="lab_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable_765B1B1ED4FD289E3A1991664E48B673" xlink:type="arc" />
    <link:label id="lab_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding_B3C1C9168712F780D85D91664E4D9352_terseLabel_en-US" xlink:label="lab_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding_B3C1C9168712F780D85D91664E4D9352" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average Remaining Contract Term</link:label>
    <link:label id="lab_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding_B3C1C9168712F780D85D91664E4D9352_label_en-US" xlink:label="lab_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding_B3C1C9168712F780D85D91664E4D9352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Weighted-Average Remaining Contractual Term Outstanding</link:label>
    <link:label id="lab_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding_B3C1C9168712F780D85D91664E4D9352_documentation_en-US" xlink:label="lab_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding_B3C1C9168712F780D85D91664E4D9352" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Weighted-Average Remaining Contractual Term Outstanding</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding" xlink:label="loc_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding_B3C1C9168712F780D85D91664E4D9352" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding_B3C1C9168712F780D85D91664E4D9352" xlink:to="lab_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding_B3C1C9168712F780D85D91664E4D9352" xlink:type="arc" />
    <link:label id="lab_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable_73EFCA833CFAE9C3934291664E4DB0AF_terseLabel_en-US" xlink:label="lab_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable_73EFCA833CFAE9C3934291664E4DB0AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average Remaining Contract Term, Exercisable</link:label>
    <link:label id="lab_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable_73EFCA833CFAE9C3934291664E4DB0AF_label_en-US" xlink:label="lab_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable_73EFCA833CFAE9C3934291664E4DB0AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Weighted-Average Remaining Contractual Term Exercisable</link:label>
    <link:label id="lab_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable_73EFCA833CFAE9C3934291664E4DB0AF_documentation_en-US" xlink:label="lab_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable_73EFCA833CFAE9C3934291664E4DB0AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Weighted-Average Remaining Contractual Term Exercisable</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:label="loc_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable_73EFCA833CFAE9C3934291664E4DB0AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable_73EFCA833CFAE9C3934291664E4DB0AF" xlink:to="lab_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable_73EFCA833CFAE9C3934291664E4DB0AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_FB17BD99402615408C870F5512541D7A_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_FB17BD99402615408C870F5512541D7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_FB17BD99402615408C870F5512541D7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_FB17BD99402615408C870F5512541D7A" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_FB17BD99402615408C870F5512541D7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_343C74C882EC8FFC3C390F83CFA20025_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_343C74C882EC8FFC3C390F83CFA20025" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Amortized Cost and Fair Value of Cash Equivalents and Short Term Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_343C74C882EC8FFC3C390F83CFA20025_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_343C74C882EC8FFC3C390F83CFA20025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_343C74C882EC8FFC3C390F83CFA20025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_343C74C882EC8FFC3C390F83CFA20025" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_343C74C882EC8FFC3C390F83CFA20025" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_0D96D8BF8C0D324EFCB3730637573C16_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0D96D8BF8C0D324EFCB3730637573C16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0D96D8BF8C0D324EFCB3730637573C16_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0D96D8BF8C0D324EFCB3730637573C16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0D96D8BF8C0D324EFCB3730637573C16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_0D96D8BF8C0D324EFCB3730637573C16" xlink:to="lab_us-gaap_NetIncomeLoss_0D96D8BF8C0D324EFCB3730637573C16" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_A817E19E1E77A442B43A7306375890B8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_A817E19E1E77A442B43A7306375890B8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of intangible asset</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_A817E19E1E77A442B43A7306375890B8_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_A817E19E1E77A442B43A7306375890B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_A817E19E1E77A442B43A7306375890B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_A817E19E1E77A442B43A7306375890B8" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_A817E19E1E77A442B43A7306375890B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_DADA49E581D567BC03B8730637589690_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_DADA49E581D567BC03B8730637589690" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Bargain purchase gain</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_DADA49E581D567BC03B8730637589690_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_DADA49E581D567BC03B8730637589690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Bargain Purchase, Gain Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:label="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_DADA49E581D567BC03B8730637589690" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_DADA49E581D567BC03B8730637589690" xlink:to="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_DADA49E581D567BC03B8730637589690" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_A2F82591F070089A61D873063758F9CD_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_A2F82591F070089A61D873063758F9CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_A2F82591F070089A61D873063758F9CD_label_en-US" xlink:label="lab_us-gaap_Depreciation_A2F82591F070089A61D873063758F9CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_A2F82591F070089A61D873063758F9CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_A2F82591F070089A61D873063758F9CD" xlink:to="lab_us-gaap_Depreciation_A2F82591F070089A61D873063758F9CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_93D64828D53A978CCED3730637584603_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_93D64828D53A978CCED3730637584603" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of premium/discount on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_93D64828D53A978CCED3730637584603_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_93D64828D53A978CCED3730637584603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_93D64828D53A978CCED3730637584603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_93D64828D53A978CCED3730637584603" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_93D64828D53A978CCED3730637584603" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_F870B25BBCB4A2BF2307730637586BB3_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_F870B25BBCB4A2BF2307730637586BB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_F870B25BBCB4A2BF2307730637586BB3_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_F870B25BBCB4A2BF2307730637586BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_F870B25BBCB4A2BF2307730637586BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_F870B25BBCB4A2BF2307730637586BB3" xlink:to="lab_us-gaap_PaidInKindInterest_F870B25BBCB4A2BF2307730637586BB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77486A723452D6250DE5730637594587_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77486A723452D6250DE5730637594587" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77486A723452D6250DE5730637594587_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77486A723452D6250DE5730637594587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77486A723452D6250DE5730637594587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77486A723452D6250DE5730637594587" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77486A723452D6250DE5730637594587" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_A22DEA6632951B9D815C73063759F918_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A22DEA6632951B9D815C73063759F918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation and warrant expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_A22DEA6632951B9D815C73063759F918_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A22DEA6632951B9D815C73063759F918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A22DEA6632951B9D815C73063759F918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_A22DEA6632951B9D815C73063759F918" xlink:to="lab_us-gaap_ShareBasedCompensation_A22DEA6632951B9D815C73063759F918" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_FCC8BEC74971AB5ABF3773063759E0E9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_FCC8BEC74971AB5ABF3773063759E0E9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_FCC8BEC74971AB5ABF3773063759E0E9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_FCC8BEC74971AB5ABF3773063759E0E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_FCC8BEC74971AB5ABF3773063759E0E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_FCC8BEC74971AB5ABF3773063759E0E9" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_FCC8BEC74971AB5ABF3773063759E0E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2F4C1B4173E4D1A82F0373063759E642_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2F4C1B4173E4D1A82F0373063759E642" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2F4C1B4173E4D1A82F0373063759E642_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2F4C1B4173E4D1A82F0373063759E642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2F4C1B4173E4D1A82F0373063759E642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2F4C1B4173E4D1A82F0373063759E642" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2F4C1B4173E4D1A82F0373063759E642" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9B24473E65DDBC9611ED7306375AE4CE_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9B24473E65DDBC9611ED7306375AE4CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9B24473E65DDBC9611ED7306375AE4CE_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9B24473E65DDBC9611ED7306375AE4CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9B24473E65DDBC9611ED7306375AE4CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9B24473E65DDBC9611ED7306375AE4CE" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9B24473E65DDBC9611ED7306375AE4CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_C2D92C7166A93230AAF37306375AEAFD_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_C2D92C7166A93230AAF37306375AEAFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_C2D92C7166A93230AAF37306375AEAFD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_C2D92C7166A93230AAF37306375AEAFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_C2D92C7166A93230AAF37306375AEAFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_C2D92C7166A93230AAF37306375AEAFD" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_C2D92C7166A93230AAF37306375AEAFD" xlink:type="arc" />
    <link:label id="lab_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_5319879CB53875ED911B7306375AA261_terseLabel_en-US" xlink:label="lab_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_5319879CB53875ED911B7306375AA261" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent and other</link:label>
    <link:label id="lab_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_5319879CB53875ED911B7306375AA261_label_en-US" xlink:label="lab_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_5319879CB53875ED911B7306375AA261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Deferred Rent And Other Operating Liabilities</link:label>
    <link:label id="lab_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_5319879CB53875ED911B7306375AA261_documentation_en-US" xlink:label="lab_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_5319879CB53875ED911B7306375AA261" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Deferred Rent And Other Operating Liabilities</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities" xlink:label="loc_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_5319879CB53875ED911B7306375AA261" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_5319879CB53875ED911B7306375AA261" xlink:to="lab_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_5319879CB53875ED911B7306375AA261" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3212DD2324F98CF77C4D7306375A96F2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3212DD2324F98CF77C4D7306375A96F2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3212DD2324F98CF77C4D7306375A96F2_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3212DD2324F98CF77C4D7306375A96F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3212DD2324F98CF77C4D7306375A96F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3212DD2324F98CF77C4D7306375A96F2" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3212DD2324F98CF77C4D7306375A96F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E5CFB874883514E5E91B7306375A46E5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E5CFB874883514E5E91B7306375A46E5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E5CFB874883514E5E91B7306375A46E5_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E5CFB874883514E5E91B7306375A46E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E5CFB874883514E5E91B7306375A46E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E5CFB874883514E5E91B7306375A46E5" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E5CFB874883514E5E91B7306375A46E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_A805F564FBDF7E6F54D07306375B40BF_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_A805F564FBDF7E6F54D07306375B40BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of intangible asset</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_A805F564FBDF7E6F54D07306375B40BF_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_A805F564FBDF7E6F54D07306375B40BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_A805F564FBDF7E6F54D07306375B40BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_A805F564FBDF7E6F54D07306375B40BF" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_A805F564FBDF7E6F54D07306375B40BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_AA337AE12A2C0132E8957306375B5557_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_AA337AE12A2C0132E8957306375B5557" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_AA337AE12A2C0132E8957306375B5557_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_AA337AE12A2C0132E8957306375B5557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_AA337AE12A2C0132E8957306375B5557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_AA337AE12A2C0132E8957306375B5557" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_AA337AE12A2C0132E8957306375B5557" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_CB6E922CF1CCE8FA91C37306375BAC88_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_CB6E922CF1CCE8FA91C37306375BAC88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_CB6E922CF1CCE8FA91C37306375BAC88_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_CB6E922CF1CCE8FA91C37306375BAC88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_CB6E922CF1CCE8FA91C37306375BAC88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_CB6E922CF1CCE8FA91C37306375BAC88" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_CB6E922CF1CCE8FA91C37306375BAC88" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DD8293CA6C87830736177306375BB6BC_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DD8293CA6C87830736177306375BB6BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DD8293CA6C87830736177306375BB6BC_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DD8293CA6C87830736177306375BB6BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DD8293CA6C87830736177306375BB6BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DD8293CA6C87830736177306375BB6BC" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DD8293CA6C87830736177306375BB6BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_6893A66DF1D7C61E772C7306375B41FC_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition_6893A66DF1D7C61E772C7306375B41FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents acquired in connection with merger</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_6893A66DF1D7C61E772C7306375B41FC_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition_6893A66DF1D7C61E772C7306375B41FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_6893A66DF1D7C61E772C7306375B41FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition_6893A66DF1D7C61E772C7306375B41FC" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition_6893A66DF1D7C61E772C7306375B41FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_39E5C502800B0DFA44DC7306375B95F4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_39E5C502800B0DFA44DC7306375B95F4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_39E5C502800B0DFA44DC7306375B95F4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_39E5C502800B0DFA44DC7306375B95F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39E5C502800B0DFA44DC7306375B95F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39E5C502800B0DFA44DC7306375B95F4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_39E5C502800B0DFA44DC7306375B95F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_23194D7F8F503FCBA4767306375C3152_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_23194D7F8F503FCBA4767306375C3152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_23194D7F8F503FCBA4767306375C3152_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_23194D7F8F503FCBA4767306375C3152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_23194D7F8F503FCBA4767306375C3152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_23194D7F8F503FCBA4767306375C3152" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_23194D7F8F503FCBA4767306375C3152" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7643789BDA40E5FBA9437306375C4602_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7643789BDA40E5FBA9437306375C4602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7643789BDA40E5FBA9437306375C4602_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7643789BDA40E5FBA9437306375C4602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7643789BDA40E5FBA9437306375C4602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7643789BDA40E5FBA9437306375C4602" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7643789BDA40E5FBA9437306375C4602" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_31BD1E020C259429503E7306375CA47E_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_31BD1E020C259429503E7306375CA47E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_31BD1E020C259429503E7306375CA47E_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_31BD1E020C259429503E7306375CA47E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_31BD1E020C259429503E7306375CA47E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_31BD1E020C259429503E7306375CA47E" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_31BD1E020C259429503E7306375CA47E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0FDD1843A41F928DCE88732E12EE2974_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0FDD1843A41F928DCE88732E12EE2974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options and common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0FDD1843A41F928DCE88732E12EE2974_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0FDD1843A41F928DCE88732E12EE2974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0FDD1843A41F928DCE88732E12EE2974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_0FDD1843A41F928DCE88732E12EE2974" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0FDD1843A41F928DCE88732E12EE2974" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B42710D53F9C66E089D47306375DE9CF_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B42710D53F9C66E089D47306375DE9CF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B42710D53F9C66E089D47306375DE9CF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B42710D53F9C66E089D47306375DE9CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_B42710D53F9C66E089D47306375DE9CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_B42710D53F9C66E089D47306375DE9CF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B42710D53F9C66E089D47306375DE9CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9785640274CCF292B6A67306375DAE9E_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9785640274CCF292B6A67306375DAE9E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9785640274CCF292B6A67306375DAE9E_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9785640274CCF292B6A67306375DAE9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9785640274CCF292B6A67306375DAE9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9785640274CCF292B6A67306375DAE9E" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9785640274CCF292B6A67306375DAE9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14CBCA56470AFC7FCAAD7306375D1C86_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14CBCA56470AFC7FCAAD7306375D1C86" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14CBCA56470AFC7FCAAD7306375D1C86_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14CBCA56470AFC7FCAAD7306375D1C86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14CBCA56470AFC7FCAAD7306375D1C86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14CBCA56470AFC7FCAAD7306375D1C86" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14CBCA56470AFC7FCAAD7306375D1C86" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93389E3DB774BCE11B7C7306375D8EB7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93389E3DB774BCE11B7C7306375D8EB7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and restricted cash, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93389E3DB774BCE11B7C7306375D8EB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93389E3DB774BCE11B7C7306375D8EB7" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93389E3DB774BCE11B7C7306375D8EB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_CB0F7693BACA472314187306375D8360_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_CB0F7693BACA472314187306375D8360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock exchanged for common stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_CB0F7693BACA472314187306375D8360_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_CB0F7693BACA472314187306375D8360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_CB0F7693BACA472314187306375D8360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_CB0F7693BACA472314187306375D8360" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_CB0F7693BACA472314187306375D8360" xlink:type="arc" />
    <link:label id="lab_alpn_IssuanceOfDebtDiscount_2E0A8CB832E35290041B7306375EE94B_terseLabel_en-US" xlink:label="lab_alpn_IssuanceOfDebtDiscount_2E0A8CB832E35290041B7306375EE94B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount in connection with issuance of debt</link:label>
    <link:label id="lab_alpn_IssuanceOfDebtDiscount_2E0A8CB832E35290041B7306375EE94B_label_en-US" xlink:label="lab_alpn_IssuanceOfDebtDiscount_2E0A8CB832E35290041B7306375EE94B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Debt Discount</link:label>
    <link:label id="lab_alpn_IssuanceOfDebtDiscount_2E0A8CB832E35290041B7306375EE94B_documentation_en-US" xlink:label="lab_alpn_IssuanceOfDebtDiscount_2E0A8CB832E35290041B7306375EE94B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of debt, discount.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IssuanceOfDebtDiscount" xlink:label="loc_alpn_IssuanceOfDebtDiscount_2E0A8CB832E35290041B7306375EE94B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_IssuanceOfDebtDiscount_2E0A8CB832E35290041B7306375EE94B" xlink:to="lab_alpn_IssuanceOfDebtDiscount_2E0A8CB832E35290041B7306375EE94B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaid_DC3A5B08F74B483DF8447306375E5489_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_DC3A5B08F74B483DF8447306375E5489" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_DC3A5B08F74B483DF8447306375E5489_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_DC3A5B08F74B483DF8447306375E5489" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_DC3A5B08F74B483DF8447306375E5489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_DC3A5B08F74B483DF8447306375E5489" xlink:to="lab_us-gaap_IncomeTaxesPaid_DC3A5B08F74B483DF8447306375E5489" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_DE777349DEEA2662E3747306375EBA4D_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_DE777349DEEA2662E3747306375EBA4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_DE777349DEEA2662E3747306375EBA4D_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_DE777349DEEA2662E3747306375EBA4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_DE777349DEEA2662E3747306375EBA4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_DE777349DEEA2662E3747306375EBA4D" xlink:to="lab_us-gaap_InterestPaidNet_DE777349DEEA2662E3747306375EBA4D" xlink:type="arc" />
    <link:label id="lab_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity_FC8FDD02DC14A7F448747306375E8D5F_terseLabel_en-US" xlink:label="lab_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity_FC8FDD02DC14A7F448747306375E8D5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclass of preferred stock warrant liability to equity</link:label>
    <link:label id="lab_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity_FC8FDD02DC14A7F448747306375E8D5F_label_en-US" xlink:label="lab_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity_FC8FDD02DC14A7F448747306375E8D5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Preferred Stock Warrant Liability To Equity</link:label>
    <link:label id="lab_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity_FC8FDD02DC14A7F448747306375E8D5F_documentation_en-US" xlink:label="lab_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity_FC8FDD02DC14A7F448747306375E8D5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification of preferred stock warrant liability to equity.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity" xlink:label="loc_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity_FC8FDD02DC14A7F448747306375E8D5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity_FC8FDD02DC14A7F448747306375E8D5F" xlink:to="lab_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity_FC8FDD02DC14A7F448747306375E8D5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4958D07B3BCB2A7F88954ED1570D05A7_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4958D07B3BCB2A7F88954ED1570D05A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4958D07B3BCB2A7F88954ED1570D05A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4958D07B3BCB2A7F88954ED1570D05A7" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4958D07B3BCB2A7F88954ED1570D05A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C1D451E47BE49CADA0D64ED1662839E7_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C1D451E47BE49CADA0D64ED1662839E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on Sale of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C1D451E47BE49CADA0D64ED1662839E7_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C1D451E47BE49CADA0D64ED1662839E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C1D451E47BE49CADA0D64ED1662839E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C1D451E47BE49CADA0D64ED1662839E7" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C1D451E47BE49CADA0D64ED1662839E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_95685FE23CD5F5482E4C4FB2E915D35E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_95685FE23CD5F5482E4C4FB2E915D35E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_95685FE23CD5F5482E4C4FB2E915D35E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_95685FE23CD5F5482E4C4FB2E915D35E" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_95685FE23CD5F5482E4C4FB2E915D35E" xlink:type="arc" />
    <link:label id="lab_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB_terseLabel_en-US" xlink:label="lab_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB_label_en-US" xlink:label="lab_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB_documentation_en-US" xlink:label="lab_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesTable" xlink:label="loc_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:to="lab_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9" xlink:type="arc" />
    <link:label id="lab_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580_terseLabel_en-US" xlink:label="lab_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nivalis Therapeutics, Inc.</link:label>
    <link:label id="lab_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580_label_en-US" xlink:label="lab_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nivalis Therapeutics Inc [Member]</link:label>
    <link:label id="lab_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580_documentation_en-US" xlink:label="lab_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nivalis Therapeutics Inc.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580" xlink:to="lab_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580" xlink:type="arc" />
    <link:label id="lab_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6_terseLabel_en-US" xlink:label="lab_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6_label_en-US" xlink:label="lab_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6_documentation_en-US" xlink:label="lab_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesLineItems" xlink:label="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="lab_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2B445E1C49D0ACD400954FB2E91E3C78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2B445E1C49D0ACD400954FB2E91E3C78" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2B445E1C49D0ACD400954FB2E91E3C78_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2B445E1C49D0ACD400954FB2E91E3C78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2B445E1C49D0ACD400954FB2E91E3C78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2B445E1C49D0ACD400954FB2E91E3C78" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2B445E1C49D0ACD400954FB2E91E3C78" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_90FD89D79BDDEDF2726A4FB2E91E28D8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_90FD89D79BDDEDF2726A4FB2E91E28D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_90FD89D79BDDEDF2726A4FB2E91E28D8_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_90FD89D79BDDEDF2726A4FB2E91E28D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_90FD89D79BDDEDF2726A4FB2E91E28D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_90FD89D79BDDEDF2726A4FB2E91E28D8" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_90FD89D79BDDEDF2726A4FB2E91E28D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_D52BA9CF30521AFDCBB04FB2E91E614C_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_D52BA9CF30521AFDCBB04FB2E91E614C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D acquired in business combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_D52BA9CF30521AFDCBB04FB2E91E614C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_D52BA9CF30521AFDCBB04FB2E91E614C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_D52BA9CF30521AFDCBB04FB2E91E614C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_D52BA9CF30521AFDCBB04FB2E91E614C" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_D52BA9CF30521AFDCBB04FB2E91E614C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent_6351B8B904EA8DA5B1AC4FB2E91E2A8E_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent_6351B8B904EA8DA5B1AC4FB2E91E2A8E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability, IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent_6351B8B904EA8DA5B1AC4FB2E91E2A8E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent_6351B8B904EA8DA5B1AC4FB2E91E2A8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent_6351B8B904EA8DA5B1AC4FB2E91E2A8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent_6351B8B904EA8DA5B1AC4FB2E91E2A8E" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent_6351B8B904EA8DA5B1AC4FB2E91E2A8E" xlink:type="arc" />
    <link:label id="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95_terseLabel_en-US" xlink:label="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D acquired in business combination, tax basis</link:label>
    <link:label id="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95_label_en-US" xlink:label="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets On Tax Basis</link:label>
    <link:label id="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95_documentation_en-US" xlink:label="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed indefinite lived intangible assets on tax basis.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis" xlink:label="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95" xlink:to="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5202224DEDEB73FBF6FE4FB2E91E5066_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5202224DEDEB73FBF6FE4FB2E91E5066" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5202224DEDEB73FBF6FE4FB2E91E5066_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5202224DEDEB73FBF6FE4FB2E91E5066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5202224DEDEB73FBF6FE4FB2E91E5066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5202224DEDEB73FBF6FE4FB2E91E5066" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5202224DEDEB73FBF6FE4FB2E91E5066" xlink:type="arc" />
    <link:label id="lab_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D_terseLabel_en-US" xlink:label="lab_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit and net operating loss carryforwards</link:label>
    <link:label id="lab_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D_label_en-US" xlink:label="lab_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit And Net Operating Loss Carryforwards</link:label>
    <link:label id="lab_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D_documentation_en-US" xlink:label="lab_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax credit and net operating loss carryforwards.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TaxCreditAndNetOperatingLossCarryforwards" xlink:label="loc_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D" xlink:to="lab_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_785DA3103FDFD27C5C544FB2E91F8186_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_785DA3103FDFD27C5C544FB2E91F8186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_785DA3103FDFD27C5C544FB2E91F8186_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_785DA3103FDFD27C5C544FB2E91F8186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_785DA3103FDFD27C5C544FB2E91F8186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_785DA3103FDFD27C5C544FB2E91F8186" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_785DA3103FDFD27C5C544FB2E91F8186" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_22C412B12ECD5E49FDE64FB2E91F32A4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_22C412B12ECD5E49FDE64FB2E91F32A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest or penalties related to unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_22C412B12ECD5E49FDE64FB2E91F32A4_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_22C412B12ECD5E49FDE64FB2E91F32A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_22C412B12ECD5E49FDE64FB2E91F32A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_22C412B12ECD5E49FDE64FB2E91F32A4" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_22C412B12ECD5E49FDE64FB2E91F32A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F067FE3C0D3BF6294CAE4F21330C90BF_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F067FE3C0D3BF6294CAE4F21330C90BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F067FE3C0D3BF6294CAE4F21330C90BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F067FE3C0D3BF6294CAE4F21330C90BF" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F067FE3C0D3BF6294CAE4F21330C90BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_427AFED376746C9B99C24F21330FA70C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_427AFED376746C9B99C24F21330FA70C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_427AFED376746C9B99C24F21330FA70C_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_427AFED376746C9B99C24F21330FA70C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_427AFED376746C9B99C24F21330FA70C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_427AFED376746C9B99C24F21330FA70C" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_427AFED376746C9B99C24F21330FA70C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7580E0954A2F0518E6644F21331058C9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7580E0954A2F0518E6644F21331058C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7580E0954A2F0518E6644F21331058C9_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7580E0954A2F0518E6644F21331058C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7580E0954A2F0518E6644F21331058C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7580E0954A2F0518E6644F21331058C9" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7580E0954A2F0518E6644F21331058C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0F4DFE3EA6AF5E04F0434F2133114D4D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0F4DFE3EA6AF5E04F0434F2133114D4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0F4DFE3EA6AF5E04F0434F2133114D4D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0F4DFE3EA6AF5E04F0434F2133114D4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0F4DFE3EA6AF5E04F0434F2133114D4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0F4DFE3EA6AF5E04F0434F2133114D4D" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0F4DFE3EA6AF5E04F0434F2133114D4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2C97E8C3E7584801EF704F213311D9F3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2C97E8C3E7584801EF704F213311D9F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2C97E8C3E7584801EF704F213311D9F3_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2C97E8C3E7584801EF704F213311D9F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2C97E8C3E7584801EF704F213311D9F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2C97E8C3E7584801EF704F213311D9F3" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2C97E8C3E7584801EF704F213311D9F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_37435BEEF51206D8AA594F2133110169_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_37435BEEF51206D8AA594F2133110169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_37435BEEF51206D8AA594F2133110169_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_37435BEEF51206D8AA594F2133110169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_37435BEEF51206D8AA594F2133110169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_37435BEEF51206D8AA594F2133110169" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_37435BEEF51206D8AA594F2133110169" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_70AC2D65EA19D14A94E84F2133119217_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_70AC2D65EA19D14A94E84F2133119217" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_70AC2D65EA19D14A94E84F2133119217_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_70AC2D65EA19D14A94E84F2133119217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_70AC2D65EA19D14A94E84F2133119217" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_70AC2D65EA19D14A94E84F2133119217" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_70AC2D65EA19D14A94E84F2133119217" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7CB9D439E651646AB49C82E6ED485537_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_7CB9D439E651646AB49C82E6ED485537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7CB9D439E651646AB49C82E6ED485537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7CB9D439E651646AB49C82E6ED485537" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_7CB9D439E651646AB49C82E6ED485537" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4E2EFBD5A1485A2311C382E6FD1EB03B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_4E2EFBD5A1485A2311C382E6FD1EB03B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4E2EFBD5A1485A2311C382E6FD1EB03B_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_4E2EFBD5A1485A2311C382E6FD1EB03B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4E2EFBD5A1485A2311C382E6FD1EB03B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_4E2EFBD5A1485A2311C382E6FD1EB03B" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_4E2EFBD5A1485A2311C382E6FD1EB03B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_457053605E9AE27FC27432379B79D623_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_457053605E9AE27FC27432379B79D623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_457053605E9AE27FC27432379B79D623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_457053605E9AE27FC27432379B79D623" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_457053605E9AE27FC27432379B79D623" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_11A11A51B81AEC5BF37832379B79597D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_11A11A51B81AEC5BF37832379B79597D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_11A11A51B81AEC5BF37832379B79597D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_11A11A51B81AEC5BF37832379B79597D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_11A11A51B81AEC5BF37832379B79597D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_11A11A51B81AEC5BF37832379B79597D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_11A11A51B81AEC5BF37832379B79597D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2" xlink:to="lab_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_205AD37CCE8386F00F820F55124A83B3_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_205AD37CCE8386F00F820F55124A83B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_205AD37CCE8386F00F820F55124A83B3_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_205AD37CCE8386F00F820F55124A83B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_205AD37CCE8386F00F820F55124A83B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_205AD37CCE8386F00F820F55124A83B3" xlink:to="lab_us-gaap_MoneyMarketFundsMember_205AD37CCE8386F00F820F55124A83B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_721B3AE1D97F06C101DC0F55124ACE8A_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_721B3AE1D97F06C101DC0F55124ACE8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_721B3AE1D97F06C101DC0F55124ACE8A_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_721B3AE1D97F06C101DC0F55124ACE8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_721B3AE1D97F06C101DC0F55124ACE8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_721B3AE1D97F06C101DC0F55124ACE8A" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_721B3AE1D97F06C101DC0F55124ACE8A" xlink:type="arc" />
    <link:label id="lab_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9_terseLabel_en-US" xlink:label="lab_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities and commercial paper</link:label>
    <link:label id="lab_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9_label_en-US" xlink:label="lab_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities And Commercial Paper [Member]</link:label>
    <link:label id="lab_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9_documentation_en-US" xlink:label="lab_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities and commercial paper.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CorporateDebtSecuritiesAndCommercialPaperMember" xlink:label="loc_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9" xlink:to="lab_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83A1C67B7ECDBB50D6A00F55124B23EE_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83A1C67B7ECDBB50D6A00F55124B23EE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83A1C67B7ECDBB50D6A00F55124B23EE_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83A1C67B7ECDBB50D6A00F55124B23EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83A1C67B7ECDBB50D6A00F55124B23EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83A1C67B7ECDBB50D6A00F55124B23EE" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83A1C67B7ECDBB50D6A00F55124B23EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E4C7253851CBB693A7910F55124B2BAF_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E4C7253851CBB693A7910F55124B2BAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E4C7253851CBB693A7910F55124B2BAF_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E4C7253851CBB693A7910F55124B2BAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E4C7253851CBB693A7910F55124B2BAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E4C7253851CBB693A7910F55124B2BAF" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E4C7253851CBB693A7910F55124B2BAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BFA39D132679160E82F10F55124B4FF9_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BFA39D132679160E82F10F55124B4FF9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BFA39D132679160E82F10F55124B4FF9_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BFA39D132679160E82F10F55124B4FF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BFA39D132679160E82F10F55124B4FF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BFA39D132679160E82F10F55124B4FF9" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BFA39D132679160E82F10F55124B4FF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_AAC9AC1C2E0E5F6AA3470F55124B3094_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_AAC9AC1C2E0E5F6AA3470F55124B3094" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair market value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_AAC9AC1C2E0E5F6AA3470F55124B3094_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_AAC9AC1C2E0E5F6AA3470F55124B3094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_AAC9AC1C2E0E5F6AA3470F55124B3094" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_AAC9AC1C2E0E5F6AA3470F55124B3094" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_AAC9AC1C2E0E5F6AA3470F55124B3094" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_9DBA3160CF495D6561D20F55124CEFF2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_9DBA3160CF495D6561D20F55124CEFF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gains and losses on securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_9DBA3160CF495D6561D20F55124CEFF2_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_9DBA3160CF495D6561D20F55124CEFF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_9DBA3160CF495D6561D20F55124CEFF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_9DBA3160CF495D6561D20F55124CEFF2" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_9DBA3160CF495D6561D20F55124CEFF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_21EC833314B453F84A31730634D3F8E0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_21EC833314B453F84A31730634D3F8E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_21EC833314B453F84A31730634D3F8E0_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_21EC833314B453F84A31730634D3F8E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_21EC833314B453F84A31730634D3F8E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_21EC833314B453F84A31730634D3F8E0" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_21EC833314B453F84A31730634D3F8E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_FB24EA1FDFB7D0AEDF3D730634D49365_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_FB24EA1FDFB7D0AEDF3D730634D49365" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. - Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_FB24EA1FDFB7D0AEDF3D730634D49365_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_FB24EA1FDFB7D0AEDF3D730634D49365" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_FB24EA1FDFB7D0AEDF3D730634D49365" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_FB24EA1FDFB7D0AEDF3D730634D49365" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_FB24EA1FDFB7D0AEDF3D730634D49365" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E8A15F05C5C8F5012C06730634D449CE_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E8A15F05C5C8F5012C06730634D449CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. - State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E8A15F05C5C8F5012C06730634D449CE_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E8A15F05C5C8F5012C06730634D449CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E8A15F05C5C8F5012C06730634D449CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E8A15F05C5C8F5012C06730634D449CE" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E8A15F05C5C8F5012C06730634D449CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_D1E739678F304EB767C3730634D4030F_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_D1E739678F304EB767C3730634D4030F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_D1E739678F304EB767C3730634D4030F_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_D1E739678F304EB767C3730634D4030F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_D1E739678F304EB767C3730634D4030F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_D1E739678F304EB767C3730634D4030F" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_D1E739678F304EB767C3730634D4030F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_AE5D3347D035A9D907B6730634D444A9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_AE5D3347D035A9D907B6730634D444A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_AE5D3347D035A9D907B6730634D444A9_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_AE5D3347D035A9D907B6730634D444A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_AE5D3347D035A9D907B6730634D444A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_AE5D3347D035A9D907B6730634D444A9" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_AE5D3347D035A9D907B6730634D444A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_99F0783EA664EC40DA4F730634D4E53B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_99F0783EA664EC40DA4F730634D4E53B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. - Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_99F0783EA664EC40DA4F730634D4E53B_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_99F0783EA664EC40DA4F730634D4E53B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_99F0783EA664EC40DA4F730634D4E53B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_99F0783EA664EC40DA4F730634D4E53B" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_99F0783EA664EC40DA4F730634D4E53B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_FADE50A347CC7A5F2D34730634D51D71_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_FADE50A347CC7A5F2D34730634D51D71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. - State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_FADE50A347CC7A5F2D34730634D51D71_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_FADE50A347CC7A5F2D34730634D51D71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_FADE50A347CC7A5F2D34730634D51D71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_FADE50A347CC7A5F2D34730634D51D71" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_FADE50A347CC7A5F2D34730634D51D71" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_D682F5457BB1833DA9C4730634D539F9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_D682F5457BB1833DA9C4730634D539F9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_D682F5457BB1833DA9C4730634D539F9_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_D682F5457BB1833DA9C4730634D539F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_D682F5457BB1833DA9C4730634D539F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_D682F5457BB1833DA9C4730634D539F9" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_D682F5457BB1833DA9C4730634D539F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_CE14C5FBE160A395D5DB730634D5007C_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_CE14C5FBE160A395D5DB730634D5007C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CE14C5FBE160A395D5DB730634D5007C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_CE14C5FBE160A395D5DB730634D5007C" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_CE14C5FBE160A395D5DB730634D5007C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_18DD20B55D08DC8AA72932379BB5F0D8_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_18DD20B55D08DC8AA72932379BB5F0D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_18DD20B55D08DC8AA72932379BB5F0D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_18DD20B55D08DC8AA72932379BB5F0D8" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_18DD20B55D08DC8AA72932379BB5F0D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8417AB8128F95EBD4B5332379BB56A04_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8417AB8128F95EBD4B5332379BB56A04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8417AB8128F95EBD4B5332379BB56A04_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8417AB8128F95EBD4B5332379BB56A04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8417AB8128F95EBD4B5332379BB56A04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8417AB8128F95EBD4B5332379BB56A04" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8417AB8128F95EBD4B5332379BB56A04" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureTextBlockSupplementAbstract_167367EBFE6B0B2C6EBE4F12F2927ED9_label_en-US" xlink:label="lab_us-gaap_DisclosureTextBlockSupplementAbstract_167367EBFE6B0B2C6EBE4F12F2927ED9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_167367EBFE6B0B2C6EBE4F12F2927ED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_167367EBFE6B0B2C6EBE4F12F2927ED9" xlink:to="lab_us-gaap_DisclosureTextBlockSupplementAbstract_167367EBFE6B0B2C6EBE4F12F2927ED9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_18964F997806ADC1AAA14F12F2965858_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_18964F997806ADC1AAA14F12F2965858" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Consolidated Balance Sheets Information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_18964F997806ADC1AAA14F12F2965858_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_18964F997806ADC1AAA14F12F2965858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_18964F997806ADC1AAA14F12F2965858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_18964F997806ADC1AAA14F12F2965858" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_18964F997806ADC1AAA14F12F2965858" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_45B0BB41927C69CCB1787819D839FF7D_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_45B0BB41927C69CCB1787819D839FF7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_45B0BB41927C69CCB1787819D839FF7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_45B0BB41927C69CCB1787819D839FF7D" xlink:to="lab_us-gaap_DebtDisclosureAbstract_45B0BB41927C69CCB1787819D839FF7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E" xlink:to="lab_us-gaap_DebtInstrumentTable_5DDD40540237B289EC3E7819D845994E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0376E3679D62647857A87819D845CFEE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_0376E3679D62647857A87819D845CFEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0376E3679D62647857A87819D845CFEE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_0376E3679D62647857A87819D845CFEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0376E3679D62647857A87819D845CFEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_0376E3679D62647857A87819D845CFEE" xlink:to="lab_us-gaap_DebtInstrumentAxis_0376E3679D62647857A87819D845CFEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_F2F6D5B71AE3B52CCEF67819D845E0EB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_F2F6D5B71AE3B52CCEF67819D845E0EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_F2F6D5B71AE3B52CCEF67819D845E0EB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_F2F6D5B71AE3B52CCEF67819D845E0EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F2F6D5B71AE3B52CCEF67819D845E0EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F2F6D5B71AE3B52CCEF67819D845E0EB" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_F2F6D5B71AE3B52CCEF67819D845E0EB" xlink:type="arc" />
    <link:label id="lab_alpn_TermLoanMember_D6AD1A323B8CCFB97A137819D845BA7E_terseLabel_en-US" xlink:label="lab_alpn_TermLoanMember_D6AD1A323B8CCFB97A137819D845BA7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_alpn_TermLoanMember_D6AD1A323B8CCFB97A137819D845BA7E_label_en-US" xlink:label="lab_alpn_TermLoanMember_D6AD1A323B8CCFB97A137819D845BA7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_alpn_TermLoanMember_D6AD1A323B8CCFB97A137819D845BA7E_documentation_en-US" xlink:label="lab_alpn_TermLoanMember_D6AD1A323B8CCFB97A137819D845BA7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term loan.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TermLoanMember" xlink:label="loc_alpn_TermLoanMember_D6AD1A323B8CCFB97A137819D845BA7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_TermLoanMember_D6AD1A323B8CCFB97A137819D845BA7E" xlink:to="lab_alpn_TermLoanMember_D6AD1A323B8CCFB97A137819D845BA7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_8C599E6330A1A00ABB5C7819D8463176_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_8C599E6330A1A00ABB5C7819D8463176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_8C599E6330A1A00ABB5C7819D8463176_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_8C599E6330A1A00ABB5C7819D8463176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_8C599E6330A1A00ABB5C7819D8463176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_8C599E6330A1A00ABB5C7819D8463176" xlink:to="lab_us-gaap_VariableRateAxis_8C599E6330A1A00ABB5C7819D8463176" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_0E7D4CF125A2701A9EFA7819D8466F66_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_0E7D4CF125A2701A9EFA7819D8466F66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_0E7D4CF125A2701A9EFA7819D8466F66_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_0E7D4CF125A2701A9EFA7819D8466F66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_0E7D4CF125A2701A9EFA7819D8466F66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_0E7D4CF125A2701A9EFA7819D8466F66" xlink:to="lab_us-gaap_VariableRateDomain_0E7D4CF125A2701A9EFA7819D8466F66" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrimeRateMember_9773922AECD793A16B397819D846AFEB_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember_9773922AECD793A16B397819D846AFEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_9773922AECD793A16B397819D846AFEB_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember_9773922AECD793A16B397819D846AFEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_9773922AECD793A16B397819D846AFEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember_9773922AECD793A16B397819D846AFEB" xlink:to="lab_us-gaap_PrimeRateMember_9773922AECD793A16B397819D846AFEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_E96B1B253A8223570E277819D84CBAC4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_E96B1B253A8223570E277819D84CBAC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_E96B1B253A8223570E277819D84CBAC4_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_E96B1B253A8223570E277819D84CBAC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_E96B1B253A8223570E277819D84CBAC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_E96B1B253A8223570E277819D84CBAC4" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_E96B1B253A8223570E277819D84CBAC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_A6CCE150A5E15A0A44DE7819D84CF61C_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_A6CCE150A5E15A0A44DE7819D84CF61C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_A6CCE150A5E15A0A44DE7819D84CF61C_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_A6CCE150A5E15A0A44DE7819D84CF61C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_A6CCE150A5E15A0A44DE7819D84CF61C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A6CCE150A5E15A0A44DE7819D84CF61C" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_A6CCE150A5E15A0A44DE7819D84CF61C" xlink:type="arc" />
    <link:label id="lab_alpn_SeriesAOnePreferredStockWarrantsMember_6BB9BF5A65166515C3027819D84D62E1_terseLabel_en-US" xlink:label="lab_alpn_SeriesAOnePreferredStockWarrantsMember_6BB9BF5A65166515C3027819D84D62E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 Preferred Stock Warrants</link:label>
    <link:label id="lab_alpn_SeriesAOnePreferredStockWarrantsMember_6BB9BF5A65166515C3027819D84D62E1_label_en-US" xlink:label="lab_alpn_SeriesAOnePreferredStockWarrantsMember_6BB9BF5A65166515C3027819D84D62E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A One Preferred Stock Warrants [Member]</link:label>
    <link:label id="lab_alpn_SeriesAOnePreferredStockWarrantsMember_6BB9BF5A65166515C3027819D84D62E1_documentation_en-US" xlink:label="lab_alpn_SeriesAOnePreferredStockWarrantsMember_6BB9BF5A65166515C3027819D84D62E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A-1 preferred stock warrants.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SeriesAOnePreferredStockWarrantsMember" xlink:label="loc_alpn_SeriesAOnePreferredStockWarrantsMember_6BB9BF5A65166515C3027819D84D62E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_SeriesAOnePreferredStockWarrantsMember_6BB9BF5A65166515C3027819D84D62E1" xlink:to="lab_alpn_SeriesAOnePreferredStockWarrantsMember_6BB9BF5A65166515C3027819D84D62E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_FEAB232B48FDACE1B2A27819D84D0F53_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_FEAB232B48FDACE1B2A27819D84D0F53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_FEAB232B48FDACE1B2A27819D84D0F53_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_FEAB232B48FDACE1B2A27819D84D0F53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_FEAB232B48FDACE1B2A27819D84D0F53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_FEAB232B48FDACE1B2A27819D84D0F53" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_FEAB232B48FDACE1B2A27819D84D0F53" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_DB3C1405F7B07F24ECFF7819D84D23FF_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_DB3C1405F7B07F24ECFF7819D84D23FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_DB3C1405F7B07F24ECFF7819D84D23FF_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_DB3C1405F7B07F24ECFF7819D84D23FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DB3C1405F7B07F24ECFF7819D84D23FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_DB3C1405F7B07F24ECFF7819D84D23FF" xlink:to="lab_us-gaap_EquityComponentDomain_DB3C1405F7B07F24ECFF7819D84D23FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_EB41E5BD1A163A2BB88A7819D84E6AA2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_EB41E5BD1A163A2BB88A7819D84E6AA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_EB41E5BD1A163A2BB88A7819D84E6AA2_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_EB41E5BD1A163A2BB88A7819D84E6AA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EB41E5BD1A163A2BB88A7819D84E6AA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_EB41E5BD1A163A2BB88A7819D84E6AA2" xlink:to="lab_us-gaap_CommonStockMember_EB41E5BD1A163A2BB88A7819D84E6AA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:to="lab_us-gaap_DebtInstrumentLineItems_C12FBFA1290FB30AB8617819D84E090B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_95ADDBB14D5A705502F27819D84E33DA_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_95ADDBB14D5A705502F27819D84E33DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Term loan drew down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_95ADDBB14D5A705502F27819D84E33DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_95ADDBB14D5A705502F27819D84E33DA" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_95ADDBB14D5A705502F27819D84E33DA" xlink:type="arc" />
    <link:label id="lab_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_8E3FB559145003C5F1897819D84E30C9_terseLabel_en-US" xlink:label="lab_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_8E3FB559145003C5F1897819D84E30C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of equal monthly payments</link:label>
    <link:label id="lab_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_8E3FB559145003C5F1897819D84E30C9_label_en-US" xlink:label="lab_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_8E3FB559145003C5F1897819D84E30C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Number Of Equal Monthly Payment</link:label>
    <link:label id="lab_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_8E3FB559145003C5F1897819D84E30C9_documentation_en-US" xlink:label="lab_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_8E3FB559145003C5F1897819D84E30C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument number of equal monthly payment.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DebtInstrumentNumberOfEqualMonthlyPayment" xlink:label="loc_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_8E3FB559145003C5F1897819D84E30C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_8E3FB559145003C5F1897819D84E30C9" xlink:to="lab_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_8E3FB559145003C5F1897819D84E30C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5288150DA6E84AA9C86F7819D84F8B11_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5288150DA6E84AA9C86F7819D84F8B11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument variable interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5288150DA6E84AA9C86F7819D84F8B11_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5288150DA6E84AA9C86F7819D84F8B11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5288150DA6E84AA9C86F7819D84F8B11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5288150DA6E84AA9C86F7819D84F8B11" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5288150DA6E84AA9C86F7819D84F8B11" xlink:type="arc" />
    <link:label id="lab_alpn_DebtInstrumentFinalPaymentPercentage_225713C883A61281A9B07819D84F9368_terseLabel_en-US" xlink:label="lab_alpn_DebtInstrumentFinalPaymentPercentage_225713C883A61281A9B07819D84F9368" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt final payment fee percentage</link:label>
    <link:label id="lab_alpn_DebtInstrumentFinalPaymentPercentage_225713C883A61281A9B07819D84F9368_label_en-US" xlink:label="lab_alpn_DebtInstrumentFinalPaymentPercentage_225713C883A61281A9B07819D84F9368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Final Payment Percentage</link:label>
    <link:label id="lab_alpn_DebtInstrumentFinalPaymentPercentage_225713C883A61281A9B07819D84F9368_documentation_en-US" xlink:label="lab_alpn_DebtInstrumentFinalPaymentPercentage_225713C883A61281A9B07819D84F9368" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument final payment percentage.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DebtInstrumentFinalPaymentPercentage" xlink:label="loc_alpn_DebtInstrumentFinalPaymentPercentage_225713C883A61281A9B07819D84F9368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_DebtInstrumentFinalPaymentPercentage_225713C883A61281A9B07819D84F9368" xlink:to="lab_alpn_DebtInstrumentFinalPaymentPercentage_225713C883A61281A9B07819D84F9368" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_85E9AE100E9EAC887A6F7819D84F85F3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_85E9AE100E9EAC887A6F7819D84F85F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt final payment fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_85E9AE100E9EAC887A6F7819D84F85F3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_85E9AE100E9EAC887A6F7819D84F85F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_85E9AE100E9EAC887A6F7819D84F85F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_85E9AE100E9EAC887A6F7819D84F85F3" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_85E9AE100E9EAC887A6F7819D84F85F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF2DDECA977FF1B0970C7819D84F9BB1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF2DDECA977FF1B0970C7819D84F9BB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued, exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF2DDECA977FF1B0970C7819D84F9BB1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF2DDECA977FF1B0970C7819D84F9BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF2DDECA977FF1B0970C7819D84F9BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF2DDECA977FF1B0970C7819D84F9BB1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DF2DDECA977FF1B0970C7819D84F9BB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_603C4A36053DBDF747F17819D84F9354_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_603C4A36053DBDF747F17819D84F9354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_603C4A36053DBDF747F17819D84F9354_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_603C4A36053DBDF747F17819D84F9354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_603C4A36053DBDF747F17819D84F9354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_603C4A36053DBDF747F17819D84F9354" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_603C4A36053DBDF747F17819D84F9354" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_D41B7CC3E007560A68807819D84F489D_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_D41B7CC3E007560A68807819D84F489D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable for shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_D41B7CC3E007560A68807819D84F489D_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_D41B7CC3E007560A68807819D84F489D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_D41B7CC3E007560A68807819D84F489D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_D41B7CC3E007560A68807819D84F489D" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_D41B7CC3E007560A68807819D84F489D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_6033FCAF609B792813F87819D8506A11_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_6033FCAF609B792813F87819D8506A11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_6033FCAF609B792813F87819D8506A11_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_6033FCAF609B792813F87819D8506A11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6033FCAF609B792813F87819D8506A11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_6033FCAF609B792813F87819D8506A11" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_6033FCAF609B792813F87819D8506A11" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_C3D6FFD08767D027305C7819D850A2CC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_C3D6FFD08767D027305C7819D850A2CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_C3D6FFD08767D027305C7819D850A2CC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_C3D6FFD08767D027305C7819D850A2CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_C3D6FFD08767D027305C7819D850A2CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_C3D6FFD08767D027305C7819D850A2CC" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_C3D6FFD08767D027305C7819D850A2CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_F4F0E1DC4F9B55507B27736A7EF43A47_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_F4F0E1DC4F9B55507B27736A7EF43A47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_F4F0E1DC4F9B55507B27736A7EF43A47_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_F4F0E1DC4F9B55507B27736A7EF43A47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_F4F0E1DC4F9B55507B27736A7EF43A47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_F4F0E1DC4F9B55507B27736A7EF43A47" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_F4F0E1DC4F9B55507B27736A7EF43A47" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6C478B448605260682A8736ABA4CC735_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6C478B448605260682A8736ABA4CC735" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6C478B448605260682A8736ABA4CC735_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6C478B448605260682A8736ABA4CC735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6C478B448605260682A8736ABA4CC735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6C478B448605260682A8736ABA4CC735" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6C478B448605260682A8736ABA4CC735" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D24D50C495DEA632D1F2736AEDB88F6F_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D24D50C495DEA632D1F2736AEDB88F6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D24D50C495DEA632D1F2736AEDB88F6F_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D24D50C495DEA632D1F2736AEDB88F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D24D50C495DEA632D1F2736AEDB88F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D24D50C495DEA632D1F2736AEDB88F6F" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D24D50C495DEA632D1F2736AEDB88F6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_54378B65D1E1AED5623D736B245A258E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_54378B65D1E1AED5623D736B245A258E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_54378B65D1E1AED5623D736B245A258E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_54378B65D1E1AED5623D736B245A258E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_54378B65D1E1AED5623D736B245A258E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_54378B65D1E1AED5623D736B245A258E" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_54378B65D1E1AED5623D736B245A258E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1CC4ED9F615C2FE932AC736B51737FF5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1CC4ED9F615C2FE932AC736B51737FF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1CC4ED9F615C2FE932AC736B51737FF5_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1CC4ED9F615C2FE932AC736B51737FF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1CC4ED9F615C2FE932AC736B51737FF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1CC4ED9F615C2FE932AC736B51737FF5" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1CC4ED9F615C2FE932AC736B51737FF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_58DA8F264334CD722037736B927C4EA7_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_58DA8F264334CD722037736B927C4EA7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future principal payments</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_58DA8F264334CD722037736B927C4EA7_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_58DA8F264334CD722037736B927C4EA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_58DA8F264334CD722037736B927C4EA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_58DA8F264334CD722037736B927C4EA7" xlink:to="lab_us-gaap_LongTermDebt_58DA8F264334CD722037736B927C4EA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_E6F1A40A7480300C6AA44EC065E73BA6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_E6F1A40A7480300C6AA44EC065E73BA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Nivalis common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_E6F1A40A7480300C6AA44EC065E73BA6_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_E6F1A40A7480300C6AA44EC065E73BA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_E6F1A40A7480300C6AA44EC065E73BA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_E6F1A40A7480300C6AA44EC065E73BA6" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_E6F1A40A7480300C6AA44EC065E73BA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_12A162A063FD58D0BD6D4EC065E79AEF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_12A162A063FD58D0BD6D4EC065E79AEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per share fair value of Nivalis common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_12A162A063FD58D0BD6D4EC065E79AEF_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_12A162A063FD58D0BD6D4EC065E79AEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_12A162A063FD58D0BD6D4EC065E79AEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_12A162A063FD58D0BD6D4EC065E79AEF" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_12A162A063FD58D0BD6D4EC065E79AEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A7EE53E73E1F0E55BD594EC065E88C2F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A7EE53E73E1F0E55BD594EC065E88C2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Nivalis stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A7EE53E73E1F0E55BD594EC065E88C2F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A7EE53E73E1F0E55BD594EC065E88C2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A7EE53E73E1F0E55BD594EC065E88C2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A7EE53E73E1F0E55BD594EC065E88C2F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A7EE53E73E1F0E55BD594EC065E88C2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D0793311915BD31E4C354EC065E87437_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D0793311915BD31E4C354EC065E87437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average per share fair value of Nivalis stock options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D0793311915BD31E4C354EC065E87437_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D0793311915BD31E4C354EC065E87437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D0793311915BD31E4C354EC065E87437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D0793311915BD31E4C354EC065E87437" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D0793311915BD31E4C354EC065E87437" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2036DCAE9ABD9547EFBC4EC065E8B0DC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2036DCAE9ABD9547EFBC4EC065E8B0DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2036DCAE9ABD9547EFBC4EC065E8B0DC_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2036DCAE9ABD9547EFBC4EC065E8B0DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2036DCAE9ABD9547EFBC4EC065E8B0DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2036DCAE9ABD9547EFBC4EC065E8B0DC" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2036DCAE9ABD9547EFBC4EC065E8B0DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A10BECAEB42B1AE49CD673692A7AE778_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A10BECAEB42B1AE49CD673692A7AE778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A10BECAEB42B1AE49CD673692A7AE778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A10BECAEB42B1AE49CD673692A7AE778" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A10BECAEB42B1AE49CD673692A7AE778" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6A34FB15C6F42FFFD68D73692A7BDF75_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6A34FB15C6F42FFFD68D73692A7BDF75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6A34FB15C6F42FFFD68D73692A7BDF75_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6A34FB15C6F42FFFD68D73692A7BDF75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6A34FB15C6F42FFFD68D73692A7BDF75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6A34FB15C6F42FFFD68D73692A7BDF75" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6A34FB15C6F42FFFD68D73692A7BDF75" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_CA45D6589247AB2916DB4EC17DFDBAF2_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_CA45D6589247AB2916DB4EC17DFDBAF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CA45D6589247AB2916DB4EC17DFDBAF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CA45D6589247AB2916DB4EC17DFDBAF2" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_CA45D6589247AB2916DB4EC17DFDBAF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_4674BF9EE74B959BD37E4EC1BA9441AD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_4674BF9EE74B959BD37E4EC1BA9441AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_4674BF9EE74B959BD37E4EC1BA9441AD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_4674BF9EE74B959BD37E4EC1BA9441AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_4674BF9EE74B959BD37E4EC1BA9441AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_4674BF9EE74B959BD37E4EC1BA9441AD" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_4674BF9EE74B959BD37E4EC1BA9441AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_BC3EFC1DE8969520BF7D4EE70582B07F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_BC3EFC1DE8969520BF7D4EE70582B07F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_BC3EFC1DE8969520BF7D4EE70582B07F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_BC3EFC1DE8969520BF7D4EE70582B07F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_BC3EFC1DE8969520BF7D4EE70582B07F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_BC3EFC1DE8969520BF7D4EE70582B07F" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_BC3EFC1DE8969520BF7D4EE70582B07F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredOfferingCosts_B9405AD1CE5585582D9977C7C9A9EC96_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_B9405AD1CE5585582D9977C7C9A9EC96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_B9405AD1CE5585582D9977C7C9A9EC96_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_B9405AD1CE5585582D9977C7C9A9EC96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_B9405AD1CE5585582D9977C7C9A9EC96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts_B9405AD1CE5585582D9977C7C9A9EC96" xlink:to="lab_us-gaap_DeferredOfferingCosts_B9405AD1CE5585582D9977C7C9A9EC96" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidInsurance_38535B6D4900B513A32577C4DDAC4D8A_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance_38535B6D4900B513A32577C4DDAC4D8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_38535B6D4900B513A32577C4DDAC4D8A_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance_38535B6D4900B513A32577C4DDAC4D8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_38535B6D4900B513A32577C4DDAC4D8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance_38535B6D4900B513A32577C4DDAC4D8A" xlink:to="lab_us-gaap_PrepaidInsurance_38535B6D4900B513A32577C4DDAC4D8A" xlink:type="arc" />
    <link:label id="lab_alpn_PrepaidResearchAndDevelopment_B0CE4B4BBC3D1A32013577C4DDAC44D3_terseLabel_en-US" xlink:label="lab_alpn_PrepaidResearchAndDevelopment_B0CE4B4BBC3D1A32013577C4DDAC44D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label id="lab_alpn_PrepaidResearchAndDevelopment_B0CE4B4BBC3D1A32013577C4DDAC44D3_label_en-US" xlink:label="lab_alpn_PrepaidResearchAndDevelopment_B0CE4B4BBC3D1A32013577C4DDAC44D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Research And Development</link:label>
    <link:label id="lab_alpn_PrepaidResearchAndDevelopment_B0CE4B4BBC3D1A32013577C4DDAC44D3_documentation_en-US" xlink:label="lab_alpn_PrepaidResearchAndDevelopment_B0CE4B4BBC3D1A32013577C4DDAC44D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid research and development.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PrepaidResearchAndDevelopment" xlink:label="loc_alpn_PrepaidResearchAndDevelopment_B0CE4B4BBC3D1A32013577C4DDAC44D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_PrepaidResearchAndDevelopment_B0CE4B4BBC3D1A32013577C4DDAC44D3" xlink:to="lab_alpn_PrepaidResearchAndDevelopment_B0CE4B4BBC3D1A32013577C4DDAC44D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_B041045D0E2DA3E83C4077C4DDAC44DF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent_B041045D0E2DA3E83C4077C4DDAC44DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_B041045D0E2DA3E83C4077C4DDAC44DF_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent_B041045D0E2DA3E83C4077C4DDAC44DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_B041045D0E2DA3E83C4077C4DDAC44DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent_B041045D0E2DA3E83C4077C4DDAC44DF" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent_B041045D0E2DA3E83C4077C4DDAC44DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_D0FB03C3C4EB524E571077C4DDAC2D48_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_D0FB03C3C4EB524E571077C4DDAC2D48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_D0FB03C3C4EB524E571077C4DDAC2D48_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_D0FB03C3C4EB524E571077C4DDAC2D48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_D0FB03C3C4EB524E571077C4DDAC2D48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent_D0FB03C3C4EB524E571077C4DDAC2D48" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent_D0FB03C3C4EB524E571077C4DDAC2D48" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DE155C5FE73E57DA7D8277C4DDAC8FF0_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DE155C5FE73E57DA7D8277C4DDAC8FF0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DE155C5FE73E57DA7D8277C4DDAC8FF0_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DE155C5FE73E57DA7D8277C4DDAC8FF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DE155C5FE73E57DA7D8277C4DDAC8FF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DE155C5FE73E57DA7D8277C4DDAC8FF0" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DE155C5FE73E57DA7D8277C4DDAC8FF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9284922247D4240588CE91664FCAECC9_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_9284922247D4240588CE91664FCAECC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9284922247D4240588CE91664FCAECC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9284922247D4240588CE91664FCAECC9" xlink:to="lab_us-gaap_EarningsPerShareAbstract_9284922247D4240588CE91664FCAECC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_1C5FC82198032A69D4D691664FCB4404_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_1C5FC82198032A69D4D691664FCB4404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_1C5FC82198032A69D4D691664FCB4404_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_1C5FC82198032A69D4D691664FCB4404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1C5FC82198032A69D4D691664FCB4404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_1C5FC82198032A69D4D691664FCB4404" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_1C5FC82198032A69D4D691664FCB4404" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_DC5014C70D7B8E94E63691664FCCEBD7_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_DC5014C70D7B8E94E63691664FCCEBD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_DC5014C70D7B8E94E63691664FCCEBD7_label_en-US" xlink:label="lab_us-gaap_WarrantMember_DC5014C70D7B8E94E63691664FCCEBD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_DC5014C70D7B8E94E63691664FCCEBD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_DC5014C70D7B8E94E63691664FCCEBD7" xlink:to="lab_us-gaap_WarrantMember_DC5014C70D7B8E94E63691664FCCEBD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2B8B25A320C4A3DAD0E491664FCC624F_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_2B8B25A320C4A3DAD0E491664FCC624F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2B8B25A320C4A3DAD0E491664FCC624F_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_2B8B25A320C4A3DAD0E491664FCC624F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2B8B25A320C4A3DAD0E491664FCC624F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_2B8B25A320C4A3DAD0E491664FCC624F" xlink:to="lab_us-gaap_EmployeeStockOptionMember_2B8B25A320C4A3DAD0E491664FCC624F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9E2C4E58331E4F421E4C91664FCC0F3E_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9E2C4E58331E4F421E4C91664FCC0F3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9E2C4E58331E4F421E4C91664FCC0F3E_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9E2C4E58331E4F421E4C91664FCC0F3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9E2C4E58331E4F421E4C91664FCC0F3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9E2C4E58331E4F421E4C91664FCC0F3E" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9E2C4E58331E4F421E4C91664FCC0F3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5076078726D31219FECD32379AB4F10F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5076078726D31219FECD32379AB4F10F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5076078726D31219FECD32379AB4F10F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5076078726D31219FECD32379AB4F10F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5076078726D31219FECD32379AB4F10F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5076078726D31219FECD32379AB4F10F" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5076078726D31219FECD32379AB4F10F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_C6316549BE51044A1F3832379AB48E84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_C6316549BE51044A1F3832379AB48E84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_C6316549BE51044A1F3832379AB48E84_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_C6316549BE51044A1F3832379AB48E84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_C6316549BE51044A1F3832379AB48E84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_C6316549BE51044A1F3832379AB48E84" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_C6316549BE51044A1F3832379AB48E84" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_38890359B4506528D2A332379AB488A0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_38890359B4506528D2A332379AB488A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_38890359B4506528D2A332379AB488A0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_38890359B4506528D2A332379AB488A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_38890359B4506528D2A332379AB488A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_38890359B4506528D2A332379AB488A0" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_38890359B4506528D2A332379AB488A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_C07E9E90A753E95AFFF332379AB495C5_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_C07E9E90A753E95AFFF332379AB495C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Net Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_C07E9E90A753E95AFFF332379AB495C5_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_C07E9E90A753E95AFFF332379AB495C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_C07E9E90A753E95AFFF332379AB495C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_C07E9E90A753E95AFFF332379AB495C5" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_C07E9E90A753E95AFFF332379AB495C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_230A7B8DBCDFC3B1A7E932379AB40DD8_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_230A7B8DBCDFC3B1A7E932379AB40DD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Net Research and Development Tax Credit Carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_230A7B8DBCDFC3B1A7E932379AB40DD8_label_en-US" xlink:label="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_230A7B8DBCDFC3B1A7E932379AB40DD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Tax Credit Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:label="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_230A7B8DBCDFC3B1A7E932379AB40DD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_230A7B8DBCDFC3B1A7E932379AB40DD8" xlink:to="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_230A7B8DBCDFC3B1A7E932379AB40DD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_EE42545F6138BDF9127432379AB45501_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_EE42545F6138BDF9127432379AB45501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Unrecognized Tax benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_EE42545F6138BDF9127432379AB45501_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_EE42545F6138BDF9127432379AB45501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_EE42545F6138BDF9127432379AB45501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_EE42545F6138BDF9127432379AB45501" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_EE42545F6138BDF9127432379AB45501" xlink:type="arc" />
    <link:label id="lab_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_C67BA027D086F9CB6B9B9166508DC7FC_terseLabel_en-US" xlink:label="lab_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_C67BA027D086F9CB6B9B9166508DC7FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Use of Estimates</link:label>
    <link:label id="lab_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_C67BA027D086F9CB6B9B9166508DC7FC_label_en-US" xlink:label="lab_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_C67BA027D086F9CB6B9B9166508DC7FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis Of Presentation And Use Of Estimates Policy [Text Block]</link:label>
    <link:label id="lab_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_C67BA027D086F9CB6B9B9166508DC7FC_documentation_en-US" xlink:label="lab_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_C67BA027D086F9CB6B9B9166508DC7FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis of presentation and use of estimates.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:label="loc_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_C67BA027D086F9CB6B9B9166508DC7FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_C67BA027D086F9CB6B9B9166508DC7FC" xlink:to="lab_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_C67BA027D086F9CB6B9B9166508DC7FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_A61556F5F311B804D88C9166508DAA5F_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_A61556F5F311B804D88C9166508DAA5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_A61556F5F311B804D88C9166508DAA5F_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_A61556F5F311B804D88C9166508DAA5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_A61556F5F311B804D88C9166508DAA5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_A61556F5F311B804D88C9166508DAA5F" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_A61556F5F311B804D88C9166508DAA5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_834A87A8C4E7F6FB8FF59166508D9AD6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_834A87A8C4E7F6FB8FF59166508D9AD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_834A87A8C4E7F6FB8FF59166508D9AD6_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_834A87A8C4E7F6FB8FF59166508D9AD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_834A87A8C4E7F6FB8FF59166508D9AD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_834A87A8C4E7F6FB8FF59166508D9AD6" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_834A87A8C4E7F6FB8FF59166508D9AD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_B14E37DDC0271D6A06469166508E3518_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_B14E37DDC0271D6A06469166508E3518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_B14E37DDC0271D6A06469166508E3518_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_B14E37DDC0271D6A06469166508E3518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_B14E37DDC0271D6A06469166508E3518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_B14E37DDC0271D6A06469166508E3518" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_B14E37DDC0271D6A06469166508E3518" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_28CC044F0B72E1A39F3A9166508E4C4F_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_28CC044F0B72E1A39F3A9166508E4C4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_28CC044F0B72E1A39F3A9166508E4C4F_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_28CC044F0B72E1A39F3A9166508E4C4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_28CC044F0B72E1A39F3A9166508E4C4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_28CC044F0B72E1A39F3A9166508E4C4F" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_28CC044F0B72E1A39F3A9166508E4C4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_EDB7A1CADABE60E805B69166508E2CE9_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_EDB7A1CADABE60E805B69166508E2CE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_EDB7A1CADABE60E805B69166508E2CE9_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_EDB7A1CADABE60E805B69166508E2CE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_EDB7A1CADABE60E805B69166508E2CE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_EDB7A1CADABE60E805B69166508E2CE9" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_EDB7A1CADABE60E805B69166508E2CE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_89985A68C2BF036CA4939166508EA619_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_89985A68C2BF036CA4939166508EA619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_89985A68C2BF036CA4939166508EA619_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_89985A68C2BF036CA4939166508EA619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_89985A68C2BF036CA4939166508EA619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_89985A68C2BF036CA4939166508EA619" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_89985A68C2BF036CA4939166508EA619" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_FF4EABA061AA6AEC64E29166508EAAC5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_FF4EABA061AA6AEC64E29166508EAAC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_FF4EABA061AA6AEC64E29166508EAAC5_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_FF4EABA061AA6AEC64E29166508EAAC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_FF4EABA061AA6AEC64E29166508EAAC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_FF4EABA061AA6AEC64E29166508EAAC5" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_FF4EABA061AA6AEC64E29166508EAAC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3CB2F42CE77084A9308C9166508EDCD7_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3CB2F42CE77084A9308C9166508EDCD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3CB2F42CE77084A9308C9166508EDCD7_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3CB2F42CE77084A9308C9166508EDCD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3CB2F42CE77084A9308C9166508EDCD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3CB2F42CE77084A9308C9166508EDCD7" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3CB2F42CE77084A9308C9166508EDCD7" xlink:type="arc" />
    <link:label id="lab_alpn_AccruedLiabilitiesPolicyPolicyTextBlock_948D454C8F555116338F9166508FBD4F_terseLabel_en-US" xlink:label="lab_alpn_AccruedLiabilitiesPolicyPolicyTextBlock_948D454C8F555116338F9166508FBD4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_alpn_AccruedLiabilitiesPolicyPolicyTextBlock_948D454C8F555116338F9166508FBD4F_label_en-US" xlink:label="lab_alpn_AccruedLiabilitiesPolicyPolicyTextBlock_948D454C8F555116338F9166508FBD4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities Policy [Policy Text Block]</link:label>
    <link:label id="lab_alpn_AccruedLiabilitiesPolicyPolicyTextBlock_948D454C8F555116338F9166508FBD4F_documentation_en-US" xlink:label="lab_alpn_AccruedLiabilitiesPolicyPolicyTextBlock_948D454C8F555116338F9166508FBD4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued liabilities policy.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AccruedLiabilitiesPolicyPolicyTextBlock" xlink:label="loc_alpn_AccruedLiabilitiesPolicyPolicyTextBlock_948D454C8F555116338F9166508FBD4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_AccruedLiabilitiesPolicyPolicyTextBlock_948D454C8F555116338F9166508FBD4F" xlink:to="lab_alpn_AccruedLiabilitiesPolicyPolicyTextBlock_948D454C8F555116338F9166508FBD4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_4439F375B5858F3910DE9166508FE015_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_4439F375B5858F3910DE9166508FE015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases and Deferred Rent</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_4439F375B5858F3910DE9166508FE015_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_4439F375B5858F3910DE9166508FE015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_4439F375B5858F3910DE9166508FE015" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_4439F375B5858F3910DE9166508FE015" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_4439F375B5858F3910DE9166508FE015" xlink:type="arc" />
    <link:label id="lab_alpn_CommonStockWarrantsPolicyTextBlock_271054446269AD1643E19166508F84D4_terseLabel_en-US" xlink:label="lab_alpn_CommonStockWarrantsPolicyTextBlock_271054446269AD1643E19166508F84D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_alpn_CommonStockWarrantsPolicyTextBlock_271054446269AD1643E19166508F84D4_label_en-US" xlink:label="lab_alpn_CommonStockWarrantsPolicyTextBlock_271054446269AD1643E19166508F84D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrants Policy [Text Block]</link:label>
    <link:label id="lab_alpn_CommonStockWarrantsPolicyTextBlock_271054446269AD1643E19166508F84D4_documentation_en-US" xlink:label="lab_alpn_CommonStockWarrantsPolicyTextBlock_271054446269AD1643E19166508F84D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock warrants policy.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CommonStockWarrantsPolicyTextBlock" xlink:label="loc_alpn_CommonStockWarrantsPolicyTextBlock_271054446269AD1643E19166508F84D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_CommonStockWarrantsPolicyTextBlock_271054446269AD1643E19166508F84D4" xlink:to="lab_alpn_CommonStockWarrantsPolicyTextBlock_271054446269AD1643E19166508F84D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_BC71826A2825591E97689166508F6718_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_BC71826A2825591E97689166508F6718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_BC71826A2825591E97689166508F6718_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_BC71826A2825591E97689166508F6718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_BC71826A2825591E97689166508F6718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_BC71826A2825591E97689166508F6718" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_BC71826A2825591E97689166508F6718" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_BD07979440D565D68EFF9166508F40B8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_BD07979440D565D68EFF9166508F40B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_BD07979440D565D68EFF9166508F40B8_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_BD07979440D565D68EFF9166508F40B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_BD07979440D565D68EFF9166508F40B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_BD07979440D565D68EFF9166508F40B8" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_BD07979440D565D68EFF9166508F40B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_95EF921AB4FBF5FD6E3D9166508F812C_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_95EF921AB4FBF5FD6E3D9166508F812C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_95EF921AB4FBF5FD6E3D9166508F812C_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_95EF921AB4FBF5FD6E3D9166508F812C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_95EF921AB4FBF5FD6E3D9166508F812C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_95EF921AB4FBF5FD6E3D9166508F812C" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_95EF921AB4FBF5FD6E3D9166508F812C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1CF04D80AF02123306BC916650909565_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1CF04D80AF02123306BC916650909565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1CF04D80AF02123306BC916650909565_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1CF04D80AF02123306BC916650909565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1CF04D80AF02123306BC916650909565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1CF04D80AF02123306BC916650909565" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1CF04D80AF02123306BC916650909565" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_0E79ED22ECEBEB8A20369166509085CB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0E79ED22ECEBEB8A20369166509085CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_0E79ED22ECEBEB8A20369166509085CB_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0E79ED22ECEBEB8A20369166509085CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_0E79ED22ECEBEB8A20369166509085CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_0E79ED22ECEBEB8A20369166509085CB" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0E79ED22ECEBEB8A20369166509085CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49B7AA7B420EA68E54AB91665090FC53_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49B7AA7B420EA68E54AB91665090FC53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49B7AA7B420EA68E54AB91665090FC53_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49B7AA7B420EA68E54AB91665090FC53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49B7AA7B420EA68E54AB91665090FC53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49B7AA7B420EA68E54AB91665090FC53" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49B7AA7B420EA68E54AB91665090FC53" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38FCA240EA6F36279968916650904A57_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38FCA240EA6F36279968916650904A57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued and Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38FCA240EA6F36279968916650904A57_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38FCA240EA6F36279968916650904A57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38FCA240EA6F36279968916650904A57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38FCA240EA6F36279968916650904A57" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38FCA240EA6F36279968916650904A57" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2F28F6D10A2FA3EB4E679166509035AC_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_2F28F6D10A2FA3EB4E679166509035AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2F28F6D10A2FA3EB4E679166509035AC_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_2F28F6D10A2FA3EB4E679166509035AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2F28F6D10A2FA3EB4E679166509035AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_2F28F6D10A2FA3EB4E679166509035AC" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_2F28F6D10A2FA3EB4E679166509035AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8A113385BCA4DBBB807491665090124A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8A113385BCA4DBBB807491665090124A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8A113385BCA4DBBB807491665090124A_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8A113385BCA4DBBB807491665090124A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8A113385BCA4DBBB807491665090124A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8A113385BCA4DBBB807491665090124A" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8A113385BCA4DBBB807491665090124A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_32B9845996523BDE5E554EDB9CFB40B5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_32B9845996523BDE5E554EDB9CFB40B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_32B9845996523BDE5E554EDB9CFB40B5_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_32B9845996523BDE5E554EDB9CFB40B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_32B9845996523BDE5E554EDB9CFB40B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_32B9845996523BDE5E554EDB9CFB40B5" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_32B9845996523BDE5E554EDB9CFB40B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09" xlink:to="lab_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_013368E292CE94F7F89B4ED97FB69677_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_013368E292CE94F7F89B4ED97FB69677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_013368E292CE94F7F89B4ED97FB69677_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_013368E292CE94F7F89B4ED97FB69677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_013368E292CE94F7F89B4ED97FB69677" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_013368E292CE94F7F89B4ED97FB69677" xlink:to="lab_us-gaap_ScenarioForecastMember_013368E292CE94F7F89B4ED97FB69677" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966_label_en-US" xlink:label="lab_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966" xlink:to="lab_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F_label_en-US" xlink:label="lab_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F" xlink:to="lab_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F" xlink:type="arc" />
    <link:label id="lab_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB_terseLabel_en-US" xlink:label="lab_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laurel Venture Capital Ltd.</link:label>
    <link:label id="lab_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB_label_en-US" xlink:label="lab_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laurel Venture Capital Ltd. [Member]</link:label>
    <link:label id="lab_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB_documentation_en-US" xlink:label="lab_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laurel Venture Capital Ltd. [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_LaurelVentureCapitalLtd.Member" xlink:label="loc_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB" xlink:to="lab_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B" xlink:type="arc" />
    <link:label id="lab_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31_terseLabel_en-US" xlink:label="lab_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSNOR</link:label>
    <link:label id="lab_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31_label_en-US" xlink:label="lab_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSNOR [Member]</link:label>
    <link:label id="lab_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31_documentation_en-US" xlink:label="lab_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSNOR [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_GSNORMember" xlink:label="loc_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31" xlink:to="lab_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31" xlink:type="arc" />
    <link:label id="lab_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5_terseLabel_en-US" xlink:label="lab_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Sheet</link:label>
    <link:label id="lab_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5_label_en-US" xlink:label="lab_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Sheet [Member]</link:label>
    <link:label id="lab_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5_documentation_en-US" xlink:label="lab_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Sheet [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TermSheetMember" xlink:label="loc_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5" xlink:to="lab_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F90B57177FBF83B152714ED699D60BAB_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F90B57177FBF83B152714ED699D60BAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F90B57177FBF83B152714ED699D60BAB_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F90B57177FBF83B152714ED699D60BAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F90B57177FBF83B152714ED699D60BAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F90B57177FBF83B152714ED699D60BAB" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F90B57177FBF83B152714ED699D60BAB" xlink:type="arc" />
    <link:label id="lab_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803_terseLabel_en-US" xlink:label="lab_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments eligible to be received</link:label>
    <link:label id="lab_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803_label_en-US" xlink:label="lab_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Purchase Agreement Potential Milestone Payments Eligible to be Received</link:label>
    <link:label id="lab_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803_documentation_en-US" xlink:label="lab_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Purchase Agreement Potential Milestone Payments Eligible to be Received</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived" xlink:label="loc_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803" xlink:to="lab_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803" xlink:type="arc" />
    <link:label id="lab_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712_terseLabel_en-US" xlink:label="lab_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, amount derecognized upon sale</link:label>
    <link:label id="lab_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712_label_en-US" xlink:label="lab_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Amount Derecognized Upon Sale</link:label>
    <link:label id="lab_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712_documentation_en-US" xlink:label="lab_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets, Amount Derecognized Upon Sale</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IntangibleAssetsAmountDerecognizedUponSale" xlink:label="loc_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712" xlink:to="lab_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_73074696DE05BC227D254EDC14F52334_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_73074696DE05BC227D254EDC14F52334" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of intangible asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_73074696DE05BC227D254EDC14F52334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_73074696DE05BC227D254EDC14F52334" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_73074696DE05BC227D254EDC14F52334" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12136B76945A417E3ABC32379D1355B5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12136B76945A417E3ABC32379D1355B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12136B76945A417E3ABC32379D1355B5_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12136B76945A417E3ABC32379D1355B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12136B76945A417E3ABC32379D1355B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12136B76945A417E3ABC32379D1355B5" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12136B76945A417E3ABC32379D1355B5" xlink:type="arc" />
    <link:label id="lab_alpn_AccruedResearchAndDevelopmentCurrent_E2CE07D7B5A370E82CCB73063589FA65_terseLabel_en-US" xlink:label="lab_alpn_AccruedResearchAndDevelopmentCurrent_E2CE07D7B5A370E82CCB73063589FA65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:label id="lab_alpn_AccruedResearchAndDevelopmentCurrent_E2CE07D7B5A370E82CCB73063589FA65_label_en-US" xlink:label="lab_alpn_AccruedResearchAndDevelopmentCurrent_E2CE07D7B5A370E82CCB73063589FA65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Current</link:label>
    <link:label id="lab_alpn_AccruedResearchAndDevelopmentCurrent_E2CE07D7B5A370E82CCB73063589FA65_documentation_en-US" xlink:label="lab_alpn_AccruedResearchAndDevelopmentCurrent_E2CE07D7B5A370E82CCB73063589FA65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Current</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_alpn_AccruedResearchAndDevelopmentCurrent_E2CE07D7B5A370E82CCB73063589FA65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_AccruedResearchAndDevelopmentCurrent_E2CE07D7B5A370E82CCB73063589FA65" xlink:to="lab_alpn_AccruedResearchAndDevelopmentCurrent_E2CE07D7B5A370E82CCB73063589FA65" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5716CDE6A4969A8ADDDB73063589A6A6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5716CDE6A4969A8ADDDB73063589A6A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5716CDE6A4969A8ADDDB73063589A6A6_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5716CDE6A4969A8ADDDB73063589A6A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5716CDE6A4969A8ADDDB73063589A6A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5716CDE6A4969A8ADDDB73063589A6A6" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5716CDE6A4969A8ADDDB73063589A6A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_63E058604937EEF2BE2E73063589701E_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_63E058604937EEF2BE2E73063589701E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal and professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_63E058604937EEF2BE2E73063589701E_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_63E058604937EEF2BE2E73063589701E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_63E058604937EEF2BE2E73063589701E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_63E058604937EEF2BE2E73063589701E" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_63E058604937EEF2BE2E73063589701E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A7243A61FDF09FC7AF707306358ACFFB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A7243A61FDF09FC7AF707306358ACFFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A7243A61FDF09FC7AF707306358ACFFB_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A7243A61FDF09FC7AF707306358ACFFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_A7243A61FDF09FC7AF707306358ACFFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_A7243A61FDF09FC7AF707306358ACFFB" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A7243A61FDF09FC7AF707306358ACFFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_B82ACFCD2930F86C99247306358AE8FB_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_B82ACFCD2930F86C99247306358AE8FB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_B82ACFCD2930F86C99247306358AE8FB_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_B82ACFCD2930F86C99247306358AE8FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B82ACFCD2930F86C99247306358AE8FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_B82ACFCD2930F86C99247306358AE8FB" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_B82ACFCD2930F86C99247306358AE8FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1E1294DB675B0D8D8003CC99B062A4F8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1E1294DB675B0D8D8003CC99B062A4F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1E1294DB675B0D8D8003CC99B062A4F8_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1E1294DB675B0D8D8003CC99B062A4F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1E1294DB675B0D8D8003CC99B062A4F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1E1294DB675B0D8D8003CC99B062A4F8" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1E1294DB675B0D8D8003CC99B062A4F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_771F2D7972E101876F98CC99B06241FA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_771F2D7972E101876F98CC99B06241FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_771F2D7972E101876F98CC99B06241FA_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_771F2D7972E101876F98CC99B06241FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_771F2D7972E101876F98CC99B06241FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_771F2D7972E101876F98CC99B06241FA" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_771F2D7972E101876F98CC99B06241FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_726BD8548DCE854C1F39CC99B0630966_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_726BD8548DCE854C1F39CC99B0630966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_726BD8548DCE854C1F39CC99B0630966_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_726BD8548DCE854C1F39CC99B0630966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_726BD8548DCE854C1F39CC99B0630966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_726BD8548DCE854C1F39CC99B0630966" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_726BD8548DCE854C1F39CC99B0630966" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_E32077F3433D63552492CC99B0637702_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_E32077F3433D63552492CC99B0637702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_E32077F3433D63552492CC99B0637702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_E32077F3433D63552492CC99B0637702" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_E32077F3433D63552492CC99B0637702" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_375984B869DD0E526559CC99B06316DD_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_375984B869DD0E526559CC99B06316DD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_375984B869DD0E526559CC99B06316DD_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_375984B869DD0E526559CC99B06316DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_375984B869DD0E526559CC99B06316DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_375984B869DD0E526559CC99B06316DD" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_375984B869DD0E526559CC99B06316DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:type="arc" />
    <link:label id="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211_negatedLabel_en-US" xlink:label="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211_label_en-US" xlink:label="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Liabilities</link:label>
    <link:label id="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211_documentation_en-US" xlink:label="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed accrued liabilities.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:label="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211" xlink:to="lab_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_B26D1F1DD83EC9D68276CC99B064307A_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_B26D1F1DD83EC9D68276CC99B064307A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_B26D1F1DD83EC9D68276CC99B064307A_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_B26D1F1DD83EC9D68276CC99B064307A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_B26D1F1DD83EC9D68276CC99B064307A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_B26D1F1DD83EC9D68276CC99B064307A" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_B26D1F1DD83EC9D68276CC99B064307A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F2B4EB43B4C515394A08CC99B0646776_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F2B4EB43B4C515394A08CC99B0646776" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F2B4EB43B4C515394A08CC99B0646776_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F2B4EB43B4C515394A08CC99B0646776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F2B4EB43B4C515394A08CC99B0646776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F2B4EB43B4C515394A08CC99B0646776" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F2B4EB43B4C515394A08CC99B0646776" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_4E7E2CCACD664EA61B0CCC99B06465B1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_4E7E2CCACD664EA61B0CCC99B06465B1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Bargain purchase gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:label="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_4E7E2CCACD664EA61B0CCC99B06465B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_4E7E2CCACD664EA61B0CCC99B06465B1" xlink:to="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_4E7E2CCACD664EA61B0CCC99B06465B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_E62CABC7F7CAA28312BBCC99B065E7D6_positiveVerboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_E62CABC7F7CAA28312BBCC99B065E7D6" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E62CABC7F7CAA28312BBCC99B065E7D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E62CABC7F7CAA28312BBCC99B065E7D6" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_E62CABC7F7CAA28312BBCC99B065E7D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_DE7FEAC78151DA20931CD2933EA0652B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_DE7FEAC78151DA20931CD2933EA0652B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_DE7FEAC78151DA20931CD2933EA0652B_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_DE7FEAC78151DA20931CD2933EA0652B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_DE7FEAC78151DA20931CD2933EA0652B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_DE7FEAC78151DA20931CD2933EA0652B" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_DE7FEAC78151DA20931CD2933EA0652B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9E5FA92EC4086431EF04D2933EA065A5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_9E5FA92EC4086431EF04D2933EA065A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9E5FA92EC4086431EF04D2933EA065A5_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_9E5FA92EC4086431EF04D2933EA065A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9E5FA92EC4086431EF04D2933EA065A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_9E5FA92EC4086431EF04D2933EA065A5" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_9E5FA92EC4086431EF04D2933EA065A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_11B5299D0CD0B99EB98ED2933EA08063_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_11B5299D0CD0B99EB98ED2933EA08063" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_11B5299D0CD0B99EB98ED2933EA08063_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_11B5299D0CD0B99EB98ED2933EA08063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_11B5299D0CD0B99EB98ED2933EA08063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_11B5299D0CD0B99EB98ED2933EA08063" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_11B5299D0CD0B99EB98ED2933EA08063" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_C95C0704EC25F3E7CBBDD2974362A145_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_C95C0704EC25F3E7CBBDD2974362A145" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C95C0704EC25F3E7CBBDD2974362A145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_C95C0704EC25F3E7CBBDD2974362A145" xlink:to="lab_us-gaap_MoneyMarketFundsMember_C95C0704EC25F3E7CBBDD2974362A145" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_00F8A419DEE1D2C6BEAED29743DADE40_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember_00F8A419DEE1D2C6BEAED29743DADE40" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_00F8A419DEE1D2C6BEAED29743DADE40_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember_00F8A419DEE1D2C6BEAED29743DADE40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_00F8A419DEE1D2C6BEAED29743DADE40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember_00F8A419DEE1D2C6BEAED29743DADE40" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember_00F8A419DEE1D2C6BEAED29743DADE40" xlink:type="arc" />
    <link:label id="lab_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_43A7786400F9EC31B5C2D297445233C8_verboseLabel_en-US" xlink:label="lab_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_43A7786400F9EC31B5C2D297445233C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities and commercial paper</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CorporateDebtSecuritiesAndCommercialPaperMember" xlink:label="loc_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_43A7786400F9EC31B5C2D297445233C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_43A7786400F9EC31B5C2D297445233C8" xlink:to="lab_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_43A7786400F9EC31B5C2D297445233C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7693574841B115498973D2933EA0174E_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7693574841B115498973D2933EA0174E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value assets disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7693574841B115498973D2933EA0174E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7693574841B115498973D2933EA0174E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7693574841B115498973D2933EA0174E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE" xlink:to="lab_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:to="lab_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:type="arc" />
    <link:label id="lab_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10_terseLabel_en-US" xlink:label="lab_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Before January 1 2018</link:label>
    <link:label id="lab_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10_label_en-US" xlink:label="lab_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Before January 1 2018 [Member]</link:label>
    <link:label id="lab_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10_documentation_en-US" xlink:label="lab_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Before January 1 2018 [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BeforeJanuary12018Member" xlink:label="loc_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10" xlink:to="lab_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10" xlink:type="arc" />
    <link:label id="lab_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA_terseLabel_en-US" xlink:label="lab_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After January 1 2018</link:label>
    <link:label id="lab_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA_label_en-US" xlink:label="lab_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After January 1 2018 [Member]</link:label>
    <link:label id="lab_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA_documentation_en-US" xlink:label="lab_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After January 1 2018 [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AfterJanuary12018Member" xlink:label="loc_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA" xlink:to="lab_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_80D3DFAEE466C2B6F86F4FB2E8CFEE20_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_80D3DFAEE466C2B6F86F4FB2E8CFEE20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_80D3DFAEE466C2B6F86F4FB2E8CFEE20_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_80D3DFAEE466C2B6F86F4FB2E8CFEE20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_80D3DFAEE466C2B6F86F4FB2E8CFEE20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_80D3DFAEE466C2B6F86F4FB2E8CFEE20" xlink:to="lab_us-gaap_DomesticCountryMember_80D3DFAEE466C2B6F86F4FB2E8CFEE20" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_B1401C6BA0036E0A88624FB9FD5B7D99_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_B1401C6BA0036E0A88624FB9FD5B7D99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_B1401C6BA0036E0A88624FB9FD5B7D99_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_B1401C6BA0036E0A88624FB9FD5B7D99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_B1401C6BA0036E0A88624FB9FD5B7D99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_B1401C6BA0036E0A88624FB9FD5B7D99" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_B1401C6BA0036E0A88624FB9FD5B7D99" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_6BBB6DE8163C80BBDDA54FB2E8CF8DFE_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_6BBB6DE8163C80BBDDA54FB2E8CF8DFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_6BBB6DE8163C80BBDDA54FB2E8CF8DFE_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_6BBB6DE8163C80BBDDA54FB2E8CF8DFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6BBB6DE8163C80BBDDA54FB2E8CF8DFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_6BBB6DE8163C80BBDDA54FB2E8CF8DFE" xlink:to="lab_us-gaap_OperatingLossCarryforwards_6BBB6DE8163C80BBDDA54FB2E8CF8DFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_24DF532E340E38E070678272BD020581_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_24DF532E340E38E070678272BD020581" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unrecognized benefits &#8211; beginning of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_24DF532E340E38E070678272BD020581" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_24DF532E340E38E070678272BD020581" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_24DF532E340E38E070678272BD020581" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C6D7663458091D87D836828FFB7A80D8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C6D7663458091D87D836828FFB7A80D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross increases (decreases) &#8211; prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C6D7663458091D87D836828FFB7A80D8_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C6D7663458091D87D836828FFB7A80D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C6D7663458091D87D836828FFB7A80D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C6D7663458091D87D836828FFB7A80D8" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C6D7663458091D87D836828FFB7A80D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_37E1DB0995D5F1E27927829036D4DBFC_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_37E1DB0995D5F1E27927829036D4DBFC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross increases (decreases) &#8211; prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_37E1DB0995D5F1E27927829036D4DBFC_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_37E1DB0995D5F1E27927829036D4DBFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_37E1DB0995D5F1E27927829036D4DBFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_37E1DB0995D5F1E27927829036D4DBFC" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_37E1DB0995D5F1E27927829036D4DBFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0729D36C773844517FC28272BD06507F_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0729D36C773844517FC28272BD06507F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross increases &#8211; current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0729D36C773844517FC28272BD06507F_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0729D36C773844517FC28272BD06507F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0729D36C773844517FC28272BD06507F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0729D36C773844517FC28272BD06507F" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0729D36C773844517FC28272BD06507F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_FE2BBC416F056061D8498272BD064A46_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_FE2BBC416F056061D8498272BD064A46" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unrecognized benefit &#8211; end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_FE2BBC416F056061D8498272BD064A46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_FE2BBC416F056061D8498272BD064A46" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_FE2BBC416F056061D8498272BD064A46" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_B02EEC3D1E100DA97CF0CC2FE89E33B0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_B02EEC3D1E100DA97CF0CC2FE89E33B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro forma revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_B02EEC3D1E100DA97CF0CC2FE89E33B0_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_B02EEC3D1E100DA97CF0CC2FE89E33B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_B02EEC3D1E100DA97CF0CC2FE89E33B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_B02EEC3D1E100DA97CF0CC2FE89E33B0" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_B02EEC3D1E100DA97CF0CC2FE89E33B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90AD500E6AEA4EC3D32ECC2FE89ECBE9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90AD500E6AEA4EC3D32ECC2FE89ECBE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro forma net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90AD500E6AEA4EC3D32ECC2FE89ECBE9_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90AD500E6AEA4EC3D32ECC2FE89ECBE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90AD500E6AEA4EC3D32ECC2FE89ECBE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90AD500E6AEA4EC3D32ECC2FE89ECBE9" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90AD500E6AEA4EC3D32ECC2FE89ECBE9" xlink:type="arc" />
    <link:label id="lab_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74_terseLabel_en-US" xlink:label="lab_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro forma basic and diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74_label_en-US" xlink:label="lab_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Pro Forma Earnings Per Share Basic And Diluted</link:label>
    <link:label id="lab_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74_documentation_en-US" xlink:label="lab_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition pro forma earnings per share basic and diluted.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="loc_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74" xlink:to="lab_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74" xlink:type="arc" />
    <link:label id="lab_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B_label_en-US" xlink:label="lab_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B_documentation_en-US" xlink:label="lab_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DocumentAndEntityInformationAbstract" xlink:label="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="lab_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_2BC33FF3E326D37E8E32CC2FE9AEBC7D_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_2BC33FF3E326D37E8E32CC2FE9AEBC7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_2BC33FF3E326D37E8E32CC2FE9AEBC7D_label_en-US" xlink:label="lab_dei_EntityRegistrantName_2BC33FF3E326D37E8E32CC2FE9AEBC7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2BC33FF3E326D37E8E32CC2FE9AEBC7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_2BC33FF3E326D37E8E32CC2FE9AEBC7D" xlink:to="lab_dei_EntityRegistrantName_2BC33FF3E326D37E8E32CC2FE9AEBC7D" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_859E6A2BC79E2A068981CC2FE9AE3C49_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_859E6A2BC79E2A068981CC2FE9AE3C49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_859E6A2BC79E2A068981CC2FE9AE3C49_label_en-US" xlink:label="lab_dei_TradingSymbol_859E6A2BC79E2A068981CC2FE9AE3C49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_859E6A2BC79E2A068981CC2FE9AE3C49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_859E6A2BC79E2A068981CC2FE9AE3C49" xlink:to="lab_dei_TradingSymbol_859E6A2BC79E2A068981CC2FE9AE3C49" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_CC37C96BA028BD4CF027CC2FE9AF9EF6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_CC37C96BA028BD4CF027CC2FE9AF9EF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_CC37C96BA028BD4CF027CC2FE9AF9EF6_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_CC37C96BA028BD4CF027CC2FE9AF9EF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_CC37C96BA028BD4CF027CC2FE9AF9EF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_CC37C96BA028BD4CF027CC2FE9AF9EF6" xlink:to="lab_dei_EntityCentralIndexKey_CC37C96BA028BD4CF027CC2FE9AF9EF6" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7AB3288F1B739D9BC98BCC2FE9AF1CAB_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_7AB3288F1B739D9BC98BCC2FE9AF1CAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7AB3288F1B739D9BC98BCC2FE9AF1CAB_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_7AB3288F1B739D9BC98BCC2FE9AF1CAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_7AB3288F1B739D9BC98BCC2FE9AF1CAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_7AB3288F1B739D9BC98BCC2FE9AF1CAB" xlink:to="lab_dei_CurrentFiscalYearEndDate_7AB3288F1B739D9BC98BCC2FE9AF1CAB" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_EC786E72C3E007431C93CC2FE9B0CA45_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_EC786E72C3E007431C93CC2FE9B0CA45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_EC786E72C3E007431C93CC2FE9B0CA45_label_en-US" xlink:label="lab_dei_EntityFilerCategory_EC786E72C3E007431C93CC2FE9B0CA45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_EC786E72C3E007431C93CC2FE9B0CA45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_EC786E72C3E007431C93CC2FE9B0CA45" xlink:to="lab_dei_EntityFilerCategory_EC786E72C3E007431C93CC2FE9B0CA45" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_1E306FF5718AD0097A21CC2FE9AD9747_terseLabel_en-US" xlink:label="lab_dei_DocumentType_1E306FF5718AD0097A21CC2FE9AD9747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_1E306FF5718AD0097A21CC2FE9AD9747_label_en-US" xlink:label="lab_dei_DocumentType_1E306FF5718AD0097A21CC2FE9AD9747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1E306FF5718AD0097A21CC2FE9AD9747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_1E306FF5718AD0097A21CC2FE9AD9747" xlink:to="lab_dei_DocumentType_1E306FF5718AD0097A21CC2FE9AD9747" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_B6925BE8133D5D9ACB20CC2FE9AE8BA4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_B6925BE8133D5D9ACB20CC2FE9AE8BA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_B6925BE8133D5D9ACB20CC2FE9AE8BA4_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_B6925BE8133D5D9ACB20CC2FE9AE8BA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_B6925BE8133D5D9ACB20CC2FE9AE8BA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_B6925BE8133D5D9ACB20CC2FE9AE8BA4" xlink:to="lab_dei_DocumentPeriodEndDate_B6925BE8133D5D9ACB20CC2FE9AE8BA4" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_565A10EEFBD59F4F2150CC2FE9AE4F99_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_565A10EEFBD59F4F2150CC2FE9AE4F99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_565A10EEFBD59F4F2150CC2FE9AE4F99_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_565A10EEFBD59F4F2150CC2FE9AE4F99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_565A10EEFBD59F4F2150CC2FE9AE4F99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_565A10EEFBD59F4F2150CC2FE9AE4F99" xlink:to="lab_dei_DocumentFiscalYearFocus_565A10EEFBD59F4F2150CC2FE9AE4F99" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5BA350B15A642210E34ECC2FE9AE2B56_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_5BA350B15A642210E34ECC2FE9AE2B56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5BA350B15A642210E34ECC2FE9AE2B56_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_5BA350B15A642210E34ECC2FE9AE2B56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5BA350B15A642210E34ECC2FE9AE2B56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_5BA350B15A642210E34ECC2FE9AE2B56" xlink:to="lab_dei_DocumentFiscalPeriodFocus_5BA350B15A642210E34ECC2FE9AE2B56" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_C2383F8B39556A88B630CC2FE9AE3CB3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_C2383F8B39556A88B630CC2FE9AE3CB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_C2383F8B39556A88B630CC2FE9AE3CB3_label_en-US" xlink:label="lab_dei_AmendmentFlag_C2383F8B39556A88B630CC2FE9AE3CB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C2383F8B39556A88B630CC2FE9AE3CB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_C2383F8B39556A88B630CC2FE9AE3CB3" xlink:to="lab_dei_AmendmentFlag_C2383F8B39556A88B630CC2FE9AE3CB3" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5F17EF28BFD638475EE7CC33BE26F767_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_5F17EF28BFD638475EE7CC33BE26F767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5F17EF28BFD638475EE7CC33BE26F767_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_5F17EF28BFD638475EE7CC33BE26F767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_5F17EF28BFD638475EE7CC33BE26F767" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_5F17EF28BFD638475EE7CC33BE26F767" xlink:to="lab_dei_EntityEmergingGrowthCompany_5F17EF28BFD638475EE7CC33BE26F767" xlink:type="arc" />
    <link:label id="lab_dei_EntityExTransitionPeriod_241A661C1D661769911ACC33E3D65AB3_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_241A661C1D661769911ACC33E3D65AB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_241A661C1D661769911ACC33E3D65AB3_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_241A661C1D661769911ACC33E3D65AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_241A661C1D661769911ACC33E3D65AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_241A661C1D661769911ACC33E3D65AB3" xlink:to="lab_dei_EntityExTransitionPeriod_241A661C1D661769911ACC33E3D65AB3" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_10519DEDDEC02E3B4952CC34083CD501_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_10519DEDDEC02E3B4952CC34083CD501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_10519DEDDEC02E3B4952CC34083CD501_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_10519DEDDEC02E3B4952CC34083CD501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_10519DEDDEC02E3B4952CC34083CD501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_10519DEDDEC02E3B4952CC34083CD501" xlink:to="lab_dei_EntitySmallBusiness_10519DEDDEC02E3B4952CC34083CD501" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_43BF1CA1922BE3ACBDA9CC343221575C_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_43BF1CA1922BE3ACBDA9CC343221575C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_43BF1CA1922BE3ACBDA9CC343221575C_label_en-US" xlink:label="lab_dei_EntityShellCompany_43BF1CA1922BE3ACBDA9CC343221575C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_43BF1CA1922BE3ACBDA9CC343221575C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_43BF1CA1922BE3ACBDA9CC343221575C" xlink:to="lab_dei_EntityShellCompany_43BF1CA1922BE3ACBDA9CC343221575C" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_D291025CC50359C7D549CC2FE9B010B5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_D291025CC50359C7D549CC2FE9B010B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_D291025CC50359C7D549CC2FE9B010B5_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_D291025CC50359C7D549CC2FE9B010B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_D291025CC50359C7D549CC2FE9B010B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_D291025CC50359C7D549CC2FE9B010B5" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_D291025CC50359C7D549CC2FE9B010B5" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_8182E6B33E98A850FF5BCC2FE9AF9EDC_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_8182E6B33E98A850FF5BCC2FE9AF9EDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_8182E6B33E98A850FF5BCC2FE9AF9EDC_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_8182E6B33E98A850FF5BCC2FE9AF9EDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_8182E6B33E98A850FF5BCC2FE9AF9EDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_8182E6B33E98A850FF5BCC2FE9AF9EDC" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_8182E6B33E98A850FF5BCC2FE9AF9EDC" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_8F8EDD9B40D94AB1F968CC2FE9AF417C_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_8F8EDD9B40D94AB1F968CC2FE9AF417C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_8F8EDD9B40D94AB1F968CC2FE9AF417C_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_8F8EDD9B40D94AB1F968CC2FE9AF417C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_8F8EDD9B40D94AB1F968CC2FE9AF417C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_8F8EDD9B40D94AB1F968CC2FE9AF417C" xlink:to="lab_dei_EntityVoluntaryFilers_8F8EDD9B40D94AB1F968CC2FE9AF417C" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_B14F50F02F8C335F95E7CC2FE9AF3560_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_B14F50F02F8C335F95E7CC2FE9AF3560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_B14F50F02F8C335F95E7CC2FE9AF3560_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_B14F50F02F8C335F95E7CC2FE9AF3560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_B14F50F02F8C335F95E7CC2FE9AF3560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_B14F50F02F8C335F95E7CC2FE9AF3560" xlink:to="lab_dei_EntityCurrentReportingStatus_B14F50F02F8C335F95E7CC2FE9AF3560" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_96AC4D112DCE6B6EBA47CC2FE9B026DA_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_96AC4D112DCE6B6EBA47CC2FE9B026DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_96AC4D112DCE6B6EBA47CC2FE9B026DA_label_en-US" xlink:label="lab_dei_EntityPublicFloat_96AC4D112DCE6B6EBA47CC2FE9B026DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_96AC4D112DCE6B6EBA47CC2FE9B026DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_96AC4D112DCE6B6EBA47CC2FE9B026DA" xlink:to="lab_dei_EntityPublicFloat_96AC4D112DCE6B6EBA47CC2FE9B026DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:to="lab_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_5616DF45C08752DCF6CE9141DB8701E5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_5616DF45C08752DCF6CE9141DB8701E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_5616DF45C08752DCF6CE9141DB8701E5_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_5616DF45C08752DCF6CE9141DB8701E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5616DF45C08752DCF6CE9141DB8701E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_5616DF45C08752DCF6CE9141DB8701E5" xlink:to="lab_us-gaap_SubsequentEventMember_5616DF45C08752DCF6CE9141DB8701E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditMember_B84046BAC48D676C04E49141DB8700AD_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_B84046BAC48D676C04E49141DB8700AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_B84046BAC48D676C04E49141DB8700AD_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_B84046BAC48D676C04E49141DB8700AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_B84046BAC48D676C04E49141DB8700AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember_B84046BAC48D676C04E49141DB8700AD" xlink:to="lab_us-gaap_LineOfCreditMember_B84046BAC48D676C04E49141DB8700AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="lab_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:type="arc" />
    <link:label id="lab_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D_terseLabel_en-US" xlink:label="lab_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office and laboratory space</link:label>
    <link:label id="lab_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D_label_en-US" xlink:label="lab_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Square Feet Area Of Office And Laboratory Space Under Lease</link:label>
    <link:label id="lab_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D_documentation_en-US" xlink:label="lab_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Square Feet Area Of Office And Laboratory Space Under Lease</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease" xlink:label="loc_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D" xlink:to="lab_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_97F33CE9E2585B9495159141DB871347_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_97F33CE9E2585B9495159141DB871347" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, annual base rent</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_97F33CE9E2585B9495159141DB871347_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_97F33CE9E2585B9495159141DB871347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_97F33CE9E2585B9495159141DB871347" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_97F33CE9E2585B9495159141DB871347" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_97F33CE9E2585B9495159141DB871347" xlink:type="arc" />
    <link:label id="lab_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921_terseLabel_en-US" xlink:label="lab_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, annual base rent increasing percentage</link:label>
    <link:label id="lab_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921_label_en-US" xlink:label="lab_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Annual Base Rent Increasing Percentage</link:label>
    <link:label id="lab_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921_documentation_en-US" xlink:label="lab_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Annual Base Rent Increasing Percentage</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage" xlink:label="loc_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921" xlink:to="lab_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921" xlink:type="arc" />
    <link:label id="lab_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2_terseLabel_en-US" xlink:label="lab_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of option to extend term lease</link:label>
    <link:label id="lab_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2_label_en-US" xlink:label="lab_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Options To Extend Term Lease</link:label>
    <link:label id="lab_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2_documentation_en-US" xlink:label="lab_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Options To Extend Term Lease</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfOptionsToExtendTermLease" xlink:label="loc_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2" xlink:to="lab_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LessorOperatingLeaseRenewalTerm_3820A976C20967610BD59141DB87E83C_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseRenewalTerm_3820A976C20967610BD59141DB87E83C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease renewal term</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseRenewalTerm_3820A976C20967610BD59141DB87E83C_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseRenewalTerm_3820A976C20967610BD59141DB87E83C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LessorOperatingLeaseRenewalTerm_3820A976C20967610BD59141DB87E83C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseRenewalTerm_3820A976C20967610BD59141DB87E83C" xlink:to="lab_us-gaap_LessorOperatingLeaseRenewalTerm_3820A976C20967610BD59141DB87E83C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecurityDeposit_9A2621F0AFF8568463179141DB87E878_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit_9A2621F0AFF8568463179141DB87E878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_9A2621F0AFF8568463179141DB87E878_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit_9A2621F0AFF8568463179141DB87E878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_9A2621F0AFF8568463179141DB87E878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit_9A2621F0AFF8568463179141DB87E878" xlink:to="lab_us-gaap_SecurityDeposit_9A2621F0AFF8568463179141DB87E878" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_A14A72055FF57CCCC8049141DB87E714_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_A14A72055FF57CCCC8049141DB87E714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_A14A72055FF57CCCC8049141DB87E714_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_A14A72055FF57CCCC8049141DB87E714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_A14A72055FF57CCCC8049141DB87E714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_A14A72055FF57CCCC8049141DB87E714" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_A14A72055FF57CCCC8049141DB87E714" xlink:type="arc" />
    <link:label id="lab_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE_terseLabel_en-US" xlink:label="lab_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional office and laboratory space</link:label>
    <link:label id="lab_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE_label_en-US" xlink:label="lab_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Square Feet Area Of Office And Laboratory Space Under Lease</link:label>
    <link:label id="lab_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE_documentation_en-US" xlink:label="lab_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional square feet area of office and laboratory space under lease.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease" xlink:label="loc_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE" xlink:to="lab_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_11BD32A4915E4DAD4BB59141DB8776D0_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract_11BD32A4915E4DAD4BB59141DB8776D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_11BD32A4915E4DAD4BB59141DB8776D0_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract_11BD32A4915E4DAD4BB59141DB8776D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_11BD32A4915E4DAD4BB59141DB8776D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract_11BD32A4915E4DAD4BB59141DB8776D0" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract_11BD32A4915E4DAD4BB59141DB8776D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_2B2D7C6BA1A71969C07B9141DB877124_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_2B2D7C6BA1A71969C07B9141DB877124" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Maximum tenant improvement allowance</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_2B2D7C6BA1A71969C07B9141DB877124_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_2B2D7C6BA1A71969C07B9141DB877124" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_2B2D7C6BA1A71969C07B9141DB877124" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_2B2D7C6BA1A71969C07B9141DB877124" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_2B2D7C6BA1A71969C07B9141DB877124" xlink:type="arc" />
    <link:label id="lab_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1_negatedTerseLabel_en-US" xlink:label="lab_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additional maximum tenant improvement allowance</link:label>
    <link:label id="lab_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1_label_en-US" xlink:label="lab_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For (Proceeds From) Additional Tenant Allowance</link:label>
    <link:label id="lab_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1_documentation_en-US" xlink:label="lab_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For (Proceeds From) Additional Tenant Allowance</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PaymentsForProceedsFromAdditionalTenantAllowance" xlink:label="loc_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1" xlink:to="lab_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1" xlink:type="arc" />
    <link:label id="lab_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5_terseLabel_en-US" xlink:label="lab_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of tenant improvement allowance</link:label>
    <link:label id="lab_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5_label_en-US" xlink:label="lab_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Additional Maximum Tenant Improvement Allowance Amortization Rate</link:label>
    <link:label id="lab_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5_documentation_en-US" xlink:label="lab_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Additional Maximum Tenant Improvement Allowance Amortization Rate</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate" xlink:label="loc_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5" xlink:to="lab_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquipmentMember_9BDD30011129562648A8CC2FE848D522_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember_9BDD30011129562648A8CC2FE848D522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_9BDD30011129562648A8CC2FE848D522_label_en-US" xlink:label="lab_us-gaap_EquipmentMember_9BDD30011129562648A8CC2FE848D522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_9BDD30011129562648A8CC2FE848D522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_9BDD30011129562648A8CC2FE848D522" xlink:to="lab_us-gaap_EquipmentMember_9BDD30011129562648A8CC2FE848D522" xlink:type="arc" />
    <link:label id="lab_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017_terseLabel_en-US" xlink:label="lab_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General equipment and furniture</link:label>
    <link:label id="lab_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017_label_en-US" xlink:label="lab_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Equipment And Furniture [Member]</link:label>
    <link:label id="lab_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017_documentation_en-US" xlink:label="lab_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General equipment and furniture.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_GeneralEquipmentAndFurnitureMember" xlink:label="loc_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017" xlink:to="lab_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_B7F35B02833756E9C0FECC2FE8480A82_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_B7F35B02833756E9C0FECC2FE8480A82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_B7F35B02833756E9C0FECC2FE8480A82_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_B7F35B02833756E9C0FECC2FE8480A82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_B7F35B02833756E9C0FECC2FE8480A82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_B7F35B02833756E9C0FECC2FE8480A82" xlink:to="lab_us-gaap_ComputerEquipmentMember_B7F35B02833756E9C0FECC2FE8480A82" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_16564395A9019343FF83CC2FE848CF5B_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_16564395A9019343FF83CC2FE848CF5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_16564395A9019343FF83CC2FE848CF5B_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_16564395A9019343FF83CC2FE848CF5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_16564395A9019343FF83CC2FE848CF5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_16564395A9019343FF83CC2FE848CF5B" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_16564395A9019343FF83CC2FE848CF5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4F826DD8D950CD203A9BCC2FE8482FD5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_4F826DD8D950CD203A9BCC2FE8482FD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4F826DD8D950CD203A9BCC2FE8482FD5_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_4F826DD8D950CD203A9BCC2FE8482FD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4F826DD8D950CD203A9BCC2FE8482FD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_4F826DD8D950CD203A9BCC2FE8482FD5" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_4F826DD8D950CD203A9BCC2FE8482FD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5D1D58C1ED2C7946F3ADCC2FE849F993_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5D1D58C1ED2C7946F3ADCC2FE849F993" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5D1D58C1ED2C7946F3ADCC2FE849F993_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5D1D58C1ED2C7946F3ADCC2FE849F993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5D1D58C1ED2C7946F3ADCC2FE849F993" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5D1D58C1ED2C7946F3ADCC2FE849F993" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5D1D58C1ED2C7946F3ADCC2FE849F993" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_C063110B236622C8CFE7CC2FE84927DF_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_C063110B236622C8CFE7CC2FE84927DF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_C063110B236622C8CFE7CC2FE84927DF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_C063110B236622C8CFE7CC2FE84927DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C063110B236622C8CFE7CC2FE84927DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_C063110B236622C8CFE7CC2FE84927DF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_C063110B236622C8CFE7CC2FE84927DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_2ACC6F67C66DED6D54F0CCC7F2A1852F_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_2ACC6F67C66DED6D54F0CCC7F2A1852F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2ACC6F67C66DED6D54F0CCC7F2A1852F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_2ACC6F67C66DED6D54F0CCC7F2A1852F" xlink:to="lab_us-gaap_Depreciation_2ACC6F67C66DED6D54F0CCC7F2A1852F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_80C3DFF66F2044BBEA9332379CCD424B_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_80C3DFF66F2044BBEA9332379CCD424B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_80C3DFF66F2044BBEA9332379CCD424B_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_80C3DFF66F2044BBEA9332379CCD424B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_80C3DFF66F2044BBEA9332379CCD424B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_80C3DFF66F2044BBEA9332379CCD424B" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_80C3DFF66F2044BBEA9332379CCD424B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_F908C55E775BB954CDF7738E225B44F5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock_F908C55E775BB954CDF7738E225B44F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Shares of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_F908C55E775BB954CDF7738E225B44F5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock_F908C55E775BB954CDF7738E225B44F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_F908C55E775BB954CDF7738E225B44F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock_F908C55E775BB954CDF7738E225B44F5" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock_F908C55E775BB954CDF7738E225B44F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_83EFED176DA3F944877473692A694EC4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_83EFED176DA3F944877473692A694EC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_83EFED176DA3F944877473692A694EC4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_83EFED176DA3F944877473692A694EC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_83EFED176DA3F944877473692A694EC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_83EFED176DA3F944877473692A694EC4" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_83EFED176DA3F944877473692A694EC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D275A93252479BC0FDD473692A69719C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D275A93252479BC0FDD473692A69719C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D275A93252479BC0FDD473692A69719C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D275A93252479BC0FDD473692A69719C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D275A93252479BC0FDD473692A69719C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D275A93252479BC0FDD473692A69719C" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D275A93252479BC0FDD473692A69719C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_87DCAC73CF9049F47B0C73692A6A0D28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_87DCAC73CF9049F47B0C73692A6A0D28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_87DCAC73CF9049F47B0C73692A6A0D28_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_87DCAC73CF9049F47B0C73692A6A0D28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_87DCAC73CF9049F47B0C73692A6A0D28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_87DCAC73CF9049F47B0C73692A6A0D28" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_87DCAC73CF9049F47B0C73692A6A0D28" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F64CFAA8930A5D48AC3E73692A6A35EE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F64CFAA8930A5D48AC3E73692A6A35EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F64CFAA8930A5D48AC3E73692A6A35EE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F64CFAA8930A5D48AC3E73692A6A35EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F64CFAA8930A5D48AC3E73692A6A35EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F64CFAA8930A5D48AC3E73692A6A35EE" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F64CFAA8930A5D48AC3E73692A6A35EE" xlink:type="arc" />
    <link:label id="lab_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689_terseLabel_en-US" xlink:label="lab_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:label id="lab_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689_label_en-US" xlink:label="lab_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:label id="lab_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689_documentation_en-US" xlink:label="lab_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of business.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DescriptionOfBusinessTable" xlink:label="loc_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:to="lab_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:type="arc" />
    <link:label id="lab_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86_terseLabel_en-US" xlink:label="lab_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AIS Operating Co Inc Preexisting Stockholders, Optionholders, and Warrantholders</link:label>
    <link:label id="lab_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86_label_en-US" xlink:label="lab_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">A I S Operating Co Inc Preexisting Stockholders Optionholders And Warrantholders [Member]</link:label>
    <link:label id="lab_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86_documentation_en-US" xlink:label="lab_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AIS Operating Co., Inc. preexisting stockholders optionholders and warrantholders.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember" xlink:label="loc_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86" xlink:to="lab_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86" xlink:type="arc" />
    <link:label id="lab_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1_terseLabel_en-US" xlink:label="lab_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:label id="lab_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1_label_en-US" xlink:label="lab_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:label id="lab_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1_documentation_en-US" xlink:label="lab_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of business.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DescriptionOfBusinessLineItems" xlink:label="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:to="lab_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D1ABE635C696BC9C39100F55134BCA83_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D1ABE635C696BC9C39100F55134BCA83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D1ABE635C696BC9C39100F55134BCA83_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D1ABE635C696BC9C39100F55134BCA83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D1ABE635C696BC9C39100F55134BCA83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D1ABE635C696BC9C39100F55134BCA83" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D1ABE635C696BC9C39100F55134BCA83" xlink:type="arc" />
    <link:label id="lab_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F_terseLabel_en-US" xlink:label="lab_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage immediately following merger consummation</link:label>
    <link:label id="lab_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F_label_en-US" xlink:label="lab_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership Percentage Immediately Following Effective Merger Consummation</link:label>
    <link:label id="lab_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F_documentation_en-US" xlink:label="lab_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ownership Percentage Immediately Following Effective Merger Consummation</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation" xlink:label="loc_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F" xlink:to="lab_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_C22DC8D223D230EA49820F55134CAE7B_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_C22DC8D223D230EA49820F55134CAE7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_C22DC8D223D230EA49820F55134CAE7B_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_C22DC8D223D230EA49820F55134CAE7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_C22DC8D223D230EA49820F55134CAE7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued_C22DC8D223D230EA49820F55134CAE7B" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued_C22DC8D223D230EA49820F55134CAE7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_09496BED1AA8BEE1BED40F551351E3E7_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_09496BED1AA8BEE1BED40F551351E3E7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, purchase price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_09496BED1AA8BEE1BED40F551351E3E7_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_09496BED1AA8BEE1BED40F551351E3E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_09496BED1AA8BEE1BED40F551351E3E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_09496BED1AA8BEE1BED40F551351E3E7" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_09496BED1AA8BEE1BED40F551351E3E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3C3ECF886781516412EE0F551351D3E3_positiveLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3C3ECF886781516412EE0F551351D3E3" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:type="resource" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3C3ECF886781516412EE0F551351D3E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3C3ECF886781516412EE0F551351D3E3" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3C3ECF886781516412EE0F551351D3E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_297B993AFD9B17D18E6E7369037FE00D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_297B993AFD9B17D18E6E7369037FE00D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_297B993AFD9B17D18E6E7369037FE00D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_297B993AFD9B17D18E6E7369037FE00D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_297B993AFD9B17D18E6E7369037FE00D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_297B993AFD9B17D18E6E7369037FE00D" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_297B993AFD9B17D18E6E7369037FE00D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_12FC56D95601B87E5AF232379AC842B0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_12FC56D95601B87E5AF232379AC842B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Future Minimum Lease Payments for Non-cancelable Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_12FC56D95601B87E5AF232379AC842B0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_12FC56D95601B87E5AF232379AC842B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_12FC56D95601B87E5AF232379AC842B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_12FC56D95601B87E5AF232379AC842B0" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_12FC56D95601B87E5AF232379AC842B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_9BF4CA2C444C558397084EE7053D5B1A_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_9BF4CA2C444C558397084EE7053D5B1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9BF4CA2C444C558397084EE7053D5B1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9BF4CA2C444C558397084EE7053D5B1A" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_9BF4CA2C444C558397084EE7053D5B1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EB4E3878D424EFA8C1EF4EE7053D18D4_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EB4E3878D424EFA8C1EF4EE7053D18D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) Retirement Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EB4E3878D424EFA8C1EF4EE7053D18D4_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EB4E3878D424EFA8C1EF4EE7053D18D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EB4E3878D424EFA8C1EF4EE7053D18D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EB4E3878D424EFA8C1EF4EE7053D18D4" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EB4E3878D424EFA8C1EF4EE7053D18D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6B7B11404E643966AEEBCD390B405C4C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6B7B11404E643966AEEBCD390B405C4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6B7B11404E643966AEEBCD390B405C4C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6B7B11404E643966AEEBCD390B405C4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6B7B11404E643966AEEBCD390B405C4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6B7B11404E643966AEEBCD390B405C4C" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6B7B11404E643966AEEBCD390B405C4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_FEA149E7E03FAE7637AECD390B40DEA4_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_FEA149E7E03FAE7637AECD390B40DEA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_FEA149E7E03FAE7637AECD390B40DEA4_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_FEA149E7E03FAE7637AECD390B40DEA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_FEA149E7E03FAE7637AECD390B40DEA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_FEA149E7E03FAE7637AECD390B40DEA4" xlink:to="lab_us-gaap_TitleOfIndividualAxis_FEA149E7E03FAE7637AECD390B40DEA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4E8F9BE054C5712C347DCD390B40B5E0" xlink:type="arc" />
    <link:label id="lab_alpn_EmployeesMember_35EDED410FF17FF58E80CD390B414E47_terseLabel_en-US" xlink:label="lab_alpn_EmployeesMember_35EDED410FF17FF58E80CD390B414E47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_alpn_EmployeesMember_35EDED410FF17FF58E80CD390B414E47_label_en-US" xlink:label="lab_alpn_EmployeesMember_35EDED410FF17FF58E80CD390B414E47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees [Member]</link:label>
    <link:label id="lab_alpn_EmployeesMember_35EDED410FF17FF58E80CD390B414E47_documentation_en-US" xlink:label="lab_alpn_EmployeesMember_35EDED410FF17FF58E80CD390B414E47" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EmployeesMember" xlink:label="loc_alpn_EmployeesMember_35EDED410FF17FF58E80CD390B414E47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_EmployeesMember_35EDED410FF17FF58E80CD390B414E47" xlink:to="lab_alpn_EmployeesMember_35EDED410FF17FF58E80CD390B414E47" xlink:type="arc" />
    <link:label id="lab_alpn_NonEmployeesMember_7794E748D31A06A64C3BCD390B41E6AA_terseLabel_en-US" xlink:label="lab_alpn_NonEmployeesMember_7794E748D31A06A64C3BCD390B41E6AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Employee</link:label>
    <link:label id="lab_alpn_NonEmployeesMember_7794E748D31A06A64C3BCD390B41E6AA_label_en-US" xlink:label="lab_alpn_NonEmployeesMember_7794E748D31A06A64C3BCD390B41E6AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Employees [Member]</link:label>
    <link:label id="lab_alpn_NonEmployeesMember_7794E748D31A06A64C3BCD390B41E6AA_documentation_en-US" xlink:label="lab_alpn_NonEmployeesMember_7794E748D31A06A64C3BCD390B41E6AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Employees [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NonEmployeesMember" xlink:label="loc_alpn_NonEmployeesMember_7794E748D31A06A64C3BCD390B41E6AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_NonEmployeesMember_7794E748D31A06A64C3BCD390B41E6AA" xlink:to="lab_alpn_NonEmployeesMember_7794E748D31A06A64C3BCD390B41E6AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_BA88EC05523CE4BBC80BCD390B415BFD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_BA88EC05523CE4BBC80BCD390B415BFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_BA88EC05523CE4BBC80BCD390B415BFD_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_BA88EC05523CE4BBC80BCD390B415BFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_BA88EC05523CE4BBC80BCD390B415BFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_BA88EC05523CE4BBC80BCD390B415BFD" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_BA88EC05523CE4BBC80BCD390B415BFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_B7FC417C16EE5B365766CD390B419868" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_872BAF454674A23108A5CD390B416B3E_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_872BAF454674A23108A5CD390B416B3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_872BAF454674A23108A5CD390B416B3E_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_872BAF454674A23108A5CD390B416B3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_872BAF454674A23108A5CD390B416B3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_872BAF454674A23108A5CD390B416B3E" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_872BAF454674A23108A5CD390B416B3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_727F99D1B735ACEB4852CD390B427008_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_727F99D1B735ACEB4852CD390B427008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_727F99D1B735ACEB4852CD390B427008_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_727F99D1B735ACEB4852CD390B427008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_727F99D1B735ACEB4852CD390B427008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_727F99D1B735ACEB4852CD390B427008" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_727F99D1B735ACEB4852CD390B427008" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1028C031FE437501BB50CD390B42B345_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1028C031FE437501BB50CD390B42B345" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1028C031FE437501BB50CD390B42B345_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1028C031FE437501BB50CD390B42B345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1028C031FE437501BB50CD390B42B345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1028C031FE437501BB50CD390B42B345" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1028C031FE437501BB50CD390B42B345" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF9AF0230C188037027BCD390B423D19_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF9AF0230C188037027BCD390B423D19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF9AF0230C188037027BCD390B423D19_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF9AF0230C188037027BCD390B423D19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF9AF0230C188037027BCD390B423D19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF9AF0230C188037027BCD390B423D19" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF9AF0230C188037027BCD390B423D19" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4C35FE3A7DCFDACFDDCC4EE70637474B_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4C35FE3A7DCFDACFDDCC4EE70637474B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4C35FE3A7DCFDACFDDCC4EE70637474B_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4C35FE3A7DCFDACFDDCC4EE70637474B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4C35FE3A7DCFDACFDDCC4EE70637474B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4C35FE3A7DCFDACFDDCC4EE70637474B" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4C35FE3A7DCFDACFDDCC4EE70637474B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A_label_en-US" xlink:label="lab_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A" xlink:to="lab_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448_terseLabel_en-US" xlink:label="lab_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448_label_en-US" xlink:label="lab_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448" xlink:to="lab_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_44F4AA06C529D4DF4D5691B71FD6214B_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_44F4AA06C529D4DF4D5691B71FD6214B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_44F4AA06C529D4DF4D5691B71FD6214B_label_en-US" xlink:label="lab_srt_MaximumMember_44F4AA06C529D4DF4D5691B71FD6214B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_44F4AA06C529D4DF4D5691B71FD6214B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_44F4AA06C529D4DF4D5691B71FD6214B" xlink:to="lab_srt_MaximumMember_44F4AA06C529D4DF4D5691B71FD6214B" xlink:type="arc" />
    <link:label id="lab_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F_terseLabel_en-US" xlink:label="lab_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cowen and Company, LLC</link:label>
    <link:label id="lab_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F_label_en-US" xlink:label="lab_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cowen and Company, LLC [Member]</link:label>
    <link:label id="lab_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F_documentation_en-US" xlink:label="lab_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cowen and Company, LLC [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CowenandCompanyLLCMember" xlink:label="loc_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F" xlink:to="lab_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F" xlink:type="arc" />
    <link:label id="lab_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7_terseLabel_en-US" xlink:label="lab_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Piper Jaffray &amp; Co.</link:label>
    <link:label id="lab_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7_label_en-US" xlink:label="lab_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Piper Jaffray &amp; Co. [Member]</link:label>
    <link:label id="lab_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7_documentation_en-US" xlink:label="lab_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Piper Jaffray &amp; Co. [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PiperJaffrayCo.Member" xlink:label="loc_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7" xlink:to="lab_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_5B3EC5131AE3CFB46F3D91B71FD7D982_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_5B3EC5131AE3CFB46F3D91B71FD7D982" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_5B3EC5131AE3CFB46F3D91B71FD7D982_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_5B3EC5131AE3CFB46F3D91B71FD7D982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_5B3EC5131AE3CFB46F3D91B71FD7D982" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_5B3EC5131AE3CFB46F3D91B71FD7D982" xlink:to="lab_us-gaap_EmployeeStockMember_5B3EC5131AE3CFB46F3D91B71FD7D982" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9" xlink:to="lab_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:to="lab_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:type="arc" />
    <link:label id="lab_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08_terseLabel_en-US" xlink:label="lab_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08_label_en-US" xlink:label="lab_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Eighteen Plan [Member]</link:label>
    <link:label id="lab_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08_documentation_en-US" xlink:label="lab_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Eighteen Plan [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TwoThousandAndEighteenPlanMember" xlink:label="loc_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08" xlink:to="lab_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08" xlink:type="arc" />
    <link:label id="lab_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE_terseLabel_en-US" xlink:label="lab_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement Grant</link:label>
    <link:label id="lab_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE_label_en-US" xlink:label="lab_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Grant [Member]</link:label>
    <link:label id="lab_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE_documentation_en-US" xlink:label="lab_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inducement Grant [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_InducementGrantMember" xlink:label="loc_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE" xlink:to="lab_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE" xlink:type="arc" />
    <link:label id="lab_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A_terseLabel_en-US" xlink:label="lab_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive Stock Option</link:label>
    <link:label id="lab_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A_label_en-US" xlink:label="lab_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Stock Option [Member]</link:label>
    <link:label id="lab_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A_documentation_en-US" xlink:label="lab_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Stock Option [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncentiveStockOptionMember" xlink:label="loc_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A" xlink:to="lab_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A" xlink:type="arc" />
    <link:label id="lab_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE_terseLabel_en-US" xlink:label="lab_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Plan 2018, Stock Plan 2015 And Equity Incentive Plan 2015</link:label>
    <link:label id="lab_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE_label_en-US" xlink:label="lab_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Plan 2018, Stock Plan 2015 And Equity Incentive Plan 2015 [Member]</link:label>
    <link:label id="lab_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE_documentation_en-US" xlink:label="lab_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Plan 2018, Stock Plan 2015 And Equity Incentive Plan 2015 [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member" xlink:label="loc_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE" xlink:to="lab_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE" xlink:type="arc" />
    <link:label id="lab_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B_terseLabel_en-US" xlink:label="lab_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Plan 2018</link:label>
    <link:label id="lab_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B_label_en-US" xlink:label="lab_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Plan 2018 [Member]</link:label>
    <link:label id="lab_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B_documentation_en-US" xlink:label="lab_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Plan 2018 [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_StockPlan2018Member" xlink:label="loc_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B" xlink:to="lab_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8" xlink:to="lab_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:type="arc" />
    <link:label id="lab_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C_terseLabel_en-US" xlink:label="lab_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Initial Reserves</link:label>
    <link:label id="lab_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C_label_en-US" xlink:label="lab_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Initial Reserves [Member]</link:label>
    <link:label id="lab_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C_documentation_en-US" xlink:label="lab_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Initial Reserves [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CommonStockInitialReservesMember" xlink:label="loc_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C" xlink:to="lab_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C" xlink:type="arc" />
    <link:label id="lab_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071_terseLabel_en-US" xlink:label="lab_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legacy Plan Cancellations</link:label>
    <link:label id="lab_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071_label_en-US" xlink:label="lab_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legacy Plan Cancellations [Member]</link:label>
    <link:label id="lab_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071_documentation_en-US" xlink:label="lab_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legacy Plan Cancellations [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_LegacyPlanCancellationsMember" xlink:label="loc_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071" xlink:to="lab_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_DECEA53175C154B7D17B91B71FDA1A29_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_DECEA53175C154B7D17B91B71FDA1A29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_DECEA53175C154B7D17B91B71FDA1A29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_DECEA53175C154B7D17B91B71FDA1A29" xlink:to="lab_us-gaap_EmployeeStockOptionMember_DECEA53175C154B7D17B91B71FDA1A29" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="lab_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_62106B3770B79A8A64A991B71FDB29BA_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_62106B3770B79A8A64A991B71FDB29BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock converted to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_62106B3770B79A8A64A991B71FDB29BA_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_62106B3770B79A8A64A991B71FDB29BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_62106B3770B79A8A64A991B71FDB29BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_62106B3770B79A8A64A991B71FDB29BA" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_62106B3770B79A8A64A991B71FDB29BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_E25B4F3C127D9A1999AC91B71FDBF210_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_E25B4F3C127D9A1999AC91B71FDBF210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_E25B4F3C127D9A1999AC91B71FDBF210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_E25B4F3C127D9A1999AC91B71FDBF210" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_E25B4F3C127D9A1999AC91B71FDBF210" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_429C6B05EF776ECC537C91B71FDBB470_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares_429C6B05EF776ECC537C91B71FDBB470" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of unvested common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_429C6B05EF776ECC537C91B71FDBB470_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares_429C6B05EF776ECC537C91B71FDBB470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_429C6B05EF776ECC537C91B71FDBB470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares_429C6B05EF776ECC537C91B71FDBB470" xlink:to="lab_us-gaap_TreasuryStockCommonShares_429C6B05EF776ECC537C91B71FDBB470" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_42B52E0F6D308D2888AF91B71FDB6687_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_42B52E0F6D308D2888AF91B71FDB6687" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_42B52E0F6D308D2888AF91B71FDB6687_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_42B52E0F6D308D2888AF91B71FDB6687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_42B52E0F6D308D2888AF91B71FDB6687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_42B52E0F6D308D2888AF91B71FDB6687" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_42B52E0F6D308D2888AF91B71FDB6687" xlink:type="arc" />
    <link:label id="lab_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE_terseLabel_en-US" xlink:label="lab_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount of common stock eligible to be sold</link:label>
    <link:label id="lab_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE_label_en-US" xlink:label="lab_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Amount Of Common Stock Eligible To Be Sold</link:label>
    <link:label id="lab_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE_documentation_en-US" xlink:label="lab_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Amount Of Common Stock Eligible To Be Sold</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_MaximumAmountOfCommonStockEligibleToBeSold" xlink:label="loc_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE" xlink:to="lab_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE" xlink:type="arc" />
    <link:label id="lab_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1_terseLabel_en-US" xlink:label="lab_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of compensation for services</link:label>
    <link:label id="lab_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1_label_en-US" xlink:label="lab_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Percentage of Compensation for Services</link:label>
    <link:label id="lab_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1_documentation_en-US" xlink:label="lab_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Percentage of Compensation for Services</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices" xlink:label="loc_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1" xlink:to="lab_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_C4552B97464818896F3191B71FDCF273_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_C4552B97464818896F3191B71FDCF273" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_C4552B97464818896F3191B71FDCF273_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_C4552B97464818896F3191B71FDCF273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_C4552B97464818896F3191B71FDCF273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_C4552B97464818896F3191B71FDCF273" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_C4552B97464818896F3191B71FDCF273" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_BA8CE2FCA27553F66B1C91B71FDC8B24_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_BA8CE2FCA27553F66B1C91B71FDC8B24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_BA8CE2FCA27553F66B1C91B71FDC8B24_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_BA8CE2FCA27553F66B1C91B71FDC8B24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_BA8CE2FCA27553F66B1C91B71FDC8B24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_BA8CE2FCA27553F66B1C91B71FDC8B24" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_BA8CE2FCA27553F66B1C91B71FDC8B24" xlink:type="arc" />
    <link:label id="lab_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52_terseLabel_en-US" xlink:label="lab_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per unit, common stock to warrant ratio (in shares)</link:label>
    <link:label id="lab_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52_label_en-US" xlink:label="lab_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement Ratio Of Common Stock To Warrants</link:label>
    <link:label id="lab_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52_documentation_en-US" xlink:label="lab_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement Ratio Of Common Stock To Warrants</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PurchaseAgreementRatioOfCommonStockToWarrants" xlink:label="loc_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52" xlink:to="lab_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52" xlink:type="arc" />
    <link:label id="lab_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB_terseLabel_en-US" xlink:label="lab_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price per unit (in dollars per unit)</link:label>
    <link:label id="lab_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB_label_en-US" xlink:label="lab_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement Aggregate Purchase Price Per Unit</link:label>
    <link:label id="lab_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB_documentation_en-US" xlink:label="lab_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement Aggregate Purchase Price Per Unit</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PurchaseAgreementAggregatePurchasePricePerUnit" xlink:label="loc_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB" xlink:to="lab_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5C77DFE6EE32A471FD7E91B71FDC97F3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5C77DFE6EE32A471FD7E91B71FDC97F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5C77DFE6EE32A471FD7E91B71FDC97F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5C77DFE6EE32A471FD7E91B71FDC97F3" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5C77DFE6EE32A471FD7E91B71FDC97F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_E60F6FEDB9365E64C4A491B97FBCE256_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_E60F6FEDB9365E64C4A491B97FBCE256" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_E60F6FEDB9365E64C4A491B97FBCE256_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_E60F6FEDB9365E64C4A491B97FBCE256" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_E60F6FEDB9365E64C4A491B97FBCE256" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_E60F6FEDB9365E64C4A491B97FBCE256" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_E60F6FEDB9365E64C4A491B97FBCE256" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14CD82C8CC25D08F582091B71FDD59CC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14CD82C8CC25D08F582091B71FDD59CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14CD82C8CC25D08F582091B71FDD59CC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14CD82C8CC25D08F582091B71FDD59CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14CD82C8CC25D08F582091B71FDD59CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14CD82C8CC25D08F582091B71FDD59CC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14CD82C8CC25D08F582091B71FDD59CC" xlink:type="arc" />
    <link:label id="lab_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75_terseLabel_en-US" xlink:label="lab_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding stock maximum</link:label>
    <link:label id="lab_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75_label_en-US" xlink:label="lab_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share based Payment Award Annual Additional Shares Authorized Percent</link:label>
    <link:label id="lab_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75_documentation_en-US" xlink:label="lab_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share based Payment Award Annual Additional Shares Authorized Percent</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent" xlink:label="loc_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75" xlink:to="lab_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_E04BA13CCA3F0F27613091B71FDDCFB7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_E04BA13CCA3F0F27613091B71FDDCFB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_E04BA13CCA3F0F27613091B71FDDCFB7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_E04BA13CCA3F0F27613091B71FDDCFB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_E04BA13CCA3F0F27613091B71FDDCFB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_E04BA13CCA3F0F27613091B71FDDCFB7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_E04BA13CCA3F0F27613091B71FDDCFB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1E369B725C5F5F46911191B71FDE7C5B_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1E369B725C5F5F46911191B71FDE7C5B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1E369B725C5F5F46911191B71FDE7C5B_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1E369B725C5F5F46911191B71FDE7C5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1E369B725C5F5F46911191B71FDE7C5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1E369B725C5F5F46911191B71FDE7C5B" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1E369B725C5F5F46911191B71FDE7C5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38651EC26A6BFE6057C291B71FDEE6B0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38651EC26A6BFE6057C291B71FDEE6B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38651EC26A6BFE6057C291B71FDEE6B0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38651EC26A6BFE6057C291B71FDEE6B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38651EC26A6BFE6057C291B71FDEE6B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38651EC26A6BFE6057C291B71FDEE6B0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38651EC26A6BFE6057C291B71FDEE6B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_02133D8A6A33DA370F7E91B71FDE03E0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_02133D8A6A33DA370F7E91B71FDE03E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_02133D8A6A33DA370F7E91B71FDE03E0_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_02133D8A6A33DA370F7E91B71FDE03E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_02133D8A6A33DA370F7E91B71FDE03E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_02133D8A6A33DA370F7E91B71FDE03E0" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_02133D8A6A33DA370F7E91B71FDE03E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_12EF3BFDE3D02A921FE891B71FDE7784_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_12EF3BFDE3D02A921FE891B71FDE7784" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to nonvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_12EF3BFDE3D02A921FE891B71FDE7784_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_12EF3BFDE3D02A921FE891B71FDE7784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_12EF3BFDE3D02A921FE891B71FDE7784" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_12EF3BFDE3D02A921FE891B71FDE7784" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_12EF3BFDE3D02A921FE891B71FDE7784" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35475648EF2A7191082091B71FDED7C7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35475648EF2A7191082091B71FDED7C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period over which unrecognized compensation expense related to nonvested stock options is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35475648EF2A7191082091B71FDED7C7_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35475648EF2A7191082091B71FDED7C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35475648EF2A7191082091B71FDED7C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35475648EF2A7191082091B71FDED7C7" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35475648EF2A7191082091B71FDED7C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_06F6A3CAF47D584A698091B71FDFB9D9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_06F6A3CAF47D584A698091B71FDFB9D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_06F6A3CAF47D584A698091B71FDFB9D9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_06F6A3CAF47D584A698091B71FDFB9D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_06F6A3CAF47D584A698091B71FDFB9D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_06F6A3CAF47D584A698091B71FDFB9D9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_06F6A3CAF47D584A698091B71FDFB9D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7C0B62C4B053B448615091B71FDF86E6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7C0B62C4B053B448615091B71FDF86E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7C0B62C4B053B448615091B71FDF86E6_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7C0B62C4B053B448615091B71FDF86E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7C0B62C4B053B448615091B71FDF86E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7C0B62C4B053B448615091B71FDF86E6" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7C0B62C4B053B448615091B71FDF86E6" xlink:type="arc" />
    <link:label id="lab_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C_terseLabel_en-US" xlink:label="lab_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extended vesting period of number of unvested share options (in shares)</link:label>
    <link:label id="lab_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C_label_en-US" xlink:label="lab_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extended Vesting Period Of Number Of Unvested Share Options</link:label>
    <link:label id="lab_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C_documentation_en-US" xlink:label="lab_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extended vesting period of number of unvested share options .</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions" xlink:label="loc_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C" xlink:to="lab_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C" xlink:type="arc" />
    <link:label id="lab_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889_terseLabel_en-US" xlink:label="lab_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889_label_en-US" xlink:label="lab_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Employees</link:label>
    <link:label id="lab_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889_documentation_en-US" xlink:label="lab_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of employees.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfEmployees" xlink:label="loc_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889" xlink:to="lab_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889" xlink:type="arc" />
    <link:label id="lab_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814_terseLabel_en-US" xlink:label="lab_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional compensation expense</link:label>
    <link:label id="lab_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814_label_en-US" xlink:label="lab_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Compensation Expense</link:label>
    <link:label id="lab_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814_documentation_en-US" xlink:label="lab_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional compensation expense.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AdditionalCompensationExpense" xlink:label="loc_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814" xlink:to="lab_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_48A266016B0817F2794E4EE7078DD6F3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_48A266016B0817F2794E4EE7078DD6F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_48A266016B0817F2794E4EE7078DD6F3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_48A266016B0817F2794E4EE7078DD6F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_48A266016B0817F2794E4EE7078DD6F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_48A266016B0817F2794E4EE7078DD6F3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_48A266016B0817F2794E4EE7078DD6F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4ACB4C7F77581BB0EE458272BD3A0C23_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4ACB4C7F77581BB0EE458272BD3A0C23" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4ACB4C7F77581BB0EE458272BD3A0C23_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4ACB4C7F77581BB0EE458272BD3A0C23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4ACB4C7F77581BB0EE458272BD3A0C23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4ACB4C7F77581BB0EE458272BD3A0C23" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4ACB4C7F77581BB0EE458272BD3A0C23" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of:</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5AFB0923AF67848746378272BD3BD851_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5AFB0923AF67848746378272BD3BD851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5AFB0923AF67848746378272BD3BD851_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5AFB0923AF67848746378272BD3BD851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5AFB0923AF67848746378272BD3BD851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5AFB0923AF67848746378272BD3BD851" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5AFB0923AF67848746378272BD3BD851" xlink:type="arc" />
    <link:label id="lab_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1689DE4DF23FBAF9BEAD8272BD3B0441_negatedTerseLabel_en-US" xlink:label="lab_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1689DE4DF23FBAF9BEAD8272BD3B0441" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1689DE4DF23FBAF9BEAD8272BD3B0441_label_en-US" xlink:label="lab_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1689DE4DF23FBAF9BEAD8272BD3B0441" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:label id="lab_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1689DE4DF23FBAF9BEAD8272BD3B0441_documentation_en-US" xlink:label="lab_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1689DE4DF23FBAF9BEAD8272BD3B0441" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation permanent differences.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="loc_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1689DE4DF23FBAF9BEAD8272BD3B0441" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1689DE4DF23FBAF9BEAD8272BD3B0441" xlink:to="lab_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1689DE4DF23FBAF9BEAD8272BD3B0441" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_82D97CF776F1C34DA6CC8272BD3B4C3F_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_82D97CF776F1C34DA6CC8272BD3B4C3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal research and development credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_82D97CF776F1C34DA6CC8272BD3B4C3F_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_82D97CF776F1C34DA6CC8272BD3B4C3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_82D97CF776F1C34DA6CC8272BD3B4C3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_82D97CF776F1C34DA6CC8272BD3B4C3F" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_82D97CF776F1C34DA6CC8272BD3B4C3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD0AE32CF64705B0C2A78272BD3BAB5B_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD0AE32CF64705B0C2A78272BD3BAB5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD0AE32CF64705B0C2A78272BD3BAB5B_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD0AE32CF64705B0C2A78272BD3BAB5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD0AE32CF64705B0C2A78272BD3BAB5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD0AE32CF64705B0C2A78272BD3BAB5B" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD0AE32CF64705B0C2A78272BD3BAB5B" xlink:type="arc" />
    <link:label id="lab_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_F498131CB8A1B2F1B07E8272BD3C0D45_terseLabel_en-US" xlink:label="lab_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_F498131CB8A1B2F1B07E8272BD3C0D45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit of a lower tax rate</link:label>
    <link:label id="lab_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_F498131CB8A1B2F1B07E8272BD3C0D45_label_en-US" xlink:label="lab_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_F498131CB8A1B2F1B07E8272BD3C0D45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Benefit Of Lower Tax Rate</link:label>
    <link:label id="lab_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_F498131CB8A1B2F1B07E8272BD3C0D45_documentation_en-US" xlink:label="lab_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_F498131CB8A1B2F1B07E8272BD3C0D45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation benefit of lower tax rate.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate" xlink:label="loc_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_F498131CB8A1B2F1B07E8272BD3C0D45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_F498131CB8A1B2F1B07E8272BD3C0D45" xlink:to="lab_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_F498131CB8A1B2F1B07E8272BD3C0D45" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_E7A168E33897B81D10208272BD3C11D8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_E7A168E33897B81D10208272BD3C11D8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_E7A168E33897B81D10208272BD3C11D8_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_E7A168E33897B81D10208272BD3C11D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_E7A168E33897B81D10208272BD3C11D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_E7A168E33897B81D10208272BD3C11D8" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_E7A168E33897B81D10208272BD3C11D8" xlink:type="arc" />
    <link:label id="lab_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_201C29A92BEC3DC744E28272BD3D5176_terseLabel_en-US" xlink:label="lab_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_201C29A92BEC3DC744E28272BD3D5176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible merger costs</link:label>
    <link:label id="lab_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_201C29A92BEC3DC744E28272BD3D5176_label_en-US" xlink:label="lab_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_201C29A92BEC3DC744E28272BD3D5176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Non Deductible Merger Related Costs</link:label>
    <link:label id="lab_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_201C29A92BEC3DC744E28272BD3D5176_documentation_en-US" xlink:label="lab_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_201C29A92BEC3DC744E28272BD3D5176" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, non-deductible merger related costs.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts" xlink:label="loc_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_201C29A92BEC3DC744E28272BD3D5176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_201C29A92BEC3DC744E28272BD3D5176" xlink:to="lab_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_201C29A92BEC3DC744E28272BD3D5176" xlink:type="arc" />
    <link:label id="lab_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_DD85D5CF940B9C76DCA18272BD3D0DBC_terseLabel_en-US" xlink:label="lab_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_DD85D5CF940B9C76DCA18272BD3D0DBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bargain purchase gain</link:label>
    <link:label id="lab_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_DD85D5CF940B9C76DCA18272BD3D0DBC_label_en-US" xlink:label="lab_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_DD85D5CF940B9C76DCA18272BD3D0DBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Bargain Purchase Gain</link:label>
    <link:label id="lab_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_DD85D5CF940B9C76DCA18272BD3D0DBC_documentation_en-US" xlink:label="lab_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_DD85D5CF940B9C76DCA18272BD3D0DBC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, bargain purchase gain.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain" xlink:label="loc_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_DD85D5CF940B9C76DCA18272BD3D0DBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_DD85D5CF940B9C76DCA18272BD3D0DBC" xlink:to="lab_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_DD85D5CF940B9C76DCA18272BD3D0DBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_56912757026B14C5F1DB8272BD3D8B4B_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_56912757026B14C5F1DB8272BD3D8B4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax rate change</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_56912757026B14C5F1DB8272BD3D8B4B_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_56912757026B14C5F1DB8272BD3D8B4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_56912757026B14C5F1DB8272BD3D8B4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_56912757026B14C5F1DB8272BD3D8B4B" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_56912757026B14C5F1DB8272BD3D8B4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D417590F9D8079EDF6578272BD3DAC50_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D417590F9D8079EDF6578272BD3DAC50" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D417590F9D8079EDF6578272BD3DAC50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D417590F9D8079EDF6578272BD3DAC50" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D417590F9D8079EDF6578272BD3DAC50" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:to="lab_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D496D3F90C784745F7D1916650E28771_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D496D3F90C784745F7D1916650E28771" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D496D3F90C784745F7D1916650E28771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D496D3F90C784745F7D1916650E28771" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D496D3F90C784745F7D1916650E28771" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049" xlink:to="lab_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1FA2965730CAB68A717C916650E39808_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1FA2965730CAB68A717C916650E39808" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1FA2965730CAB68A717C916650E39808_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1FA2965730CAB68A717C916650E39808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1FA2965730CAB68A717C916650E39808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_1FA2965730CAB68A717C916650E39808" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1FA2965730CAB68A717C916650E39808" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_37FAE444F3C461E4575D916650E366B2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_37FAE444F3C461E4575D916650E366B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_37FAE444F3C461E4575D916650E366B2_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_37FAE444F3C461E4575D916650E366B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_37FAE444F3C461E4575D916650E366B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_37FAE444F3C461E4575D916650E366B2" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_37FAE444F3C461E4575D916650E366B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_84846C6B5D7584A5365A916650E32844_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_84846C6B5D7584A5365A916650E32844" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_84846C6B5D7584A5365A916650E32844_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_84846C6B5D7584A5365A916650E32844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_84846C6B5D7584A5365A916650E32844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_84846C6B5D7584A5365A916650E32844" xlink:to="lab_us-gaap_OperatingExpenses_84846C6B5D7584A5365A916650E32844" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4300F0FDAF47CA2BE6B0916650E36BB5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_4300F0FDAF47CA2BE6B0916650E36BB5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4300F0FDAF47CA2BE6B0916650E36BB5_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_4300F0FDAF47CA2BE6B0916650E36BB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_4300F0FDAF47CA2BE6B0916650E36BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_4300F0FDAF47CA2BE6B0916650E36BB5" xlink:to="lab_us-gaap_OperatingIncomeLoss_4300F0FDAF47CA2BE6B0916650E36BB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_DCB90E40FF613B33D5CC916650E4670A_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_DCB90E40FF613B33D5CC916650E4670A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_DCB90E40FF613B33D5CC916650E4670A_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_DCB90E40FF613B33D5CC916650E4670A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DCB90E40FF613B33D5CC916650E4670A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DCB90E40FF613B33D5CC916650E4670A" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_DCB90E40FF613B33D5CC916650E4670A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_72A37C2AAC9AC4959A8E916650E44E00_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_72A37C2AAC9AC4959A8E916650E44E00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bargain purchase gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:label="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_72A37C2AAC9AC4959A8E916650E44E00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_72A37C2AAC9AC4959A8E916650E44E00" xlink:to="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_72A37C2AAC9AC4959A8E916650E44E00" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_136835EC5DA298527B17916650E4A896_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_136835EC5DA298527B17916650E4A896" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_136835EC5DA298527B17916650E4A896_label_en-US" xlink:label="lab_us-gaap_InterestExpense_136835EC5DA298527B17916650E4A896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_136835EC5DA298527B17916650E4A896" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_136835EC5DA298527B17916650E4A896" xlink:to="lab_us-gaap_InterestExpense_136835EC5DA298527B17916650E4A896" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestAndOtherIncome_86DEA2D3DA574501AAE5916650E4166C_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome_86DEA2D3DA574501AAE5916650E4166C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_86DEA2D3DA574501AAE5916650E4166C_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome_86DEA2D3DA574501AAE5916650E4166C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_86DEA2D3DA574501AAE5916650E4166C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome_86DEA2D3DA574501AAE5916650E4166C" xlink:to="lab_us-gaap_InterestAndOtherIncome_86DEA2D3DA574501AAE5916650E4166C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D5F7B82F84DD7A594F1D916650E4FA11_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D5F7B82F84DD7A594F1D916650E4FA11" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D5F7B82F84DD7A594F1D916650E4FA11_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D5F7B82F84DD7A594F1D916650E4FA11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D5F7B82F84DD7A594F1D916650E4FA11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D5F7B82F84DD7A594F1D916650E4FA11" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D5F7B82F84DD7A594F1D916650E4FA11" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E1D1431418C205AA56F0916650E4B6DB_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E1D1431418C205AA56F0916650E4B6DB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E1D1431418C205AA56F0916650E4B6DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_E1D1431418C205AA56F0916650E4B6DB" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_E1D1431418C205AA56F0916650E4B6DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_EF0931851F497A1B7248916650E5BB83_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_EF0931851F497A1B7248916650E5BB83" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss attributable to common stockholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EF0931851F497A1B7248916650E5BB83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_EF0931851F497A1B7248916650E5BB83" xlink:to="lab_us-gaap_NetIncomeLoss_EF0931851F497A1B7248916650E5BB83" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_950D6120041FFFA8A70F916650E52E63_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_950D6120041FFFA8A70F916650E52E63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_950D6120041FFFA8A70F916650E52E63_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_950D6120041FFFA8A70F916650E52E63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_950D6120041FFFA8A70F916650E52E63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_950D6120041FFFA8A70F916650E52E63" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_950D6120041FFFA8A70F916650E52E63" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D2C19E2E6BE9960847E8916650E5DE96_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D2C19E2E6BE9960847E8916650E5DE96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D2C19E2E6BE9960847E8916650E5DE96_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D2C19E2E6BE9960847E8916650E5DE96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D2C19E2E6BE9960847E8916650E5DE96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D2C19E2E6BE9960847E8916650E5DE96" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D2C19E2E6BE9960847E8916650E5DE96" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_AA3EBD3DBAA0A009E148916650E5A618_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_AA3EBD3DBAA0A009E148916650E5A618" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_AA3EBD3DBAA0A009E148916650E5A618_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_AA3EBD3DBAA0A009E148916650E5A618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_AA3EBD3DBAA0A009E148916650E5A618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_AA3EBD3DBAA0A009E148916650E5A618" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_AA3EBD3DBAA0A009E148916650E5A618" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C2E5902C339D7BCEBA87916650E53A26_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C2E5902C339D7BCEBA87916650E53A26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used to compute basic and diluted net loss per share attributable to common stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C2E5902C339D7BCEBA87916650E53A26_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C2E5902C339D7BCEBA87916650E53A26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C2E5902C339D7BCEBA87916650E53A26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C2E5902C339D7BCEBA87916650E53A26" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C2E5902C339D7BCEBA87916650E53A26" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_0188ED34FC9A286131FA916650E62CBF_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_0188ED34FC9A286131FA916650E62CBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share attributable to common stockholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_0188ED34FC9A286131FA916650E62CBF_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_0188ED34FC9A286131FA916650E62CBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_0188ED34FC9A286131FA916650E62CBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_0188ED34FC9A286131FA916650E62CBF" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_0188ED34FC9A286131FA916650E62CBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_948EB82DEADA2729EC1C73063796EE1C_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_948EB82DEADA2729EC1C73063796EE1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_948EB82DEADA2729EC1C73063796EE1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_948EB82DEADA2729EC1C73063796EE1C" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_948EB82DEADA2729EC1C73063796EE1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69" xlink:to="lab_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00" xlink:to="lab_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_044C23BE3406FBA6E4DD730637977FDD_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_044C23BE3406FBA6E4DD730637977FDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_044C23BE3406FBA6E4DD730637977FDD_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_044C23BE3406FBA6E4DD730637977FDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_044C23BE3406FBA6E4DD730637977FDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_044C23BE3406FBA6E4DD730637977FDD" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_044C23BE3406FBA6E4DD730637977FDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8D9CF4AA1C8FBA144C11730637975C71_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8D9CF4AA1C8FBA144C11730637975C71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8D9CF4AA1C8FBA144C11730637975C71_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8D9CF4AA1C8FBA144C11730637975C71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8D9CF4AA1C8FBA144C11730637975C71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8D9CF4AA1C8FBA144C11730637975C71" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8D9CF4AA1C8FBA144C11730637975C71" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B7B39C050BF64DCC4777730637971E5D_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B7B39C050BF64DCC4777730637971E5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B7B39C050BF64DCC4777730637971E5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B7B39C050BF64DCC4777730637971E5D" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B7B39C050BF64DCC4777730637971E5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_947BDB4A9078CBF545A37306379839F9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_947BDB4A9078CBF545A37306379839F9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_947BDB4A9078CBF545A37306379839F9_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_947BDB4A9078CBF545A37306379839F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_947BDB4A9078CBF545A37306379839F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_947BDB4A9078CBF545A37306379839F9" xlink:to="lab_us-gaap_AssetsCurrent_947BDB4A9078CBF545A37306379839F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_C73DD2E11515CD14B294730637981BE7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_C73DD2E11515CD14B294730637981BE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_C73DD2E11515CD14B294730637981BE7_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_C73DD2E11515CD14B294730637981BE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_C73DD2E11515CD14B294730637981BE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_C73DD2E11515CD14B294730637981BE7" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_C73DD2E11515CD14B294730637981BE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4AF99F875093061D167F73063798EC14_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_4AF99F875093061D167F73063798EC14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4AF99F875093061D167F73063798EC14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4AF99F875093061D167F73063798EC14" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_4AF99F875093061D167F73063798EC14" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2EA132701F377C7EA85673063798723A_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2EA132701F377C7EA85673063798723A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2EA132701F377C7EA85673063798723A_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2EA132701F377C7EA85673063798723A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2EA132701F377C7EA85673063798723A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2EA132701F377C7EA85673063798723A" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2EA132701F377C7EA85673063798723A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_7FB1E5C29CE4AF06147673063798E8E5_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_7FB1E5C29CE4AF06147673063798E8E5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_7FB1E5C29CE4AF06147673063798E8E5_label_en-US" xlink:label="lab_us-gaap_Assets_7FB1E5C29CE4AF06147673063798E8E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7FB1E5C29CE4AF06147673063798E8E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_7FB1E5C29CE4AF06147673063798E8E5" xlink:to="lab_us-gaap_Assets_7FB1E5C29CE4AF06147673063798E8E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, convertible preferred stock, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_A87D10475FDC518AC72473063799C384_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_A87D10475FDC518AC72473063799C384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_A87D10475FDC518AC72473063799C384_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_A87D10475FDC518AC72473063799C384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_A87D10475FDC518AC72473063799C384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_A87D10475FDC518AC72473063799C384" xlink:to="lab_us-gaap_AccountsPayableCurrent_A87D10475FDC518AC72473063799C384" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5AE71F6E280F0235D2C773063799A262_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_5AE71F6E280F0235D2C773063799A262" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5AE71F6E280F0235D2C773063799A262" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5AE71F6E280F0235D2C773063799A262" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_5AE71F6E280F0235D2C773063799A262" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_E7974CD03019FB97FE087306379995F7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_E7974CD03019FB97FE087306379995F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_E7974CD03019FB97FE087306379995F7_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_E7974CD03019FB97FE087306379995F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_E7974CD03019FB97FE087306379995F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_E7974CD03019FB97FE087306379995F7" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_E7974CD03019FB97FE087306379995F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_20FB841109AD554D36EA7306379A47EA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent_20FB841109AD554D36EA7306379A47EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent, current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_20FB841109AD554D36EA7306379A47EA_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent_20FB841109AD554D36EA7306379A47EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_20FB841109AD554D36EA7306379A47EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent_20FB841109AD554D36EA7306379A47EA" xlink:to="lab_us-gaap_DeferredRentCreditCurrent_20FB841109AD554D36EA7306379A47EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_48FC67CFD73D9FFF7D737306379AF4E2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_48FC67CFD73D9FFF7D737306379AF4E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_48FC67CFD73D9FFF7D737306379AF4E2_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_48FC67CFD73D9FFF7D737306379AF4E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_48FC67CFD73D9FFF7D737306379AF4E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_48FC67CFD73D9FFF7D737306379AF4E2" xlink:to="lab_us-gaap_LongTermDebtCurrent_48FC67CFD73D9FFF7D737306379AF4E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_99997FC6AE426FD2C68A7306379A779A_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_99997FC6AE426FD2C68A7306379A779A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_99997FC6AE426FD2C68A7306379A779A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_99997FC6AE426FD2C68A7306379A779A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_99997FC6AE426FD2C68A7306379A779A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_99997FC6AE426FD2C68A7306379A779A" xlink:to="lab_us-gaap_LiabilitiesCurrent_99997FC6AE426FD2C68A7306379A779A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_A0E8B359E565F2B0100D730637D071D4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_A0E8B359E565F2B0100D730637D071D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent, long-term portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_A0E8B359E565F2B0100D730637D071D4_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_A0E8B359E565F2B0100D730637D071D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_A0E8B359E565F2B0100D730637D071D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_A0E8B359E565F2B0100D730637D071D4" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_A0E8B359E565F2B0100D730637D071D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_74B1FC84DB2598292CBF730637D15356_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_74B1FC84DB2598292CBF730637D15356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_74B1FC84DB2598292CBF730637D15356_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_74B1FC84DB2598292CBF730637D15356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_74B1FC84DB2598292CBF730637D15356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_74B1FC84DB2598292CBF730637D15356" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_74B1FC84DB2598292CBF730637D15356" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_F17F803831CE46CD3398730637D10646_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_F17F803831CE46CD3398730637D10646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_F17F803831CE46CD3398730637D10646_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_F17F803831CE46CD3398730637D10646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_F17F803831CE46CD3398730637D10646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_F17F803831CE46CD3398730637D10646" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_F17F803831CE46CD3398730637D10646" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_153B6E1792956F2335A7730637D10D39_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_153B6E1792956F2335A7730637D10D39" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_153B6E1792956F2335A7730637D10D39_label_en-US" xlink:label="lab_us-gaap_Liabilities_153B6E1792956F2335A7730637D10D39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_153B6E1792956F2335A7730637D10D39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_153B6E1792956F2335A7730637D10D39" xlink:to="lab_us-gaap_Liabilities_153B6E1792956F2335A7730637D10D39" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3BE24FEA2E3583DD4E47730637D1F39D_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_3BE24FEA2E3583DD4E47730637D1F39D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3BE24FEA2E3583DD4E47730637D1F39D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_3BE24FEA2E3583DD4E47730637D1F39D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3BE24FEA2E3583DD4E47730637D1F39D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_3BE24FEA2E3583DD4E47730637D1F39D" xlink:to="lab_us-gaap_CommitmentsAndContingencies_3BE24FEA2E3583DD4E47730637D1F39D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12008DCCD2C75B71D17E730637D1C9F7_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12008DCCD2C75B71D17E730637D1C9F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, $0.001 par value per share; 10,000,000 shares authorized at December 31, 2018 and 2017; zero shares issued and outstanding at December 31, 2018 and 2017</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12008DCCD2C75B71D17E730637D1C9F7_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12008DCCD2C75B71D17E730637D1C9F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12008DCCD2C75B71D17E730637D1C9F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12008DCCD2C75B71D17E730637D1C9F7" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12008DCCD2C75B71D17E730637D1C9F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:to="lab_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_980900B41B107953C3F6730637D2EFB7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding_980900B41B107953C3F6730637D2EFB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value per share; 200,000,000 shares authorized at December 31, 2018 and 2017; 13,904,672 shares issued and 13,854,205 shares outstanding at December 31, 2018; 13,881,645 shares issued and 13,831,178 shares outstanding at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_980900B41B107953C3F6730637D2EFB7_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding_980900B41B107953C3F6730637D2EFB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_980900B41B107953C3F6730637D2EFB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding_980900B41B107953C3F6730637D2EFB7" xlink:to="lab_us-gaap_CommonStockValueOutstanding_980900B41B107953C3F6730637D2EFB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_4D9FD9109CF4ED6B0C65730637D2C251_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_4D9FD9109CF4ED6B0C65730637D2C251" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost; 50,467 shares at December 31, 2018 and 2017</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_4D9FD9109CF4ED6B0C65730637D2C251_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_4D9FD9109CF4ED6B0C65730637D2C251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_4D9FD9109CF4ED6B0C65730637D2C251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_4D9FD9109CF4ED6B0C65730637D2C251" xlink:to="lab_us-gaap_TreasuryStockValue_4D9FD9109CF4ED6B0C65730637D2C251" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_9C04DDD24FFEDE1FE10F730637D2478E_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_9C04DDD24FFEDE1FE10F730637D2478E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_9C04DDD24FFEDE1FE10F730637D2478E_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_9C04DDD24FFEDE1FE10F730637D2478E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9C04DDD24FFEDE1FE10F730637D2478E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9C04DDD24FFEDE1FE10F730637D2478E" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_9C04DDD24FFEDE1FE10F730637D2478E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1F6341DC30FDAE5E4617730637D2A2B1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1F6341DC30FDAE5E4617730637D2A2B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1F6341DC30FDAE5E4617730637D2A2B1_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1F6341DC30FDAE5E4617730637D2A2B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1F6341DC30FDAE5E4617730637D2A2B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1F6341DC30FDAE5E4617730637D2A2B1" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1F6341DC30FDAE5E4617730637D2A2B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_26491770425F4ED80F61730637D371E3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_26491770425F4ED80F61730637D371E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_26491770425F4ED80F61730637D371E3_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_26491770425F4ED80F61730637D371E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26491770425F4ED80F61730637D371E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26491770425F4ED80F61730637D371E3" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_26491770425F4ED80F61730637D371E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_519D9A641AC4D35EDBA5730637D37B30_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_519D9A641AC4D35EDBA5730637D37B30" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_519D9A641AC4D35EDBA5730637D37B30_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_519D9A641AC4D35EDBA5730637D37B30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_519D9A641AC4D35EDBA5730637D37B30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_519D9A641AC4D35EDBA5730637D37B30" xlink:to="lab_us-gaap_StockholdersEquity_519D9A641AC4D35EDBA5730637D37B30" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_A9980DE2FF6B3EDF973D730637D30C71_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_A9980DE2FF6B3EDF973D730637D30C71" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, convertible preferred stock, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_A9980DE2FF6B3EDF973D730637D30C71_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_A9980DE2FF6B3EDF973D730637D30C71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_A9980DE2FF6B3EDF973D730637D30C71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_A9980DE2FF6B3EDF973D730637D30C71" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_A9980DE2FF6B3EDF973D730637D30C71" xlink:type="arc" />
    <link:label id="lab_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD_terseLabel_en-US" xlink:label="lab_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD_label_en-US" xlink:label="lab_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD_documentation_en-US" xlink:label="lab_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents significant accounting policies.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SignificantAccountingPoliciesTable" xlink:label="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="lab_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E59261C80F0BB992CAA4916650692D2B_verboseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E59261C80F0BB992CAA4916650692D2B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E59261C80F0BB992CAA4916650692D2B_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E59261C80F0BB992CAA4916650692D2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E59261C80F0BB992CAA4916650692D2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E59261C80F0BB992CAA4916650692D2B" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E59261C80F0BB992CAA4916650692D2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF" xlink:type="arc" />
    <link:label id="lab_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260_terseLabel_en-US" xlink:label="lab_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office And Laboratory Leases</link:label>
    <link:label id="lab_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260_label_en-US" xlink:label="lab_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office And Laboratory Leases [Member]</link:label>
    <link:label id="lab_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260_documentation_en-US" xlink:label="lab_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office And Laboratory Leases [Member]</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OfficeAndLaboratoryLeasesMember" xlink:label="loc_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260" xlink:to="lab_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:to="lab_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_9A7D019D6BA00820F3ED9166506B6F63_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_9A7D019D6BA00820F3ED9166506B6F63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_9A7D019D6BA00820F3ED9166506B6F63_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_9A7D019D6BA00820F3ED9166506B6F63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_9A7D019D6BA00820F3ED9166506B6F63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_9A7D019D6BA00820F3ED9166506B6F63" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_9A7D019D6BA00820F3ED9166506B6F63" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_8133D1FEA8A4F4930E5D9166506B97CF_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_8133D1FEA8A4F4930E5D9166506B97CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_8133D1FEA8A4F4930E5D9166506B97CF_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_8133D1FEA8A4F4930E5D9166506B97CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_8133D1FEA8A4F4930E5D9166506B97CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_8133D1FEA8A4F4930E5D9166506B97CF" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_8133D1FEA8A4F4930E5D9166506B97CF" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_C2852600991722C486E091665072E3BD_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_C2852600991722C486E091665072E3BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_C2852600991722C486E091665072E3BD_label_en-US" xlink:label="lab_srt_MinimumMember_C2852600991722C486E091665072E3BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C2852600991722C486E091665072E3BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_C2852600991722C486E091665072E3BD" xlink:to="lab_srt_MinimumMember_C2852600991722C486E091665072E3BD" xlink:type="arc" />
    <link:label id="lab_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8_terseLabel_en-US" xlink:label="lab_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8_label_en-US" xlink:label="lab_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8_documentation_en-US" xlink:label="lab_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents significant accounting policies.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="lab_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_D8544E8150127584C2F9916650738115_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_D8544E8150127584C2F9916650738115" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_D8544E8150127584C2F9916650738115_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_D8544E8150127584C2F9916650738115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_D8544E8150127584C2F9916650738115" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_D8544E8150127584C2F9916650738115" xlink:to="lab_us-gaap_NumberOfOperatingSegments_D8544E8150127584C2F9916650738115" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_207DCE5788D71AC5457191665073529E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_207DCE5788D71AC5457191665073529E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives of the assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_207DCE5788D71AC5457191665073529E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_207DCE5788D71AC5457191665073529E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_207DCE5788D71AC5457191665073529E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_207DCE5788D71AC5457191665073529E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_207DCE5788D71AC5457191665073529E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B29A9D177940B5B1DCFF91665073E0CC_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B29A9D177940B5B1DCFF91665073E0CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B29A9D177940B5B1DCFF91665073E0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B29A9D177940B5B1DCFF91665073E0CC" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B29A9D177940B5B1DCFF91665073E0CC" xlink:type="arc" />
    <link:label id="lab_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C_terseLabel_en-US" xlink:label="lab_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum percentage of income tax benefit realized upon ultimate settlement (greater than)</link:label>
    <link:label id="lab_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C_label_en-US" xlink:label="lab_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Percentage Of Income Tax Benefit Realized On Settlement</link:label>
    <link:label id="lab_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C_documentation_en-US" xlink:label="lab_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum percentage of Income tax benefit realized on settlement.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement" xlink:label="loc_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C" xlink:to="lab_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_C1F25FC23170605965B79170E122D4E7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_C1F25FC23170605965B79170E122D4E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_C1F25FC23170605965B79170E122D4E7_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_C1F25FC23170605965B79170E122D4E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_C1F25FC23170605965B79170E122D4E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_C1F25FC23170605965B79170E122D4E7" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_C1F25FC23170605965B79170E122D4E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_029CB5E404A1166F22F7917089FB6861_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_029CB5E404A1166F22F7917089FB6861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_029CB5E404A1166F22F7917089FB6861_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_029CB5E404A1166F22F7917089FB6861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_029CB5E404A1166F22F7917089FB6861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_029CB5E404A1166F22F7917089FB6861" xlink:to="lab_us-gaap_OperatingLeaseLiability_029CB5E404A1166F22F7917089FB6861" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4CB31D0872035168ED4391665074F6D3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4CB31D0872035168ED4391665074F6D3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase in accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4CB31D0872035168ED4391665074F6D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4CB31D0872035168ED4391665074F6D3" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4CB31D0872035168ED4391665074F6D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_429F39E7D949D1E2354A916650741843_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_429F39E7D949D1E2354A916650741843" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_429F39E7D949D1E2354A916650741843" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_429F39E7D949D1E2354A916650741843" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_429F39E7D949D1E2354A916650741843" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_F7C797F6D2D7A47B387191664D6A5CC9_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_F7C797F6D2D7A47B387191664D6A5CC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_F7C797F6D2D7A47B387191664D6A5CC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_F7C797F6D2D7A47B387191664D6A5CC9" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_F7C797F6D2D7A47B387191664D6A5CC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610" xlink:to="lab_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610" xlink:type="arc" />
    <link:label id="lab_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4_terseLabel_en-US" xlink:label="lab_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alpine BioVentures GP, LLC</link:label>
    <link:label id="lab_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4_label_en-US" xlink:label="lab_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alpine Bio Ventures G P L L C [Member]</link:label>
    <link:label id="lab_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4_documentation_en-US" xlink:label="lab_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alpine BioVentures GP, LLC.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AlpineBioVenturesGPLLCMember" xlink:label="loc_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4" xlink:to="lab_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4E786A7BE12D8989D7CE91664D738515_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4E786A7BE12D8989D7CE91664D738515" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4E786A7BE12D8989D7CE91664D738515" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4E786A7BE12D8989D7CE91664D738515" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4E786A7BE12D8989D7CE91664D738515" xlink:type="arc" />
    <link:label id="lab_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC_terseLabel_en-US" xlink:label="lab_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued to purchase shares of common stock (in shares)</link:label>
    <link:label id="lab_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC_label_en-US" xlink:label="lab_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Warrants Issued To Purchase Shares Of Common Stock</link:label>
    <link:label id="lab_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC_documentation_en-US" xlink:label="lab_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Warrants Issued To Purchase Shares Of Common Stock</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock" xlink:label="loc_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC" xlink:to="lab_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_A2B3E99618B441856FD191664D73D5CC_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_A2B3E99618B441856FD191664D73D5CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options and common stock warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_A2B3E99618B441856FD191664D73D5CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_A2B3E99618B441856FD191664D73D5CC" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_A2B3E99618B441856FD191664D73D5CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18BFCB9DC1B7D5B08C5491664D73176D_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18BFCB9DC1B7D5B08C5491664D73176D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage by noncontrolling owners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18BFCB9DC1B7D5B08C5491664D73176D_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18BFCB9DC1B7D5B08C5491664D73176D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18BFCB9DC1B7D5B08C5491664D73176D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18BFCB9DC1B7D5B08C5491664D73176D" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18BFCB9DC1B7D5B08C5491664D73176D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_04D0A9204EC372273C3B91664D730A51_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_04D0A9204EC372273C3B91664D730A51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses related to shared services agreement</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_04D0A9204EC372273C3B91664D730A51_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_04D0A9204EC372273C3B91664D730A51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_04D0A9204EC372273C3B91664D730A51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_04D0A9204EC372273C3B91664D730A51" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_04D0A9204EC372273C3B91664D730A51" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_1CD5345A4A55B6E65EBC91664D74165C_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_1CD5345A4A55B6E65EBC91664D74165C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses related to shared services agreement</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_1CD5345A4A55B6E65EBC91664D74165C_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_1CD5345A4A55B6E65EBC91664D74165C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_1CD5345A4A55B6E65EBC91664D74165C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_1CD5345A4A55B6E65EBC91664D74165C" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent_1CD5345A4A55B6E65EBC91664D74165C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_75AE400F9508B51118D98272BD0CBD56_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_75AE400F9508B51118D98272BD0CBD56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_75AE400F9508B51118D98272BD0CBD56_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_75AE400F9508B51118D98272BD0CBD56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_75AE400F9508B51118D98272BD0CBD56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_75AE400F9508B51118D98272BD0CBD56" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_75AE400F9508B51118D98272BD0CBD56" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_22202F54A71D9A1C9AEF4EE70545B51B_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_22202F54A71D9A1C9AEF4EE70545B51B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_22202F54A71D9A1C9AEF4EE70545B51B_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_22202F54A71D9A1C9AEF4EE70545B51B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_22202F54A71D9A1C9AEF4EE70545B51B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_22202F54A71D9A1C9AEF4EE70545B51B" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_22202F54A71D9A1C9AEF4EE70545B51B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2A786D9E21A564234C2E32379AFA9447_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2A786D9E21A564234C2E32379AFA9447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2A786D9E21A564234C2E32379AFA9447_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2A786D9E21A564234C2E32379AFA9447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2A786D9E21A564234C2E32379AFA9447" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2A786D9E21A564234C2E32379AFA9447" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2A786D9E21A564234C2E32379AFA9447" xlink:type="arc" />
    <link:label id="lab_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69_terseLabel_en-US" xlink:label="lab_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares to be issued upon exercise of outstanding stock options</link:label>
    <link:label id="lab_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69_label_en-US" xlink:label="lab_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares To Be Issued Upon Exercise Of Outstanding Stock Options [Member]</link:label>
    <link:label id="lab_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69_documentation_en-US" xlink:label="lab_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares to be issued upon exercise of outstanding stock options.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember" xlink:label="loc_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69" xlink:to="lab_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69" xlink:type="arc" />
    <link:label id="lab_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C_terseLabel_en-US" xlink:label="lab_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares to be issued upon conversion of common stock warrants</link:label>
    <link:label id="lab_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C_label_en-US" xlink:label="lab_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares To Be Issued Upon Conversion Of Common Stock Warrants [Member]</link:label>
    <link:label id="lab_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C_documentation_en-US" xlink:label="lab_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares to be issued upon conversion of common stock warrants.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember" xlink:label="loc_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C" xlink:to="lab_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C" xlink:type="arc" />
    <link:label id="lab_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C_terseLabel_en-US" xlink:label="lab_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future stock grants</link:label>
    <link:label id="lab_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C_label_en-US" xlink:label="lab_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Available For Future Stock Grants [Member]</link:label>
    <link:label id="lab_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C_documentation_en-US" xlink:label="lab_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares available for future stock grants.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharesAvailableForFutureStockGrantsMember" xlink:label="loc_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C" xlink:to="lab_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C" xlink:type="arc" />
    <link:label id="lab_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7_terseLabel_en-US" xlink:label="lab_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares to be issued under employee stock purchase plan</link:label>
    <link:label id="lab_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7_label_en-US" xlink:label="lab_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares To Be Issued Under Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7_documentation_en-US" xlink:label="lab_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares to be issued under employee stock purchase plan.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember" xlink:label="loc_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7" xlink:to="lab_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E91E7D56EA8291326F2973692A4A608A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E91E7D56EA8291326F2973692A4A608A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock reserved for future issuance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E91E7D56EA8291326F2973692A4A608A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E91E7D56EA8291326F2973692A4A608A" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E91E7D56EA8291326F2973692A4A608A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6BDAF26FB95B6B5ADE3632379DA7858B_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6BDAF26FB95B6B5ADE3632379DA7858B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6BDAF26FB95B6B5ADE3632379DA7858B_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6BDAF26FB95B6B5ADE3632379DA7858B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6BDAF26FB95B6B5ADE3632379DA7858B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6BDAF26FB95B6B5ADE3632379DA7858B" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6BDAF26FB95B6B5ADE3632379DA7858B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Cash_91173E73F86987AB894F4EC065AE9638_terseLabel_en-US" xlink:label="lab_us-gaap_Cash_91173E73F86987AB894F4EC065AE9638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_91173E73F86987AB894F4EC065AE9638_label_en-US" xlink:label="lab_us-gaap_Cash_91173E73F86987AB894F4EC065AE9638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_91173E73F86987AB894F4EC065AE9638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_91173E73F86987AB894F4EC065AE9638" xlink:to="lab_us-gaap_Cash_91173E73F86987AB894F4EC065AE9638" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_A2F301A7A5C71733039B4FC686A829CC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_A2F301A7A5C71733039B4FC686A829CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_A2F301A7A5C71733039B4FC686A829CC_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_A2F301A7A5C71733039B4FC686A829CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_A2F301A7A5C71733039B4FC686A829CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_A2F301A7A5C71733039B4FC686A829CC" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_A2F301A7A5C71733039B4FC686A829CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EB62CC59A82EE9E810964FC686A87E3A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EB62CC59A82EE9E810964FC686A87E3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EB62CC59A82EE9E810964FC686A87E3A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EB62CC59A82EE9E810964FC686A87E3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EB62CC59A82EE9E810964FC686A87E3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EB62CC59A82EE9E810964FC686A87E3A" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EB62CC59A82EE9E810964FC686A87E3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_0DBB782996C04011B464730636BC546D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_0DBB782996C04011B464730636BC546D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Consideration Transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_0DBB782996C04011B464730636BC546D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_0DBB782996C04011B464730636BC546D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_0DBB782996C04011B464730636BC546D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_0DBB782996C04011B464730636BC546D" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_0DBB782996C04011B464730636BC546D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E141FA9AF7212CBCA0C5733D3B9A268B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E141FA9AF7212CBCA0C5733D3B9A268B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Adjusted Allocation of Purchase Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E141FA9AF7212CBCA0C5733D3B9A268B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E141FA9AF7212CBCA0C5733D3B9A268B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E141FA9AF7212CBCA0C5733D3B9A268B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E141FA9AF7212CBCA0C5733D3B9A268B" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E141FA9AF7212CBCA0C5733D3B9A268B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_5FCC4B71DBDC4A878654730636BDED25_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_5FCC4B71DBDC4A878654730636BDED25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Pro Forma Financial Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_5FCC4B71DBDC4A878654730636BDED25_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_5FCC4B71DBDC4A878654730636BDED25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_5FCC4B71DBDC4A878654730636BDED25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_5FCC4B71DBDC4A878654730636BDED25" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_5FCC4B71DBDC4A878654730636BDED25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:type="arc" />
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8B14A0D0335012A43E3D91B703CB8095_terseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8B14A0D0335012A43E3D91B703CB8095" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8B14A0D0335012A43E3D91B703CB8095" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8B14A0D0335012A43E3D91B703CB8095" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8B14A0D0335012A43E3D91B703CB8095" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966" xlink:to="lab_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4" xlink:type="arc" />
    <link:label id="lab_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346_terseLabel_en-US" xlink:label="lab_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kite</link:label>
    <link:label id="lab_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346_label_en-US" xlink:label="lab_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kite [Member]</link:label>
    <link:label id="lab_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346_documentation_en-US" xlink:label="lab_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kite.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_KiteMember" xlink:label="loc_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346" xlink:to="lab_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B" xlink:to="lab_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementProductAgreementMember_1C36F4AAC823DD6FD37091B703CCC0C7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementProductAgreementMember_1C36F4AAC823DD6FD37091B703CCC0C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and Licensing Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementProductAgreementMember_1C36F4AAC823DD6FD37091B703CCC0C7_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementProductAgreementMember_1C36F4AAC823DD6FD37091B703CCC0C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementProductAgreementMember" xlink:label="loc_us-gaap_CollaborativeArrangementProductAgreementMember_1C36F4AAC823DD6FD37091B703CCC0C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementProductAgreementMember_1C36F4AAC823DD6FD37091B703CCC0C7" xlink:to="lab_us-gaap_CollaborativeArrangementProductAgreementMember_1C36F4AAC823DD6FD37091B703CCC0C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:type="arc" />
    <link:label id="lab_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212_terseLabel_en-US" xlink:label="lab_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of programs</link:label>
    <link:label id="lab_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212_label_en-US" xlink:label="lab_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Programs From License Technology</link:label>
    <link:label id="lab_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212_documentation_en-US" xlink:label="lab_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Programs From License Technology</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfProgramsFromLicenseTechnology" xlink:label="loc_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212" xlink:to="lab_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_781B718183CF4C27483F91B703CD25A9_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_781B718183CF4C27483F91B703CD25A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_781B718183CF4C27483F91B703CD25A9_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_781B718183CF4C27483F91B703CD25A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_781B718183CF4C27483F91B703CD25A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_781B718183CF4C27483F91B703CD25A9" xlink:to="lab_us-gaap_ContractWithCustomerLiability_781B718183CF4C27483F91B703CD25A9" xlink:type="arc" />
    <link:label id="lab_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1_terseLabel_en-US" xlink:label="lab_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestones receivable (up to)</link:label>
    <link:label id="lab_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1_label_en-US" xlink:label="lab_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Revenue Recognition Milestone Method Milestones Receivable</link:label>
    <link:label id="lab_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1_documentation_en-US" xlink:label="lab_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Future Revenue Recognition Milestone Method Milestones Receivable</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable" xlink:label="loc_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1" xlink:to="lab_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1" xlink:type="arc" />
    <link:label id="lab_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B_terseLabel_en-US" xlink:label="lab_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eligible to receive additional research support payment</link:label>
    <link:label id="lab_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B_label_en-US" xlink:label="lab_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eligible To Receive Additional Research Support Payment</link:label>
    <link:label id="lab_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B_documentation_en-US" xlink:label="lab_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eligible to receive additional research support payment.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EligibleToReceiveAdditionalResearchSupportPayment" xlink:label="loc_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B" xlink:to="lab_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B" xlink:type="arc" />
    <link:label id="lab_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498_terseLabel_en-US" xlink:label="lab_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498_label_en-US" xlink:label="lab_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:label id="lab_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498_documentation_en-US" xlink:label="lab_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of tranches.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfTranches" xlink:label="loc_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498" xlink:to="lab_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2085C10BC6910814EC2591B703D31FAD_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2085C10BC6910814EC2591B703D31FAD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2085C10BC6910814EC2591B703D31FAD_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2085C10BC6910814EC2591B703D31FAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2085C10BC6910814EC2591B703D31FAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2085C10BC6910814EC2591B703D31FAD" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2085C10BC6910814EC2591B703D31FAD" xlink:type="arc" />
    <link:label id="lab_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20_terseLabel_en-US" xlink:label="lab_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange rate of common stock issued</link:label>
    <link:label id="lab_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20_label_en-US" xlink:label="lab_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Common Stock Issued, Exchange Rate</link:label>
    <link:label id="lab_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20_documentation_en-US" xlink:label="lab_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Common Stock Issued, Exchange Rate</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessCombinationCommonStockIssuedExchangeRate" xlink:label="loc_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20" xlink:to="lab_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_C3B02A0FC32A6B9A02DF73AD7B3C4BD8_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_C3B02A0FC32A6B9A02DF73AD7B3C4BD8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Bargain purchase gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:label="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_C3B02A0FC32A6B9A02DF73AD7B3C4BD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_C3B02A0FC32A6B9A02DF73AD7B3C4BD8" xlink:to="lab_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_C3B02A0FC32A6B9A02DF73AD7B3C4BD8" xlink:type="arc" />
    <link:label id="lab_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC_terseLabel_en-US" xlink:label="lab_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percenatge of projected cash flows discounted to their present value using discount rate</link:label>
    <link:label id="lab_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC_label_en-US" xlink:label="lab_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Projections Discount Rate</link:label>
    <link:label id="lab_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC_documentation_en-US" xlink:label="lab_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flow projections discount rate.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CashFlowProjectionsDiscountRate" xlink:label="loc_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC" xlink:to="lab_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquisitionCosts_EDB994EF50B555B0297C73AD7B3C1840_terseLabel_en-US" xlink:label="lab_us-gaap_AcquisitionCosts_EDB994EF50B555B0297C73AD7B3C1840" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition-related costs</link:label>
    <link:label id="lab_us-gaap_AcquisitionCosts_EDB994EF50B555B0297C73AD7B3C1840_label_en-US" xlink:label="lab_us-gaap_AcquisitionCosts_EDB994EF50B555B0297C73AD7B3C1840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition Costs, Period Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquisitionCosts" xlink:label="loc_us-gaap_AcquisitionCosts_EDB994EF50B555B0297C73AD7B3C1840" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquisitionCosts_EDB994EF50B555B0297C73AD7B3C1840" xlink:to="lab_us-gaap_AcquisitionCosts_EDB994EF50B555B0297C73AD7B3C1840" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98BA121E0329FC99CC697DC9C3672FCE_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98BA121E0329FC99CC697DC9C3672FCE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98BA121E0329FC99CC697DC9C3672FCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98BA121E0329FC99CC697DC9C3672FCE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98BA121E0329FC99CC697DC9C3672FCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2F7DC63CB65667549D0E7DC9C36705DF_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2F7DC63CB65667549D0E7DC9C36705DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2F7DC63CB65667549D0E7DC9C36705DF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2F7DC63CB65667549D0E7DC9C36705DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2F7DC63CB65667549D0E7DC9C36705DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2F7DC63CB65667549D0E7DC9C36705DF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2F7DC63CB65667549D0E7DC9C36705DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5008A4651646DBAD584D7DC9C3674A64_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5008A4651646DBAD584D7DC9C3674A64" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5008A4651646DBAD584D7DC9C3674A64_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5008A4651646DBAD584D7DC9C3674A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5008A4651646DBAD584D7DC9C3674A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5008A4651646DBAD584D7DC9C3674A64" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5008A4651646DBAD584D7DC9C3674A64" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_933C403E501D2FAE7ACE7DC9C367A177_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_933C403E501D2FAE7ACE7DC9C367A177" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_933C403E501D2FAE7ACE7DC9C367A177_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_933C403E501D2FAE7ACE7DC9C367A177" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_933C403E501D2FAE7ACE7DC9C367A177" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_933C403E501D2FAE7ACE7DC9C367A177" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_933C403E501D2FAE7ACE7DC9C367A177" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64D253553A994A3165137DC9C3689F76_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64D253553A994A3165137DC9C3689F76" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at ending of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64D253553A994A3165137DC9C3689F76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64D253553A994A3165137DC9C3689F76" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64D253553A994A3165137DC9C3689F76" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8B3337D475C1A4843CAC7DC9C368BB37_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8B3337D475C1A4843CAC7DC9C368BB37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8B3337D475C1A4843CAC7DC9C368BB37_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8B3337D475C1A4843CAC7DC9C368BB37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8B3337D475C1A4843CAC7DC9C368BB37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8B3337D475C1A4843CAC7DC9C368BB37" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8B3337D475C1A4843CAC7DC9C368BB37" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3B2D836AF339FAEE17537DC9C3680B09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3B2D836AF339FAEE17537DC9C3680B09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3B2D836AF339FAEE17537DC9C3680B09_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3B2D836AF339FAEE17537DC9C3680B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3B2D836AF339FAEE17537DC9C3680B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3B2D836AF339FAEE17537DC9C3680B09" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3B2D836AF339FAEE17537DC9C3680B09" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16E701095D5A5CD65C937DC9C368D667_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16E701095D5A5CD65C937DC9C368D667" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16E701095D5A5CD65C937DC9C368D667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16E701095D5A5CD65C937DC9C368D667" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16E701095D5A5CD65C937DC9C368D667" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_117F7E964091C0E8B44B7DC9C3692E98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_117F7E964091C0E8B44B7DC9C3692E98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_117F7E964091C0E8B44B7DC9C3692E98_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_117F7E964091C0E8B44B7DC9C3692E98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_117F7E964091C0E8B44B7DC9C3692E98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_117F7E964091C0E8B44B7DC9C3692E98" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_117F7E964091C0E8B44B7DC9C3692E98" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_BC26ED7D0C0123CB4B8A7DC9C369A6F0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_BC26ED7D0C0123CB4B8A7DC9C369A6F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_BC26ED7D0C0123CB4B8A7DC9C369A6F0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_BC26ED7D0C0123CB4B8A7DC9C369A6F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_BC26ED7D0C0123CB4B8A7DC9C369A6F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_BC26ED7D0C0123CB4B8A7DC9C369A6F0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_BC26ED7D0C0123CB4B8A7DC9C369A6F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D6E0C195FF8ECB471A957DC9C3698BE5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D6E0C195FF8ECB471A957DC9C3698BE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D6E0C195FF8ECB471A957DC9C3698BE5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D6E0C195FF8ECB471A957DC9C3698BE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D6E0C195FF8ECB471A957DC9C3698BE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D6E0C195FF8ECB471A957DC9C3698BE5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D6E0C195FF8ECB471A957DC9C3698BE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5DC7C0FFBC3033309E327DC9C369F497_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5DC7C0FFBC3033309E327DC9C369F497" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at ending of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5DC7C0FFBC3033309E327DC9C369F497" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5DC7C0FFBC3033309E327DC9C369F497" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5DC7C0FFBC3033309E327DC9C369F497" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_FD868577B9D2E4CB983F7DC9C3690DE6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_FD868577B9D2E4CB983F7DC9C3690DE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_FD868577B9D2E4CB983F7DC9C3690DE6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_FD868577B9D2E4CB983F7DC9C3690DE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_FD868577B9D2E4CB983F7DC9C3690DE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_FD868577B9D2E4CB983F7DC9C3690DE6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_FD868577B9D2E4CB983F7DC9C3690DE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9E788034A11C6DCCB9E07DC9C369959B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9E788034A11C6DCCB9E07DC9C369959B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9E788034A11C6DCCB9E07DC9C369959B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9E788034A11C6DCCB9E07DC9C369959B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9E788034A11C6DCCB9E07DC9C369959B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9E788034A11C6DCCB9E07DC9C369959B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9E788034A11C6DCCB9E07DC9C369959B" xlink:type="arc" />
    <link:label id="lab_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069_terseLabel_en-US" xlink:label="lab_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average Remaining Contract Term (in years)</link:label>
    <link:label id="lab_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069_label_en-US" xlink:label="lab_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069_documentation_en-US" xlink:label="lab_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, weighted-average remaining contractual life.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:to="lab_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D0C23A746FCAA2058D627DC9C36AF201_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D0C23A746FCAA2058D627DC9C36AF201" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D0C23A746FCAA2058D627DC9C36AF201_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D0C23A746FCAA2058D627DC9C36AF201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D0C23A746FCAA2058D627DC9C36AF201" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D0C23A746FCAA2058D627DC9C36AF201" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D0C23A746FCAA2058D627DC9C36AF201" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_C93DD1442DB08AC913007DC9C36A84DA_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_C93DD1442DB08AC913007DC9C36A84DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_C93DD1442DB08AC913007DC9C36A84DA_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_C93DD1442DB08AC913007DC9C36A84DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_C93DD1442DB08AC913007DC9C36A84DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_C93DD1442DB08AC913007DC9C36A84DA" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_C93DD1442DB08AC913007DC9C36A84DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BCF4E027B8A61237960B7DC9C36A01F3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BCF4E027B8A61237960B7DC9C36A01F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BCF4E027B8A61237960B7DC9C36A01F3_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BCF4E027B8A61237960B7DC9C36A01F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BCF4E027B8A61237960B7DC9C36A01F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BCF4E027B8A61237960B7DC9C36A01F3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BCF4E027B8A61237960B7DC9C36A01F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_68A9F66BC0AFC318C9457DC9C36DF42E_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_68A9F66BC0AFC318C9457DC9C36DF42E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_68A9F66BC0AFC318C9457DC9C36DF42E_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_68A9F66BC0AFC318C9457DC9C36DF42E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_68A9F66BC0AFC318C9457DC9C36DF42E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_68A9F66BC0AFC318C9457DC9C36DF42E" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_68A9F66BC0AFC318C9457DC9C36DF42E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_6278D8C3594A811C65657DC9C36EB022_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_6278D8C3594A811C65657DC9C36EB022" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_6278D8C3594A811C65657DC9C36EB022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_6278D8C3594A811C65657DC9C36EB022" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_6278D8C3594A811C65657DC9C36EB022" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_E56B64C004E5A5DB18D87DC9C77D3E2F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_E56B64C004E5A5DB18D87DC9C77D3E2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_E56B64C004E5A5DB18D87DC9C77D3E2F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_E56B64C004E5A5DB18D87DC9C77D3E2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_E56B64C004E5A5DB18D87DC9C77D3E2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_E56B64C004E5A5DB18D87DC9C77D3E2F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_E56B64C004E5A5DB18D87DC9C77D3E2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2DB096A580B940904E517DCBBEBBFD9D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2DB096A580B940904E517DCBBEBBFD9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2DB096A580B940904E517DCBBEBBFD9D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2DB096A580B940904E517DCBBEBBFD9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2DB096A580B940904E517DCBBEBBFD9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2DB096A580B940904E517DCBBEBBFD9D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2DB096A580B940904E517DCBBEBBFD9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2E88D289E9F268D2938A32379B045CB9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2E88D289E9F268D2938A32379B045CB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share Attributable to Common Stockholders Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2E88D289E9F268D2938A32379B045CB9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2E88D289E9F268D2938A32379B045CB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2E88D289E9F268D2938A32379B045CB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2E88D289E9F268D2938A32379B045CB9" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2E88D289E9F268D2938A32379B045CB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_590CB46D266E1F729C43CC2FE9932F10_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_590CB46D266E1F729C43CC2FE9932F10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_590CB46D266E1F729C43CC2FE9932F10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_590CB46D266E1F729C43CC2FE9932F10" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_590CB46D266E1F729C43CC2FE9932F10" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_43C50DD0358C39738BA5CC2FE993B0EB_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_43C50DD0358C39738BA5CC2FE993B0EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_43C50DD0358C39738BA5CC2FE993B0EB_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_43C50DD0358C39738BA5CC2FE993B0EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_43C50DD0358C39738BA5CC2FE993B0EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_43C50DD0358C39738BA5CC2FE993B0EB" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_43C50DD0358C39738BA5CC2FE993B0EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_FB3E989D115600ACDD33CC2FE9949A7A_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_FB3E989D115600ACDD33CC2FE9949A7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_FB3E989D115600ACDD33CC2FE9949A7A_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_FB3E989D115600ACDD33CC2FE9949A7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_FB3E989D115600ACDD33CC2FE9949A7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_FB3E989D115600ACDD33CC2FE9949A7A" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_FB3E989D115600ACDD33CC2FE9949A7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8A295CE03F09B74A03C6CC2FE994C266_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_8A295CE03F09B74A03C6CC2FE994C266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8A295CE03F09B74A03C6CC2FE994C266_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_8A295CE03F09B74A03C6CC2FE994C266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8A295CE03F09B74A03C6CC2FE994C266" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_8A295CE03F09B74A03C6CC2FE994C266" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_8A295CE03F09B74A03C6CC2FE994C266" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_B42FF4F9DED05CCC4D6BCC2FE9941536_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_B42FF4F9DED05CCC4D6BCC2FE9941536" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_B42FF4F9DED05CCC4D6BCC2FE9941536_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_B42FF4F9DED05CCC4D6BCC2FE9941536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B42FF4F9DED05CCC4D6BCC2FE9941536" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_B42FF4F9DED05CCC4D6BCC2FE9941536" xlink:to="lab_us-gaap_CommonStockSharesIssued_B42FF4F9DED05CCC4D6BCC2FE9941536" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_BAEC68623A6EC2DEC273CC2FE995768D_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares_BAEC68623A6EC2DEC273CC2FE995768D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_BAEC68623A6EC2DEC273CC2FE995768D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares_BAEC68623A6EC2DEC273CC2FE995768D" xlink:to="lab_us-gaap_TreasuryStockCommonShares_BAEC68623A6EC2DEC273CC2FE995768D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276_label_en-US" xlink:label="lab_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:to="lab_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232" xlink:to="lab_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE" xlink:to="lab_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_AEDB25F7076DCBD8F55291D70C5BD3FF_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_AEDB25F7076DCBD8F55291D70C5BD3FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_AEDB25F7076DCBD8F55291D70C5BD3FF_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_AEDB25F7076DCBD8F55291D70C5BD3FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_AEDB25F7076DCBD8F55291D70C5BD3FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_AEDB25F7076DCBD8F55291D70C5BD3FF" xlink:to="lab_us-gaap_TreasuryStockMember_AEDB25F7076DCBD8F55291D70C5BD3FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7C376D5290F9B9B1F6A291D70C5BC329_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_7C376D5290F9B9B1F6A291D70C5BC329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7C376D5290F9B9B1F6A291D70C5BC329_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_7C376D5290F9B9B1F6A291D70C5BC329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7C376D5290F9B9B1F6A291D70C5BC329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_7C376D5290F9B9B1F6A291D70C5BC329" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_7C376D5290F9B9B1F6A291D70C5BC329" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7D984F562243C800F84791D70C5BF103_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7D984F562243C800F84791D70C5BF103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7D984F562243C800F84791D70C5BF103_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7D984F562243C800F84791D70C5BF103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7D984F562243C800F84791D70C5BF103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7D984F562243C800F84791D70C5BF103" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7D984F562243C800F84791D70C5BF103" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_FC39EE026DF83D73686B91D70C5B99E8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_FC39EE026DF83D73686B91D70C5B99E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_FC39EE026DF83D73686B91D70C5B99E8_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_FC39EE026DF83D73686B91D70C5B99E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_FC39EE026DF83D73686B91D70C5B99E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_FC39EE026DF83D73686B91D70C5B99E8" xlink:to="lab_us-gaap_RetainedEarningsMember_FC39EE026DF83D73686B91D70C5B99E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738" xlink:to="lab_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_250A5731570D2A7FC46191D70C5C047B_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_250A5731570D2A7FC46191D70C5C047B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, convertible preferred stock, shares (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_250A5731570D2A7FC46191D70C5C047B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_250A5731570D2A7FC46191D70C5C047B" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_250A5731570D2A7FC46191D70C5C047B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3C164EF385209EB1422E91D70C5CDA4B_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3C164EF385209EB1422E91D70C5CDA4B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, convertible preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3C164EF385209EB1422E91D70C5CDA4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3C164EF385209EB1422E91D70C5CDA4B" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3C164EF385209EB1422E91D70C5CDA4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_1FDD5C0C5B4B4FBBE1EB91D70C5C939B_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_1FDD5C0C5B4B4FBBE1EB91D70C5C939B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_1FDD5C0C5B4B4FBBE1EB91D70C5C939B_label_en-US" xlink:label="lab_us-gaap_SharesIssued_1FDD5C0C5B4B4FBBE1EB91D70C5C939B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_1FDD5C0C5B4B4FBBE1EB91D70C5C939B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_1FDD5C0C5B4B4FBBE1EB91D70C5C939B" xlink:to="lab_us-gaap_SharesIssued_1FDD5C0C5B4B4FBBE1EB91D70C5C939B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0E975F3E8D3DE388478B91D70C5C564B_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0E975F3E8D3DE388478B91D70C5C564B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0E975F3E8D3DE388478B91D70C5C564B_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0E975F3E8D3DE388478B91D70C5C564B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0E975F3E8D3DE388478B91D70C5C564B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0E975F3E8D3DE388478B91D70C5C564B" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0E975F3E8D3DE388478B91D70C5C564B" xlink:type="arc" />
    <link:label id="lab_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE_terseLabel_en-US" xlink:label="lab_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of convertible preferred stock (in shares)</link:label>
    <link:label id="lab_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE_label_en-US" xlink:label="lab_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label id="lab_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE_documentation_en-US" xlink:label="lab_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary equity stock issued during period shares new issues.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE" xlink:to="lab_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FF17279218E2C5F18AD691D70C5D703B_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FF17279218E2C5F18AD691D70C5D703B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FF17279218E2C5F18AD691D70C5D703B_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FF17279218E2C5F18AD691D70C5D703B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FF17279218E2C5F18AD691D70C5D703B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FF17279218E2C5F18AD691D70C5D703B" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FF17279218E2C5F18AD691D70C5D703B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_95EC692A2A513AED3A8D91D70C5D9A56_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_95EC692A2A513AED3A8D91D70C5D9A56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect of changes related to adoption of new revenue standard</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_95EC692A2A513AED3A8D91D70C5D9A56_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_95EC692A2A513AED3A8D91D70C5D9A56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_95EC692A2A513AED3A8D91D70C5D9A56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_95EC692A2A513AED3A8D91D70C5D9A56" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_95EC692A2A513AED3A8D91D70C5D9A56" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6D2E885B0A4A3C2F4AF91D70C5D996A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6D2E885B0A4A3C2F4AF91D70C5D996A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6D2E885B0A4A3C2F4AF91D70C5D996A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6D2E885B0A4A3C2F4AF91D70C5D996A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6D2E885B0A4A3C2F4AF91D70C5D996A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11F33BA3797DC31E440891D70C5D76C6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11F33BA3797DC31E440891D70C5D76C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11F33BA3797DC31E440891D70C5D76C6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11F33BA3797DC31E440891D70C5D76C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11F33BA3797DC31E440891D70C5D76C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11F33BA3797DC31E440891D70C5D76C6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11F33BA3797DC31E440891D70C5D76C6" xlink:type="arc" />
    <link:label id="lab_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C_negatedTerseLabel_en-US" xlink:label="lab_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C_label_en-US" xlink:label="lab_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Shares Conversion Of Convertible Securities</link:label>
    <link:label id="lab_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C_documentation_en-US" xlink:label="lab_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary equity shares conversion of convertible securities.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:label="loc_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C" xlink:to="lab_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C" xlink:type="arc" />
    <link:label id="lab_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472_negatedTerseLabel_en-US" xlink:label="lab_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock</link:label>
    <link:label id="lab_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472_label_en-US" xlink:label="lab_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Value Conversion Of Convertible Securities</link:label>
    <link:label id="lab_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472_documentation_en-US" xlink:label="lab_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary equity value conversion of convertible securities.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:label="loc_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472" xlink:to="lab_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28CE5D0CC5F8047E935491D70C5E5EAF_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28CE5D0CC5F8047E935491D70C5E5EAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28CE5D0CC5F8047E935491D70C5E5EAF_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28CE5D0CC5F8047E935491D70C5E5EAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28CE5D0CC5F8047E935491D70C5E5EAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28CE5D0CC5F8047E935491D70C5E5EAF" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28CE5D0CC5F8047E935491D70C5E5EAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42BEFC49AE9A73F3F5E991D70C5EC858_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42BEFC49AE9A73F3F5E991D70C5EC858" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42BEFC49AE9A73F3F5E991D70C5EC858_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42BEFC49AE9A73F3F5E991D70C5EC858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42BEFC49AE9A73F3F5E991D70C5EC858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42BEFC49AE9A73F3F5E991D70C5EC858" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42BEFC49AE9A73F3F5E991D70C5EC858" xlink:type="arc" />
    <link:label id="lab_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974_terseLabel_en-US" xlink:label="lab_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock acquired in business combination (in shares)</link:label>
    <link:label id="lab_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974_label_en-US" xlink:label="lab_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Acquired During Period Shares In Business Combination</link:label>
    <link:label id="lab_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974_documentation_en-US" xlink:label="lab_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock acquired during period shares in business combination.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_StockAcquiredDuringPeriodSharesInBusinessCombination" xlink:label="loc_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974" xlink:to="lab_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974" xlink:type="arc" />
    <link:label id="lab_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6_terseLabel_en-US" xlink:label="lab_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock acquired in business combination</link:label>
    <link:label id="lab_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6_label_en-US" xlink:label="lab_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Acquired During Period Value In Business Combination</link:label>
    <link:label id="lab_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6_documentation_en-US" xlink:label="lab_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock acquired during period value in business combination.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_StockAcquiredDuringPeriodValueInBusinessCombination" xlink:label="loc_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6" xlink:to="lab_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6" xlink:type="arc" />
    <link:label id="lab_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76_terseLabel_en-US" xlink:label="lab_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment of par value from $0.0001 per share to $0.001 per share</link:label>
    <link:label id="lab_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76_label_en-US" xlink:label="lab_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment Of Par Value</link:label>
    <link:label id="lab_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76_documentation_en-US" xlink:label="lab_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustment of par value.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AdjustmentOfParValue" xlink:label="loc_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76" xlink:to="lab_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76" xlink:type="arc" />
    <link:label id="lab_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404_terseLabel_en-US" xlink:label="lab_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of warrant liability to equity</link:label>
    <link:label id="lab_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404_label_en-US" xlink:label="lab_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital Conversion Of Warrant Liability To Equity</link:label>
    <link:label id="lab_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404_documentation_en-US" xlink:label="lab_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to additional paid in capital conversion of warrant liability to equity.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity" xlink:label="loc_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404" xlink:to="lab_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404" xlink:type="arc" />
    <link:label id="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238_terseLabel_en-US" xlink:label="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options and common stock warrants (in shares)</link:label>
    <link:label id="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238_label_en-US" xlink:label="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Of Stock Options And Common Stock Warrants Share</link:label>
    <link:label id="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238_documentation_en-US" xlink:label="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise of stock options and common stock warrants share.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare" xlink:label="loc_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238" xlink:to="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238" xlink:type="arc" />
    <link:label id="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0_terseLabel_en-US" xlink:label="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options and common stock warrants</link:label>
    <link:label id="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0_label_en-US" xlink:label="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Of Stock Options And Common Stock Warrants</link:label>
    <link:label id="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0_documentation_en-US" xlink:label="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise of stock options and common stock warrants.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ExerciseOfStockOptionsAndCommonStockWarrants" xlink:label="loc_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0" xlink:to="lab_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_D6EB640157A5BAA5D7AD91D70C5F87F5_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_D6EB640157A5BAA5D7AD91D70C5F87F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_D6EB640157A5BAA5D7AD91D70C5F87F5_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_D6EB640157A5BAA5D7AD91D70C5F87F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_D6EB640157A5BAA5D7AD91D70C5F87F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_D6EB640157A5BAA5D7AD91D70C5F87F5" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_D6EB640157A5BAA5D7AD91D70C5F87F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6FF598B5D47B2C5A51B291D70C5FCF83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6FF598B5D47B2C5A51B291D70C5FCF83" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6FF598B5D47B2C5A51B291D70C5FCF83_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6FF598B5D47B2C5A51B291D70C5FCF83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6FF598B5D47B2C5A51B291D70C5FCF83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6FF598B5D47B2C5A51B291D70C5FCF83" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6FF598B5D47B2C5A51B291D70C5FCF83" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_DFA4C5A114AE1A8A7D2F91D70C60D420_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_DFA4C5A114AE1A8A7D2F91D70C60D420" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_DFA4C5A114AE1A8A7D2F91D70C60D420_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_DFA4C5A114AE1A8A7D2F91D70C60D420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_DFA4C5A114AE1A8A7D2F91D70C60D420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_DFA4C5A114AE1A8A7D2F91D70C60D420" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_DFA4C5A114AE1A8A7D2F91D70C60D420" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_996B55D49A5AD6A5A70291D70C600D90_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_996B55D49A5AD6A5A70291D70C600D90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_996B55D49A5AD6A5A70291D70C600D90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_996B55D49A5AD6A5A70291D70C600D90" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_996B55D49A5AD6A5A70291D70C600D90" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple_E099CDB14B8151FA3FAB91D70C6089BD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple_E099CDB14B8151FA3FAB91D70C6089BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple_E099CDB14B8151FA3FAB91D70C6089BD_label_en-US" xlink:label="lab_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple_E099CDB14B8151FA3FAB91D70C6089BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Operations before Extraordinary Items</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple" xlink:label="loc_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple_E099CDB14B8151FA3FAB91D70C6089BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple_E099CDB14B8151FA3FAB91D70C6089BD" xlink:to="lab_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple_E099CDB14B8151FA3FAB91D70C6089BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_263EE22B5FB3D7CFA02791D70C60DF8D_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_263EE22B5FB3D7CFA02791D70C60DF8D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, convertible preferred stock, shares (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_263EE22B5FB3D7CFA02791D70C60DF8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_263EE22B5FB3D7CFA02791D70C60DF8D" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_263EE22B5FB3D7CFA02791D70C60DF8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_846D60EA6D342C05F72091D70C60598C_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_846D60EA6D342C05F72091D70C60598C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, convertible preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_846D60EA6D342C05F72091D70C60598C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_846D60EA6D342C05F72091D70C60598C" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_846D60EA6D342C05F72091D70C60598C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_E57D82E7DBACE9701A0A91D70C61CDEC_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_E57D82E7DBACE9701A0A91D70C61CDEC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, shares issued (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_E57D82E7DBACE9701A0A91D70C61CDEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_E57D82E7DBACE9701A0A91D70C61CDEC" xlink:to="lab_us-gaap_SharesIssued_E57D82E7DBACE9701A0A91D70C61CDEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_770712EF3B65F2D910B691D70C618904_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_770712EF3B65F2D910B691D70C618904" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_770712EF3B65F2D910B691D70C618904" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_770712EF3B65F2D910B691D70C618904" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_770712EF3B65F2D910B691D70C618904" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_D65F4AF15BB722FA6C4D32379B79C14F_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_D65F4AF15BB722FA6C4D32379B79C14F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_D65F4AF15BB722FA6C4D32379B79C14F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_D65F4AF15BB722FA6C4D32379B79C14F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_D65F4AF15BB722FA6C4D32379B79C14F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_D65F4AF15BB722FA6C4D32379B79C14F" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_D65F4AF15BB722FA6C4D32379B79C14F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_A76B961EE3121100FED07819AF26D648_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_A76B961EE3121100FED07819AF26D648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_A76B961EE3121100FED07819AF26D648_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_A76B961EE3121100FED07819AF26D648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_A76B961EE3121100FED07819AF26D648" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_A76B961EE3121100FED07819AF26D648" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_A76B961EE3121100FED07819AF26D648" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_539B9297298AE154FED2730636D5960B_terseLabel_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_539B9297298AE154FED2730636D5960B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance without Adoption of ASC 606</link:label>
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_539B9297298AE154FED2730636D5960B_label_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_539B9297298AE154FED2730636D5960B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Calculated under Revenue Guidance in Effect before Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_539B9297298AE154FED2730636D5960B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_539B9297298AE154FED2730636D5960B" xlink:to="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_539B9297298AE154FED2730636D5960B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_0BB55DA7518FEB8195CA730636DC0631_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0BB55DA7518FEB8195CA730636DC0631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0BB55DA7518FEB8195CA730636DC0631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0BB55DA7518FEB8195CA730636DC0631" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0BB55DA7518FEB8195CA730636DC0631" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397_label_en-US" xlink:label="lab_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Related Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:to="lab_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_E1F6C8183CD7171B9D7F730636DD7095_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_E1F6C8183CD7171B9D7F730636DD7095" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E1F6C8183CD7171B9D7F730636DD7095" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_E1F6C8183CD7171B9D7F730636DD7095" xlink:to="lab_us-gaap_NetIncomeLoss_E1F6C8183CD7171B9D7F730636DD7095" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9C943BFB53ED62F313A791664E1DE6CA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9C943BFB53ED62F313A791664E1DE6CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average estimated fair value at grant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9C943BFB53ED62F313A791664E1DE6CA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9C943BFB53ED62F313A791664E1DE6CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9C943BFB53ED62F313A791664E1DE6CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9C943BFB53ED62F313A791664E1DE6CA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9C943BFB53ED62F313A791664E1DE6CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D0263B1F1212ABEF2FB791664E1E14B1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D0263B1F1212ABEF2FB791664E1E14B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D0263B1F1212ABEF2FB791664E1E14B1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D0263B1F1212ABEF2FB791664E1E14B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D0263B1F1212ABEF2FB791664E1E14B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D0263B1F1212ABEF2FB791664E1E14B1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D0263B1F1212ABEF2FB791664E1E14B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_945437C6F2ABECF4939591664E1E7D8E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_945437C6F2ABECF4939591664E1E7D8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_945437C6F2ABECF4939591664E1E7D8E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_945437C6F2ABECF4939591664E1E7D8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_945437C6F2ABECF4939591664E1E7D8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_945437C6F2ABECF4939591664E1E7D8E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_945437C6F2ABECF4939591664E1E7D8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8278ADB8AF859FD67CE991664E1E7C1B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8278ADB8AF859FD67CE991664E1E7C1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term of options (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8278ADB8AF859FD67CE991664E1E7C1B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8278ADB8AF859FD67CE991664E1E7C1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8278ADB8AF859FD67CE991664E1E7C1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8278ADB8AF859FD67CE991664E1E7C1B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8278ADB8AF859FD67CE991664E1E7C1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E0BCF806AD09912948BD91664E1E81B0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E0BCF806AD09912948BD91664E1E81B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected stock price volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E0BCF806AD09912948BD91664E1E81B0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E0BCF806AD09912948BD91664E1E81B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E0BCF806AD09912948BD91664E1E81B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E0BCF806AD09912948BD91664E1E81B0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E0BCF806AD09912948BD91664E1E81B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_406098AA8625F4D1D75891664E1E4FD1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_406098AA8625F4D1D75891664E1E4FD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected stock price volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_406098AA8625F4D1D75891664E1E4FD1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_406098AA8625F4D1D75891664E1E4FD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_406098AA8625F4D1D75891664E1E4FD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_406098AA8625F4D1D75891664E1E4FD1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_406098AA8625F4D1D75891664E1E4FD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D16D2462C73C179FC2391664E1E85B2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D16D2462C73C179FC2391664E1E85B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D16D2462C73C179FC2391664E1E85B2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D16D2462C73C179FC2391664E1E85B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D16D2462C73C179FC2391664E1E85B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D16D2462C73C179FC2391664E1E85B2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D16D2462C73C179FC2391664E1E85B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_E3111864862C3F50F69B0F55127A22F3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_E3111864862C3F50F69B0F55127A22F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock acquired in business combination (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_E3111864862C3F50F69B0F55127A22F3_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_E3111864862C3F50F69B0F55127A22F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_E3111864862C3F50F69B0F55127A22F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_E3111864862C3F50F69B0F55127A22F3" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_E3111864862C3F50F69B0F55127A22F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_CD99D11596CDBBE86AF591664DB3D6AC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_CD99D11596CDBBE86AF591664DB3D6AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_CD99D11596CDBBE86AF591664DB3D6AC_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_CD99D11596CDBBE86AF591664DB3D6AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_CD99D11596CDBBE86AF591664DB3D6AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_CD99D11596CDBBE86AF591664DB3D6AC" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_CD99D11596CDBBE86AF591664DB3D6AC" xlink:type="arc" />
    <link:label id="lab_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_24F7ACFE852B1751C8EB91664DB4687F_terseLabel_en-US" xlink:label="lab_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_24F7ACFE852B1751C8EB91664DB4687F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset basis</link:label>
    <link:label id="lab_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_24F7ACFE852B1751C8EB91664DB4687F_label_en-US" xlink:label="lab_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_24F7ACFE852B1751C8EB91664DB4687F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Attributable To Deductible And Non Deductible Goodwill And Intangible Assets</link:label>
    <link:label id="lab_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_24F7ACFE852B1751C8EB91664DB4687F_documentation_en-US" xlink:label="lab_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_24F7ACFE852B1751C8EB91664DB4687F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets attributable to deductible and non-deductible goodwill and intangible assets.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets" xlink:label="loc_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_24F7ACFE852B1751C8EB91664DB4687F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_24F7ACFE852B1751C8EB91664DB4687F" xlink:to="lab_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_24F7ACFE852B1751C8EB91664DB4687F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DE2643B369BF67EEA6A391664DB4BC2E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DE2643B369BF67EEA6A391664DB4BC2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DE2643B369BF67EEA6A391664DB4BC2E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DE2643B369BF67EEA6A391664DB4BC2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DE2643B369BF67EEA6A391664DB4BC2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DE2643B369BF67EEA6A391664DB4BC2E" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DE2643B369BF67EEA6A391664DB4BC2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8FA8F2C6FB182E65EEAC91664DB41672_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8FA8F2C6FB182E65EEAC91664DB41672" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8FA8F2C6FB182E65EEAC91664DB41672_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8FA8F2C6FB182E65EEAC91664DB41672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8FA8F2C6FB182E65EEAC91664DB41672" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8FA8F2C6FB182E65EEAC91664DB41672" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8FA8F2C6FB182E65EEAC91664DB41672" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9DB7D3C9DC31AD28EEE891664DB41756_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9DB7D3C9DC31AD28EEE891664DB41756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9DB7D3C9DC31AD28EEE891664DB41756_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9DB7D3C9DC31AD28EEE891664DB41756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9DB7D3C9DC31AD28EEE891664DB41756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9DB7D3C9DC31AD28EEE891664DB41756" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9DB7D3C9DC31AD28EEE891664DB41756" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_AE4F710571A28E3EFEF491664DB50BCC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_AE4F710571A28E3EFEF491664DB50BCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_AE4F710571A28E3EFEF491664DB50BCC_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_AE4F710571A28E3EFEF491664DB50BCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_AE4F710571A28E3EFEF491664DB50BCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_AE4F710571A28E3EFEF491664DB50BCC" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_AE4F710571A28E3EFEF491664DB50BCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_00AB07EDF442F9C7BD2991664DB5C983_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_00AB07EDF442F9C7BD2991664DB5C983" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_00AB07EDF442F9C7BD2991664DB5C983_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_00AB07EDF442F9C7BD2991664DB5C983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_00AB07EDF442F9C7BD2991664DB5C983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_00AB07EDF442F9C7BD2991664DB5C983" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_00AB07EDF442F9C7BD2991664DB5C983" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_AC2F0369E3F42846D52391664DB5FF3B_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_AC2F0369E3F42846D52391664DB5FF3B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_AC2F0369E3F42846D52391664DB5FF3B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_AC2F0369E3F42846D52391664DB5FF3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_AC2F0369E3F42846D52391664DB5FF3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_AC2F0369E3F42846D52391664DB5FF3B" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_AC2F0369E3F42846D52391664DB5FF3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_F7645FDDCD642232BB3391664DB5838F_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_F7645FDDCD642232BB3391664DB5838F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_F7645FDDCD642232BB3391664DB5838F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_F7645FDDCD642232BB3391664DB5838F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_F7645FDDCD642232BB3391664DB5838F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_F7645FDDCD642232BB3391664DB5838F" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_F7645FDDCD642232BB3391664DB5838F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_4DACF73DD3AA804E810491664DB58C6B_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_4DACF73DD3AA804E810491664DB58C6B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_4DACF73DD3AA804E810491664DB58C6B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_4DACF73DD3AA804E810491664DB58C6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_4DACF73DD3AA804E810491664DB58C6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_4DACF73DD3AA804E810491664DB58C6B" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_4DACF73DD3AA804E810491664DB58C6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_E40CBA6825F088BDC55891664DB65B57_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_E40CBA6825F088BDC55891664DB65B57" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fixed asset basis</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_E40CBA6825F088BDC55891664DB65B57_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_E40CBA6825F088BDC55891664DB65B57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_E40CBA6825F088BDC55891664DB65B57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_E40CBA6825F088BDC55891664DB65B57" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_E40CBA6825F088BDC55891664DB65B57" xlink:type="arc" />
    <link:label id="lab_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_68E54A2ECDF7C6AE2D4C91664DB6A9BD_negatedLabel_en-US" xlink:label="lab_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_68E54A2ECDF7C6AE2D4C91664DB6A9BD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangible asset basis</link:label>
    <link:label id="lab_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_68E54A2ECDF7C6AE2D4C91664DB6A9BD_label_en-US" xlink:label="lab_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_68E54A2ECDF7C6AE2D4C91664DB6A9BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Attributable To Deductible And Non Deductible Goodwill And Intangible Assets</link:label>
    <link:label id="lab_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_68E54A2ECDF7C6AE2D4C91664DB6A9BD_documentation_en-US" xlink:label="lab_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_68E54A2ECDF7C6AE2D4C91664DB6A9BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities attributable to deductible and non-deductible goodwill and intangible assets.</link:label>
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets" xlink:label="loc_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_68E54A2ECDF7C6AE2D4C91664DB6A9BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_68E54A2ECDF7C6AE2D4C91664DB6A9BD" xlink:to="lab_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_68E54A2ECDF7C6AE2D4C91664DB6A9BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_D43D5E35BA590E26EB4991664DB6C9F0_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_D43D5E35BA590E26EB4991664DB6C9F0" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_D43D5E35BA590E26EB4991664DB6C9F0_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_D43D5E35BA590E26EB4991664DB6C9F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_D43D5E35BA590E26EB4991664DB6C9F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_D43D5E35BA590E26EB4991664DB6C9F0" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_D43D5E35BA590E26EB4991664DB6C9F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_679AFEB3F9C2694223A191664DB63361_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_679AFEB3F9C2694223A191664DB63361" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_679AFEB3F9C2694223A191664DB63361_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_679AFEB3F9C2694223A191664DB63361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_679AFEB3F9C2694223A191664DB63361" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_679AFEB3F9C2694223A191664DB63361" xlink:to="lab_us-gaap_DeferredTaxLiabilities_679AFEB3F9C2694223A191664DB63361" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_71A1C7A65B4582CABFE332379CCD88E3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_71A1C7A65B4582CABFE332379CCD88E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_71A1C7A65B4582CABFE332379CCD88E3_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_71A1C7A65B4582CABFE332379CCD88E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_71A1C7A65B4582CABFE332379CCD88E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_71A1C7A65B4582CABFE332379CCD88E3" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_71A1C7A65B4582CABFE332379CCD88E3" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>alpn-20181231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/A401KRetirementPlan" xlink:href="alpn-20181231.xsd#A401KRetirementPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformation" xlink:href="alpn-20181231.xsd#AdditionalConsolidatedBalanceSheetsInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" xlink:href="alpn-20181231.xsd#AdditionalConsolidatedBalanceSheetsInformationAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:href="alpn-20181231.xsd#AdditionalConsolidatedBalanceSheetsInformationPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationTables" xlink:href="alpn-20181231.xsd#AdditionalConsolidatedBalanceSheetsInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombination" xlink:href="alpn-20181231.xsd#BusinessCombination" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#BusinessCombinationAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfAdjustedAllocationOfPurchaseConsiderationDetails" xlink:href="alpn-20181231.xsd#BusinessCombinationScheduleOfAdjustedAllocationOfPurchaseConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfFairValueOfConsiderationTransferredDetails" xlink:href="alpn-20181231.xsd#BusinessCombinationScheduleOfFairValueOfConsiderationTransferredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfProFormaFinancialInformationDetails" xlink:href="alpn-20181231.xsd#BusinessCombinationScheduleOfProFormaFinancialInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/BusinessCombinationTables" xlink:href="alpn-20181231.xsd#BusinessCombinationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestments" xlink:href="alpn-20181231.xsd#CashEquivalentsAndShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsDetails" xlink:href="alpn-20181231.xsd#CashEquivalentsAndShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:href="alpn-20181231.xsd#CashEquivalentsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreement" xlink:href="alpn-20181231.xsd#CollaborationAndLicenseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreementDetails" xlink:href="alpn-20181231.xsd#CollaborationAndLicenseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingencies" xlink:href="alpn-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForNonCancelableOperatingLeasesDetails" xlink:href="alpn-20181231.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForNonCancelableOperatingLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesTables" xlink:href="alpn-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheets" xlink:href="alpn-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="alpn-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="alpn-20181231.xsd#ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="alpn-20181231.xsd#ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="alpn-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="alpn-20181231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/DescriptionOfBusiness" xlink:href="alpn-20181231.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/DescriptionOfBusinessDetails" xlink:href="alpn-20181231.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/DocumentAndEntityInformation" xlink:href="alpn-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurements" xlink:href="alpn-20181231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alpn-20181231.xsd#FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/FairValueMeasurementsTables" xlink:href="alpn-20181231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxes" xlink:href="alpn-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfNetOperatingLossCarryforwardsDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryOfNetOperatingLossCarryforwardsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryTaxCreditCarryforwardsDetails" xlink:href="alpn-20181231.xsd#IncomeTaxesSummaryTaxCreditCarryforwardsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/IncomeTaxesTables" xlink:href="alpn-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LongTermDebt" xlink:href="alpn-20181231.xsd#LongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LongTermDebtNarrativeDetails" xlink:href="alpn-20181231.xsd#LongTermDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" xlink:href="alpn-20181231.xsd#LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LongTermDebtTables" xlink:href="alpn-20181231.xsd#LongTermDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssets" xlink:href="alpn-20181231.xsd#LossOnSaleOfIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssetsDetails" xlink:href="alpn-20181231.xsd#LossOnSaleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShare" xlink:href="alpn-20181231.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShareAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#NetLossPerShareAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:href="alpn-20181231.xsd#NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/NetLossPerShareTables" xlink:href="alpn-20181231.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/PropertyAndEquipment" xlink:href="alpn-20181231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentDetails" xlink:href="alpn-20181231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentTables" xlink:href="alpn-20181231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/RelatedPartyTransactions" xlink:href="alpn-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/RelatedPartyTransactionsDetails" xlink:href="alpn-20181231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficit" xlink:href="alpn-20181231.xsd#StockholdersDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitAdditionalInformationDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockBasedCompensationExpenseDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockOptionAssumptionsDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitScheduleOfStockOptionAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfWarrantsDetails" xlink:href="alpn-20181231.xsd#StockholdersDeficitScheduleOfWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeficitTables" xlink:href="alpn-20181231.xsd#StockholdersDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/StockholdersDeflicitSummaryOfOptionActivityDetails" xlink:href="alpn-20181231.xsd#StockholdersDeflicitSummaryOfOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNewAccountingPronouncementsDetails" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfNewAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="alpn-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/A401KRetirementPlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9BF4CA2C444C558397084EE7053D5B1A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EB4E3878D424EFA8C1EF4EE7053D18D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9BF4CA2C444C558397084EE7053D5B1A" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EB4E3878D424EFA8C1EF4EE7053D18D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_167367EBFE6B0B2C6EBE4F12F2927ED9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_7C6A3691E58F677CCB784F102D8FF20E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_167367EBFE6B0B2C6EBE4F12F2927ED9" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_7C6A3691E58F677CCB784F102D8FF20E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_B4C30D3618DB3F80BAB173063588FB00" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_alpn_AccruedResearchAndDevelopmentCurrent_E2CE07D7B5A370E82CCB73063589FA65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_B4C30D3618DB3F80BAB173063588FB00" xlink:to="loc_alpn_AccruedResearchAndDevelopmentCurrent_E2CE07D7B5A370E82CCB73063589FA65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5716CDE6A4969A8ADDDB73063589A6A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_B4C30D3618DB3F80BAB173063588FB00" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5716CDE6A4969A8ADDDB73063589A6A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_63E058604937EEF2BE2E73063589701E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_B4C30D3618DB3F80BAB173063588FB00" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_63E058604937EEF2BE2E73063589701E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_A7243A61FDF09FC7AF707306358ACFFB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_B4C30D3618DB3F80BAB173063588FB00" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_A7243A61FDF09FC7AF707306358ACFFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B82ACFCD2930F86C99247306358AE8FB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_B4C30D3618DB3F80BAB173063588FB00" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_B82ACFCD2930F86C99247306358AE8FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_6EEF275895E29A5AD7DC77C4DDAB3818" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_B9405AD1CE5585582D9977C7C9A9EC96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_6EEF275895E29A5AD7DC77C4DDAB3818" xlink:to="loc_us-gaap_DeferredOfferingCosts_B9405AD1CE5585582D9977C7C9A9EC96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_38535B6D4900B513A32577C4DDAC4D8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_6EEF275895E29A5AD7DC77C4DDAB3818" xlink:to="loc_us-gaap_PrepaidInsurance_38535B6D4900B513A32577C4DDAC4D8A" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PrepaidResearchAndDevelopment" xlink:label="loc_alpn_PrepaidResearchAndDevelopment_B0CE4B4BBC3D1A32013577C4DDAC44D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_6EEF275895E29A5AD7DC77C4DDAB3818" xlink:to="loc_alpn_PrepaidResearchAndDevelopment_B0CE4B4BBC3D1A32013577C4DDAC44D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_B041045D0E2DA3E83C4077C4DDAC44DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_6EEF275895E29A5AD7DC77C4DDAB3818" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_B041045D0E2DA3E83C4077C4DDAC44DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_D0FB03C3C4EB524E571077C4DDAC2D48" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_6EEF275895E29A5AD7DC77C4DDAB3818" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_D0FB03C3C4EB524E571077C4DDAC2D48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DE155C5FE73E57DA7D8277C4DDAC8FF0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_6EEF275895E29A5AD7DC77C4DDAB3818" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DE155C5FE73E57DA7D8277C4DDAC8FF0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_B4BA679617EC0745251D4FC686A757C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_A2F301A7A5C71733039B4FC686A829CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_B4BA679617EC0745251D4FC686A757C0" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_A2F301A7A5C71733039B4FC686A829CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EB62CC59A82EE9E810964FC686A87E3A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_B4BA679617EC0745251D4FC686A757C0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EB62CC59A82EE9E810964FC686A87E3A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombination" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_18DD20B55D08DC8AA72932379BB5F0D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8417AB8128F95EBD4B5332379BB56A04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_18DD20B55D08DC8AA72932379BB5F0D8" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8417AB8128F95EBD4B5332379BB56A04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2C9015FA8EA1486330FD73AD7B323DD7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE1E07D48D1DD6223B1E73AD7B32D291" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2C9015FA8EA1486330FD73AD7B323DD7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE1E07D48D1DD6223B1E73AD7B32D291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_082D46668BC5C2A102AF73AD7B32B8CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE1E07D48D1DD6223B1E73AD7B32D291" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_082D46668BC5C2A102AF73AD7B32B8CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6E3490A4436AEDDEF7373AD7B32FE5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_082D46668BC5C2A102AF73AD7B32B8CC" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6E3490A4436AEDDEF7373AD7B32FE5B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_5FF177204FD2049ABFA173AD7B321234" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6E3490A4436AEDDEF7373AD7B32FE5B" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_5FF177204FD2049ABFA173AD7B321234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9D5AF7DBA6AE80E3167E73AD7B32735E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE1E07D48D1DD6223B1E73AD7B32D291" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9D5AF7DBA6AE80E3167E73AD7B32735E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_5F046201C69B97A3E2DB73AD7B32E563" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9D5AF7DBA6AE80E3167E73AD7B32735E" xlink:to="loc_us-gaap_RelatedPartyDomain_5F046201C69B97A3E2DB73AD7B32E563" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember" xlink:label="loc_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_38637403936ED2A94CB273AD7B322479" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5F046201C69B97A3E2DB73AD7B32E563" xlink:to="loc_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_38637403936ED2A94CB273AD7B322479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_BE1E07D48D1DD6223B1E73AD7B32D291" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_AEF3999A611C29940CDE73AD7B3CD28E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_AEF3999A611C29940CDE73AD7B3CD28E" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessCombinationCommonStockIssuedExchangeRate" xlink:label="loc_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_alpn_BusinessCombinationCommonStockIssuedExchangeRate_95C69FB38DAB6EB569B773AD7B3CDB20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0F64C0A0C78C7F11BC2873AD7B3C92D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0F64C0A0C78C7F11BC2873AD7B3C92D9" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation" xlink:label="loc_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_A3B8A74B252539C52CB873AD7B3CFA02" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_A3B8A74B252539C52CB873AD7B3CFA02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_D9149C52CE4DA1E00D0873AD7B3C4BE2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_D9149C52CE4DA1E00D0873AD7B3C4BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:label="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_C3B02A0FC32A6B9A02DF73AD7B3C4BD8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_C3B02A0FC32A6B9A02DF73AD7B3C4BD8" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CashFlowProjectionsDiscountRate" xlink:label="loc_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_alpn_CashFlowProjectionsDiscountRate_A56561E234E3F974FE7873AD7B3C5ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquisitionCosts" xlink:label="loc_us-gaap_AcquisitionCosts_EDB994EF50B555B0297C73AD7B3C1840" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9C0D40CDE4A73986265E73AD7B3C5632" xlink:to="loc_us-gaap_AcquisitionCosts_EDB994EF50B555B0297C73AD7B3C1840" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfAdjustedAllocationOfPurchaseConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C6957C7BC7BA75727E44CC99B055432C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E8F87F4E1CDD632100E0CC99B0612C44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C6957C7BC7BA75727E44CC99B055432C" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E8F87F4E1CDD632100E0CC99B0612C44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FBE78D15F74AB89CEF13CC99B061504F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E8F87F4E1CDD632100E0CC99B0612C44" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_FBE78D15F74AB89CEF13CC99B061504F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2F8DB0A56F77DCD9BE6BCC99B061D08B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FBE78D15F74AB89CEF13CC99B061504F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2F8DB0A56F77DCD9BE6BCC99B061D08B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_41916FA10A8D8ADB9832CC99B0619541" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2F8DB0A56F77DCD9BE6BCC99B061D08B" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_41916FA10A8D8ADB9832CC99B0619541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_FACA2E490BFC1109A31BCC99B062E939" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E8F87F4E1CDD632100E0CC99B0612C44" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_FACA2E490BFC1109A31BCC99B062E939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_FACA2E490BFC1109A31BCC99B062E939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1E1294DB675B0D8D8003CC99B062A4F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1E1294DB675B0D8D8003CC99B062A4F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_771F2D7972E101876F98CC99B06241FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_771F2D7972E101876F98CC99B06241FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_726BD8548DCE854C1F39CC99B0630966" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_726BD8548DCE854C1F39CC99B0630966" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_E32077F3433D63552492CC99B0637702" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_E32077F3433D63552492CC99B0637702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_375984B869DD0E526559CC99B06316DD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_CB15B18B6C59C51DC878CC99B0628121" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_375984B869DD0E526559CC99B06316DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_FACA2E490BFC1109A31BCC99B062E939" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:label="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:to="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_F1E02DC7500472DB55A1CC99B0638211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_B26D1F1DD83EC9D68276CC99B064307A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_B26D1F1DD83EC9D68276CC99B064307A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F2B4EB43B4C515394A08CC99B0646776" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_BAABFF1D2ED9D986CF30CC99B0633EE5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F2B4EB43B4C515394A08CC99B0646776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:label="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_4E7E2CCACD664EA61B0CCC99B06465B1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_FACA2E490BFC1109A31BCC99B062E939" xlink:to="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_4E7E2CCACD664EA61B0CCC99B06465B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E62CABC7F7CAA28312BBCC99B065E7D6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_FACA2E490BFC1109A31BCC99B062E939" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E62CABC7F7CAA28312BBCC99B065E7D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfFairValueOfConsiderationTransferredDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C9EA03776BF53EAD54194EC065E6DD3A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C9EA03776BF53EAD54194EC065E6DD3A" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DB3BA2FC0195435E05F54EC065E6B70E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DB3BA2FC0195435E05F54EC065E6B70E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_477983D1525D8F6CD2134EC065E62DCF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DB3BA2FC0195435E05F54EC065E6B70E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_477983D1525D8F6CD2134EC065E62DCF" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_F8C7C25F8048C16EC00E4EC065E7868A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_477983D1525D8F6CD2134EC065E62DCF" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_F8C7C25F8048C16EC00E4EC065E7868A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_759AC5093C9E7E59F2C34EC065E6FF4E" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_E6F1A40A7480300C6AA44EC065E73BA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_E6F1A40A7480300C6AA44EC065E73BA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_12A162A063FD58D0BD6D4EC065E79AEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_12A162A063FD58D0BD6D4EC065E79AEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A7EE53E73E1F0E55BD594EC065E88C2F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A7EE53E73E1F0E55BD594EC065E88C2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D0793311915BD31E4C354EC065E87437" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D0793311915BD31E4C354EC065E87437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2036DCAE9ABD9547EFBC4EC065E8B0DC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_64650756FC26BA41C9334EC065E7DF43" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2036DCAE9ABD9547EFBC4EC065E8B0DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_29AE634F62F5D6DDB50BCC2FE89CFC91" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C3D1E58384BC45AE200ECC2FE89C0486" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_29AE634F62F5D6DDB50BCC2FE89CFC91" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C3D1E58384BC45AE200ECC2FE89C0486" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_593BCCAED552E3437AFBCC2FE89D6701" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C3D1E58384BC45AE200ECC2FE89C0486" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_593BCCAED552E3437AFBCC2FE89D6701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0B209F49637238CE6F16CC2FE89DA4A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_593BCCAED552E3437AFBCC2FE89D6701" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0B209F49637238CE6F16CC2FE89DA4A7" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_4B6800D9A7D496AAE2EECC9B618FC3B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0B209F49637238CE6F16CC2FE89DA4A7" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_4B6800D9A7D496AAE2EECC9B618FC3B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8ECCD7BA9B58C1E46A56CC2FE89EA142" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C3D1E58384BC45AE200ECC2FE89C0486" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8ECCD7BA9B58C1E46A56CC2FE89EA142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_B02EEC3D1E100DA97CF0CC2FE89E33B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ECCD7BA9B58C1E46A56CC2FE89EA142" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_B02EEC3D1E100DA97CF0CC2FE89E33B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90AD500E6AEA4EC3D32ECC2FE89ECBE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ECCD7BA9B58C1E46A56CC2FE89EA142" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90AD500E6AEA4EC3D32ECC2FE89ECBE9" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="loc_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8ECCD7BA9B58C1E46A56CC2FE89EA142" xlink:to="loc_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_FE054D7C54C306D381AACC2FE89ECC74" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/BusinessCombinationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_B8D8806080A462350EB3730636BC26E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_0DBB782996C04011B464730636BC546D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_B8D8806080A462350EB3730636BC26E7" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_0DBB782996C04011B464730636BC546D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E141FA9AF7212CBCA0C5733D3B9A268B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_B8D8806080A462350EB3730636BC26E7" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E141FA9AF7212CBCA0C5733D3B9A268B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_5FCC4B71DBDC4A878654730636BDED25" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_B8D8806080A462350EB3730636BC26E7" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_5FCC4B71DBDC4A878654730636BDED25" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_2EA4CD30F6CE51FD6AF132379CCD316D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_80C3DFF66F2044BBEA9332379CCD424B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_2EA4CD30F6CE51FD6AF132379CCD316D" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_80C3DFF66F2044BBEA9332379CCD424B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_61D92340B883A00328500F551249DCD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_61D92340B883A00328500F551249DCD6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10" xlink:to="loc_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_870B18EB2CCE3C79F1B10F551249E2F2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_205AD37CCE8386F00F820F55124A83B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_205AD37CCE8386F00F820F55124A83B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_721B3AE1D97F06C101DC0F55124ACE8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_721B3AE1D97F06C101DC0F55124ACE8A" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CorporateDebtSecuritiesAndCommercialPaperMember" xlink:label="loc_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_508C15DCE5C8AD92BB040F5512497EB6" xlink:to="loc_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_0510EC05E62756C381FE0F55124A85F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E1460B9ABBE96E9921E10F5512493F10" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83A1C67B7ECDBB50D6A00F55124B23EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83A1C67B7ECDBB50D6A00F55124B23EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E4C7253851CBB693A7910F55124B2BAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E4C7253851CBB693A7910F55124B2BAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BFA39D132679160E82F10F55124B4FF9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BFA39D132679160E82F10F55124B4FF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_AAC9AC1C2E0E5F6AA3470F55124B3094" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ED344574C2A042FA5FB30F55124A06E0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_AAC9AC1C2E0E5F6AA3470F55124B3094" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_9DBA3160CF495D6561D20F55124CEFF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_61D92340B883A00328500F551249DCD6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_9DBA3160CF495D6561D20F55124CEFF2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_FB17BD99402615408C870F5512541D7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_343C74C882EC8FFC3C390F83CFA20025" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_FB17BD99402615408C870F5512541D7A" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_343C74C882EC8FFC3C390F83CFA20025" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A10BECAEB42B1AE49CD673692A7AE778" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6A34FB15C6F42FFFD68D73692A7BDF75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A10BECAEB42B1AE49CD673692A7AE778" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6A34FB15C6F42FFFD68D73692A7BDF75" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4671DF4C576893BBF09791B703C3F1D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4671DF4C576893BBF09791B703C3F1D3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_28AE265FFD59E01C135C91B703C8BFA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:to="loc_srt_RangeAxis_28AE265FFD59E01C135C91B703C8BFA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_97D1FC898196C57C813E91B703C88B25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_28AE265FFD59E01C135C91B703C8BFA3" xlink:to="loc_srt_RangeMember_97D1FC898196C57C813E91B703C88B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_594A9B05E3CFF729FE5E91B703C86610" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_97D1FC898196C57C813E91B703C88B25" xlink:to="loc_srt_MaximumMember_594A9B05E3CFF729FE5E91B703C86610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A437CD79F6784B24F1F091B703C90860" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A437CD79F6784B24F1F091B703C90860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_33462FD939EB95B69B4D91B703C9A931" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A437CD79F6784B24F1F091B703C90860" xlink:to="loc_us-gaap_TypeOfAdoptionMember_33462FD939EB95B69B4D91B703C9A931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_EA80A008F5C72EE5D0C191B703CAF268" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_33462FD939EB95B69B4D91B703C9A931" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_EA80A008F5C72EE5D0C191B703CAF268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_FFA23D98E3B63798238591B703CA0015" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_FFA23D98E3B63798238591B703CA0015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_AF147E842C672C36B13691B703CA4E54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_FFA23D98E3B63798238591B703CA0015" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_AF147E842C672C36B13691B703CA4E54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8B14A0D0335012A43E3D91B703CB8095" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_AF147E842C672C36B13691B703CA4E54" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8B14A0D0335012A43E3D91B703CB8095" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:to="loc_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0DF37FCE9174FCA95C3591B703CB6966" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_KiteMember" xlink:label="loc_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9CE5B005C46E2451755391B703CBECA4" xlink:to="loc_alpn_KiteMember_32240E2D5BF4FDC51BE591B703CBC346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9AF9E43A8E93E85A05AC91B703CC653B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementProductAgreementMember" xlink:label="loc_us-gaap_CollaborativeArrangementProductAgreementMember_1C36F4AAC823DD6FD37091B703CCC0C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6C9DA690349A6E32280891B703CC44C0" xlink:to="loc_us-gaap_CollaborativeArrangementProductAgreementMember_1C36F4AAC823DD6FD37091B703CCC0C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A31038D46DF4D320C03791B703C65100" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfProgramsFromLicenseTechnology" xlink:label="loc_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_alpn_NumberOfProgramsFromLicenseTechnology_6BEB0D07E3682E731FFE91B703CD2212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_781B718183CF4C27483F91B703CD25A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_us-gaap_ContractWithCustomerLiability_781B718183CF4C27483F91B703CD25A9" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable" xlink:label="loc_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable_CA6BDDF6745C72A46F6491B703CD2AD1" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EligibleToReceiveAdditionalResearchSupportPayment" xlink:label="loc_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_alpn_EligibleToReceiveAdditionalResearchSupportPayment_505A93271677CEE719DE91B703D24C0B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfTranches" xlink:label="loc_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_alpn_NumberOfTranches_4B17711704A6F42FD97F91B70A0AC498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C74C6831BB9DD1ABA2FC91B703D3DD06" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C74C6831BB9DD1ABA2FC91B703D3DD06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2085C10BC6910814EC2591B703D31FAD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D6CE39DD56B0DEA0DFF691B703CD18AD" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2085C10BC6910814EC2591B703D31FAD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E54BC373A7BAC67B235032379D13A66A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12136B76945A417E3ABC32379D1355B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E54BC373A7BAC67B235032379D13A66A" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12136B76945A417E3ABC32379D1355B5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6A070917372A44003D7A9141DB87A10D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6A070917372A44003D7A9141DB87A10D" xlink:to="loc_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9EAC0B20BC041DFD2C819141DB8732F1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5616DF45C08752DCF6CE9141DB8701E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4530DD0CA67FF8E484B39141DB87F8D4" xlink:to="loc_us-gaap_SubsequentEventMember_5616DF45C08752DCF6CE9141DB8701E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_91C8777A7EC026D197129141DB87CA43" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_B84046BAC48D676C04E49141DB8700AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_C4E2456458460AA1360B9141DB87D725" xlink:to="loc_us-gaap_LineOfCreditMember_B84046BAC48D676C04E49141DB8700AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_DB159ED6A8FD6C4AC1199141DB87CCB9" xlink:to="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease" xlink:label="loc_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_8182F4EC15AC705817769141DB877B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_97F33CE9E2585B9495159141DB871347" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_97F33CE9E2585B9495159141DB871347" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage" xlink:label="loc_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage_DDE3BCB07AEBB291D5B29141DB873921" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfOptionsToExtendTermLease" xlink:label="loc_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_alpn_NumberOfOptionsToExtendTermLease_6F1B6F5732C24A9092519141DB870FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LessorOperatingLeaseRenewalTerm_3820A976C20967610BD59141DB87E83C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_LessorOperatingLeaseRenewalTerm_3820A976C20967610BD59141DB87E83C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_9A2621F0AFF8568463179141DB87E878" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_SecurityDeposit_9A2621F0AFF8568463179141DB87E878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_A14A72055FF57CCCC8049141DB87E714" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_A14A72055FF57CCCC8049141DB87E714" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease" xlink:label="loc_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease_271C93770969FDD56D529141DB8781EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_11BD32A4915E4DAD4BB59141DB8776D0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_11BD32A4915E4DAD4BB59141DB8776D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_2B2D7C6BA1A71969C07B9141DB877124" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_2B2D7C6BA1A71969C07B9141DB877124" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PaymentsForProceedsFromAdditionalTenantAllowance" xlink:label="loc_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_alpn_PaymentsForProceedsFromAdditionalTenantAllowance_B78DC9A17830BD29D8E89141DB87F3D1" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate" xlink:label="loc_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8F31929CF76A892451C59141DB87A7FD" xlink:to="loc_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate_0AB0902F1BA6DBC1FB889141DB8723D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForNonCancelableOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F067FE3C0D3BF6294CAE4F21330C90BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_427AFED376746C9B99C24F21330FA70C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F067FE3C0D3BF6294CAE4F21330C90BF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_427AFED376746C9B99C24F21330FA70C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7580E0954A2F0518E6644F21331058C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F067FE3C0D3BF6294CAE4F21330C90BF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7580E0954A2F0518E6644F21331058C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0F4DFE3EA6AF5E04F0434F2133114D4D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F067FE3C0D3BF6294CAE4F21330C90BF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0F4DFE3EA6AF5E04F0434F2133114D4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2C97E8C3E7584801EF704F213311D9F3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F067FE3C0D3BF6294CAE4F21330C90BF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2C97E8C3E7584801EF704F213311D9F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_37435BEEF51206D8AA594F2133110169" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F067FE3C0D3BF6294CAE4F21330C90BF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_37435BEEF51206D8AA594F2133110169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_70AC2D65EA19D14A94E84F2133119217" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F067FE3C0D3BF6294CAE4F21330C90BF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_70AC2D65EA19D14A94E84F2133119217" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B79A73B233270285886032379AC8D0F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_12FC56D95601B87E5AF232379AC842B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B79A73B233270285886032379AC8D0F1" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_12FC56D95601B87E5AF232379AC842B0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_948EB82DEADA2729EC1C73063796EE1C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_948EB82DEADA2729EC1C73063796EE1C" xlink:to="loc_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_044C23BE3406FBA6E4DD730637977FDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_044C23BE3406FBA6E4DD730637977FDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8D9CF4AA1C8FBA144C11730637975C71" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8D9CF4AA1C8FBA144C11730637975C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B7B39C050BF64DCC4777730637971E5D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B7B39C050BF64DCC4777730637971E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_947BDB4A9078CBF545A37306379839F9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B362469D74D79E4406673063797FC00" xlink:to="loc_us-gaap_AssetsCurrent_947BDB4A9078CBF545A37306379839F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_C73DD2E11515CD14B294730637981BE7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_C73DD2E11515CD14B294730637981BE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4AF99F875093061D167F73063798EC14" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4AF99F875093061D167F73063798EC14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2EA132701F377C7EA85673063798723A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2EA132701F377C7EA85673063798723A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7FB1E5C29CE4AF06147673063798E8E5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_963E964BF38CB2ADCBE973063796AE69" xlink:to="loc_us-gaap_Assets_7FB1E5C29CE4AF06147673063798E8E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_948EB82DEADA2729EC1C73063796EE1C" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_A87D10475FDC518AC72473063799C384" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:to="loc_us-gaap_AccountsPayableCurrent_A87D10475FDC518AC72473063799C384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5AE71F6E280F0235D2C773063799A262" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5AE71F6E280F0235D2C773063799A262" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_E7974CD03019FB97FE087306379995F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_E7974CD03019FB97FE087306379995F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_20FB841109AD554D36EA7306379A47EA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_20FB841109AD554D36EA7306379A47EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_48FC67CFD73D9FFF7D737306379AF4E2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:to="loc_us-gaap_LongTermDebtCurrent_48FC67CFD73D9FFF7D737306379AF4E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_99997FC6AE426FD2C68A7306379A779A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1878B4792E2CBC2F74B673063799285C" xlink:to="loc_us-gaap_LiabilitiesCurrent_99997FC6AE426FD2C68A7306379A779A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_A0E8B359E565F2B0100D730637D071D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_A0E8B359E565F2B0100D730637D071D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_74B1FC84DB2598292CBF730637D15356" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_74B1FC84DB2598292CBF730637D15356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_F17F803831CE46CD3398730637D10646" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_F17F803831CE46CD3398730637D10646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_153B6E1792956F2335A7730637D10D39" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:to="loc_us-gaap_Liabilities_153B6E1792956F2335A7730637D10D39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3BE24FEA2E3583DD4E47730637D1F39D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3BE24FEA2E3583DD4E47730637D1F39D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12008DCCD2C75B71D17E730637D1C9F7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12008DCCD2C75B71D17E730637D1C9F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:to="loc_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_980900B41B107953C3F6730637D2EFB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:to="loc_us-gaap_CommonStockValueOutstanding_980900B41B107953C3F6730637D2EFB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_4D9FD9109CF4ED6B0C65730637D2C251" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:to="loc_us-gaap_TreasuryStockValue_4D9FD9109CF4ED6B0C65730637D2C251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9C04DDD24FFEDE1FE10F730637D2478E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9C04DDD24FFEDE1FE10F730637D2478E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1F6341DC30FDAE5E4617730637D2A2B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1F6341DC30FDAE5E4617730637D2A2B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26491770425F4ED80F61730637D371E3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26491770425F4ED80F61730637D371E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_519D9A641AC4D35EDBA5730637D37B30" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_596A3294F349EFC8E48F730637D24AB4" xlink:to="loc_us-gaap_StockholdersEquity_519D9A641AC4D35EDBA5730637D37B30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_A9980DE2FF6B3EDF973D730637D30C71" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7D7D3112BA64141B77C773063798C2DE" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_A9980DE2FF6B3EDF973D730637D30C71" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_FA50964F7659FF9FA764CC2FE9935014" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_590CB46D266E1F729C43CC2FE9932F10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FA50964F7659FF9FA764CC2FE9935014" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_590CB46D266E1F729C43CC2FE9932F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_43C50DD0358C39738BA5CC2FE993B0EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FA50964F7659FF9FA764CC2FE9935014" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_43C50DD0358C39738BA5CC2FE993B0EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_2B1F9E5C70993C52107ACC2FE9931E7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FA50964F7659FF9FA764CC2FE9935014" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_2B1F9E5C70993C52107ACC2FE9931E7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_FB3E989D115600ACDD33CC2FE9949A7A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FA50964F7659FF9FA764CC2FE9935014" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_FB3E989D115600ACDD33CC2FE9949A7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_B5A48679CE353FED9E4CCC2FE99425D3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FA50964F7659FF9FA764CC2FE9935014" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_B5A48679CE353FED9E4CCC2FE99425D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8A295CE03F09B74A03C6CC2FE994C266" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FA50964F7659FF9FA764CC2FE9935014" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8A295CE03F09B74A03C6CC2FE994C266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B42FF4F9DED05CCC4D6BCC2FE9941536" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FA50964F7659FF9FA764CC2FE9935014" xlink:to="loc_us-gaap_CommonStockSharesIssued_B42FF4F9DED05CCC4D6BCC2FE9941536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ADF9F5EDE5FB5AD61EA0CC2FE994CC23" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FA50964F7659FF9FA764CC2FE9935014" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ADF9F5EDE5FB5AD61EA0CC2FE994CC23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_BAEC68623A6EC2DEC273CC2FE995768D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FA50964F7659FF9FA764CC2FE9935014" xlink:to="loc_us-gaap_TreasuryStockCommonShares_BAEC68623A6EC2DEC273CC2FE995768D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_99C6C3FC036D6914A73F91D70C52AE06" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_99C6C3FC036D6914A73F91D70C52AE06" xlink:to="loc_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A06629CD38CB34C9485991D70C567232" xlink:to="loc_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_CC7B2F3726C663FAC3F491D70C57C866" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_C62AD33D5A4D6155C9DD91D70C5610CE" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_CC7B2F3726C663FAC3F491D70C57C866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8CBD8C4E7BE94E390AAE91D70C5A8625" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8CBD8C4E7BE94E390AAE91D70C5A8625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8CBD8C4E7BE94E390AAE91D70C5A8625" xlink:to="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_55A0E525CF30C2B195C191D70C5A9E9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:to="loc_us-gaap_CommonStockMember_55A0E525CF30C2B195C191D70C5A9E9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_AEDB25F7076DCBD8F55291D70C5BD3FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:to="loc_us-gaap_TreasuryStockMember_AEDB25F7076DCBD8F55291D70C5BD3FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7C376D5290F9B9B1F6A291D70C5BC329" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7C376D5290F9B9B1F6A291D70C5BC329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7D984F562243C800F84791D70C5BF103" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7D984F562243C800F84791D70C5BF103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_FC39EE026DF83D73686B91D70C5B99E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9DB14A08BF29F06B203D91D70C5A1DD1" xlink:to="loc_us-gaap_RetainedEarningsMember_FC39EE026DF83D73686B91D70C5B99E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09BFEC48837E548892E691D70C551276" xlink:to="loc_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_25BB887059CBDCF5621291D70C5BD738" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_250A5731570D2A7FC46191D70C5C047B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_250A5731570D2A7FC46191D70C5C047B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3C164EF385209EB1422E91D70C5CDA4B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3C164EF385209EB1422E91D70C5CDA4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_1FDD5C0C5B4B4FBBE1EB91D70C5C939B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_SharesIssued_1FDD5C0C5B4B4FBBE1EB91D70C5C939B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0E975F3E8D3DE388478B91D70C5C564B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0E975F3E8D3DE388478B91D70C5C564B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_272BD0FD7A994343302491D70C5DCDBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FF17279218E2C5F18AD691D70C5D703B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FF17279218E2C5F18AD691D70C5D703B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_95EC692A2A513AED3A8D91D70C5D9A56" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_95EC692A2A513AED3A8D91D70C5D9A56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6D2E885B0A4A3C2F4AF91D70C5D996A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6D2E885B0A4A3C2F4AF91D70C5D996A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11F33BA3797DC31E440891D70C5D76C6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11F33BA3797DC31E440891D70C5D76C6" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:label="loc_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities_E8133C1187A79529674F91D70C5D410C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:label="loc_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_TemporaryEquityValueConversionOfConvertibleSecurities_F78480D80425EE467C3091D70C5EA472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28CE5D0CC5F8047E935491D70C5E5EAF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28CE5D0CC5F8047E935491D70C5E5EAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42BEFC49AE9A73F3F5E991D70C5EC858" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42BEFC49AE9A73F3F5E991D70C5EC858" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_StockAcquiredDuringPeriodSharesInBusinessCombination" xlink:label="loc_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination_7BE6296E99F3D8878D1891D70C5EC974" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_StockAcquiredDuringPeriodValueInBusinessCombination" xlink:label="loc_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_StockAcquiredDuringPeriodValueInBusinessCombination_A776F129706E606A08BF91D70C5E75A6" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AdjustmentOfParValue" xlink:label="loc_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_AdjustmentOfParValue_E54AD295BCC2AFC42A0A91D70C5F8E76" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity" xlink:label="loc_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity_D3C38ED32C39439E291791D70C5FA404" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare" xlink:label="loc_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare_1FFA074008762F6B8CB491D70C5FE238" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ExerciseOfStockOptionsAndCommonStockWarrants" xlink:label="loc_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_alpn_ExerciseOfStockOptionsAndCommonStockWarrants_535D2EA3C12A5E57B69591D70C5F8EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_D6EB640157A5BAA5D7AD91D70C5F87F5" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_D6EB640157A5BAA5D7AD91D70C5F87F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6FF598B5D47B2C5A51B291D70C5FCF83" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6FF598B5D47B2C5A51B291D70C5FCF83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_DFA4C5A114AE1A8A7D2F91D70C60D420" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_DFA4C5A114AE1A8A7D2F91D70C60D420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_996B55D49A5AD6A5A70291D70C600D90" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_996B55D49A5AD6A5A70291D70C600D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple" xlink:label="loc_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple_E099CDB14B8151FA3FAB91D70C6089BD" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple_E099CDB14B8151FA3FAB91D70C6089BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_263EE22B5FB3D7CFA02791D70C60DF8D" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_263EE22B5FB3D7CFA02791D70C60DF8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_846D60EA6D342C05F72091D70C60598C" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_846D60EA6D342C05F72091D70C60598C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_E57D82E7DBACE9701A0A91D70C61CDEC" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_SharesIssued_E57D82E7DBACE9701A0A91D70C61CDEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_770712EF3B65F2D910B691D70C618904" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_AE41B6FAA5EA545C5A5591D70C5CA530" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_770712EF3B65F2D910B691D70C618904" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7CB9D439E651646AB49C82E6ED485537" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4E2EFBD5A1485A2311C382E6FD1EB03B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7CB9D439E651646AB49C82E6ED485537" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4E2EFBD5A1485A2311C382E6FD1EB03B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0D96D8BF8C0D324EFCB3730637573C16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1" xlink:to="loc_us-gaap_NetIncomeLoss_0D96D8BF8C0D324EFCB3730637573C16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_A817E19E1E77A442B43A7306375890B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_A817E19E1E77A442B43A7306375890B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:label="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_DADA49E581D567BC03B8730637589690" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:to="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_DADA49E581D567BC03B8730637589690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_A2F82591F070089A61D873063758F9CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:to="loc_us-gaap_Depreciation_A2F82591F070089A61D873063758F9CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_93D64828D53A978CCED3730637584603" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_93D64828D53A978CCED3730637584603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_F870B25BBCB4A2BF2307730637586BB3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:to="loc_us-gaap_PaidInKindInterest_F870B25BBCB4A2BF2307730637586BB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77486A723452D6250DE5730637594587" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77486A723452D6250DE5730637594587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A22DEA6632951B9D815C73063759F918" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ED4ED8CDEE56D5A3F47E73063757E3D5" xlink:to="loc_us-gaap_ShareBasedCompensation_A22DEA6632951B9D815C73063759F918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_FCC8BEC74971AB5ABF3773063759E0E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_FCC8BEC74971AB5ABF3773063759E0E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2F4C1B4173E4D1A82F0373063759E642" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2F4C1B4173E4D1A82F0373063759E642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9B24473E65DDBC9611ED7306375AE4CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9B24473E65DDBC9611ED7306375AE4CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_C2D92C7166A93230AAF37306375AEAFD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_C2D92C7166A93230AAF37306375AEAFD" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities" xlink:label="loc_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_5319879CB53875ED911B7306375AA261" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9074697DA30BC4CDE6B7730637599E75" xlink:to="loc_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities_5319879CB53875ED911B7306375AA261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3212DD2324F98CF77C4D7306375A96F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5E4219C912523C6C1C5E73063757BFB1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3212DD2324F98CF77C4D7306375A96F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E5CFB874883514E5E91B7306375A46E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E5CFB874883514E5E91B7306375A46E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_A805F564FBDF7E6F54D07306375B40BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_A805F564FBDF7E6F54D07306375B40BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_AA337AE12A2C0132E8957306375B5557" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_AA337AE12A2C0132E8957306375B5557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_CB6E922CF1CCE8FA91C37306375BAC88" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_CB6E922CF1CCE8FA91C37306375BAC88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DD8293CA6C87830736177306375BB6BC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DD8293CA6C87830736177306375BB6BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_6893A66DF1D7C61E772C7306375B41FC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_6893A66DF1D7C61E772C7306375B41FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39E5C502800B0DFA44DC7306375B95F4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B2C476CBB0BD64F829DE7306375A3293" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39E5C502800B0DFA44DC7306375B95F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_23194D7F8F503FCBA4767306375C3152" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_23194D7F8F503FCBA4767306375C3152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7643789BDA40E5FBA9437306375C4602" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7643789BDA40E5FBA9437306375C4602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_31BD1E020C259429503E7306375CA47E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_31BD1E020C259429503E7306375CA47E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0FDD1843A41F928DCE88732E12EE2974" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0FDD1843A41F928DCE88732E12EE2974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_B42710D53F9C66E089D47306375DE9CF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC7120203CD64610B0B27306375C2B8E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_B42710D53F9C66E089D47306375DE9CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9785640274CCF292B6A67306375DAE9E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9785640274CCF292B6A67306375DAE9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14CBCA56470AFC7FCAAD7306375D1C86" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14CBCA56470AFC7FCAAD7306375D1C86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93389E3DB774BCE11B7C7306375D8EB7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93389E3DB774BCE11B7C7306375D8EB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9388884A064D41226C0473063757BC67" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_CB0F7693BACA472314187306375D8360" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_CB0F7693BACA472314187306375D8360" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IssuanceOfDebtDiscount" xlink:label="loc_alpn_IssuanceOfDebtDiscount_2E0A8CB832E35290041B7306375EE94B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9" xlink:to="loc_alpn_IssuanceOfDebtDiscount_2E0A8CB832E35290041B7306375EE94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_DC3A5B08F74B483DF8447306375E5489" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9" xlink:to="loc_us-gaap_IncomeTaxesPaid_DC3A5B08F74B483DF8447306375E5489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_DE777349DEEA2662E3747306375EBA4D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9" xlink:to="loc_us-gaap_InterestPaidNet_DE777349DEEA2662E3747306375EBA4D" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity" xlink:label="loc_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity_FC8FDD02DC14A7F448747306375E8D5F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_14716599AB8F35E76CE77306375DC2F9" xlink:to="loc_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity_FC8FDD02DC14A7F448747306375E8D5F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D496D3F90C784745F7D1916650E28771" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D496D3F90C784745F7D1916650E28771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1FA2965730CAB68A717C916650E39808" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1FA2965730CAB68A717C916650E39808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_37FAE444F3C461E4575D916650E366B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_37FAE444F3C461E4575D916650E366B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_AAED47F1FBCB66B5DBDB916650E34216" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_AAED47F1FBCB66B5DBDB916650E34216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_84846C6B5D7584A5365A916650E32844" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E3254BCE139D76FE791A916650E20049" xlink:to="loc_us-gaap_OperatingExpenses_84846C6B5D7584A5365A916650E32844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_4300F0FDAF47CA2BE6B0916650E36BB5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:to="loc_us-gaap_OperatingIncomeLoss_4300F0FDAF47CA2BE6B0916650E36BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DCB90E40FF613B33D5CC916650E4670A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DCB90E40FF613B33D5CC916650E4670A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:label="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_72A37C2AAC9AC4959A8E916650E44E00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DCB90E40FF613B33D5CC916650E4670A" xlink:to="loc_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_72A37C2AAC9AC4959A8E916650E44E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_136835EC5DA298527B17916650E4A896" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DCB90E40FF613B33D5CC916650E4670A" xlink:to="loc_us-gaap_InterestExpense_136835EC5DA298527B17916650E4A896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_86DEA2D3DA574501AAE5916650E4166C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DCB90E40FF613B33D5CC916650E4670A" xlink:to="loc_us-gaap_InterestAndOtherIncome_86DEA2D3DA574501AAE5916650E4166C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D5F7B82F84DD7A594F1D916650E4FA11" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D5F7B82F84DD7A594F1D916650E4FA11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E1D1431418C205AA56F0916650E4B6DB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E1D1431418C205AA56F0916650E4B6DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EF0931851F497A1B7248916650E5BB83" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:to="loc_us-gaap_NetIncomeLoss_EF0931851F497A1B7248916650E5BB83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_950D6120041FFFA8A70F916650E52E63" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_950D6120041FFFA8A70F916650E52E63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D2C19E2E6BE9960847E8916650E5DE96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_950D6120041FFFA8A70F916650E52E63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D2C19E2E6BE9960847E8916650E5DE96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_AA3EBD3DBAA0A009E148916650E5A618" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_950D6120041FFFA8A70F916650E52E63" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_AA3EBD3DBAA0A009E148916650E5A618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C2E5902C339D7BCEBA87916650E53A26" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C2E5902C339D7BCEBA87916650E53A26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_0188ED34FC9A286131FA916650E62CBF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34D94653583C8DDDFD4F916650E263D2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_0188ED34FC9A286131FA916650E62CBF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/DescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3E48466ACC5B9CDBA19432379DA7BCAD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6BDAF26FB95B6B5ADE3632379DA7858B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3E48466ACC5B9CDBA19432379DA7BCAD" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6BDAF26FB95B6B5ADE3632379DA7858B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/DescriptionOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77C109CDCF1D8FBD44650F551349D138" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DescriptionOfBusinessTable" xlink:label="loc_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77C109CDCF1D8FBD44650F551349D138" xlink:to="loc_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_274FE7D47322D03CBFEC0F55134AEB48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_274FE7D47322D03CBFEC0F55134AEB48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E165D957B83AB39087140F55134A0081" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_274FE7D47322D03CBFEC0F55134AEB48" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E165D957B83AB39087140F55134A0081" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_07D10072D7D350286B670F55134A72B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E165D957B83AB39087140F55134A0081" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_07D10072D7D350286B670F55134A72B5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_03250104F8E97B294AA80F55134B5357" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:to="loc_dei_LegalEntityAxis_03250104F8E97B294AA80F55134B5357" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_73336379C7ADE5F5A0C60F55134B000F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_03250104F8E97B294AA80F55134B5357" xlink:to="loc_dei_EntityDomain_73336379C7ADE5F5A0C60F55134B000F" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember" xlink:label="loc_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_73336379C7ADE5F5A0C60F55134B000F" xlink:to="loc_alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember_96261BA548FB62E98DB90F55134BFF86" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DescriptionOfBusinessLineItems" xlink:label="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DescriptionOfBusinessTable_3362D5844C8A75BC43C60F5513498689" xlink:to="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D1ABE635C696BC9C39100F55134BCA83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D1ABE635C696BC9C39100F55134BCA83" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation" xlink:label="loc_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:to="loc_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation_B653C5B4870E33AE745C0F55134C328F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_C22DC8D223D230EA49820F55134CAE7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_C22DC8D223D230EA49820F55134CAE7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_09496BED1AA8BEE1BED40F551351E3E7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_09496BED1AA8BEE1BED40F551351E3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3C3ECF886781516412EE0F551351D3E3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DescriptionOfBusinessLineItems_3DAA4314889626734D280F55134BF2E1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3C3ECF886781516412EE0F551351D3E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DocumentAndEntityInformationAbstract" xlink:label="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2BC33FF3E326D37E8E32CC2FE9AEBC7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_EntityRegistrantName_2BC33FF3E326D37E8E32CC2FE9AEBC7D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_859E6A2BC79E2A068981CC2FE9AE3C49" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_TradingSymbol_859E6A2BC79E2A068981CC2FE9AE3C49" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_CC37C96BA028BD4CF027CC2FE9AF9EF6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_EntityCentralIndexKey_CC37C96BA028BD4CF027CC2FE9AF9EF6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_7AB3288F1B739D9BC98BCC2FE9AF1CAB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_CurrentFiscalYearEndDate_7AB3288F1B739D9BC98BCC2FE9AF1CAB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_EC786E72C3E007431C93CC2FE9B0CA45" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_EntityFilerCategory_EC786E72C3E007431C93CC2FE9B0CA45" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1E306FF5718AD0097A21CC2FE9AD9747" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_DocumentType_1E306FF5718AD0097A21CC2FE9AD9747" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_B6925BE8133D5D9ACB20CC2FE9AE8BA4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_DocumentPeriodEndDate_B6925BE8133D5D9ACB20CC2FE9AE8BA4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_565A10EEFBD59F4F2150CC2FE9AE4F99" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_DocumentFiscalYearFocus_565A10EEFBD59F4F2150CC2FE9AE4F99" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5BA350B15A642210E34ECC2FE9AE2B56" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5BA350B15A642210E34ECC2FE9AE2B56" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C2383F8B39556A88B630CC2FE9AE3CB3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_AmendmentFlag_C2383F8B39556A88B630CC2FE9AE3CB3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_5F17EF28BFD638475EE7CC33BE26F767" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_EntityEmergingGrowthCompany_5F17EF28BFD638475EE7CC33BE26F767" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_241A661C1D661769911ACC33E3D65AB3" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_EntityExTransitionPeriod_241A661C1D661769911ACC33E3D65AB3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_10519DEDDEC02E3B4952CC34083CD501" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_EntitySmallBusiness_10519DEDDEC02E3B4952CC34083CD501" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_43BF1CA1922BE3ACBDA9CC343221575C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_EntityShellCompany_43BF1CA1922BE3ACBDA9CC343221575C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_D291025CC50359C7D549CC2FE9B010B5" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_D291025CC50359C7D549CC2FE9B010B5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_8182E6B33E98A850FF5BCC2FE9AF9EDC" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_8182E6B33E98A850FF5BCC2FE9AF9EDC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_8F8EDD9B40D94AB1F968CC2FE9AF417C" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_EntityVoluntaryFilers_8F8EDD9B40D94AB1F968CC2FE9AF417C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_B14F50F02F8C335F95E7CC2FE9AF3560" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_EntityCurrentReportingStatus_B14F50F02F8C335F95E7CC2FE9AF3560" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_96AC4D112DCE6B6EBA47CC2FE9B026DA" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_DocumentAndEntityInformationAbstract_72C2DD208E951FEE0ED1CC2FE9AD8C7B" xlink:to="loc_dei_EntityPublicFloat_96AC4D112DCE6B6EBA47CC2FE9B026DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_B76BE532DFAB6552359C32379CCDDD93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_71A1C7A65B4582CABFE332379CCD88E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_B76BE532DFAB6552359C32379CCDDD93" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_71A1C7A65B4582CABFE332379CCD88E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_97FE43263A829FE1CD394EC065AC397D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_91173E73F86987AB894F4EC065AE9638" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_97FE43263A829FE1CD394EC065AC397D" xlink:to="loc_us-gaap_Cash_91173E73F86987AB894F4EC065AE9638" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_56246104D05834941153D2933E9D717B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_56246104D05834941153D2933E9D717B" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_63AB06DBC9792C892A3ED2933E9FE8B0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_DE7FEAC78151DA20931CD2933EA0652B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_DE7FEAC78151DA20931CD2933EA0652B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9E5FA92EC4086431EF04D2933EA065A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9E5FA92EC4086431EF04D2933EA065A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_11B5299D0CD0B99EB98ED2933EA08063" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_526FC20296CAC682C70AD2933E9F3D83" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_11B5299D0CD0B99EB98ED2933EA08063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E75B6E8F92AA56B2F0C5D296C2D241F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E75B6E8F92AA56B2F0C5D296C2D241F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B7E4ADD2D534FBE61449D296C2DCFF5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E75B6E8F92AA56B2F0C5D296C2D241F5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B7E4ADD2D534FBE61449D296C2DCFF5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C95C0704EC25F3E7CBBDD2974362A145" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B7E4ADD2D534FBE61449D296C2DCFF5A" xlink:to="loc_us-gaap_MoneyMarketFundsMember_C95C0704EC25F3E7CBBDD2974362A145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_00F8A419DEE1D2C6BEAED29743DADE40" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B7E4ADD2D534FBE61449D296C2DCFF5A" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_00F8A419DEE1D2C6BEAED29743DADE40" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CorporateDebtSecuritiesAndCommercialPaperMember" xlink:label="loc_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_43A7786400F9EC31B5C2D297445233C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B7E4ADD2D534FBE61449D296C2DCFF5A" xlink:to="loc_alpn_CorporateDebtSecuritiesAndCommercialPaperMember_43A7786400F9EC31B5C2D297445233C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_557D10214F6E1ABF15E0D2933E9D5427" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7693574841B115498973D2933EA0174E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A5D4C60221E7E1BA5806D2933EA0FBA1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7693574841B115498973D2933EA0174E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D7C4746F40C3C97882194EC065B2A708" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_032F4ACAB977539282FF4EC065B28CFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D7C4746F40C3C97882194EC065B2A708" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_032F4ACAB977539282FF4EC065B28CFC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0E7F55962FD239BA6E284EE705821930" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_BC3EFC1DE8969520BF7D4EE70582B07F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0E7F55962FD239BA6E284EE705821930" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_BC3EFC1DE8969520BF7D4EE70582B07F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_95685FE23CD5F5482E4C4FB2E915D35E" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesTable" xlink:label="loc_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_95685FE23CD5F5482E4C4FB2E915D35E" xlink:to="loc_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_381EBEC1CBF44584BCA04FB2E9170A2E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DFD6EFDA47575AA947A64FB2E917D6A9" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_AF249EF31F6175C917694FB2E91C3580" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesLineItems" xlink:label="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesTable_1D8EB0649DE0EB6737A64FB2E91613DB" xlink:to="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2B445E1C49D0ACD400954FB2E91E3C78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2B445E1C49D0ACD400954FB2E91E3C78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_90FD89D79BDDEDF2726A4FB2E91E28D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_90FD89D79BDDEDF2726A4FB2E91E28D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_D52BA9CF30521AFDCBB04FB2E91E614C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_D52BA9CF30521AFDCBB04FB2E91E614C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent_6351B8B904EA8DA5B1AC4FB2E91E2A8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent_6351B8B904EA8DA5B1AC4FB2E91E2A8E" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis" xlink:label="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis_AF85B4F4F28201D6FA324FB2E91E3B95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5202224DEDEB73FBF6FE4FB2E91E5066" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5202224DEDEB73FBF6FE4FB2E91E5066" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TaxCreditAndNetOperatingLossCarryforwards" xlink:label="loc_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_alpn_TaxCreditAndNetOperatingLossCarryforwards_3EAFFBF8AF31E39D00194FB2E91FA91D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_785DA3103FDFD27C5C544FB2E91F8186" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_785DA3103FDFD27C5C544FB2E91F8186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_22C412B12ECD5E49FDE64FB2E91F32A4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesLineItems_CD3B98A83BCD96B93B8E4FB2E91DA5F6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_22C412B12ECD5E49FDE64FB2E91F32A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6CD48FCD6F48D9FBC27191664DB330A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6CD48FCD6F48D9FBC27191664DB330A6" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_CD99D11596CDBBE86AF591664DB3D6AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_CD99D11596CDBBE86AF591664DB3D6AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_866A0585EAC2C901E6E091664DB4A3A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_866A0585EAC2C901E6E091664DB4A3A2" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets" xlink:label="loc_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_24F7ACFE852B1751C8EB91664DB4687F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:to="loc_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_24F7ACFE852B1751C8EB91664DB4687F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DE2643B369BF67EEA6A391664DB4BC2E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DE2643B369BF67EEA6A391664DB4BC2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8FA8F2C6FB182E65EEAC91664DB41672" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8FA8F2C6FB182E65EEAC91664DB41672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9DB7D3C9DC31AD28EEE891664DB41756" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9DB7D3C9DC31AD28EEE891664DB41756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_AE4F710571A28E3EFEF491664DB50BCC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_AE4F710571A28E3EFEF491664DB50BCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_00AB07EDF442F9C7BD2991664DB5C983" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_00AB07EDF442F9C7BD2991664DB5C983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_AC2F0369E3F42846D52391664DB5FF3B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_AC2F0369E3F42846D52391664DB5FF3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_F7645FDDCD642232BB3391664DB5838F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_665455C4856E3D4A61F691664DB38E05" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_F7645FDDCD642232BB3391664DB5838F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6CD48FCD6F48D9FBC27191664DB330A6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_4DACF73DD3AA804E810491664DB58C6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_4DACF73DD3AA804E810491664DB58C6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_E40CBA6825F088BDC55891664DB65B57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_E40CBA6825F088BDC55891664DB65B57" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets" xlink:label="loc_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_68E54A2ECDF7C6AE2D4C91664DB6A9BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0" xlink:to="loc_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets_68E54A2ECDF7C6AE2D4C91664DB6A9BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_D43D5E35BA590E26EB4991664DB6C9F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_A43B92C7E5BFBA5FE68691664DB532C0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_D43D5E35BA590E26EB4991664DB6C9F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_679AFEB3F9C2694223A191664DB63361" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6CD48FCD6F48D9FBC27191664DB330A6" xlink:to="loc_us-gaap_DeferredTaxLiabilities_679AFEB3F9C2694223A191664DB63361" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5F9C9C9ACAACACE34CD38272BD027345" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5F9C9C9ACAACACE34CD38272BD027345" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_24DF532E340E38E070678272BD020581" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_24DF532E340E38E070678272BD020581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C6D7663458091D87D836828FFB7A80D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_C6D7663458091D87D836828FFB7A80D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_37E1DB0995D5F1E27927829036D4DBFC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_37E1DB0995D5F1E27927829036D4DBFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0729D36C773844517FC28272BD06507F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0729D36C773844517FC28272BD06507F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_FE2BBC416F056061D8498272BD064A46" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_F27E0E486989F6244A988272BD02238C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_FE2BBC416F056061D8498272BD064A46" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_E5C5E9D3ABF694F975AB8272BD3A417C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4ACB4C7F77581BB0EE458272BD3A0C23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E5C5E9D3ABF694F975AB8272BD3A417C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4ACB4C7F77581BB0EE458272BD3A0C23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E5C5E9D3ABF694F975AB8272BD3A417C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5AFB0923AF67848746378272BD3BD851" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5AFB0923AF67848746378272BD3BD851" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="loc_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1689DE4DF23FBAF9BEAD8272BD3B0441" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:to="loc_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_1689DE4DF23FBAF9BEAD8272BD3B0441" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_82D97CF776F1C34DA6CC8272BD3B4C3F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_82D97CF776F1C34DA6CC8272BD3B4C3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD0AE32CF64705B0C2A78272BD3BAB5B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD0AE32CF64705B0C2A78272BD3BAB5B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate" xlink:label="loc_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_F498131CB8A1B2F1B07E8272BD3C0D45" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:to="loc_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate_F498131CB8A1B2F1B07E8272BD3C0D45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_E7A168E33897B81D10208272BD3C11D8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_E7A168E33897B81D10208272BD3C11D8" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts" xlink:label="loc_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_201C29A92BEC3DC744E28272BD3D5176" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:to="loc_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts_201C29A92BEC3DC744E28272BD3D5176" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain" xlink:label="loc_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_DD85D5CF940B9C76DCA18272BD3D0DBC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:to="loc_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain_DD85D5CF940B9C76DCA18272BD3D0DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_56912757026B14C5F1DB8272BD3D8B4B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8DD2CEE9A9BD29C54EE38272BD3A1C1F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_56912757026B14C5F1DB8272BD3D8B4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D417590F9D8079EDF6578272BD3DAC50" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E5C5E9D3ABF694F975AB8272BD3A417C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D417590F9D8079EDF6578272BD3DAC50" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfNetOperatingLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F42C9A9814C57DB8AAC94FB2E8CEE293" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesTable" xlink:label="loc_alpn_IncomeTaxesTable_9E6F92A156A8AB1954A04FB2E8CE192D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F42C9A9814C57DB8AAC94FB2E8CEE293" xlink:to="loc_alpn_IncomeTaxesTable_9E6F92A156A8AB1954A04FB2E8CE192D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesTable_9E6F92A156A8AB1954A04FB2E8CE192D" xlink:to="loc_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_5007A040F320D595EFB64FBA7BBBB0BE" xlink:to="loc_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BeforeJanuary12018Member" xlink:label="loc_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:to="loc_alpn_BeforeJanuary12018Member_E298F37AB4499C8A8F4A4FBB15644E10" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AfterJanuary12018Member" xlink:label="loc_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_691490E88379C06C2D394FBB90FFF84E" xlink:to="loc_alpn_AfterJanuary12018Member_F856F7A2CC3F18DDD12A4FBB6059B3EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesTable_9E6F92A156A8AB1954A04FB2E8CE192D" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5BE34FE1A381A84B97054FB2E8CE78B0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_80D3DFAEE466C2B6F86F4FB2E8CFEE20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:to="loc_us-gaap_DomesticCountryMember_80D3DFAEE466C2B6F86F4FB2E8CFEE20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_B1401C6BA0036E0A88624FB9FD5B7D99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0A1172BC07E4DA0386284FB2E8CEC044" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_B1401C6BA0036E0A88624FB9FD5B7D99" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesLineItems" xlink:label="loc_alpn_IncomeTaxesLineItems_F9A47129ACEC214A61174FB2E8CF050F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesTable_9E6F92A156A8AB1954A04FB2E8CE192D" xlink:to="loc_alpn_IncomeTaxesLineItems_F9A47129ACEC214A61174FB2E8CF050F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6BBB6DE8163C80BBDDA54FB2E8CF8DFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesLineItems_F9A47129ACEC214A61174FB2E8CF050F" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6BBB6DE8163C80BBDDA54FB2E8CF8DFE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1CC3F859D2F1DE153840730634D3EFBD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_21EC833314B453F84A31730634D3F8E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1CC3F859D2F1DE153840730634D3EFBD" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_21EC833314B453F84A31730634D3F8E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_FB24EA1FDFB7D0AEDF3D730634D49365" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_21EC833314B453F84A31730634D3F8E0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_FB24EA1FDFB7D0AEDF3D730634D49365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E8A15F05C5C8F5012C06730634D449CE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_21EC833314B453F84A31730634D3F8E0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E8A15F05C5C8F5012C06730634D449CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_D1E739678F304EB767C3730634D4030F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_21EC833314B453F84A31730634D3F8E0" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_D1E739678F304EB767C3730634D4030F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_AE5D3347D035A9D907B6730634D444A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1CC3F859D2F1DE153840730634D3EFBD" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_AE5D3347D035A9D907B6730634D444A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_99F0783EA664EC40DA4F730634D4E53B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_AE5D3347D035A9D907B6730634D444A9" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_99F0783EA664EC40DA4F730634D4E53B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_FADE50A347CC7A5F2D34730634D51D71" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_AE5D3347D035A9D907B6730634D444A9" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_FADE50A347CC7A5F2D34730634D51D71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_D682F5457BB1833DA9C4730634D539F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_AE5D3347D035A9D907B6730634D444A9" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_D682F5457BB1833DA9C4730634D539F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CE14C5FBE160A395D5DB730634D5007C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1CC3F859D2F1DE153840730634D3EFBD" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_CE14C5FBE160A395D5DB730634D5007C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryTaxCreditCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_EC21A3876479C571CF6E8272BD0AB1A1" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesTable" xlink:label="loc_alpn_IncomeTaxesTable_F37267D99C81E0A7CC738272BD0B1087" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EC21A3876479C571CF6E8272BD0AB1A1" xlink:to="loc_alpn_IncomeTaxesTable_F37267D99C81E0A7CC738272BD0B1087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_45068F5FFF88575A15AD8272BD0B2EF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesTable_F37267D99C81E0A7CC738272BD0B1087" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_45068F5FFF88575A15AD8272BD0B2EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_28CAEB420B353D0E7C6D8272BD0C3064" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_45068F5FFF88575A15AD8272BD0B2EF7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_28CAEB420B353D0E7C6D8272BD0C3064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1AA6E586FB0BBA1F16B58272BD0C05D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_28CAEB420B353D0E7C6D8272BD0C3064" xlink:to="loc_us-gaap_DomesticCountryMember_1AA6E586FB0BBA1F16B58272BD0C05D0" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncomeTaxesLineItems" xlink:label="loc_alpn_IncomeTaxesLineItems_EACFA3A5C29E415DB95D8272BD0C5377" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesTable_F37267D99C81E0A7CC738272BD0B1087" xlink:to="loc_alpn_IncomeTaxesLineItems_EACFA3A5C29E415DB95D8272BD0C5377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_75AE400F9508B51118D98272BD0CBD56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_IncomeTaxesLineItems_EACFA3A5C29E415DB95D8272BD0C5377" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_75AE400F9508B51118D98272BD0CBD56" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8F16C35C44BEA63E485432379AB4ADEA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5076078726D31219FECD32379AB4F10F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8F16C35C44BEA63E485432379AB4ADEA" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5076078726D31219FECD32379AB4F10F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_C6316549BE51044A1F3832379AB48E84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8F16C35C44BEA63E485432379AB4ADEA" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_C6316549BE51044A1F3832379AB48E84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_38890359B4506528D2A332379AB488A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8F16C35C44BEA63E485432379AB4ADEA" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_38890359B4506528D2A332379AB488A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_C07E9E90A753E95AFFF332379AB495C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8F16C35C44BEA63E485432379AB4ADEA" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_C07E9E90A753E95AFFF332379AB495C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:label="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_230A7B8DBCDFC3B1A7E932379AB40DD8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8F16C35C44BEA63E485432379AB4ADEA" xlink:to="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_230A7B8DBCDFC3B1A7E932379AB40DD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_EE42545F6138BDF9127432379AB45501" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8F16C35C44BEA63E485432379AB4ADEA" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_EE42545F6138BDF9127432379AB45501" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_910F04095966D64392CE7819AF1DEC78" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1DE0F25E6F0CEA5A3AA67818E84E8B38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_910F04095966D64392CE7819AF1DEC78" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1DE0F25E6F0CEA5A3AA67818E84E8B38" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_45B0BB41927C69CCB1787819D839FF7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1DB59B02E5D3F614FD1778193C8FBAE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_45B0BB41927C69CCB1787819D839FF7D" xlink:to="loc_us-gaap_DebtInstrumentTable_1DB59B02E5D3F614FD1778193C8FBAE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B45F9C0C129DC593E5A478193C8F5E75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1DB59B02E5D3F614FD1778193C8FBAE4" xlink:to="loc_us-gaap_DebtInstrumentAxis_B45F9C0C129DC593E5A478193C8F5E75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_875A39AAA5A90902DB3578193C8F89FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_B45F9C0C129DC593E5A478193C8F5E75" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_875A39AAA5A90902DB3578193C8F89FC" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TermLoanMember" xlink:label="loc_alpn_TermLoanMember_F830B48B1A7AC780A5DB78193C905A36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_875A39AAA5A90902DB3578193C8F89FC" xlink:to="loc_alpn_TermLoanMember_F830B48B1A7AC780A5DB78193C905A36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_3E93BD129A02D2DFB44878193C9087D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1DB59B02E5D3F614FD1778193C8FBAE4" xlink:to="loc_us-gaap_VariableRateAxis_3E93BD129A02D2DFB44878193C9087D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_B973A2D6D80BCC4CBE3378193C90796B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_3E93BD129A02D2DFB44878193C9087D1" xlink:to="loc_us-gaap_VariableRateDomain_B973A2D6D80BCC4CBE3378193C90796B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_E1B7650472BC6D6005D978193C907B38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_B973A2D6D80BCC4CBE3378193C90796B" xlink:to="loc_us-gaap_PrimeRateMember_E1B7650472BC6D6005D978193C907B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_C6892C88AFD2F854F92578193C91E2E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1DB59B02E5D3F614FD1778193C8FBAE4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_C6892C88AFD2F854F92578193C91E2E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_C7A7A90B61B67389C09F78193C9158AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_C6892C88AFD2F854F92578193C91E2E3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_C7A7A90B61B67389C09F78193C9158AD" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SeriesAOnePreferredStockWarrantsMember" xlink:label="loc_alpn_SeriesAOnePreferredStockWarrantsMember_672F24F4AC65A234EECF78193C916CBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C7A7A90B61B67389C09F78193C9158AD" xlink:to="loc_alpn_SeriesAOnePreferredStockWarrantsMember_672F24F4AC65A234EECF78193C916CBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0DF904D916047C10D62978193C91D4E5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1DB59B02E5D3F614FD1778193C8FBAE4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0DF904D916047C10D62978193C91D4E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B8D625BEBFE11BD6452D78193C9286C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0DF904D916047C10D62978193C91D4E5" xlink:to="loc_us-gaap_EquityComponentDomain_B8D625BEBFE11BD6452D78193C9286C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_46C42DC924B08D9DF07278193C924823" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B8D625BEBFE11BD6452D78193C9286C3" xlink:to="loc_us-gaap_CommonStockMember_46C42DC924B08D9DF07278193C924823" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_47CFBFA245D89106EA5178193C92A513" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1DB59B02E5D3F614FD1778193C8FBAE4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_47CFBFA245D89106EA5178193C92A513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_DC948AC5E5C80711E5B278193C92ABD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47CFBFA245D89106EA5178193C92A513" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_DC948AC5E5C80711E5B278193C92ABD9" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DebtInstrumentNumberOfEqualMonthlyPayment" xlink:label="loc_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_5388158239829477007478193C937A59" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47CFBFA245D89106EA5178193C92A513" xlink:to="loc_alpn_DebtInstrumentNumberOfEqualMonthlyPayment_5388158239829477007478193C937A59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8BA8A9D0C5099E51EE6D78193C93D552" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47CFBFA245D89106EA5178193C92A513" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8BA8A9D0C5099E51EE6D78193C93D552" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_DebtInstrumentFinalPaymentPercentage" xlink:label="loc_alpn_DebtInstrumentFinalPaymentPercentage_F7DD331CB97193CD902378193C93BDE2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47CFBFA245D89106EA5178193C92A513" xlink:to="loc_alpn_DebtInstrumentFinalPaymentPercentage_F7DD331CB97193CD902378193C93BDE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_E73F41A24FDC353FBA2378193C93A043" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47CFBFA245D89106EA5178193C92A513" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_E73F41A24FDC353FBA2378193C93A043" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45D30FF13B385714F4B178193C938D85" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47CFBFA245D89106EA5178193C92A513" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45D30FF13B385714F4B178193C938D85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_C0FEB5DE49232041EE1C78193C93A0CB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47CFBFA245D89106EA5178193C92A513" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_C0FEB5DE49232041EE1C78193C93A0CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_469C5C0EA96D6398239878193C9342AF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47CFBFA245D89106EA5178193C92A513" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_469C5C0EA96D6398239878193C9342AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_9B485B7C413CDB00A25C78193C94018F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47CFBFA245D89106EA5178193C92A513" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_9B485B7C413CDB00A25C78193C94018F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1ED1ADADB0DEE4CC8DF578193C946E2F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47CFBFA245D89106EA5178193C92A513" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1ED1ADADB0DEE4CC8DF578193C946E2F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_41DFE505CAACD6FCF870736A04DEBBDF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_F4F0E1DC4F9B55507B27736A7EF43A47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41DFE505CAACD6FCF870736A04DEBBDF" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_F4F0E1DC4F9B55507B27736A7EF43A47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6C478B448605260682A8736ABA4CC735" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41DFE505CAACD6FCF870736A04DEBBDF" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6C478B448605260682A8736ABA4CC735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D24D50C495DEA632D1F2736AEDB88F6F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41DFE505CAACD6FCF870736A04DEBBDF" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_D24D50C495DEA632D1F2736AEDB88F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_54378B65D1E1AED5623D736B245A258E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41DFE505CAACD6FCF870736A04DEBBDF" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_54378B65D1E1AED5623D736B245A258E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1CC4ED9F615C2FE932AC736B51737FF5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41DFE505CAACD6FCF870736A04DEBBDF" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1CC4ED9F615C2FE932AC736B51737FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_58DA8F264334CD722037736B927C4EA7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41DFE505CAACD6FCF870736A04DEBBDF" xlink:to="loc_us-gaap_LongTermDebt_58DA8F264334CD722037736B927C4EA7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_EBFD725C7D7EC9257B457368DC3154AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_297B993AFD9B17D18E6E7369037FE00D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_EBFD725C7D7EC9257B457368DC3154AA" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_297B993AFD9B17D18E6E7369037FE00D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4958D07B3BCB2A7F88954ED1570D05A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C1D451E47BE49CADA0D64ED1662839E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4958D07B3BCB2A7F88954ED1570D05A7" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C1D451E47BE49CADA0D64ED1662839E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5D1CD7D6D3E19C1334FB4ED625BF77A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5D1CD7D6D3E19C1334FB4ED625BF77A8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_F99055118DBACF5D19E44EDB68A93699" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_32B9845996523BDE5E554EDB9CFB40B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_BD543B7700576F7AC1864EE3527F8143" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_32B9845996523BDE5E554EDB9CFB40B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:to="loc_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_5A65FE1B8D851260A88C4ED962DAFD09" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_013368E292CE94F7F89B4ED97FB69677" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_428E100A88EA7BBBB90A4ED962DB0E7D" xlink:to="loc_us-gaap_ScenarioForecastMember_013368E292CE94F7F89B4ED97FB69677" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:to="loc_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4D9C5FB29ACA29C6E66B4ED74D674966" xlink:to="loc_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_LaurelVentureCapitalLtd.Member" xlink:label="loc_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_E35E00B3B190F376302D4ED74D6DAC1F" xlink:to="loc_alpn_LaurelVentureCapitalLtd.Member_6A0D27233CE4846231AC4ED769C95FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9E700B60DEEBBF3F9EB64ED70E191701" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_GSNORMember" xlink:label="loc_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581010B303D772AC3C924EE3D778D35B" xlink:to="loc_alpn_GSNORMember_9D3A47D4249576E574814ED7359BCA31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8540A616556342340F814ED6CCDC9DA6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:to="loc_us-gaap_DebtInstrumentAxis_8540A616556342340F814ED6CCDC9DA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B196B6093A7166F64D0C4ED6CCDD16C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8540A616556342340F814ED6CCDC9DA6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B196B6093A7166F64D0C4ED6CCDD16C5" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TermSheetMember" xlink:label="loc_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B196B6093A7166F64D0C4ED6CCDD16C5" xlink:to="loc_alpn_TermSheetMember_956BFCD40059A58E4B6B4ED6F16A13C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CF84E8660DB59D43F0224ED625BFA147" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F90B57177FBF83B152714ED699D60BAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F90B57177FBF83B152714ED699D60BAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_B670E4DAFB455A47EE5F4ED81310F4DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_B670E4DAFB455A47EE5F4ED81310F4DC" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived" xlink:label="loc_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:to="loc_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived_46424A43F8C6485CAEA44ED8DC5E4803" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IntangibleAssetsAmountDerecognizedUponSale" xlink:label="loc_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:to="loc_alpn_IntangibleAssetsAmountDerecognizedUponSale_5F3DBBD1115F2F4445994EDB352F0712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_73074696DE05BC227D254EDC14F52334" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_18E9D099C95B969D9E964ED625C2CC18" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_73074696DE05BC227D254EDC14F52334" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6E0D8C90B4EA606F000F32379B7984A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_D65F4AF15BB722FA6C4D32379B79C14F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6E0D8C90B4EA606F000F32379B7984A8" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_D65F4AF15BB722FA6C4D32379B79C14F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/NetLossPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_47B43FDA14C93E5153350F551275C356" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_47B43FDA14C93E5153350F551275C356" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5EDEA08F4C883694EE1C0F7945C40F7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE" xlink:to="loc_dei_LegalEntityAxis_5EDEA08F4C883694EE1C0F7945C40F7D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_17F281160E41F3249FD30F7945CEF73D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5EDEA08F4C883694EE1C0F7945C40F7D" xlink:to="loc_dei_EntityDomain_17F281160E41F3249FD30F7945CEF73D" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_0578A46062E64EFA91C50F7962CB2A17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_17F281160E41F3249FD30F7945CEF73D" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_0578A46062E64EFA91C50F7962CB2A17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1E4B7368BB9D3AEEFBD60F7914BA86FE" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1F75B45C4091303684790F551275A0A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1F75B45C4091303684790F551275A0A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_E3111864862C3F50F69B0F55127A22F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1CF7C28F43C2C839B42C0F7914C1AE96" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_E3111864862C3F50F69B0F55127A22F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9284922247D4240588CE91664FCAECC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9284922247D4240588CE91664FCAECC9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_A2EB9F7FF8EE30585B9491664FCB96EA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1C5FC82198032A69D4D691664FCB4404" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1C5FC82198032A69D4D691664FCB4404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_DC5014C70D7B8E94E63691664FCCEBD7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:to="loc_us-gaap_WarrantMember_DC5014C70D7B8E94E63691664FCCEBD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2B8B25A320C4A3DAD0E491664FCC624F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60382C8CD6D3845E838991664FCBFD6E" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2B8B25A320C4A3DAD0E491664FCC624F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58798CDC7E7EEC03102991664FCB7C22" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9E2C4E58331E4F421E4C91664FCC0F3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F5FEA0D80AD33636219F91664FCC6334" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9E2C4E58331E4F421E4C91664FCC0F3E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_886932945071CC60597332379B04EDC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2E88D289E9F268D2938A32379B045CB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_886932945071CC60597332379B04EDC9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2E88D289E9F268D2938A32379B045CB9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A265E5BB65E43845B80F4EE7078D5C02" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_48A266016B0817F2794E4EE7078DD6F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A265E5BB65E43845B80F4EE7078D5C02" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_48A266016B0817F2794E4EE7078DD6F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_322307F55BDC56807990CC2FE846B274" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_322307F55BDC56807990CC2FE846B274" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F3DE08DCA663D11C9E5CC2FE84738F7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_9BDD30011129562648A8CC2FE848D522" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:to="loc_us-gaap_EquipmentMember_9BDD30011129562648A8CC2FE848D522" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_GeneralEquipmentAndFurnitureMember" xlink:label="loc_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:to="loc_alpn_GeneralEquipmentAndFurnitureMember_D200A0BD5D21E99F3C2FCC2FE848E017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_B7F35B02833756E9C0FECC2FE8480A82" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:to="loc_us-gaap_ComputerEquipmentMember_B7F35B02833756E9C0FECC2FE8480A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_16564395A9019343FF83CC2FE848CF5B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_778F7B37B9E455B4096FCC2FE847BBEF" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_16564395A9019343FF83CC2FE848CF5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B900674021C2FF2715DFCC2FE8473E28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4F826DD8D950CD203A9BCC2FE8482FD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4F826DD8D950CD203A9BCC2FE8482FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5D1D58C1ED2C7946F3ADCC2FE849F993" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5D1D58C1ED2C7946F3ADCC2FE849F993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C063110B236622C8CFE7CC2FE84927DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0379D654C7200D894E02CC2FE8481805" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_C063110B236622C8CFE7CC2FE84927DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2ACC6F67C66DED6D54F0CCC7F2A1852F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_322307F55BDC56807990CC2FE846B274" xlink:to="loc_us-gaap_Depreciation_2ACC6F67C66DED6D54F0CCC7F2A1852F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_457053605E9AE27FC27432379B79D623" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_11A11A51B81AEC5BF37832379B79597D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_457053605E9AE27FC27432379B79D623" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_11A11A51B81AEC5BF37832379B79597D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_3358916619FE5824A6294EE70545FFE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_22202F54A71D9A1C9AEF4EE70545B51B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_3358916619FE5824A6294EE70545FFE1" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_22202F54A71D9A1C9AEF4EE70545B51B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_F7C797F6D2D7A47B387191664D6A5CC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_F7C797F6D2D7A47B387191664D6A5CC9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_50CFE42545F3134E8B3F91664D6B7F70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_50CFE42545F3134E8B3F91664D6B7F70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2B2C8B4FFB6629EAC3A691664D6B780A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_50CFE42545F3134E8B3F91664D6B7F70" xlink:to="loc_us-gaap_EquityComponentDomain_2B2C8B4FFB6629EAC3A691664D6B780A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CAF70E41F4934EC90B2791664D6B6AE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2B2C8B4FFB6629EAC3A691664D6B780A" xlink:to="loc_us-gaap_CommonStockMember_CAF70E41F4934EC90B2791664D6B6AE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_A7BFAF1C6A5F2650B94691664D6C8C05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_A7BFAF1C6A5F2650B94691664D6C8C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_FB0A643E0B19FB43011E91664D6C947C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_A7BFAF1C6A5F2650B94691664D6C8C05" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_FB0A643E0B19FB43011E91664D6C947C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_9D72F34B3E25ABC8E00891664D6C4BE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_FB0A643E0B19FB43011E91664D6C947C" xlink:to="loc_us-gaap_SubsequentEventMember_9D72F34B3E25ABC8E00891664D6C4BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9A3705F1C94DB10BD34591664D6DBA72" xlink:to="loc_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AlpineBioVenturesGPLLCMember" xlink:label="loc_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3AF3B7FC61699ADD9B1C91664D72F610" xlink:to="loc_alpn_AlpineBioVenturesGPLLCMember_C351E9AFB61A893E276291664D7206D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8664757A644DAE5728AF91664D6ABC71" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4E786A7BE12D8989D7CE91664D738515" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4E786A7BE12D8989D7CE91664D738515" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock" xlink:label="loc_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock_6F61ACBB5E199A6063C591664D739CCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_A2B3E99618B441856FD191664D73D5CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_A2B3E99618B441856FD191664D73D5CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18BFCB9DC1B7D5B08C5491664D73176D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18BFCB9DC1B7D5B08C5491664D73176D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_04D0A9204EC372273C3B91664D730A51" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_04D0A9204EC372273C3B91664D730A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_1CD5345A4A55B6E65EBC91664D74165C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BF2E597DCA53B71B41FD91664D7268B2" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_1CD5345A4A55B6E65EBC91664D74165C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_97D41EE8612CEC01B26F4EE7063716BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4C35FE3A7DCFDACFDDCC4EE70637474B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_97D41EE8612CEC01B26F4EE7063716BF" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4C35FE3A7DCFDACFDDCC4EE70637474B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_9CBE975BF1E53552F45491B71FD44814" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9CBE975BF1E53552F45491B71FD44814" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_912E1134A450D0C9FE6C91B71FD4A06E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_912E1134A450D0C9FE6C91B71FD4A06E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_294DED175E1D1DE2FD6991B71FD5C577" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_912E1134A450D0C9FE6C91B71FD4A06E" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_294DED175E1D1DE2FD6991B71FD5C577" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_590847B26FBDD945570491B71FD5EA58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_294DED175E1D1DE2FD6991B71FD5C577" xlink:to="loc_us-gaap_SubsequentEventMember_590847B26FBDD945570491B71FD5EA58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_A60923AA344B8E12FE9891B71FD5257A" xlink:to="loc_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_44F4AA06C529D4DF4D5691B71FD6214B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D637BBBDCEBC42A0902A91B71FD5A448" xlink:to="loc_srt_MaximumMember_44F4AA06C529D4DF4D5691B71FD6214B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_24D2B92168C29F6577B491B71FD66432" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_dei_LegalEntityAxis_24D2B92168C29F6577B491B71FD66432" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9EE8928A152A7C09F49391B71FD6886A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_24D2B92168C29F6577B491B71FD66432" xlink:to="loc_dei_EntityDomain_9EE8928A152A7C09F49391B71FD6886A" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CowenandCompanyLLCMember" xlink:label="loc_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9EE8928A152A7C09F49391B71FD6886A" xlink:to="loc_alpn_CowenandCompanyLLCMember_CCADC39DBB19E1FE00FD91B71FD6D06F" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PiperJaffrayCo.Member" xlink:label="loc_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9EE8928A152A7C09F49391B71FD6886A" xlink:to="loc_alpn_PiperJaffrayCo.Member_85F148DF043342AF7E7E91B71FD673E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2B4AD0280B1388AA23EE91B71FD762D1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_5B3EC5131AE3CFB46F3D91B71FD7D982" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_817AAD2D9B4F2D5C6A0D91B71FD7D5E6" xlink:to="loc_us-gaap_EmployeeStockMember_5B3EC5131AE3CFB46F3D91B71FD7D982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_AAE28EC554D692FCD46691B71FD7239B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_AAE28EC554D692FCD46691B71FD7239B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3ECD24067729E7D53BF891B71FD730C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AAE28EC554D692FCD46691B71FD7239B" xlink:to="loc_us-gaap_EquityComponentDomain_3ECD24067729E7D53BF891B71FD730C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_110130DC6DAD5A3635EE91B71FD872FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3ECD24067729E7D53BF891B71FD730C6" xlink:to="loc_us-gaap_CommonStockMember_110130DC6DAD5A3635EE91B71FD872FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_C24FA16AD17808BB067391B71FD8FBB9" xlink:to="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_TwoThousandAndEighteenPlanMember" xlink:label="loc_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:to="loc_alpn_TwoThousandAndEighteenPlanMember_69C38D48B26695A3F68491B71FD94D08" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_InducementGrantMember" xlink:label="loc_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:to="loc_alpn_InducementGrantMember_4E1743EAEF0D7F9012CF91B71FD9FBAE" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_IncentiveStockOptionMember" xlink:label="loc_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:to="loc_alpn_IncentiveStockOptionMember_21079AA3EEE2A39C867591B71FD9906A" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member" xlink:label="loc_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:to="loc_alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member_4561DCE24234860395BC91B71FD956CE" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_StockPlan2018Member" xlink:label="loc_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_A9BBB886B433561122F191B71FD8261C" xlink:to="loc_alpn_StockPlan2018Member_9B2B7EC95A2F586DC3CF91B71FD99A9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5DA4CB7E22C4E68ED9AF91B71FD968D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CommonStockInitialReservesMember" xlink:label="loc_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:to="loc_alpn_CommonStockInitialReservesMember_3784D2DFE2C5FBD2B9C991B71FDA771C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_LegacyPlanCancellationsMember" xlink:label="loc_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:to="loc_alpn_LegacyPlanCancellationsMember_597EEAED7E6CD87B4E0491B71FDA1071" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_DECEA53175C154B7D17B91B71FDA1A29" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC33FFA04D47DF0925F191B71FDA4592" xlink:to="loc_us-gaap_EmployeeStockOptionMember_DECEA53175C154B7D17B91B71FDA1A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4D8A8871AB18F5AEAA0391B71FD4A25F" xlink:to="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_62106B3770B79A8A64A991B71FDB29BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_62106B3770B79A8A64A991B71FDB29BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_E25B4F3C127D9A1999AC91B71FDBF210" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_E25B4F3C127D9A1999AC91B71FDBF210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_429C6B05EF776ECC537C91B71FDBB470" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_TreasuryStockCommonShares_429C6B05EF776ECC537C91B71FDBB470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_42B52E0F6D308D2888AF91B71FDB6687" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_42B52E0F6D308D2888AF91B71FDB6687" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_MaximumAmountOfCommonStockEligibleToBeSold" xlink:label="loc_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_MaximumAmountOfCommonStockEligibleToBeSold_A362D01F87A64DC8E6D691B71FDC50FE" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices" xlink:label="loc_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices_60B45E5A3D66B78317C391B71FDCE2D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_C4552B97464818896F3191B71FDCF273" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_C4552B97464818896F3191B71FDCF273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_BA8CE2FCA27553F66B1C91B71FDC8B24" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_BA8CE2FCA27553F66B1C91B71FDC8B24" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PurchaseAgreementRatioOfCommonStockToWarrants" xlink:label="loc_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_PurchaseAgreementRatioOfCommonStockToWarrants_B41644B12480B913684791B71FDC1B52" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_PurchaseAgreementAggregatePurchasePricePerUnit" xlink:label="loc_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_PurchaseAgreementAggregatePurchasePricePerUnit_9020F264398821D41D1991B71FDC2ADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5C77DFE6EE32A471FD7E91B71FDC97F3" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5C77DFE6EE32A471FD7E91B71FDC97F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_11C48B48F077648994A291B71FDD4F9C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_11C48B48F077648994A291B71FDD4F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_E60F6FEDB9365E64C4A491B97FBCE256" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_E60F6FEDB9365E64C4A491B97FBCE256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_EF8421748ABED4388C7E91B71FDD032C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_DeferredOfferingCosts_EF8421748ABED4388C7E91B71FDD032C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14CD82C8CC25D08F582091B71FDD59CC" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14CD82C8CC25D08F582091B71FDD59CC" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent" xlink:label="loc_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent_CAAF9110EAF8F3B10D0F91B71FDDCC75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_E04BA13CCA3F0F27613091B71FDDCFB7" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_E04BA13CCA3F0F27613091B71FDDCFB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1E369B725C5F5F46911191B71FDE7C5B" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1E369B725C5F5F46911191B71FDE7C5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38651EC26A6BFE6057C291B71FDEE6B0" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38651EC26A6BFE6057C291B71FDEE6B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_02133D8A6A33DA370F7E91B71FDE03E0" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_02133D8A6A33DA370F7E91B71FDE03E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_12EF3BFDE3D02A921FE891B71FDE7784" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_12EF3BFDE3D02A921FE891B71FDE7784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35475648EF2A7191082091B71FDED7C7" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35475648EF2A7191082091B71FDED7C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_06F6A3CAF47D584A698091B71FDFB9D9" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_06F6A3CAF47D584A698091B71FDFB9D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7C0B62C4B053B448615091B71FDF86E6" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7C0B62C4B053B448615091B71FDF86E6" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions" xlink:label="loc_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions_CDD1EE3AA1A83F9D42E091B71FDFC17C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfEmployees" xlink:label="loc_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_NumberOfEmployees_12219A7DABBA5AC053CF91B71FDFA889" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AdditionalCompensationExpense" xlink:label="loc_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_34B2BCE8F1BD7EC7D82691B71FDA24FC" xlink:to="loc_alpn_AdditionalCompensationExpense_DE5641D26C6AF42D871E91B71FDFB814" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_A3474609DD8465FE4EDD73692A48CE55" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0E098147AB21DF6AE11873692A4873F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_A3474609DD8465FE4EDD73692A48CE55" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0E098147AB21DF6AE11873692A4873F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B35758117BF613899BAA73692A484953" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0E098147AB21DF6AE11873692A4873F8" xlink:to="loc_us-gaap_AwardTypeAxis_B35758117BF613899BAA73692A484953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_B35758117BF613899BAA73692A484953" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember" xlink:label="loc_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37" xlink:to="loc_alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember_328B486461DF8CDB93B673692A49FE69" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember" xlink:label="loc_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37" xlink:to="loc_alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember_4C35F4B3B2D2FCED493873692A49801C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharesAvailableForFutureStockGrantsMember" xlink:label="loc_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37" xlink:to="loc_alpn_SharesAvailableForFutureStockGrantsMember_B81CC11B73AF3FA11BCF73692A491C4C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember" xlink:label="loc_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42A8D7769D63F2A6BE3F73692A48BF37" xlink:to="loc_alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember_8A39C278512B0836E0C77393D106E8A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2BCCF002A0271F77702473692A4A58BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0E098147AB21DF6AE11873692A4873F8" xlink:to="loc_us-gaap_ClassOfStockLineItems_2BCCF002A0271F77702473692A4A58BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E91E7D56EA8291326F2973692A4A608A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2BCCF002A0271F77702473692A4A58BB" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E91E7D56EA8291326F2973692A4A608A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_D00E5BE8AF09A5DB7516CD390B3CF930" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91A8176905AE0DCEDDFACD2B86C634E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_D00E5BE8AF09A5DB7516CD390B3CF930" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91A8176905AE0DCEDDFACD2B86C634E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_40A1AC52A30896FF917ECD2B86C61431" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91A8176905AE0DCEDDFACD2B86C634E7" xlink:to="loc_us-gaap_TitleOfIndividualAxis_40A1AC52A30896FF917ECD2B86C61431" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_52F26071B2494BA696E4CD2B86C6661C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_40A1AC52A30896FF917ECD2B86C61431" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_52F26071B2494BA696E4CD2B86C6661C" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_EmployeesMember" xlink:label="loc_alpn_EmployeesMember_58B0A2B5B9A4B351A21CCD2B86C6B91E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_52F26071B2494BA696E4CD2B86C6661C" xlink:to="loc_alpn_EmployeesMember_58B0A2B5B9A4B351A21CCD2B86C6B91E" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NonEmployeesMember" xlink:label="loc_alpn_NonEmployeesMember_31E368A78CCD3A3E5551CD2B86C6A8CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_52F26071B2494BA696E4CD2B86C6661C" xlink:to="loc_alpn_NonEmployeesMember_31E368A78CCD3A3E5551CD2B86C6A8CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ED268AA1ED321A526D08CD2B86C60D1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91A8176905AE0DCEDDFACD2B86C634E7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ED268AA1ED321A526D08CD2B86C60D1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9FBD9B195FA7590A0E95CD2B86C692CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ED268AA1ED321A526D08CD2B86C60D1A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9FBD9B195FA7590A0E95CD2B86C692CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6099E8DB6EAC66B706FACD2B86C62037" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9FBD9B195FA7590A0E95CD2B86C692CB" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6099E8DB6EAC66B706FACD2B86C62037" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4E1C56465AD2804DF59ECD2B86C617C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9FBD9B195FA7590A0E95CD2B86C692CB" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4E1C56465AD2804DF59ECD2B86C617C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5217A6159496167D15FECD2B86C6A172" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91A8176905AE0DCEDDFACD2B86C634E7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5217A6159496167D15FECD2B86C6A172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9DAF4BEDB1D7C95CB8F0CD2B86C6693C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5217A6159496167D15FECD2B86C6A172" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9DAF4BEDB1D7C95CB8F0CD2B86C6693C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockOptionAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_16E16B94638E2AEEC46A91664E1C3695" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ECF1319A59B5154CDBD091664E1CD28E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_16E16B94638E2AEEC46A91664E1C3695" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ECF1319A59B5154CDBD091664E1CD28E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_043E6FF78921078323FA91664E1C4A7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ECF1319A59B5154CDBD091664E1CD28E" xlink:to="loc_srt_RangeAxis_043E6FF78921078323FA91664E1C4A7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_120178A284A85BCC6AEE91664E1CB3FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_043E6FF78921078323FA91664E1C4A7B" xlink:to="loc_srt_RangeMember_120178A284A85BCC6AEE91664E1CB3FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_520C13B49BC8C691B81691664E1D13D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_120178A284A85BCC6AEE91664E1CB3FE" xlink:to="loc_srt_MinimumMember_520C13B49BC8C691B81691664E1D13D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_17A316AE560028A57CC391664E1D3A69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_120178A284A85BCC6AEE91664E1CB3FE" xlink:to="loc_srt_MaximumMember_17A316AE560028A57CC391664E1D3A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ECF1319A59B5154CDBD091664E1CD28E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9C943BFB53ED62F313A791664E1DE6CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9C943BFB53ED62F313A791664E1DE6CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D0263B1F1212ABEF2FB791664E1E14B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_D0263B1F1212ABEF2FB791664E1E14B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_945437C6F2ABECF4939591664E1E7D8E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_945437C6F2ABECF4939591664E1E7D8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8278ADB8AF859FD67CE991664E1E7C1B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8278ADB8AF859FD67CE991664E1E7C1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E0BCF806AD09912948BD91664E1E81B0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E0BCF806AD09912948BD91664E1E81B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_406098AA8625F4D1D75891664E1E4FD1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_406098AA8625F4D1D75891664E1E4FD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D16D2462C73C179FC2391664E1E85B2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D1DE1C03F845CF7E65EA91664E1D6BBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D16D2462C73C179FC2391664E1E85B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_459ECFC244D99678F01F91664E4741F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_EDA44F2A78AAE19705B991664E47FF16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_459ECFC244D99678F01F91664E4741F0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_EDA44F2A78AAE19705B991664E47FF16" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NumberOfWarrantsAvailableTobeExercised" xlink:label="loc_alpn_NumberOfWarrantsAvailableTobeExercised_3B54EAE49CE6F7C9704D9175D2BCA1CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_459ECFC244D99678F01F91664E4741F0" xlink:to="loc_alpn_NumberOfWarrantsAvailableTobeExercised_3B54EAE49CE6F7C9704D9175D2BCA1CF" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding" xlink:label="loc_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding_D04984A033FBB0A2584491664E472E27" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_459ECFC244D99678F01F91664E4741F0" xlink:to="loc_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding_D04984A033FBB0A2584491664E472E27" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ClassofWarrantorRightWeightedAveragePriceExercisable" xlink:label="loc_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable_765B1B1ED4FD289E3A1991664E48B673" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_459ECFC244D99678F01F91664E4741F0" xlink:to="loc_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable_765B1B1ED4FD289E3A1991664E48B673" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding" xlink:label="loc_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding_B3C1C9168712F780D85D91664E4D9352" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_459ECFC244D99678F01F91664E4741F0" xlink:to="loc_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding_B3C1C9168712F780D85D91664E4D9352" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:label="loc_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable_73EFCA833CFAE9C3934291664E4DB0AF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_459ECFC244D99678F01F91664E4741F0" xlink:to="loc_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable_73EFCA833CFAE9C3934291664E4DB0AF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeficitTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5A72A0403B571B805A6273692A6961D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_F908C55E775BB954CDF7738E225B44F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5A72A0403B571B805A6273692A6961D6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_F908C55E775BB954CDF7738E225B44F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_83EFED176DA3F944877473692A694EC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5A72A0403B571B805A6273692A6961D6" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_83EFED176DA3F944877473692A694EC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D275A93252479BC0FDD473692A69719C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5A72A0403B571B805A6273692A6961D6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D275A93252479BC0FDD473692A69719C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_87DCAC73CF9049F47B0C73692A6A0D28" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5A72A0403B571B805A6273692A6961D6" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_87DCAC73CF9049F47B0C73692A6A0D28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F64CFAA8930A5D48AC3E73692A6A35EE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5A72A0403B571B805A6273692A6961D6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F64CFAA8930A5D48AC3E73692A6A35EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/StockholdersDeflicitSummaryOfOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_DD0495F791566F4AEE457DC9C35FF0D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_DD0495F791566F4AEE457DC9C35FF0D1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_ACE0D88688E6ED85852D7DC9C363A51D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4" xlink:to="loc_us-gaap_AwardTypeAxis_ACE0D88688E6ED85852D7DC9C363A51D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CFEF8884BA020652FC897DC9C3634F11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ACE0D88688E6ED85852D7DC9C363A51D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CFEF8884BA020652FC897DC9C3634F11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9A3B3443BC35B15ABF4A7DC9C3642E5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CFEF8884BA020652FC897DC9C3634F11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9A3B3443BC35B15ABF4A7DC9C3642E5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2EACC06739A113092F7D7DC9C362ACE4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98BA121E0329FC99CC697DC9C3672FCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98BA121E0329FC99CC697DC9C3672FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2F7DC63CB65667549D0E7DC9C36705DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2F7DC63CB65667549D0E7DC9C36705DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5008A4651646DBAD584D7DC9C3674A64" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5008A4651646DBAD584D7DC9C3674A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_933C403E501D2FAE7ACE7DC9C367A177" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_933C403E501D2FAE7ACE7DC9C367A177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64D253553A994A3165137DC9C3689F76" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24B26466A955BA2E917E7DC9C36420D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64D253553A994A3165137DC9C3689F76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8B3337D475C1A4843CAC7DC9C368BB37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8B3337D475C1A4843CAC7DC9C368BB37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3B2D836AF339FAEE17537DC9C3680B09" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3B2D836AF339FAEE17537DC9C3680B09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16E701095D5A5CD65C937DC9C368D667" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16E701095D5A5CD65C937DC9C368D667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_117F7E964091C0E8B44B7DC9C3692E98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_117F7E964091C0E8B44B7DC9C3692E98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_BC26ED7D0C0123CB4B8A7DC9C369A6F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_BC26ED7D0C0123CB4B8A7DC9C369A6F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D6E0C195FF8ECB471A957DC9C3698BE5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D6E0C195FF8ECB471A957DC9C3698BE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5DC7C0FFBC3033309E327DC9C369F497" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5DC7C0FFBC3033309E327DC9C369F497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_FD868577B9D2E4CB983F7DC9C3690DE6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_FD868577B9D2E4CB983F7DC9C3690DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9E788034A11C6DCCB9E07DC9C369959B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86A97A8CDF387F27A7DA7DC9C368FAB9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9E788034A11C6DCCB9E07DC9C369959B" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D0C23A746FCAA2058D627DC9C36AF201" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_D0C23A746FCAA2058D627DC9C36AF201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_C93DD1442DB08AC913007DC9C36A84DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_C93DD1442DB08AC913007DC9C36A84DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BCF4E027B8A61237960B7DC9C36A01F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_F193B138BD37099B64B57DC9C36A9069" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BCF4E027B8A61237960B7DC9C36A01F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_985B68EC117C077E4E3B7DC9C36467C3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_68A9F66BC0AFC318C9457DC9C36DF42E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_68A9F66BC0AFC318C9457DC9C36DF42E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_6278D8C3594A811C65657DC9C36EB022" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_6278D8C3594A811C65657DC9C36EB022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_E56B64C004E5A5DB18D87DC9C77D3E2F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_E56B64C004E5A5DB18D87DC9C77D3E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2DB096A580B940904E517DCBBEBBFD9D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_CFAF59AA0A90A47F0E137DC9C36D3FF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2DB096A580B940904E517DCBBEBBFD9D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_610CCA71A07FED18CB3332379AFA3F07" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2A786D9E21A564234C2E32379AFA9447" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_610CCA71A07FED18CB3332379AFA3F07" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2A786D9E21A564234C2E32379AFA9447" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E486D2FF090BAF8979E6916650680264" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SignificantAccountingPoliciesTable" xlink:label="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E486D2FF090BAF8979E6916650680264" xlink:to="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CBCD423E1DC71133D32891665068B2A4" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E59261C80F0BB992CAA4916650692D2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3FE534657CCCAC80815A91665068A7A0" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E59261C80F0BB992CAA4916650692D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_8BB8B6842D63A48CE3BB91665069F47D" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_OfficeAndLaboratoryLeasesMember" xlink:label="loc_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_96A89670E3CC9C81E2F391665069B5BF" xlink:to="loc_alpn_OfficeAndLaboratoryLeasesMember_9FA0DDD718EF36D7AEDC9166506AC260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_29724EA822D41D77785C9166506A0924" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_us-gaap_StatementScenarioAxis_29724EA822D41D77785C9166506A0924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_A7BCBA0C8273150D9C8D9166506A1582" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_29724EA822D41D77785C9166506A0924" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_A7BCBA0C8273150D9C8D9166506A1582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_6CD83A669D1FE529CE9A9166506A16F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_A7BCBA0C8273150D9C8D9166506A1582" xlink:to="loc_us-gaap_ScenarioForecastMember_6CD83A669D1FE529CE9A9166506A16F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_FB6E5C224FCBA9AC251D9166506B0996" xlink:to="loc_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_9A7D019D6BA00820F3ED9166506B6F63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_9A7D019D6BA00820F3ED9166506B6F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_8133D1FEA8A4F4930E5D9166506B97CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_CAE84E24FE89AC9F10219166506B9390" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_8133D1FEA8A4F4930E5D9166506B97CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_410B6E8BE3A2E18BEF1F9166506CA92D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_410B6E8BE3A2E18BEF1F9166506CA92D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7A2C8EE20C23225DEA8E9166506C9761" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_410B6E8BE3A2E18BEF1F9166506CA92D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7A2C8EE20C23225DEA8E9166506C9761" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_NivalisTherapeuticsIncMember" xlink:label="loc_alpn_NivalisTherapeuticsIncMember_AAEE9550EACA6C1120B091665071A32E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7A2C8EE20C23225DEA8E9166506C9761" xlink:to="loc_alpn_NivalisTherapeuticsIncMember_AAEE9550EACA6C1120B091665071A32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F71ECEE04DE39A45858691665071D487" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_srt_RangeAxis_F71ECEE04DE39A45858691665071D487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_E1838F64F49AA9171A2291665071C3CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_F71ECEE04DE39A45858691665071D487" xlink:to="loc_srt_RangeMember_E1838F64F49AA9171A2291665071C3CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C2852600991722C486E091665072E3BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_E1838F64F49AA9171A2291665071C3CE" xlink:to="loc_srt_MinimumMember_C2852600991722C486E091665072E3BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_F5801A0FFAC97243A14A91665072D016" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_E1838F64F49AA9171A2291665071C3CE" xlink:to="loc_srt_MaximumMember_F5801A0FFAC97243A14A91665072D016" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SignificantAccountingPoliciesTable_E310B9143AB944A4D82C91665068B3DD" xlink:to="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_65448CBDF42E0E2DE1A491665072A88E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_65448CBDF42E0E2DE1A491665072A88E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_D8544E8150127584C2F9916650738115" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_D8544E8150127584C2F9916650738115" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_207DCE5788D71AC5457191665073529E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_207DCE5788D71AC5457191665073529E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B29A9D177940B5B1DCFF91665073E0CC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B29A9D177940B5B1DCFF91665073E0CC" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement" xlink:label="loc_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement_3AE847D50C33138D7B36916650739B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_C1F25FC23170605965B79170E122D4E7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_C1F25FC23170605965B79170E122D4E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_029CB5E404A1166F22F7917089FB6861" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_OperatingLeaseLiability_029CB5E404A1166F22F7917089FB6861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4CB31D0872035168ED4391665074F6D3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4CB31D0872035168ED4391665074F6D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_429F39E7D949D1E2354A916650741843" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alpn_SummaryOfSignificantAccountingPoliciesLineItems_ADC07E5DBAB347446C3B9166507264D8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_429F39E7D949D1E2354A916650741843" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:type="locator" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:label="loc_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_C67BA027D086F9CB6B9B9166508DC7FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_C67BA027D086F9CB6B9B9166508DC7FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_A61556F5F311B804D88C9166508DAA5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_A61556F5F311B804D88C9166508DAA5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_834A87A8C4E7F6FB8FF59166508D9AD6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_834A87A8C4E7F6FB8FF59166508D9AD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_B14E37DDC0271D6A06469166508E3518" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_B14E37DDC0271D6A06469166508E3518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_28CC044F0B72E1A39F3A9166508E4C4F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_28CC044F0B72E1A39F3A9166508E4C4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_EDB7A1CADABE60E805B69166508E2CE9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_EDB7A1CADABE60E805B69166508E2CE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_89985A68C2BF036CA4939166508EA619" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_89985A68C2BF036CA4939166508EA619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_FF4EABA061AA6AEC64E29166508EAAC5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_FF4EABA061AA6AEC64E29166508EAAC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3CB2F42CE77084A9308C9166508EDCD7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3CB2F42CE77084A9308C9166508EDCD7" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_AccruedLiabilitiesPolicyPolicyTextBlock" xlink:label="loc_alpn_AccruedLiabilitiesPolicyPolicyTextBlock_948D454C8F555116338F9166508FBD4F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_alpn_AccruedLiabilitiesPolicyPolicyTextBlock_948D454C8F555116338F9166508FBD4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_4439F375B5858F3910DE9166508FE015" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_4439F375B5858F3910DE9166508FE015" xlink:type="arc" />
    <link:loc xlink:href="alpn-20181231.xsd#alpn_CommonStockWarrantsPolicyTextBlock" xlink:label="loc_alpn_CommonStockWarrantsPolicyTextBlock_271054446269AD1643E19166508F84D4" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_alpn_CommonStockWarrantsPolicyTextBlock_271054446269AD1643E19166508F84D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_BC71826A2825591E97689166508F6718" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_BC71826A2825591E97689166508F6718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_BD07979440D565D68EFF9166508F40B8" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_BD07979440D565D68EFF9166508F40B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_95EF921AB4FBF5FD6E3D9166508F812C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_95EF921AB4FBF5FD6E3D9166508F812C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1CF04D80AF02123306BC916650909565" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1CF04D80AF02123306BC916650909565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_0E79ED22ECEBEB8A20369166509085CB" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_0E79ED22ECEBEB8A20369166509085CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49B7AA7B420EA68E54AB91665090FC53" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49B7AA7B420EA68E54AB91665090FC53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38FCA240EA6F36279968916650904A57" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38FCA240EA6F36279968916650904A57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2F28F6D10A2FA3EB4E679166509035AC" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2F28F6D10A2FA3EB4E679166509035AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8A113385BCA4DBBB807491665090124A" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8A6883A9E868D15A4199166508DCBF2" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8A113385BCA4DBBB807491665090124A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNewAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_557EE864AE3B8C4F9F1B730636D3AE45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_557EE864AE3B8C4F9F1B730636D3AE45" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_C28F96A535072153BBD9730636D49874" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_C28F96A535072153BBD9730636D49874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_55C9772034B8FED100F3730636D46CBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_C28F96A535072153BBD9730636D49874" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_55C9772034B8FED100F3730636D46CBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E0E9086A59F8090BBDBE730636D55DB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_55C9772034B8FED100F3730636D46CBC" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_E0E9086A59F8090BBDBE730636D55DB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_539B9297298AE154FED2730636D5960B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_55C9772034B8FED100F3730636D46CBC" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_539B9297298AE154FED2730636D5960B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AE83082E141BA4B352E1730636D5390C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AE83082E141BA4B352E1730636D5390C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_EB3212203B03E44732F3730636DAC236" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AE83082E141BA4B352E1730636D5390C" xlink:to="loc_us-gaap_TypeOfAdoptionMember_EB3212203B03E44732F3730636DAC236" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_829763A31D1B51C53745730636DBF395" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_EB3212203B03E44732F3730636DAC236" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_829763A31D1B51C53745730636DBF395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2E967C4746E8529D0AB6730636D483B6" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0BB55DA7518FEB8195CA730636DC0631" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:to="loc_us-gaap_StockholdersEquityNoteAbstract_0BB55DA7518FEB8195CA730636DC0631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DB556D353662D3E328F7730636DC3CA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0BB55DA7518FEB8195CA730636DC0631" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DB556D353662D3E328F7730636DC3CA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_64C4C9DCC61E96F8FDB7730636DB724E" xlink:to="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B0836BA5B3FCE09ED329730636DC55B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B0836BA5B3FCE09ED329730636DC55B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E1F6C8183CD7171B9D7F730636DD7095" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_E9F298629E70F9471413730636DC3397" xlink:to="loc_us-gaap_NetIncomeLoss_E1F6C8183CD7171B9D7F730636DD7095" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CA45D6589247AB2916DB4EC17DFDBAF2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_4674BF9EE74B959BD37E4EC1BA9441AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CA45D6589247AB2916DB4EC17DFDBAF2" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_4674BF9EE74B959BD37E4EC1BA9441AD" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>fig01.jpg
<TEXT>
begin 644 fig01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     S,R  "2
MD@ "     S,R  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MO_A,_$W_ $,&I?\ @4_^-'_"9^)O^A@U+_P*?_&L2BCE78.>7<V_^$S\3?\
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M_P!#!J7_ (%/_C1_PF?B;_H8-2_\"G_QK$HHY5V#GEW-O_A,_$W_ $,&I?\
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M_A7/?:)O^>K_ /?1H^T3?\]7_P"^C1J&G8Z'^P])_P"@79?^ Z?X4?V'I/\
MT"[+_P !T_PKGOM$W_/5_P#OHT?:)O\ GJ__ 'T:-0T['0_V'I/_ $"[+_P'
M3_"C^P])_P"@79?^ Z?X5SWVB;_GJ_\ WT:/M$W_ #U?_OHT:AIV.A_L/2?^
M@79?^ Z?X4?V'I/_ $"[+_P'3_"N>^T3?\]7_P"^C1]HF_YZO_WT:-0T['0_
MV'I/_0+LO_ =/\*/[#TG_H%V7_@.G^%<]]HF_P">K_\ ?1H^T3?\]7_[Z-&H
M:=CH?[#TG_H%V7_@.G^%']AZ3_T"[+_P'3_"N>^T3?\ /5_^^C1]HF_YZO\
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M-_SU?_OHT?:)O^>K_P#?1HU#3L=#_8>D_P#0+LO_  '3_"C^P])_Z!=E_P"
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M_A7/?:)O^>K_ /?1H^T3?\]7_P"^C1J&G8Z'^P])_P"@79?^ Z?X4?V'I/\
MT"[+_P !T_PKGOM$W_/5_P#OHT?:)O\ GJ__ 'T:-0T['0_V'I/_ $"[+_P'
M3_"C^P])_P"@79?^ Z?X5SWVB;_GJ_\ WT:/M$W_ #U?_OHT:AIV.A_L/2?^
M@79?^ Z?X4?V'I/_ $"[+_P'3_"N>^T3?\]7_P"^C1]HF_YZO_WT:-0T['0_
MV'I/_0+LO_ =/\*/[#TG_H%V7_@.G^%<]]HF_P">K_\ ?1H^T3?\]7_[Z-&H
M:=CH?[#TG_H%V7_@.G^%']AZ3_T"[+_P'3_"N>^T3?\ /5_^^C1]HF_YZO\
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MM6L]5M'U%HS"(X+I#YHYZJ.6./Y#TH T(?$-I/XHN-!2.875O )W<J-A4[>
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MH&3FMZO-VUA?$GQ&T@7-M)H_V ,\:WJ&.:X+=% Z#IZ]S7I% !1110(****
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M$R\.?]!JS_[^BM*\T^RU&-8]0LX+I%.56>)7 /J 15/_ (1C0/\ H!Z;_P"
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M?7B/_L(-_-J[NJ]M8VED9#9VL-N96WR&*,+O;U..IH&<=\5O^1;L/^PC'_Z
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MB_45V-<='_K%^HKL:3+B<KJ'_(1G_P!\U6JSJ'_(1G_WS5:F2%%%% @HHHH
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M _RH YGXGVLLGAVVOH5+_8+I)G4#^'IG\R*ZRRO8-1L8KNSD62&90RL#V/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #H_]8OU%=C7'
M1_ZQ?J*[&DRXG*ZA_P A&?\ WS5:NAGCLS.YDM@S9Y.>M1^58_\ /H/^^C0*
MQA45N^58_P#/H/\ OHT>58_\^@_[Z-.X6,*BMWRK'_GT'_?1H\JQ_P"?0?\
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M<+&%16[Y5C_SZ#_OHT>58_\ /H/^^C1<+&%16[Y5C_SZ#_OHT>58_P#/H/\
MOHT7"QA45N^58_\ /H/^^C1Y5C_SZ#_OHT7"QA45N^58_P#/H/\ OHT>58_\
M^@_[Z-%PL85%;OE6/_/H/^^C1Y5C_P ^@_[Z-%PL85%;OE6/_/H/^^C1Y5C_
M ,^@_P"^C1<+&%16[Y5C_P ^@_[Z-'E6/_/H/^^C1<+&%16[Y5C_ ,^@_P"^
MC1Y5C_SZ#_OHT7"QA45N^58_\^@_[Z-'E6/_ #Z#_OHT7"QA45N^58_\^@_[
MZ-'E6/\ SZ#_ +Z-%PL85%;OE6/_ #Z#_OHT>58_\^@_[Z-%PL85%;OE6/\
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MRTF0C_2Q<*[(#T9HP,@<]Z[B":.YMXYX'$D4JAT=>C*1D&@!]%%<]XR\5?\
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M8YRP) R#UJ3Q=I^O>$=#C\0Q>*-1N[V*9/M$,KC[.^XX(6,# &?T]*I^(/\
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MKM_'OQ!TG4-,@F&BZ,'D^URQE!-(PZ+GD_=7\C[5;^'_ /R-_C3_ +"(_F]
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M;+<IY<DBH&.P\,!GH2,C/;-:GV>7_GF:/L\O_/,T 5X84M[>.&(;8XU"*/0
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M[[-'VZZ_Y^)?^^S4%% $_P!NNO\ GXE_[[-'VZZ_Y^)?^^S4%% $_P!NNO\
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M -]FC[==?\_$O_?9J"B@"?[==?\ /Q+_ -]FC[==?\_$O_?9J"B@"?[==?\
M/Q+_ -]FC[==?\_$O_?9J"B@"?[==?\ /Q+_ -]FC[==?\_$O_?9J"B@"?[=
M=?\ /Q+_ -]FC[==?\_$O_?9J"B@"?[==?\ /Q+_ -]FC[==?\_$O_?9J"B@
M"?[==?\ /Q+_ -]FC[==?\_$O_?9J"B@"?[==?\ /Q+_ -]FC[==?\_$O_?9
MJ"B@"?[==?\ /Q+_ -]FC[==?\_$O_?9J"B@"?[==?\ /Q+_ -]FC[==?\_$
MO_?9J"B@"?[==?\ /Q+_ -]FC[==?\_$O_?9J"B@"?[==?\ /Q+_ -]FC[==
M?\_$O_?9J"B@"?[==?\ /Q+_ -]FC[==?\_$O_?9J"B@"?[==?\ /Q+_ -]F
MC[==?\_$O_?9J"B@"?[==?\ /Q+_ -]FC[==?\_$O_?9J"B@"?[==?\ /Q+_
M -]FC[==?\_$O_?9J"B@"?[==?\ /Q+_ -]FC[==?\_$O_?9J"B@"?[==?\
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MQ)MQSTPHX^OM6Q0(**** "K&G_\ (1@_WQ5>K&G_ /(1@_WQ0,-0_P"0C/\
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MC5]'E@D-G:VZ21*)2""50GGJ?O&NIU&/3_ASX2O+C2(2&D<>6DCELR'@'GL
M,_A531_^2S>(/^O2+_T&*IOBG;27'@EVB7<()TD?'9>1_P"S"D,33/ EMJ5C
M'>>+9;C4[Z=1(ZR3,J1$C.U0I'3I4NEZ#JOAOQ-'%I4LMSH,Z'S8YY@3;M_L
MYY]/U]JZBRNXK^P@N[=@T4\:R*0>Q&:HW_B&RT[6K'2IO,:ZOL^6L:YV@=V]
M!U_(TP.1O-$T_7OBY>VNK6_VB%-.615WLN&#(,Y4@]":O:M\._#=OI-S/9PO
MI\T,;2+<)<.=A S_ !,1BJ-YI7]K_%R]M_M][8[=.5_,LIO+<_,@P3@\<]/8
M50\7>'KC0FM[R_U#5-9T3>%N8)[MBT>>AR."/P'ZT@.M\ :G=ZMX.M;C4&:2
M8%H_-;K(%. 3Z^F?:NEJII?V+^R;;^RA&+,Q@PB,?+MQQ5NF!Q_Q0_Y$2Y_Z
MZQ_^A"JUG\-O#4NE6]Q+#,CO"LC.)V&"5R35GXH?\B)<_P#76/\ ]"%5['X:
M>&[G3+:62VFWRPJS$3MU*@T /^'=U<M_:]B;J2\L+&Z\NTN';<67G(SW  4_
MC5/3HIOB'J=]=WUU/%HEK,8;>UA<H)B.K,1UX(/X_G/X.DFT;Q=JGA59FN+&
MUC$]N[@;H\[?E)'^_P#I2_"QA;:+J&ES?+=6=ZXE0]1D 9_-3^5(!VI^!?[+
MA%]X(::ROX6!$ G)CF&>0V\^GX<5%\1Q)<^%-'6_B$<LFH0B:-6R 2C[@".W
M6NPU;5+;1M+GU"])$,"[FV]3V 'N37&?$*ZCU;P?HUS!YL45UJ$+(2-K@%'P
M?8]Z8&L?AMX4((&EX]Q<2\?^/5F>#S+I/CG6/#UO=2W.G01"6/S&W>4WR_+G
M_@1_[Y^M/UKP3J2Z7,^C>)=;EN54D0W%X667_9XQC-6/AQ)I$VAR/IEL;>[#
M[;U9&+2%_4D\XZX_'WH [&BBB@1XOX-NI-(\:"]=L6MY>2V,GLQP5_7'Y&O3
MO%VJG1O"U[=)GSMGEP@=2[?*,?GG\*\[TS36U+P+XD\G/GVNH&YB(ZAD&3_X
M[NKHI-27QAJWAFUC :%8AJ5V.H!7Y54C_?R*0R#X663Z;<:]92G+P31H_P!0
M&S^M6OA+_P B9)_U]O\ ^@K4O@G_ )&CQ;_U_#^;USGP_P#!>B^(/#;7FIP2
M23"X:,%92O "GH/K3 WOBM_R+=A_V$8__0'J_P"-]<O-/BL=+T=@FH:I-Y,<
MA_Y9KP"WUY'Z^E<GX[\&Z-X=TFSN]+ADCF>]2(EI2WRE6/0^X%;?CG%EXN\,
M:G.=MK'<&*1^R$D8S^OY4 78_AOHCPYU$W5]=D?-=RW#A\^HP<?SJQX7T_6]
M'O[W3[^5KO2TPUG<RR!I.WRGOW[^GO735E0>(;*Y\27&B0^8UU;QB21@N44<
M<9SUY% &K4<\R6UO)/*=L<:%V/H ,FI*J:K;O=Z->V\0R\UO(B_4J0*!'$Z%
MITOCY9M9\03S_P!GM*R6MA'(43:.,MCJ>WX&K-_X-N="F@O_  ,9(9ED ELG
MG)BE3OG<?Z_2K/PQN4E\#V]NO$MK))'*IZJ2Y;^3"M[7-<L_#VEM?Z@6\I65
M $&68D] /S/T!H&<K\1;9-0N/#5K=H1'<7ZQRH&YPQ4$9'UJT_PO\.;3]G2Y
MMY/X9(YSE3^-0^-91/J7A"90RK)J43 ,,$9*GD>M=O0!QW@O4K^'5-2\-:Q.
MUS<:>0T,[?>DB/3)_%?S]JI>.M1U^ZTO4H+&S-EIMLA$]U*<-..FU!Z'U[_S
MDT%Q?_%K7KVW^:""V6V+CH6^3^J-^5;7CK_D1M5_ZX_U% $VA3_9O FG3XW>
M5IL3X]<1 UROA?PS;^+]*_M_Q-)->7%V[^4HE9%@4,5&T ]<@^W3BNN\-JC>
M#-)60 H=/A# ]"/+&:YO2-%US2HY8_"&L:9=Z1)(QC%R6<PG/(4IP<>Y_"@"
MUX,O[B#6-7\.7=S)=#3G4V\TIRQC/\)/?'%=A7G_ ()LI;?QWXA+W+79C5$F
MN&&-\IY;CM@@C'8 5Z!0!7O[R/3M.N+R?_5V\32-] ,UQ&@Z')XVL_[;\4S3
M2PW#-]GL8Y2D4: X[')/!KJO$]K)>^%=3MX!NDDMG"CU..E9WP]NHKKP+I_E
M-DQ*8G']U@3Q^6#^- &?<>$[WP[J%K>>"S((C(%N;"6?,;)ZC<>OYGGZU5\<
M:=;ZMXZ\.6-ZI>"995=0Q!(Z]1]*ZS7O$%EX=LH[G4/,*R2"-%B7<S$^@S[5
MSGB4[OB1X5.",B4X/4<4 22_"_0A&38-=65P!\DT<Y)4_C5CP+K%[?6U]IFK
MOYE_I4_DR2YSO7G!)[GY3S]*ZNO,]$O[B.^\9:]I-M)>DS+%;)$A?S&W$9 '
M) R&^E %_P"(.LW-S:WFBZ0>8;<SZA,.D<>,A/JW'X?C71>#?^1*TG_KU3^5
M<)_:/]G^!M3M9]"UW[=>QN]W>SV6U&<]RV>%'^>M=;\/]3^V^%[6V^Q7EO\
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MI&JJXVVT;97AHGV]1[C)%5)?!>KW=K]AU#Q9=3Z?T:$6ZJ[+Z&3))_&NQHH
MYW5_"4.HV6E6EK<?9(=-G25!LW[@O;.1^?-:'B'2/[>T"ZTWS_(^T*!YFS=M
MPP/3(ST]:TJ* *]A:_8=-MK3?O\ (A2+?C&[: ,X[=*S=>\/?VW>Z5<?:O(_
MLZZ6XV^7N\S!!V]1CIUYK:HH *YS3/"?]C^*;O5-/O?+M;P9FLO*XW>H;/'.
M3T[D5T=% ')-X*N;*_N+CPUKDVDI<N7E@\A9H]QZD D8K0\/>&(]#FN;N:\F
MO[^Z(\ZYFX) [ =A6[10!R/_  A5W87-P?#>O3Z5;7#%I+;R%E4$]=N3\M:%
MAX/TVS\.W&DRA[F.[):YED/SRN?XB?4$#%;U% '&IX*U>"S_ +/MO%MW'IX&
MT0FW4N%Z;1)G(XJGXWTBUT/X7OI]B&\J*2/ESEF.\9)-=]5/5-*LM:L&LM3A
M\ZW8@E-[+D@Y'((- '+1>"KZ?2HK$>)+M-)= 3:")2P4\[?,Z[>V,5MZGX7L
MK_PH=!BS;6P15C*#)3:00??ISZY-;"(L<:H@PJ@ #T%.H YP^$VO_#1TGQ#J
M#:B5<-#<K"(7BP %QC.2.>3US5&3P1J-]#'9ZSXGNKS3T(S;B!8V<#LS@DM^
M-=C10!@:YX6BU>WTN"WG%G%ITZ2HBQ[@0HP%ZC'UYK?HHH$%%%% !1110 58
MT_\ Y",'^^*KU8T__D(P?[XH&&H?\A&?_?-5ZL:A_P A&?\ WS5>@"&ZM8+Z
MTEM;N)98)5*NC#AA7+0>#-4TQ&@T'Q1<V=H<[8);=9]@]%)(Q77T4 8&@>$[
M;0[J>]DN)K[4+@8ENISEB/0#L/\ "LVZ\%:D?$%]JFE>(GT]KU@71;0/P!@#
M);^E=C10!QI\!W.H2Q_\))XBN]4MXVW"W"")&/N 3FNBU;1++6='?3;N+%NP
M 4)QLQT*^F*T** .-;P1J5Q:+I]_XINY],7 -N(%5V4?PF3.2/K6EXDM%L?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$961BW]XN/Z'\*RM/\+ZB]GXMM;E?LO]J74KVTF\,&4EL$X)(!R,@\\UV]%
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MO^%?%!\1_P!HQ3V?V&[T^Y-O-!YOF=.C9P.I![=J .@ID4T4ZDPR)(%8J2C
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M[B**6<E88W<!I".2%!Z_A3=0ENH=.GDT^W6YNE0F*)GVAV[ GM7ED]CKEO\
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MNDD3AE/XBI:\S\!I;6?Q,\167AY]VB)$K$(VZ-)OEX4_]]C\/:O3* "BBB@
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M1?V%Q$+>8;,FSC880KZ<>F.X[YKKOB?(DT7AB6)P\;ZK$RLIR&!Z$5U:>&[
M>%%\/2AYK(0>1^\(+%1T.0,9'7..M9A\ :<VCZ9ILM[?RPZ7<"XMV>1"V1T4
MG;ROMU]Z!&5J"*WQZTLL,E=(8K['=*/ZFG?$7CQ!X-8<'^UXQGV++FNEE\.6
MDWBV#Q$TDXNX+8VRH&'EE<L<D8SGYCWHUKPY::[=Z9<7<DZ/IMRMS"(F #,"
M#AL@Y'';% S@KNSU.X^-VIQ6&M#1[B:RC:WD:T2?S4"IN4!L8Y4GCT-:&K^$
M=3NKW3&\1^.H',%TLMK'+810EW!!PI#@D^W-=3XB\(Z7XF\E]026.XMS^YN;
M=]DB?0_XU1TWX?Z78:M'J=U=:AJUY#_JI=1N?-,9]1P.: .IKS&]\/Z9XD^-
M=_::U;?:8$TM953S&3#!D&<J0>C&O3JR(O#EI#XMG\1+).;N>V%LR%AY87*G
M(&,Y^4=Z /.?&7@'3_"C0>(=$TU+JSMG'VRPN"9%*'^(9R?KDGL?6MGXA7L6
MM?"$WNBX-F_DN508VH& VX'3!QD=L5Z#-#'<020SH'BD4HZ,.&!&"*P] \':
M=X>TN[TVWDN+JQNF+-;W3*ZID8(& .#[YZ4",33=#\47.CVT]EX]7[(\*M'C
M2(<!,<#KZ5R_B+05T7X-W-MINKQ:Q;_V@LSSVZ *JG V_*S#[V#U[]*ZT_"W
M2%1X+;4]9MK)SEK*&](A/M@@G]:Z2UT#2[/0_P"QX+.,6&PH82,A@>N<]2?6
M@!;F]TZ+PW)>R^6^FK:F1A@%6BVYQ@\'(XQ7F&MSKJOB[PA>Z'/_ &%9W5O(
MEE+):(PB?<P_U>=OS97'/\0-=6/A;HP40&^U9M/#[QIS7A-OG.?NXS^M;VL^
M&-)UW2$TV_M5-O%CR1'\AAP,#:1TXH&<EXA\(ZW?:+);>(_'T"V$C*',^F0Q
M+G(*_-N&#D>M0>(A;6/Q \#)>SK-%%$Z>=T#MM 5N_5L'K6S%\,](-Q#)J-_
MJNJQP',5O?W?F1K_ ,!P/RK'\?:;:ZK\1/"VGWT>^WG29'4''&.Q'2@1H_%V
M2 ?#^>&7!GFGB6W7N7W G _W=U4=?26/XC^!TN3F98I!(<]6V#/ZUN6'P]TJ
MSU2"_NKK4=4FMO\ CW&H7/FK!Z;1@=/?-7O$?A.Q\3-:274]W:W%FQ:"XLY?
M+D0G&<'!]!0,YNT=(/CQ?B\PK7&FK]E+_P 6-N0OY-^1H^+;H^DZ1:Q<WTNI
M1FW4?>X!!(_$C\Q70:OX,TS7-/LX-1:Y>>R15AOA+BX& !DN!R3C)XZ\U#I/
M@/2]+U9=3GN+[5+Y!B.XU&X\YH_IP!0!BE0WQ\4D9*Z3D>QSC^M7/&>DZ;K6
MOZ9;QZS)I/B"-6>RDC4DLO.0>@['N._7-;O_  C5G_PEW_"1>9/]K^S_ &;9
MN'E[<YSC&<_C3/$7A33/$\4(U%9$EMVW07$#[)(C['\!0!R7]M>+_"&N:79^
M)+FTU:QU"X6V2:)-LJDD '  SU]\^N:]'KF-,\ Z;8:M%J5U>:CJMW#_ *F7
M4;GS3%[C@5T] !4D'_'PGUJ.I(/^/A/K0 3_ /'P_P!:CJ2?_CX?ZU'0!Q'Q
M>_Y)S=_]=8O_ $,5B_$3_D5?"7_7S!_Z!7>>(_#]KXGT633+^2:.&1E8M"P#
M9!R.H(_2J>O^"]/\1:18Z?>7%W%%8E6B>!U5\A=HR2I_3% '0UB:[_PE/VB+
M_A&?['\G;^]_M#S=V[/;9VQZUA_\*OL_^AC\1_\ @</_ (BNNTZR73=-@LTF
MFG6! @DG;<[8[L>YH K:'_;?V%_^$D_L_P"U>8=GV#?LV8&,[^<YS[8Q7)>+
M?^2K^#_^VW\J[^LC4?#5GJ?B'3=8GDG6XTW=Y2HP"-NZ[@1D_@10!S_Q>_Y)
MS=_]=8O_ $,57G^$OAB_T)19VCV=W)"&6=9Y&PV.X8D8S75>(_#]KXGT633+
M^2:.&1E8M"P#9!R.H(_2M*&,0PI$N2J*%&>N * //OA=?6]FU]X;O+"WL-8L
M7Q+Y2X-RH_CSWQ^6"".M>B5@W_A"PO\ Q1:>(!-<VM_:C;NMW4"5?1P0<C!(
MXQP?I5.TT1H_BI?:S%%.(I-/$,LD@ 1I"R8"=SA4YZ\F@#JJ\[\*?\ED\5_]
M<T_]EKT2L;3_  O9:;XEU#7();AKG4 !*CLI1<8^Z ,]NY- '*?"K_C\\4_]
MA-OYM7H,WF_9Y/L^SSMI\OS,[=V.,X[9KBF^%>F"\N;BWUG6[5KF5I9%M[I4
M4L3GH$]ZT]!\%6^@:E]LBU?5[QMA3R[RY$B<]\;1SQ0!'9_\)_\ ;H/M_P#P
MC?V7S%\[R?/W[,_-MSQG&<9XS7-?#S2[.V^('BI+N)&O[>ZW0&1?F6-F8[E]
M,@KD^X]:].KGM=\%:9KU_'J#R75C?QKM6[L9O*DQZ$X.: .=NH8+/XZ:8-+5
M8WN+*1K]8N 1M;:6'J2%_2L[3_#&D>)OBEXJCUNT^TK 8FC'FNFTE>?ND>E=
MQX>\(Z9X;DGGM//N+RX_UUW=2^9+(/0G_ 5+IWAJSTSQ#J6L023M<:EM\U78
M%%V]-H R/Q)H$>;>)_".G> =:L_$%GID=]HQD"7-K/\ O/()/#*3_7//'<8]
M:M+F"]LX;FSD66"9 \;IT92.#3=0L+?5-.GL;V,26]PA213W!KE[WPA:Z7\.
M+_0K>74KVW*$Q)E7E!R"%7"@8W#/3N:!G85P7Q<LYI/"]KJ$"&0:=>)/(H'\
M'()_,BNMT"SET[PUIEE< ":VM(H9 #D;E0 _J*O21I+&T<J*Z."K*PR&!Z@B
M@"'3[^VU33X;VQE66"9 Z,ISP?Z^U8LOBZ$>.(/#5I;-=2M$9;B9)!BW]F&/
MIW[BL\_#+2HI96TK4=8TF.4DO#8WA1#GV(-;/A[PII/AB.0:7 1+,<RSRMOD
MD^K&@#'M-3T?QKJVJ:'KND0+<Z;,42.=@[2+TWJ< CIV[$5S7C7P?IG@O2G\
M0^&;R?2;R&10D2S$K-EL%0#STR<9(P#Q79^(? NB^)+M+R\CEM[U!@75K)Y<
MF/<]#^(JE8?#/1+34(KR\GO]5EA;='_:%QY@0_0  _CF@1SWQ-!U33?"(OXB
MANKE!-'TQN"[A[=36U_PJ'PC_P ^<_\ X$O_ (UO>(/"]EXDEL'OI;B,V$XG
MB\EE&6&.#D'CCMBMF@9';P);6T4$0Q'$@103G@# KA]6_P"2Y:#_ -@Z7_VI
M7>5D7'ARTN?%=IX@DDG%W:0M"B*P\LJ<YR,9S\Q[T <O\8(DG\-Z5%*-R2:M
M"K#.,@I(#3==^$/AZZTF5=#M38WRJ6A?SG=6;L&#$\'VKJO$7ART\36EM;W\
MD\:6URMRAA8 EE! !R#Q\QK7H X?X8:O9W>BS::NGP:;J-@_EW=O$FW<>F_U
M/3!]"/3%=Q6#_P (A8)XP_X22WFN;>\9-DL<3J(YAC'S J2>W0CH#6]0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 *OWA]:UZR%^\/K6O0-&7<?\?#_ %J.M1K>)F)9
M 2>M)]FA_N"@+&916G]FA_N"C[-#_<% 6,RJL.EV%M>2W=O8VT5S-_K)HX55
MW^K 9-;OV:'^X*/LT/\ <% 6,RBM/[-#_<%'V:'^X* L9E%:?V:'^X*/LT/]
MP4!8S**T_LT/]P4?9H?[@H"QF45I_9H?[@H^S0_W!0%C,HK3^S0_W!1]FA_N
M"@+&916G]FA_N"C[-#_<% 6,RBM/[-#_ '!1]FA_N"@+&916G]FA_N"C[-#_
M '!0%C,HK3^S0_W!1]FA_N"@+&95>:PL[B[ANI[2"6X@SY4SQ@O'GKM)Y'X5
MM_9H?[@H^S0_W!0%C,HK3^S0_P!P4?9H?[@H"QF45I_9H?[@H^S0_P!P4!8S
M**T_LT/]P4?9H?[@H"QF45I_9H?[@H^S0_W!0%C,J2#_ (^$^M7_ +-#_<%*
MMO$K J@!'2@+&?/_ ,?#_6HZU&MXF8ED!)ZTGV:'^X* L9E%:?V:'^X*/LT/
M]P4!8S**T_LT/]P4?9H?[@H"QF45I_9H?[@H^S0_W!0%C,HK3^S0_P!P4?9H
M?[@H"QF45I_9H?[@H^S0_P!P4!8S**T_LT/]P4?9H?[@H"QF45I_9H?[@H^S
M0_W!0%C,HK3^S0_W!1]FA_N"@+&916G]FA_N"C[-#_<% 6,RBM/[-#_<%'V:
M'^X* L9E%:?V:'^X*/LT/]P4!8S**T_LT/\ <%'V:'^X* L9E%:?V:'^X*/L
MT/\ <% 6,RBM/[-#_<%'V:'^X* L9E%:?V:'^X*/LT/]P4!8S**T_LT/]P4?
M9H?[@H"QF45I_9H?[@H^S0_W!0%C,HK3^S0_W!1]FA_N"@+&916G]FA_N"C[
M-#_<% 6,RBM/[-#_ '!1]FA_N"@+&916G]FA_N"C[-#_ '!0%C,HK3^S0_W!
M1]FA_N"@+&916G]FA_N"C[-#_<% 6,RBM/[-#_<%'V:'^X* L9E%:?V:'^X*
M/LT/]P4!8S**T_LT/]P4?9H?[@H"QF45I_9H?[@H^S0_W!0%C,HK3^S0_P!P
M4?9H?[@H"QF45I_9H?[@H^S0_P!P4!8S**T_LT/]P4?9H?[@H"QF45I_9H?[
M@H^S0_W!0%C,HK3^S0_W!1]FA_N"@+&916G]FA_N"C[-#_<% 6,U?O#ZUKU%
*]FA_N"I:0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>fig02.jpg
<TEXT>
begin 644 fig02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     S8S  "2
MD@ "     S8S  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                       R,#$Y.C R.C(W(# X.C S.C,T #(P,3DZ,#(Z
M,C<@,#@Z,#,Z,S0   !$ &$ =@!I &0 ( !- &D ; !L &4 <@   /_A"Q]H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG
M[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR
M9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U
M+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#$Y+3 R+3(W5# X.C S.C,T+C8R
M-CPO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D
M,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D
M9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS
M(R(^/')D9CIL:3Y$879I9"!-:6QL97(\+W)D9CIL:3X\+W)D9CI397$^#0H)
M"0D\+V1C.F-R96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO
M>#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@
M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8
M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4
M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ_\  $0@"W 7W P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
M           ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $
M$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ
M-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(
MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8
MV=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        !
M @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'
M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#
M1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66
MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F
MY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBFO(D2%Y75%'4L< 4 .HJF=8TU3
MAM1M ?0SK_C2?VSIG_02M/\ O^O^- %VBJ7]LZ9_T$K3_O\ K_C1_;.F?]!*
MT_[_ *_XT 7:*I?VSIG_ $$K3_O^O^-']LZ9_P!!*T_[_K_C0!=HJE_;.F?]
M!*T_[_K_ (T?VSIG_02M/^_Z_P"- %VBJ7]LZ9_T$K3_ +_K_C1_;.F?]!*T
M_P"_Z_XT 7:*I?VSIG_02M/^_P"O^-']LZ9_T$K3_O\ K_C0!=HJE_;.F?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDCL!Z5T$?BI+SQ#'8SV<1MO/"1-C+*P;Y6_/%4?&L37'B:UA3[TD"*/J784
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MM[:YNX(9[DD0122!6E(Z[0>6QD=*X#QMKND)\0?"0?5+)3974_VH&X0>1F,
M;^?E_&K?C-&D^*'@,(,D2WC?@(T)_054\;:%I#_$'PD7TNR8WMU/]J)MT/GX
MC!&_CYOQH [M]9TR/35U&34;1+%AE;IIU$1^CYQ4]K=V]];)<65Q%<0.,K+$
MX=6^A'!K@/'NA"VOM U"+0AJ>A:491<:7;1#"A@-KB/HP'/'^)K9\"+X9DL[
MV\\'R,MM<RAIK7<0MO(!@@1G[A/?U^@% SJZ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/X:U4:_!XF\)30IJL47D3VUQQ%=Q9SM)'1AV/TZ8KL** .#N-0^(NLP?88-
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M:8F&>*/,S_\ /20\NQ]<DG]*CU;PW_;'B72=2NKK_1M++RI9^7P\I& Y;/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4G$2[UCZ[ V,A?;I0!9HHHH&%%%% !1110 4444 %%%% !112$A5)8X ZDT
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M9=*U[28'_M.& Q*7\LL-Q.W[N">.:X.B@#M(-1TSQ#H$5CJET+2YAQAW( )
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M/49['/-<G10!UR:/X:T^VF>]U)+TG[@B?D>P"DY/UKDW*EV* A<\ G) IM%
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MVQTN PZ996]G$3DQV\2QKGUP *B&AZ2--?3AI=E]AD;<]M]G3RF.0<E<8)R
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MYN[\*?++E<+&I/4_Y[59\-_\EK\9_P#7&S_]%+7<VUI;V5NL%G!%;PK]V.)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP905.0>A%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M62$,;.*V2UCD(Y&_8>>: ,?QSIES_P *N\-Z7K-S'=3&_M8)IX6++("&7(.
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M!@/P)S]2:MZ?XGM3I TW6[1KB% %1DQG Z=QR/4&N8HH Z;4O$FGMHYT[2+
MQ1L,;I0/E^G)Y]\TNC^)+&VT)M,U2VEEBR1^[QR"<X/(QS7,44 =7I?B73=.
MCOHTMYTCGD+1*J@[1MQ@\UF^'_$,FB2.C1^=;2G+IG!!]16-10!U\7B70M/:
M2?2]+D2Y<=6  'ZG ^@K*TK7?L_B)M3U'?(7#;O+ SR,#@D<5BT4 :NH:G#=
M^)CJ,:R"$RH^U@-V !GO[59\4:Y;:W-;M:I*@B5@WF #.<>A-8-% !1110 4
M444 %%%% !6UX1_Y&JS_ .!_^@-6+6_X+@:7Q)&X&1"C,3Z<8_K0!Z11110
M$ @@C(/4&L^YTW.6M_\ O@_TK0HH YYE*L0P((Z@TE;=Q:QW"_-PW9A63/;R
M6[X<<=CV- $5%%% !1110!9M+QK=L'YHSU'I6NCK(@9#E3T-<_4]K=-;/ZH>
MJT ;=%-CD65 Z'*FG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4_Y[VG_?;?\ Q-'_  @>J?\ />T_[[;_ .)H YBBNG_X0/5/^>]I_P!]M_\
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M>_MK2_\ H)6?_?\ 7_&C^VM+_P"@E9_]_P!?\:\AHH ]>_MK2_\ H)6?_?\
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M%S_SS_\ 'A1]@N?^>?\ X\*\_P#[9U3_ *"5W_W_ &_QH_MG5/\ H)7?_?\
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MH **** "BLS6M=MM%MPTW[R9ON1*>6]_8>]</>^+M6NW.R?[.F>$B&,?CUH
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MK5%>2_VSJG_02N_^_P"W^-']LZI_T$KO_O\ M_C0!ZU17DO]LZI_T$KO_O\
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MC^ZHZ"J%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#U'PGJ;:GH4;2MNFA/E.3U..A_+'Z
MUM5Q?P[8E-03L#&1^.[_  KM*!A1110 4444 %%%% !1110 4444 <)XXU5I
M;U=.B;$<(#28/WF/(_(?SKDZOZZYD\07Y/\ S\./R./Z50H **U=-\/W6J:?
M->6\D*QPDA@[$$X&>, ^M95 !114MO;S7=PD%M&9)7.%4=Z (J*Z5? NJE-Q
MDM5/]TNV?Y5B:AIMUI=R8+R/8^,@]0P]0: *M%=%;>"M1NK2&XCFM0DR*ZAG
M;(!&>?EITO@?4H87E:>U*HI8X=NW_ : .;HHK8TCPS>:S:-<6LD"(KE")&(.
M< ]@?6@#'HKI_P#A ]4_Y[VG_?;?_$UBZKI<^D7GV:Y:-GVALQDD8/U H I4
M5NV/A#5;Z 2A(X%;E?.8@D?0 FH=4\-:CI,/G7"))%G!DB.0OUX!H R**UM'
M\/7>M12/:R0H(V /F,1U^@-:!\!ZH!Q-:'V#M_\ $T <S15F^L+G3;HV]Y&8
MY!R/0CU![U BAY%4LJ!B!N;H/<T -HK7U7PU>Z1:I<3M#+$S;=T3$X],Y J'
M2-%NM:FDCM-B^6N6:0D >@X!_P B@#.HJ>\MC97DMNTD<C1MM+1DE2?;-04
M%%%% !1110 45-:VLUY<I;VL9DE<X51W[T^_L9M-O7M;G;YL8&[:<CD _P!:
M *U=9X'U5HKUM.E;,<P+1Y/W6')_,?RKDZOZ$YC\06!'_/P@_,X_K0!ZQ111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5'<3I;6TL\IPD:%V^@&:DK(\5.8_"]X1_=4?FP']: /.=0OI=2OY;J
M<Y:0Y S]T=@/I56BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** %5BK!E)!!R".U>H^&]4.JZ+'-(<
MS(?+D]R._P"(P:\MKMOA^Y,5^G960_GN_P * .QHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ JEK7_ " -0_Z]I/\ T$U=JEK7_( U#_KVD_\ 030!Y#1110(**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD:X>@#M_#%]%K.CS:+?G+*F$/<IVQ[J<?I3[MD\(>&1;0N&O;@GYQZ]V^@&
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+XN_P"15O/^ ?\
MH:UM5B^+O^15O/\ @'_H:T >94444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5VGP^_YB'_;+_V:
MN+KM/A]_S$/^V7_LU '9T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52UK_D :A_U[2?\
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MB)X<?X^]>F:?J%OJ=FES:/N1NH[J?0^]=>%Q4:\;/XBHRN6:***[2CR76?\
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M1110 4444 %%%% !1110 4444 %%%:GARS@O]?MK:[3S(GW;ER1G"DCD>XH
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MMSZC=P?Q%2>&/#UWI&H37FH[(HTC*K\X.[IS[#CO3O#-VM_XJU6YC^XX^7W
M. ?R% &+:OI4?B>^?6MQC69]B[25)W'KBN@TG^R]>$\9T..WB4?)*(P-X^H
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M1WB\43B<9%CD9]6/ /Y9-3PW_P#:'Q(B93F.(O$GT"-G]<UT&L3Q:1I=]?Q
M":4#!'=L;5_*N'\(_P#(U6?_  /_ - :@#6U^Q&I>.;:T<D+)&NXCT&2?T%7
M=<UY/#LL.GZ=9P[0@9PPXQGIQWXZFJNM7J:?X^M+F;B-8U#'T!W#/ZU-XI\.
MW>JW\-YI^R560(P+ 8Y/S>XYH O7\D$W@6:6TB$,4D.\1CHI+9(_/-5=%_Y)
MY<_]<9_Y&K>H6GV'P-+;;PYB@VEAT)SS^M0>'+=KKP.]O&0'F25%+= 3D<T
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MHHHKO+/)=9_Y#U__ -?,G_H1JE5W6?\ D/7_ /U\R?\ H1JE0 4444 %%%%
M!1110 5+;W,]K(7M9Y(7(P6C<J2/3(KI?#FC6%_H%Y<W<'F31,P1M[#&%!Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ!?@_P#/PY_,Y_K5"NL\<:4T5ZNHQ+F.8!9,#[K#@?F/Y5R= !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %7]"0R>(+ #_ )^$/Y'/]*H5UG@?2FEO6U&5<1P@K'D?>8\'\A_.@#NZ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "LCQ4AD\+W@']U3^3 _TK7J.X@2YMI8)1E)$*-]",4 >.45:U"QE
MTV_EM9QAHS@''WAV(^M5: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *[;X?H1%?OV9D'Y;O\ &N*5
M2S!5!))P !UKU'PWIATK18X9!B9SYDGL3V_ 8% &K1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?\(?H7_/C_Y&?_XJ@#R^BO4/^$/T+_GQ_P#(S_\ Q5'_  A^A?\ /C_Y&?\
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MJ?\ 0-N_^_#?X5ZU10!Y+_8VJ?\ 0-N_^_#?X4?V-JG_ $#;O_OPW^%>M44
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MO4J* .<T#PG#I<BW-VRSW(^[@?+&?;U/O71T44 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_NDC /X&M"B@#S?0_B!!X5TNWT3QW;W&E7EC&(%N! TD-PJC"LK*#U &>/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM^+;G1_#.D-:6XOM9U41Q6L+?*KR%06=L=%&<G'KVZ@ ZVBN%&B?$80_:?\
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MPW*G'3/6@9V%%>?:GXR\3/\ $&_\+^'M-L;AX8HI(Y[DNJ0J5!9I"#SR0
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M ')ZK_R6W0?^P9/_ #KN*@>QM)+Z.\>UA:ZC4HDYC!=%/4!NH!]*GH&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &3XHT1/$?A>_TJ3 -Q$0C'^%QRK?@P!K@O">I7'CSQ-I3:C&X7PY9G[8
MDB_>O6)CY]<*I;ZFO4ZI6&D6&F37DMA;+#)>S&>X92?WCD8)Y^G;CKZT >32
M+<PW-Q\+HED$=QJ8>.0=$L&_>L ?4$$=NN*Z_P"(L:11>$(XE"(GB2R55 P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "LC4AB[^JBM>LG5/^/I?]P?S- %.BBB@ J:TXO(O]ZH:EM?^/N+_>%
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M3]7T47#!89M3LS#'(3T ;)'/OB@#HM%US3O$6EIJ.CW'VBU=BJR;&3)!P>&
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M,1SO<R332MNDF<]68]S6%>> ;NWUJZU+PEXBN-!>]?S+F 6ZSPN_=@C$ $T
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M]?TH\6>&_P#A*-)BL?M7V7R[F.XW^7OSL.<8R.OK0!SOQ?\ ^18TS_L+V_\
M[-4WQ#_Y#7@W_L-Q?R-;/C#PQ_PE>EVUG]K^R?9[R.YW^5OW;,_+C(QG/6G^
M(?#?]O7NC7'VK[/_ &7?+=[?+W>;@?=ZC'UY^E %3X@:-/JOA=Y].R-2TV1;
MZR8=?,CYQ[Y&1CU(KGM<UJ+Q[;^&]#TYB8-85;Z_"G_5V\9^9#]7&WZK7HTD
MB0Q/)*P1$4LS,<  =37GOPHT.VCCU7Q';P-#%JEU(+*-O^6=L') 'IEB3CV%
M 'H:JJ*%0!548  P *6BB@84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %5M0&;)_8C^=6:@O!FSD
M^E &)1110 4444 ;=B<V4?T_K4]5=..;,>Q(JU0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %8^HG-ZWL!_*MBL2\.;
MR3ZXH @HHHH *L6(S>Q_4_RJO5K3AF\'L#0!L4444 %%%% !1110 445A^%M
M"OM L9X-2URZUF26<R++<C!C4_PCD\?IZ 4 7KW1K#4=0L;Z\@\RXT]V>V?>
MP\LL,$X!P>/7-7J** "BBB@ HHHH **** "BBB@ HHHH ***P]:T*^U/6M*O
M;37+K3X+&7?/:PCY+H9'RMR..,<@]?QH W**** "BBB@ HHKCM-OKN3XOZU9
MO=3-:QZ? Z0&0E$8GDA>@)]: .QHHKCM-OKN3XOZU9O=3-:QZ? Z0&0E$8GD
MA>@)]: .QHHK#UK0K[4]:TJ]M-<NM/@L9=\]K"/DNAD?*W(XXQR#U_&@#4O[
M&#4]/GLKQ6>WN$,<JJ[(64\$94@C\#3K.T@T^RAL[.)8;>!!''&O15 P!7*>
M-+Z[M?%'A&*UNIH8[C4&29(Y"HE7;T8#J/8UV- !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %,F7=!(/52/TI]% '.T4K#:Q'H<4E !1110!J:4W[AU]&S^E7JS-*;$DB^
MH!_S^=:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9.L:AKVK^.?"-]JNG'2;#[>4MK25@TSMMY=\?=[ #ZT =#9_\EUU'_L"1_\
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M\1:YK0T>70=-O_+$%A*NQF91\TA3^$G/3WKOZ!A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 8=VNR\D'^UG\^:AJYJ:;;H-_>6J= !1110!9T]]MXO^T"*V:P(G\N9'_NL#
M6_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_ .?_P"(KP;-&:/91#ZU/R/>?^%G^$?^@H__ (!S_P#Q%'_"S_"/_04?_P
MY_\ XBO!LT9H]E$/K4_(]Y_X6?X1_P"@H_\ X!S_ /Q%'_"S_"/_ $%'_P#
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M=)[L@_H: .DHJG8:M8ZFI-E<)*0,E>C#\#S5R@ HHHH **** "BBB@ HHHH
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M_P"^%_\ BJ .FHKF?^$\TS_GA=_]\+_\51_PGFF?\\+O_OA?_BJ .FHKF?\
MA/-,_P">%W_WPO\ \51_PGFF?\\+O_OA?_BJ .FHKF?^$\TS_GA=_P#?"_\
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M] UR55:1Z>%DW3] HHHK(Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#$\3:\-&LPL.&NI@?+
M!Z*/[QKS>::2XF:6=VDD<Y9F.2:U/%-TUUXCNB>D3>4H] O'\\UCT %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!)#-);S++ [1R(<JRG!%>D>&=>&LV96;"W4('F =&']X5YG6QX6N
MFM?$=J0>)&\IAZ@\?SQ0!Z?1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4450URZ:RT*[G3AEC(4^A/ /ZT <
MAXJ\227<\EA9.5MD)61@?]8?\/YURU%% !1110 4444 %%%% !1110 4444
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MA'X?^%5O=1+GRK!KQO4DJ7/^%95).*T.C#P4Y>]LC!OO#_PS\/2BSU>0-<
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M$*_:$/\ 9]H1)<'^]Z)^..?8'VKK?B_XM"JOAK3GP!A[LIV'58_Y$_A[UG>
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M/^-'_"<:K_=M_P#OV?\ &C^T:'F'.CT.BO//^$XU7^[;_P#?L_XT?\)QJO\
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M HHHH *NZ-_R'K#_ *^8_P#T(52J[HW_ "'K#_KYC_\ 0A0!ZU1110 4444
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MGP^_YB'_ &R_]FH [.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-V]N<>PH XBBBB@ HHHH **** "BBB@ KM/A]_S$/^V7_LU<77:?#[_F(?\
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MYQ^M6?\ A )?^@@G_?H_XUT?AS_D7++_ *Y_UK3K>G@J$H)M=.[&HJQQ/_"
M2_\ 003_ +]'_&C_ (0"7_H()_WZ/^-=M16GU##_ ,OXL?(CB?\ A )?^@@G
M_?H_XT?\(!+_ -!!/^_1_P :[:BCZAA_Y?Q8<B.)_P"$ E_Z""?]^C_C1_P@
M$O\ T$$_[]'_ !KMJ*/J&'_E_%AR(XG_ (0"7_H()_WZ/^-'_" 2_P#003_O
MT?\ &NVHH^H8?^7\6'(CB?\ A )?^@@G_?H_XT?\(!+_ -!!/^_1_P :[:BC
MZAA_Y?Q8<B.)_P"$ E_Z""?]^C_C1_P@$O\ T$$_[]'_ !KMJ*/J&'_E_%AR
M(XG_ (0"7_H()_WZ/^-'_" 2_P#003_OT?\ &NVHH^H8?^7\6'(CB?\ A )?
M^@@G_?H_XT?\(!+_ -!!/^_1_P :[:BCZAA_Y?Q8<B.)_P"$ E_Z""?]^C_C
M1_P@$O\ T$$_[]'_ !KMJ*/J&'_E_%AR(XG_ (0"7_H()_WZ/^-'_" 2_P#0
M03_OT?\ &NVHH^H8?^7\6'(CB?\ A )?^@@G_?H_XT?\(!+_ -!!/^_1_P :
M[:BCZAA_Y?Q8<B.)_P"$ E_Z""?]^C_C1_P@$O\ T$$_[]'_ !KMJ*/J&'_E
M_%AR(Q/#OA]M"^T[[@3>=MQA-N,9]_>MNBBNJG3C3BHQV&E8\EUG_D/7_P#U
M\R?^A&J57=9_Y#U__P!?,G_H1JE5C"BBB@ HHHH **** "E ).!R:2I((6N+
MB.&/[\C!%SZDXH Z6/P7L@B;4M3ALY)>%C90>?3)(R?I69KN@3Z'+&))!+%)
MG;(HQR.H([5L:GIVG:.MLFL37NHS%3LC5\(/IW'YU:\>_P#'A9<8^<\>G% &
M=%X-V6L<FIZG!9/)T1P#^&21S5#7/#L^B>6[2+/!)PLBC'/H171OKFE:C:PK
MXCL)('V_*\D3;3Z[2.?2J/B?188M*BU"PNI9+<;0(WD+J%/0KG\.* ((/!VV
MSCGU/4H;$R<JC@'\,DCFJ6N>')]%2.7S5N()#@2*,8/H170#7=,O[&"/Q)82
M0MMPLCQ-M;IDJ1R.U5?$FBVZZ+'J&G74KVR;0L;R%E"G@;<]/I0!3L_")ETY
M+S4;^*QCD *[QG@],DD8^E0ZUX8DT>**<W GMG8*9%3!7/MG^M:%SH]IH^DV
MSZ[<W=QN/RVT+?(IQ[_SXJ_XC,9\#VQAC:*,^5L1CDJ,<"@#GM>\.MHL,$R7
M/VF*;(WA-N#U'<]>?RH3P[_Q31U>>Z\H8)6+RL[N<#G/<^U;=I&?$/@46R8:
MYM6"KGU7I_XZ<5%XTG2SL+'2;<X5%#,,]@,+_7\J ,_3_"C7.FK?7U]%8POR
MA<9R/4Y( IFK^%I=-L5O;>Y2[M^-SH,8!Z'J<BM73==LWT."UUZPD\B,!$F,
M1:-L#CZ''I3M4T6PNO#KW>BW4H@A4N(C(QC(')X;D&@#BJ*** "BBB@ HHHH
M **** "KNC?\AZP_Z^8__0A5*KNC?\AZP_Z^8_\ T(4 >M4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8OB[
M_D5;S_@'_H:UM5B^+O\ D5;S_@'_ *&M 'F5%%% !1110 4444 %%%% !73^
M _\ D/3?]>S?^A+7,5?TC5Y]&NVN+5(W=D*$2 D8R#V(]* .FN-?T:+6IYKW
M3'-Y;S,BRQX(;:< G)'/'H:QI?$1N_$UOJ5RC+#"PVQIR0H_+FLBYN&NKN:X
MD #S.SL%Z DYXJ*@#7\2:M!K&J+<VJ2(@B"8D !R"3V)]:MZ+XF2ST]M/U.W
M^TVASM P2!UQ@]17.T4 =6WBC3M/L9(?#UB\$DG627''OU.:S/#NMC1M1DGG
M1Y8Y4VOM^]G.<\_YYK'HH Z*Z\064&KPW^B6LD3AG:<2_P#+7=CW/O5V7Q#X
M=NKC[7=:5*]R1\V0"I^OS8/UQ7(44 ;-KJ]I!XFBU!;/[/;H3^ZAY/W2.^!W
M]JL7&OVLOBZ'55CF$" 94J-W0CIG'ZUBVMG<7TPBM(7F<]E'3Z^E/M=.NKV\
M-K:Q;YAGY=P'3KR3B@"YXCU2'5]5^TVRR*GEA<2  Y&?0FKOB7Q!:ZS:VT5K
M',C1,2WF*!GCV)K"N[2:QNGM[I-DJ8W+D''&>HJ&@ HHHH **** "BBB@ HH
MHH *[3X??\Q#_ME_[-7%UVGP^_YB'_;+_P!FH [.BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ^/2>329I"?F/UHS7J'RXN:,TF:,TP%S1FDS1F@!<T9I,T9H 7-
M&:3-&: %S7:_"C6_[(\?6J2,%AOE-J^3QEN5_'< /QKB<T^&>2WN(YX'*2QL
M'1AU4@Y!J9*ZL7"3A)270]D^+7A274_&&A3VRM_Q,7%E(RC(0ALAO^^6;\$K
M3^,FJQZ3X)MM'M<(;R18P@XQ%'@G'X[!79Z->V?B?1=+U<(C_*)X^<^5(4*L
M/J-S"O"_BYKG]K^.IH8I-T%@@MTPV06ZL?KDX_X#7+3O*23Z'J5^6G"4X_:/
M4_@__P DWL_^NLO_ *&:\Z^"5Y%!XVF@DC+/<6C)&X4G:0RL0<= 0.I[@#O7
MH?P?=?\ A6]KEA\LLN>>GSFN%^!DVSQ+?QBSDE\RW&;A5&(<'.">V[_V7\C^
M<76C_78ZS6_ASK6I?$6/7K?6EBM5D1P"S^9$ !E5'3!P>XZ]#6%\=-3LI9-,
MTZ(QR7D)>20CDQ*0  ?KC./85U&KZ'H,FLW*3>.]2TVXGD+/91ZRJ*K-S@(>
M0.>GY5PGC[X5G0-)EUO2]0FO8$8-.MQ@R?,<;]PZ\D9X]Z(-<RNPK1DH24%O
MOJ>@?"O_ ))79?\ ;?\ ]&-7SIFOHSX2XE^&%B@89W3*<<X_>-_C7-VGP+L+
M:82:KKTDT /*QP"'/_ BS549QC*5R:M&=6G3Y>W^1L?!.UEM_ ,DD@PMS>R2
M1^ZA53^:&O$/$,Z7/B;5)X6#1RWDKJP[@N2#7LGC#XA:)X6\-_V'X4FAFNA%
MY,7V=MR6RXQN+<@M[<G/)]_"<U=)-MR?4PQ,HJ,::=["YHS29HS6YQ"YHS29
MHS0 N:,TF:,T +FC-)FC- "YHS29HS0!V7PG_P"2G:5_VV_]$O7TE7S9\)O^
M2GZ5])O_ $2]?2=<5?XCV<!_"?K_ )!1117.=X4444 (JA1A0 /0"EHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /)=9_Y#U__P!?,G_H1JE5W6?^0]?_ /7S)_Z$:I4 %%%% !1110 4
M444 %/CD>&5)(SM=&#*?0CI3** .K;QP9(XS/I<$EQ&/EE9N%/J!C(_.J6L>
M)WU>PMX9+;RIX6#^<LG4XYXQQZ]:P:* .H3QIYMJL6J:9!>E?XF( /O@@\U0
MUKQ)<:PD<0C6VMXSE8T.>>Q)K&HH ZB+QHTEHL&J:=#?;?XG(&?<@@C-4=:\
M2SZO"ENL*VULASY:'.3VR>./:L6B@#J(O&C&RCAO].BNWCQAW;'(Z'&#S4.H
M^+'U31WLKFT4.S9$J/@#!R/EQZ<=:YVB@#MO ]I?6LURUQ"\5NZ#!D4C<W8C
M/;!//TKF]?O_ .T=<N9PVY-VR/G(VC@?GU_&@^(=4-BMG]K80*@0*JJ/E QC
M(&:S: .CL/%\MOIZV=_9QWT2@*N\XX]#P0:CU3Q5+?:?]BM+6.RMSPRQG.1Z
M=!@5@44 %%%% !1110 4444 %%%% !5W1O\ D/6'_7S'_P"A"J57=&_Y#UA_
MU\Q_^A"@#UJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K%\7?\BK>?\  /\ T-:VJQ?%W_(JWG_ /_0UH \R
MHHHH **** "BBB@#<\.^'3K322SRF&UB.&8=6/H/3ZUJVGA?1-1NBNGZE+*D
M9(E7(W>Q!V],^WXU/X:7[3X*O[>V'[X^8N!QDE1C_"J'@>UG76Y93&ZI'$R.
M2,8.1Q]: *1\/&?Q1-I=DY$<9R9).2JX&3QC/6M0>&=!FNGL+?5)?MJY&TX(
MR.HZ#/TS6EI$B#QMJ\9(WLJE?H,9_F*IS:Y'::S+#%X91KJ-V(>,#>P_O<)G
MGUH PK+0MWBE=)ORRC+!FC(!("E@1GUXK9E\+:)::@+:\U*5'F(\F,$;L>YQ
MCDY]*BL-2;5?'MI.]L;9PC(T;-DY"-["J7B1B?&TF2>)(@/;Y5H AU_P^VDZ
MA#!;NTR7'^JR/FSG&/U'YUIMX9T?3HX4UO4GCN91G;'@ ?H>/<XK4\2.D?B+
M0VEQM$IZ]N5P:7Q+J4&GWD7VG1(;T2* LSXZY/R\J?K^- '*^(- ?19HRDGG
M6\V3&^/T-;U_X3T338Q/>WUQ#!]WD@DMVQA?Z5F>(]=EU"RAM)M+>Q,;AUWL
M>@!& -H]:TOB"[!+! ?E)D)'N-O^)H S=*T#3]2FO)S?-'8V[$*20'8 9W'(
MX'X5;/A;2[_3);G0[Z65H\\2XP2.<= 146A:!9RZ'-JM_')<A0Q2!&(R%^G.
M:WO#LZ7.BW,D.GK8Q$D(JY^?Y>N3UH J>!8[-;.9X97:Z;'GH1PHRVW''<>Y
MK/MM/TVX\5)#I=_=@,KM+)&VQE;T!VCBIOA]_K+_ .D?_LU4_"ZLOC!BRD9\
MW&1UH K7NC377BV73K>:69LC,T[;F V@DD_Y[5IMX;\/V]TME<ZI*+LX& 0!
MG\CCZ$U?T^6-/B%J2/@.\0V$^P4D?Y]*Y;6-.O#XDN8?(D>2:9FCP/O G((_
M/\* %U;09-(U2*WE?S(9F&R0#&1G!_$5NW_A+1].*37>H30VYX(8@LS>V!_0
MU/XPD1?[+@8YF\T-^ P#^O\ *JWQ!_UEA])/_9: *.O^&8-.T^._TZX>>W8@
M'?@\'HP(QQ7-UW.I_P#).+?_ '(OYBN&H **** "BBB@ KM/A]_S$/\ ME_[
M-7%UVGP^_P"8A_VR_P#9J .SHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /CR9#%
M/)&XPRL5(]Z9FNM^)OA^30/&]X-F+:[8W,# <88DD?@<C\JY'->G%W5SYJ<7
M"3BQ<T9I,T9JB!<T9I,T9H 7-&:3-&: %S1FDS1F@!<T9I,T9H 7-&:3-&:
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M .?+_P BO_\ %4 >945Z;_PB.A_\^7_D5_\ XJC_ (1'0_\ GR_\BO\ _%4
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M '_7_&C^V=,_Z"5I_P!_U_QKR6B@#UK^V=,_Z"5I_P!_U_QH_MG3/^@E:?\
M?]?\:\EHH ]:_MG3/^@E:?\ ?]?\:/[9TS_H)6G_ '_7_&O):* /6O[9TS_H
M)6G_ '_7_&C^V=,_Z"5I_P!_U_QKR6B@#UK^V=,_Z"5I_P!_U_QH_MG3/^@E
M:?\ ?]?\:\EHH ]:_MG3/^@E:?\ ?]?\:/[9TS_H)6G_ '_7_&O):* /6O[9
MTS_H)6G_ '_7_&I(]3L9F"PWMO(3T"RJ?ZUY#10![/17F.C^);W29%7>TUMG
MYHG.>/8]J]'LKV#4+-+FU?=&XX]1['WH GHHHH **** "BB@D*"6. .I- !5
M"\O]F8X#EN[>E17=^7S' <+W;UJC0 9SUHHHH **** "IK6V:YDP.%'WCZ4D
M$#W$FU.G<^E;4,2PQA$& /UH 5$6- B# '2G444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZXZ].O% $%%3P65U=*S6MM-,J_>,<9;'Y4EO9W-WN^RV\LVS[WEH6V_7'TH
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MTZD<UU= !17*>(?&B:/XTT'P_"L;RZE(?/+9S''@A<<]2WUX!]:ZN@ HHHH
M**** "BBB@ HHHH **** "BBN5U;6;^U^)GA_2H)]ME>6]P\\6Q3O*KE3DC(
MQ[&@#JJ*P]%M?$<&M:K+KFH6MSI\LN=/AACVO"F3PQP,G&.Y_#I6Y0 4444
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M<_A5FT^)'A&[TT7HUVSA7:"T4TH25?8H><_3- %?POX@U<>(+KPSXK2 ZE!
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M444 %%%% !1110 5M>$?^1JL_P#@?_H#5BUM>$?^1JL_^!_^@-0!Z;44UQ'
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M?"G_ %ZW?_H% #/">L3CQ1XX;4KR>2TL+E6199"RPH%8G:"< <=JIZ18Z_\
M$&W&N:CKM_H>EW!)LK'3)1')Y8. SR8.2<9Q_*G>$+1+_P 5?$*SFR([BY6)
ML>C(X/\ .H- \7+X TZ+PWXXAGL_L68[;48X6D@N(_X2"H)!Z#&/K0!0\5V7
MBKPC)I,<'B.]U#2;G4X$:2>0BXB;=]PN,;T89SGN!^.G\0+_ ,0Q>/?#NG>&
M+QH)[V&=-KN?*' S(R]&*C)&0>E8WC3QL?%']CQ:'97/]D1ZK;F:_GB,:RON
M^5$!Y(ZDGV'X]3KW_)9?"G_7K=_^@4 4]5\&Z[HVCW&K:;XTUJXU*TB:<QW4
MH>WFVC)7RL87.,=378^&]7_M_P ,Z?JNP(;NW61D'16(Y ]LYJ37?^1=U'_K
MUE_] -8OPS_Y)IHG_7O_ .S&@"[XP\1?\(QX<EOXX?M%RSK#;09_UDK'"CZ=
M_H*P(/ VO:E"+KQ%XSUB*]<;C#IDP@AB/]W !W >O&:UO'OAZZ\1^%V@TQU2
M_MIDNK7><*9$.0#]1D?7%8]M\6]#MX?)\2PWFC:D@Q):S6KMEAUV%0<CT)Q0
M!L>%[7Q/IM[=6&O74>IV$:JUI?G"RMR<HZCJ1Z_S[<8WB1?&>LWS7?C2+PUH
M]I.T$$$%Y'#<W.WK(6)RH)Z<?XGLO"WB/4_$EY=W3Z2]AHRJHLY+D%9IV[MM
M[+Z?U[</:6GA_P "WU[IOC7P[;S6+W#S66KOIZSJT;'.QSM+!E_SVR 3OX@A
M\%7,%Y8>.XO$6E-,L=W9W=['/<1HQQYD; Y.,Y(QT_3?U[_DLOA3_KUN_P#T
M"L2WOO#/B+6+6S\%>"M,OX#*#=W]QI:Q011]]I*@EO08_P#K;>O?\EE\*?\
M7K=_^@4 '@O_ )*!XX_Z^K?_ -%FNOU'_D%W7_7%_P#T$UR'@O\ Y*!XX_Z^
MK?\ ]%FNOU'_ )!=U_UQ?_T$T#/(FO[S3OV>]"GT^[GM)?M*+YD$A1L&9\C(
M[5O?$"_\0Q>/?#NG>&+QH)[V&=-KN?*' S(R]&*C)&0>E<U??\FYZ%_U]1_^
MCGKM=>_Y++X4_P"O6[_] H$4]5\&Z[HVCW&K:;XTUJXU*TB:<QW4H>WFVC)7
MRL87.,=36CJ?CT6/POM_$ZPH;B[@C$4);"^<_&"<_=!R>O0=JZ37?^1=U'_K
MUE_] ->>VGAV?Q+\!](MK)(Y+NW1+F".4 I(Z,?D(/&""1SQS0!#!;65[!]J
MUOXM/'J#C<4L-5AB@C/]W8#\P'X5O^!_$\MUK5[X<OM8M-;EM85N+;4+1E83
M0YVD/M) =3C/KG/UP8O%'PV@M]FN>%[72]148DL9M&!?=W"D)@CT)Q71^!$C
MO+F]U2V\)V6@63XCLW%JL-S,G5BX X4D @?SQF@#LZ***!A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%9GB/6E\.^&[W5GA,ZVD7F>4&V[NV
M,]NM &G17.Z-KNHZY\/4UJRM83J5Q:22P6^?D,F&V*22."0 >1^%9FL>)_$>
M@?"F;7M6L+.WUR#;YEMRT2YG"#[KG^ @_>Z_E0!VM%9WA_4)=6\,Z7J-PJ+-
M>6<4\BQ@A0SH&(&2>,FM&@ HHHH ***Y'Q=XKOM \5>%],LXK=X=7N7AG:56
M+* 8Q\N" #\YZ@]J .NHHHH **** "BLGQ5JL^A^$]2U.T6-YK2W:5%E!*D@
M=\$''XU'X/UBX\0>$-.U6\2-)[J+>ZQ A0<D< DGMZT ;5%%% !1110 4444
M %%%8&M7?B:#Q#I4.AZ=;7.EROC4)Y6 >%<CE1O&>,]C0!OT444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>ST^RTY)%T^T@M
M5E<R2"")4#L>K' Y/O5BLW_A(=*_X2+^P?MB_P!I^5YWV?:V=GKG&/PSFM*@
M"".QM(KZ6\BM84NIE"RSK& [@= 6ZD#WJO::'I-A=O=6.EV5M</]Z:&W1';Z
MD#)J_10!2O\ 1=+U5D;5--L[UH_N&X@63;]-P.*N(BQQJD:A44855& !Z4M%
M &=>>'=$U&X^T:AH]A=3?\])[5';\R,U>AABMX5BMXTBC085$4*JCT %49_$
M&EVWB&VT.:[5-2NHC+#;[3EU&<G.,#[K=3V-/FUFP@UJWTF6?;?7,;2Q0[&.
MY5ZG(&!^)H 2;0M)N+];Z?2[*6[4@K</;H9!_P "(S4][86>I6QM]1M(+N$G
M)BGC#J3]#Q5BB@""SLK73[9;>PMH;6!?NQ0QA%'X#BENK2VOK5[:^MXKF"08
M>*9 ZMWY!X-344 5Y;"SFDMY)K2"1[4Y@9XP3"<8RI_AXXXJ=E5U*N RL,$$
M9!%+10!#:6EM86J6UC;Q6UO&,)%"@15YSP!P*FHJC!K-A=:S=Z5!/NO;-$>>
M+8PV!AE3DC!S[&@"UY$/VC[1Y2>=LV>9M&[;G.,]<9[47%O#=V\EO=0QSPR*
M5>.10RN#V(/!%244 -BBC@A2*!%CCC4*B(,*H'   Z"FQP0PO*\42(TS;Y&5
M0"[8 R?4X 'T J2B@ K,F\-:%<79NI]%TZ6X)R9GM$+Y_P!XC-:=% " !5 4
M  #  [4M%% $-U:6U];M!>V\5Q"WWHY4#J?P/%5+7P]HMC'*ECI%A;),I218
M;9$#J>H.!R/:M&B@"H^DZ=+IR6$FGVKV<>-ELT*F-<=,+C QVJW110!!!8VE
MK-/+:VL,,EPV^9XXPIE;U8CJ?<U%J&CZ;JRJNJ:=:7JK]T7,"R8^FX&KE% %
M#^P='%FEH-*L?LR.)$A^S)L5QT8+C (]:OT56U'4+;2M.GO[^7RK:W0R2OM+
M;5'4X )/X4 6:*BM;F*]LX;JV??#/&LD;8(W*PR#@\]#4M !39(TE0K(N13J
M* ,BZL'ART>6C_454KHJIW.GI+EHOD?T[&@#)HITD;Q/MD4J:;0 4444 %2/
M_P @'5?^O9__ $%JCJ1_^0#JO_7L_P#Z"U 'FU%* 20 ,D] *UD\*ZU)&'6Q
M8 C/S.H/Y$YH R**MIIEX^HBP$#"Z)QY;$ ],]^.E=5K_A98=+@&D6@+1DM,
MY<;L8[DG]!0!Q5%:D7AS5I[>*>&T+QS8*$.O/&?7C\:4>&]6:\:U%I^^5 Y7
MS$^Z3C.<T 95%6(K"YFU#[%''FXWE-FX=1U&>G:EOK"YTVX\B]C\N3:&V[@>
M/PH K45K1>%]9GA$D=BVTC(W.JG\B<U%9Z+=W&L+8R6[K(I!D4D*0N>3S0!G
M45U_BGPY]FMX9-*M%6"!&,S[AGMR<G)KG;G2+ZTL(KRX@V6\V/+?>ISD9' .
M>E %*BKT&C7]QI[WT,&ZVC!+/O48QUXSFG6FA:C?6GVJUMC)#G&X.O7Z9S0!
MGT5>OM&O],\O[;;^7YIP@W*V?R)JROA?66A\T6+[<9P64'\LYH R**<Z-&Y2
M12K*<%6&"#5[08TFUZSCF19$:4!E89!_"@#/HKKO$GAZXN=:"Z/8*(UA4MY:
MJBYR?H,US-[876G3^3>PM$^,@'N/8]#0!7HKH_$22+IML9-$AT\;AB6-T8OQ
MT^49]ZH_\(UJ^V(BR8B;[FUU.>,\X/'XT 95%:%]H>HZ;&)+VU:-"<;@0P'X
M@G%16&F7FIR,EC TI498C  ^I/% %2BNT\+: ]O>74>LV"$[%*>:BN.IS@\B
MJ.C1-_;&HI!HT.HJLA 1V11&-QZ;A_*@#F:*T8M+O=3U&YCLK4;T=BT0=0$Y
MZ9) XZ<5+%X8UB:,O'8MM!(Y91G'ID\T 9-%/EAD@F:*9&213AE88(-:0\,Z
MP;?S_L,FS&<9&['^[G/Z4 95;7A'_D:K/_@?_H#53O-'OM/MH[B[@\N*7[C;
MU.>,] :N>$?^1JL_^!_^@-0!U]Q_Q]2_[Y_G4=27'_'U+_OG^=1T %%%% !1
M15NVL'F^9_D3]30!6CB>5]L:DFM6UL4@PS_,_P"@JQ%"D*;8UP/YT^@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***JZGJ$6DZ1>:C<*[0V<#SR+&
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MPN1WPI)^HH U+[4M1\-_&ZSANKZYDT?78-D4,LS-'%*,#Y5)P#D+T_YZ5/\
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M=^M4!KU]J6NV<TL@B<.J?N1MRI89!/4BMB[O/"NKW*7M[+-%-@;XPC?-CL<
M_H:Q]8U/3I-5MYM(LUBC@8,2%V>8<@].PX_6@#:\>7,\,EK%%/(D<B,'17(#
M<CJ.])XC_P"1$TK_ +8_^BC3-?U/0=9LQ,;F7[3%&PBCV,!N/KQCMZT6VM:-
MJ/AR'3M8DD@:%54%5)^Z, @@'MZT 3:+_P D]O?]R7^53>&[AK3P1<7$?WXO
M-=<^H'%0'7=#A\-W>GV4CQXC=(@Z,3(2.N<<9)/7%4]+UFPM_!UU8S3[;F19
M J;&.<CCG&* &>%9)M4\2(^H3R7!@C:1/,<L <@<9Z=:W[GY-<-P_B:&!4<
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MZTS4M96;QA;WVD!KORT "JC MUW#&,]#5[4[SPS>72WMZ+A;E%&^W\LJ7P.
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MGXPA3Y8UUV9E4= 2!G^5 '<4444#"BBB@ HHHH **** "BBB@ HHHH ****
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M$4*HST IU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR6S6\95=_E@]\9&3GGKS6Y10!B7/A6PU'PA!X>U9/M5O%;QQ;P-C;D4 .O\
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M0V#D9VD9&0..E '*_"?PY_8/@J&:9&6ZU$BXD#')5,8C3/LN/S-=O2 !5 4
M #  [4M PHHHH @FLX9^67#?WAUJA?6IM=#U/Y@P:V?'_?)K6JEK/_(!O_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *AO(?M-C/ .LL;)S[C%344 >,LI5BK#!!P0>U
M)75^+_#\EO<OJ-HFZ"0YE51_JV]?H:Y2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *<K%'#*<,IR#Z4VB@#1O=?U/4+?R+N[9X\\J%5<_7 &:SJ**
M"BBB@ HHHH **** "BBB@ HHHH *Z'P3;M-XA64#Y88V8GZC']:P8HI)YEBA
M1GD<X55&237I?AK1/[&T\B7!N9B&D([>B_A0!LT444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>fig03.jpg
<TEXT>
begin 644 fig03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     S<X  "2
MD@ "     S<X  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MCIT4^U>U44!8\B\!Z3:ZOXDUW4]&EUJYMVM&LX]7U.[WBZ+ 8PIC5N-O7=P
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M<]UHKF_#?C6PU_$#_P"BWF/]2YX?_=/?Z=:Z2@84444 %%%% !1110 4444
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M2O+ZZSXD79N/%SPYRMM$D8'U&[_V:N3H)84444 %%%% !1110 4444 %%%%
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MQIIH&----.--- "&FFG&FF@!IIAIYIAH$--(:4TAH ::::<::: &FD-*:0T
M----4-5L]1N_*_LS5/[/VYW_ .CK+OSC'7ICG\ZSCH_B+_H:/_*?'_C0!O&F
MFL(Z1XB_Z&C_ ,I\?^--.D>(?^AG_P#*?'_C0!NFD-81TCQ#_P!#/_Y3X_\
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M6H8F-31Z,W****XCL"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI324"$-)2FDIB$-(:4TAI@(:0TII#3$(:;3C3:8@---.--- BAJ6I_V=Y?\
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M($?=3U_'^7UK&O55*#D;4:3JSY3JK6VCL[2*V@&(XD"*/85+117SK=]3W]M
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M .@TT^$- U(?\2K4C&YZ+O#_ /CIP?UKDZ*Z*6?XJ#][7^OF9RPU*6Z-74/
MNJV>6M@EY&/^>9PW_?)_IFN<EBDAD:.9&C=3AE<8(_"NCL/$FIZ?@1W!DC'_
M "SE^8?XC\*WDUG1/$:+;ZU:K#,>%D8\#Z/U'X\5]!A.(:55\M31_P!?+\CB
MJY>MX,\\I55G8*@+,QP !DDUU&L>!KRS;S-,S>0,> /OK]?4>XKHO"_A)-)V
MWE]B2\(^4#E8OIZGWKWIXNE&',G<XH86I*?*U8D\(^&O['M?M-VH^V3#D?\
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M?R'O^7K7TL<91G#G3T/.>%JJ7+8A\(^&3JMP+R\3%E&W /\ RU([?3U_*O3
M   !@#H*9##';PI% BQQH,*JC  I]>17K2K2N]CUZ-%4HV04445@;!1110 4
M444 %%%% !1110 4444 %8VM>(8=+4Q1 2W)'W,\+[G_  J+Q'KW]G1_9K5@
M;IQR?^>8]?K7#,[.Y9V+,QR23DFO$S#,?9/V5+XNK[?\$UA"^K'W]S<:C.9K
MF5G?MD\#V [5192O45:HKYESE)WEJ:\J*E%6#$I]OI3# >QHN39D5%/\E_\
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M=G L0[D#D_4]35FM\#A:N&A:I._ET7ZBE)-Z(****]$@**** "BBB@ HHHH
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M5&Q/[J_E2]DPN4JFBAW?,_3L/6I]B?W5_*G4XTK.["X4445L(**** "BBB@
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MC4Z?=IH>IR_Z',W^CNY_U3G^'Z']#]37LM<4XN+L>U2J*I&Z"BBBH-0HHHH
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M\+^IS^%?-CNTDC/(Q9V)+,3R2>]=%&-WS'!C*EER(2BBBND\T**** "BBB@
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MYU7J^B:?>>%M+\:WFIPFWC<-';M,,"9OGQCU!W+T]?:O**T@]SFK*R3M9_\
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MO+S[9YJ:TL[:PM4MK&WCMX$&%CB0*H_ 5-4SGS/8NA1]DM[A11169T!1110
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M=<GYG/4^E/MK9;=..6/5JFK.4KG1"G;5A1114&H4444 %%%% !1110 4444
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M/6_A[HAT/P;:1RIMGN/](E&.<MT'X+@5T]%%<#=W<]V,5&*B@HHHI%!1110
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M+?\ [0UM:1^1X8\-I%$/NM<.$ _X @_]FK%UET.N.#?VF9%OX(\372YBT6[
M_P"FB;/_ $+%6Q\-O%K+D:0V/>>,?^S5C7GQ]\9W+9@-A:#TAM\_^ADUGM\;
M/'I;(UE%'H+.''_H%1[:1K]4I]V='-X!\4P*2^C7! _N%7_D361=Z5J&G_\
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MJOJ<R_40*?X1[^I_ >_;UR5:G-HCU<-0Y%S2W"BBBL3L"BBB@ HHHH ****
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M%\SM8GEBY<S6I]*T5#:7=O?V<5W93)/;S*'CEC;*N#T(-34C4**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !117*_$;QE%X)\(SWX*F\E_<V<9YW2$=<>
M@ZGZ8[T <1\9_B>=%AD\-:!/C4)4Q=SH>;="/N@]F([]A[GCYWJ6ZNI[Z\EN
MKN5IIYG,DDCG)9B<DFHJ" HHHH **** "BBB@ HHHH **** "BBB@#T_X0_$
MU_"FH+H^LRDZ-<OP['_CU<_Q#_9/<?CZY^F58,H92"",@@]:^%Z^BO@5X\;5
M]+?PUJDVZ[LDW6KN>9(1QM]RO\B/2@:9Z_11104%%%% !1110 4444 %%%%
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M&F'4+S_G[G_[^G_&@+G<T5P9U&]'_+Y/_P!_372:-KB7P$%QA+@#Z!_I[^U
M7-BBBB@84444 %%%% !1110 4444 %%%% !1110 4444 %?*_P 9O%G_  DW
MCN:"W?=8Z7FVAP>&8']XWXL,?117T3XXU_\ X1GP1JFK*<2P0$0_]=&^5/\
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M /C;QZ&'Q&\0[^O]I7'Y>8V/TKGZZ[XJVC67Q2UV)OXKCS1]'4/_ .S5R-!
M4444 %>Q7-K>:C^R[I::.DDQM[YWO4A&3L$DIY Z@%HS[ 9[5X[73^#OB!KW
M@>64Z+/&T$QS);7"EXV/][&00?<$>_2@"'2]$\577A>_OM*@OCHT8W7;1R%8
MF"@Y)7(WX .3@XKO_&W_ ";GX0_Z^5_] EKF_%/QB\4>*])?3;IK6SM9>)4L
MXV0R#T)9F./88S5K0/C=XD\.:!::18V6ER6]HFQ&FBD+D9SR1(!W]*!F_P"$
M(9;']G7Q3)J\<D5M<.3:^<I <E4"LN>H+8Y'<5<^"?C+6-;\46VBWDRKI^G:
M4Z0P1K@$AD 9O5L'Z>@KSWQC\3O$7C>WCMM5D@@M(VW_ &:U0HC-ZG))/YXK
M/\&^,=0\$:T^J:3#;33O T!6Y5F7:2#GY6!S\H[T 36/BG4O"/C#4]0T9HTN
M7::$/(F[8&?J!TSQWR/:O0/BS<S7OPG\$75W*TT\T*R22.<EV,2DD_C7C]S.
MUU=S7$@ >5V=@O0$G/%;^O>.-2\0^&M(T.]@M4MM)0) \*,'8!0OS$L0>!V
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M+W?_ .M78(BQH$10JJ,  < 4H    P!T HH*2L%%%% PHHHH **** "BBB@
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MM#_W[%'V&T_Y]8?^_8J>B@"O]@L_^?2#_OV*/[/L_P#GT@_[]#_"K%% %?\
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M%?8.O?#?PGXD=I-3T:#SVZSP9B<GU)7&?QS7!:E^SEI,SLVDZW=V@/19XEF
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-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>fig04.jpg
<TEXT>
begin 644 fig04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     S,X  "2
MD@ "     S,X  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?_OX:KT5Z1\W=EC[?>?\_<__ '\-'V^\_P"?N?\ [^&J]% 798^WWG_/W/\
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M )^Y_P#OX:KT4!=EC[?>?\_<_P#W\-'V^\_Y^Y_^_AJO10%V6/M]Y_S]S_\
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MJO10%V6/M]Y_S]S_ /?PT?;[S_G[G_[^&J]% 798^WWG_/W/_P!_#1]OO/\
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M )^Y_P#OX:KT4!=EC[?>?\_<_P#W\-'V^\_Y^Y_^_AJO10%V6/M]Y_S]S_\
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M='U/5%9M-TZ[O APQMX&DV_7 KU_X?\ Q!U7Q+XXN[*X,0TYH7>WA6,*80I
M'(Y/!YS^&*C\1>.K_0_B9:Z#H\<%MI\=Q$+B)85_?-*0S'/4??[8YSG-+GE>
MUB_8T^53YM-CQN>":UG>&YB>&5#AHY%*LI]P>E=O\)?#<.O>*WFOK=)[.QB+
MR1R*&1V;Y54@]?XC_P !K=^.MG#'J&CW:1JLL\<J.X'+!2F,_3<:W? NGW/A
MCX2W.I6MK+/J-[&UQ'%'&79B1MB&%Y(Z-^)I2G>%UU'3H\M=Q>RU$\>^%]#U
M/P#=:AX<T^R@ELI&D\RV@2,L(V*2*2 ,@88_\!%>0>%H8[CQAHT-Q&DL4E_
MCQNH964R*""#U!%>P?".+58=$U'1]>TR\MX@_F1M=0.@<.,.OS#U&?\ @1KS
M6STA]!^+5CI<F3]FU:%5)ZLOF*5/XJ0:4':\2JT>;DJ)6N=3\7/#L$6K:3;>
M'='C226*5FBL;4 O@KR0@YZUYK?:7?Z9(J:E8W-F[#*K<0M&3],BO</BKXRO
M_"RV,.C".*ZNPQ:Y9 S(BD< $$<D]_2C1[S_ (69\++S^V88OM<)DB$H3 $J
MJ&5P.W##/KSV-*,W&*;V*JT83J22>IX+11170><%%%% !1110 4444 %%%%
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M"M'P_P#\C-IG_7Y%_P"ABLZBM#G3L[GL'QY_Y@/_ &\?^TJQ_@?_ ,CM>?\
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M_H,E>?UZ!\/O^1*\;_\ 7@O_ *#)7G]1'XF;S^"'S_,****LP"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KT#QA_P DK\'?[LW\
MQ7G]>@>,/^25^#O]V;^8J);HVI_#+T_5'G]%%%68A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!Z!JG_)!=&_["C_ ,I:\_KT#5/^2"Z-_P!A
M1_Y2UY_40Z^IO6W7H@HHHJS **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBBM#G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /0/A]_R)7C?_KP7_T&2O/Z] ^'W_(E>-_^O!?_ $&2O/ZB/Q,W
MG\$/G^844459@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7H'C#_DE?@[_=F_F*\_KT#QA_R2OP=_NS?S%1+=&U/X9>GZH\_HHH
MJS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN=^(&K^$[5K&W\&VMK]MM)5D:]MTPJ[1P,CAR3@D\]*(VT5M1U>:\I.7NO\
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MZ] \8?\ )*_!W^[-_,5$MT;4_AEZ?JCS^BBBK,0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ] U3_D@NC?\ 84?^4M>?UZ!JG_)!=&_["C_R
MEKS^HAU]3>MNO1!1115F 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 7]#_Y&'3O^OJ+_ -#%='\5_P#DIFI_2'_T4E<YH?\ R,.G?]?47_H8KH_B
MO_R4S4_I#_Z*2H^V;K^"_5?J<;1115F 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZA\#/\
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M+?\ \"9?_BJ/;Q#ZE4[H^<Z*^C/^%3>#O^@6_P#X$R__ !5'_"IO!W_0+?\
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M $"W_P# F7_XJCV\0^I5.Z/G.BOHS_A4W@[_ *!;_P#@3+_\51_PJ;P=_P!
MM_\ P)E_^*H]O$/J53NCYSHKZ,_X5-X._P"@6_\ X$R__%4?\*F\'?\ 0+?_
M ,"9?_BJ/;Q#ZE4[H^<Z*^C/^%3>#O\ H%O_ .!,O_Q5'_"IO!W_ $"W_P#
MF7_XJCV\0^I5.Z/G.BOHS_A4W@[_ *!;_P#@3+_\51_PJ;P=_P! M_\ P)E_
M^*H]O$/J53NCYSHKZ,_X5-X._P"@6_\ X$R__%4?\*F\'?\ 0+?_ ,"9?_BJ
M/;Q#ZE4[H^<Z*^C/^%3>#O\ H%O_ .!,O_Q5'_"IO!W_ $"W_P# F7_XJCV\
M0^I5.Z/G.O0/&'_)*_!W^[-_,5Z9_P *F\'?] M__ F7_P"*JGXLM_A_H]AI
MFC>*&:""W1FM(OW[8!//*9[^IK.>(A&TI:(Z</EV(JMTZ4>:36RNWWZ(^?Z*
M]LT;P_\ "OQ!]I_LA'N/LL7FS?/<KL7U^;&?PK,W_!?_ )[O^5W_ (4OKM!*
M[E^*-HY!F4I."I2;6ZY975]KZ'DU%>V:SX?^%?A_[-_:Z/;_ &J+S8?GN6WK
MZ_+G'XT:-X?^%?B#[3_9"/<?98O-F^>Y78OK\V,_A3^MT>;EOK\C/^Q,?[/V
MWLWR][.W;>UMSQ.BO6=_P7_Y[O\ E=_X5IZSX?\ A7X?^S?VNCV_VJ+S8?GN
M6WKZ_+G'XTOKM!JZE^*-)9!F49*#I23>RY97=M[:'B=%>V:+X?\ A7XA:Y&C
MH]P;6+S9OGN4VKZ_-C/X5F;_ (+_ //=_P KO_"CZ[02NY?B@CD&92DX*E)M
M;KEE=7VOH>345[9K'A_X5Z MJ=71[<7<7FP?/<MO7U^7..O>C1?#_P *_$+7
M(T='N#:Q>;-\]RFU?7YL9_"G];H\W+?7Y&?]B8_V?MO9OE[V=NV]K;GB=%>L
M[_@O_P ]W_*[_P *T]8\/_"O0%M3JZ/;B[B\V#Y[EMZ^ORYQU[TOKM!JZE^*
M-)9!F49*$J4DWLN65W;>VAXG17MFB^'_ (5^(6N1HZ/<&UB\V;Y[E-J^OS8S
M^%9F_P""_P#SW?\ *[_PH^NT$KN7XH(Y!F4I."I2;6ZY975]KZ'DU%>V:QX?
M^%>@+:G5T>W%W%YL'SW+;U]?ESCKWHT7P_\ "OQ"UR-'1[@VL7FS?/<IM7U^
M;&?PI_6Z/-RWU^1G_8F/]G[;V;Y>]G;MO:VYXG17K._X+_\ /=_RN_\ "M/6
M/#_PKT!;4ZNCVXNXO-@^>Y;>OK\N<=>]+Z[0:NI?BC2609E&2A*E)-[+EE=V
MWMH>)T5[9HOA_P"%?B%KD:.CW!M8O-F^>Y3:OK\V,_A69O\ @O\ \]W_ "N_
M\*/KM!*[E^*".09E*3@J4FUNN65U?:^AY-17MFL>'_A7H"VIU='MQ=Q>;!\]
MRV]?7Y<XZ]Z-%\/_  K\0M<C1T>X-K%YLWSW*;5]?FQG\*?UNCS<M]?D9_V)
MC_9^V]F^7O9V[;VMN>)T5ZSO^"__ #W?\KO_  K3UCP_\*] 6U.KH]N+N+S8
M/GN6WKZ_+G'7O2^NT&KJ7XHTED&91DH2I23>RY97=M[:'B=%>V:+X?\ A7XA
M:Y&CH]P;6+S9OGN4VKZ_-C/X5F;_ (+_ //=_P KO_"CZ[02NY?B@CD&92DX
M*E)M;KEE=7VOH>345[9K'A_X5Z MJ=71[<7<7FP?/<MO7U^7..O>C1?#_P *
M_$+7(T='N#:Q>;-\]RFU?7YL9_"G];H\W+?7Y&?]B8_V?MO9OE[V=NV]K;GB
M=%>M>9\%MN/.;/KB\_PKK+/X8^!]0L;>\M-/>2WN(EEB?[1*-RL,@X+9'![T
M1Q=*?PNXJ^2X[#).O3<4^Z:_-'SS17T9_P *F\'?] M__ F7_P"*H_X5-X._
MZ!;_ /@3+_\ %5I[>)R_4JG='SG17T9_PJ;P=_T"W_\  F7_ .*H_P"%3>#O
M^@6__@3+_P#%4>WB'U*IW1\YT5]&?\*F\'?] M__  )E_P#BJ/\ A4W@[_H%
MO_X$R_\ Q5'MXA]2J=T?.=%?1G_"IO!W_0+?_P "9?\ XJC_ (5-X._Z!;_^
M!,O_ ,51[>(?4JG='SG17T9_PJ;P=_T"W_\  F7_ .*H_P"%3>#O^@6__@3+
M_P#%4>WB'U*IW1\YT5]&?\*F\'?] M__  )E_P#BJ/\ A4W@[_H%O_X$R_\
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M\_KZ=E\">'I_#T&B263&P@E,T<7G/PYSSG.?XCWK._X5-X._Z!;_ /@3+_\
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M+_\ %4?\*F\'?] M_P#P)E_^*H]O$/J53NCYSHKZ,_X5-X._Z!;_ /@3+_\
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M_P"@6_\ X$R__%4?\*F\'?\ 0+?_ ,"9?_BJ/;Q#ZE4[H^<Z*^C/^%3>#O\
MH%O_ .!,O_Q5'_"IO!W_ $"W_P# F7_XJCV\0^I5.Z/G.BOHS_A4W@[_ *!;
M_P#@3+_\51_PJ;P=_P! M_\ P)E_^*H]O$/J53NCYSHKZ,_X5-X._P"@6_\
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M_P! M_\ P)E_^*H]O$/J53NCYSHKZ,_X5-X._P"@6_\ X$R__%4?\*F\'?\
M0+?_ ,"9?_BJ/;Q#ZE4[H^<Z*^C/^%3>#O\ H%O_ .!,O_Q5'_"IO!W_ $"W
M_P# F7_XJCV\0^I5.Z/G.BOHS_A4W@[_ *!;_P#@3+_\51_PJ;P=_P! M_\
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M!_A1_;%[_P ]1_WP/\*I44!=EW^V+W_GJ/\ O@?X4?VQ>_\ /4?]\#_"J5%
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M2HKH/)NR[_;%[_SU'_? _P */[8O?^>H_P"^!_A5*B@+LN_VQ>_\]1_WP/\
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MW_GJ/^^!_A5*B@+LN_VQ>_\ /4?]\#_"C^V+W_GJ/^^!_A5*B@+LN_VQ>_\
M/4?]\#_"C^V+W_GJ/^^!_A5*B@+LN_VQ>_\ /4?]\#_"C^V+W_GJ/^^!_A5*
MB@+LN_VQ>_\ /4?]\#_"C^V+W_GJ/^^!_A5*B@+LN_VQ>_\ /4?]\#_"C^V+
MW_GJ/^^!_A5*B@+LN_VQ>_\ /4?]\#_"C^V+W_GJ/^^!_A5*B@+LN_VQ>_\
M/4?]\#_"C^V+W_GJ/^^!_A5*B@+LN_VQ>_\ /4?]\#_"C^V+W_GJ/^^!_A5*
MB@+LN_VQ>_\ /4?]\#_"C^V+W_GJ/^^!_A5*B@+LN_VQ>_\ /4?]\#_"C^V+
MW_GJ/^^!_A5*B@+LN_VQ>_\ /4?]\#_"C^V+W_GJ/^^!_A5*B@+LN_VQ>_\
M/4?]\#_"C^V+W_GJ/^^!_A5*B@+LN_VQ>_\ /4?]\#_"C^V+W_GJ/^^!_A5*
MB@+LN_VQ>_\ /4?]\#_"C^V+W_GJ/^^!_A5*B@+LN_VQ>_\ /4?]\#_"C^V+
MW_GJ/^^!_A5*B@+LN_VQ>_\ /4?]\#_"C^V+W_GJ/^^!_A5*B@+LN_VQ>_\
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MW_GJ/^^!_A1_;%[_ ,]1_P!\#_"J5% 79=_MB]_YZC_O@?X4?VQ>_P#/4?\
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M!=>(/AMJDFH-ON+>&:%I,??'EY!/OSC\*K?!W_D 7_\ U]#_ -!%,"])\5=
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M,5B)R>_WS7/6M>%^_P"C/7RUU%#$>S2?[MWN]ES1U7=[:'0T445T'D!1110
M51U76;#1((YM4G\B*201JY1F&X] < XZ=ZO5C^*M'&N^&+VQ S(\>Z+V=>5_
M48_&@9JS31V\$DTS!(XU+NQ[ #)-<'\0]3M-8^'(O=.E,MO)<)L<HRYP2#PP
M!ZBJE_XDFU3X8V%I;G=J.HR+I[+WR#AB?J,9_P!ZKGQ#L(M+^&D-C;_ZNWDB
MC4^N,\_C2 [$7EOI^BQW-[,D$$<*EI'. .!65#X]\,SI*T6JH1"I9P8W!P.N
M 5R?PS6#XK4:AK7A/2+KFQG;S)4S@2%0, _J/^!5H?$#0].D\%W<HM(8I+5
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MNE2N5M+Z2!9P#C< J #/_ C^E '20>//#-PTJQ:K&3$C.P,;C(4$G&1\W /
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MH&,UC_DLWA__ *])?_09:Z?5_$&EZ#&CZM>);A_N@@LS?0 $US&L?\EF\/\
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M,\9^']7NA;:?J4<DS<*C*R%OIN S^%7K_6+#3)[:&_N%@>Z8K%N4X8@9.3C
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M'Y3$X4]CD#FNBHH *Y[PSH-UHVH:W/=20NNH7K7$0C8DJI).&R!SSVS70T4
M<YXF\-3ZM=6FI:1>?8M5LL^5*PRKJ>JM[=?7J>.:H6_A;6]4UJTO_%M_:S1V
M+;X;6T4["_\ >)('M7944#"N2U[POJDOB6+7_#E[!;WHB\J2.Y4E'7\ 3_\
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MWS_]>@+,RJ*U?[%C_P"?U/\ OG_Z]']BQ_\ /ZG_ 'S_ /7H"S(]-_X\;_\
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MZW/,LS*HK5_L6/\ Y_4_[Y_^O1_8L?\ S^I_WS_]>@+,RJ*U?[%C_P"?U/\
MOG_Z]']BQ_\ /ZG_ 'S_ /7H"S,JBM7^Q8_^?U/^^?\ Z]']BQ_\_J?]\_\
MUZ LS*HK5_L6/_G]3_OG_P"O1_8L?_/ZG_?/_P!>@+,RJ*U?[%C_ .?U/^^?
M_KT?V+'_ ,_J?]\__7H"S,JBM7^Q8_\ G]3_ +Y_^O1_8L?_ #^I_P!\_P#U
MZ LS*HK5_L6/_G]3_OG_ .O1_8L?_/ZG_?/_ ->@+,RJ*U?[%C_Y_4_[Y_\
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M .?U/^^?_KT!9F516K_8L?\ S^I_WS_]>C^Q8_\ G]3_ +Y_^O0%F95%:O\
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M %Z LS*HK5_L6/\ Y_4_[Y_^O1_8L?\ S^I_WS_]>@+,RJ*U?[%C_P"?U/\
MOG_Z]']BQ_\ /ZG_ 'S_ /7H"S,JBM7^Q8_^?U/^^?\ Z]']BQ_\_J?]\_\
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MG_?/_P!>@+,RJ*U?[%C_ .?U/^^?_KT?V+'_ ,_J?]\__7H"S,JBM7^Q8_\
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MHXQU7[H3'8YX.>E<-;:IXC\1^"-2U#3X]'T+1C%.6CCBW22 *=V?X1GIG -
M'9Z+XULM>\(W>N6,3YM(Y#+;NV&5E7=MSZ$8Y_\ U5REI\96O[%VLO#%W<W<
M99GA@E+JD8 ^<L$XYSQCMUYK.^&/_),/$_\ NR_^B:T?@8BCP]J;A1O:Z )[
MD!!C^9_.@"Q;?&.TOM-4V&BWEUJC,1]@A^;@#.[< >/PS[5L^"?B%:^,)[BT
M-G)8WMNN]H7?>"N<$@X'0D @CN*XKX)Q(/$&N,% *1JJGT!<\?H/RIW@T;?C
MQK@7@%KG.._S@T ;NI_%N'2_$U_I$^CRR&U8QQ/%-N:9\C V[>,Y]3T[U)I'
MQ7AN=>32=?T:YT2:5@L9G8GD]-P*J5SZ\US&C&W'[0MY]IV9\Z81;O[^SC'O
MC-6?CGY7VC1/*_X_/WOW?O;<KC]<X_&@!OQ?_P"1V\/_ .Z/_1E=YXP\;Z?X
M/MXOM,<ES=W'^IMHOO-[D]A^?TKS_P"+'F?\)=X:\_\ UOEIO^OF#-5_B&-1
MD^,=@EE<QVUSLA%I+< %$.3@\@_Q9['F@#K-,^*T;ZM#8>(]#N]#>X($3S$E
M3GH3E5('OS7H->1:[\/O'_B:.&/6]:TJZ6 EH^"FTGKRL0]*]6L8YH=/MX[I
M@TR1*LC*<@L ,G/&>:!D]%%% !1110 4444 %%%% %BW_P!1/_N_XU7JQ;_Z
MB?\ W?\ &J] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%% !1110 4444 %%%% %A_\ D'I_O_XU7JP__(/3_?\ \:KT %%%% !1110
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M\&_\(7IMS:?;_MOGS>;O\GR]O &,;CZ5T]% ''^"? /_  AU_?W/]I?;/M@
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MR\955QC8?[OZT]+&;;YTO4Y;_A$?$G_0OZK_ . 4G_Q-'_"(^)/^A?U7_P
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MO[/PO_/E?=_P3>_X6)XT_P"@C;?^0?\ &NX^''CZ\\17<^E:TL9O(D,L<\8
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MK@X%>4P3FZMX[AEV&50Y7TR,XK[!KYS\/?#;6/%=C-?Z=<V,42SM$1/(X;(
M;LIXPPIV=B&US)'&T5Z1_P *0\2?\_NE?]_9/_C='_"D/$G_ #^Z5_W]D_\
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M *YU[1'(DL:R1,KHX#*RG(8'H0: .>\:>,;7P=I"W,\9GN)B4MX <;R.I)[
M<9^HKE+8_%76[?\ M""ZL-*B<;X[66-=Q'8<HQ'XD52^*NV#X@^&;K4!_P 2
MY63S"P^7"R@O_P".D5ZTK!E#*001D$=Z!'#^#_$GBJXUV;1/%.CE9(4WF]B
M5 .V><'/;;^74B[\1O%$OA;PH]Q92".^G<16Y(#;3U+8/!P ?Q(KJA(AD:,.
MI=0"R@\@'H<?@?RKQ;X@:WIVK_%"RT_5KH0Z1I; 3MM9@6^\XPH)YPJ].U '
M6_"SQE>^)K&]M=:G\W4+60-N**A:,].% '!!_,4_XK>(]5\-:'97&BW7V:66
MXV.WEH^5VDX^8&N(A\3:/I?QBCU;0;T2Z;J)"W.(W0(7X;(8#^(!ZZ/XY?\
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M2KRLRR#C@;3RWUP!7->%='U*W^-6L7UQIUW%:2-<;+AX&6-LN,88C!S7JM%
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M(OBZ;PGH<36"*U[=R&.)G&5C &68COC@ >IKRO\ X3SQ>W)\1)D\_P#+(?\
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M_"3:Y_?T[_ORW_QRM?P_X@EU.XEM+V*-+B-!(K1$[9%S@G!Z$''&3U'-<O\
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M %C?2JM6K'_6-]* *M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3/"FEV-[I-^;FULXHI=L2MEU0 \[N>10,SXA<:@VS34^URLVT%6^1#T)9N@
M[]_8UVUEH\5GH"Z6)'=/*9'D/5BV2S>V22<=!TJOI7B#3;V86L2265PV66WN
M(_+9_4CLWO@DCO6Q3)/(Y].U73)3:WEE=L\? D@@>2.0=F!4$#/H>1^ICQ>?
M\^6H_P#@'+_\37HMWXOT>SO)+5IY)I8CMD$$#R!#Z%@,9]LY%0_\)MI'_3W_
M . DG^%>)/+\)S.\[>5T8.G"^YP&+S_GRU'_ , Y?_B:,7G_ #Y:C_X!R_\
MQ-=__P )MI'_ $]_^ DG^%'_  F^D#K]L_\  23_  J/[/P?_/S\4+V<.YG^
M!]'O+>XN=3OX9(!+&L4$<H*N5R2S,#R,G  //!SUKL:J:=J=GJUH+G3YQ-'G
M:>"I4]PRG!4^Q&:MU[-&G&E34(;(W225D%%%%:C"BBB@ HHHH R_&&K#0_ 6
MH:BUK%=B%X_W,WW6RZ+S],Y_"IM$N_M_A_3KP1+"+BUBE\I/NIN0' ]AG%0^
M,-(.N^ M0TY;F*U,SQ_O9C\JX=&Y_+'XU-HEI_9_A_3K,R+*;>UBB\Q/NOM0
M#(]CBL5S>U?:WXGHR]A_9\;?Q.=]_AY5;RWOYEZBBBMCS@(#*0PR#P0>]<%<
MP3:??26\ARR<@@8#*>AQ@?IT.17>U7O;2UNH"+U%*)\VYCC9[Y[4 <1]I;^Z
M*/M+?W16W##X72%474;60*,;FO Q/U.>:?Y?AC_G^L__  *7_&D.Y@_:6_NB
MN.N_%GB&3Q)=Z9H]C9S_ &?Y@'!!V\<DEP.IKT_R_#'_ #_6?_@4O^->27%I
M<W7Q2UF/PWJMA8X3<)[J0>6R?)E0=K G)'Y&@+F]HVJ>)YK_ &ZUIMK;VVPG
M?$V3N[#[Y_E6K/K=G;3>5<W=K#)_<DE"G\B:@TBUO=+T_5;CQ)KVD:@R6S/:
M1VLZY#@$\@*N<\>M<]X*\*>&?$/A2\O?$&HI'J4TKJLLER$,. "&VDC/)R<_
MI0%SL1=%E!4*0>00>M+]I;^Z*M>'=)\,Z1HL5G_;MM?A,XF>Y0<>@P>GYUJ>
M7X8_Y_K/_P "E_QH"Y@_:6_NBC[2W]T5O>7X8_Y_K/\ \"E_QI?+\,?\_MG_
M .!2_P"- 7,#[2W]T4AN'/  'TK&\ :U;ZQJVM1:[>VWDVY3[/N=8^KR@\\9
MX5?\FNXAT[PY>WZ""ZAN)%4_Z/'=[@P]2@/.*!F=X6LC?:H^HNBO:VZM'"[+
MG?(3ABI] !M[@DD?PFO'OBFDME\2-2WQ;4E\N1., J4 R/Q!'X&OI%$2*-4C
M5411A548 'H!63K_ (6T3Q+%&NN6,=QY.=CEBC)Z@,I!Q[=*Z,/5]C/F*IU.
M25SY5^UG^X/SH^UG^X/SKZ)_X5;X$_Y\%_\  R3_ .*H_P"%6^!/^?!?_ R3
M_P"*KTO[1CV9U?64?.WVL_W!^=;W@=)]1\>Z)!;P[R+V.5@.RHVYC^ !KVO_
M (5;X$_Y\%_\#)/_ (JMSP]X0\/>'&>;0K".&208:;>9&(] S$D#V%9U<<IP
M<4MR98A.+2.)^.%O(ND:3<Q1?NX[AT=@.A91C/\ WR:\:^T?[/ZU]8WUC:ZE
M926E_!'<6\HP\<BY!%<@WPO\#AB#8@'N#>2<?^/5X-6BYRNCULMSB&$H^RG%
MO7H?/WVC_9_6C[1_L_K7T!_PK#P-_P ^0_\  V3_ .*H_P"%8>!O^?(?^!LG
M_P 56?U:7<]+_6*C_(_P/GXS,PVHA9FX '))] *^K=)@>VT6R@F&)(K>-&'H
M0H!K!TCX?^$M+OTO=.TZ-KB(Y1GF>78?4!B1GWZUU-;TJ?LT[GAYIF*QTH\J
MLE^H4445L>.%%%% !1110!8?_D'I_O\ ^-5ZL/\ \@]/]_\ QJO0 4444 %%
M%% !1110!PVO^%M2;6+B\TU/M$5RPD95D"LC8 (Y(!'&<YS[5F?\(WK_ /T#
MYO\ O_%_\771:KXHO(]4GM--6W1;=@CR7"EMS8!( #+@#(YSZU3_ .$FUO\
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MU\VWE?[[Q9 (;U920,]P5ZG)KSCXPZO>W7BB#0E:;[#% DSPPC)D=BW)'?
MQ^-;>IS:_+?6J>%7872AWD160$QX SA^"-Q6O.?%ESXAM/%[RZZ[QZ@+= "=
MF=GS8^[QZUV8.*E629K12=0RO[/3_GUO_P#OR*/[/3_GUO\ _OR*?_;VI_\
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MM=J,M YSD?WE/<?KZ@5ITQ!1110 4444 %%%% !1110 4444 %%%% !1110
MZ/\ UB_45)=_\?3?A_*HX_\ 6+]14EW_ ,?3?A_*@"&BBB@ HHHH **** "N
M!^#O_(GW7_7^_P#Z+CKOJX'X._\ (GW7_7^__HN.K7PLPE_%C\_T.^HHHJ#<
M*X'X@_\ (X>#/^O\_P#HR&N^K@?B#_R.'@S_ *_S_P"C(:NG\1A7_A_=^9W%
MS=VUE#YMY<16\><;Y7"C/IDU2_X231/^@O8_^!"_XUXU\3[VYU/Q]-92B6:W
MLU5(X(STRH8MC!YYZX[5RW]GC_H&W_YC_P"(KCE7Y962/J<+DCKT8U93M?R_
MX*/H[_A)-$_Z"]C_ .!"_P"-'_"2:)_T%['_ ,"%_P :^<?[/'_0-O\ \Q_\
M11_9X_Z!M_\ F/\ XBI^L/L=/^KT?^?OX+_,^EK35=/OW*6-];7#@9*Q2JQ
M]< U;KY=CDN=%OK>_L(KJRGA?<DDG<CM]T<>H[U]/6TWVBUBFQM\Q ^/3(S6
MU.ISH\?,,O>"E%<UTR2BBBM3S HHHH **** "BBB@ HHHH **** "BBB@ JU
M8_ZQOI56K5C_ *QOI0!5HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH L6_^HG_ -W_ !JO5BW_ -1/_N_XU7H
M**** "BBB@ HHHH **** .5^).AW?B#P'?66G+YER"DL<8ZOM8$@>^ <>]?,
MTGVF&1HY0Z.AVLK#!!]".U?8=-,:,<LBD^I%==#$RHII(VIU7!6/CSS)O[QH
M\R;^\:^PO)C_ .>:?]\BCR8_^>:?]\BNC^T)?RFOUE]CY A2[NIT@MTDEED.
MU(XUW,Q] !UKZ@\!:+<>'_ NF:;>\7$<;/*O]UG8N5_#=C\*Z!8T4Y5%!]A3
MJYJ^)E6LFMC&I5<PHHHKE,@HHHH **** "BBB@ KF;/2]'B^)>HZC;ZKYNK3
M6JI/88_U2 18;/\ P%?^^JZ:N!TJVG7XZZ[<-#(L+Z>@60H=K';!P#T['\JP
MK.SAIU_1GJY=%RAB+2M:F^VOO1TU_370[ZHKFVAO+62WNHUEAD7:Z,."*EHK
M<\HX^7PGJ$%RJ6EQ!<6I/WKAV66,=AP"'/O\OOD\U-_PBUW_ ,]H?S/^%=51
M0%SE?^$6N_\ GM#^9_PH_P"$6N_^>T/YG_"NJHH"YRO_  BUW_SVA_,_X4?\
M(M=_\]H?S/\ A7544!<Y7_A%KO\ Y[0_F?\ "C_A%KO_ )[0_F?\*ZJB@+G*
M_P#"+7?_ #VA_,_X4?\ "+7?_/:'\S_A7544!<Y7_A%KO_GM#^9_PH_X1:[_
M .>L/_?1_P *ZJB@+G)6?A&YN'_XG,T*0!N;>V9F\T=MSD @'NH'_ L$BNIE
M@CFMW@=?W;H4*CC@C&*DHH \NN/"FNV$QMX[%[^).([B&1!O7MN#,"&]>,>A
M["/^P=>_Z EU_P!_(O\ XNO5:*\V668>3OJ9>RB>5?V#KW_0$NO^_D7_ ,71
M_8&O?] 2Z_[^1?\ Q=>JT5/]EX?S^\/91.6\'>';K2VN+[4E$=Q.JQI &#&)
M 2>2.-Q)YP2!@<GFNIHHKT:=.-."A'9&B22L@HHHJQA1110 4444 9?C#2#K
MO@+4-.6YBM3,\?[V8_*N'1N?RQ^-3:):?V?X?TZS,BRFWM8HO,3[K[4 R/8X
MK(^)_P#R2;5_]^'_ -'1U?\ "?\ R)>B?]@^#_T6M<Z:]NU;6WZL]>49_P!E
M1ES>[[1Z6Z\L=;_H:U%%%=!Y 5Q6J^'[G3)I)=/MVN+%R7\N%<O;DG) 4?>7
MT"\CI@CIVM% ' Q6-Y-"LB6=R%89 >!E/X@C(_&G?V9??\^DW_?LUWE% [G!
M_P!F7W_/I-_W[-']F7W_ #Z3?]^S7>44!<X/^S+[_GTF_P"_9H_LR^_Y])O^
M_9KO** N<'_9E]_SZ3?]^S1_9E]_SZ3?]^S7>44!<X/^S+[_ )])O^_9H_LR
M^_Y])O\ OV:[RB@+G!_V9??\^DW_ '[-1/:7JW"0)I]W)*X)4+"P7\7.%'XD
M5Z#10%S%\.Z(^F))<7I1KR< -L)*Q*.B GKUR3@9/T%>3_&[0=0C\0PZ[!&[
MV<ENL+R*,B-U)X;TR",'ZU[E1UZUK2J.E-214)N$KH^.O,F_O&CS)O[QK["\
MF/\ YYI_WR*/)C_YYI_WR*[O[0E_*='UE]CX]\R;^\:ZSX<:#J.N^-=.DA23
M[-97"7$\VWY4"'< 3ZD@#'OGM7TMY,?_ #S3_OD4X*%&%  ] *BICI3BXVW)
MEB&U:QYW\8]"OM5\/6EWIT3S&QE9I8T&6V,.6 [X('X$GM7A/G/_ 'J^NZ:8
MHR<F-2?]VO(J45-W/1P.;U,'3]FHW1\C><_]ZCSG_O5]<>3'_P \T_[Y%'DQ
M_P#/-/\ OD5'U9=SO_UCJ?\ /M?>?*.G:??ZW?QV&F1-/<3':JJ.GN?0#N:^
MJK"V^Q:=;6H;=Y$2QY]< #^E3*BI]U0OT%+6M.FJ:/(S#,)XZ47)62"BBBM3
MS0HHHH **** +#_\@]/]_P#QJO5A_P#D'I_O_P"-5Z "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "L+6/$#VMRUCIL:2W2IEY)#^[A)Z;
M@.6/?:,<=QD5NUY[8S&3SVDD\R22XE9F(QD[R,?AC'X4 B[<W^H7<8BOX[2_
MMVYDA,9C;.."C9.TCWR?<=:SY(O*A:XM7>YLT.)"PQ-:\#B1>I_WA_\ 7K2A
MD5&.]=P/'N/I2S6N9%N[24Q3)]V= ,@?W2.A'L>*112BN 5&X[E/1A5^&YPN
MR0>9&>WI6<UMY]QMMXX[.]8Y:U+8@N3CK$W\#G^Z>/\ T*HX;@J[H0R.AQ)$
MXPR'T([4 :US91W$8=68A3N21#AXSZ@CD5;L/$+VC"#6W!C)Q'> 84^SXX4^
M_0^W?-M[DJ=T38/<5;VQ7:D*%#$?-&>C4 =6"&4%3D'D$=Z*X^TN[K0V(MT:
MXM.=UJ3AD/JA/X_*>.>"._3V.H6VI6PGLY1(F<'C!4^A!Y!]C3)+-%%% !11
M10 4444 %%%% !1110 4444 .C_UB_45)=_\?3?A_*HX_P#6+]14EW_Q]-^'
M\J (:*** "BBB@""\>[2W)T^"&>;(PD\QB7'?Y@K']*SOM/B3_H$Z5_X-)/_
M )'K8HH Q_M/B3_H$Z5_X-)/_D>N)^%,VL)X5N1I]C8SQ_;6RT]Z\3 [$XP(
MFXZ<Y_"O3JX'X._\B?=?]?[_ /HN.K7PLQE_$C\_T.F^T^)/^@3I7_@TD_\
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MWD82ZF:15.0"!UKZ?TW_ )!5I_UQ3_T$5\K:=9WFL:C#8:?&T]Q.P143^9]
M.YKZNMX?L]K%#G=Y:!,XZX&*[,,G9MGR'$,H.=.,>B?Z$E%%%=1\P%%%% !1
M110 4444 %%%% !1110 4444 %6K'_6-]*JU:L?]8WTH JT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6+?\
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M "#T_P!__&J]6'_Y!Z?[_P#C5>@ HHHH **** "BBB@ HHHH **** "BBB@
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M,I*/1AW'Z^AJA!=*T:L&#HPRK YR*T(+DHNT_/&>QH W-*UV._?[/<Q_9KP
MYB8Y#@=2A[C]1W%:M<-J#K';FZ3Y&@_>Q-W!7G']/QKMXG\V%),%=RAL'J,T
MR6.HHHH **** "BBB@ HHHH **** '1_ZQ?J*DN_^/IOP_E4<?\ K%^HJ2[_
M ./IOP_E0!#1110 4444 %%%% !7 _!W_D3[K_K_ '_]%QUWU<#\'?\ D3[K
M_K_?_P!%QU:^%F$OXL?G^AWU%%%0;A7 _$'_ )'#P9_U_G_T9#7?5P/Q!_Y'
M#P9_U_G_ -&0U=/XC"O_  _N_,[>\@M+BW*W\4,L(.2)E!7/KSQ67]A\+_\
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M]8WTH JT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[_C5>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&C[--_<-8OVVZ_Y^9O\ OX:/MMU_S\S?]_#0%S:^S3?W#1]FF_N&L7[;=?\
M/S-_W\-'VVZ_Y^9O^_AH"YM?9IO[AH^S3?W#6+]MNO\ GYF_[^&C[;=?\_,W
M_?PT!<VOLTW]PT?9IO[AK%^VW7_/S-_W\-'VVZ_Y^9O^_AH"YM?9IO[AH^S3
M?W#6+]MNO^?F;_OX:/MMU_S\S?\ ?PT!<VOLTW]PT?9IO[AK%^VW7_/S-_W\
M-'VVZ_Y^9O\ OX: N;7V:;^X:/LTW]PUB_;;K_GYF_[^&C[;=?\ /S-_W\-
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M7_/S-_W\-'VVZ_Y^9O\ OX: N;7V:;^X:/LTW]PUB_;;K_GYF_[^&C[;=?\
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M\!_D*K0?\?,7^^/YU9UC_D*2_P# ?Y"@?0I45POQ'M8KZ\\-VEP"T,^HK%(
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M3Q66EE\42VHC;/EPQJ-ZG/JO&.W<URO@*+^Q?B-KFDR\;@QCS_$ V5_\=;-
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MQGJ: .2\6W>O75SHC:WIMM80C4(_+5)_,DSGG)'&*W-:_P"2M^'/^O>?_P!
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M0****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5ST'B74;OXAWWA^9HS865HLL2A,,&*Q$Y/?[YKH:PX=,TB'QW=ZA;ZIYNJS6
MJI<6./\ 4J%CPV?<!?\ OJL:O->-GU_S/3P'LN2O[2-_<=M+V=XZ^6E]3<HK
M*\2ZPNA>'[J^\R%)40^2LS8#O@D+U&3QT'I7.7GBNX?X72:K8:A"VIQ10F5H
MMC&)F=005Y X)X(K8\T[BBLJVUW3TM;1+[4K2.ZEA1C'),BL25!^[FM6@04A
M 92& ((P0>]4H]:TJ6Z%M%J5F]P3@1+.I?/TSFK%S=VUE&KWEQ%;HS!%:5PH
M+'H 3W]J ,*3P!X7DNC.VD1;R<X5W"_]\@X_2N@BBC@A6*"-8XT&%1%P%'H
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MGBMH6EN94BC7EGD8*!^)J&SU.PU'=_9][;76W[WD2J^/K@T"+5%%% !1110
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MNR1.&5NW!'%-AO;6XN)H(+F&6: @2QI("T>>FX#D?C0(GHHHH **** )(/\
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MNY_B4NFPW2R::UAYZHBJ06SU#8S^N*!G5T444""BBB@ HHHH **** "BBB@
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MM+I5$,F]3NQCL#D=.XJ3QUX?O->TZT.G>7)-9W F$$IPLH]#_GUH X[Q)?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVEM,UM'9NKS",E%/S\%N@/(IOB*RNI_B#X;N8;::2"'S/-E2,E8\CC)Z#\:
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MU= _X^I?]S^M95:N@?\ 'U+_ +G]:!K<RJ***!!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &CIO\ QXW_ /US']:S
MJT=-_P"/&_\ ^N8_K6=0/H%%%% @HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"2#_CYB_WQ_.K.L?\ (4E_X#_(56@_X^8O]\?SJSK'_(4E_P"
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M?>CIK^FNAV=%%%;GD!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!!XFTPZS\-]1L!/';F6:/][*?E7#H>?RQ4
M6D6OV+1+&U,BR>1;QQ[TZ-M4#(]N*K?$#_DD&K_]=HO_ $;'3O#7_(IZ1_UY
M0_\ H KG37MVK:V7YL]B4:G]E1ES>[[1Z6Z\L=;_ *&G11170>.%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% $D'_ !\Q?[X_G5G6/^0I+_P'^0JM!_Q\Q?[X_G5G6/\ D*2_\!_D
M*!]"E1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *U= _X^I?]S^M95:N@?\?4O^Y_6@:W
M)_LVG?\ /LW_ 'V?\:/LVG?\^S?]]G_&DHI%"_9M._Y]F_[[/^-'V;3O^?9O
M^^S_ (TE% "_9M._Y]F_[[/^-'V;3O\ GV;_ +[/^-)10 OV;3O^?9O^^S_C
M1]FT[_GV;_OL_P"-)10 OV;3O^?9O^^S_C1]FT[_ )]F_P"^S_C244 +]FT[
M_GV;_OL_XT?9M._Y]F_[[/\ C244 +]FT[_GV;_OL_XT?9M._P"?9O\ OL_X
MTE% "_9M._Y]F_[[/^-'V;3O^?9O^^S_ (TE% "_9M._Y]F_[[/^-'V;3O\
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MTE% "_9M._Y]F_[[/^-'V;3O^?9O^^S_ (TE% "_9M._Y]F_[[/^-'V;3O\
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M[[/^-'V;3O\ GV;_ +[/^-)10 OV;3O^?9O^^S_C1]FT[_GV;_OL_P"-)10
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MTE% "_9M._Y]F_[[/^-'V;3O^?9O^^S_ (TE% "_9M._Y]F_[[/^-'V;3O\
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MO^^S_C244 +]FT[_ )]F_P"^S_C1]FT[_GV;_OL_XTE% "_9M._Y]F_[[/\
MC1]FT[_GV;_OL_XTE% "_9M._P"?9O\ OL_XT?9M._Y]F_[[/^-)10 OV;3O
M^?9O^^S_ (T?9M._Y]F_[[/^-)10 OV;3O\ GV;_ +[/^-'V;3O^?9O^^S_C
M244 +]FT[_GV;_OL_P"-'V;3O^?9O^^S_C244 +]FT[_ )]F_P"^S_C1]FT[
M_GV;_OL_XTE% "_9M._Y]F_[[/\ C1]FT[_GV;_OL_XTE% "_9M._P"?9O\
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MW (C!.!P>,G!Z\ #WH&=W17E%UXJ\:^!=2LV\8S6NI:?=MM9X$4%,8SC"KR
M<X((/K6C\0O'6HZ1J^G:-H$EM;S7L:RF\G(VJK,57KP!P22<T >C45YC::A\
M2-(UJR6_$'B"QN#EWLT7:%S@_.%7!YR,\&O3J "BBB@ HHHH **** +%O_J)
M_P#=_P :KU8M_P#43_[O^-5Z "LKQ-K?_".>&[O5OL_VG[,H;RM^S=E@.N#C
MKZ5YVOQBNV\:C3_[-A_LXW/V?^(S?>V[LYQ[XQ[9KK_B9_R3?5_^N:?^C%H
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M_@P(_"O//V:_^1;UK_K[3_T"JYO>5BN;WE8]IKPZ_P#VD/L.I7-I_P (KO\
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M '?\:KT 8G_"&^'_ .W_ .VO[+A_M#?O\[+8W?WMN=N[OG&:H?$S_DF^K_\
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M;32C#.&9CCT&2<#V&*VJ** //?AO_P C5XV_["C?^AR5-\1O^0]X-_[#$?\
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MJ[@"> 2>/2E^(7BZTU#Q&OA:YOVTW2XF!U&Y$;,TG /EJ%!..G/3/TY]7HH
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MCPEXFO19Z+K<,]RV=L+H\3/CT#@9_"I?$/C[PSX4U""R\0:F+.XN$#QJT,C
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M2.%GSAW!;!'OMQGZBO<ZJ+NKE1=U<****HH**** "BBB@ HHHH R_&&K#0_
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M30!Z/6=::_IM]K-WI5K<[[VS ,\7EL-@/3DC!Z]C6#_PM7P9_P!!G_R5F_\
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M;EGFNC(J2/DD+&H)/W=N23C)/2@#TBBN6\->-$U72]1DUB :=>:22+Z$MD(
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M[L;1\O.[OO\ US[UT[HLB,CJ&5A@J1D$>E<P_P -?"#W9N&T2'S,YP)'"_\
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M0?15.!QQGIU.3@#W>W\/:5:: ^B6=E';:=)$T30093*L,-R,')!ZYS[URO\
MPI+X??\ 0O\ _D[<?_'*7+*UD'+*UD6_ 'B/P5?6)T;P+<(\-C&&:)8)8\ G
M[Q+J-Q)[\FNQKG?#7@+PUX0N)Y_#NF_8Y+A DC>?))N .0/G8XKHJT5[:EJ]
MM0HHHIE!1110 4444 %%%% '-?$__DDVK_[\/_HZ.K_A/_D2]$_[!\'_ *+6
MG>,-6&A^ M0U%K6*[$+Q_N9ONMET7GZ9S^%3:)=_;_#^G7@B6$7%K%+Y2?=3
M<@.![#.*YTE[=N^MOU9Z\I3_ +*C'E]WVCUOUY8Z6_4;KZ/+X;U..($NUI*J
M@>I0XK"^%TB2?#?2O+(.U9%8#L?,:NMKB?!\1\,>(]3\,396WED-[II/1HV^
M^@/JIQQ]370>09?@#['_ ,)7XT^V^1G^U&V^;C^_)TS4/Q5_LE;'3VT?[.-=
M^V)]E-KM\WOZ=L[>O?%=/>?#7PE?WT]W=Z3YD]Q(TLK_ &F4;F8Y)P&P.3VJ
MUI'@7PUH=T+G3-)BBG7[LCLTC+]"Q./PH$,\;:K+HW@+4KPLJW M_+4IV=\)
MD?0MG\*7P)I":+X)TRU5<.T(FE]W?YC_ #Q^%:>KZ-8:]ISV&K0?:+9R&9-[
M+D@Y'*D&KD:+%&L:#"J JCT H&<_J^C>);S4I)M*\5_V;;,!MMO[.CEVG'/S
M,<G)YKDOB7;W=MH'AR#4KW[?<KJ*B2X\D1^9U_A' XX_"O3ZSM7T#3=>2W35
MK;[0MO*)8AYC+M<=_E(S^- %G[!9_P#/I!_W[%<#X118_C#XJ6-0JB-,!1@#
M[M>C5G6F@:;8ZS=ZK:VVR]O !/+YC'>!TX)P.G84 </\)4MM';6]"N-D6IPW
MK%D8X:2,* I'J!AC_P "]Z=IA74OC+K%QH4RK#'IWDW%Q&-R><2,>Q(Q_P".
MFNLUKP=H'B*99M8TV.XE48$@9D8CT)4@G\:NZ3HNG:%9_9=(LX[6'.2J#[Q]
M2>I/UH Q+/0/%L-]!+=^-?M,"2*TL']E1)YB@\KN!R,CC(Z5@7&A:!XK\7:H
MVD:AJ&B:[:2[)VB<)YI'\87.2.!R".WK7I%8>M>"_#WB&Y%QJ^F1SS@8\P,R
M,1[E2"?QH Y7POJVL1Z[KOAS4M4368+.T,B7JJ 5) ^0D=^3W.-IYJ;X0:K8
MR^!$M$EC2XLWD,ZEL$ L6#'VP<9]JZBVT'2] T2[M]'LH[6-HV+!!DL=IZD\
MG\:X7X>>#= \1> [&XUC38[B9)) )-[(V-YX)4C(^M BLEM)XEO/B!J.C9>V
MG@6WA,><3NBC=M]<[?\ Q\58\%:!8:UX2M;F#Q?K]LT46V>WAU((D##@@+M^
M5>X]J]+L-/M-+LTM-/MX[>WC&%CC7 %85_\ #SPKJ=XUU>:/$TSG<S1N\88^
MI"D T <HNB:/)X'\6#PGJM]J\]PH^TR7#;R70ECAMHW$C//.>*ZCP7K>FR?#
MW3KD74*16=G''<,S >4R* =WIR*W]/TVSTFR2TTVVCMK=/NQQK@?7W/O6'=_
M#OPI>WS7EQHT)F9MS%7=%)]2H('Z4#.-\7^(6\4>!=&U/[$UG&^NQK$K/NWJ
M%<;N@[Y&/:MOQS_R4#P1_P!?,_\ [3KJM1\/:5JMC;65]9J]M:R++!$C,@1E
M!"XVD= 3QTI]]HFGZEJ%C?7MOYMQI[,]L^]AY9.,\ X/0=<T <E??\EYTW_L
M#G_T.2J_PUE33M;\2:->R!+\:@\PC<X:1#_$/7U_$5VLFB:?+KT6M/;YU"*'
MR$FWMPF2<;<X_B/.,U4UOPAH/B*19-9TV.XE48$FYD;'IN4@D4 0Z=XKBU3Q
MA>Z+8VXEALH0\MXLN5#G^#&.OX]CZ5A:D?-^.FCK'R8=,=I,?P@EP,_F/SKK
M=+T?2_#NGM!IEM%96RY=\'\RS'D\=R:YSP7;/JNN:MXNG1E6_806*L,$6Z8
M;'^T0#^'O0!V=%%% !1110 4444 %%%% %A_^0>G^_\ XU7JP_\ R#T_W_\
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M=2.;6;I<[I"!';)_?;/&?8_X S^$O#FF^'A)<37\>H:Q=G-S>22 LY)^ZO/
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** +%O\ ZB?_ '?\:KU8M_\
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M&&63:@+8SD_[()/X8K@]'T_5=/\ C19?V]?K>WUSISSR%%PD>2RA%]AM]NM
MST^[O+:PMFN+ZXAMH$QNEF<(JY.!DGCK6;_PEWAO_H8-*_\  V/_ .*KEOC!
M>0Q^'].L+ARD=Y?()2 3B->6.!R>JU2AOOA^=0@M=0\*RZ6+@XAGO]/\J.3T
MP<G\\4 >CWE]::=;FXU"ZAM800#)/($4$].3Q6>/%OAQF 7Q!I9). !>Q\_K
M7)?%V]@2PT73[QBL%U?J\VU228T^\ !U^\*KVE[X!;5;>SO?"TNDR3D>1+J%
M@(DD/;!R?S- 'IE07E_::=;^?J%U!:PY \R>0(N3VR>*GK@_C)_R3]_^OF/^
MM '2?\)=X;_Z&#2O_ V/_P"*J_8ZC9:G 9M-O+>\B5MADMY5D4-@'&0>N"/S
MK"L_ _AB2Q@=]"L2S1J23".3BK[)HO@W0KFXB@BL+&',THB3 +' Z#J3@#\J
M ->BN#;XB:HFG#5W\(7JZ-PWVK[0GF!/[WE8SC'?./>NTT^_M]4TZ"^LI/,M
M[A!)&V.H- %BBBB@ HHHH **** +#_\ (/3_ '_\:KU8?_D'I_O_ .-5Z "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ='_ *Q?J*DN_P#C
MZ;\/Y5''_K%^HJ2[_P"/IOP_E0!#1110!7-_9A6)NX %E\DDR#B3^Y_O<CCK
MS3[F[M[* S7D\5O$.KRN%4?B:X.P\&^);6'1(Y+W3V_L_4WN9>"=T38X&4Y?
M!DY//(P:S?%4FFR?%>*+QN[+HZ68-BLF1"TF1DMC_@7Y+GB@#T6RUO2M2D*:
M=J=G=N.JP7".1^ -7J\_UCP-H.N:8+CP3)86FIP.KP7-I-A!SSNV9[9YQ6Y=
M>)I](\1:)HNI6JN=2B(-XDF%$RCE0NWH3C!S_%0!TE%<MKWCBWT/Q?I6A26W
MFM?[=\WF[?)W-M7C!SDCU%7-9\2_V9XBT?1X+3[5/J3L#^\V^2BC)?&#GC/'
M'2@#6MK^TO))DM+J"=[=S',L4@8QL/X6 Z'V-21S1S;O*D1]C%&VL#M8=0?0
MUQ7AW4XA)XKD\.^'\WMOJ+K)%]M/^F2;R"^7&$[G'2LGX0ZG>0>%9EO+$1:7
M#YL[:DUPI!8$94IU'&3NZ<4 >G5!=W]II\:/?W4%JDCB-&FD"!F/103U/!XK
MC$^(6I7UK+J&B>$KR^TJ(G_2C.L;. >2L9!+=.U9'Q"\16&N> =$UBR=OLQU
M6)F##YD*I)N!'J,4 >HU!<7]I:30175U!!)<-LA220*TK>B@]3R.E<9=?$/4
M;"U74[[PE>PZ,Q'^EF=/,52>&,74=1U-;6KZ-%XCO=!U&!HC#9S"[6;+;BI
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M -1/_N_XU7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@V^L-)A\J$6\K,2<L[;#EB>YXKH*BNK=;NTFMY"P29&C8KU (QQ0,Y7X5?\
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M",<4 >:^#_\ D@>H_P#7I>_^@O3?!_@BYU'PAIUW'XKURS6:+<(+>Z*HG)X
M["NTTWPC8:7X1F\.V\URUG-'+&SNRF0"0$'!"@=^.*OZ-I,&AZ-;:9:/(\-L
MFQ&E(+$9SS@ ?I0(RO#?@?2_#5U+>0/<7E],NU[N[DWN1W X&/Y^]='110,*
M*** "BBB@ HHHH **** "BBB@ JU8_ZQOI56K5C_ *QOI0!5HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH L6_
M^HG_ -W_ !JO5BW_ -1/_N_XU7H **** "BBB@ HHHH **** "BBB@ HHHH
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MLVSTJ]:EC:%6C0JJ+]R/-)\O/&,;/7UUMNU8GGTFRF^/-J+&)$%O:_:;I4
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MG%=22]NW?6WZL\&4I_V5&/+[OM'K?KRQTM^I>HHHKH/("BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"P__(/3_?\ \:KU8?\ Y!Z?[_\ C5>@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** '1_ZQ?J*DN_\ CZ;\/Y5''_K%^HJ2[_X^
MF_#^5 $-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5JQ_P!8WTJK5JQ_UC?2@"K14_V.
M;T'YT?8YO0?G0!!14_V.;T'YT?8YO0?G0!!14_V.;T'YT?8YO0?G0!!14_V.
M;T'YT?8YO0?G0!!14_V.;T'YT?8YO0?G0!!14_V.;T'YT?8YO0?G0!!14_V.
M;T'YT?8YO0?G0!!14_V.;T'YT?8YO0?G0!!14_V.;T'YT?8YO0?G0!!14_V.
M;T'YT?8YO0?G0!!14_V.;T'YT?8YO0?G0!!14_V.;T'YT?8YO0?G0!!14_V.
M;T'YT?8YO0?G0 MO_J)_]W_&J]78;>1(I0P&6&!S4/V.;T'YT 045/\ 8YO0
M?G1]CF]!^= $%%3_ &.;T'YT?8YO0?G0!!14_P!CF]!^='V.;T'YT 045/\
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MKNN:RME?^#[_ $J$HS&YN-^T$=N8U'/UK-N?'GB6"ZEB3X?ZK*L;E5D428<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>fig05.jpg
<TEXT>
begin 644 fig05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     S<V  "2
MD@ "     S<V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                       R,#$Y.C R.C(W(# X.C$R.C,Q #(P,3DZ,#(Z
M,C<@,#@Z,3(Z,S$   !$ &$ =@!I &0 ( !- &D ; !L &4 <@   /_A"Q]H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG
M[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR
M9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U
M+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#$Y+3 R+3(W5# X.C$R.C,Q+C<U
M.3PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D
M,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D
M9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS
M(R(^/')D9CIL:3Y$879I9"!-:6QL97(\+W)D9CIL:3X\+W)D9CI397$^#0H)
M"0D\+V1C.F-R96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO
M>#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@
M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8
M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4
M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ_\  $0@!N0+6 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
M           ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $
M$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ
M-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(
MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8
MV=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        !
M @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'
M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#
M1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66
MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F
MY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ Y/QJW_%?>(/^PG<_^C6K$WUK
M>-F_XN!XA_["=S_Z-:L/=003;Z-]0[J-U $V^C?4.ZC=0!-OHWU#NHW4 3;Z
M-]0[J-U $V^C?4.ZC=0!-OHWU#NHW4 3;Z-]0[J-U $V^C?4.ZC=0!-OHWU#
MNHW4 3;Z-]0[J-U $V^C?4.ZC=0!-OHWU#NHW4 3;Z-]0[J-U $V^C?4.ZC=
M0!-OHWU#NHW4 3;Z-]0[J-U $V^C?4.ZC=0!-OHWU#NHW4 3;Z-]0[J-U $V
M^C?4.ZC=0!-OHWU#NHW4 3;Z-]0[J-U $V^C?4.ZC=0!-OHWU#NHW4 3;Z-]
M0[J-U $V^C?4.ZC=0!-OHWU#NHW4 3;Z-]0[J-U $V^C?4.ZC=0!-OHWU#NH
MW4 3;Z-]0[J-U $V^C?4.ZC=0!-OHWU#NHW4 3;Z-]0[J-U $V^C?4.ZC=0!
M-OHWU#NHW4 3;Z-]0[J-U $V^C?4.ZC=0!-OHWU#NHW4 3;Z-]0[J-U $V^C
M?4.ZC=0!-OHWU#NHW4 3;Z-]0[J-U $V^C?4.ZC=0!-OHJ'=10!K^-V_XN#X
MA_["ES_Z-:L/=6OXY;_BX?B+_L*7/_HUJPMU $VZO=?@/H&C:QX7U*75M)L;
MZ1+S:KW-LDA4;%. 6!P*\$W5]$_LYG/A'5?^O[_VFM T?/FZO==<T#1H?V;H
MM4BTFQ2_-G:L;M;9!*298P3OQG)!(//>H-WP!]?_ $OKJ/B*=+_X9[NCX>_Y
M!?D6WV7[W^K\^/'W_F_/F@+'SA965YJ5R+?3K6>[G(R(H(R[$?0<U/J.B:MH
MZJ=6TN]L0YPIN;=X]Q]MP%?0G@;0KWPQ\&H[[PGIT5]K^HP)<#>RIO+D8R6(
M&$4YQD9(/K6CX2L/%GB'P[J>C_%33(FCD $,P>(F0-G(Q&2%*X!!X//J,T!8
M^:]-T+6-8C=](TF^OTC(#M:VSRA3Z':#BI+3PYKM_9_:['1=1N;8@D30VDCI
MQ_M 8KW+X"6+Z9%XGT^1@[VFH"!F QDKN4G]*A\!?$S6?$'Q8O-$F\E-) F2
MWMTB5?)$9^4@CDY Y!X],4!8\.T_1=6U<N-*TN]OC&<.+:W>3;]=H.*K7-O<
M65R]O>02V\\9P\4J%64^X/(KW;QW\1=3\)_$VQT+08[:TT_S(Y;N-;=<W#RM
MER3VX(Y&#G.2:;\>?#Z:EKGA5H5CBFOKAK*28+\QW,FS/J!E_P Z L>*:=HF
MK:PK'2=+O;X(<,;:W>3:??:#4%[97FFW)M]1M9[2<#)BGC*,!]#S7T[XML?%
M?A[PWINC?"O2HE2,%99M\0,2C&,"0@,S$DECGI[UE>.M"O\ Q-\&)+[Q9I\-
MEX@TV%K@E&5MNPG=@J2,,@SC. 2/2@+'GOP1T*PU7Q!JE_K5I;W=CI]F6>.Y
MB610S'@X;C@*]'PS^'\7Q!UR^U?4H_LNCPSDF"#"AW)W>4N/NJ 1G&.",>UW
MPE_Q3G[._B36"@$^JRFVC8'!9#B/]"TIKMOA&3#\#I9;0;9\73Y0<EQG!^O
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MN+6.1Y) N^0;F&2!R/H!7@7Q)\/?\(OX^U&QCCV6SOY]L  !Y;\@ #L#E?\
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MTQ,)W9)W(1&QX'!!QD8ZF@+'R[NK6\,:!=^*O$EIH]AA9;A\%V&1&H&68_0
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MO+-?^'/BOPOI9U'7=*^RVH<(9/M$3_,>@PK$U](_$8^"QI%I_P +!_X\_/\
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M1OHWT >R_$;P9X'\%>"X+1+@W'B<HBYAN#\YS\SNA)"KC('3M[UC:/\ "?\
MM7X63^,O[:\KRK>>;[']DW9\HL,;]XZ[?3C->9[Z-] $NZOH?X'Z?!X8^'&J
M^+M2&U;@/(&[^1"#^I;?]<"OG/?1OH ]?/[1OBS)QIVB@=LPR_\ QVO3/#.M
M?\+@^$NHP:E';Q7LOF6TJQ(0B2##1L Q)XRAZ]0:^5-]&^@+GT%\*M>TS5_
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ME/A__P! #_R=N/\ XY1_PI3X?_\ 0 _\G;C_ ..4!8^4-U&ZOJ__ (4I\/\
M_H ?^3MQ_P#'*/\ A2GP_P#^@!_Y.W'_ ,<H"Q\H;J-U?5__  I3X?\ _0 _
M\G;C_P".4?\ "E/A_P#] #_R=N/_ (Y0%CY0W4;J^K_^%*?#_P#Z '_D[<?_
M !RC_A2GP_\ ^@!_Y.W'_P <H"Q\H;J-U?5__"E/A_\ ] #_ ,G;C_XY1_PI
M3X?_ /0 _P#)VX_^.4!8^4-U&ZOJ_P#X4I\/_P#H ?\ D[<?_'*/^%*?#_\
MZ '_ ).W'_QR@+'RANHW5]7_ /"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\
M)VX_^.4!8^4-U&ZOJ_\ X4I\/_\ H ?^3MQ_\<H_X4I\/_\ H ?^3MQ_\<H"
MQ\H;J-U?5_\ PI3X?_\ 0 _\G;C_ ..4?\*4^'__ $ /_)VX_P#CE 6/E#=1
MNKZO_P"%*?#_ /Z '_D[<?\ QRC_ (4I\/\ _H ?^3MQ_P#'* L?*&ZC=7U?
M_P *4^'_ /T /_)VX_\ CE'_  I3X?\ _0 _\G;C_P".4!8^4-U&ZOJ__A2G
MP_\ ^@!_Y.W'_P <H_X4I\/_ /H ?^3MQ_\ '* L?*&ZC=7U?_PI3X?_ /0
M_P#)VX_^.4?\*4^'_P#T /\ R=N/_CE 6/E#=1NKZO\ ^%*?#_\ Z '_ ).W
M'_QRC_A2GP__ .@!_P"3MQ_\<H"Q\H;J-U?5_P#PI3X?_P#0 _\ )VX_^.4?
M\*4^'_\ T /_ "=N/_CE 6/E#=1NKZO_ .%*?#__ * '_D[<?_'*/^%*?#__
M * '_D[<?_'* L?*&ZC=7U?_ ,*4^'__ $ /_)VX_P#CE'_"E/A__P! #_R=
MN/\ XY0%CY0W4;J^K_\ A2GP_P#^@!_Y.W'_ ,<H_P"%*?#_ /Z '_D[<?\
MQR@+'RANHW5]7_\ "E/A_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE 6
M/E#=1NKZO_X4I\/_ /H ?^3MQ_\ '*/^%*?#_P#Z '_D[<?_ !R@+'RANHW5
M]7_\*4^'_P#T /\ R=N/_CE'_"E/A_\ ] #_ ,G;C_XY0%CY0W4;J^K_ /A2
MGP__ .@!_P"3MQ_\<H_X4I\/_P#H ?\ D[<?_'* L?*&ZC=7U?\ \*4^'_\
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M5]7_ /"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\ )VX_^.4!8^4-U&ZOJ_\
MX4I\/_\ H ?^3MQ_\<H_X4I\/_\ H ?^3MQ_\<H"Q\H;J-U?5_\ PI3X?_\
M0 _\G;C_ ..4?\*4^'__ $ /_)VX_P#CE 6/E#=1NKZO_P"%*?#_ /Z '_D[
M<?\ QRC_ (4I\/\ _H ?^3MQ_P#'* L?*&ZC=7U?_P *4^'_ /T /_)VX_\
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M7U?_ ,*4^'__ $ /_)VX_P#CE'_"E/A__P! #_R=N/\ XY0%CY0W4;J^K_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3_O^O^-']L:9_P!!&T_[_K_C0!\T:7X.UNRU?1O!D\4\UAXH^Q:MJ$C@D1E
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M_P! ^[_\#'_QH_X9U^'G_0/N_P#P,?\ QKNO[?\ ^H=>?]^Z/[?_ .H=>?\
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M_?NCZU1[_F'*S7HK(_M__J'7G_?NC^W_ /J'7G_?NCZU1[_F'*S7HK(_M_\
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M[+T__GRM_P#OTO\ A1_9>G_\^5O_ -^E_P *=L3WC]S_ ,Q7PO:7WK_(K_\
M"0Z3_P _T7ZUE>)?%FAVN@7:S7Z!IX9(HPJLV6*G X'%;O\ 9>G_ //E;_\
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M_P"^JL(ZR('C8,IY!'>O=A6I5':$D_1G$X2CNA:***U)"BBB@ HHHH ****
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MC_KF:33/^0;!_NUYC_Y&*_P?^W(Z/^8?Y_H6J***],YPHHHH **** "BBB@
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MC_-A6+XQ_P"1*U?_ *])/_0:VJQ?&/\ R)6K_P#7I)_Z#77'='#/X&0^!/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2&/Q$%*2AN^S_KH?93R[#S<(N>RMNN]_U/2K+4+74(V>SF$JJ<$@'@U8KF?
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MJ2OW84445V&04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]VA;HHHKZ<\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2$@;Y(VSMR?49'UQ6GXH\,VGCOP>^D:O]HM8+L1R2+&0)$((;'.1U&#7044
M<IXM^'^G>+(].>6[O=.O],S]DO[&7RYHP1AAG'((%5)?A/X<?P)!X6C6YBM[
M>;[3#=I+BX2?.?-W_P![GTQ7;44 <YX.\$Z?X,M+M+.>ZO;J^F\^[O;R3?+.
M_J3[?U-<3J_P^U'Q!\;=2U*6?4M+TV32HX4OK&81F1L@/&>O!&>U>LT4 >/>
M*/AM'X<\(Z%IWAO2-3U6/3+Z2X2YL[U8;VSWD$M'D8<=B/855\)>%O$.BZ!X
M^U:VT>^BN=<58]/LKR=9+ER%9?,D;. 2TA8Y/8^U>UT4 8?@OP\OA3P5I6AJ
MP=K.W5'8=&?JQ_%B:W*** "BBB@ HHHH =)_K&^IIM.D_P!8WU--H **** "
MBBB@ HHHH **** "BBN"\3?%[0_#.O7.F2V6I7HL%1M1N;.WWQ60?[N\Y]^U
M '>UX%\;/'&@ZUJFB^'=.NWDU/3M>B^TQ&%E"8R#\Q&#R1TKWFVN(KNUBN;:
M19(9D$D;KT92,@C\*\D^/\,::;X7=(T5VUZ'+!0">#WH ]?HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K,T__ )"U_P#4?UK0EE6&%I'^
MZHR<5B66IV\>I74C%MLQ&WBO%S#$4:6)H*I)+5OY<LE^9V4*<Y4Y\JZ?JC>H
MHHKVCC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.ZLKC=Y4PO H;:Q4\%@>H(JM;?&/XC7<>K26_@6S==&=DOS]KQY#*"6!YYP
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M7@'E,<X&2V#T/3->V0P16\8CMXDB0<A44*/R%$<$,4CO%$B/(<NRJ 6/N>]
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M5E<;O+F6\"AMK%3P6!Z@BO:]BA-@4;<8VXXQZ4V&&*WB$<$:11KT1%  _ 4
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M^&OA;X2\):N=3T;3F2["E(GEG>7R5/4(&)V]:Z^B@ HI'<1QL[9(4$G:I)_
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M,K#U!% $E%%% #I/]8WU--ITG^L;ZFFT %%%% !1110 4444 %%%% !1110
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M=O-#\06$5EJ%LK-^ZRH.U@&4@DX(SZ^M<]\)P/\ A8WB@XYW2<_]MC2^%O\
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M(Y''7ECC/3.,9Q0/J>RT444#'2?ZQOJ:;3I/]8WU--H **** "BBB@ HHHH
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M+>^(8-<N;+?J-N (Y_-<;<9Q\H.T]3VK8HH YW5? 7AC6]1-_J>DQ37+$%I
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..4*JCV J6B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>fig06.jpg
<TEXT>
begin 644 fig06.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     S Q  "2
MD@ "     S Q  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  FOBG_H9-7_ / ^7_XJL'-&:"#>_P"$U\4_]#)J_P#X'R__ !5'_":^*?\
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M]#)J_P#X'R__ !5'_":^*?\ H9-7_P# ^7_XJL'-&: -[_A-?%/_ $,FK_\
M@?+_ /%4?\)KXI_Z&35__ ^7_P"*K!S1F@#>_P"$U\4_]#)J_P#X'R__ !5'
M_":^*?\ H9-7_P# ^7_XJL'-&: -[_A-?%/_ $,FK_\ @?+_ /%4?\)KXI_Z
M&35__ ^7_P"*K!S1F@#>_P"$U\4_]#)J_P#X'R__ !5'_":^*?\ H9-7_P#
M^7_XJL'-&: -[_A-?%/_ $,FK_\ @?+_ /%4?\)KXI_Z&35__ ^7_P"*K!S1
MF@#>_P"$U\4_]#)J_P#X'R__ !5'_":^*?\ H9-7_P# ^7_XJL'-&: -[_A-
M?%/_ $,FK_\ @?+_ /%4?\)KXI_Z&35__ ^7_P"*K!S1F@#>_P"$U\4_]#)J
M_P#X'R__ !5'_":^*?\ H9-7_P# ^7_XJL'-&: -[_A-?%/_ $,FK_\ @?+_
M /%4?\)KXI_Z&35__ ^7_P"*K!S1F@#>_P"$U\4_]#)J_P#X'R__ !5'_":^
M*?\ H9-7_P# ^7_XJL'-&: -[_A-?%/_ $,FK_\ @?+_ /%4?\)KXI_Z&35_
M_ ^7_P"*K!S1F@#>_P"$U\4_]#)J_P#X'R__ !5'_":^*?\ H9-7_P# ^7_X
MJL'-&: -[_A-?%/_ $,FK_\ @?+_ /%4?\)KXI_Z&35__ ^7_P"*K!S1F@#>
M_P"$U\4_]#)J_P#X'R__ !5'_":^*?\ H9-7_P# ^7_XJL'-&: -[_A-?%/_
M $,FK_\ @?+_ /%4?\)KXI_Z&35__ ^7_P"*K!S1F@#>_P"$U\4_]#)J_P#X
M'R__ !5'_":^*?\ H9-7_P# ^7_XJL'-&: -[_A-?%/_ $,FK_\ @?+_ /%4
M?\)KXI_Z&35__ ^7_P"*K!S1F@#>_P"$U\4_]#)J_P#X'R__ !5'_":^*?\
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M7]MDVX],;JA\/SV\7B2REOM1NM.@$P,EY:Y,L(_O+CG/TY]CTH UO&G@?4_
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MC- 'N'B3XA>&+_\ 9_M?#=IJ?F:O'9VD;6WV>489&0L-Q7;QM/>O$LTS-&:
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M4^'_ /T /_)VX_\ CE=W10!PG_"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\
M)VX_^.5W=% '"?\ "E/A_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE=W
M10!PG_"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\ )VX_^.5W=% '"?\ "E/A
M_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE=W10!PG_"E/A__ - #_P G
M;C_XY1_PI3X?_P#0 _\ )VX_^.5W=% '"?\ "E/A_P#] #_R=N/_ (Y1_P *
M4^'_ /T /_)VX_\ CE=W10!PG_"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\
M)VX_^.5W=% '"?\ "E/A_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE=W
M10!PG_"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\ )VX_^.5W=% '"?\ "E/A
M_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE=W10!PG_"E/A__ - #_P G
M;C_XY1_PI3X?_P#0 _\ )VX_^.5W=% '"?\ "E/A_P#] #_R=N/_ (Y1_P *
M4^'_ /T /_)VX_\ CE=W10!PG_"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\
M)VX_^.5W=% '"?\ "E/A_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE=W
M10!PG_"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\ )VX_^.5W=% '"?\ "E/A
M_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE=W10!PG_"E/A__ - #_P G
M;C_XY1_PI3X?_P#0 _\ )VX_^.5W=% '"?\ "E/A_P#] #_R=N/_ (Y1_P *
M4^'_ /T /_)VX_\ CE=W10!PG_"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\
M)VX_^.5W=% '"?\ "E/A_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE=W
M10!PG_"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\ )VX_^.5W=% '"?\ "E/A
M_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE=W10!PG_"E/A__ - #_P G
M;C_XY1_PI3X?_P#0 _\ )VX_^.5W=% '"?\ "E/A_P#] #_R=N/_ (Y1_P *
M4^'_ /T /_)VX_\ CE=W10!PG_"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\
M)VX_^.5W=% '"?\ "E/A_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE=W
M10!PG_"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\ )VX_^.5W=% '"?\ "E/A
M_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE=W10!PG_"E/A__ - #_P G
M;C_XY1_PI3X?_P#0 _\ )VX_^.5W=% '"?\ "E/A_P#] #_R=N/_ (Y1_P *
M4^'_ /T /_)VX_\ CE=W10!PG_"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\
M)VX_^.5W=% '"?\ "E/A_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE=W
M10!PG_"E/A__ - #_P G;C_XY1_PI3X?_P#0 _\ )VX_^.5W=% '"?\ "E/A
M_P#] #_R=N/_ (Y1_P *4^'_ /T /_)VX_\ CE=W10!PG_"E/A__ - #_P G
M;C_XY1_PI3X?_P#0 _\ )VX_^.5W=% '"?\ "E/A_P#] #_R=N/_ (Y5G3?A
M%X'TW5;2^LM$\JYM9TFA?[7.=KJP*G!?!Y ZUV5.C_UB_44 7:*** *%%%%
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MALC/0DL>>O%1?#&PATOXQ^(+&T),%M!/%'DY(43Q@#/MTH"Y[11110,****
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M34]1CYA2('8A'0]!T[   'FG:QX5\>KKL][X=\6J(922L%X/EC![!0C*<>N
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M444 %%%% !1110 4444 %%%% !3H_P#6+]13:='_ *Q?J* +M%%% %"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "G1_ZQ?J*;3H_]8OU% %VBBB@"A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS(^T$R86W!.$''/T'I7MM !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !112%@OWB!]30 M%('4G 8$^QI: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IT?^L7ZBFTZ/_6+]10!=HHHH H44
M44 %%%% !1110 4444 %%%% !1110 5YK\0=>\+Q>-/#*WWBZSTC5=*O?/\
M)E0R*T;KM='(XC)4\,Q'7/->E5\OMJ'@VS\1^,8O''A+6M9O[K6+H174-MO$
M<6\J@5BZD8]O:@#T6+X7:W+XOL[BT\16\GA)-7_M^*W$>Z4SEMP4,."ARQSG
MOT/6O6Z\+^$?Q6MM/\.^'_".I:+KAO\ S%M!<"U'DKN?"DL6S@ C/'&*]TH
M**Y_QEXG_P"$8T99+6W^VZG=R"WT^R# -<3-P!_NCJQ[ &L/P+XY,_PIL?$?
MCC4+6UEDFFBGG;$<899W10,<=% H /!?_)5/B'_U]6/_ *2K7>5YQ\.-4L=:
M^(7C[4-)NH[NTFN;+RYHFRK8MP#@_4$?A7H] !7/3> O#%Q.\TVD1-)(Q9FW
M-R2<D]:Z&JC:K8*Q5KN$$'!!<<5$ZT*6LI6^=A."ENKCM.TVTTFQ2STZ$06\
M9)6-22!DY/7W-6:9#-'/$)(75T/1E.0:?5*2DN9.]QVMH<3<_#:SU;XDW7BC
MQ"UOJ<!LTM;2QFMPR0 '+,<DAB23@X&,UGW/PBLTU_7;S0[F/2['6]&ETZ>Q
M@@ 02,,+* "!P,\8[UU<_BNP@\;VOA9DG-_<VCW:L%'EJBG&"<YR?85R^O\
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M* . \#Q1P_%#XA1PHL:"ZLL*HP!_HP[5W]<'X+_Y*I\0_P#KZL?_ $E6N\H
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M/:99748(2:"U1'7(P<$"HKOX>^#KZ\FN[WPQI,]Q.YDEEDLT9G8G)))'))H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@#=FVD@9[FNOKS+XSV236N@WVK:==:IX=L+UI=6M+8MDQE"%<JI&0K<GV^M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *='_ *Q?J*;3H_\
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MO/HK>+=)$'QNUK59#>1;+"43[;D[QB,Y;&&Z<^M?05 ".Z11M)(RHB@LS,<
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MK6H^+-7\-^*;*T@O[""&YCEL=QBEBD'^T<Y#<=.QKMJ "BBB@ HHHH ****
M"BBB@ HHHH **** "G1_ZQ?J*;3H_P#6+]10!=HHHH H4444 %%%% !1110
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M:3*XZ%F&0?X,>M4?#VDWJ:]\3/ _@?6#:V"11FQWS;T@E;'F('Y*_P 49[C
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M'Y4N@_#3PSX:\67OB+1[-X+Z\5ED_>DHH9@S;5/3) _I7644 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4Z/_ %B_44VG1_ZQ?J* +M%%% %"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MG1_ZQ?J*;3H_]8OU% %VBBB@"A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3H_P#6
,+]1110!=HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>fig07.jpg
<TEXT>
begin 644 fig07.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     S0X  "2
MD@ "     S0X  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,NK_ /@?+_\ %4?\)MXH_P"AEU?_ ,#Y?_BJY_=1NH Z#_A-O%'_ $,NK_\
M@?+_ /%4?\)MXH_Z&75__ ^7_P"*KG]U&Z@#H/\ A-O%'_0RZO\ ^!\O_P 5
M1_PFWBC_ *&75_\ P/E_^*KG]U&Z@#H/^$V\4?\ 0RZO_P"!\O\ \51_PFWB
MC_H9=7_\#Y?_ (JN?W4;J .@_P"$V\4?]#+J_P#X'R__ !5'_";>*/\ H9=7
M_P# ^7_XJN?W4;J .@_X3;Q1_P!#+J__ ('R_P#Q5'_";>*/^AEU?_P/E_\
MBJY_=1NH Z#_ (3;Q1_T,NK_ /@?+_\ %4?\)MXH_P"AEU?_ ,#Y?_BJY_=1
MNH Z#_A-O%'_ $,NK_\ @?+_ /%4?\)MXH_Z&75__ ^7_P"*KG]U&Z@#H/\
MA-O%'_0RZO\ ^!\O_P 51_PFWBC_ *&75_\ P/E_^*KG]U&Z@#H/^$V\4?\
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M,NK_ /@?+_\ %4?\)MXH_P"AEU?_ ,#Y?_BJY_=1NH Z#_A-O%'_ $,NK_\
M@?+_ /%4?\)MXH_Z&75__ ^7_P"*KG]U&Z@#H/\ A-O%'_0RZO\ ^!\O_P 5
M1_PFWBC_ *&75_\ P/E_^*KG]U&Z@#H/^$V\4?\ 0RZO_P"!\O\ \51_PFWB
MC_H9=7_\#Y?_ (JN?W4;J .@_P"$V\4?]#+J_P#X'R__ !5'_";>*/\ H9=7
M_P# ^7_XJN?W4;J .@_X3;Q1_P!#+J__ ('R_P#Q5'_";>*/^AEU?_P/E_\
MBJY_=1NH Z#_ (3;Q1_T,NK_ /@?+_\ %4?\)MXH_P"AEU?_ ,#Y?_BJY_=1
MNH Z#_A-O%'_ $,NK_\ @?+_ /%4?\)MXH_Z&75__ ^7_P"*KG]U&Z@#H/\
MA-O%'_0RZO\ ^!\O_P 51_PFWBC_ *&75_\ P/E_^*KG]U&Z@#H/^$V\4?\
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M,NK_ /@?+_\ %4?\)MXH_P"AEU?_ ,#Y?_BJY_=1NH Z#_A-O%'_ $,NK_\
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M(# X/% 6/(MU&ZO?X;_X?Z=\4'\'P^#[2X>XN&$MY-$CK'*PW;%0J<(,@<$
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M%M*YY!X# X'R\'GKP:[>V\,^%?A?\.;;7?%6D1ZSJMYL AG0.H=@6$8!RJ@
M'+8))'T% 6/"]U&ZO<;KPYX7^)_PVN]>\+Z+'HVJV(<&"W4*K.JAC&0 %8$$
M8; .3]17'?#C5/A[H^EWMYXOMWOM4&[R;:6W,D94#("CD;B>[8QQTY) L>?[
MJ-U?1O@ZU\*_$O1[T7?@"#18T"^7-' J"56SADD5%.1CD>XZYKD?A+\.]'U/
MQ9XA76U6_31;G[-% Y^5VW.-[+W'R<#IR?2@+'D&ZC=7N3>+O \&J3:;XO\
MAQ%X?MB&$5S+8KN?'J%0$>Q4MUZ]ZX'1/"FD>,OBH=(\-3W"Z&SF;S)1B1(0
M 6 S[G:">>03GF@5CB]U&ZO=O$7B+X<^!_$D?AEO!MI=QP!%N[IX5=X=P!&"
MREG."">1U[GBN3^,W@"R\)7]GJ>A(8]-ORRF'.1#(.< GG# Y [8/L*!V/-=
MU&ZHMU&Z@1+NHW5%NHW4 2[J-U1;J-U $NZC=46ZC=0!+NHW5%NHW4 2[J-U
M1;J-U $NZC=46ZC=0!ZU^ST<_$&^_P"P7)_Z-BHIG[.YS\0K[_L%R?\ HV*B
M@I'D6ZC=46ZC=0(EW4;JBW4;J )=U&ZHMU&Z@"7=1NJ+=1NH EW4;JBW4;J
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MQR3@<=34VEZM=Z+JEOJ.FS>3=VSAXI-H;:P[X((/XB@#VWX[G'Q$\+_[B_\
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M7:P(S[XH ]FN/'WQ>30Y=1N?!UC%:+&S2%[>1750.24,NX<>HJY\(]$L]/\
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M_P"P5)_Z-BHH&CQ[=1NKZ1_X9T\)?]!'6O\ O_%_\:H_X9T\)?\ 01UK_O\
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M$=:_[_Q?_&J/^&=/"7_01UK_ +_Q?_&J L?-VZC=7TC_ ,,Z>$O^@CK7_?\
MB_\ C5'_  SIX2_Z".M?]_XO_C5 6/F[=1NKZ1_X9T\)?]!'6O\ O_%_\:H_
MX9T\)?\ 01UK_O\ Q?\ QJ@+'S=NHW5](_\ #.GA+_H(ZU_W_B_^-4?\,Z>$
MO^@CK7_?^+_XU0%CYNW4;J^D?^&=/"7_ $$=:_[_ ,7_ ,:H_P"&=/"7_01U
MK_O_ !?_ !J@+'S=NHW5](_\,Z>$O^@CK7_?^+_XU1_PSIX2_P"@CK7_ '_B
M_P#C5 6/F[=1NKZ1_P"&=/"7_01UK_O_ !?_ !JC_AG3PE_T$=:_[_Q?_&J
ML?-VZC=7TC_PSIX2_P"@CK7_ '_B_P#C5'_#.GA+_H(ZU_W_ (O_ (U0%CYN
MW4;J^D?^&=/"7_01UK_O_%_\:H_X9T\)?]!'6O\ O_%_\:H"Q\W;J-U?2/\
MPSIX2_Z".M?]_P"+_P"-4?\ #.GA+_H(ZU_W_B_^-4!8^;MU&ZOI'_AG3PE_
MT$=:_P"_\7_QJC_AG3PE_P!!'6O^_P#%_P#&J L?-VZC=7TC_P ,Z>$O^@CK
M7_?^+_XU1_PSIX2_Z".M?]_XO_C5 6/F[=1NKZ1_X9T\)?\ 01UK_O\ Q?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!-;?ZP_2BBV_UA^E% $-%%% !1110 4444 %%%% !1110 4444
M 171F%G,;0*9Q&WE!NA;'&?QKQE?V@QINDS:;XAT"YA\8V[BW.G(N(II2<!@
MV3A3P<<GGC/6O9;R*6:QGBMY/+F>-EC?.-K$<'\Z^?;7PA\(TLKSP[JVOOJ7
MB!HY)[S5][EK:2)#O8-T"@[CM.[/?.!@ ]J\$W/B"\\(VESXPMTM=7F,DDT$
M8 $2F1BB\$]$VCDD^O-;U<[X!T^XTSP1I]K=ZT==8!WCU$L6\^-G9HSDD_P%
M1U/2NBH *BNKNWL;9[B]GBMX$^_+*X15YQR3P*EKYY^.WC6TUNXU7PH-7%A;
MZ3 )IH"IW:A<G!2(<?=0'<?4X^H /H2.1)8UDB971P&5E.0P/0@TZN!T;Q'J
M]S\/_#MSX%TVSUV(VBQ7#37OV<1,B*N!E3GG<#Z8J7X?^/=0\6ZYXBTG5]'A
MTRZT*6**017/G!V??GG:.FS]: .YHHHH **** "BBB@ HHHH **** "BBB@
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M0:*9#-'<01S0MNCD4.C#N",@T^@ HHHH **** "BBB@ HHHH **** "BBB@
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M]*Z:N<\ ZGI.L>";&^\.Z9)I6G2F3RK26)8VCQ(P;*J2!E@3U[UT= !1110
M5Y+\*?\ DK?Q0_Z_[?\ ]K5ZU7DOPI_Y*W\4/^O^W_\ :U 'K51S6\5PH69
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M7,JB1GW2, "V6)/11[<5EW_PT\(ZG)J;WFC(YU9TDO56:1%F=3D,55@ <\Y
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M%_7$GS^NFUCI>)J.E[+H%%%%>F<P4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH *\E^%/_)6_BA_U_V__M:O6J\E^%/_ "5OXH?]?]O_ .UJ /6J***
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M.F_$CXD6;7=S>F&\MT-Q=.&ED_UW+$  G\!0![)1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %9UR6O[P6B?ZF/#3-_>]%_S_2I[^Z-O"!$-TTAV
MQK[^M/L[86MN$ZL>7;U->;B/]IJ_5E\*UE^D?GU\O4Z(?NX^T>_3_,G "J !
M@#@"BBBO2.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** )K;_ %A^E%%M_K#]** (:*** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110 4444 36W^L/THHMO]8?I10!#1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":V_UA^E%%M_K#]**
M(:*** "BBB@ HHHH **** "BBB@ HHHH \'^*_B2+P=\??#>OW=E/>6]KI3A
MHX5RQ+&51C/'5@:-6_:.TC4-%O;*/PYJJ/<V\D2L0N 64@']:]XJ-[F")MLD
MT:-Z,X!H \^^ :-'\$]#5U*L&N,@C!_X^)*]%I$=9%#1LKJ>A4Y%+0 4444
M%>2_"G_DK?Q0_P"O^W_]K5ZU7DOPI_Y*W\4/^O\ M_\ VM0!ZU1110 4444
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M-HRXR5;_ #TJA;>'H#"S:G_I5Q(0SR,>A]![4ND2O9W,FDW+9:,;H&/\4?\
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MHH **** "BBB@ HHHH **** )K;_ %A^E%%M_K#]** (:*** "BBB@ HHHH
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MY7[197\8255895L D8/UKIZ\S\#ZQ9^*OBUXDUW0RUQI2V%K:+>*N$EE4LQ
M)ZX# 5Z90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% $UM_K#]**+;_ %A^E% $-%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "*BHN$4*/0#%(D4<>?+14SU
MVC&:=10 4444 %%%% !1110 4444 %%%% #7C208D17 [,,TB11Q@A(U4'J
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M' )<'OZ4 =S17*^&OB%I7BJSU*YT^WO(TTV-9)A.B L"&/RX8Y^X>N.U<_\
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MBBB@":V_UA^E%%M_K#]** (:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M*"2/3;12JR.N-Q\KRP/J<EL=A0(=\)O^2B^*/]Y__1IIWA3Q)XL\6>'_ !7
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MQ0 9 )ZJ#T_&@:/2+;_6'Z446W^L/THH&0T444 %%%% !1110 4444 %%%%
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/K;_6'Z446W^L/THH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>fig08.jpg
<TEXT>
begin 644 fig08.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     S,U  "2
MD@ "     S,U  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ \XWT;ZAW4;J"";?1OJ'=1NH
MFWT;ZAW4;J )M]&^H=U&Z@";?1OJ'=1NH FWT;ZAW4;J )M]&^H=U&Z@";?1
MOJ'=1NH FWT;ZAW4;J )M]&^H=U&Z@";?1OJ'=1NH FWT;ZAW4;J )M]&^H=
MU&Z@";?1OJ'=1NH FWT;ZAW4;J )M]&^H=U&Z@";?1OJ'=1NH FWT;ZAW4;J
M )M]&^H=U&Z@";?1OJ'=1NH FWT;ZAW4;J )M]&^H=U&Z@";?1OJ'=1NH FW
MT;ZAW4;J )M]&^H=U&Z@";?1OJ'=1NH FWT;ZAW4;J )M]&^H=U&Z@";?1OJ
M'=1NH FWT;ZAW4;J )M]&^H=U&Z@";?1OJ'=1NH FWT;ZAW4;J )M]&^H=U&
MZ@";?1OJ'=1NH FWT;ZAW4;J )M]&^H=U&Z@";?6WX*;_BOO#_\ V$[;_P!&
MK7/;JW/!+?\ %P/#W_83MO\ T:M 'V%11106?#FZC=4.ZC=003;J-U0[J-U
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MCPW=1NKO==;_ (R(/_8=A_\ 1BUUO[21Q=>'?]RX_G'0*Q#\6/ GAOPS\/\
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M_$V76K>X^'^HPOI<\:AH]MO^Z;NV9%R5(P>"3UXKY=O]4OM5NS=:I>W%[<$
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MJ:ZN'GN97FFD.YY)&+,Q]23UH$?2?Q=./@1IW_;I_P"@5KVVO:SXT^$UG?>
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MK_Z-6N<WUO\ @1O^+C>&_P#L*VO_ *.6@#[5HHHH*/@;=1NKZO\ ^%*?#_\
MZ '_ ).W'_QRC_A2GP__ .@!_P"3MQ_\<H%8^4-U&ZOJ_P#X4I\/_P#H ?\
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MC=7U?_PI3X?_ /0 _P#)VX_^.4?\*4^'_P#T /\ R=N/_CE 6/E#=1NKZO\
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M4^'_ /T /_)VX_\ CE'_  I3X?\ _0 _\G;C_P".4!8^4-U&ZOJ__A2GP_\
M^@!_Y.W'_P <H_X4I\/_ /H ?^3MQ_\ '* L?*&ZC=7U?_PI3X?_ /0 _P#)
MVX_^.4?\*4^'_P#T /\ R=N/_CE 6/E#=1NKZO\ ^%*?#_\ Z '_ ).W'_QR
MC_A2GP__ .@!_P"3MQ_\<H"Q\H;J-U?5_P#PI3X?_P#0 _\ )VX_^.4?\*4^
M'_\ T /_ "=N/_CE 6/E#=1NKZO_ .%*?#__ * '_D[<?_'*/^%*?#__ * '
M_D[<?_'* L?*&ZC=7U?_ ,*4^'__ $ /_)VX_P#CE'_"E/A__P! #_R=N/\
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M !1110 4444 %%<C)\3_  O%*T;W<H920?W#=?RIO_"T_"O_ #^2_P#?A_\
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M-I8:6YWO&K,=Q'898\]3Z<4?!2P\#KKE_<>&[+5]+UN"W\FZL-5D.]8V93N
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M8DB7SF78#GC@X[4[*K+31D\TL-!*6J/?:X3XB>.+_P )W5C%IT5M+]H1V<3
MDC!&.A'K7)^!U\7>*+.[CMO$,EM:JZB661B\G(/"YY'YBM^]^#MK=^6_]LW3
M3\^;+,H<R'\QC]:%&,)>\PE4J5:=Z:)OA_X]U/Q7K-Q::A!;1QQP&0&%6!SD
M#N3ZUZ%7DT6AW/PKUF+5E8ZCI<Z^3<NJ;7AR1SC/L/Y>E>IVEW!?6D5U9RK-
M!*H9'4\,*FHE>\=C3#RER\L]T34445D=(4444 %%%% !7GMK_P 4+X_:T/R:
M-K3;HO[L,OI[<G'T(]*]"K$\6^'T\2>'YK/@3K^\MW/\+CI^?3\:RJQ;5X[H
M]' 5X4YNE5^">C\NS^3U/ _%/A77[CQ=JTT&BW\D<EY*R.MNQ# N<$'%>L_"
MWPI::;X4M+R^TE8=5=I/,>>+]XOSD#K]WC'2M3P/XF75]"$6H2K'J%DWD7"N
MP!)' ;\<?F#6CX@\5:7X<LQ-?3AG<9B@CY>3Z#T]^E-5(N//?0QG@:\,0\.H
MWE>VG7^MSF]6\6>!4U:YCU33H9[N-RDLDEBKDE>.I&3TK#\%ZO;>'/&!L+5G
M'A_7V:;3GD7;Y<@)4I^8V_\ ?/K7,:CX7\2:WJ5QJ<6AW*)=R-,JD= QR.M;
M-O9#5_!Q\)7L#V'B'2V:XL/,^4R')? /J<D?D>U<M*O.4[3T70^@S'*,+1PB
MJ8:7--6YE=.RMKHNSL>ST5S7@/Q./%'AB*XF^6]@/DW:="L@[X]^O_ZJZ6NX
M^4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *='_K%^HIM.C_UB_44 7:*** *%%%% !1110!Y;\4]0\$^'?$6G:WXC:]?5
M?LDUNMI8\M<VS*P82#IL!).21SZXXS_A)X>\*:7XROSI>MZEJ.JV^GQ+%;ZA
MQ]EM9 LBJG8@94''3TYJQ\5?"'BBXURYU_PA8V^J-?:++HUW:2N%>-')/F1D
MD#/S=,]N^>'?#+PSXJE\5)XF\86%MI1L](32+6TAD#NZJ02[D$\\=,]^@QR
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M>)+'Q-9276F^;Y<<GEMYB[3G /\ 6O-?'_@[7]7\975YIVG23V[J@5PZ@'"
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M5RN1[,G3PKX6613'I>GAP05(1<YK;FA2XMY(9ANCD4HPSC((P:\[M#(+R$Q
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M7^B[LM>[JSG?"\4B:N2Z,H\L\D?2NPHHK;"X?ZO3Y+W%)W=PHHHKJ)"BBB@
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MR>;>T^6/T+>O]?RK<KCH_O:CK=-E^K^;_(IZ*P4445V$A1110 4444 %%%%
M!1110 4444 %%%% !1110!CZ[H\VJ20F%T7RP0=Q/?%1Z)H<^F7;RRR(P9-O
MRD^HK<HKD>$I.M[;[17,[6"BBBNLD**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *='_K%^HIM.C_UB_44 7:*** *%%%% !45U:PWUG-:7
M<8E@GC:.5#T96&"/R-2T4 </_P *8^'O_0KVG_?3_P#Q5:OA[X?>%?"FH/?>
M'M&@L;F2(Q-)&6)*$@D<D]U'Y5T=% !1110 4444 >1?$#_DX/X=_P"[<?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPM87RW+_ &R\V-N$5S*I3/N%49^AKOZJV^I65U?7-G;7,<MQ:!?/C1LF/=G
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MTU"W5UBNX$G17 #!64, <9YP:LT %>;R? [PU+*SM?:KEF).)H^__;.O2**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
4HHH *='_ *Q?J*** +M%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>fig09.jpg
<TEXT>
begin 644 fig09.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     S<V  "2
MD@ "     S<V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M7Q,M?"/]F;_M 4_:_M&-N5+?<V\]/6@#M**** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(V6WM[4-'YY0<LS*1C)!]>>P%==XY_Y(;<?]>%O_ .A)1\,/^2*6/_7&Y_\
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M"ZL9'NPRI<PM&6&P<@,!D4 8?PBUN]TBX\2Z7?W,ES9:3$\JJ23M\MF#;<]
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M?9+,/]G!&2ORX 'NL8_-JY-->TWQWK]W>_$#Q)<:;9*W^C6=O&[X&> ,*RC
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M 5TWQ8\%:AK6DZ7>^'XS/=Z22!%QOD0[>1ZD%1Q[F@11_:!_Y%;2_P#K]/\
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M,_W8_P#T4U>T5XIXWM]<TWXTP>(--\.ZAJL%M'&0+>!RKG801O"D#K0#._\
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M6EI%9S*0Q?RUW C@@C&/8D5WMNTKVL37,:Q3,@,B*VX*V.0#QG![T%$E%%%
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M&9UA!"C#D< DGMZUNT %%%8'C7Q1_P (?X8FU?[)]L\IT3R?-\O.XXZX/\J
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M!=\6?\G':%_NP_S>I==U_P 3>./B/<^%O"VI/I5G8;A/<1,5;*D!V)'/WCM
M!'O[1>+/^3CM"_W8?YO4.JC4OA;\4K[Q$UA+>Z-JAD:1XA]W>P<C/0,&'&>"
M/T ,[X@V?CCP/8VJOXNOKZPGEPEPLKQ2JX7[K'<3@C/\1'':D^,6G7HTW0]7
MN-6N+B&Z@C1;.0L5C<1@LX);!+=^!]:J_%#X@-XTTNTCT[3;NVTF&;?Y]RF/
M-EVD <$C@;NYZ]JW?C-_R(7A7_='_HI: +VO>(M7^'G@S2]$LM3EU?6M38M%
M=3@EH4.T  ,6R<G YQUXI+WP9\1-)T>36H?&ES<W\*&:2R+L8\ 9(7)*D]>-
MH%6OB=X3U/5-*T/7] B:XO-+C0O HRS+PP*CO@CD=3GVJGJ/QJ.IZ'+IFE:#
M?C7+B(Q&(KN6-B,9&/F/7@8% $&M?$*_\0_!=M4M;B73]3M[V.WN'M)6C).,
MY!!R 0>GJ#5_PSX<\5Z]X-GUF]\5:@;B_P!/(L[>*>2,0L""C$AN20N"<?Q'
M)-<YK'A"Z\)? N9=379>WM_%-+'G/EC&%4^_4GZUZU\/?^2<Z%_UY1_RH&<E
M\+?'1G\$ZD/$=W(]UHI9YI+ARTC1G)&2>200R_D*9\)+K7/$NI:MXFU?4+QK
M225HK6S:=S"I)W,0N<?*,*..YK@_B7H-UIGQ+NM-T1SM\0+&YMXS]XO)DJ1_
MOINKWSPYHD'ASPY9:3:\I:Q!2V,;VZLWXDD_C0!IUXU\ _\ C^\4_P#72#^<
MU>RU\Y?#;Q_I?@:^US^UK>\F^V21^7]F16QL,F<[F']X?K0#W.R^+^LZIIGB
MKPW%INI7=I',Q\U+>=HUD^=1R >>O>I?B-XLUZZ\9V7@OPE<&TN9PIGN%.&!
M8$XSU4!1N)'/]><^)NN6WB34O!FK6*2QV]R69%F ##$JCD D=O6M?XC:;JOA
MCXC6/CK2[-[RV15%PJ G80I0@^@*'KV- &9XXT;QSX(\.+=+XQOM0LY)%6=O
M,=)(7[88L3M[=1UZ5LZEX^O_  W\&-#NXIWGU;48]B3SL9&7!)9SGJ1P.?6N
M>^(GQ-7QCX3%GHVE7D-H)$>[N;A!M4CH@()')[G!XZ5HZOX/OO$_P/\ #DVE
MQ--=Z?$9! !\TB-G<%'<\ @=^:!>A>L_!?Q&CTA=:3QC<G4RGG#3I69XSQG8
M<G;GMC;C/>H/A)K>KZCX7\4RZEJ=[=2V\0,3W%P[M&=DGW23QR!T]*FM/C7/
M/HZZ?#H%]-XDV>5Y21@QF3&-V/O=>=N/;/>LSX,,6\)>,&8Y)B!)/?\ =R4
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M(9HA(?G]\MNZ>F.<4 :?CWQAJ)^)TNC:AK>H:#I%N%426((8Y0'><$$@D^^
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M:(S!L*3SE>0"#U'0CGK0!E:C<:WX5L1J^E?%"TUN>(AIK%[T2!AGD*K.V[\
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MU7Q]IGCFZ\#P:\]S<SOY8NKHF4Q+MW^8I;)'R=N?SP:O7E[XK^'/Q$TFSO\
MQ)<ZS9W[)O%PS$%6?:PVL6VD=00?ZBKL'_)T]Q_US'_I(M5_C7_R/OAK_=7_
M -&B@#2\3:SJEO\ 'S1M/@U*[BLI%AWVR3L(WSNSE0<&CXOZSJFF>*O#<6FZ
ME=VD<S'S4MYVC63YU'(!YZ]ZB^*>GW^B>/\ 1O&=I927=I;!%N%C&2I5B>?0
M%6P#TR*Q]3U23XN_$#1/[#TZZ@L+ @SW$ZCY1N#,3@D#I@#.2: -/Q__ ,G
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M_H9=(_\  ^+_ .*H VZ*Q/\ A-/"W_0RZ1_X'Q?_ !5'_":>%O\ H9=(_P#
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M51_PFGA;_H9=(_\  ^+_ .*H VZ*Q/\ A-/"W_0RZ1_X'Q?_ !5'_":>%O\
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M6_Z&72/_  /B_P#BJ/\ A-/"W_0RZ1_X'Q?_ !5 &W16)_PFGA;_ *&72/\
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M;_H9=(_\#XO_ (JC_A-/"W_0RZ1_X'Q?_%4 ;=%8G_":>%O^AETC_P #XO\
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M  /B_P#BJ -NBL3_ (33PM_T,ND?^!\7_P 51_PFGA;_ *&72/\ P/B_^*H
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MC_P/B_\ BJ/^$T\+?]#+I'_@?%_\50!MT5B?\)IX6_Z&72/_  /B_P#BJ/\
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M ,50!MUPGCWX<?\ "4WUMK&D7W]FZS:X"3X.' .5R1R"#T(_PKH/^$T\+?\
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M"O5=:DG;3[*41+'?3NJ,X'W,]OI7#?&BTM[;P_8W[W"?VI;.(@I/WU;KG^E
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MO0F@#"U;PII3^);,VNDZ;!:D*6#6R!7/IC')K5G\.^&AJAMFT#3T#1\$6<8
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M^F1VKH-;\YKC3UM56*YN3B27ICCIFJ_B*WL;^XM-*N)R)KD&*58CRPQ_%[4
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M3/#=S-!)<6=W(TJ1])6.=H/J:7X=+"GCWQFML_F19LL-GK^[?/ZT >C4444
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MB77(;J![5@QI%9)+/'?1K-)*8XGB?Y%/8$^E33Z=;Q6\4ES?LTN\.\J/P6]
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M@>6,1<&,9"MZ&J4]IJ>NW\4LA6"U@<90\'CO4"6<L>B^9<7;J9OWPE5OO9[
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M9FDU-0WE2-*<1JC!0H'3&*T/$+F7PQX'AU>XGBT>Z1?MDH)YQMQGZ#/ZGG%
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MD6)2%'4?*"2?UKS/4?WFN?$9PV!Y /U^=:[OP*1%\/=(\N;RY9(,#)P.IZT
M:]Y>I');2 @E';<O\59EG'=W&O7.HWQDAM(U!17X IU_8VT$\4\MPZ[3G+'A
MC[5HW+)?Z>EPMPJ)&#@3-B-_]Z@9A:/_ ,3CQ3-J21*#%P_'0=B*ORZQ&^H6
M8B )CD;?NZ_A6)I+((TEM[L0WMT[(B;L1MBI;I)M(^SRPI$T\;EF\_\ CSZ>
MM &E91WEQKMSJ-^7AM(P#&K<"J>C21ZOXJFOEC1)H^'&.,#IMK:O#'JFC)<B
MY\A%&3YC80GT;VK M2-+MTD7:MU*Q ?^#'UH V7U6-6MBF&:.1MX/WOPJO9P
MWEQK=SJ.H,T-HB@HK< 57O+>.UO(;VXEC,76'RS]YN^ZMB[,>IZ6DYN/)1 >
M)#A&_P![VH Q=)']L>*I=02%0T7#9'8="*T;C4E-S8^6H9EE;?G[P^E8,*+9
MVZ_9M01+JY<K'('_ '?XFIYK"SM&MY'O9"R-N+AOOGN* +]M!?76MS7^HLT-
MI",Q*>,&JFG$:UXMFU""-1+$,-O'8="*WG>+4-,2X>;RHXP>)3A&_P!ZN,V2
MRZ#<26%VMOJ%R7CB8/A3CWH \NT95>ZU3>[J4U"5V5C\H^8\BK.BQ+I/Q(TV
M[E\NXM+B0*(^IB;_ )Z>WUJ'P[''+IUS&23+]H>.4MU9P>:O>&IX3X_BNM3:
MW,#(+6-%/",/XFH ]0DD&H>/K>:(;8T(R)>"_':N@O;R&'5#\FZ51\G'&:Y>
M'YM-O-5B/F2@[8V'.W!_AK1OHDGT^TNIKCRVC^9U4_._% #H[/4=8U]-1NY/
M)M(3E8B< 'U J!G.I^.8WB&RWAQA9N"Q]JVK*\M]7\/&65VM(22A9_E(QWKG
M,^5IMS>1R^9*AQ'*#G'/7- '1WNH6UOKCJX)D504]!6<MIJ&M:O%J%VX@M;=
MLJF<?C4!M;6"Q6>XNC-)(H/WLN3Z"M:PN[74_#C&:22V@)*%WX(Q0!C^:=2\
M<1/"=D$9 *3<%_I6K>ZD(M=GB6"25=@\MD7*@^E8+L%2[OU88B0+%)G[N.,U
M=ELI+;1AY]U(C,OF*ZMR^><"@"=;+4M8U:"]N"L5M"W"="/<5:_M*"&&-HY%
M;RY6W#/)^E.TR^%_X;\R^D^S#)3=G!P._P!:S+BSCL;M;RX,*VX ,(!^^WO0
M!/8I=7&NSZE>>9!:*@($G 'O4.@.=7\37=ZL* H-N0."!T(]ZV=30:AI4;K<
M+&BC.&;"/['VKED\G3%B6UU%4N+MS'&R/^Z!]": -^;4DB\AXRI99V#J?O8]
MJKV,5W<:W<:A>M)#:*F55N,>YK/?2[:SDAGN;MPRMN+.WRNW?'K71712^TV*
M9;@1I'R!(V$?V;VH Q-%;^VO%$UX(462'@X'&T="/>KW]M1;D"??CG;<&ZD>
MU8E@! N^&[6*\N96CC\ML1GVJ?4%.CQQRI'&\Z-O8S#ACWQ0!HV:7D^NW.I7
MQ>&S6,;0W&/<U5T.=-5\57-R(HP\:X''!4="/>M>]":MH<<K7/D*%W,&;",?
M1O:N?MF71X8FRJSS2%4=?N$>Y]* -F?5%A, BVLZSMY@/7'M4%C#>3ZU<:A?
M-)'9JF55N,56U"".VO8K^[EC\D8:,1'EG[@^U;-[LU+24E%QY"J-P#-A7]F]
MJ ,71V.M^*I;OR(Q)#QTXVCH1[UH'5D$:&,;G2X8,&^]CVK#2.+3H5-OJ"I/
M<2%%E5_D!]"?2I9=/L[*.)Y+UV9'\QI WWF[CZ4 :-K!>W&LSZA?LT-FB94$
MXQ[FJ^ELFL>*I+I8D+0CJP[#N*VW\K4M.BD:<Q)'SB0X23V;VKEM/*J"\=RD
M-U<7#11%6PA]!]* -B?5P9XHTB9FCN"26';V]Z;%!?W>M27VH-Y5E$NY!T(/
MO6??Q3:?'&R2*+FWD\UA,?E?Z5T,CQ:KHT<LTK6X"[FR<*QQT/M0!SMU)'J?
MCJVGA^5$"C][U;Z5T5_=PIK$"[-SJ>#C@5R]NJ26EWJ4+>9*F8HCV4CN*OW,
M2SZ9;3W%QLD3#'8WSL<4 /DLM1USQ"EY=2>19VK[E7.,D=ZJ76=7\=VTML?+
M2W(W";CS /3UK=L+ZWU707>9GM85)C9Y/E/'<UST:JEA=W,,HE>+(BESG'I@
MT =%J&H6L6K!6&95Y4#H*S&LM1US6TO;N46]G;G*IG R.]0+;6T.FI/<W7F2
M2#<6+9;/H*UM,O+?4]!D,YDMH0QC+2\' [T 8US)_:OC:W:#,<4& 5FX\PC^
M[ZULW^H(GB)8Q \J(H*M&,@-Z5@1OYJW5[&ZD0@QPR$_=QT.:LBPFM]'!GNY
M%)_?M(C<OGLOO0!9FL=2UW68;NY98+2WDR$S@Y'>J&HR+J7CBS>#Y5A8*WF_
MQX]*W-*U%+_0'>[9K9%)0._!('<^]8,5NGDWFHQ-YKQJ5B)YQCH1[T =+J%Y
M!%JB@IN?^'C@&LB6TU+7==CNIW\BSMVSL)P"1WIMQ&MUH]K<3W'ENI#MAL.W
M'05JZ7?P:MH<CR%[:%&,1:3@X'>@##O6_M3QO:^0"D5N1D3<;\>GK6[J5];0
M:NBR [U&Y1V!KG(P%LKRYCE\YX2PAESG&.G-6([:W738[F[NS++*H)RV6SZ"
M@"Q-::AK^K175Q(+>SMVW!0<9([U3OI#J?C.V^SMLAAP&$W DP?X?6MO2;VV
MU'09?-,EO"K&)FEX/'>L%0K-<WB.'CMT*Q.3T(_BH W-0OUA\0B)8'EC$8VM
M&,A6]#5.6SU+7=0BGF*P6L#_ '#P>.]0"SEAT4-/=2*9?WPE5N6SV!]:T]&U
M!;_09&O6-LB$Q^8W!('?ZT 8^IW27GBRRCB!$$+J&,O\1'I70ZC>PVM^=R%C
ML^3 ^4&N86%"E[>Q%IO)0B+=SG'0CWJXZKJ&B6]Q/<>1*F&:-CAG&.@'K0!+
M+;:CKU]!/(RP6L# E3P"1WJOJ5PU_P"*K:&([;:/ (EZ,?:M?2+^WU+1I0QD
M@A4F(M)P16&1%$EU-$6N?(!\MSSC']: -W4=1M;'5O*D_P">'R@=,U0>WU#7
M9H99-D%I"P.&XSCO5:VM[9M-^V7MPKR2KG;(WS@^@]ZU=%OK:_T*96:6*%&,
M;/+P10!DZC<B]\2V<$9*01, 1+P'/M6OJ>I+::LT$<$DT;0X7RUR%;WK"NWB
M2\GN(LS06MN2C-S@CN*N);.NA+/+<NANHO-60-R2>P]Z )9;34=9:W>7;!;6
M[ LK<$X[U<^%(46/B4(<J/$-U@CN,)4/A^^:ZT.6/47*JA,?F,>2/?WJ3X2J
MBZ7XB6%MT8U^Y"GU&U,4 =]1110 5Y9XO7=\8%^17QX?SAA_TW:O4Z\I\:,1
M\7XU5MC2: $4Y[FX:@#:M;Z"/2$AAC>*0?,8L8+?AZ5*=+T;5H[2]U.TD>;3
MYO/MR693&X(.0 1GE1P<UD6*&VN%DN9U>1%VD[LD"K46H*5G,EQN7)(*G.T?
MXT 7;W2M+U[3W@U:S2Y@:3<B/D$'UR.0?I4>D>&=)T+>F@V<5KY@_>'<S$^Q
M9B3^&:@@U"&-$\F4S9.[/7%1V]\9+^9PSI" <@]SZT :6FZ#HNC:1=V&EVIA
MCO"?/ D=@[$8/))(X]*AM/#6DV/AV71(;)192[A)%YKG=GK\V<C\#5:;4(5A
MC!>55D<(-HYR>_TJ1;Y8[@VZR2&1!DY[B@"PWA[2Y-*CT:.VCDTY(]A@=BZK
MSGJ3G/OG-5[#PIX9\/9FTG2?)N6^7SLLY&?0L3@?2JL>HI#%<S^?CYR JGC/
MO4@O5>"-9[IXV<;^#Q]* -"PT72].U>;4TM0MY=*//F#L=V.G!.!T["K5U>)
M-?)A)&C)Y;'6L-KL74@>*:1(XQM;T/UI[WOEVP6.<XW9!![4 5]2\#>#YKX2
M1Z&J7+ON)#.L?_?(.W]*W[W3M/O=.&G7MM;SV:H%,+J-J@=,>F.V.E9,^I0^
M?$LL\BMLW GHWM3!K<$EM,T<4DAR48A<X/I0 _1O!WAW0;S[=IMA'"Q/RR%V
M=@/8L3C\*L7_ (6T*\OKV[6R_?ZBFR[=IG'F)QQC=@=!TQ5:VOECT]/.29@6
M 5"O*_\ UJE-XDEQDO)\B\@=,4 6[:UL='TR*SLHXX+* %47>6*@DD\DD]2:
MQ_LZVMXU\/,FA+?*J#);WIUQJ$,NG3L$^1CM'F#O[529WCM[.""66.3 Y;CY
M: (-9O!J>K)<6=HT+VT#,6NEQG'.17DUE.TAO=7\OS'U"?>V#T(..E>Q3/ \
M\YN/M#M&"F"/O#VKQF-)[+Q1K]OH]NS6PG0_O&P8\C.,4 4KJ>=?$1ACA=[V
M>='4CH%!Y'ITKV6YEN]7U%!I"&S*)APXVJWJ#7DOB*[N6T^)9H!;-Y\9C*'+
M/AAZ<U[%9M'=W2L&EAP@\P-QEL4 :=A%;66E3Q-E)I3B0V_0'_"LRUL/[/M;
MA9;87/F280JN2P]ZL3M;6B,?-8"9MA.>YJ2.W6!5MDNYPX8,-QYQZ4 49[2>
MX*6EBT<)V'="#A![GWK2E^R6'A<VY64RHFQ_(&=[>OTJH(X8]2FNFN % (95
M;G\:;"(GLW\ZY:*-V^1PV.* (+&TB_L>TBGM,_O%<[5^;(/6K/B>]-YJ5NL,
M4DL0(24*,@4K(\MQ"EE=9CA3!;=RWUI\8$5O.6G56D?=N5NE "^(OL1T6/38
M8[@C<NQ0.GN:8L?E0VMO,B2I'&0['D9]13I?LTB0">[9&89$F[[WMFE-Q$EK
M<X5GP=C<?=R.U %./396F\ZZF1[,R!HFSR!Z#VJ]K\']K-%'9?*8V!*3< @=
M<5!9V\4>DJDK2NF054]5J3RX+FY603S[K<;<J> />@!+@1&42/;0I%$-HD(Y
M7_=J.RL3#J OIV-U:'_5XY=O<U++Y,EE<'S T<APID/RCZ56"FUL[.VAN2LZ
MC'WOE(SS0 [59(]4\26GDP2@P(03<+A3]*OV-Q!IIOVGA99)S_K$'RDX[&JT
MGV=;N25KF5Y$! C8U$ELKP)YUU(%D8.$D/ QV% #/#\D<%W+/=VMUYD1VQ,$
M^\#ZTV5DOO$+75K&\*0@B02C!8^HK1:7=J2_OW "GY >M5O-LS)-,97)_C5C
MT]A0!X]J\\]SXMURY@C0W3NH"$991BLVRL+FW\10QW)>-)9%8W[]$QSC/OTK
M7\5HMWXSN/[&*V$JHOFM-QYG'&*Q]6.K7EO%IEPIFN[AP;2.V']TY8L* /<;
M>!O[4>]00@2+_%]X<4V^A66U$5P8TFD8&/R.X]Z9IGEV>DVMQ>-)(TL8#,1T
M/3%6+F*&2:WC*M'*HRN!SB@"?3GAT RQ2V\]QY_S'RERHQZU1L_.ENK^\A6-
M(;EP%CEX9!TQBK$<[O<SRB69(U^78/XL]Z@>.V:U-F/M1=V!+J/FH FU.58]
M#72[6&831_W5^7UJ:VU6#3/#\,-S975Q*\9#[4R ?>DMHX[>0%+B:9XU(8.<
ML?K4<=R8K"9Y6N"-P!51R* *^F1R)I)V^6C2MN6-N,#-%QIZ7]]Y\$NTQ#$Z
M9X'TJS%<VHG@"Q2/E28^/YU'I^QKJ[N7BFC64Y*,, _2@"Y)-;S>'EL[9"P(
MPKR#Y*JV\%Q#I\%HPMF*@EPQX_"G.()EB@'G0QRY9(@,8Q[5+&]NUPJ(CL\2
MD/D=/K0!GMI<.H7$DT$K (P8D'ICL*L:_J<>I:4MG'9W$<LC+AY4P%P>]11F
M**UG>(N%F8;?+Z#Z5*_RPVZ7L\TV 2S*<@T 6+>-X+RVN;I$86BD 0<XS5%6
M2Y\527C17'V:;YFRO<#BI%CAFNI;H37<"C@CHC5-*WD6<$"/,RYYE7OS0!!K
M-]'K5Y;P6UE-!(IYEG3!./0U:N) OG&XF3[/@*2#\RG%)<740O DOG-(H^4D
M<8QS52[GM;G2]L-K-(LQSO5<DX- "Z7;PZ3=VUU=/(3SM4=3FK.I*;G7K>Z4
M1QQVP/#\%\^M.C,*P6R312R28.UF&=OUIN(!Y]Q+YD@7&01_*@!DY#J[:@\*
MQR< Q'YZ-*B70%$DL<]PK<A8AG945X;:;3(D$+ 2-E3C]YP>U3^9(VIQQQ22
MQJB_O.V>.* ((V>_UZ:^LK>.V0#E9AM?I4\TPAT0V-TDIEN#D-&/0]Z@-Q \
M4LS1W>]SA@%YJ6WMX;>X0?:+F5TY"RGD_2@"31[Q=-L97OK:>:6;[RHN<XZ9
MJ7X87"W7C3QC,D2Q*QLL(HP!^[<4R"Z)N+B8K./[R$?RI?A;)'+XQ\8/ C(A
M-EA7&"/W;T >FT444 >4^,(8I?C;IYFC9Q%I".NT9VD3OR?;FMB^U$7.L(L0
M:2 X5]O(4^OUK*\7B8_&2+[.P4C006R>H^T-3[5EL[.;S)XT=I"RLK<#ZT ;
MNM:7HM]]@NKVW>:XL&)M"'8>6QQR0#@_='7/2C4](TO7M-AL]9L4NXP=PSD;
M#ZA@01^!K/:Z@:UB$]SY;-CY]WW_ /ZU3#4%3<1-^Z2/IGK0 :5X6TK18YXM
M)LX(+68;9AN9F;_@1)/<]ZM1>&]$TWPW/HVF6YBL[I7WQ"5V#EUVMR22,CT-
M9FGW7FVLK3S8W.=N#QMJ3[9'*PMDE<%>05^]]: + \.Z/'X93P__ &?FPQ\T
M(D?'+;C\V=W7GK4EWH-A?:7#I$L$4^FPQ*BPNQ81A1@8.<Y [YS4*W@28[;I
MF"K\RYY^IJC!J4=O:W$TMRO+G:%;CZ'WH T+#PMX:\-6[S:-IZQ3R+L+HS2-
M^;$D#Z4[3='TK3+F:\M+,Q7-](LMRX=FWL,X."2!]X],=:I"]CD@19+@6[.-
MY8' (]!3)+NXFO%:TN8S"D>TY;DT =!?W<=Q<JH'F1,-C*!D"L"]\ >"XR;O
M^QH_./15=]N?=,[<?A1;77V:SF,L\:NSDJP;@58EO('M(A/<>66Q\^?O?_6H
M O7FEZ=JFCQ6.HV,5U;\'RV7A?\ =QT_"L_2?!VB:%=23Z+8P0!EVL[.SLOT
M+$D5*FI+%*0DA*QQY ['WJKI]TLT=Q(\K .Q^7VH N7'A#PX;?4 MG^\U8#[
M4WG/B9@VX?Q<<\\8J:*TMM,TFWTZUM (X%"JG+ 8]SS5 W<+HEN))",_+MZ@
M^M.^U 7'EK<R,R+EAGK0!G:O:7.H:@(;:5#;^5^\7/R(?\:GU26TM/"Y@B69
MW$?E!81D%L=3[52@,,"7=R]R '<_(K?+GW]Z<L4+V(6XNC )#NW!L<>E $%K
M:Q+I>G[[/<$D5V15Y+>M3^);R*]N4:&.::';L:.,9\L^OL:5A))<(MG<@1PQ
M\,&Z@=S4ML([2RG_ 'Z!Y6+;P>-Q]: )-2NK*R\+B)8[@^=%Y:H!R6(ZM52S
MA:#1+6(HLIR"R,,@"I;@6TFFQ"[N& 9@#(#W_P *?'<0P7>R,M)Y<.1W##UH
M I3Z9+<S22VLT?V(IMDC9O\ 5MZCWK3O!#)X?_L^Q9EDDA\M6/W&;Z^M4-,@
MB\NZEW2JDK$M$W3GTJ9X[:6.& /.@# H%ZJ?6@"&VL3!I<%DUG \D6-_R_*6
M]:BN=-:]U#R[9U\H18=0?D1_;WK1C9([QHTDE=T&6![^]5+=8+=+NY$^%=B"
MBGC/^- %J^O;>U\-26WD73,8_(_=KD%O[Q]J\R\=)Y5MH>FW*Q16LN9&<\ ,
M.F?>O15C5M/"W%[*JNV<ANB^E</\6EMY/"0\K<6@EB\N0C@_-W- '+ZM%>7%
ME.AARL;*0BC_ %F*Z'X=:A]GT'7I+N*4O?$(EK$O,!QCYAVS6-&^IP[G:ZM&
M)4$DMP!CM6G\."LMWK=W.TRVMS/'MG7[K$ C(/H* ._T>R?3-#@@5XU>8ABK
M'@Y[475I_:-X$B?;Y2_,5/R*?3ZU9BNK3SE0HT[1C*\9X_O5!8[6U.XG$<\4
M#*<JPPK'UH T;>YM4T:6VBC>3)*.Q&5SZFL^PM;BQL9(!]F+2R94 _*5-2S/
M;^2H7SK>*9_+*@8W,>]/*V\,D5IMD:1'!  YQZ_2@"I<V$6H-'%%(JW,;?,L
M9^51Z_6KZ:C;Z982V<]C<SD@DL$RA]S55!#_ &U<7*#8$C*OY/3\?>DAN9#8
M2//-,8YI/*4(>54]Z (K"WN8M/DC;[.(;Q^%)Y"G^&I]>N1/H\&G6<-P&M6'
M1>./2HI[>UN(8[!#=AHV#B1!S]:MPJD,CRPW$LVV/85)R=WJ?>@!ZZM::?I*
M6TFGW4SO%N<F/*!O>L:&SO[[?.9$_L\\-#*?N>ZBM2&Z$>FRO,;AT9R'7'(_
M^M46GPI):RM+*P5V(1">B_XT 7]4B@?0DLK.5U=HL18/RL>P/O6:+1(K"VLW
MTZ.25 &D.S*[O7ZU,8K>8)9K+, IW+M^\#ZU8C"17!VW4C[$PRD]3ZGWH SK
MW3KF_O%BAFBDM!'\Z%OEC;V]ZT-7DM+;PR((A/(VSRE6$9!;'4^U4+?R;2WN
MIVN5'F.<*K?*3[^]3"*&2S2.:[:W+_.6#8!'H* (K:TB73M.66UW>7(KE57G
M=ZT_Q+=IJ&I1>5'--;D"*1(QG9ZD>].82S7R&SN?W44>,ANN/6GVRI:6%QFX
M17D<L'5N ?>@";6+JQL?#/DQ1W+;H_+C3'?'!>JEHC)H]I$\:2M@,RL,A?I4
MUPMM/81+=W+)N(!D!Z__ %J?'-#!+MCW2+%%P>S"@"A+ITUU/)+%*ALMNUXW
M/W#ZBM2_$4V@K863,LC1;$9N$8_XU2TN-/L]U)(T@65B?+/I[4]XK:=(K;S)
MUVL&0)]Y30!'%:>5IL%D;2%WB \S*_*6]:BO-*:]U ):2HUN8<2 'Y(V[X]Z
MT$:-+MDCDD=D3+ ]#[GWJA:^3;6]W<"<@/(?W:GY<T 7=1OK:V\,O:""[=O+
M\A3&N1N_O'VJE:V 73=/6>!76)UD*Q#+$CN:E\E9+)8Y[V5 WSDAN,>E&U9[
MM#;S31I#']Y#]['K0 SQ)=P:CJ$4L4-S*FT1.B+D(/7ZU<U+4[6U\._9X[:[
M;?%Y4>4[^IIMOY=K87'ES[C*Q8NIZ&FW+0G38%N9Y=K,!O4]#[^U %?2[-[#
M188$:,22L'92>#[4VZM/[1O<02@"),.5/RHWI]:L07=H)_+"/,T(R.,C _BJ
M#3U3[9=SI%/% X)9&7 9O44 :*WEL-#>UBC>;=^ZD8C*Y]35&PMI['3C;Q_9
MCO?Y1GY2M/GEMQ:PJJS013R"+:HP6)[GVJ39;Q31V*J[21L&  YQZ_2@"G<6
M,.HS+;Q2!;B/[ZJ?D4>H]ZOMJEO8:5+93V-U.=A7<$RI]ZK(D/\ :UQ=Q A5
M0HXC]?\ &B*>1=-=IYIGCFEV+L.=JGUH CT^TNH--$3"W\FY?(0=E/8^]9?Q
M)U$/X)GL[.WN!Y,921MOR(,<FM::&WG2.R1KM2GSB2,<U!K8MX?#NHNTDMS$
M+5TD3.2>.<^] 'BYL[NZTJ"WM,+;BW!W1<>8?2NG^&$$PU"X>1H[.54$0LY3
MM,@_OXKF-,AU:.W272[JV,;?ZN%^L8[9%;O@ W-[\09-12&26&WMS%<2,,J9
M >=M 'IUW:'4KP1Q/M$2_.5/R*WI]:U8;NU71)+:*-Y<_NW;&5SZFLVQ"G4;
MF<1SQ6[*=R,,*S>OUJ>:2W%O&$6:WAF?RRH&"S'N: (K"VN+*P:!?LQ,C_*
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M64MA<3GEMVS*-[FJ2F$Z]-.D;*8XB&\H?+^/O2P7$KV4TLSS[)',:HO4+ZT
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M)'V?RS&XRV3\P^M;]Y\-M.N71TNKB,QG<%4C!(]:BE^'D3MO2=HV8_.%/!%
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M(MQF,/(NQ7!^?/I]*[M?#6D*F/L,.3]YMO+?6LRY\!:9<7:SB26/;]U$(P*
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MY^E '5V>HQS1N?-^13L D/4^WO3SJEO<J54QF6#G$AX&/ZUZ WA_2FC*"QA
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MQE62.5=P ;)'UKB+BWBN8F@N4$D;=0PS7.>$IW\)_$@6+2$6-]F-5)X4GE:
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M44 %%%% !1110 4444 %<5X7_P"2K>.O^X?_ .B#7:UQ7A?_ )*MXZ_[A_\
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MJ?\ V%[C_P!EKOJX6'X5V=HTW]G^)O$ME'-*TK16M^(TW,>3@)0!W5<#:_\
M)P5Y_P!@ ?\ HY*ZCP_H'_"/VLL']JZIJ?F/O\S4KGSG7C& <# ]J2/PW9Q^
M,9?$BR3_ &R2S^QF,L/+V;@V<8SG(]?PH&:]>._'G4"T>E:*Y*17;>:SM]P%
M3P#7L5>7_'Z* _#=IFC4W"W4(B<CE<MSS0!XIJL-R89I9F*Q1%<JOW7^E>L_
ML_::L>GZMJR3H1J$B$0 _/%M!'S#MFO,]2N;BT5P;?[2"H;:!E5 %>A_L\+=
MSPZ]J<MN\-G=RHUN6&%; (.* -WXN:C]H?3= CVYN)1)*64Y [8-:]G;K;VL
M,"+L55"A1VKEKN?_ (2/XJ7$ZY-MIPV)R&#-Z_2NS@3]Z,_PC./2@!ERJ(P5
M1SW-4YAP#5F9M\S&JTQY H Y[QA'')X8N?-(!494GUKL/ EX;/X<V-SJ<Z^5
M'%D2G^YGBN"\<W!:SM=/0G-S* P SD9K0\?3R6>F:)X3L7$1E"F<HVWCTQ[T
M 2:MXVUWQ'<26_A*-EM0Y7[3C:"/J:SIM \5O&I_MTB1N75&('X^M=1I6F0Z
M7IL5I:)M*CYL=SZU=.V,8*@OW.: .,M_%OC#PF?,U0+J5GNP5;[P&.,'M7I?
MAGQ18>*+$SV+?,@'FQD\H2*YR>-67#J&4]01D5S>CJOA'QQ;M;_)::AE''8-
MVH ]AHI%(901T-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<K\2K6[N_A]JL=DPR+=V=>[J!R![UU5>5?'N_O+7PSI5K9W,E
MO'?7ZP3&)L,R$<B@#Y]2Q\3ZG8I+;RPQVYB\A87!R!ZD>M>H? >6#0?%4^CZ
MU.LNJ26V^*8-\HCS]SZUR5[):Z!FP2>3S1\R([?,X]![URSMJM]J"M*6TZY=
M]L# E)AZ$GTH ^W:*^5_#EWXUT2&2%M>DN&9\@S2,X'YU[+\(O'-WXPT6\CU
M>2 W]C<M RQ<;E&,-B@#T.BBB@#@/BTI@TW0M5=-]KINKP3W*D9 3/4^V<#\
M:[V.1)8UDB=71P&5E.0P/0@U'>6=OJ%G+:7L*3V\RE)(W&0P/:N0'PPTZ*%K
M6SUS7[2P;/\ H,%^1" >J@$$X]LT"(?$OB>P\1> ?%T>F^:RZ?%);R2LHV.X
M'.P@G(_Q%;'P]_Y)SH7_ %Y1_P JL'PCI*>$9O#=G"UII\T31,(3\^#U.3G+
M>YS7/P?"NUM[5+6'Q5XI2U1=JP+J0"!?[NT)@"@#/AO_ /B\'B?5[*/SX=)T
M7R9BO1I00X7/K\I'X5F^&_ "^+/!DVKW.M7EE-K):=[>Q81VJ')&&B'#=.<_
M_7KT?P_X9TKPQIAL=(MA'$QW2,YW-*WJQ/6L%_A=I(\^*QU+6=/L;AB9;"TO
M=D#9ZC:02 >X!H XI=7?4_#G@34KJ&"VBL-;6TD:!=L7!PK #@#"_2NL^+W[
M[PM8649S<7>J6\4*#JS9/05TD_A+1;CPL/#KV2C3%3:D2D@I@Y# ]<YYSZUG
M:5\/M-T[5K?4;F_U/5;BT4K:_P!HW/FK![J,#GW.?T% $*9U?XN2,03!H-@$
M7VGG.3_Y#4?G785FZ3H5KH]QJ,]N\LDNHW1N9GE()!( "C 'R@#@<GWK2H&%
M%%% !7%?#;_F;/\ L9;S_P!DKM:XKX;?\S9_V,MY_P"R4 =K1110!Q7A?_DJ
MWCK_ +A__H@UVM<5X7_Y*MXZ_P"X?_Z(-=K0 4444 %%%% !1110 4444 %%
M%% !7"I\5+*XNKJ"P\.>([_[),T$LEI8K*@93@C(?^==U7C/@'Q7_P (_=>)
M(/[!UO4_,U:5_,TVS\Y%YQ@G(P?:@1Z#X>\=Z7XAU*734@O=/U&)-[6>H0>3
M(5]0,G-92?%2RN+JZ@L/#GB._P#LDS02R6EBLJ!E.",A_P"=4M,AU7Q9\3[#
MQ)-HEYH^GZ9:R1)]N4)+.S!AC9U &[/X=>:/A#_S-/\ V&9: .C\.^.M(\27
MTMA MU9:A"NY[*^A\J4#UQR#^!KI*\]^(L:6OC#P7J4&$O#JB6I<<,T3D!@?
M4<G_ +Z/K762>*_#T5VUK+KVF)<(YC:%KR,.K@X*E<YSGC% Q+'Q+9W_ (HU
M/088YUNM,6-IG=1L8.H8;3G)X/.0*UZX'PW_ ,EK\9_]<;/_ -%+7?4 8>J>
M+])TGQ!I^B3RM)?W\FR.*( F,?WGYX'Z^U;E>3:WX3TOPOXW\&?V<DLEQ<ZA
M(UQ=7$ADEF(5>68_7MBO6: "BBB@ HHHH *Q_%FH/I/A'4[^)79[>W9P$ZGZ
M5L5'/'%-;O'<(KQ,I#*PR"* /DNUBGFL_,M'!^USM*S(?F0MR<U9\"Z6-4^(
MNEVC7"PR6-V+EI)#@2X/W5/<U%9%X3JKVPVQ1ZG-M1>I&X\"G^&I;[5?B7H5
MK9Z>Z26]XMQ,53[L?JU 'UB3@9/ KQR"ZEU_XH7][+N\NT!BB5@"$ [9KT[Q
M-JJ:+X;O;YR,QQ':&'!8]!7FWP^M-NC/>N09+N0N[9/Y4 =C H+\C(45!(VZ
M0FK"?);,V.M5,T 02\2&N.\61I/XET6)=Z3-*OS)Z9ZUU['+$USOAZ ZW\56
ME*EH-/CW,P.53T_.@#N/&7C"'PKIB(P:>]F7;&J$=?4UP?\ PC^N^(IUO=<U
M-H$89$<3$D"F0RKXJ^)VH7MQ\\=J=D2%<84=/QKN/+W9. BK[4 </<_#Z+,D
MEGJ-PCD84EC^IHM/$?B;P/<1QWDSZCI8QN+C)0=, ]J[5Y"_& !["J-W;QW$
M+PS*&C<<@T =EH>L6VO:/!J%FV8YESCNI]*T*\S^'-T=,U[4-"<_NPWFPC_9
M->F4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q7PV_YF
MS_L9;S_V2NUKBOAM_P S9_V,MY_[)0!VM%%% !7%?\UZ_P"Y:_\ ;JNUKBO^
M:]?]RU_[=4 =K1110 4444 %%%% !1110 4444 %%%% !1110 5FZ[K^F^&M
M+?4=9N5M[9" 7(S^E:1(4$L< =2:^?OC?XNT6YUNQA@O3>&Q?9<VB [22>&W
M=#B@#OO^%Y> VX75I.>,_9GX^O%>)W^M6EQXX\1W=G,+G39[A6-[TP<<#%59
M+LZG'J,VF7L=K;QKCB$,9./3M7&>']+N->F33K2X:UA;)N92OW".@QWS0!V%
M_P")+;3=8L-1TZ95U*WD 3$>X!"1N]NE?56A:YI_B#2H;W2[I+B)U!RO4?4=
MJ^.-4\.7GAJ!V5O/M-P#W!'?MQ7?? ;7/L7CR6PGNOLXO5R(2<K(0/TH ^FZ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "FNBR1LCC*L""/:E9@BEF. !
MDD]JX:[^+_A.TNY(?MZ2A"1YD; J2.H!H \>^)WA.R\$>,+,6*W-U9ZEO86(
M.Y$/<[?QK-A@CT[P^8)8/M"9_P"/>(9SD]A[4?$3QX=?\4)KFE6-VMK:_(DM
MPOR<\'%-UJX$NAN;>*X9W"LKV_4=S0!%I\5S9-/$B-Y*8.#Z'T^E<WKUEYVI
M07D%Y+)9QG,DJ/\ -"?8]JZ3^VENK.#RLH'&)&;_ )9X]?K4]I'8QZ4R11JU
MI("#N'+GWH ZKX.?$XVWB!_#VN:C)<VTX'V*YN'R00.02:^@P<C(Y%?'UKX1
ML;:,2//(ODAGC96P5)YKZ ^"=YJ%]\-;.749WN!O=8Y9&)=E#'J: /0:RSXG
MT 77V8ZYIHN,X\K[7'OS],YKE_B3<W5W>>'_  Q:SR6T>MW3+<RQ'#^3&%+*
M#[[OTK:;P!X5;23IW]A6(@*;=PA'F#WW_>S[YS0!M7M_9Z;:FYU&[@M(%(!E
MGD"*">G)XK.3QAX9ED"1>(M)=V. JWT9)_\ 'JX+X@:'/X<^",NEW&HR:CY$
M\8CFE3:P3>,+U.<5U\'@;PK>:- D_AW3?WD*[F2U1&/ YW* 0??- CI@0R@J
M001D$=ZH'7]&74?L#:M8B\SM^S&Y3S,^FW.:X;P/_:%I;>+O"=M=.QTARFGS
M2M\T:R(Q09]BN?QKB4U/P:OPQDTB>P1O$>6A,@C!8W.XXD^T?=VYP?O=.* N
M>^RRQP0O+,ZQQH"S.YP%'J3VJG8:WI6JNZ:7J=G>M'RZVUPDA7Z[2<5YMXSO
M4AA\&:%XIN7:T>#S]3V$N;IXXUVH-O+;GST]0:NZ;)X3OO&VEB'2-2\+ZM;J
MS6L<EHMJMXF,%3C(88SQP: /2J***!A1110 4444 %%%% !1110 5Q7A?_DJ
MWCK_ +A__H@UVM<5X7_Y*MXZ_P"X?_Z(- ':T444 <5_S7K_ +EK_P!NJ[6N
M*_YKU_W+7_MU7:T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4C,%4LQP ,DGM2URWCCQIH_A;2)5U&5I)YXRB6T&#*P(Q
MD#VH Y[7/C?H.C:Q/8)8ZA?F!MKS6L89,^F<UY_\4OBII/BOPC_9L>G:C8WQ
MGC>!;I JOANO7I7GT?B:*UAN; 1/;^9./(DE&&92>2WO5+Q;9M;ZA:SQ->WT
M&P@S2'<J,>F#Z4 =%)XDMK0/#?R*UPJ@2B(_*_'\-=)\*?B/9>'H=8LM3FGM
M;6<;K!91\D. <KCMDUQ.G_#Z&XT>*\FN97U-QE@6_=@]L5SFI17=M?2Z=<LL
MEPDBJP!X8]L4 ?0_P]L]]I<ZJX'F7DA(P>B_2NXC^2%W/4US7@E8H/"=E!$^
MZ1(@'S]X'T-=+<?) J=_2@"H3GDU78[G-3N<(:IS2K!;R2N<*BEB: ,#38VU
MKXLVT4D)>"Q7>"C="/XC232Q>)/BM=W#?/!8?)&'7JPJ?P(RVFA>(?$MRT8D
M8,J,PQM'H#[U'\/;,KIL^HSC#W4A89.?EH&=I$?O,>BC'-5B<DFK#G;:CU8U
M6H$,F/R5QOC1V:ZTJ"&14D>X7J.0<\8KKYCE@*YO2XCK?Q6M@/FAL%W;2,KG
MWH ]=MPRVT8D #A &QZXJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *P/&7A*Q\8Z"^GZAN7:=\4BG!C?'!!J[KOB#3?#>G
M&]UBZCMHL[5+MC>W91[UP&N_&OPVFBSK:&XN+B12B108WY(H \-MK(-JESIL
MD<L\NG7C+]NN/FW!3T#5J:U&EW,%2WD>:)/,%PHXX_ASZUG:%J\_]M7-E>6\
MD"7&ZY"S#YRQ-6;S45L_$D4K0W4<+QB,EO\ 5[O7ZT 2SNS::B7\[6VY/DD!
MQSZ'WKD],FOO#5]<W46HW-E>[B\/E/A9AVR.^:ZB:XM]0N56]!V+)^YC/\9[
M'Z5)K6EVVKK##+M2>!@ZL., =OI0![U\+/'EOXV\*PR-(HU"W41W,9/.X#DX
M]*[BODK2[%_#GB#1I=$NYX;JYOXU=5<A7R>01W%?6<6_RE\W ?'S;>F: '5F
M3^)M"M;K[-<ZUIT-QG'E27:*^?H3FN=^)^J7MIH-CIFE3-!=ZS?16*S*<&-7
M/)!['H/Q-:5GX \+66EBP71+.:/;M=YX5>1_<N1G/?/;MB@#>FN[>VM&NKBX
MBBMT7>TSN%15]2QXQ[UE#QGX7) 'B32"3T OHO\ XJN8U;PTWA3X3^(]/34)
M;RT\F9[6.5>;>,](P<G('KQWJ;P1X1\.7_P_T>6]T'39I9K-#)*]HA=B1U+8
MSGWH$=Q%+'/$LL$BR1N,JZ-D,/4$52N=?T:SO19W>K6,%TV,02W**YS_ +).
M:XKP;!_PB_Q+UGPI9._]E/:KJ%K"[%O(RP5E!/8EOT'U/&:;J7A+2_">M:9X
MPLTN_$(FF6XG$0F:9R3M99@"$ZCJ1@YH"Y[NS!5+,0% R23TJA9:_H^I7+6^
MG:M8W<Z_>B@N4=A]0#FO+]>N;G3OA?X3T?Q!?&**^E1-0G67=_HZY8IN7J=N
MT<9SC'-71+X+O=:T6V_L34_#%S%.KZ?>&R6V$Y'1-W.X-QPPR?7GD"YZG111
M0,**** "N*^&W_,V?]C+>?\ LE=K7%?#;_F;/^QEO/\ V2@#M:*** .*\+_\
ME6\=?]P__P!$&NUKBO"__)5O'7_</_\ 1!KM: "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KBOAM_S-G_8RWG_LE=K7%?#;_F;/^QEO/_9* .UHHHH
M*XK_ )KU_P!RU_[=5VM<5_S7K_N6O_;J@#M:*** "BBB@ HHHH **** "BBB
M@ HHHH ***XGXK^)U\,>!;J9+@0W$V(HP!EFW<<4 >=?$+QMKGB#Q??^'M U
M7^R[2Q!AG9 '\\D=?;BO-Y+*?P]I!@U*U^WVX.W[43SD_K3]&TR+3)K/7+B)
MK=?*;[3(TA;<Q[UJ:@TVM:0T]E<[+1B)(7*YWX[8H J>$+?38Y+IK6W,4L;
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M96T*['\L.P[<]Z]+TW1UTJU+,VZ9^"?:@"RQRQ/J:K2'<YJ=CM4FJS.J@NY
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MU+2YEFMYEW*1V]C6A7B/P,F%EXJ\2Z5!N%JKQM$F[(3@YKVZ@ HHHH ****
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M[8996<(IX13V/O3/!]FESXFN;D;F$ V(Q/S+_P#6H ]+T6ZDTNXBVJKAL>8
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M_:+2?=Y<FQEW88J>& /4'M7#Z'>>./$NC_\ "2VFJ6MI#,S26FD-:*RR1J2
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M@OH+RR"F)AO#_P 1]C6/)?KI&J6\'A^,$L";JWW<$]N:VTUS1KET7S@LKC&
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MZU<KRKX&>*-0UO0[K3[X-+%IQ5(;H_\ +4'MGOCI7JM !1110 4444 %%%%
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MJM%MOLWE8VX(.[=GGITQ6_0!XK;:!XAA^#VEV(TZ^9(=39]1L(E:.:>WWDD
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M\9^'=>BTC5M/UW2H9(1:/LE6+AI.QSZU]@Z7?PZIID%Y;/OCE0,#0!;HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KBO"__)5O'7_</_\
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MX?QAXWU'QEKMA/,+.T2VA)!<X#'.<#WH L>.O%TGBWQ58:QHVFW&GRV=NR7
MO%VK(N<G&.^.E9'B6Y;7_!P?2XI1O=9,,.54=<U<C_M/7)(+6Z\J,7<)="O!
M"].:DTSR;0-H0N$+0 HPS\["@"EH^LZ9%I5I:37*VK2+RS-@N:V((;6?5DGB
MN_-GMU*; V>#ZU -&TL1#R[2&Z>!@/G7)2L/Q-'';[;F*8V1ED5,1':[9..:
M '>,H!K",+>&9[RS8*CH.-O>N3NR^8HHM\1D^7:..?>N[U.QDTS1HA#-*2F
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M9;S_ -DH [6BBB@#BO"__)5O'7_</_\ 1!KM:XKPO_R5;QU_W#__ $0:[6@
MHHHH **** "BBB@ JK?:G8Z9"9=0NHK=!WD<"N5\>>-!H42Z98H\FHW:E8VC
M8#RCZFN#M/!USJ"_:/$E[)=3.,D%RV* /5+7Q7X>U6%!#J-M(LS%55FQN_ U
MRGB+X;YF.J>$;EK:X.7:-6RDASGBL23P/HS1JD4;Q;1C<&Y-06.H>(? DFZ.
M26_TS*@QL=VQ?;TH&6=*\8207TFF>(U^QW,1*EW7"N:ZV*7<-\+J0>FTY!J-
M+GPO\1])$;M#]JV$E&&)(F/%<E=Z+XC\!RLUO&=2TO)(VGYE&.IH$=R'69=L
MHPU0R6[)R.5K'T3Q)8:Y"&MI"'S@QM]X<5M1S%!R=Z^GI0!7(!ZBHGBQROY5
MH&*.<9C.#Z56=&0X88H S+VR@O[9X+J,,KJ5Z<BN;2#7?!4AN/#ER9[3)S;2
MC( ]:[-T##WJ%D*]>AH TO"GQ T_Q(1;OBVO>\+'K@=JZBXN8;2V>XN9%BBC
M&YG8X %>2ZYX5M-2!GM\6MT.?-C.WM[5P>N_$;Q9I_AR_P!$OK8SVLR>4ES*
M"VT?7\* .D\=_%K2_%/AC5=$MM%U)UG!ABNA&-H8'[V?3BN+T#5IXU&FZHN^
M]@C#;XA\I0C@?7UJAI>IZ@NER16TEK/#!&))63..>WUJ\]D-!NX]5NYXU-\@
M4!SPO?B@#!\/3+HFK:BVK+L?<9$+]%!/!KI6GTS4; A=35HKGY=P?OZ"IY-/
MT^ZN!/=[)GG4+M;D./2JEWIMJ+%K>*SAM C%@P7"K[CWH N:H\$&EQV-PCRP
M3J(2%&21CK7G'V&;3A/#)%*A#$Q,PYV]JZSPM9_;+*XO1>2W)WM"@D;(4CN*
MQ]4,K0RO+,Q:%SS(>3["@"/P?:RZUXQC:=Y;F.W4']Y\W([>U?1GA2S:*UW3
M0E'W$_,.<=J\B^%U@OD?V@J[9)IMJ!3]X#KD5[O:9%N7DX..GI0!'<-NF/M5
M68]!4Q.2359SN<T <OXYNF32([.(@/=2!3GTJWXW3['X<\/>&+) CS!2\:-T
M'?-5EACUWXGZ?8N)/(M?WC[<$%AS^5/OB-?^+5R^0T5@NS.,8QVH&=98VRVU
MK!;Q]$4+T]/6I;EMTV!VXJ2$ ,S?W1WJL3EB:!"$X%9.KWHL=)N;GG*H=N/6
MM.4X2N0\<W#-86^GP\R74H4\X(% '4_"'3Q#X8EOW ,MY*69BN#_ /JKT"J&
MAV,>FZ#96<*,B0PJH5CDCBK] !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ,EFC@A:6>18HT&6=V "CU)-5=/UK2M6+C2M3
ML[TI]\6TZR;?KM)Q7&_$2)=4\5>$-"O&_P")=?7<TES'DA93&JE5..Q)/'_Z
MZU;[POX:TW7-.U:WCATN_M]Z6\5JR0"[)7_5E<?/]!S0!MWNO:1IMPL&HZK8
MVDS_ '8Y[A$9OH"<U<\Z/R?.\Q?*V[M^X;=N,YSZ5YQ\,_#VDZ_X+_MO7+*V
MU+4-5FF>YFN8Q(PP[*%!.=HPH/'K]*R-.T34=:\%>+/">D7)\O3=6:.S$SG#
M1ALF$GTX_,T"/4K'7M'U.9H=-U6QO)5ZI;W*2,/P!K#MO'5C<?$"[\.M<V,<
M=O$H20W"[I9RV#&!GJ.A7DYKB_M6FV6MZ(?%7@VX\+W5K=(+>^TY4,$C]!&[
M*/NGTY/7G&:WM+TVQ;XW:VQLK<E+&&9"8E^60MDN..&)[]: .CT?7&_L6ZOM
M?U31?+AN6C-Q97'[F-<@*KLQX?)P1[BM!=<TE]2.G)JEDU\"0;87"&4'_=SF
MO&C_ ,D!\5_]A=O_ $?#6UX\\*Z1I_P]TA]/LX[:Z6[M@+N-<3$MPS%^I)SG
MD]<4!<]+M];TJ[OGLK34[.>[3.^"*X1I%QURH.14T5_9S7LUG#=P275N 9H$
MD!>,$9&Y>HR.F:\Z\::'I7A_6/!4FB:?;V,@UF&#?!&%9D8@$$]6S[Y[^M7_
M  W_ ,EK\9_]<;/_ -%+0!U.JZW;VFGZL;.YMIK[3K5YGM_,#-&0A9=Z@Y /
M'ID56\+^(&U;P38:WJS6]LT\/F2L#LC3DC^(G ^IKBG.?'?Q,QS_ ,2N+_TF
MJM;OH/\ PJ_P=%XA2_O"S;[;3+)=YNW4GAD_B SZCK0!Z98:]H^JRM%IFJV-
MY(HR4M[E)"!] 36);>.K&X^(%WX=:YL8X[>)0DAN%W2SEL&,#/4="O)S7":G
M*5\=>$KRU\(-X<W7XA\X^7&TRM@%2B>Q/)]:Z72]-L6^-VML;*W)2QAF0F)?
MED+9+CCAB>_6@#JO#=_>:C83R:A=Z7=2)<O&KZ7(7C51C"L3_&.X^E3VWB#1
MKR]-G9ZO8SW(SF"*Y1G'_ 0<UXU#>7%M\(-3@MI7A%[XB>UFD0X*QL5W<^^,
M?C79^.?!F@:;\.[R73=.M[*XTV'SK:Z@0)*CJ00=XY).._KZT =Q<:KI]I<>
M1=7UM!-Y9E\N295;8#@M@G.,]^E)I^K:=JT;2:5?VMZB'#-;3+(%/N5)KR^6
MUA\4_$GP@^N0+.MQH"7,T+CY7?!;##N QSCV%:HL+31?CK8Q:3;16<5YI+F>
M*!0B.0QP2HXS\HH ]&HHHH&%<5\-O^9L_P"QEO/_ &2NUKBOAM_S-G_8RWG_
M +)0!VM%%% !7%?\UZ_[EK_VZKM:XK_FO7_<M?\ MU0!VM%%% !1110 4444
M %%%% !7A7Q+^(_B#_A,/[$\+W_]GI WE7#A Y+9Z\]*Z#Q?\7I["_OM.\,Z
M8;YK/='<W>_:MNX]C]['6O*_#%U]L75-0O+@:A/?W/F27!7:=Y'I0!<M]*N]
M'CO7O=6%V;Z3?-(8AR2.:9I]C86V\:);&;Y"DLY<\9]C6Z;:)K,VTX!W+R":
MQ;.SGT*<JC8L9S]=I["@ U/25O?"ZZ?+>>7"LJD<<@>E5O$.F_8]!B339&40
M)E5&221WIEUIUW%XPM[J_O,VJ(1$F,?2M@74T>HM9F,3?:E+!B?N?A0!S/AR
MXUZZB@FUZ'%I*IQ)QEJC)7PGXAD\I3]DOCYCY/W<>]=#>R"S^SZ5)<!KAD,L
M8 ZJO)J*ZMX?$.AE' *N-P'<,.E ')^*M9LIT#:.#<-*P60_=^8\ 5W/PX^$
M6M7OB*PU#Q-IGV*PM5+;"X/G'J#CM7&_#O1H[GXJ66E>+X]UFVYT'3++RO3W
MK[#4 * O  XH % 50%& !@"EHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"QEO/_ &2@#M:*** "N*_YKU_W+7_MU7:UQ7_->O\ N6O_ &ZH [6BBB@
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M*=H6CE.8P?\ 9%:$.K:9#(D4<8,B_(Q0?<'J?:@"J/$-Y [V[Z9<N6&(G1.
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M]U@J2,/0\B@9T\3;+@%N_%-N4VS'T/-5K.Y6\L(;E#G>H/XU>F'FVRR#J.M
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M2(PPSD?C5/6M-MK;PPNG6P4BV7?&F>2!SC-)X<U1=0M[&0JT,@B(,!4_GF@
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M\IL2+Z#Z4 8=K:V\1_X^5BLVDW,&;#%O[I_V?:C6'6Z6ZDTF2%HX[8J\$?W
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M>K>&+35]0E-RRK=!0$F(KD=5L-3TMDACCB186)%Q&.&'^U7J<%JLM[-*\?#
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M* "BBB@ HHK/UW6+;0-$NM3O6Q#;1F1O?% &A7FWC_XO:%X=L]1TVUO6.L+
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M6/GZ3):Z9*DB(1T/09KKHM(T]=.6T:56B_N.>AJG>Z-#I[?;K=2I7@PIT?\
M"O$/HSC]8L[:VL8[F%-B08'[GA@3UQ5._NM.%Q:VU^TELTH/E7#G&S\?>MGQ
M.MTEJEO%#'Y<IRY4?=[URWB#[/K6LZ59S6LZJN=P8<G [4 7#"NE6LUU'?M)
M*PRJ7#Y7\*PY_$2C1Y;NXN0E^S "U1L9YXP*ZN2WMY(0]PL,D6  W45SWB?1
M3,B26=G;B6/[CE>>?6@"'2[2\\?Z]9:/J3VEAJ$3AH_,.WCK^>*^P;6+R+.&
M$G/EQJN?7 Q7R)#I_P#Q)PL$L;:Q"0[72G]YQS@'Z5]/> _$,7BCP78:I#OV
MR)M._KE>#^HH Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XK
MPO\ \E6\=?\ </\ _1!KM:XKPO\ \E6\=?\ </\ _1!H [6BBB@#BO\ FO7_
M '+7_MU7:UQ7_->O^Y:_]NJ[6@ HHHH **** "BBB@ HHHH **** *.JZ/8Z
MU9O;:A;I*C#&6'(^AKS#4_!^N>#;B6^\/L+VQ;): YRBYKUV@@$8(R* /+]$
M\66>L,8)$-O=+G?%)U&*Z%)2HP1O3^50^)_AMINLM+>V&ZRU Y?S(C@.V.,U
MQ46O:UX3NA9>*HI&BW86YV\'CCF@#IO$.EI?:?YL#*CQ'?EO05S=K,]W"<<;
M3@GN:U]7OH;W2H9M/N%DC,B[RC9X]#4"""4#;M3T*]#0!F7L3QIE'<@\')IM
MK +:!F3<X;YC6G/!U1B#]*IF ))M#LL1'/- &#KV@6OB33V(B6.X +*Y&#FN
M0\&:U'I3W>F:K(MO('RK,<;\=:]+AA\C=@LR[N":\XU"PCN?'MS$L,4JLIP&
M'W<C^= #[>[&A^/$FMV'V:]X+=L'_P"O7IEDCVV)7*%=V"W<YKQGQ%IL^G0V
MUC=S9D53*DB'H,]*]&T764U#P_9OO+(T?EN0>C"@#>\02+#&%"9,G.<<5DI'
M+=1Q+;0ONW @@< 9K2EN4N-&$;1M)*AV[R,@UMZ%9M;:>OG+M=AT(Y% %#Q+
MIIU'PS-%UEB'F(?<5:T!AXR^$]UIDGS7-JI"9Z@CE?ZBM J Q5N0>#]*YOP1
M=?\ "-_$6YTN4[;>\)V9Z<\B@"QX"U$W6CM:3'][;G!![5V%L=R/$?PKA;J#
M_A%?BA<0?=M;T^8GIANOZUVJ-Y<RMVH B9<,5/TJJ1AB#6A=IMD##HU4IAR#
M0!C^'KK^P?B,L;';;ZHFP^F\=*]5KR#Q7;2&P2]M_P#7VCB5"/:O4-$U)-8T
M.TOXCD3QAC['O^M %^BBB@ HHHH **** "BBB@ IKEA&Q098#@>M.HH ^4YU
MDUSQ;K=]K<CW<\%[)#'%,=RQJ#P .U$]I9VD$JV]M'$T@()1<8]S3?$5U!<_
M%76&L([A+9'9)?+'RF7/)IMS=.]PT%MY;DQ8RWKZ&OIL$HNA%V/C<Q4UBI+F
MN@T"YUSPIXD75O"C6LGF6_DR+/DJ3GKQ4&M^./%?BW6)7U*[N[":V7;%#I[E
M4+#^+%6-/A:2WV$O#L;YP./F]O:DTV2..ZN7R2RL<RMV'IFG+!4IU.=CAF->
M%-TT]MCTWP3\5WE^&VHR:I*@UC28&VI.>9MHX)]<FO/],^(?BS3M2M_$M]J/
MF6]W*#+:NQ,<<9/.!V(KDM0T*74->E%O/(B3Q$L4; 8&NAT\VW]G+97,:R+;
M+L*.,[@*XJ>7.\E+;H>A7S2T82I[]4>U:Y\:O#FDV]J;7S-4FN8A(([+#[,_
MWO2G>"OBYI_BS7'TB6SN+"[\LRIYX"AE]/K7@>F:);Z/JD]\9!%#.#M&<;<]
MA3GGU*+4K36K%E2>QN Z$DCS4'.T^N:REETHTG+[78VCFL95E&WN]SZ]HKE_
M 'C2'QQX=_M"&/RI(W,4R?W7'6NHKRCVPHHHH ***X?X@?$7_A#I;2RL+'^T
M=3O,^3;;]N0.I)II-NR$VDKLZ[4M2M=)T^6]OY1#;Q#+N>U> ?$OXCVGCZZT
M[0/#$TEQ8RLQO$9"@?!XY-8/Q,^*FK^+X++09+.32E+_ .GP [U;D%?FQTIF
MH/8Z'86T\+IYY7]RR#)7UX%=^&POM'S2TL>;C,9[-*$%=M&7XQ.CV]G#;6ZX
MOHF4I$N3T-;WA[49-9\3ZMJ%Y;;#<+$N2<XPH%<YH^AWNN^)KK4C(;>6/;RR
MY!!^M=ZUO;:+&/L496:7JH&=WO7=[-NK[2731'FNHHT?81UOJR/_ (1#2[W4
M)WN$+. ,!7*[?RK(N="U+PW.OV>X\^*?]W@##<]QZGWK=TV.]FOYIK>)IY),
M>8QXZ5MMICW=Q;RZB3'''RA_NM7-BN1Q;:U.O">TA-1YM#G!I.EV:1-(8H+K
M <E^')]ZCFT_S=82ZNQ') 8OW>>F[U%=C/H]A>2,[".>0KM)ZG%93:?]BE-E
M%^]3'F!I.0OL*\H]HY'RDLM:DA59=SKYNV/[I]S[UGK_ &=JS3K:W4MI.LA6
M2%&VM[OBM22[GBU^6YN[9V6-3&HA7DCUK!\.VUO+J.H:B$\N62=HP9>A'I]:
M )-6U*321!:6MPD\38661SEU'<YK-O/$L]EJ2IH#K?K'#OF9CN5%[_C74R6-
MJ9"&MX6F R05ZCW]JY!M%EM]>+QK#:V;'?,%^7>.Z_2@#U+X!^'5N?$=YXMM
M[JW,4T1B>&-LL')R3]*]^KYI\#ZO#X6^(-A=6P\K3=1Q:+#!POF,>&(KZ6H
M**** "BBB@ HHHH **** "BBB@ KBOAM_P S9_V,MY_[)7:UQ7PV_P"9L_[&
M6\_]DH [6BBB@#BO"_\ R5;QU_W#_P#T0:[6N*\+_P#)5O'7_</_ /1!KM:
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M/!6LXDF&_P"S3@D[QR<$^U>XUY$HN#Y9;GO0G&<5*+N@HHHJ2@HHHH ****
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MV^:TE\R('^XU.<;7-81N?^$?\=:?J8^6"<_9Y_H>AH ]<HH!R,CI10 4444
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MS(Q)RF/[OIFNI\'_  ST7P;<27-HT]Y<OTGNVWNGK@]LUV-% !1110 4444
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MX(J6[7.V0=#6!X4U$:GX>A;.7C&UJZ&/][:LAZK0(H3+P#6)XCL/M^C2HO\
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MM8:<9Q;B:.K71CC4E)"[2=N@/O[5<^'?@73_ (A6&IZIK#/#<0W#6L<EL<8
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M\+_\E6\=?]P__P!$&@#M:*** .*_YKU_W+7_ +=5VM<5_P UZ_[EK_VZKM:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q/%'A+2_%NF_9-6A
M#!3E)5 WH?4'M6W10!X9<_!#7%O);&RU2(Z/)*)3)*Q,Y8=#GI3)/A#XS:Z:
MS_M&QDTUVVF9V;S_ "^XZ=:]VHH S?#NAV_AKP[9:/9%FM[.(1H7ZD5I444
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M9;S_ -DH [6BBB@ KBO^:]?]RU_[=5VM<5_S7K_N6O\ VZH [6BBB@ HHHH
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M*** "BBB@ HHHH *XKPO_P E6\=?]P__ -$&NUKBO"__ "5;QU_W#_\ T0:
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MU/T(XH FHK/F\0:-;7XLKC5K&*[)P+>2Y19"?]TG-:% !1110 4444 %%%%
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M .UHHHH XKPO_P E6\=?]P__ -$&NUKBO"__ "5;QU_W#_\ T0:[6@ HHHH
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M-(8UCA18T4855& !["G4#,FS\,Z9:W*W3PM>7:]+F\<S2 ^Q;.WZ+@5K444
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M!KG&7>C*>A&*J?"FYF75=;LQ&RVJR[DR>C=Z /3:*** "BBB@ HHHH ****
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MML^HVOE),QZ $$\GWQ0!UM%<]KWC/3]!U&'3C;WNHZC,AD6ST^'S9 G]XC(
M'U/:K'ASQ3I_B>"=K 3PS6K^7<6MS'Y<L+=@R_@?R- &S1110 4444 %%%%
M!1110 5Q7PV_YFS_ +&6\_\ 9*[6N*^&W_,V?]C+>?\ LE ':T444 %<5_S7
MK_N6O_;JNUKBO^:]?]RU_P"W5 ':T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 R9#) Z#@LI /X5\RWUB=,UK5=%UK"26LH992>9@W/'KB
MOIVOG#QM%_;7Q:U];S]XNGK&+8GCRB5YQ]:[,%*2K+E.#,(Q>';ET.=N[2TT
M77(M9:*.[MHY4#6#-\LN3C)[\=:^K+9@]I$RKM#(I ';BOE :/<3ZSI^FW\<
M<+7TF1>E_P#5!3^7-?6%LGEVL29W;4 SZ\56.M[70G+N;V.I)1117">B%%%%
M !1110 4444 <]X_+CX>:Z8@S/\ 89=H7K]VOG?3K'^TO#6FPK.8PL2[R%Y#
M>]?4\JH\3+* R$88$<$5\IS2ZE:>(-?O+ ">T2]DCBL\X"\_>S_2O1P$^6HU
M;<\O,X<U).^S-+X6P0R_% VMTS67V?+1RX_X^"#T_&OIROES0CJ6K>--!CM&
M;[;'<QSW%LJ\)%GDEOZ5]1UCC%:L]3HP3O06E@HHHKD.P**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XKPO\ \E6\
M=?\ </\ _1!KM:XKPO\ \E6\=?\ </\ _1!H [6BBB@#BO\ FO7_ '+7_MU7
M:UQ7_->O^Y:_]NJ[6@ HHHH **** "BBB@#S_P"(5SJW_"9>$=/T?5)].^W/
M=1S-$W!7:G)7H2 6VYZ'FLVZTO6]+^(5EX;T[Q3JS6&J6C2SR74PFFBV$Y\M
MB/E)P!TXR3Z8Z/Q3H>HZCXZ\):C96_F6NG2W#74F]1Y894"\$Y.<'IFI=0T:
M_G^*6DZO%!NL;>QFBEEWJ-KL>!C.3^ H$97AF2^T7XH:AX9?5;[4K$Z<M[$;
M^;S9(VWJI&X\XYK'NM0T'Q)\3-;.OZI8VMCIMDVFVZ7-RD9>20$2N Q[<KGZ
M5O7ND:Y;?$O5/$&G:?\ :(FT(V]L?-C&^XWJ57!8$#C.3Q3O!OP]TS3_  M:
MIXCT>QO-5EW374MS!',^]CDKN(.<<#@XZT 1_"76_P"T/"LFE37$=Q<Z+,;1
MI(W#+)&"?+8$9!& 0/\ =KF/AGX0U#6/A_;W;>)-4TU&>3['%8S>6B8<@LX_
MC)8'@]A73VWA6Z\._%&/4O#NG1QZ)J%KY-[%!Y<:P.OW7"9'H.@[L>]9'@^V
M\?>$/!\.DKX=M[USO:$F^C3[*2YX<9(8?Q?*?XL=: .I^'FNWVN^%R^K%6OK
M.YDLYY%&!(R'[V/<$?C74USW@CPY+X7\-)9W<RSWDLKW%U(OW6D<Y./;H/PK
MH:!A1110 4444 %%%% !1110 4444 %>4?%?1+FVUK3_ !'I\9)B^6<K[=#^
M5>KU#=6D%[;M!=1K)&PP5:@#B;*^CU"QCN(&#)(H8X[$U99MT2@_>6N4U;P1
MK_A:]:Y\*2/<69&YX6;.#G@8J&+7?%1NDMI/#LC.J9?:.I]<]J .GNI(XHB\
MSA$49+'L*Y;2H'\8^/H7MF)L-.PPD&=K&M.'P?XE\0@_VO<K8VSC#0PC+$>A
M-=[X>\.:?X:T\6FF1E5ZLS')8^M &L.!39(HYDVRHLB]<,,BG44 4HM'TZ"1
MI(;*!'8Y9@@R?QJXJA1A0 /:EHH **** "BBB@ HHHH *\X^-DGD^%]'DV.^
MS686V(,LV$DX [FO1ZXSXF:!J7B'1M+@T>V^T26^J0W$B^8J;8U5P3\Q&>HX
MZT"94U'X@7=[IT]KIW@CQ,]Q/&T:"ZL/*CY!'S-DX%<GXD\/W/ACX2^%=,OS
M_I*:U$\JA@0C,)6V@CTS^>:]JKB?BEH>K:]X?TZ+0K+[;<6VI17+1>:D?R*C
MYY8@=2!^- ':21I+&T<JJZ."K*PR&!Z@BO./AGJ-EH>D^(;2\OK>VT[3]:F@
MMYIY0B!<\*"3CMG\35^XU_XAW<#067@NWT^9QA;FXU2*5(_?:H!-:7AGP/8:
M-X2CT?5(H-4:24W%TUQ$'668]6PV>G !]J -6#4M*\16=W;Z5JUO<CRRDDEC
M<J[Q;@0#E2=IX.#[5Y_%X;TSPQ\8_#=KI,!19+.YDED=B[RN5;+,QY)KT;3M
M%TO1_,_LG3;.Q\W'F?9H%CWXSC.T#.,G\S7/:KH>HW/Q6T+6(;?=86EI-'--
MO4;&8-@8SD]>PH ZZO'OC1IES9:GI_B*/$EMD6LZL"1$IR2Y_P :]AKROX]S
M2KX9TBVC8A;G4DCD7/#K@Y4^U:4VXS36YG6C&5.2EM8\JU"PTK5-/=8;E(HS
M+D3AL9]P:]@^!^I?;O!4T(MX85LKEH%>)<>< !\[>I/K7C^IZ--;+-/IT,+P
MVT9*VS#AF'8"O8O@C9V]MX(>6"X666YG,L\:'B%R!E,=L>E>EF%K1ON>3E=[
MRML>CT445Y)[84444 >,?&YBOB[PGOW"$&8LV,KG QFO-_$&G.EG<ZB2UPPQ
MB#&-]>V?&\(/AG>2*%%R'00/CE"6'->*1W>L6*VUE<*+A=F9+TXR1C/2O8R^
M7N.*/"S*%JL9W^1Z]\"8H#X+^U1SGSIF/F6Q&/)(->H5XY\!X+QIM<OS(\VG
M7+I]EF9=NXC.[ ^M>QUY532;/9IN\$[6T//O@W&MQX2N=7F^>_U&]EDN96^\
M2#@ GVZX]Z[&^T+3=2U*RO[VU66ZL&+6TN2#&3UZ'GIT-<A;:-XD\$ZM?'PU
MI\&LZ+?3FX%D;@02VTAZ[6;Y2IXX]NW=\>C>)/%7BC3]2\26D>C:=I;^;!8Q
MW(FDFD[%V7C''3\/>H+*G@S_ )+%XV_[8?RJ7XSQI%X+@U1,+>:?>Q2VTG\2
MMNP0#^OX#TJG%8^+?#OQ$\0ZOIGA?^UK74FC$;?VA%!@*.N#D_H*M7.C>*?'
M.JV"^*-,M]%T6RG%R]HMR)Y+AUZ LO&W\NOY '83:?H^F:E=>([E8[>Y-N(I
M[N20@"('..3@<@=JY#PL\OBSXA77C&.W:UTF"S^PV;R+M:Z^;<9,'^'J/R]#
M57QUIGBK6_%L,8\./J_AVS"NELNH16ZW,N =SY)) )Q@@=/?GI=#U+Q#J$YL
M-9\'C1K#R2HE348I@.,! B $<?EB@#B/"^K>(-.T_7(_!.B#7=):[EEMKV9Q
M!N8_> 4\R@8[8S^E=;\*H[&'X?VD6G7+W&QY!/YD7EM'*6RR%>V,_P!>]9>@
MVGC+P1I3:!8:#!K5G [FSO%O4AVJS%L2*W)(+'I]/>NA\">'+KPWH,T>I2QR
MWU]=R7MUY0^19'QD+[  4 =+1110,**** "BBB@ HHHH **** "BBB@ KBOA
MM_S-G_8RWG_LE=K7%?#;_F;/^QEO/_9* .UHHHH XKPO_P E6\=?]P__ -$&
MNUKBO"__ "5;QU_W#_\ T0:[6@ HHHH **** "BBB@#D/BI>W6G?#/5;K3[F
M:UN(_)V302%'7,R X(Y'!(_&N7\46GB#PYX?T[Q':^)M1GU2>XA6:":4&U;S
M.JB+&  <#Z9KK_B1H]]K_P /M2TW28/M%W/Y7EQ[U7=B5&/+$#H#WJMXVT+4
M=7\':?8Z=;^=<PW-M(Z;U7"H?F.20.*!&)K-KJG@WQ%X:N8_$>JZB=2U%+.\
MANY@T3A^-RIC"8]![?C+\2M3LKSQ%X?\,W]Y;VEI+.+V^DGE6-?*3.U22?XB
M#^0K8\=:'J.LW_AB33;?SDL=7AN;@[U79&IY;DC/T&35+1?!SZIXMU[7/&.D
MV\WVB98;""Z6.8) @X;'S $\>_7UH H>#]9T_3OBAK.B:;J%K=Z?JP_M&U-M
M,LBI+_RT3Y20"<$X]%%5H=!O-=^,GBU(M5O--LXDM//:QD\N61C"-B[^H'#$
MX]JU/&7@;R1I>K>!]'M+?5--O%E\JVCC@\^,_>4G@'MU[9]:C%CXMTCXB:_K
MVF:,E[87ZVRBV>Z2*23;$ 64Y(!4@@@]=W% %WPE>:EI?C35/">I7\VIPV]N
MEW:75R<RA&."KG^+!/7_ /4.WKC_  GH6KGQ'J?B?Q+%%:WM]&L$-G%()!;Q
M+V+#@DD \<?G@=A0,**** "BBB@ HHHH **** "BBB@ HHHH \9UG2Y/!7Q!
MEU/[NF7K_-CHF[U_&NM@N([N!)[>19(V&593GBNLU72;/6M/>SU&%987Z@BO
M,9_AMXBT6_,GAO4%-NSEA&QP%'8$=Z .GD;<V[IQS6!K_B"VT6W\R4LTKY6(
M*,Y:HK/PWX\O59;ZXAMDD?[_ %<#V':NBT;X:Z=9W*7>J.^HW"\YG.0#]* *
MOPO\.3V5E+K.HJ5NKXEL'LIKT"D1%C0)&H55&  , 4M  0",$9'H:,"BB@ H
MHHH **** "BBB@ HHHH \M^(]_\ V7\3_"%[]DNKSR5F/D6D?F2OP!A5XR:E
M\5>)-3\8>';G0=&\&Z['->@1F;4;46\<8W [LDG/3VK8\3>']3U#XE>%]5L[
M;S+*P\W[3+YBCR\CC@G)_ &NUH$>5ZS8'2OB)\.M/:3S&M+9H"_][;&%S^E>
MA>([*WU'PSJ-I>JK02VSAMPX'RD@_@0#^%<CXZT?7YO&WAW7-!TC^U$TU93)
M%]ICAR6X RQ_H:9JUQ\0/$^GRZ3'X<MM ANE,4]Y-J"3E4/#;0F#G''X_C0!
M-\.O$=A9_"_09->U2TLWDCECB-U<+'O6.1E&-Q&< +^E=)?VNE^-- DMH=1\
M^QE8!Y=/N1\^#DIN7/'J*9:>#M#@T+3]+NM,M+Z'3XO+A-U;K(1G&YAN!P6(
MR<5J6.G66F6WV?3;.WLX,EO*MXEC7)ZG &*!GGW@C3+/1OBQXMT_3+=+:U@M
M[01Q)T7]V"?U).?>NK\:Z))XA\(7VG02^5)(F5;/<<X_2L[1-#U&S^*'B;5[
MBWV6-]%;+;R[U.\I& W .1@CN!747S^7IURXXVQ,>/H:!'S!87%K>10QZDD<
M=_'NCE@Q@QXX!8>]:WPN>#0OB;9V5J(;T:B'WR-\QMMH)^7TS7.Z3I\FI:";
MS*_;[F:3,[_><!C]X_2NG^&&G*?BC"FHO#:R6 )M0G'VHE>?KBO:Q#OA4Y[Z
M'@85*.+<:>VI]%T445XI] %%%% !1110 4444 >/_'<V\O\ 8MG$&35II&-I
M/_#'C!;/U%>9ZYJ,,FGR6#0+/=J  <94GO7J/QNTJY$VC^)$9/LFE%Q<!O1\
M &O-[^UMM8T"1K">%3.,I<J>GK@U[. M[-]SP<RO[:-]NYZO\#KX3>"19-N$
MMLYW*?NC)XQ7IE>5? G5(9/#EQHH\F2YTY@)9XQS)NY&3WKU6O)GI)GMTW>"
M9Y]I4:ZA\=M>EO?WC:9901V8?G8'568KZ<DC/N:[75M(L-=TV33]6MEN;67&
M^-B1G!R.1R.17,>(O#FL6WBJ+Q5X2^SR7H@^SW=E<,46ZCSQANS#CKZ#Z&CK
M4?C7QC8G1I-$B\.V4Y NKJ6]2=RF<E45.YQU/Z5!1#XYACM_B#\/885VQQW$
MR(N<X $0 KO-5L;;4](N[*^"&WGB9)-XR ".OX=?PKA_&OAS6(]5\(77AC2F
MU.+0S)OB:Z2(D8C"Y9SR3M/.#TIVIWWQ!\0V$NF6_ABVT);E3%+>3ZBD^Q&X
M)54YSC/K0!%\,M/M/$?PST)M:@%RVG7+/;%F8;61VVG@\X'&#QQ3?%M\/''B
M.P\+:$HGCL;R.ZU&^49CMPF?D#=W.2/T]<3^)O#^OZ/\/]/\->!K62X4#RKF
M=)XX7"=6P6/!<D\C..:;X=N/$OA^QM],T[X;K9VBL [C6H68YZNW&6- %75;
MV]L?C#//X3LO[:O6L5BU&U9A$EN,@H?-/ )&/EP?\+'P_FDN?''B6YUR,V&O
M3^5YNGA!MCA4;5=7S^\SQD_XU:N=(\0^&?&VIZYX=TZ+6+/6%C-S:FX6&2*1
M!@,K-P1R>/?VJQX9T369_&5]XK\1V\-A/-:BSMK&*42&.(,&)=QP3D#I0!V=
M%%% PHHHH **** "BBB@ KBOAM_S-G_8RWG_ +)7:UQ7PV_YFS_L9;S_ -DH
M [6BBB@ KBO^:]?]RU_[=5VM>=ZMK-EHGQRCGU&0QQR^'A$I S\QN2?Z&FDV
M[(4FDKL]$HKE;GXAZ%")%CG:251PNPX)^M4'^)^G!XE2/.X?/S]VMEAZK^R8
M/$TE]H[FBN,MOB9H[^9]H+1A6P" 3D>M3#XE>'2I)N7 '?8:'AZJ^RQK$4G]
MI'6T5R=O\2?#ER)/+NFR@)(*&D@^)?AN9@GVIU9C@ QFE["K_*Q^WI?S(ZVB
ML.7QCHL*@R777IA2:K'X@>'@S#[8<J,GY#4^RJ/HQ^VIK[2.EHKF$^(?AU[=
MIEO&VJ<',9S56?XE:0,&U+2KW)!%4J%5_99+Q%)?:1V-%<,?B?IXA9O+^?.
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M:<IN&,XKP/2[V!H+W26?8^GAK5;@)PZKQO'O7;@8N-5\VAY^8R4J*Y==3?\
M"=U>Q_$FS'AMO,N9L&\3 P(,\G-?1=?./P^U:W\-_$2UNKAO]%O+86@D[O(3
MPQ':O?KG7=-M8R\UTF <<'-8XJ,G6>AT8*45AXZFA163)XGTF*$2O=J%-5)?
M'.@PL UYDGT7-<ZI3>R.IU::W:.AHKFQX_\ #Y( NSS_ +!JS_PE^B_\_B_E
M0Z51;Q8E6IO:2-NBN</CSP^+D0&\.\G'W#BM4:UI[1[Q<IM^M)TYK=#52$MF
M7J*JV^I6ES&7BG0J.N6Q2S:A:0)NDN(P/]X5/*]B^9;EFBLW_A(=,\[ROM2;
M_3-5Y_%NC6S,LMVH*]0!FJ5.;Z$.I!;LVJ*YK_A/_#W_ #^'_O@U-!XVT*XW
M>7=_=ZY4BJ]C47V63[>D_M(WZ*P9/&>AQ1EVO!M]AFG:?XPT74]PM+L$KU##
M%+V4[7L5[6FW:Z-RBL]]=TY&"FY3).!@U<^TP?\ /:/_ +Z%1RM="U)/9DE%
M5CJ-F&8&YCR@R?F%5XM>TV:#S4ND*>I-/EEV%S1[FC16%-XRT2"01R7@W'T&
M:B/CK0!NS>?=Z_*:KV51_99'MJ:^TCHJ*R/^$HTCR%F^UKL;I5:X\<:#;.JR
MWG+' PI-"I3>R&ZM-;M'0455CU*SDMQ,MQ'L(R"6%);:K976_P FX0[#@Y.*
MCE9?,NY;HJ(W4 ZSQC_@8J.34+2)U62XC#-T&X468719KBO"_P#R5;QU_P!P
M_P#]$&NJFU6QM_\ 6W,8_P"!"N.\&7<-]\3/&]Q;/OB?[!M;UQ"P/ZBCE=KB
MYDW8[RBBBD4<5_S7K_N6O_;JNUKS[4]4M-(^-_VF_D\N+_A&]N<9Y^TD_P!#
M6RGQ$\.NI(NV 'K&:TC3G)7BC.52$7:3L=117(3_ !(T7 ^QRF9L_,"I7 J
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M4WAZJ^R)8FB_M'745R3_ !*\.)%O:Y<>VPT+\2_#CVKS"Z?"#E?+.:7L*O\
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M_I)&?NC;T%1K<02[5DF:1D.#\N,FEJ&@Q]-68.I8KGDG'0UQ.G*MCXMU>WD
M:/"%IL^U>@-YAG*-,3N4[5V_K7!Z:+>SU'5++4!O:!@7D7DRYZ?E23]^(2_A
M2_KJ)XF(FDL+[3IR+V-ML$6SB0$X/Z5W,5LA2-74!@H/XUYMK<GV3Q-I=Y'*
M9;=&/DV[?*$]:]*2XAF*709BW"@XZ9H?\20X_P *(\(&D\P$-MX\LGI3)+;S
MFWR'#=L/P*85M_M4L)4AGRQ(/6F(+<VK+*&\M&QWY]Z8BQ]E5F4NY8H.N:5X
M8I83E0Y)YYQ4 DBM73R03'*.*>!"8)<(0%;##UHU C?2HV93QG&,[NE,&GO$
MK#S_ )0>!BI9([5HH3,6"+]U>>M2>2?*G,<N.=QXZ4[L5AOV*-X0#'F3.6.>
M_K1]C0/O" GHS9ZTZWF\ZUWB4A@>7QUH#PQ2LGF,IFY(QUI:CT*]W#]FT^X-
MNGS,IVJ&X)]*Y+P]!]HM7#3\K.6DBQ]T]QFNHUAS:^'KYX 96MHRZ)CN!D?6
MN2T#3&?3DO+:]Q+<MY\[8_B/6.G!OVA-5+V7S$@LFM/&2OJR[K24XML'H_;@
M?SKNEM40+D$YYVES7"Z)*]]X[F&HRD210D01XR!@]<UVRSPR*OFLTAC.TG&.
M:A?%+U-'\,;]A\UDL[MR5SU.:A3241!Y;!77W^]5DD"\ 9CG''%1""(O(#*2
M[')..AJ[LDA%CY<@.X@GJ@&?UJ9M.C9UZA8_NKG[OM23M+:PQ.+GY2<'"YS5
MIU*;B)?EQ@KBB[ @^QH=S-&,-]U=W3\:0VP8+'N;*=/F-*(DN+5(/.)5.3D8
MR:6;"31S-+AL8!'>D X*VUA*S8;IAC\U-%HPC^9G9OX5W'Y!30S+,\3N2PY5
ML?=%(TVV'[2;QMO<[: %^QJC!E!WXY;<<U#_ &6&^<R,SYYS5B&2&1B\$C;I
M1G)'7%"M(]N_[\AL_>VT[L"*334+Y3CT.?NT0V@VM\Q8]%?I^E3) ?-CVS\J
MI _VJ;;/(\LT,L^YHSCITHNP&KIZ(A4+DDY4$_<IQM%23S8QAOXF#=?PI[MY
M<D;2S%BG&X#K2K"%F9EDYF'S#UI78$:0,@W0DMN.<;JD>)Y&S',ZEOOMN/-0
M)E('2*8J(CT SBG+)YD<125H58<KMZT /:S5F888)_OGYJA:RR(T!:-5Z*&)
MIQGC$C6T]PSD\A=O3\:>SDP1R12E8C_LT:AH0II2+YBER<]&)Z4R33HPJ@90
M#[N#G=5N2-GG+&<@ 8"8J)XWM;%?)N=BH>N,T[L5AK6'F@9=D]\_=I_V"-FP
MT?[KNI;[U3)NDCC=9^HY&/O4T#S%EC\W#>XZ4KL=B/[/@A7W8_A7>:>D31J(
MV=M@]&-1SIY=M'*9L&,X$G<9]J>SNEXFYRRR#TZ4 *(';>TC/)N_VB,TV2SW
M,&;<THZ/O/'X4F9EA8->G<#DG9T%+'-!/,KQS,S]%RN,4:@5FTWS5R9I"%/
MR?FKKOA AC\2>+%/&/L?_H$E<]'YIDD1IRS#_9^[70_"!67Q+XM#2>8?]#^;
MU^22N/&M^S7J=V!_BOT/5****\D]D\?^(:*_Q9@+_P .AJP_[_O63);PS0G
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M_I4*QV\L,T)4A@Y. >II[?9OLZ-<AL+\N!G@TP)_LJM('=RVQ>#GOZT/#%)
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MB->(\<9]JH^&;LZ=XXN[-;@S1WF-[R'+,0.,?2B2_=0^1-/^--]=3T4P1^2
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M5MP0N0-W7'M2:@C6,_EPW'EAOGD.W.1ZU#!%$%>*1"KQS;TB!S^&:FO)OM4
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M;[K#G>>XJ].D,5BL-R/,W#"KZT-[ D4U\P1(Z1J=XSMW>M5OMD=G/-$B[HE
M)'H3_.D B>T1XT)\ECB'/WOQJ68V,ZQ$94R' X[^E4(?J,,B:6;@765C 8KL
M^\#VI89&8P<"/S!C=US5YXHELA!=?O XP!TS639A5M4)3<\,C%8\U*=T-Z,6
M[_XE\WDQW)6,'=+\O0&I]5MY1IK74-WA8E#;=OWJAO)EN8598O-EF.U5Z=*T
MW@A33U@OF\P.N#QC\*&[6!*]S/CF6Y@@F2+<W;GH:B,L5G(\9'#<D>E)!^YT
MN>V@XD0Y4>@S5F?R%MX!*O[^3C?C[M4(D6U"Z:?*?=']XH>_XU7A)FMTE6V
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M?LK8?S< CUHO=H+61$ES-%J)L[L[X67Y6Q5>V4Z?K15L,9#A4/9?6K]Z)1#
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MJQX'>GW6]+J)XD#M_&O3-:7ON96*.DQM::A-!*,N??[HJR]GF2(QCYF8Y?\
MNTZ2WA_M>&6#Y9!S,/7CBDO7F,UO]C;#,QZ=Z+W=PM9$=O<RRW<UE??,,?*V
M.M0Z6#9ZC+;R89WZC^X.U7KW>ES;R1*'*_ZQ?6HYK6#^U[:>+Y9<DR<YSQ1?
M0+#38J#%L&79CE_2DAN99+R:QOQN&!L;'6I;\S-)!]C/S[CC'>EO2\<]O(BA
MR/OK1N&Q2TT-9ZI);OAV?K_LBIS9-'=0E#G>QR?[M.N+6#^V+2X3Y9B3O]^*
M-1,[2V_V(_O-QVCUHO=A;0;#<2R7D]C?+E<?(WK5?38OLFJR1R_/(W;/W!VJ
M_>^9'-;R*H8C_6+4=Q:P?VM:W$?RS$_/WW#%%] L(UF=\3)RS,<GTIL5S))=
MS6-^F5Q\K^M2:@9R\/V/E]QP!WI;XO%-;RA=Q'^L%&X;%33E-IJCP28=G_\
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M'^W[4^^\PL6B&)(UW >E%[V"UB#[>]M??8KZ+<DIPC>OM51P+'Q#%%(//$A
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MI'D_C5@OQAAS_P! )?\ TH:J$""T\YY""6<D#-:OQ"\.>*;SQ[;ZOX;TO[;
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M=DN7JNW<TH0A=OFZ/OV/,*BN8$NK62"49212IKM'\4^'F1A_PB\()'!#+_\
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M"I_X0[!_B_XFD'(].M'UFEIJ+ZK6[#3/#<9 R8\^6.V#5;4YA%?6=FR[@&#
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M?I4T6B_$".;>?"N[MC^TH!Q^=0+X8\<P71EL?"7D*QRZ?VE V[\<T?6*7?\
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M\HQON/\ Q,X#N]NM6I=&\<RN&_X0['][_B:0<CTZT/$4M-1?5:W89]HCN<,
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MT-S\B9,8.P'I@TZ31_'3A0/!^W'!_P")I!R/SJ*+0?'B1[7\);\2[U/]I0#
M].OZTOK%+N/ZK6[$6I2^7>65H1G#JP(XJ[-"TFI$E\)LPRXZU4O?#GCF[NXY
MU\(^64(R/[2@.1Z=:L2Z1X\?;Y?A#RP/O?\ $S@.X>G6CZS2TU%]5K=AK7$,
M[>2BGRU^4-Z&NH^#B[-!UU,YVZY<#/\ P&.N470O'@0*WA(-B3>#_:4 P/3K
M^M=S\,=%U71=#U-==L?L-Q=ZI+=+#YJ281E3'*DCJ"/PKEQ-6$TE%G9A:,Z<
MFY([2BBBN(] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9FK>&]&
MUU<:QIEK=GLTL0+#Z-U'YUA+\*/!*R^8-!BW>AFD(_+=BNPHH HZ9HNF:+#Y
M6DZ?;6:8Y$,07/U(Z_C5ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>fig10.jpg
<TEXT>
begin 644 fig10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     SDQ  "2
MD@ "     SDQ  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_H!_^3<__P 71[:(?59]T?+^:,U]0?\ "GO O_0#_P#)N?\ ^+H_X4]X%_Z
M?_DW/_\ %T>VB'U6?='R_FC-?4'_  I[P+_T _\ R;G_ /BZ/^%/>!?^@'_Y
M-S__ !='MHA]5GW1\OYHS7U!_P *>\"_] /_ ,FY_P#XNC_A3W@7_H!_^3<_
M_P 71[:(?59]T?+^:,U]0?\ "GO O_0#_P#)N?\ ^+H_X4]X%_Z ?_DW/_\
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M_P *>\"_] /_ ,FY_P#XNC_A3W@7_H!_^3<__P 71[:(?59]T?+^:,U]0?\
M"GO O_0#_P#)N?\ ^+H_X4]X%_Z ?_DW/_\ %T>VB'U6?='R_FC-?4'_  I[
MP+_T _\ R;G_ /BZ/^%/>!?^@'_Y-S__ !='MHA]5GW1\OYHS7U!_P *>\"_
M] /_ ,FY_P#XNC_A3W@7_H!_^3<__P 71[:(?59]T?+^:,U]0?\ "GO O_0#
M_P#)N?\ ^+H_X4]X%_Z ?_DW/_\ %T>VB'U6?='R_FC-?4'_  I[P+_T _\
MR;G_ /BZ/^%/>!?^@'_Y-S__ !='MHA]5GW1\OYHS7U!_P *>\"_] /_ ,FY
M_P#XNC_A3W@7_H!_^3<__P 71[:(?59]T?+^:,U]0?\ "GO O_0#_P#)N?\
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M>\"_] /_ ,FY_P#XNC_A3W@7_H!_^3<__P 71[:(?59]T?+^:,U]0?\ "GO
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M_H!_^3<__P 71[:(?59]T?+^:,U]0?\ "GO O_0#_P#)N?\ ^+H_X4]X%_Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'^/M>\6:5#
M:6G@;P_'JM_>%@9[F4)!:@8Y?)&XG/ !!X/7&*7XJRZS#\+];D\-&==06 ;#
M; F4+N&\KCG.W=TYKRB?X::-#X*G\2>-M;US4O#5K8QSZ/!)<'[5:F4 L6
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MY^57(W ?,W /\1]:O4 >=_#_ ."GAWX<:_/J^AWNJ7%Q-:M:LMY+&R!2RL2
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MGWGX>?\ ),_#?_8+M_\ T6M='10 4444 %%%% !1110 4444 %%%% !1110
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M %6P^$=_X6FN+-KZY+E)%=O*&X@C)VY[>E ,\ZO_  [=ZM\(T\<ZGK=]<:A
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MQ4T7Q+;3VJV=A$B2QR.PD8J[L< *1T<=2.] 'G*^%9M&^+1\&:+K=_;6&I1
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M$"JXN7U2*\DOI3]]WV $'@=?7 Z5Z)110 4444 %%%% !1110 4444 %%%%
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MP [=2?K1^"'AO0?B+X9\4>(?%&CVE_>ZEK$Z&2ZC$KPH8T8!&(RN#(>1CH*
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MZL=V<_Q9QVILWPW\*7&CZAI<VE;K+4KS[==Q?:)1YD^0=^=V1R!P"![5U%%
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M;4]9NGMX"RR!$A!5F\LLQW)NVH!SM\C /45[E0 4444 %%%% !1110 4444
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M +>?_2F6O2: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB3\2O%NL6O@G6X/#N@:-=&R,Y)$MQ,H^<\*3@$],@8(ZGIN_#77O&%AXJO\
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M8W_+Q=*)+N1?]E.B?CSZ&@#O*QO$OBO3/"EE'/JCR%IG\N""%-\DS>BKW_\
MKCUK4M(#;6<,#2R3F*-4,LARSX&-Q/J>M<#<1G4OV@;9)PK1:9HYGB4]F9]I
M;Z_./RH W= \>:7K^JOI?V:_TW443S!::C;^3(R^H&2/US735YU\3V6P\0>#
MM6B7%Q%JBP%EX+1OC<N?3 /YFO1: .8U_P ?:7H.K+I8MK_4]0*>8UKIMOYT
MD:^K#(QZU>\->*=,\5V,ESI4DF87\N:&9-DD+>C"N5^%L9N]0\6:Q.%:XN-8
ME@+=PJ<A?H-_Z53DN3HGQHU[[$ @N]$-TR@8'FIT8COT/YT"-[4_B;H^GZI<
MV-O9ZIJCV9Q=2:?:^;';GON;(QCO70:1KVFZYHL>K:=<I)9NI;S&^79CJ&ST
MQWS7,?!^S6V^&MC/UFO))9YGZEV,A&2?HHKA+VY?2/#/Q/TVQ)BM[>]A,:+P
M$$\FUP!Z;1B@#N7^+F@*S2BSU9].63RSJB69-L#G'WLY_2NV@GBNK>.>W=9(
MI4#HZG(92,@C\*R--T2U/@6VT5HT^S-8+ RXR#E,$^_)S7)_"]KS6_@]%9PW
MTEG.C2V\=TB[FC&[((SZ X'I0!UK^+-,7QA%X:1WEU"2%IF$8!6(#G#'.02.
M0,?EQ6U7E.F>&;'PM\:-)M+!II6ETR66>>XD+R32%F!9CZ\5ZM0,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "JVI:A:Z1I5WJ6H2^3:6<+SSR;2VQ$4
MLQP 2< '@#-6:\2_:3UZ:;0=(\"Z-)YFK>(+V,&V4Q_/$&PBL6.4W2F/:W /
MEOD@ @@$7P(L]1\6^+O$OQ3UE)(#JSM9V,)Z>2"I/\ #A1'%&'!Y*2;AFO<J
MS?#N@V/A?PW8:)I4>RTL85ACRJAFQU=MH +,<L3@9))[UI4 %%%% $=S;07E
MK+:WD,<]O,ACEBE0,DBD8*L#P00<$&O"-/$_P"^)<MB]K(? 'B6ZC6VN7N2R
MZ;.1@[BQ"J.N=W)C53N8QL*][KRG]H_4=.T_X/W*:CI\=[+>74=O9^8F1!,0
MS>;D,"I"*^",Y) (*EA0!M_&;Q@G@OX6ZI>K))'>7B&QLC$[(XFD4@,K*#M*
M*&<'C.S&02*B^"/A&3P;\*=-L[RW^SZA>;KV\0[]P>3[H96P598Q&I7  *GK
MU/PY7WC\)/$VH^,/A7HNMZTT;WUPDBS/&FP.4E>/=@< D("<8&2< #B@#LJ*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N'^)
M7PMT[XE6]E]MU"\T^ZT\NUK/;%<*S8Y8$9.-HZ$'WKN*X'XG:QX_L?[.L?AM
MI$-[<7@D^T7,ZC;;!=N#EF"@G)^]G..E '"-HWQM^&\;2Z9K-GXPTF'+&*^?
M$JH!RQ+D,..@$C?2NI^%GQLL_B3J,VDOH]QINIV\+32#S%DA*A@IPW!SENFW
M\:YF+X%>*_&$BW'Q5\<W=VA;<;"P;]VIQP02 BGUQ'^->G^$?ASX5\#(W_"-
MZ1%;3.NU[EB9)G'&078DX) .!@>U '3T444 %%%% !1110 4444 %<W\1O\
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M;NST%99[J[A^:,,X "ANAY5>GJ>N#7IM5K'3K+3+?R--L[>SASGR[>)8US]
M,59H&%%%% !1110 4444 %%%% !7A-G:?\+P^,EQJ5\MO=>"O",S6]I$\.Y+
M^=A\Q#J2KKN17ZD;!$"GSL:V_C9XMOF^P?#GPH=VO^)L0REX&=(;-]R.Y(!Q
MG#9(#;460_*=IKN_ _@_3O OA&RT/2XXP(4!N)D3:;F; #RMDDY8CIDX&%'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8+B9'++;)PPC&>>?E/0<8P/7QGQW'X<U"\\?W_BFZQXOL]52+3X+B=D"6P=
MIC7.&^0G(YP.<#.:]3\%:QINK_'[79_"M[]NT^71H#J$L+[X3<JP5-IZ'Y,]
M..M 'KU%%% !1110 4444 %%%% !7FWQ@^'WACQ!X5USQ'J^F?:-6T[1KC[+
M<?:)4\ORTDD3Y58*<,2>0??BO2:YOXC?\DL\5_\ 8&O/_1#T <U^SY_R0GP]
M_P!O/_I3+7I->;?L^?\ )"?#W_;S_P"E,M>DT %%%% !1110 4444 %%%% !
M1110 445R7Q+\?6OPW\&R:Y<VWVR0S)!;VOF&/SG8Y(WA6VX17;)&/EQU(H
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M1^Z PHP%XQQOCW]EV]LHX[KX>74FHHJ8FLM0F19F;<!E'"JA&#DAMN-O!;.
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M.Z\WJ_Q_#0^7_"?P]UKQ%KMO;SZ==VMB)#]IN98S&J*C;75688+Y!4#!YZC
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MQG).<\T[Q7\4/!VO^%K[3-$U.SU>YN8]GD*A8(N1ESG&,=B.C;376?\ "N/
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M'T56TZ^AU32[6_M6#P74*31LIR"K*&!!'7@U9H **** "BBB@ HHHH ****
M"BBN/^(]KXSO]$M;'P#<0V5Q<7*K=WKD;H(>Y0'J><^N <<D4 =9<VT%Y:RV
MMY#'/;S(8Y8I4#)(I&"K \$$'!!J+3]-L=(L(['2K.WL;2+/EV]M$L<:9))P
MJ@ 9))^IKQ/X<:SXBT/XO?\ "&?\)>WCG26L6GN;XG>;&4%OE+EV.<@#&X_?
M' P:FU.Y\6_%+XF^(M!\,>+I/#6E>&FBB:2S0N\\QSD,593PR,",X^7H>: /
M;Z*\X^#GB_5?$&F:UH_B:YBNM9\/:@]C<3I@&902%<KVR5<>^WZUZ/0 4444
M %%%% !1110 4444 %%%% !5&+1-*@UF;5X-,LX]3N$$<UZENHFD7CY6?&XC
MY5X)_A'I7@'[07Q2UB&=M%\&WEW9VVFW"1:GJ-I(T9^T,K,D"NI!X56+8[@#
MMSZ+\9/%^J^'M+T71_#5S';:SXAU!+&WG?!,*D@,X7O@L@]MWTH ](HKQ#3+
MGQ;\+/B9X=T+Q/XND\2Z5XE:6)9+Q"CP3#&-I9F/+.H SCYN .*]OH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\/>[L/!?[6.J
MZIXAOX;"SUO1%\BXNF$48<>2NW>3C_E@3VZ@?7W"L3Q-X.\/^,K%;3Q-I<&H
M1(24\S(9">NUE(9?P- 'EWPY:W\2?M(^./%6D7*W.F)9PV23Q?-'*Q6+)5NA
MQY!Z9ZC\?;*S="\/:3X9TQ=.T#3X+"T4Y$4*X!/J3U)]SS6E0 4444 %%%%
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MX^Q>=:PVR)%+NNG5MR 8.0 #D<CBOHK2]'TS1+5K;1=.M-/@9S(T5I L2EB
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M@ T :OA/3)-$\%Z)I4S;Y+'3X+9VQC)2-5)QVZ5KT44 %%%% !1110 4444
M%%%% !7)>/O'UM\/[73;S4K&:>RO+Q+6:Y1L+:AC]]N.F-Q_#'>NMJKJ6F66
ML:=-8:K:PW=I.NV2&9 RL/<&@#P,2>&_#/QJ\(P?"'4H[H:S+*NMP6^I-=1R
MQC#!W+,WS@&5NN?E[9-:/@#5=(\!?&CXDV7B?5;733J-W%>VTE[((%D1FED(
M4L<''F@=><&O4?#/P\\)^#IY)_#>AVMC/("&F +R8)R5#L20N0. <<"G>)_
M'A;QF\,GB;1;>^DAQY<K;D<#.<;E()&>V<4 >=? .W%[KOQ!\3VSE['6-;?[
M,VT@.JO(^X'N#YP'3M^7L]5=-TRQT?3H;#2K2&SM(5VQPPH%51[ 5:H ****
M "BBB@ HHHH **** "N:^(FK:SHGP^U:_P##%A-J&K1Q*EM!!$TCEG=4W!5!
M)VABV/\ 9KI:* /BGQ?J>KVGPDL/#>I>!-5T3;J:WEUK%^) ;VX,<@.=\:_,
M0Q(^8D!>_6O5/B7JMYK&G_#+Q[KVD7.@)I^M_P"FV-RK%[93.A#,2JD K!GE
M?XQ^/L_BOP=H7C?2H]-\3V/VZTBF$Z1^<\>'"LH.48'HS<9QS6CJ6F6.L:=-
M8:K:PW=I,NV2&9 RL/<&@#Q3Q_JND^/?C1\-K'PQJMKJ1TZ[EO;F2SD$RQHK
M12 ,5.!GRB.O&1^/NM<YX8\ >%O!CS2>&=%M[&2;/F2KN=R,YQN8D@9[9Q71
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '@G@?X]:]KWQ#M-$UNQTV+3[FX:V\ZVBD5U<AO+&6<CD@
M#I6W\8_C#JGP_P!=L-,T"VL+F62W,]S]K1WV MM3&UUQT;.<]J\5T339_P#A
M"O%>OV8_TC1=7L;J)QU7#S*?PRZ'\*VO%5__ ,)U9>/O&D<;?98C965MD9V)
MYBY_5 ?^!U]]/+<)]<4U!<B]UK^\^6W_ *5^!R\\N6W4]:O_ (C^)Q\//"VN
MZ9!H0N]6;_2DOKE;>-1_TS\R923[98UZ=?ZC9:7:-=:G>6]G;K]Z:XE6-!]2
M2!7S/XV_Y(C\-?\ KL:Z?X@V2>-?VB]$\)Z]-*NC16OFK KE1*VQW.#ZG:%R
M.<#BO(JY=2J<OV8KVC=EK:+]=?+8T4VOP/;-,UK2]:A:;1M2L]0B4X9[2=95
M!]"5)J&_\2Z%I=XMIJ>M:=9W+\K!<7:1NWT4D&O/M'^&^@^ /&6I:UX9U>2&
M1+%W&A"8-N78?O9)=EW+D>A'4]*\:\%^&=0\;Z+JVJW'@NX\4WMU<NIU/^WD
MM6@<J#_JV^\<G.3D$$ #BN>CEN&K<U15'R*V]D[OU:6GKKT&YR6EM3ZX5E=0
MR$,K#((.014=U=6]E:R7-Y/';P1C+RRN%51ZDG@5PGP8T?Q-X?\  7]D^,+9
M[>XM;EEME:=)?W!"D#*L>C%QCL,5QW[0LLU_K?@WPY/</;:9J-X?M+@X!^>-
M,_\  0Y/XUQT<#&KC?JRFFM=5KHE?3Y%.5H\QM_%/XNOX5T'3M1\&7.CZNMS
M</#*YD\]%PN>#&XP?J:]/O+ZTTZU>YU"ZAM;=/O2SR!$7ZD\"OF;X[?#;PUX
M'T?2+GPY'):R7$K12PO.T@E"KG?\Q.".^./FZ5TWQ&MAXV_:$T/P?KES)#HL
M=OYHA1ROFOL=R?J=H7/H#CDUZDLOPU:C2E2;4;3;;6MHVZ7^XCGDF[^1ZW;Q
M>$/%=_%JMJFB:U=VA41WD8AN)(=K%EPXR5P<D<\'FKNJ>)-#T214UK6=/T]W
M&56[NDB+#V#$5X1XF\/V'PK^-?A%_!(EMX]4E6&XLO.:0,C2*A'S$G!#'&<X
M*YJ/QIX?\3^&?B9K?B&[\&VWC#2M1;*-- ;CR8^P &3&0.,E2,#BLHY;2JRC
M:H^64;Q3LGO:VKL'.UT/HBUN[>^M4N;*>*X@D&4EB<.K#U!'!J@?$^@+JG]F
M-KFFB_W;?LANX_-STQLSG/X5X+X/\5:3I7PA\;#P?_:^G:A!&)7L;VX65;4N
MWEEX65%/&>=PR-J_6N8T3X<ZGXB^'4$^D^ )KR]N@9(M=&OQ+N(<C_4,0 ."
M,'G(ZU4<FIQE/VT^5)\JORK=7N[R2MZ-WZ![1]$?6%U=6]E:R7-Y/';P1C+R
MRN%51ZDG@5Y=\4_BZ_A70=.U'P9<Z/JZW-P\,KF3ST7"YX,;C!^IK@_B./$$
MWA[X<>%/&$DUDUW,8M18RA\E9$C5BRDAB$;=U/WN>:H_';X;>&O ^CZ1<^'(
MY+62XE:*6%YVD$H5<[_F)P1WQQ\W2M<!EN&C6I>VES.;E9)7BTKK>_7=6%*;
ML['U!1117RQN%%%(S!5+-P ,F@!:*\X;]H#X9(Y5O$V&4X(^P7/_ ,;KIO"_
MCWPOXT20^&=9M[]HQEXERDBCU*, P'OB@#H:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>fig11.jpg
<TEXT>
begin 644 fig11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1":17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0>.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    'J'  '   (#   "&H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M)-U&ZH]U&Z@+$FZC=4>ZC=0%B3=1NJ/=1NH"Q)NHW5'NHW4!8DW4;JCW4;J
ML2;J-U1[J-U 6)-U&ZH]U&Z@+$VFA9-6M$<!E:= 5(R"-PXKZ%\72>"/!=M;
M3ZIX7LY5N7*(+?3X6((&>=V*^>-*/_$YLO\ KXC_ /0A7TIX^/@X6=G_ ,)U
M_J/,;[/_ *[[V.?]7ST]:YZGQ([\.O<D]/F<1_PL;X9_]"?_ .4RV_\ BJ\U
MFTN^U[4K^^\/:->S6+7,AC%O:LRQ*3D*=@(! (XKTC/P1_S]MK%^"/B#^S_%
MDNDS-B'4H_D![2)DC\UW?I0G9-I?>$ESR49-?(\YC5Y9%CB5G=R%55&2Q/0
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M3*L5)'.<<>F?:LOX G.I:U_URB_FU:^J>!OAS<>(KV\U/Q.J7,MU)+<6S:E
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MV2-RI8>F=I_ U*J.R;1K+#QNXIZH\^\&:E]D\,W<7_" _P#"0[IG/V_[/O\
M)^11LSY;=/O=1]ZK7PL\!P>)KV6]URVN?[/A4-#\A6.X;)!&_N!CD UU_P %
MS_Q;/5O^OR;_ -$QU3^!&LW]U#?Z7//OLK-%:"+8HV%F8MR!DY/J:F4G:5BX
M4TW#FUN<%XD\(:V/%FJKI_A[4/LOVR;R!#9/L,>\[=N%QMQC&..E<O+');S/
M#.C12QL5='7#*P.""#T->MZ9\0=47XU26&KWOF6"7MS80H451&&DPOW0,\H@
MR<\9]35?QAX*-W\;K*V2/_1-69;F3CC"_P"M'U^4G_@0JU-K1F4J2DN:'>QY
MQ>Z)JVFVJ7.HZ9>VD$A"I+/;NBL2,@ D8/ )JAFO4_CKKPN-:LM#@;]W9Q^=
M* >-[= ?HH_\>KRC-7%MJ[,:D%";BBQI)_XG5E_U\1_^A"OI;Q_X%_X3FRL[
M?^T?L'V61GW>1YF[(QC[PQ7RUNHW5$HMM-,UIU%"+BU>Y[9_PSY_U,__ )(?
M_;*\RU*VG\&^-98+2Y\Z?2[H&.;9MW,I!!QDX^F:P-U&ZFD^K%*4'\,;?,^K
M[WQ'I]KX,E\7Q*N'L%DC+'!;/*1G_@38^IKY]\ SR7/Q.TB>X<R2RWH=W;JS
M'))_.N2W4;JF,%%-%U*SFT[;'M7QEU)]'\?>'-2C!9K1!,%!QNVR9QGWQBMO
MQGX8M/BMI6GZMX9U2U$L"E3YI."IP2&P"59>>"._XU\];J-U')9*SV'[:[E=
M:,^E+33;#1?@WK>DZ=?I?FQLKN*XF0\><8B[#\-P_KSFN9^$GBBQO?"-SX2O
M-0.G7F)!:S(_EL5<9RC?WU8D_EZ&O$=U&ZCV>CNP]N[II;:'N;?#_P 8VD-Q
M/JWQ&GL[>,%HY3>3$,H[MN90OYFL;X0RRS?%;46N-0;4G^QRJ;MG9C, \8#9
M;GH!UKR7=1NI\KLTV3[1*2:6WF=I\5S_ ,70UC_?C_\ 125Z7\>F9/#&ELC%
M66]R"#@@[&KP#=1NHY=O(7M-):;GT)K,-E\8_!%G_9&H6]OJ=NPE>"4\H^TA
ME;'(![, >E<YKO@/PGX.\!O_ ,)#<K/K[(WE&WG*EW/W0$/\(XR2/Z"O'MU&
MZDH-:)Z%2JJ6KCJ>^^"-?@\7_#0>&X-8?2=9M81$DD4AC?"G*,N""1@!6QSU
M]16?=>"?%NDZ5->:]\29;'R^1_IDS(1_O%@<^P!KQ+=1NHY+/0/;72YE^)8G
MEDFN))9I6FD=RSR,22Y)Y))Y.?>NX^$WC"U\*^)Y5U23RK&^C$<DF,B-P<JQ
M]N2/QSVKS_=1NJVDU8QC)QES(]NU_P"#P\0^)9=8T76K-=+OI&GE;)<QEN3M
MQPP))/48S5/XL^+=+B\/V?@_P_.L\5ML6>1&#*BQC"QY[G(!/ICW->.[J-U2
MHZJ[-755FHJUSW[Q3_R;A:?]>5G_ .A)7@N:CW4;J<8\I%2?.TSV3]G_ /Y"
M6M_]<8OYM7G/C(_\5WKW_82N/_1K5@[J-U"C:38.=X*'8DS7T'I>L?\ "Q?A
MS;V.CZ\^E:[;*@D\N9HF+J,'(4@E&!SQG!QW&*^>-U&ZB4>8=.HX7\SV;6/"
M?BGP_H,E]K7Q)FMIT!(@^V3$.>P5MP8D^FVMCX%_\B)JG_7Z_P#Z*2O =U&Z
MI<+JURXU5&7,E^)I:,=.&M6O]MB8Z?Y@%QY+88+ZC@].OO7N3^#K[R;.[^%/
MB=;2QV;9()+IYH3R3O .X;NQ&!T[<U\][J-U5*-R*<U!6:/>_B[KME;^ H=#
MO[V"_P!:D,18Q* 59<%I"!]T'D ?[7UI^O?\FTQ?]>5K_P"C8Z\!W4;JGDLD
M:.NVV[;JQ[/X&\.^'M=\(;O#&K7&E>)PBK+(;IE97!&?D4C<C?0XSZBNYT6Y
MU7PAH-W<?$;Q%9W(&#%L4 J #D X4N3Q@8SQWKY?W4;J'"_4(U^5:+7^NAZU
M\&-8L(_'FJ*Q2T6^B8VT;, !\^0@]\'@>QK5UJTF^'OQ07Q;J-U ^GZE=/$\
M463(D;+]XC'8C/&>GO7B&ZC=3<-;DJK:*C;8^BO$WA?7O%.K1ZOX.\926^GW
M"+YD<=[*$3 QN0(<<@=..<\\UYE\1=.O]%>&POO&DFOY?>;9YG8PD#ABI9@#
M@GOGFN"W4;J(Q:ZA.HI)Z:^I[]\:O^29:3_U^P_^B9*/@7_R(FJ?]?K_ /HI
M*\!W4;J7)[O*5[?]YSV/4_@5J5K9^+;RVNIEB>ZM<0[V #L&!VC/?'./8U6^
M+?A"[T?7;G7+BZMWAU*[;RHD)WJ-N<D$>Q'&>U>:[J-U5R^]S&?M/W?(T=W\
M)- _MWQ]:O*FZWL!]JDR#C*GY!_WT0?H#7=>/?B_J?ASQ=<:3HMM8RQ6RJLC
MW$;L3(1DXVN. "!TZ@UX5NHW4G%-W8XU7"'+$][^'GQ9U'Q3XJ72=:M[&!9H
MF,#6Z.I+KS@[F/\ "&_*FV&@_P!A_M$.T:[;>_MY;J/ XRP.\?\ ?0)^A%>#
M;J-U+V:OH6J[LN;6S/0_C2?^+DW'_7O%_P"@UW?QJ_Y)EI/_ %^P_P#HF2O
M=U&ZGR[>1/M?BTW/HCPM"GB[X&KH^EW,(NS;-;NLC?ZMPY/S8R0",'IT(JG\
M&M(DT#7O%>ESS1SR6SVR-)$<JW$AX_.O ]U&ZER:-7W*5;6,K:HZ]_%NM^%?
M%>NMH-[]E-Q>2"7]TC[MKMC[P..IZ54U[QWXC\3V"66N:C]JMXY1*J>1&F&
M(!RJ@]&-<WNHW5=D8\TK6OH=Q\(C_P 74TC_ +;?^B)*TOCC_P E"7_KRC_F
MU>:[J-U+E][F'S_N^3S/HFSM;;XA?!>ST?2K^&.ZAM8(G#G/ER18&& Y .WK
M[YYK2^&/A^W\*Z9>Z0=3M[[4%D6>[6W.5AW#"KG_ ( 3S@^U?,FZC=4.GI:Y
MLJZ34G'5'MG[/G_,P_\ ;M_[5KG? O\ R7U?^OV\_P#0):\UW4;JKEU;[F:J
M645;8]*^./\ R4)?^O*/^;5VGQ\_Y%;3/^OW_P!D:O =U&ZCEV\ANK\6FY]
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M^)H]LNP?5)=SY$S1FOKO_A"_"W_0M:/_ . $7_Q-'_"%^%O^A:T?_P  (O\
MXFCVR[!]4EW/D3-&:^N_^$+\+?\ 0M:/_P" $7_Q-'_"%^%O^A:T?_P B_\
MB:/;+L'U27<^1,T9KZ[_ .$+\+?]"UH__@!%_P#$T?\ "%^%O^A:T?\ \ (O
M_B:/;+L'U27<^1,T9KZ[_P"$+\+?]"UH_P#X 1?_ !-'_"%^%O\ H6M'_P#
M"+_XFCVR[!]4EW/D3-&:^N_^$+\+?]"UH_\ X 1?_$T?\(7X6_Z%K1__   B
M_P#B:/;+L'U27<^1,T9KZ[_X0OPM_P!"UH__ ( 1?_$T?\(7X6_Z%K1__ "+
M_P")H]LNP?5)=SY$S1FOKO\ X0OPM_T+6C_^ $7_ ,31_P (7X6_Z%K1_P#P
M B_^)H]LNP?5)=SY$S1FOKO_ (0OPM_T+6C_ /@!%_\ $T?\(7X6_P"A:T?_
M , (O_B:/;+L'U27<^1,T9KZ[_X0OPM_T+6C_P#@!%_\31_PA?A;_H6M'_\
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MT?\ \ (O_B:/;+L'U27<^1,T9KZ[_P"$+\+?]"UH_P#X 1?_ !-'_"%^%O\
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M%^%O^A:T?_P B_\ B:/;+L'U27<^1,T9KZ[_ .$+\+?]"UH__@!%_P#$T?\
M"%^%O^A:T?\ \ (O_B:/;+L'U27<^1,T9KZ[_P"$+\+?]"UH_P#X 1?_ !-'
M_"%^%O\ H6M'_P# "+_XFCVR[!]4EW/D3-&:^N_^$+\+?]"UH_\ X 1?_$T?
M\(7X6_Z%K1__   B_P#B:/;+L'U27<^1,T9KZ[_X0OPM_P!"UH__ ( 1?_$T
M?\(7X6_Z%K1__ "+_P")H]LNP?5)=SY$S1FOKO\ X0OPM_T+6C_^ $7_ ,31
M_P (7X6_Z%K1_P#P B_^)H]LNP?5)=SY$S1FOKO_ (0OPM_T+6C_ /@!%_\
M$T?\(7X6_P"A:T?_ , (O_B:/;+L'U27<VZ***YST HHHH **** "BBB@#E=
M6\=^%([B^T:[\116-TL<D<DB.5\E@A+ 28VB11SMSD8Z5Q'AOPM\,-7U2&&Z
MT;4KR_NT,EM<^(XYRU\H&2R&7Y6XYP #CG&*W],\#?VEX/O_  ;XIL&%I!>F
MXAOXI$/VL-.9@_<JX^ZP(YSP3GC3\1V]]KGB[0M/L].GCMM+O$U&XU*0!8P
MCJ(H^<LS%N>, 9YR<4 .D^%7@*6/8WA#1P/]FS13^8&:SX?A!H&E:A#>^%;O
M5/#\D4JR-%8WK^3* <E7C8D$'IQBN]HH **** "BBB@ HHHH **** "BBB@
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M7;VJ1O\ $V&4J,;I-"B8_GNYKL] L]4L='C@U[5%U6]4L7NDMA '!/ V D#
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M PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N$^*LTUSI.E
MZ!IUI#/JFLWRPV4T[LBV;HK2&?<N&#($)&#R?;(/=UQOQ*T+7=<T2R'A2.T&
MJV=XMS;W-S,T?V9E5AN&%;=G.TJ1@AC0!EVOA3XH06R1R?$>SE91@M)H2$_F
M'&:[30+35K+1XX/$&IQZI?*6+W,5L(%8$\#8"<8&!UKC;>^^+Z0*MUHWA260
M#YG2]G0'\-A_G79:#+K,VCQOXEMK2VU EO,CLY6DC SQAF /3':@#2HHHH *
M*** "BBB@!&8*I9C@ 9)]*\O;Q;H'BGXU>%#X=U:UU'[-8:AYWV>3=Y>X18S
M]<'\J]1K@M<@BA^-?@WR8DCS8:CG:H&>(: .]HHHH **** $**>JC\JH:IH6
MFZS"L6I6D<ZJ<J2,%?H1R*T**F48R5I*Z(E",URR5T4M-T?3](MO(TZUC@CS
MDA1R3ZD]ZN!%!R% _"EHHC&,5:*LAQA&"Y8JR"BBBJ*"BBB@ HHHH **** "
MBBB@ HHHH YKQUX0_P"$UT.'3OMWV+RKE;CS/)\S.T,,8W#^]USVKI:** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH AO8'NK"XMX9WMI)8F1)H_O1DC 8>XZUP*67Q8T3$=OJ
M?A_Q- O >]A>SG(^J93]*]$HH \__P"$@^*.-H\#:3N_O_VW\OUQY>:EM+7X
MGZI>POJNH:#H5FLBM)%80O=32*#DIN?"KD<9 .*[NB@ HHHH **QM;\5Z/X?
MU'2K#5+KR[K5KD6UG$%+-(Y]AT R,D\<BH_$WC+1O":VPU::4SW;%+:UMH'F
MFF(&3M1 2<#J>E &[16-X?\ %FC>)])DU'1[P200NT<XD4QO Z_>5U8 J1[U
MC:9\5O">K:M;V%I>S@W<ABM+F:TECM[IQ_#'*RA6/T//;- '95PWB#_DM?@S
M_KPU+^4-=S7#>(/^2U^#/^O#4OY0T =S1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% %/5]3@T71+W5+O/D65N]Q)CKM12QQ^5?&^M_M!^/]3UQ[ZQU8Z9;A
M\PV<$2%$7L#N!+'U)_2O?/C!\3[+2;*?P;HEI_;GB+5HFM18Q L(A(N,OCG.
M#PO7N<#KX5-^S=\18Y8$CT^TF65%9G2\0"(D<JV<'(]@1Z9H ^CO@Y\0Y?B/
MX'&H7T20ZA:S&VNA&,*S  AP.P((X]<UW]</\)OAXOPW\%KI<DZW-[/*;B[E
M0':7( PN>P  ]^3WQ7<4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ROCO7M1
MTNUTW3/#_EKJ^MW@L[6:5=R6XVL[RE?XMJ*2!W.*ZJN4\>Z!J6JV>FZGX=\H
MZSHEV+RUBF;:DXVLCQ$]MRL1GL<4 <QX>TSQ'_:/CCP_:>+M0EOK62S:TU"^
M"S&-VB$C#9C:$)XP!T-=?X$\27'BCPI%>:C;K;:A#-+:7L*'*I/$Y1]OL2,C
MV->=Z+XN\2VOB_Q1=P?#W7_[0U=K;[-#/&J01M'#L8O/G;MW=QG(KT3P+X<N
M/#'A6.TU&=+G49YI;N]FC&%:>5R[[?8$X'L* .CJEK&KV6@Z+=ZKJDP@L[.(
MRRR'LH_F>P'<U=JMJ&G6>K:?+8ZG:Q7=I,-LL$R!D<9S@@]>10!X!K%U;ZIK
MOA#QEKFH6@U34/$=L8[7[2C?V;8A7*1G!X).&<_WB!VKT"Q=-0_:.O9G994M
M/#</V0@Y4"28EF7ZX SZ4WQ/\&/#>J7.AOHN@Z+8QV>I1W-ZOV55^T0 ,&CX
M7G)(X/'%:/B#P=JEKXFT[Q)X$;3[>]M+(Z=+97@98)[;(95!0$J5(XX/I0!Y
MY\0;F;2=;^*J:<3&MUH5G-*$X^=B8B?J4)KJOBO96]A^SU,+-5B_LRWLY;-E
M&/+9)(PI'H?\:T])^'4]YI_B>;QI<P7.J>)XQ#=_8@PBMXE0K&D>[D[<DY/4
MUEOX%\;:YI&G>%_%6I:1)X?LI(C/<6JR?:;^.(@HC*1M3.T;B">G% '::[XG
MET&ULI%T#5]7:Y4EAIENLGE$ ?>RRXSGCZ&N)3Q))XB^-7A4R:#K&C^18:A@
M:G;K%YN1%]W#-G&.>G45ZK7#>(/^2U^#/^O#4OY0T =S1110 4444 %<MXT^
M(_AKP!!"_B.^\J2?)BMXEWR.!U.T=![G%<KKW@'XCZAX@OKO2?B,UA933,\%
MJ+8GR4)X7.[G%?/OQL\'>+O#OB."[\5ZE-KD<\*K%J7EE4X_Y9GKM(ZX[YS0
M!]9>#O'GA[QYISW?AN^%P(B%FB9=LD1/3<I]?7I71U\<? [P1XTUV\O]0\+:
MQ-X>MEB$;WIB++.<YV 9&<8SGM^->]>%O WQ!TGQ-9WNO?$!M5T^(L9K,VQ7
MS05( SGC!(/X4 >FUQ/P^^)5KX[:[A^Q_8+NVP_DF;S-Z'C<#M'0\$8[CUKM
MJ^;_  I87>B^#K3QWHRE[C2[]XKR(=);<A0>/;<1[9S_  T"/:/"/C>#Q-X=
MN]7O(8]+@M+EX',MP&4!0IW%B% ^]6O;Z]IFH6ES-H^H66H?9DW.+>Z1@IP2
M Q!(7.#R:\*TC5+6+X2>1-I\-\VH>(2D"74KI"C;$.Z38P)'MG'?MBM71+"?
M1_BOJ]G/+8><=%E:>'38!#!$Q4'RPHZ@<<GD\$T!<]1\/^+;;5M,LYM1>PT^
M[O'=(;5-1BN/,VG'R,IPQZ<#I6N=2L5U)=/:\MQ>LGF+;&5?,*_WMN<XX/->
M'6.GS2? ?3-;L /MNAZ@UY&W?:),,/IT8_[M:>GWEUXBA\<>.;!)$<6K6>GD
M#E$5 78>AP ?J30%SUF#7-)NM1?3[;5+*:]C)#VT=PC2*1URH.1CO5ZOG[1O
M#.I77A;P[?VMUX1TI$N%DMKXRR0W<KACF-V((9LY^7V&.*^@: "BBB@84444
M %%%% !1110 4444 %%%% !1110 4444 %%%-DD2*-I)75$0%F9C@*!U)- #
MJ\:^(7Q:O[W6SX'^%<7]HZ_,3'/>1X,=F.C8/3<.['A?<\#+\5_$37OBCKTO
M@KX3%DLQ\NHZYRJ*G0A6[+UY'+=N.3Z7\/?AOHGPYT3['I,?FW4H!NKV0?O)
MV]_1?11P/<Y- &3\,/A+I_@&!]0OI?[4\1W0+76HRY8@GDJF>0,]3U;OZ#T2
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KDO'>O:MI@TC2O#8MTU3
M6[S[+#<7*EH[=0C2.Y4?>(53@=S76UPGQ6N -%TRQL;26ZUZ\OT71_)E$307
M"JS>:6(("JH;<"#D$C'- $?_  AWQ /+?$^0'N%T.WQ^'-=;H%CJ6G:/';:U
MJS:Q>*6+W;6ZPEP3D#8O P.*XRT'QECMD6Z/@N60#EB;D$_D,?E79Z"=;.CQ
M_P#"3BP&HY;S!IY<PXS\N-_/3&?>@#2HHHH **** "BBB@ KAO$'_):_!G_7
MAJ7\H:[FN&\0?\EK\&?]>&I?RAH [FBBB@ HHHH *CGMX;J(Q7,*31GJLBA@
M?P-244 ,AABMXA'!&D<:]%1< ?A3Z** "LG2?"VC:)HLVDZ99+%83EC) SLX
M?<,-DL2>0,5K44 <Y'\/_#$7AV30ETI#ILDWGM"TKL1)@#<&+;E.!C@CC/J:
M33OA[X7TFXCGT[24MY8X7@#I+)ED;.X-\WS'YCR<D<<\#'244 96G^&M(TK0
M'T2PM!'ITBNK0&1FR'SN&22><GO4NC:%IOA_2ETW2+46]HI8B/<S\DY.2Q)/
MXUH44 <S8_#GPEINLC5;+188KM9#(C;W*HQ.<JA.U<'I@#';%=-110 4444
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M,QV@ZKN7ID=DZ#J<GI[50 R&&*V@C@MXTBBC4*D:*%50.  !T%/HHH ****
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M(/XYF'S<^@X4>P% '7T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,_[1(]ZZ'X6WDEYX!M?M5S?7%[!--;WAOY_.E2=)"KKOP,J"./;% '84444
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M7VOW.<?:9HRD2^Y4<X_WBM5Q\,?B=\0OWGQ'\6?V38/R=+TW'3^Z=N%_$EZ
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M?^!,:]>HH K6&G66E6:6FF6<%G;H,+#;QA%'X#BK-%% !1110 4444 %%%%
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MC_OR:/\ A:?AK_GK<?\ ?DU#_P *A\)?\\+[_P &,_\ \71_PJ'PE_SPOO\
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M_P#\71RX_P#FC]S#DS/^:'W,F_X6GX:_YZW'_?DT?\+3\-?\];C_ +\FH?\
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M54 W3@_[0Q7KOA^RU+3M"MK77-4_M:^C7$MYY A\P_[HX'I0!I4444 %%%%
M!4*6EM'</<1V\232</(J ,WU/4U-10 4444 %%%>)Z/XE\1>*[R]N8_BCIWA
M]+C4KB#3M-DLK:21H4D**1N8,<X/;M0!Z]INBV&DS7\MA!Y3ZA<FZN3N)WRE
M54MR>.%' XXJ]7GWB;5_$!\0^'O!&BZLMMJ5Y:O=:CJ_V969(HP%+)&<J&=S
MWR!4OA/6M:T[Q[J/@OQ-J(U:2*R34;#4#"L4DD)8HR.JX7*MCD#D&@#O****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\+:#X:65?#^CV6FB8YD^RP+'O],D#FM6@ HHHH **** "BBB@ HHHH ****
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M;7/Q:\4Z]9RO+HVF7LUOIL3?<CN90INF3VW#;^)KV&@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "D8;E(R1D8R#2T4 9N@>'].\,:-%I>C0&"UB+,
M%+EV+,Q9B6)))))Y-:5%% !1110 4444 %%%% !1110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>fig12.jpg
<TEXT>
begin 644 fig12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     S$T  "2
MD@ "     S$T  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0 _-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9IF:,T /S1FF9HS0
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M,9,,'0 Y4@]&-<MXAU^[\2ZY/JFH")9IL92%2$4 8P 2?3UKN?@0?^*ZO/\
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M- #\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC-
M#\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC- #\
MT9IF:,T /S1FF9HS0 _-&:9FC- #\T9IF:,T /S1FF9HS0 _-%,S10!K>,C_
M ,5WKW_82N/_ $:U8N:U_&;?\5YK_P#V$KG_ -&M6+NJ5L:R^)C\T9IFZC=3
M)'YHS3-U&Z@!^:,TS=1NH ?FC-,W4;J 'YHS3-U&Z@!^:,TS=1NH ?FC-,W4
M;J 'YHS3-U&Z@!^:,TS=1NH ?FC-,W4;J 'YHS3-U&Z@!^:,TS=1NH ?FC-,
MW4;J 'YHS3-U&Z@!^:,TS=1NH ?FC-,W4;J 'YHS3-U&Z@!^:,TS=1NH ?FI
M+>2..YB>>(31JX+Q%BN\9Y&1R,],U!NHW4 >[:C\*O#/BOP[:ZAX#FBLF8;@
MS2R2)("/NMDDH0?ZY'IJ_#OP%K7@NXEN=9UV-[01,OV.&1S"I)!WDM@ C![=
M^M?/]AJ^HZ6S-IE_=6;-]XV\S1D_7!%37OB/6M2A,.HZO?W<1QE)[EW4]^A-
M8N$K6N=2JTT^;EU/3=%\2Z;>_M$3:A!*OV2Z9K>*7("LPB" _1BO'KD5J?$;
MX::[XG\>)?:<(193Q(LD[R >3MX.5ZGVQ^E>&[JTYO$VNW%F;2XUK4);8KM,
M+W3LA'IM)QBGRM.Z)55.+C-=;GM?QT*'P+IAB<.AO4VL#D,/*?!K4MM$7Q'\
M"['2VG2W>XL81%(YPHD!4H"?=@!^-?/=YKNJZA:QVM_J=Y=6\1!CAGN'=$P,
M# )P..*]>UKQ!I$G[/<6GPZM9/?BTME^RI<H901*A(VYSD $_A4.+22\S:-1
M3E*3[%OX6^ -5\(:O?ZSXD,-G%';M"B^:K C<&+D@X PO?GGM4O@#QSI^I_$
MCQ'#YJQQZE*DEF6X\SRUV=^Y4 @>QKQ.[\1:SJ%K]FO]7OKFWX_=37+NG'L3
MBJ <JP9200<@@]*ODO>YDJRC906B/?[ZP^+I\07,%AJUL+#>S07,D< 7;GA2
M-A;./;'O7,:?<^(W^-FB6?BZ_@O+RU8J#!Y>$!1C@[ .>^",\BO/?^$N\1^3
MY7]OZIY>,;/MLF,?3=6=;7UU9W:W5I<S07"'<LT4A5U/J&'-"@$JJ;5K_>>E
M_'DG_A.K(9X_LU./^VLE=9\%?^29:M_U^S?^B8Z\,O\ 5;_5;A9]4OKB]F5=
M@DN)6D8+DG&6)XR3Q[U+9>(-7TVU>VT[5;VT@=BSQ07+HK$C!) ."< #\*'"
M\>44:J55SL>L_ [Q!8BRO_#=Y*L4UQ*9X S8\W*A64>X"@XZ]?2LW3/@MX@M
M_&$*W!@_LR"=9#>"0?.@;. G4,1ZC ]37E0<JP9200<@@]*U&\6>(7M_(?7M
M3:'&/+-Y(5QZ8SBFXN[:ZB52+BE-;'JWQ-\4V>J>/?#VC:?*LWV"^1KAUY D
M+J-H/J #GZX[&C]H,D#P\,\?Z3_[2KQ:.9X94EA=HY$8,KJ<%2.A![&K>H:W
MJFK^7_:VI7=]Y6?+^TSM)LSC.-Q.,X'Y4E"S7D.5;F4D^I5S7IWP&_Y'N]_[
M!K_^C8J\NW5:L-5O]*N&GTN^N+*9EV&2WE:-BN0<94CC(''M5R5U8RIRY)*1
MZS9?\G0-_P!=I/\ TE:L7XX?\E"7_KRC_FU<$NLZDNJ?VDNHW0O\D_:A.WFY
M(Q]_.>G'7I3+[4[W5+C[1J5Y<7DVT+YEQ*TC8';)).*E1LTS251.#CW=SWCX
MH?\ )&+'_MV_]!IW@2VDU?X"3Z?I^V6ZD@NH%3<!\[,V 2>GWAU]:\,NO$.L
M7UDMG>ZM?7%JN-L$UR[H,=,*3CBF:?K>J:3O_LK4KNRW_?\ LT[1[OKM(S4\
MGNV+]NN?FMTL>T?!?1[W0-?\2:9JD8BNH$MO,0,&QN#L.1QT(KRO7?LY^(FI
M?;RPMO[5E\XKUV>:=V/PS5"'Q+K=M=3W-OK.H17%QCSI8[IU>7' W$')QVS5
M"6>2XF>:>1I99&+.[L2S$G)))ZFJ46FVS.4TX**Z'TWXRM_%!T/3HOANUK%#
MTD\O8,1X&PH6^7;USCGICO4/B:UOH/@OJ%MJ-T+Z_BLS]IF5MV7!!;GV_D*^
M>;7Q+K=C:BULM9U"VMQTAANG1!^ .*;%XBUF"SDM(-7OH[:7=YD*7+A'W?>R
MH.#GOZU'LV;/$)WTW1V6A_&+7] T2UTNSM-->"U38C2Q2%B,YY(<#OZ5S7BK
MQ3>^+]9&I:E%;Q3")8MMNK*N!GU).>?6L+=1NK512=T<SG.2Y6]#WWX&?\B)
MJG_7Z_\ Z*2O*?A]?P:=\0='N;MQ'"MP%9ST7<"H)]LD5CV'B#5]+MV@TS5;
MVSA=MS1V]R\:L<8R0",G %4-U2HZOS+=2ZC;H>]?%;X>ZYXK\2V-_HJ12Q?9
MEMY-\@3R\.S;CGJ/F[9/%7OB39KIOP32QCF69;1+:#S%Z-L*KG]*\*3Q/KJ6
M8M$UK45M@NT0B[<(!Z;<XQ44NO:M/IJZ=-JEY)9* %MGN',8 Z +G'%3R/37
M8T=:'O-+<]OU[_DVF+_KRM?_ $;'1\ _^16U/_K]_P#9%KQ&3Q!J\NF#3I=5
MO7L0H46K7+F+ .0-F<8! /3M1I_B#5])B:+2]5O;*-VW,EM<O&&/J0I'-')[
MK0*LE-2MLK'=? __ )*$W_7E)_-:V=4\0P^&OVC;N\O'"6L@B@G<_P *M F#
M] <$^V:\FL=3O=+N/M&FWEQ9S;2OF6\K1M@]L@@XIEY?W6H73W5_<S75Q)C?
M+-(7=L# R3R> !^%4XWE<S53E@HKH[GL_P 2OAIJOB3Q*NN^&1#=Q7J()1YR
MC! "AP2<%=H7ISQTJ]XAGM_AW\&U\.7=S'/J=U \(C0]Y&)=AWVJ&(!/4X]:
M\5LO$>M:9!Y.G:O?VD7_ #S@N71?R!JG<WEQ>W#3WD\MQ,_WI)7+,WU)YI<C
MT3>B+=6*O**U9[YG'[-O'_0/_P#9Z\\^#T>G2_$2W75!&Q\IS;"3H9N,?CC=
MCWQWKD?^$AUC^S?[._M:^^P[=OV7[2_E8ZXV9QBJ"R,C!D8JRG((."#34;)K
MN3*JG*+ML?26O6?CZ[\=1_8K^&S\-HT<CR*Z*=@P7#?Q[CST^7&.1S7,_M Q
MNT&@3*I,:M<*6'0$B,@?C@_E7DEUXEUR^M3;7NLZA<0$8,4MT[J?P)Q3+[7]
M7U.W2WU+5;V\AC(9([BX>15(&,@$X'!(J8P::9<ZRE%K74]N^/G_ "*VF?\
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MMDBJJVTER[1J%^Z I.,# QZ4N2R13K7<FUNK'N>FQ1_$3X'Q:3IL\:7MM!%
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M<S-UDF<NQ_$\U#NJH1Y58SJS]I+F'YHS3-U&ZK,Q^:,TS=1NH ?FC-,W4;J
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M /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\
M\FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY_
M_BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/
M;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#Z
MK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NC
MY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1
MFOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#
M_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W
M@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H
M!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\
MDW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_
M /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T
M?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>
M\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_]
M /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\
M\FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY_
M_BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/
M;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#Z
MK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NC
MY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1
MFOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#
M_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W
M@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H
M!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\
MDW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_
M /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T
M?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>
M\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_]
M /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\
M\FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY_
M_BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/
M;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#Z
MK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NC
MY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1
MFOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#
M_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W
M@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H
M!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\
MDW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_
M /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T
M?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>
M\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_]
M /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\
M\FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY_
M_BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/
M;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#Z
MK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NC
MY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1
MFOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#
M_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W
M@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H
M!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\
MDW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_
M /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T
M?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>
M\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_]
M /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\
M\FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY_
M_BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/
M;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#Z
MK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NC
MY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1
MFOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#
M_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W
M@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H
M!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\
MDW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_
M /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T
M?\*>\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>
M\"_] /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_]
M /\ \FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\
M\FY__BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY_
M_BZ/;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/
M;1#ZK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#Z
MK/NCY?S1FOJ#_A3W@7_H!_\ DW/_ /%T?\*>\"_] /\ \FY__BZ/;1#ZK/NC
MY?S17U!_PI[P+_T _P#R;G_^+HH]M$/JL^Z.VHHHKF/2"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG"C>Q("D@ ]>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,D?*S,61RJ$,%ZDG! ![^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "HXKB&=I5AECD:%_+D","4; .T^AP0<>A%25Y=9M+H7BOQ9XHMU>6WA
MUG[-J-NA.7A-M:;9O3]T2Y.<#8\A)X H ]-2XADN)((YHVFB"F2,,"R YP2.
MHS@X^E25P4>LVVC^+?'>N2!KBVL])L[MO(()D1(YW^7G!R!QSBJ&G_$2*'6+
M S^+] UQ=4N8K8:9ILT;2VC2' *D-F103\Q(4X&<9XH ],J-KB%;A+=I4$TB
MLZ1EAN95(!('4@%ER>V1ZUCZ'JUSJ&O^);2X*>5IM_%!!M7!"M:PRG/J=TC?
MABN"TJ[\0>)/'/AG4?[7@M&-EJJ/&+$.&2*^A1ER6&"RB,9[%">=W !ZS17G
M)\1^(S%XDUNYU&WM]'\.7MSNMH+0237<,*AV0EF 1L @$9SNR<8K4;4O$/A^
M[L;S7[VUOK/4[J*T^RVT&PVDDIPNUR<R*"<$L%..<9XH [*HS<0K<I;M*@G=
M&=(BPW,JD D#J0"RY/N/6N,6Z\6ZWXF\0VNE:I8Z?9Z3>QPPA[4RO/NMH961
M^0%7+\,,GYCQ\HSD-JNI^*_%OAF\T*2'3+B?2=3CFEG3S?)\NYMD<HO ?+I@
M9*_*Q/4;: /2I[B&V17N9HX59UC5I&"@LQ"JHSW)( '<FB.XAEFEBBFC>2$@
M2HK F,D9 ([9!!Y[&O/I_$FM:;-=Z3J-Q;:A<V.JZ5$;PVPC$B7-PJL/+R0"
MHSAL]>>U2#4KO1]5^(VHZ;9M>W=O+;R16Z@DR,+2+C@$T >@T5QO@[5[G4M0
MF6'QGHOBFVCC'G&Q5$DMFS\O",P(;YNI&-HQG)QV5 !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!2U/6M+T6-)-8U*ST])#M1KJ=
M8@Q] 6(R:9IFOZ/K9E&C:M8Z@8<>8+2Y279G.,[2<9P?R-<]XJMX;GXA^#8[
MF&.9"U[E9%##_4>AIOCJUM]!\/G7M'@BL]0T^2/RGA0*'5Y$1T<#[RD'./4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;8_^!$__ ,31_P ,T>/?^AML?_ B?_XF@#ZBHKY=_P"&:/'O_0VV/_@1/_\
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M9O\ P:Q?_'* /LJBOC7_ (4?\7O^?&;_ ,&L7_QRC_A1_P 7O^?&;_P:Q?\
MQR@#[*HKXU_X4?\ %[_GQF_\&L7_ ,<H_P"%'_%[_GQF_P#!K%_\<H ^RJ*^
M-?\ A1_Q>_Y\9O\ P:Q?_'*/^%'_ !>_Y\9O_!K%_P#'* /LJBOC7_A1_P 7
MO^?&;_P:Q?\ QRC_ (4?\7O^?&;_ ,&L7_QR@#[*HKXU_P"%'_%[_GQF_P#!
MK%_\<H_X4?\ %[_GQF_\&L7_ ,<H ^RJ*^-?^%'_ !>_Y\9O_!K%_P#'*/\
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M:0:E&VU<XZ!R3U[4GB?QSXCUCX0^%HK[5;AEBO[V#*N5:18H[<Q[R/O%?-<
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M\&L7_P <H ^RJ*^-?^%'_%[_ )\9O_!K%_\ '*/^%'_%[_GQF_\ !K%_\<H
M^RJ*^-?^%'_%[_GQF_\ !K%_\<H_X4?\7O\ GQF_\&L7_P <H ^RJ*^-?^%'
M_%[_ )\9O_!K%_\ '*/^%'_%[_GQF_\ !K%_\<H ^RJ*^-?^%'_%[_GQF_\
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MY\9O_!K%_P#'*N_"B;Q;X0^/%CX5UB^NK=Y9MM_:?:!(KXA9T!()!^\#P>]
M'U[17Q"]IX\^)WQ U6TTF\N]2O;0R'#W:Q;(5DV@ LP'!8<>]:G_  H_XO?\
M^,W_ (-8O_CE 'V517QK_P */^+W_/C-_P"#6+_XY1_PH_XO?\^,W_@UB_\
MCE 'V517QK_PH_XO?\^,W_@UB_\ CE'_  H_XO?\^,W_ (-8O_CE 'V517QK
M_P */^+W_/C-_P"#6+_XY1_PH_XO?\^,W_@UB_\ CE 'V517QK_PH_XO?\^,
MW_@UB_\ CE'_  H_XO?\^,W_ (-8O_CE 'V517QK_P */^+W_/C-_P"#6+_X
MY1_PH_XO?\^,W_@UB_\ CE 'V517QK_PH_XO?\^,W_@UB_\ CE'_  H_XO?\
M^,W_ (-8O_CE 'V517QK_P */^+W_/C-_P"#6+_XY1_PH_XO?\^,W_@UB_\
MCE 'V517QK_PH_XO?\^,W_@UB_\ CE'_  H_XO?\^,W_ (-8O_CE 'V517QK
M_P */^+W_/C-_P"#6+_XY1_PH_XO?\^,W_@UB_\ CE 'V517QK_PH_XO?\^,
MW_@UB_\ CE'_  H_XO?\^,W_ (-8O_CE 'V517QK_P */^+W_/C-_P"#6+_X
MY1_PH_XO?\^,W_@UB_\ CE 'V517QK_PH_XO?\^,W_@UB_\ CE'_  H_XO?\
M^,W_ (-8O_CE 'V517QK_P */^+W_/C-_P"#6+_XY1_PH_XO?\^,W_@UB_\
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MT<31SJY+-,CC@=. :]QHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6\TB^M[ZU<D+/;2K(C$=<,"10!;JK:ZG87UQ<065[;W$UJ_ESQPRJ[0M_=8
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M"RS.[76)"9)%,F4#93"G=\L9.!DBOH>VDBT#P+%)K6U(M/TT-=Y&0JQQ?/\
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M$ CH>*XSP?8Q^,_#-_87OQ"C\5-+J<=S>2VT*Q?ND5 (=G\"EHPV5 R<^I)
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MJ3Y'F+'J68K$>>F/>NHK@/@]-#=^%]1O8+S4;T7>J2RM+J5H+>8G8@P5!(.
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MIU)H ^<-6U+]GJUTR2;2+#3[ZY7!6"3[;%N&><-L/..WZBO=?!BZ G@W3O\
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MDMV8\0LZ\2,1EO;&#6[XD7QQ'K$-QX4;1YM/6#$UI?%TD>3<>5=00!C P>]
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MB[23_P!O"UD?\(9X6_Z%K1__  7Q?_$T?\(9X6_Z%K1__!?%_P#$T?Z[4/\
MGR_O0_9/N:X^+/@ =/%VDC_MY6D/Q8^'[?>\6Z2?K<+63_PAGA;_ *%K1_\
MP7Q?_$T[_A"_"W_0LZ/_ ."^+_XFC_7:A_SY?WH/9/N:@^+/P_'3Q;I(^EPM
M177Q.^'%]!Y-[XGT6>+>DFR296&Y&#*<'N&4$>A -4/^$+\+?]"SH_\ X+XO
M_B:G'@CPI@?\4QHW_@OB_P#B:E\;T%_RY?WHI4&^HMS\0/A;>ZC;7]YKV@3W
MEJ<P7$CHSQ'_ &6/(_"KI^+/@ C!\7:21_U\K5+_ (0CPI_T+&C?^"^+_P")
MJ-O!7A4-QX9T;_P7Q?\ Q-'^N]#_ )\O[T6L*WU- ?%CX?+T\6:0/I<+2_\
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M_P _E]S/J;_A;7@#_H;M)_\  D4G_"V?A_C'_"6Z3CT^T+7RU_9EC_SY6_\
MWZ7_  H_LRQ_Y\K?_OTO^%']IP_E'_J/7_Y_+[F?4W_"VO '_0W:3_X$BF_\
M+7^'V<_\)9I&?^OA:^6_[,L?^?*W_P"_2_X4?V98_P#/E;_]^E_PH_M.'\H?
MZCU_^?R^YGU-_P +:\ ?]#=I/_@2*/\ A;7@#_H;M)_\"17RS_9EC_SY6_\
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M%PD3NV  ,L1DX  _"N8UWPMX?BTB1HM!TQ&W+RMG&#U^E<M_8&C?] BP_P#
M9/\ "M:/$M*K'F5-_>;4.'ZE:',II?(]KA^*GP\MX4A@\5:/%$@VJB3J H]
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MW:3_ .!(JE_PA'A3_H6-&_\ !?%_\31_PA'A3_H6-&_\%\7_ ,37F?Z\4/\
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M?CZ>]'BPPW?[1/@F+3<27EI;W<E_Y9Y2$IA-_MNZ9H G^%( \:?$7 _YC?\
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MK[*C_"CZ(^_P_P#!AZ+\CU'X:?\ (LS_ /7VW_H"5V%<?\-/^19G_P"OMO\
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M  2_)GU]2,-RD'(R,<'%+17U9^ F1X<\+Z5X3L)K/1(&AAGN'N9=TC.SR/\
M>8EB3VINM^$](\0:EIE_J=NSW6E3BXM)4E9"CCZ$9'L>*V:* ."U3X+^"]8U
MJ\U6]LKO[7>R&6=XK^:,,Q[X5@!6F/AOX;_X1.#PVUM.^F07 N8XWNI&82!M
MP.\G=C)Z9Q7544 ( %4 = ,"LJ_\,Z7J7B+3M<NX&>_TP.+602, F\8;*@X/
M'K6M10!C^*/"NC^,=%?2O$-H+JT=@^W<5((Z$$<@U?TZPM]*TNUT^R0I;6L*
MPQ*6+%44  9/)X%6:* ,?Q1X5TGQEH;Z1K\#7%E(ZNR+(R$E3D<J0:Y!?@-X
M$0 +97X"] -3GX_\?KT>B@#&\0^$M$\4Z'_9&O6*7=F -JL2&0C@%6'(/N*S
M?"?PS\*>"KR6[T#3/*NI5V-<32M+(%_NAF)(' X'H*ZNB@#B?$/PB\(>*-?D
MUG5[*X>_D0(TL5Y+'D#H,*P%6_"WPV\-^#=0EO="@N8YY8_+8S7DLHVYST9B
M!75T4 8NE>$M'T77M4UG3K8Q7VK,K7<AD8AR.F 3@?A4FA>&=+\.-?MI,#1'
M4+IKNXW2,^Z1@ 2,GCH.!Q6M10!F>(/#ND^*=(DTS7K**\M).2D@Z'L0>H/N
M*Q?"GPP\)^"[U[S0-,\JZ9-GGS2O*ZKZ L20/I76T4 1W-M#>6TEO=1)-#*I
M5XY%#*P/4$'K7!1_ WX?1:E]L70E/[SS/L[3N8-W_7+.W\,5Z#10!@>)O!'A
M[Q?I,>G:_IL5S;PX\D#*-%QCY6&"O'I57PI\-_"W@NXEN- TQ8KF;A[B61I9
M<>@=B2![5U-% &38>&=+TSQ#J>MV<#)?ZIY?VJ0R,0^P87"DX''I19^&=+L/
M$E_KUM RZAJ$:1W$AD8AE3.WY2<#KVK6HH Y+_A6'A,>-5\5QZ9Y>K!_,\V.
M5U4OC&XH#M)]\5KZ)X9TOP[-J,NE0-$^I737=R6D9]\C=2,GCZ#BM:B@#G/%
MO@+PYXXAA3Q)IRW+0',4JL8Y(_8.I! ]LT>$_ 'AOP2DP\.Z:EO).?WL[L9)
M7]B[$DCVS71T4 9.C^&=+T&_U.\TR!HY]5N/M%VS2,V]\8R 3Q]!6M110 44
M44 %%%% '@?PFMO.\+ZDV_'_ !.KOM_M+7<_8?\ II_X[7&_!_\ Y%/4O^PU
M=_\ H2UWM?B><SDLQK?XF+V4'JT10Z?E3^\[_P!VI?[._P"FO_CM6(/N'ZU+
M7B2J2ON;QHT[;%:&RV _O,Y]JD^R_P"W^E3+WIU9N<KG;3H4^5:$*VF6^_\
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MFH_^@XW_ ("?_9UWFE_ZR3Z"M*N6IF^.C*RG^"_R..KGN8QG95/PC_D>7O\
M!V-!G^VV/_;K_P#9TS_A4,?_ $&F_P# 7_[.O3YONCZU!26<8YKX_P %_D*.
M?9BU_$_"/^1YN/A!'_T&V_\  7_[.G?\*>C_ .@VW_@+_P#9UZ..M/IO-\=_
M/^"_R&\]S'_GY^$?\CSNR^$R6FH6]R-99_)E63;]FQG!SC[]=O\ V,/^>Y_[
MX_\ KU='WA]:EKDKX[$5VG4E>WDO\CAQ.8XK$M.K.]O)?HC,.C @CSS_ -\?
M_7JE_P (HO\ S^'_ +]?_7KH**QCB*L=F<\<56CM+\CG_P#A%%_Y_#_WZ_\
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M+_M_I5?^QA_SW/\ WQ_]>M"GU'M)1V9YN+Q=:C;V<K7]#,_L<?\ /<_]\?\
MUZC_ .$*4\_;VYY_U/\ ]>M>M(?='TI2Q5:'PO\ (G"YEBFW[_X+_(Y;_A"5
M_P"@@W_?G_Z]7DT,11K']H)V@+G9UQ^-;=0M]X_6H>*K3^)_D=CQN(J:2E^"
M,S^QQ_SW_P#'?_KU?L[3[/;B/?NY)SC%/J6/[M9SJ3DK-F-6<JD>63T$\OWK
M-U'1A?7"R&<IM3;C9GN??WK5IK=:B%24'>+,J3]E+FAHS _X1D?\_9_[]_\
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M7^1YY_P@"?\ 02;_ +\?_95>TKX7)J=R\7]K-'M3=G[/G/./[WO715N>%?\
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MZ4IZ4B_='TI3TK[X_33V5?NCZ"EI%^Z/H*6OA#\V.ETS_D&P_0_SJU573/\
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M]4LUU+X?:IINEWKJL-^UPDFW=]TO& "H.>N>*[C5M0CTG1[O4)_]7:PM*WT
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M_O&FU[Z/IT=K9_\ 'C!_US7^535#9_\ 'C!_US7^535X$OB9\Q+XF>0^(O\
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M%^&_#%Q+/X?T2ST^688D>"(*6'IFKC:#I3Z\FMM80'4XXC"MV4_>!#_#GTH
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M_<=,GW!3JYD>'_C*!C[-X/\ ^_MQ2_V!\9?^?;P?_P!_;BE_JOF/9?>1_:%
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MA]X7_P"@6/\ O_)_\52_M_#?RR_#_,I9WAW]E_A_F?5']IV/_/[;_P#?U?\
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M^92S*D^C_#_,^DO[3L?^?VW_ ._J_P"-']IV/_/[;_\ ?U?\:^;Q\,/!^?\
MD#+_ .!$O_Q5.'PP\'?] 9?_  (E_P#BJ7^LV$_EE]R_S'_:%+L_Z^9]'?VG
M8_\ /[;_ /?U?\:/[3L?^?VW_P"_J_XU\Z#X7>#?^@*O_@1+_P#%TH^%W@W_
M * J_P#@1+_\74_ZSX/^67W+_,I8ZF^C/HK^T['_ )_;?_OZO^-']IV/_/[;
M_P#?U?\ &OG@?"SP9_T!5_\  B7_ .+IP^%?@O\ Z B_^!$W_P 72_UHP?\
M)+[E_F5]<I]F?0O]IV/_ #^V_P#W]7_&C^T['_G]M_\ OZO^-?/@^%7@O_H"
M+_X$S?\ Q=.'PH\%?] -?_ F;_XNE_K5@_Y)?<O\ROK4'T9] _VG8_\ /[;_
M /?U?\:/[3L?^?VW_P"_J_XUX /A/X)_Z :_^!,W_P 73Q\)O!'_ $ U_P#
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M=+_7' ?R3^Y?_)%6/9O[3L?^?VW_ ._J_P"-']IV/_/[;_\ ?U?\:\;'P8\
M?]"\O_@5/_\ %TX?!?X?_P#0O+_X%S__ !=3_KE@/Y)_<O\ Y(KD9[%_:=C_
M ,_MO_W]7_&C^T['_G]M_P#OZO\ C7CX^"WP^_Z%U?\ P+G_ /BZ</@I\/O^
MA=7_ ,"Y_P#XNE_KG@/Y)_='_P"2*]DV>O?VG8_\_MO_ -_5_P :/[3L?^?V
MW_[^K_C7D?\ PI/X>_\ 0NK_ .!<_P#\71_PI/X>_P#0NK_X%S__ !=+_73
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M^T['_G]M_P#OZO\ C1_:=C_S^V__ ']7_&O&3\&? /\ T+Z_^!4__P 73?\
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M%_\  B7_ .+I_P"M.#_DE]R_S'_8]?NOQ_R/H3^T['_G]M_^_J_XT?VG8_\
M/[;_ /?U?\:^>3\*_!G_ $!5_P# B7_XND/PL\&?] 5?_ B7_P"+H_UHP?\
M++[E_F/^Q<1_,OQ_R/H?^T['_G]M_P#OZO\ C1_:=C_S^V__ ']7_&OG8_"S
MP;_T!5_\")?_ (NFGX7>#?\ H"K_ .!$O_Q=/_6C!_RR^Y?YC_L7$?S+\?\
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M_P"-']IV/_/[;_\ ?U?\:^8C\./"?_0)7_O_ "__ !5)_P *Y\*?] E?^_\
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MQ_ZK8S^>/WO_ "/K7^T['_G]M_\ OZO^-']IV/\ S^V__?U?\:^2#X&\._\
M0-'_ '^D_P#BJ0^!_#O_ $#A_P!_I/\ XJG_ &WA_P"5_A_F/_57&_SQ^]_Y
M'UQ_:=C_ ,_MO_W]7_&C^T['_G]M_P#OZO\ C7R*?!'A[_H'#_O])_\ %4A\
M$^'O^@</^_LG_P 53_MK#_RO\/\ ,?\ JIC?YX_>_P#(^N_[3L?^?VW_ ._J
M_P"-']IV/_/[;_\ ?U?\:^0SX*\/?] X?]_7_P#BJ:?!7A__ *!X_P"_K_\
MQ5/^VL/_ "O\/\Q_ZIXW^>/WO_Y$^OO[3L?^?VW_ ._J_P"-']IV/_/[;_\
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M:/9_A_F/_4W'_P \/O?_ ,B?9_\ :=C_ ,_MO_W]7_&C^T['_G]M_P#OZO\
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M*$\G:*=7H'QX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU?\ P2_)GW!#_J4_W1_*GTR'_4I_NC^5/KZL_ 0HHHH **** "BBB@ HHHH
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M:_\ Q-+_ ,);XM_Z)AK_ /WVO_Q->Z44O]6<L_D?_@3_ ,RN5'AO_"7^+?\
MHF&O_P#?:_\ Q-*/&'BT?\TOU_\ [[7_ .)KW&BE_JQE?_/M_P#@3_S'8\0'
MC+Q:/^:7Z_\ ]]K_ /$TH\:>+?\ HE^O_P#?:_\ Q->W44O]5\K_ .?;_P#
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M=K__ 'VO_P 37M=%'^JV5?\ /M_^!2_S']:J]SQ/_A-_%O\ T2[7_P#OM?\
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MW_OI?\*]^HH_U<RW^1_>_P#,?]HXG^;\$> ?\)%XP_Z)GKO_ 'TO^%(?$'C
M_P#---=_[Z7_  KZ HI_ZN9;_(_O?^8?VEB?YOP1\_?V_P",/^B::[_WTO\
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MO_,/[;QW\_X+_(^9=_C3_HG>M_I_A2;O&G_1.];_ $_PKZ;HI_V+@?Y?Q?\
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MC^RL)_+^+'_K'F7\_P""_P CY2_LWQO_ -"!K/\ WR/\*3^S/&__ $(&L_\
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M)'E\Y(I?NNHVHQ"EMK.PR/NKUSHLB%)%#*PP589!%$<:0QA(D5$'15& /PH
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>fig13.jpg
<TEXT>
begin 644 fig13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     S@V  "2
MD@ "     S@V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MN8_BV?P%X;^WZ-;Z%]IU((VV<(-L3L.!DG( ],4W0;+X?:)X/35-9>'6+N3
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M %%%% !1110 4444 %%%)O4=6'YT +10#GI10 4444 %%!( R3B@$'H<_2@
MHHSSBB@ HHH) ZG'UH ** 01D'-% !1110 4444 %%%% !103CK2;T_O+^=
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MF3,!PJCJ"?Z4*\DY-@[4Y1@HIIB7?@*^M/'T7AII 3,X,=QCAH_[V/;T]:]
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M+=V$:U2"Y8L['QWX]_X36WL8_P"SS9FTWY8S>9OW ?[(QTJQXB^(XU[P7;:
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MR?\ "/+*(AC[5OWY,FWG&[^E>4:KH^A^)/%UEIO@&.54FR)S+O\ D.>6^;G
M&:4:EY-,JI0481:>K_K0XRBO8+[PE\.O!ZPVGB6YFNKR3!.)'W >I5",#W-9
M/C'X;V,&@CQ#X0N&NK C>\6[?A/[RGJ<=\TU43)EAYI/;0\UHKUCX<^ ]!\3
M>#9;S4[=FNO/>-9A,ZA0 ,< X[FHQ8_#%=8M-(MX+B[NFG%O+*TTJKGH6SG'
M4=J/:*]@6'ERJ3:U/*Z*[3XG>%;7PMXBBCTR%HK*XA#H"Y;##@C)R>V:W)/!
MFA:-\)UUS5[-I=2FB#1,9G4!G/R?*#CC(I\ZLGW)]C+F<>QY?7=^$OA==>+=
M!75(-4AMD:1H_+>$L?E/7.17"5[K\-!.?@]=BS\S[1_I/E>7G=NP<8QWS2J2
M<5H5AX1G.TNQ@'X$W^.-=ML_]>[?_%5PGBCPIJ7A/45M=312L@+13)RL@_Q]
MJZC0H/B9_;=K_P AM5$@+&\=_+VYYSNXZ5U_QL:+_A%=/2<K]I-TNT=\;3NQ
M[=*A2DI)-W-94Z<J;E%-6/#:*]QO/AUX+L?#MMJVHQ26L$<22W#"=SYF5'&,
M]R>W-<+-H&B>+/&5KIO@2*:&S,>ZXFFWG9SR<-STQ5JHF8SP\H[M7.(HKV"_
M\,_#3PM<1Z;KL\UQ>G&YO-?*YZ;@APOXUA>.?AS!HVEQZ[X<G:ZTN0!F!.XH
MIZ,#W6FJB;"6'G%-Z.QS_ACP1JWBH22V*I%:PG$D\AX'T'<USK#:Q7T)%?17
MPZ;PZWA23_A'EE6'_EZW[\F3;\V-W]*\KO="T+Q1XSL],\"K+'!(";EY0_R8
M.2WS^V?QJ8U+R:9=2@E"+B]7_6AQ%!.!FO8;OPU\,M!OX=&U>::2_8 -*99
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MS,<EB>I)JY'K>JPZ>;"'4[R.S8%3;K.PC(/4;<XYI2C=)#IU5"3?<]>^!O\
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M3P9<Z7J.GW$=Y,"5:(*8U(;*]3G'3M4<LFU=&O/22DHM:K0W_@S_ ,B9J?\
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M*TU[%2ZR_0Q:]X^%]VUA\);B\10[6[7$H4G@E1G'Z5X/7H?ACXAZ=H?P_NM
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MCTJBBBN(]H^>/B]_R46[_P"N<7_H KAZ[CXO?\E%N_\ KG%_Z *X>O0A\*/
MK?Q)>H44451B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCKIFC:!#;0* %EGC7=&/]D#@?7-1&#V:-JE9.\HR7W:G9> ?^2(:A_USN_\
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MYVW_ 'Y7_"C[!9_\^=M_WY7_  H]KY!]4?<^7MZ_WA^=&]?[P_.OJ'[!9_\
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M !>8#XBW>2!^[B[_ .P*X?>O]X?G7U?J%I;2R%Y;:&1SC+/$I/YD51^P6?\
MSYVW_?E?\*ZHU;)*QY=3#-S;N?+V]?[P_.C>O]X?G7U#]@L_^?.V_P"_*_X4
M?8+/_GSMO^_*_P"%5[7R,_JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]0_8+/_GSMO^_*_P"%
M'V"S_P"?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_P!X?G7U#]@L_P#GSMO^_*_X
M4?8+/_GSMO\ ORO^%'M?(/JK[GR^KKN'S#KZU]8Z'_R+VG?]>L7_ * *H1V%
MGYJ_Z';?>'_+%?\ "MN( 0H%  "C  Z5C5GS)'7AJ/LV]1U>&?')@/%5AD@?
MZ$/_ $-Z]SJI?VMO/$7GMXI6  !>,,0,^]1"7+*YO7I^T@XGR5O7^\/SHWK_
M 'A^=?4/V"S_ .?.V_[\K_A1]@L_^?.V_P"_*_X5T^U\CS?JK[GR]O7^\/SH
MWK_>'YU]0_8+/_GSMO\ ORO^%'V"S_Y\[;_ORO\ A1[7R#ZJ^Y\O;U_O#\Z-
MZ_WA^=?4/V"S_P"?.V_[\K_A1]@L_P#GSMO^_*_X4>U\@^JON?+V]?[P_.C>
MO]X?G7U#]@L_^?.V_P"_*_X4?8+/_GSMO^_*_P"%'M?(/JK[GR]O7^\/SHWK
M_>'YU]0_8+/_ )\[;_ORO^%'V"S_ .?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_
MWA^=?4/V"S_Y\[;_ +\K_A1]@L_^?.V_[\K_ (4>U\@^JON?+V]?[P_.C>O]
MX?G7U#]@L_\ GSMO^_*_X4?8+/\ Y\[;_ORO^%'M?(/JK[GR]O7^\/SHWK_>
M'YU]0_8+/_GSMO\ ORO^%'V"S_Y\[;_ORO\ A1[7R#ZJ^Y\O;U_O#\Z-Z_WA
M^=?4/V"S_P"?.V_[\K_A1]@L_P#GSMO^_*_X4>U\@^JON?+V]?[P_.C>O]X?
MG7U#]@L_^?.V_P"_*_X4?8+/_GSMO^_*_P"%'M?(/JK[GR]O7^\/SHWK_>'Y
MU]0_8+/_ )\[;_ORO^%'V"S_ .?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_WA^=
M?4/V"S_Y\[;_ +\K_A1]@L_^?.V_[\K_ (4>U\@^JON?+V]?[P_.C>O]X?G7
MU#]@L_\ GSMO^_*_X4?8+/\ Y\[;_ORO^%'M?(/JK[GR]O7^\/SHWK_>'YU]
M0_8+/_GSMO\ ORO^%'V"S_Y\[;_ORO\ A1[7R#ZJ^Y\O;U_O#\Z-Z_WA^=?4
M/V"S_P"?.V_[\K_A1]@L_P#GSMO^_*_X4>U\@^JON?+V]?[P_.C>O]X?G7U#
M]@L_^?.V_P"_*_X4?8+/_GSMO^_*_P"%'M?(/JK[GR]O7^\/SHWK_>'YU]0_
M8+/_ )\[;_ORO^%'V"S_ .?.V_[\K_A1[7R#ZJ^Y\O;U_O#\Z-Z_WA^=?4/V
M"S_Y\[;_ +\K_A1]@L_^?.V_[\K_ (4>U\@^JON?+V]?[P_.C>O]X?G7U#]@
ML_\ GSMO^_*_X4?8+/\ Y\[;_ORO^%'M?(/JK[GR]O7^\/SK=\(^+KCPCK/V
MZU59T9"DL#2;5D'N>>E?0GV"S_Y\[;_ORO\ A1]@L_\ GSMO^_*_X4G535FA
MQPTHNZD?-.K:C%J6L75]%"ELMQ*TGDJ^X(2<D \54WK_ 'A^=?4/V"S_ .?.
MV_[\K_A1]@L_^?.V_P"_*_X4_:KL)X5MWN?+V]?[P_.C>O\ >'YU]0_8+/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!T?^M3_
M 'A6I'_JU^@K+C_UJ?[PK4C_ -6OT%1(TICJAN_^/=OP_G4U0W?_ ![M^'\Z
MDUEL9M%%%:',%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\*O^1"M_^NTO_H5=E6<OB9TTO@04445)H%%%% !1110 4444 %%%% !1110
M54U7_D"WW_7N_P#Z#5NJFJ_\@6^_Z]W_ /0:0'R4OW:'^X?I0OW:'^X?I69H
M?6FC?\@#3_\ KV3^57*IZ-_R -/_ .O9/Y5<K4S"BBB@ HHHH **** "BBB@
M J[8?=;ZU2J[8?=;ZU+V*CN6Z***@W*=[W_#^M4ZN7O?\/ZU3K1;'/+X@HHH
MIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU)=T6:*J7&JZ=:2+'=W]K [C*K+,JEA[ FI9[RVM;<3W5Q##">DDD@5?S/%
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M.& /3U%4HI/0SE.4H-/R-K3_ /DO-_\ ]>Y_] 2O2*\WT_\ Y+S?_P#7N?\
MT!*](K.70WI;/U84445)L%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% PHHHH **** /.]2E.M_&.QL)/F
M@TV,R[?]KOG\Q6/\0;K3[/XF65QK-L;JR2W4RP@ [AN;U(K6MU-E\=;@R\"[
MMB8_?(4?^RFL[QMJEGH_Q6T^^U%#+;PVZET50Q(RW8\5M'=>AQ2^%M]S"\0Z
M]X,U+26M= T V=Z[C;,RJ@4?4,:[#4=:U;P9H?APQ3V]QI[(D5RP3>3QD[6S
MTQTK*\1>/_#&M:#<V%AI,S7,R;8LVZ+M;URI)K8MO#5S>_!U=/OE;[4L;3PJ
MWWE.=RK_ "%-[*XHW;?*^G0T_$WB74+/Q%HNE:*T)>^8-*TB;\)GMSZ<UG7O
MB_6M0\67>BZ#/IEC]D.UI-0S^^8<$**Q_AP;CQ#XD74[Y<KI=HMO&W7+8QD^
M^.:L^*D\%W_B*X371?:-?)_R],FU)3ZC&<_I4V2=B^:4H\R?4ZG3KKQ7<:5?
M0:I86]I?1K_H]SN!AE]]H.17&_"T:U]NU"2"2U:S6<F[1E/F2-\V-AZ#GUJY
M\-KG4)-3U*SM[R?4-%B0B"XF4C<W;&?49_*J7@+5X=);7M.EE\C5)I7-M ZG
M<[ .>./YT[630N9-Q;\S<U/5O'5O;W>HM%I>EVD))CM[LAI'4=P0<<_6I1XU
MO+KX9S>(+:*.&\CRI5EW)D'KBN%TZZT6ZT34)O$<MY>Z^S,J6;EFYXP0H].?
M\*T]-D0_ O4 '!*2,&YZ&AQ0E4;O9]&:<OB[QBWA.+Q###IZ6:@"1&4F23G!
M8#HHS[UMZGX\2P\"VFN);AKB\ 6.'=P'[\^@K+N"!\"P>,?9?ZFL/4M,N=0^
M#FCSV:&46DK2.JC)VDXS19/[Q\THK1]+D_C.[\5OX'W>(X+-H+IT93;@JT!R
M#AQT.>G!K=O/%4V@>$] L]-@6?4K^%$@5_NKVR?Q(XK$\;>--+UWP(EOITC2
MS,8S.H0CR,$<,>G7CBJ_BS2WDTCPMJDL<\EA%;K'<-;G#Q@D'(/;@'FG:Z5R
M7*S;B[Z(ZB#Q+X@T/Q%9:9XPCM'2_P"(;BU4J%;T(/N0/QJKJ'B[Q%_PG]SX
M>TI+1@1MA,J<1G&=S$=1UXQWK!LM.\-ZEXLT^W\/?VGJRHPEDNI+TA(,$'H4
MYZ=.*U+$C_A>UX,C/E'^0I617-)JU^IZ!I2Z@NFQ#6)(9+W!\UH%VH3GL/I4
MMY=Q6%C-=W+;8H4+N?0"IJS?$5A)JGAN_L82!)/ R*3ZUCNSJ=TM#C;7Q1XP
MUVQN-8T.UL8M.A8[()P6EF ZX/0&KLOCR2]^'EQKFF(D-Y P22*0;PC9_45B
M^%/&6G^'/!\FE:N)+?4;4R*ELT9W3$DGC\\5GVND76E_![59[Z,PM>3)*B,,
M$+P.?K6W*K['*INVCZ:G8>$M6\4:^EGJ5V;&'3'0AT5#YKL!]X=@":[&N>\!
M8_X072\?\\170UE+<Z*?PJX4444C0O6:J;<;@,Y[U/LC]%K*HR?4_G4V+4[(
MU=D?HM&R/T6LK)]3^=&3ZG\Z.4?/Y&KLC]%HV1^BUE9/J?SHR?4_G1RAS^1J
M[(_1:-D?HM963ZG\Z,GU/YT<H<_D:NR/T6C9'Z+65D^I_.C)]3^='*'/Y&KL
MC]%JEK2H-!O\!?\ CW?_ -!-5\GU/YU5U4G^Q;[D_P#'N_?_ &:7*'/Y'R2O
MW:'_ -6WTH7[M#_</TJ0/L;050^'=/R%_P"/=/Y5?V1^BUSVC$_V!I_)_P"/
M9._M5S)]3^=5RAS^1J[(_1:-D?HM963ZG\Z,GU/YT^4.?R-79'Z+1LC]%K*R
M?4_G1D^I_.CE#G\C5V1^BT;(_1:RLGU/YT9/J?SHY0Y_(U=D?HM&R/T6LK)]
M3^=&3ZG\Z.4.?R-79'Z+3E"C[H'X5D9/J?SJ[8_=;ZTFAJ5W8MT445)H4[WO
M^']:IU<O>_X?UJG6BV.>7Q!1113)"BBB@ HHHH *\D^,/_(>TG_KDW_H0KUN
MO)/C#_R'M)_ZY-_Z$*TI_$88C^&STG4_^14N_P#KQ?\ ]%FO/O@L,)K&/6+_
M -FKT6[A:Y\.S01\O+:,B_4IBO)/AIXCT[PUJ&I6VM3FU67 #NI(#*2,''.>
M:(ZQ:)J-*I%LL?$\9^(FF?\ 7.'_ -&&KGQGR)M(*_>'F$?7BN>\7:];^(O'
M5I>6(<VJ/%%'(PP),/DD>W-=%\9O^/C1_J__ ++6B5G$QDTXS:\B'4_A_:IX
M"?6[NZN9M4%N+AG=_EY&=N/QZU7\"^%AXQTJ637KZ[DM+1O)MX$EP%[D_3GI
M7<^(O^26W'_8.7_T$5C_  >_Y%>\_P"OG_V45/,^5LOV<?:)6Z'/_#PS:/\
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M]6OT%)NY<(M/4=4-W_Q[M^'\ZFJ&[_X]V_#^=27+8S:***T.8****8!1110
M4444 8VE>%M-T;5[W4K(3?:+TDS;Y-R\G/ QQS4^N:!IWB*Q%IJL/F1J=RE3
MAD/J#VK2HHN[W)Y5:UCDQ\-?#HAA3RKHM#()%D,Y+DCH"<=/:M2Y\+Z==^(+
M;6IA-]LM5VQXDPN,8Y&.>M;%%/F8N2*Z&1-X9TZX\30Z]()OMT*[$(D^3'/\
M./<TDGA;39?$\>ON)OMT:[5(D^3'^[CWK8HHNQ\L>Q@ZYX,T7Q!<"XOH)$N
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M *4?:IO[_P"E1446#F9+]JF_O_I1]JF_O_I45%%@YF2_:IO[_P"E'VJ;^_\
MI45%%@YF2_:IO[_Z4?:IO[_Z5%118.9DOVJ;^_\ I1]JF_O_ *5%118.9DOV
MJ;^_^E'VJ;^_^E1446#F9+]JF_O_ *4?:IO[_P"E1446#F9+]JF_O_I1]JF_
MO_I45%%@YF2_:IO[_P"E'VJ;^_\ I45%%@YF2_:IO[_Z4?:IO[_Z5%118.9D
MOVJ;^_\ I1]JF_O_ *5%118.9DZ7,K2*"_!(SQ5^/_5K]!67'_K4_P!X5J1_
MZM?H*F1I3;8ZH;O_ (]V_#^=35#=_P#'NWX?SJ326QFT445H<P4444P"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '
M(Y1@R\&I/M4O][]*AHI#NT3?:Y?[WZ4?:Y?[WZ5#119!S,F^UR_WOTH^UR_W
MOTJ&BBR#F9-]KE_O?I1]KE_O?I4-%%D',R;[7+_>_2C[7+_>_2H:*+(.9DWV
MN7^]^E'VN7^]^E0T460<S)OM<O\ >_2C[7+_ 'OTJ&BBR#F9-]KE_O?I1]KE
M_O?I4-%%D',R;[7+_>_2C[7+_>_2H:*+(.9DWVN7^]^E'VN7^]^E0T460<S)
MOM<O][]*/M<O][]*AHHL@YF3?:Y?[WZ4?:Y?[WZ5#119!S,F^UR_WOTH^UR_
MWOTJ&BBR#F9-]KE_O?I1]KE_O?I4-%%D',R;[7+_ 'OTH^UR_P![]*AHHL@Y
MF3?:Y?[WZ4?:Y?[WZ5#119!S,F^UR_WOTH^UR_WOTJ&BBR#F9-]KE_O?I1]K
ME_O?I4-%%D',R;[7+_>_2C[7+_>_2H:*+(.9DWVN7^]^E'VN7^]^E0T460<S
M)OM<O][]*/M<O][]*AHHL@YF3?:Y?[WZ4?:Y?[WZ5#119!S,F^UR_P![]**A
MHHL@YF%%%%,#RGXE3W5KX]T6?3X?M%S&@:*+!.]@PP.*O'QG\1/^A1_\@R?_
M !5,^(=EK'_"8Z5J6D:5<7WV5-W[N)F7<&!P2*=_PG'CK_H3&_[\RUMO%'$W
M:<M6BQ\3M1U&TTG2);.>:UN))UW")RN3CH<'D9[5E^*8M9\+#2M837[VXEN)
M%$\4C_NQG!PJ=,8R*T/&UKK&O>'M!G&ES_:O/62X@BC8^5]1U'XU8^)>EW^I
M:#ID6GV4]U)',I=8HRQ48[XH6ED.:;YFO(B\:ZYJ-YK.C^']*N'LCJ"+++-&
M<, W0 ]1T-9'BNVU?PSK&C6<6NW]S9RRY4RRD/G/(8C&X?6M?Q=H6IQWVA^(
M=(MFNKBQBC26V ^8@#L.O<UA>,]0U+5M>T*XO=-ETZ(R[8K:8YDSD98CL.WX
M41Z6%4OK??0WTU"\/QOGLC=W'V06Y(M_-;RP?+!SMSCK61X7M]7\2ZSK=G+K
MM_;6D,S',4I+YS@ $YVCV%;*:7?CXU3:@;*?[$;<J+CRSY9/E@8STZT[X>Z7
M?Z?K&O27UG/;I-.6B:5"H<9ZC/6E=)%)-RL^[*'@GQ+?65CX@M]5N9+TZ4K2
M1M*V2=O;<>>3ZUB6NJOJNCW6M7_C22QU0%F@L5GVI@= 4[Y[5M^%O#=]-JGB
MFWU"TGM8;]'2*62,J&R>H]?6LVSTO5-#TF;1Y?!D6H7V\BWU#[,DB 'NQ(.<
M56ER/>Y5?;4T[SX@7O\ PK&#4H2JZC-+]E,@ PK 9+8^E8]SK'_".6MCJFF>
M,7U6Z9U^UV<D_F+@\G [8Z5T>L^";[4/A_;V0%JNIP2?:"D,211LV,%<* ._
M6LM;+4]5-C867@RUTJ5"!=WES81LC ==NY>])<HY<]]>Q)XUU74I?%VA+I-[
M/;"\@1@B2';\V>2.AXJ?Q;=W?@?0X=/L=6NKBXU"<[KN[DWM$H SCT%2^*=&
MOY?'_A^:SL9IK6V15DEBB^1,9ZXX%:/Q%\,76O65K<Z:BS7-E(7\E^DBG&1S
M]*2:T*:E:36YRLNNIX5U+3I]*\6/KL$SA+N"6?S-ON/0>E;'B;4=2UOQ_;>%
M["_EL+8())I86VNW&XX/TJO!8W^N:Q916GA"UT.VC(-W+<V$1W^NS*_E5SQ1
MH^J:7XXM?%.CV4FH)M$<]O$,N!C;P/I3TN+WN7RNC%U33KO2OB=X?M;J_EOX
ME*^1+/@R;=PR&(Z\]Z]:/6O+[V'7M;^(6BZK/H=U:6B,NU63<8ESSO(Z&O4*
MB?0UH[RL*"1T.*\SULG_ (7GI!R<^6O\GKTNO/M7TK4)?C%IE_%97#V<<:A[
MA8R47A^I_$40ZCJ[+U1?^*UU-!X%F$3D>;,D;^ZG)Q^@K8\(6-M8>$[".TC1
M5D@5W*C[[$9)/KUJ?Q%HD7B'0;G3ISM\U?D?^ZPZ&N!L]2\>^%+-=*&AC4XX
MOEBG1&?"]N5_K0M8V0I/DJ<S6AZ#9:%IFFW4]U8V4,$\^3(Z+R?\/PKR31M;
MU[1/$WB"3P_I8U -</YV48^6 YY^4BNZ\&6OBMKJZO\ Q-<E(I^8[,X.WW_V
M0/2J?@'2[^P\3>(9KVRGMXIYF,3RQE1(-_4'O36E[ZD23ERVT.=L)]7^)VNV
MD]VMC;0Z=(&D6,G>1G/0DGV]*]8O+E;'3Y[EP2EO$TA [A1G^E>;>(?#NJ>&
MO&T&O>&+*>Z@F?=/!;H6QG[PP.QY^E>CS1)J6ER0RJ\:7,)1E8890PP>/7FB
M=M+;%4DU=/<\ZT&SUOQY:WFL7&N7EB!(R6D%J^Q 1_>'<=/>G:9XJU'4_ 6O
M07LS"_TT;/M$9VEANP#D=^#1HA\2>!K6[TE=!N-2C>1GM9[;YE4GNWH.E2:;
MX0U'3/ >N-=1-)J6I#>8(OF(YR!QU/)JG8R7-TO>SN6OAQ97VJ:78:SJFMZD
M_D2,L=LLQ\N11W?NQR3U]!7IGV]/[K5Q7P\LKK3_  5:6]];R6TREMT<JE6'
M/H:Z>LIZR.JBW&"+WV]/[K4?;T_NM5&BHLC;G9>^WI_=:C[>G]UJHT460<[+
MWV]/[K4?;T_NM5&BBR#G9>^WI_=:C[>G]UJHT460<[+WV]/[K5A>(/$^GQV%
MS9AFDGDC9-J<[21CDUD^)M<:!C8V;;7Q^]<?P^PKDJ^?Q^:>RDZ5'=;LZ*<&
MU>1QT/P[ME0">_E9N^Q0!4%Y\.\Q-]AO\MCA95Z_B*[BBO&69XM._/\ @C7V
M<>QZ9X=U>UET6UAB??)#$J2*.H(&*U/MZ?W6KR.WN);6=9K=RDBG@BN^T;5$
MU6Q$F LJ<2+Z'UKZ'+\QCBO<FK2_,PJ1E#5;&]]O3^ZU'V]/[K51HKV+(QYV
M7OMZ?W6H^WI_=:J-%%D'.R]]O3^ZU'V]/[K51HHL@YV7OMZ?W6H^WI_=:J-%
M%D'.R]]O3^ZU2PSK,#M!&/6LRKMA]UOK2:5AQDVRW1114FI3O>_X?UJG5R][
M_A_6J=:+8YY?$%%%%,D**** "BBB@ HHHH *9+*D$$DTIPD:EV/L!DT^N/\
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M?W3^5&UO[I_*M/SXO^>B_G1Y\7_/1?SHYF'(NYF;6_NG\J-K?W3^5:?GQ?\
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M?3[M]US: ;6)Y>/M^72N&O145S1/<P.-E4E[*IOT9V-%%%<9[(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 Z/_6I_O"M2/_5K]!67'_K4
M_P!X5J1_ZM?H*B1I3'5#=_\ 'NWX?SJ:H;O_ (]V_#^=2:RV,VBBBM#F"BBB
MF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1BF3S1VUN\T[A(XQN9CT KRWQ+\
M0+O4)7MM(=K:T!QO'#2?_6K2G3E4>AS8C$PP\;R^X]-GU"RM21<W<$1'4/(
M?RIL&IV%S@6][;R$]%60$_E7@<CO*VZ5V<^K'-"$QME&9#ZJ<5U?5%;<\O\
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M*=[W_#^M4ZN7O?\ #^M4ZT6QSR^(****9(4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "N?\=_\B5??\!_]"%=!7/\ CO\
MY$J^_P" _P#H0JZ?QKU,,1_!GZ,\8'2B@=**]@^/"BBB@ K<\%_\CKIG_76L
M.MSP7_R.NF?]=:B?P,UH?Q8^J_,]KHHHKQS[(**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ='_ *U/]X5J1_ZM?H*RX_\ 6I_O"M2/_5K]
M!42-*8ZH;O\ X]V_#^=35#=_\>[?A_.I-9;&;1116AS!1113 **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *.N7LNFZ!?7MN%,MO
MTB!QD$@9YKR>+XL>*9P3!86<H'4QVTC8_)J]/\5_\B?JW_7I)_*O+_ASXUTK
MPKI][#JC7(>>573R8MPP!CGFM8+W6[7.6K)\Z5[%W3_B[J4%\D>OZ=$L+'YC
M$C1LH]<,3FNO\;^*KG0/#=MJ>D"";SY54&52RE2I.>"/2O.?B#XLT_Q;=6B:
M3:REHR099$P[Y_AQ70>/K26P^%FC6MSQ+%)&KCT.QJ;BKK0A3E:2O>W4S$^*
MGBR1 \>FVKJ>C+:2$'\=U;/AWXL&YU!++Q%:+:M(P59HP5"D] RGD?7-=5X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N?\=_\ (E7W_ ?_ $(5T%<_X[_Y$J^_X#_Z$*NG\:]3#$?P9^C/&!THH'2B
MO8/CPHHHH *W/!?_ ".NF?\ 76L.MSP7_P CKIG_ %UJ)_ S6A_%CZK\SVNN
M;UOQ[H7A_4FL-3EN%G50Q$<!88(R.:Z2O&?'=M%>?%NVMKE=T,S6\;C.,J<
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MM(_Z](_Y4VERW$I-U'$VJ1F5$+NP55&2Q/ 'K2UYKXOF\4>(-<O-%TM3;Z9
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M@ HHHH \Q^,__'II7_71_P"0KO?#_P#R+6F_]>L?_H(JKXD\)Z=XIC@35#<
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M%%49A4]C_P A*V_ZZK_.H*GL?^0E;?\ 75?YTGL..Z/H ?=7_='\J*!]U?\
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MOMG]FQW"?8Y/+D\] N3D],$^E(#=HHHI@%%%% !1110,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .,\3Z0UK=->P+F"4Y?'\#?X5@5ZBZ+)&R2*
M&5A@J1D&N9U#P@'8R:;($S_RR?I^!KY?,,JFYNK05[[K_(ZJ=96M(Y2BM.3P
M[JL;8-J6]U.:D@\,:G,PW1+"OJYKQ5A,0W90?W&_/'N9'4@ 9)Z =Z[CPWI!
MT^T,UP,3S#D?W5]*=I7ARVTYA+*?/G'1B.%^@K8KZ/+<L="7M:WQ=%V_X)S5
M:O-H@HHHKWSG"BBB@ HHHH **** "KMA]UOK5*KMA]UOK2>Q4=RW11169N4[
MWO\ A_6J=7+WO^']:IUHMCGE\0444#GI3)"BN-\3?$O2O#]TUG;QMJ%VG#K&
MV$0^A/K6%9_&>)IP-0T=HXB>6AER1^!'-4H2:O8R=:"=FST^BJFEZK9:UI\=
M]IDXF@DZ$=0?0CL:K^(M;@\/:%<:C<#=Y8PB?WV/05-G>QI=6N:=%8GA'5-0
MUOPY!J.JQ0Q2SDLB0J0 O8\D]:V\9Z4-6=@3NKA112XSTH&)12X/I24 %%<_
MXK\8V'A2U1KH--<R@F*!#@M[D]A7G[?%W7FDWQ:3;>1G/,<A./\ >!Q5*$GJ
MC*56$'9GL%%<MX/\=67BM7A$9M;R,9:%FSN'J#73RRI#"\LIVHBEF/H!UJ6F
MG9EQDI*Z'45Y9I'Q7OKWQ-!9W=K:1V,T_EAU5MX!X7G..N.U>J 9;'O3E%QW
M%"<9K02BO(;SXL:_#J=S;06%C((I61<12$D XR<-48^+GB-"&FTJT"#[W[F0
M?J6J_9R,OK$#V*BN=\'^+[?Q;I\DL<1@N(3B6$G./0@^AKHJS::=F;1DI*Z"
MBN0\>^*]3\+QV;:7:17!G8A_,C9L8_W2*XE_B]XBC($FG6*$] T,@S^;5:@V
MKHSE6A%V9[+17E&D?$_Q%?ZQ:6L^F6J133*CLL$@(!.,Y+5U%OXPN8/B!/X=
MUB*".-AFTFC!!;T#9)ZX/3TI.#0XU8R.OHHHZ<G@#DD]JDU"BN"U_P"+&EZ7
M=/;:9;MJ,L9PSAML8/H#WJCIOQEM);A4U73'MHR<>;$^_;]15<DK;&7MJ:=K
MGI=%16MU!?6D=U9RK-!*NY)$.014M2:A1110 4444 %%%% !1110 4444 %%
M%% !1110 5S_ ([_ .1*OO\ @/\ Z$*Z"N?\=_\ (E7W_ ?_ $(5=/XUZF&(
M_@S]&>,#I10.E%>P?'A1110 5N>"_P#D==,_ZZUAUN>"_P#D==,_ZZU$_@9K
M0_BQ]5^9[71117CGV04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNM'*!X)8MAD(0!MN>O2F>(_%EUXV\-P>'-)TB]_M.9D%T)8BJ1;2"?F[C(H
MN^//&NJVJ^&[SPW=-%%J"B0Q%01+DC"G(S[<5VOAS3M:L8YGU[6CJ;S%6C7R
M1&L(QRHQU^M><^.M(ETJ3P5IZ!YOLFR-G52>C#GBO8%^XOT%/J2]BGK7_( U
M'_KUE_\ 0#7A^FZE=:5\$Y;BQD6.7^U]N6B5QC9Z,".U>X:R"=!U  9)M9<
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M[9+G,[?\"Z?I74UR3=Y,]2DN6"04445)J%%%% !1110 4444 %%%% !1110
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M?LUY:]#N^^H]0:]*L[RWU"SCNK.020R#(8?R/O7AU=3X$UMM/U<6$S?Z-='
M!_A?L?QKV<!CIQFJ=1W3_ ^7SC**<Z;KT%:2U:75?YGI]%'2BOI3X0**** "
MBBB@ HHHH *NV'W6^M4JNV'W6^M)[%1W+=%%%9FY3O>_X?UJG5R][_A_6J=:
M+8YY?$%%%%,D\B^,.B&#5+76HE_=W*^5,1V<=#^(/Z5YM7TGXCT2+Q%X?NM-
MFX,BYC;^ZXZ'^GXU\XW5K-97<MK=(4FA<HZGL1733E=6/.Q$.65^Y%6[X/\
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M;3R<!O5HS_"?;H?:M+3M2MM4M_-M7)VG#QL,/&?1AV-%@3Z,MT444%!1110
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M*UJ>W4445F=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444#"BBB@ HHHH **** "BBB@ HHHH **** .5\:>"S
MXN^QXOQ:?9BQYBW[LX]QCI7265O]DL+>VW;_ "8ECW8QG QFIJ*=W:Q*BDW(
MRM?\-Z;XELA;ZG$6V\QR(<.A]C7!/\%8S<%H]:Q'GA6MLMCZ[OZ5ZE134I+8
MF5*$W=HQ/#7A33?"UJT6GHS22?ZV:0Y9_P# >U9.N^ FUKQA;ZX-1$(A,1\C
MR=V[8<_>SW^E=C12YG>XW3BURVT"N"N/AEL\4_VSH^J_8,2B40^1N /<9W#@
MUWM%"DUL$H1EN SM&[!..2!WHHHI%A1110 4444 %%%% !1110 4444 %%%%
M !1110 4V1MD3O\ W5)_2G5'<?\ 'K-_US;^5)[#6K/#YY6GNII7Y:21F/XF
MHZ#]YOJ:*^">KN?L*22L@HHHH&%/AD,-Q%*APR2*P_.F4#[R_P"\/YT(35U9
MGNT3^9#&_P#>16_,4ZHK7_CR@_ZY+_(5+7WJV/QZ2LV@HHHIB"BBB@ HHHH
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MVHS>,+<-ICO::2W$EQTEF/=5_NCL3U_G6_:6D%C:I;VD2Q1(,!5_SR?>N+\
M>%-?\,22+J%U ;249:W0E\-Z@]J[JIE:]D:4[M7DM0HHHJ30**** "BBB@ K
M*U'1C-<_;],E^R:@H_U@&4E']UU[CWZUJU#>1W$ME-'9S+!.R$1RLNX(?7'>
MA":NCS/QO\0[RWMAI5G$UGJ*/_I3!MP7!Z*>X/\ *N^\-ZQ'KWAZTU"+@R(
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M129-%)N+3JUA(WW1_P!,V/3_ '>GI6AINJVNJ1,ULQ#QG;+#(-KQGT8'D4K
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MS:,R_#4&HVWARTAUIV>^53YK/)O).3_%WXKS7XM?\C9I?_7$?^AUZ]7#^-O
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M6NFI*(6N7V"0C(6L^NA\!?\ (^Z3_P!=JT>QSQ5Y)'=VGP8LD8&_U::7U6)
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M$-J1J%4#L!P*=115$A1110 4444 %%%% !1110 4444 <E\4O^2:ZK_NQ_\
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MT*.F:)IFC1>7I=E%;CU5>3^-7J**@V6FB"BBB@84444 %%%% !1110 4444
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M*C9N/\(.<Y_"M6@04444P"BBB@ HHHH **** '1_ZU/]X5J1_P"K7Z"LN/\
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M6?AYK7QG>ZZ;E66Z@2(0[,%=I)SG//7TJC#X.DBM_$47VY#_ &R^Y3Y1_<\
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MV_Z[+_.J]6+#_D)VO_75?YT ?0P^XO\ NC^5% ^XO^Z/Y459S!1113 ****
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MZG^1KSRO0_B5_P @VQ_ZZG^1KSRODLS_ -Y?R_(_2,A_W"/J_P PHHHKSCW
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M%%!0#K7S5KW_ ",5_P#]=VKZ5'6OFK7O^1BO_P#KNU:T=V<F*V1GU-9_\?\
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MO_(SZA_UV-9=:GB7_D9]0_Z[&LNI-UL%%%%(858L/^0E:_\ 75?YU7JQ8?\
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M_(:U/_KW7^=>;5Z3\&/^0UJ?_7NO\Z)_"Q4?XB/7:***Y3U HHHH YKXB?\
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M4H!/0$TE>4?%B6_?Q7H5A8:C<V0N@8RT,K*,EE&2 1GK7IL\%*YZQM8=C^5
M!/09KQ;Q%X.\5^#=)?6K;Q9<7HMB"Z,SC SC.&8@\XXK1\9>);S4_@[INKPW
M$MM<S3()&@D*$D;@>1ZXS2N%CUC:W]T_E25Y#8_#;Q->:1;:A;>,[K?-"LR1
M,\O&X9P3O]_2MGX:^+-3N]0O?#?B1]]_9$[)#U8 X(/KC'7TIW"QZ+117GOC
MWQQ>V,EYH7AZQFEODMS)/<@?+ FW)(]3C\J!)7/0R".HQ25PGPAN[F]\$F6\
MN)KB3[2XWS2%VQGU-=W0#T'1_P"M3_>%:D?^K7Z"LN/_ %J?[PK4C_U:_05,
MC2F.J&[_ ./=OP_G4U0W?_'NWX?SJ366QFT445H<P4444P"BBB@ HHHH ***
M* "O ?B/_P E$U3_ 'E_E7OU> _$?_DHFJ?[R_RK6EN<N)^ YBD?[C?2EI'^
MXWTKI. ^D_#7_(J:5_UZ1_RK3K,\-?\ (J:5_P!>D?\ *M.N%[GKQV04444%
M .M?-6O?\C%?_P#7=J^E1UKYJU[_ )&*_P#^N[5K1W9R8K9&?4UG_P ?]O\
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MXFOM<M9+EKJ^!$JR."@R0>!C/;UK?HHH ****8!1110 4444#"BBB@ HHHH
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MF.J&[_X]V_#^=35#=_\ 'NWX?SJ366QFT445H<P4444P"BBB@ HHHH ****
M"O ?B/\ \E$U3_>7^5>_5X#\1_\ DHFJ?[R_RK6EN<N)^ YBD?[C?2EI'^XW
MTKI. ^D_#7_(J:5_UZ1_RK3K,\-?\BII7_7I'_*M.N%[GKQV04444% .M?-6
MO?\ (Q7_ /UW:OI4=:^:M>_Y&*__ .N[5K1W9R8K9&?4UG_Q_P!O_P!=5_G4
M-36?_'_;_P#75?YUT'"CZ<@_X]HO^N:_R%/ID'_'M%_US7^0I]<1[(4444 %
M%%% !7D?QF$YU[P\+,@7!9_*)Z!LKCK[UZY7'^,_!5SXHUG2+VWO8;==/<LZ
M2(Q+\@\8^E)[#6C.3U#PK\3_ !'#_9^O:E:K9.V9"CQC\P@!/TJ[\1M&@\/?
M"&#2[4EDMYHQN/\ $222?Q)->H'DUSGCGPS-XM\-MIEM<QVSF59/,E4D<=N*
M5@N6O"'_ ")6C?\ 7E%_Z *\WT,C4/V@;VYLCNA@$@D9>G"E?YU9B^%_C&*W
M2W3QNZ6ZJ$$223!0O3 &<8KL/!G@:P\'6TGV=VN+N?B6X<<D>@]!0/1',3?&
MNVAO7MCX=O6*2%-PF&#SC/W:[G64B/AK4[A(E22:QD+,%&XCRS@$]\9K6R?6
MJNI6K7VE7=HC!&N('B#$< LI&?UIBT."^"7_ ")<_P#U]O\ R%>CCK7+> O"
M=QX/T*2PNKN*Z=YC*'B4J "!QS]*ZD=:$#W/!/$O_(SZA_UV-9=:GB7_ )&?
M4/\ KL:RZDW6P4444AA5BP_Y"5K_ -=5_G5>K%A_R$K7_KJO\Z /H8?<7_='
M\J*!]Q?]T?RHJSF"BBBF 4444 %%%% !1110!%=?\>-Q_P!<F_E7A@Z5[G=?
M\>-Q_P!<F_E7A@Z5\]G&\/G^A]IPO\-7Y?J%%%%>$?8!1110!T7@3_D<+;_<
M?^5>K5Y3X$_Y'"V_W'_E7JU?3Y3_  'Z_P"1^?\ $G^^+_"OS84445ZY\V%%
M%% !1110 4444 %%%% !1110 4444#"BBB@ HHHH **** "BBB@ JCK?_(OZ
MC_UZR?\ H)J]5'6_^1?U'_KUD_\ 030MQ/8^9EZ?C2TB]/QI:[3Q2:S_ .0A
M;?\ 79/_ $(5]0=A]!_*OE^S_P"0A;?]=D_]"%?4'8?0?RK"KT.["]0HHHK$
M[0I5^\/K24J_>'UH ^=O''_(]:M_UW-8-;WCC_D>M6_Z[FL&NR.R/'G\3 ]#
M7T!\.O\ DG^F_P"ZW_H1KY_/0U] ?#K_ ))_IO\ NM_Z$:SJ['1A?C9TU%%%
M<YZ 4444 %%%% !1110 4444 %%%% !1110 5'<?\>LW_7-OY5)4=Q_QZS?]
M<V_E2>PX_$CPL_>;ZFB@_>;ZFBO@C]B"BBB@ H'WE_WA_.B@?>7_ 'A_.@#W
M.U_X\H/^N2_R%2U%:_\ 'E!_UR7^0J6OO([(_'I?$PHHHJB0HHHH **** "K
MMA]UOK5*KMA]UOK2>Q4=RW11169N4[WO^']:IU<O>_X?UJG6BV.>7Q!1113)
M"BBB@ HHHH **** "BBB@#S+XT?\>&D_]=7_ )"O)J]9^-)QI^DD_P#/63^0
MIOP_^&=I-IJ:_P"*P! 5\R&VD.%"_P!]_P#"NB,E&%V<%2G*I6:B>4#E=P!*
M^H'%>D_!CG6M3Q_S[K_.NLG^*/@G3I6LK6U::!/EWP6PV?AGK6%\-KRTU#QU
MX@O--M_LUK,@:*+&-HS_ )-)R;B[JPXTXPFK2N>G4445@=P4444 <U\1/^2?
MZG_NK_.OGX=*^@/B*<?#_4\_W%_G7)?#SX9VU]IZ:]XH %J1OAMW. 5'\;^W
MM6T)*,;LXZM.52HE$\L'*Y4$@=2!Q70^ 3GQ[I./^>U>JS_$[P3I4QL+2U,T
M$?RE[>W'E_AGK7GNB7UGJ?Q@MKW2[;[+:376Z.+&,#UQVSUJU)M.Z,G3C"2M
M*^I[E1117,>B%%%% !1110 45SWCR\N=/\"ZI=6,\EO<10DI+&<,I]0:\YT'
M1?B)XAT&'5K+QA(D<P8K%)<2;N"1V7':E<:1[/17G'PW\6ZOJ<VJZ+XA???:
M>"1(?O<'!!/?GO7)^%8_'GC%;V73O%L]NEK+L83SOSGGC -*X<I[G17D5KXC
M\6^!/$]II_C"[&HV%XP47#,6QSC(8\\9Y!KUT$,H*G((R#ZBG<&K!161XE\2
MV/A723J&I;RFX(B1KEG8] /R[UYYX/\ &&NZ_P#%22+4)+BUM&A9DT]B0J#"
M[21ZX.?QHN%CUJBBBF(\^^+/_'EIG_71OY5YE7IOQ9_X\M,_ZZ-_*O,JA[FT
M-@HHHI%A1110!W7PI_Y#][_U[_U->J5Y7\*?^0_>_P#7O_4UZI5K8PGN%%%%
M,D**** "BBB@ HHHH **** .*^)7_(-L?^NI_D:\\KT/XE?\@VQ_ZZG^1KSR
MODLS_P!Y?R_(_2,A_P!PCZO\PHHHKSCW HHHH Z[X<?\C!<?]<#7I5>:_#C_
M )&"X_ZX&O2J^JRO_=EZL_.N(?\ ?WZ(***XWQCX>\6ZOJ<,WAGQ"-+MUCVO
M$9'7<WK\H->F> =E17A6GIX]U'QC>>&XO%TZ75HI9Y6G?RVQCIQG^(=JT/%%
MQXN\)VNA6E_XCGGN;B[<R2PS-ATR@"G(!]?SI7*Y3V6BO)_'NH>(YOB58Z'H
M&M3Z>+J!=H60J@8EN3CZ5GZXOQ#\"0PZK?>(/[2MO,"NOF,ZKZ A@.OM1<7*
M>T453TC4%U;1K/4(QM6YA64+GID9Q5RF(****8#H_P#6I_O"M2/_ %:_05EQ
M_P"M3_>%:D?^K7Z"HD:4QU0W?_'NWX?SJ:H;O_CW;\/YU)K+8S:***T.8***
M*8!1110 4444 %%%% !7@/Q'_P"2AZI_O+_*O?J\"^(J-)\1]22-2SLZA5 Y
M)]*UI;G+B?@1R](_W&^E>N^&?A%9QZ<NH>+[C8"H;R ^Q8Q_M-ZUE_$'0O!-
MCH!G\/7D7V[=A4BEWAQWX'2M/:1;LCG>'FH<S/2_#7_(J:5_UZ1_RK2K,\-?
M\BII7_7I'_*M.N9[GH1V04444% .M?-6O?\ (Q7_ /UW:OI4=:^?XO#E]XH\
M<7EAIR<^>QDD/W8USU-:TG:[9RXE-V2.:J:S_P"0A;_]=5_G7M</PT\&:!:H
M-?NT>=QC?/,$R?85YKXJL-$T[QE##X:N!/9[D)PQ;:V>1GO6L:BD[(YYT)4U
M>1[W!_Q[1?\ 7-?Y"GTR#_CVB_ZYK_(4^N4](**** "BBB@ HHHH **** "B
MBB@ HHHH *4=:2E'6@#P3Q+_ ,C/?_\ 78UEUK>*$*>*M05NOG&LFH.A;!11
M12&%6+#_ )"5K_UU7^=5ZLZ>"VJ6H'),R_SH ^A1]Q?]T?RHH'W5_P!T?RHJ
MSF"BBBF 4444 %%%% !1110!%=?\>-Q_UR;^5>&#I7N=U_QY3_\ 7)OY5X9C
M'6OGLXWA\_T/M.%_AJ_+]0HHHKPC[ **** .B\"?\CA;?[C_ ,J]6KRGP)_R
M.%M_N/\ RKU:OI\I_@/U_P C\_XD_P!\7^%?FPHHHKUSYL**** "BBB@ HHH
MH **** "BBB@ HHHH&%%%% !1110 4444 %%%% !5'6_^1?U'_KUD_\ 035Z
MJ.M_\B_J/_7K)_Z":%N)['S,O3\:6D7I^-+7:>*36?\ R$+;_KLG_H0KZ@[#
MZ#^5?+]G_P A"V_Z[)_Z$*^H.P^@_E6%7H=V%ZA1116)VA2K]X?6DI5^\/K0
M!\[>./\ D>M6_P"NYK!K>\<?\CUJW_7<U@UV1V1X\_B8'H:^@/AU_P D_P!-
M_P!UO_0C7S^>AKZ ^'7_ "3_ $W_ '6_]"-9U=CHPOQLZ:BBBN<] **** "B
MBB@ HHHH **** "BBB@ HHHH *CN/^/6;_KFW\JDJ.X_X]9O^N;?RI/8<?B1
MX6?O-]310?O-]317P1^Q!1110 4#[R_[P_G10/O+_O#^= 'N=K_QY0?]<E_D
M*EJ*U_X\H/\ KDO\A4M?>1V1^/2^)A1115$A1110 4444 %7;#[K?6J57;#[
MK?6D]BH[ENBBBLS<IWO?\/ZU3JY>]_P_K5.M%L<\OB"BBBF2%%%% !1110 4
M444 %%%% '"_$6P75-9\+V4@RDUZ0P]0 #_2H?C5K4MCIMAH5F3%%< O*%XR
MB\!?I1\4=0.DWGAS4%&?LUVTA [C S^E:/Q$\-#QUX9L]9T!EGG@0O&@/^M0
M]5^H_P :T6CBWL823:FH[Z'A'3I7I/P8_P"0UJ?_ %[K_.O.'1XY&CE1D=#A
MD88*GT(KT?X,?\AK4_\ KW7^=;3^%G%1_B(]=HHHKE/4"BBB@#(\4V0U+0'L
MG^[/-&K?3=D_RKFOC-K$FEZ%8:'8$PQ7(/F;>/W:@ +_ )]*Z#QE>MIOA6XO
MD&3;O')CU ;G]*SO'GA]?B!X1LM6T%UEN(5,L2@_ZQ2!N3ZC%5'1IO8SG=QD
MH[V/!NG2NA\!?\C[I/\ UVK DCDAE>*9&CD0[71Q@J?0BM_P%_R/ND_]=JZI
M;'F0^)'T+1117&>N%%%% !1110!S'Q(_Y)UK'_7 UYSX3O\ XDQ^%;:'PYIM
MO+IV&$4K+'NZG/)<'KGM7JGB[2+C7O"=_IEDT:SW,11#*2%!]R :C\%Z+<^'
MO"=IIE\T33P[MQB8E>6)X) ]:GJ4GH<]\/\ P7?>'HM1U3791)J5\IW@-NVC
MJ<GU)]*RO@?_ ,>.N?\ 7TO\C7J,BEXG4=64@5X_I?PZ^(.A>>NB:W9623OO
M=8YC\Q[9S&:-@W+?QQ97@T>WC_X^7E8H!UQT_F171:[\1M*\&M9Z?JUO>2SM
M:H^850CI[L*RM$^&>IS^((=:\;ZJ-1N("&2)"2N1R"3@=/3%>BRVEM.VZ>V@
ME8# ,D2L?U%&H:;&+H&M:3XXT>/4H+-FABG(1;I5RK@=< D=#7$:=_R<5J'_
M %Q/_H"5ZG%#% FR"*.)<YVQH%'Y"N,M/!VHP?%BZ\3/);&QFC*J@<^9G:HY
M&,=CWH$CMJ***H1Y]\6?^/+3/^NC?RKS*O3?BS_QY:9_UT;^5>95#W-H;!11
M12+"BBB@#NOA3_R'[W_KW_J:]4KROX4_\A^]_P"O?^IKU2K6QA/<****9(44
M44 %%%% !1110 4444 <5\2O^0;8_P#74_R->>5Z'\2O^0;8_P#74_R->>5\
MEF?^\OY?D?I&0_[A'U?YA1117G'N!1110!UWPX_Y&"X_ZX&O2J\U^''_ ",%
MQ_UP->E5]5E?^[+U9^=<0_[^_1!0.M%%>H> >4^%_P#DOFN_]<7_ /:='QF_
MY"?AO_KX;_T)*W]&\&ZEI_Q/U/Q%/);&SNXV6-4<F0$[>HQC^$]Z/B#X-U+Q
M5>:1+ILELBV4I>7SW*DC*GC /H:GH5?4Y#XAR:G#\7]-DT&)9M16W0P(X!#-
MN;U('ZU+J>A_$GQKY.G^(;>WL+)7#NR[%4_4*S$FNKU?P=J-_P#$_3?$4,EL
M+.U15D5G(D.">@QCOZUVU%@N5M.L8M,TNVL;?/E6T2Q)GJ0!BK-%%42%%%%
M#H_]:G^\*U(_]6OT%9<?^M3_ 'A6I'_JU^@J)&E,=4-W_P >[?A_.IJAN_\
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M]/I7B5_87.F7CVM]$T4R'D'O]*AFT7=%>BBBD6%;_@G36U/Q9:* =D#>:Y]
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M_@9?W7VW4]/^=K,(LO\ LHYX/Y@"K_A&VBM/BMXKA@ $8(8 =!DY/ZFL]4G
MWLIN-5:7W._HHHK(Z0HHHH YKXB?\D_U/_=7^=>5^!O'U[X/NO+8-<Z;(<RV
MY/*?[2^A]J]4^(G_ "3_ %/_ '5_G7S\.@K>FDXV9PUY.%1.)[IXN\):5\0-
M 77_  VR?;MFY77CSL=4<=FKRWP(K)\0-+5U*LL^&4]0?2NQ^!U_=+K&HZ>N
MYK-HQ*1_"CYQ^9%49+:*T^/QB@P$-X'P.Q8 G]32C>-X%3M-1JI6;>I[#111
M6)V!1110 4444 %%%% !1110 4444 %%%% !1110!Y]\6?\ CRTS_KHW\J\R
MKT_XLQL=,TZ4?=69E/Y5YA4/<VAL%%%%(L**** .Z^%/_(?O?^O?^IKU2O+O
MA1&QUJ_D'W5@ )]R37J-6MC">X4444R0HHHH **** "BBB@ HHHH XKXE?\
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MZFBO@C]B"BBB@ H'WE_WA_.B@?>7_>'\Z /<[7_CR@_ZY+_(5+45K_QY0?\
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M%^P_[='V'_;I/MS?W11]N;^Z*-0]P7[#_MT4GVYO[HHHU#W"K1115F84444
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MQK_C;7=4O/\ 67$0;;G[BYX7\!@5C+WFY+9'5!>RC&#W;N>G4445F= 4444
M<U\1/^2?ZG_NK_.OGX=!7T#\1/\ DG^I_P"ZO\Z\ C1Y9$CB1GD<A411DL3V
M%=%+X3S\3\:.D^'5G<7GQ!TL6F<PR^;(P[(.M>D^-+B*3XP^&($(,D2DO[ G
M@5:\&>'K3X<^$[C6M>94O)4WS$_\LQVC'O\ UKSG0M;N/$7Q<L]4NN'GN<JG
M]Q1PJ_@,5-^:3:V1K;V5-0>[9[G1116)UA1110 4444 %%%% !1110 4444
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MH;O_ (]V_#^=35#=_P#'NWX?SJ4:RV,VBBBM#F"BBBF 4444 %%%% !1110
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M !=='HOBZPUW0+G5[2*=;>V#EUD"[CM&3C!([>M<N/BGX.P/^)7-T_Y\XO\
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MQJ-G<6BBBI-"G>]_P_K5.KE[W_#^M4ZT6QSR^(****9(4444 %%%% !1110
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MB$>5'%5J.I+3;H?2D'_'M#_US7^0I](J>6JH#D* N?7%+7*>D%%%% !1110
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M8?\ $@T__KV3^57<#TJGHW_( T__ *]D_E5RM3,,#THP/2BB@ P/2C ]***
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M/QQX>T:WM)M2O_)CO(A+ ?)=MZGH>!Q^-(-3?HKC_P#A:W@S_H,'_P !I?\
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MV\<#/CG5@?\ GN?Y5Z7\*O%RZ[ILOAC7,321Q'RF?GS8NA4^XS_G%>:>./\
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M[K?6D]BH[ENBBBLS<IWO?\/ZU3JY>]_P_K5.M%L<\OB"BBBF2%%%% !1110
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M% !1110 ^(9F0>XJQ?'E%_&JT;;9%)[&K=ZFY%<<XJ>I:^%E*BBBJ("BBB@
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MZ#;_ /?1J>4OF-S1O^0!I_\ U[)_*KE-BB2"%(85VQQJ%11V [4ZK("BBB@
MHHHH **** "BBB@ J[8?=;ZU2J[8?=;ZTGL5'<MT445F;E.][_A_6J=7+WO^
M']:IUHMCGE\04444R0HHHH **** "BBB@ HHHH *M0WA0;9!N'K56BD--K8M
M7#P/'F,?/GL*JT44 W<****8@HHHH *LPWA0;9/F'8U6HI#3:V+5Q) \>4'S
M_2JM%% -W"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** .>\=PRW'
M@R\BMXGED8KA$&2>:\?_ +&U3_H&W?\ WZ-?00)!R.*7>W]X_G2L5&5D?/G]
MC:I_T#;O_OT:/[&U3_H&W?\ WZ-?0>]O[Q_.C>W]X_G2L5[0^?/[&U3_ *!M
MW_WZ-']C:I_T#;O_ +]&OH/>W]X_G1O;^\?SHL'M#COAI;3VOAF9+J"2%S<$
MA9%P<8%=?2DD]3FDIF;=W<****8!1110 4444 %%%% !1110 5C>+=9G\/>%
M;[5+6*.66V4,J2YVG+ <XY[ULUROQ,_Y)QJ__7-/_0UI MRE\._B ?&,5S#?
MPPVU] =PCASM9/49).0>OU%-U/QS?V/Q/LO#,=K;-:W!7=*V[S!D'ISCMZ5Y
M/I,-]X2L]&\7V3,\$LK1S+Z>J_B,_B*ZF^U"WU7XY:%?6;AX+A8G0@YZAN/P
MZ5-R[*Y[02!R3@>II ZM]UE;Z$&O)O'NI:GXE\?VW@[3;I[2W^43LI(W$C))
M]0 1Q65XC\+7OPL:SUGP[JT\D32;)DE  )]P."#3N*Q[?1572[Y=3TBTOD&U
M;F%90/3(S5JJ)"BBB@ HHHH **** "BBB@ HHHH ='_K4_WA6I'_ *M?H*RX
M_P#6I_O"M2/_ %:_05$C2F.J&[_X]V_#^=35#=_\>[?A_.I-9;&;1116AS!1
M113 **** "BBB@ HHHH *E@F,+YZJ>HJ*BD"=B^T<-R-RGYO453EC\J0KG..
M]-!*\@D'VI"23DG-"14I)A1113)"BBB@ JW;W(VB.7IT!-5**6XTVB[):(5+
M1MCO5*E#,!@,0/3-)0@;3V"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH
M**** ,_5=!T[6_*_M*#S?)SLYZ9K._X03P]_SXC_ +ZKH:*0[LY[_A!/#W_/
MB/\ OJC_ (03P]_SXC_OJNA^M% 79SW_  @GA[_GQ'_?5/M_!6@VMS'/#9[9
M(VW*<]#6]10%V%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110,**** "BBB@ HHHH ****
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MWRF<*"=I P0<= 0!S69XC\4WOQ3-GH_AS2;B.)) \[R$$ ^Y'  ]Z]N(!&"
M1Z$4BHB?<15_W5 HL%RMIEBFF:3:6,9W);0K$#CKM&,U:HHIDA1113 ****
M"BBB@ HHHH **** '1_ZU/\ >%:D?^K7Z"LN/_6I_O"M2/\ U:_05$C2F.J&
M[_X]V_#^=35#=_\ 'NWX?SJ366QFT445H<P4444P"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY#C^M6UO8V7$JX_6IU1>DMRE12L07)48&>!251 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ![M^'\ZFJ&[_P"/=OP_G4FLMC-HHHK0Y@HHHI@%%%% !1110 4444 %%%%
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M?Y-*HQTI-E1BT[CJ***DT*=[W_#^M4ZN7O?\/ZU2K1;'/+XA:*2BF2+1244
M+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
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<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>fig14.jpg
<TEXT>
begin 644 fig14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    60 P "    %   $*:0!  "    %   $+J2D0 "     S,U  "2
MD@ "     S,U  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                       R,#$Y.C R.C(W(# X.C0W.C(P #(P,3DZ,#(Z
M,C<@,#@Z-#<Z,C    !$ &$ =@!I &0 ( !- &D ; !L &4 <@   /_A"Q]H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG
M[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR
M9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U
M+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#$Y+3 R+3(W5# X.C0W.C(P+C,U
M-#PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D
M,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D
M9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS
M(R(^/')D9CIL:3Y$879I9"!-:6QL97(\+W)D9CIL:3X\+W)D9CI397$^#0H)
M"0D\+V1C.F-R96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO
M>#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@
M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8
M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4
M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ_\  $0@#!07K P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
M           ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $
M$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ
M-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(
MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8
MV=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        !
M @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'
M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#
M1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66
MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F
MY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** "
MBBJNIZA%I.D7FHW"NT-G \\BQ@%BJ*6(&2!G H M45Y?_P +]\+?\^&K_P#?
MF+_XY1_POWPM_P ^&K_]^8O_ (Y0*Z/4**QO"OBBR\7Z(-4TV*XB@,C1[;A5
M5LCKP"1^M;- PHHJAKNL6_A_0[K5;Q)'@M4WNL0!8C.. 2!W]: +]%<SX-\=
MZ9XXBNY-)@NX1:,JO]I15SNSC&UCZ&NFH **** "BBB@ HHHH **** "BBB@
M HHHH **S?$&N6WAO0;K5KY)9+>V4,ZP@%CE@. 2!W]:SO!WCC3?&]K<W&E0
M74*6SA'%RBJ22,\;6- '1T45P&O?&/P_X=UVZTF]L]2DGM6"NT,494G /!+@
M]_2@#OZ*\O\ ^%^^%O\ GPU?_OS%_P#'*N:1\:O#NM:S::9:V6J)-=RK"C21
M1A06.!G#DX_"@5ST2BBB@84444 %%%% !16'XL\5V/@W1EU/4XKB6%I5A"VZ
MJS9()[D#''K2^'O%5EXE\-#6[&*XCMOG^295#_*3G@$CMZT ;=%<?X/^)>C^
M-=2GLM*MKZ&2&+SF-S&BJ1D#C:QYYKL* "BN9\9>.],\#Q6DFK07<PNV94^S
M(K8VXSG<P]17*_\ "_?"W_/AJ_\ WYB_^.4 >H45QGAKXJ^&?%&H)8VDTUK=
M2?ZN*[C"%SZ @D9]LUV= !1110 4444 %%<9XG^*&B^%-?32-1M;^6X=%<-!
M&A3#$@<EP>WI6KXO\7V'@O2(M1U2&YEAEG$"K;*K,&*LV?F8#&%- &]167X;
MU^U\4>'[;6-/CFCM[G=L6=0'&URIR 2.JGO7'ZE\;O">GZ@]JGVZ\V-M::VA
M4QY]BS GZ@4 >B451T75[;7M%MM3L1(+>Y3?&)%PV,XY%7J "BBB@ HHHH *
M**S]9UW3/#U@UYK-Y%:0+T+GECZ*.I/L* -"BJ>D:I!K6CVNI68<0748DCWC
M#8/3(KF?"'Q.T;QIJ\NG:7;7\4T4!G9KF-%4J&5<?*Y.<L* .RHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***R_$FOVOA?P_<ZQJ$<TEO;;=ZP*"YW.%& 2!U8=Z -2BN>\'^--.\;6
M$]WI4-U#'!+Y3"Y15). >-K'CFNAH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHKDO&/Q'TCP3>6]MJMM>S/<1F1#;1HP !QSN84 =;15>PO
M(]1TVVO8 RQW,23('&& 8 C.._-6* "BL7Q'XNT7PI:K-K=ZL!?_ %<0&Z23
MZ*.?QZ5QJ_'GPHTVPVVJ*N?]88$V_H^?TH ],HK-T+Q%I7B6P%YHMY'=0YPV
MW(9#Z,IY!^M:5 !1110 45AIXPT6;Q0GA^UO%N=0969TA^98@HR=S= ?;KZX
MK<H **** "BLGQ!XHTCPO8FZUJ\2W7!V)U>0^BJ.3_+UK1M;A+RSAN8@P2:-
M9%##D C(S^= $M%%% !1110 445QGB?XH:+X4U]-(U&UOY;AT5PT$:%,,2!R
M7![>E '9T444 %%%<9/\4-%M_&P\+O:WYOC<);^8(T\O<V,'._..?2@#LZ*H
MZMK6G:#8->ZQ>16ENO\ '(>I] .I/L.:-&U:VUW1[;4['?\ 9[E=\?F+@XSC
MI^% %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K$\:?\B%K_P#V#+G_ -%-6W6)XT_Y
M$+7_ /L&7/\ Z*:@#Q7X,_\ "+?\3G_A+/[(_P"6'V?^T_*_Z:;MN_\ X#G'
MM7J'_%KO^I0_\E:\A^%7@#2_'/\ :O\ :T]Y#]C\GR_LSJN=^_.=RG^Z/UKT
M/_A07A;_ )_]7_[_ $7_ ,;H)1WU@-*L=#,V@0V:V.QI8Q9!5B?CDC;QSCK7
MFVF_'W3KB"ZDU/2)+/RD!A2*X\UIF)Z?=4 =\YKT.TT>W\/^#_[*LWD>"UMG
M1&E(+$8)Y( '?TKP/X*:1::OX_/V^%)DM+1[A$D7<I8,JCCVWY^HH&=I8_M!
M6$U\L>H:'-;6S-@S1W D*CU*[1^AKL_B)<17?PKU>XMG$D,UH'C=>C*2"#^5
M>?\ [0=C;(VBWR1*MQ(98Y) ,%U&PC/KC)Q]:W993+^S8&/;3%7KZ,!_2@#@
MOAAX]TWP/HFL27R27%Q<21>1;Q<%\!LDD\ #(_PKN?#GQTTW6-7AL=3TR33?
M/<1QS"<2H&/ W?*N!GOS6#\ -)M+BZU;4KB%)+BV\J.%F7/E[MQ8CT)P.?KZ
MUB_'.S@LOB%%):QB)KBRCFD*C&Y][KGZX44"Z'NOB?Q/IWA+17U+5G81!@B(
M@R\C'HJCUX/Y5Y>_[0T0FQ'X;=H\_>:] ./IL/\ .NW\=ZIX4M_#-M=>,K1;
MF"4AH(-FZ0L5R=O(QQU.0*X"7QE=ZCX)N]+\'^ I(M%^SR*UQ/DQJNT[FZ8+
M#KG<3F@9Z3X*\=:9XWT^6:P62">W($]O+C<F>AR.H.#S[5S6K_&.VT3QQ/H-
M_I>RVMY=DE[]IZ#;NSLV<]<8S7(_L^G_ (J'5QV^RK_Z'6!XOL8]3^.TUA/_
M *JZU*"%_P#=;8I_G0*YVUQ^T)9)>E+70)Y;8-@2O<A'(]=NTC]:]+\,>);#
MQ9H<6J:6S>4Y*LCC#1N.JGWY'YUS7Q6TC3Q\*K]([2&-;)8VM@B >4?,4?+Z
M9!(_&N8^!EZ]KX+U^15W&WE,R@]SY?3_ ,=H&=!XQ^,.C^%M1DTZVMI-3O8C
MB5(W")&?[I;!Y]@#BLO0OCSI6HZA';:OIDNF)(VT3B82HI_VOE4@>^#7&_!.
MPM]:\?7=WJD:W4L%L\Z^: W[PNHW'WY/YUZ]XG^&_A_Q;J<%]JL,JS1(48P.
M$\T=MW&3CG'(ZT!J;>M:[I_A_1Y=4U2X6*UC&=PY+D] H[DUY7+^T+:BZ*P>
M'9G@SP[W85L?[H4C]:H_'=O[/L?#NBVNY;.&-V56<L3M"JN2>3@9Y]Z=X>\5
M:CIO@ZVT>'X6WUY:/ HEE"/MNB1RY_<G.<Y')P,8- 'J7A'QCI?C/2S>:4[!
MHR%F@D&'B)Z9]CC@CK^=8WCCXHZ5X+G6S:%[_4"H8V\;A0@/3<W.,^F#7GWP
M<TG7]&\=RF[T74K&QN;=U<W-LZJ,$,N6*@9XQ^)K$T6VA\4_'MXM7030S:A<
M,\;\@B,.RJ?4?(!]* N;WB'XPZ?XL\#ZMI5QI\FG7<T:^2/-\U'(=21G P<
M]OQK6_9\_P"0'K/_ %\1_P#H)KI/BWHEC>_#F^FDMXEFL462WD"@&/# %0?0
M@D8^E<W^SY_R ]9_Z^(__030'4]?K*NO"WA^^NGN;W0M-N9Y#EY9K.-V8^Y(
MR:U:*!GS;J.F6"?']-.2RMUL?[2A3[,(E$>TA<C;C&/:O?+?PGX=M+B.XM=
MTN&:-@R21V4:LA'0@@9!KPW5/^3D4_["L'\EKZ(H$@K%\4>*]+\(:2;_ %>5
ME4G;'$@R\K>BC^O2MJOGSX]WTLWC2SLV)$-O9AE4]"S,V3^2J/PH!FZ?VAH/
MM&!X<D\G/W_M@W8_W=F/UKTSPMXKTSQ?HXU#29&*AMDL4@P\3>C#^HXILGA#
M1Y?")\.-:(MB8?+PB@$'&-X./O\ ?/K65I_A#2OA]X<UBZ\/BX$QM'D9IIBV
MXHK%>.GZ4!J9/B[XSZ1X:U.33K*TDU2YA8K-LE$<:-_=W8.2._'%1>%?C9I&
MOZG%8:C9R:5-,P6)VE$D;,>@+8&"?IBO*/ASJESI6OW&I6_A>X\27"1_*(@Q
M,!)^^<(W)P1GZUI^/%U_QGJEOJ%OX!U72[A$*S,EO))YW.03B->1SSSV]*!7
M/1OCO_R3R+_K_C_]!>G_  G_ .2.C_MX_FU9GQ7ENI_@OH\NHI)'=R/:M.D@
M(99#$Q8$'D'.:T_A/_R1T?\ ;Q_-J!]3A_V?_P#D;]2_Z\#_ .C$KW^O /V?
M_P#D;]2_Z\#_ .C$KW^@%L>-?M"_\>.A?]=)OY)75>!_"7AV^\ :/->:#ID\
MTUFADEDM(R[$CDEL9S[URO[0O_'CH7_72;^25C: OQ??PU9+H.?[,, %M@V@
M/EXXY;YOSYH%U,+XK:%8>%/'JQZ#_H\;P1W(CC;_ %#[F&!W'W0WXU[3XL\=
M2>$/!>FZU-8?;I+IXHGC\WRL%HV<G.T_W<8QWKSW0O@_XBUKQ(-4\=7"B/>'
MF1IA++/C^'(X XQUX' 'IT?Q\ 7P#8A0 !J48 ';]U+0!GW'[0-G%;VQ@T*2
M::1-TZ?:MJQ')X#;/FXP>@ZXKT&]\9Z=I'A&WU[6@]C'<1*ZV[8:0EAD( .I
M_EWQ7#?!WP9HEWX'34]4TJUOKB[F?#W4"R;54[0%# XY!KE?CUJ$TWC&ST\D
MBWM;,.B9XW,QR<?15'X4#-Z7]H6V%SMA\.RO!G[[W85L?[NPC]:]"\'^.=(\
M:6+S:6[1SQ8\ZVEP'C]_<>X_2KNE^&-)TKP]'HT%E UFL81T>,$2^I;/4GKS
M7A'AA/\ A%_CW_9^F.1;?;I+79G.8VSA3ZXX_$4 2_&C_DJ=O_U[P?\ H35Z
MM\3M?L/#GAFWN]4T*VUN%[Q8EM[G;M5BCG?\RL,@*1T[UY3\:/\ DJ=O_P!>
M\'_H35W'Q]_Y$*R_["<?_HJ6@0Z]^(5MI/P?L-<TW0(;6&_FDM8[&&4(D!)E
M^8$)@\H3C ^]UKQ;PCK^G>'=4EN]6T&WUR-HBB07# *A)!W8*L"<#'3O7N?P
M\_Y(/!_UZW?_ *,EKA/V?_\ D;]2_P"O _\ HQ* /4M7\::'X*\(Z?=7$(@2
M:!?LMA;@9/R@[1T  R,G_P#57$0?M"VK706Y\/31P9YDCN@[ ?[I4#]:Y7XR
MW4UY\4_LKQO<);Q0Q1P(3EPPW%1CN2V/RKH-?\2:MKGA.70A\*]1MH3'MMV6
M*0_9V'1E'DCI]1GI0%SU_1=:L?$&DPZEI4XGMIAE6'!![@CL1Z5Y;:?M!6DD
M-R]YH3P-&@,*)=;S*^1\OW!M&,G//3I5OX&6.M:7I^L6>L:?>V,(EBE@6Z@>
M/<S!@^W<!G[JYQ[5YM\)- L_$7CR*#4H!<6UO \[Q,,JV, ;O;+"@=SV;P5\
M38/%>F:E?WFG-I5MIJAIIGF$B8()ZX!R .F/3UKE[_\ :#LHKIDTW09KJ$'
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M7IS]:]A^%_Q!_P"$NMY; Z;]C&FVT0\S[1O\SC;TVC'W?>N!_: _Y&_3?^O
M?^C'KT7QE?SZ;\$KBXM6*R?V?!$&4X(#E$/Z,:!=3)\1_'+1M(OY+32;*35F
MB;:\JRB.,GOM;!)^N,4_PQ\;]&US4([+5+1])EE.V.1Y1)$3V!; Q]<8]ZP_
M@%HEC-::CJ\\"2W<<RPQ.XSY8VY)7T)SU]OK3/CYH=C;Q:;J]O!'#=32M#,R
M  RC&03ZD8//O0/7<]'\<^*KOP?HBZI;:1_:<"OMGQ<>68@>C?=;(SQVQQ5'
MPC\2M,\3^&KW5;A!I[:?EKJ%I-^Q,9# X&0<'MU&*L> YO\ A(?A?I?]K*+D
M7%J89A)SYB@E.?J!7SIXMTU?#'BK5M&TV^,UJK^6VQC\RY#!&]2I !]UH"Y[
M?X-^*USXT\1_V=8^'3% @+RW3WF?+0="5V=3P,9_'BJ/Q!\:Z+H7C2*PU'P=
M8:O<-%&PNYRF\ DX',;'CZUT'PI\/Z?HG@6TFL)4N);]!//<+_$W]WZ+R,>N
M?6O+/C1_R5.W_P"O>#_T)J Z'O.MZW8>'=(FU+5IQ#;0CDXR6/90.Y/I7E5Q
M^T+:K<E;3P]++!GAY+L(Q'^Z%(_6HOVA+Z58]$L%)$+F69QV9AM _++?G7>>
M!/#^F0?#73+7['"\5]8QRW(9 ?.+J&.[U^]B@"?P7X[TKQM8R2Z=OAN(,>=;
M2XW)GH>."#Z_RKD+SQKHL7Q:71'\'6$E\;V.+^U"4\P,=N'_ -7G(S_>[=:Z
MGPK\-]!\'WS7FDBZ:X>,QEYIR<J2#C P#T':O(]4_P"3D4_["L'\EH 7XU^*
M_P"V/$ T/[%Y/]DRL/.\W=YN]5/W<#;C'J:U/!7Q;FTWPJ-*M_#_ -J.DV1E
M9_MFWS%#C)QL.,!L]3TJ]^T+_P >.A?]=)OY)7;_  ]MHKSX4:5:W"[X9[,Q
MR*>ZDD$?D:!=1GP]^(,/CRUO7%C]AGM'4-%YWF95@<-G:.X(Z=JJ_$'XG0^!
M+RSM%T[^T)KB-I67[1Y7EKG /W6SD[ORKS7X;RR^"OC%<:%>-A)GDLF)Z,0=
MT;?C@8_WJ<Z?\+#^/C+_ *RQMI\''(\F'^C,/_'Z!W/>M-N9KS2[6YNK?[--
M-$LCP;]WEDC.W.!G'3I5FBB@84444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6)XT_P"1"U__ +!ES_Z*
M:MNN*^(GQ$_X0+^SO^)7]O\ MWF_\O'E;-FS_9;.=_MTH \4^'?Q$_X0+^T?
M^)7]O^W>5_R\>5LV;_\ 9;.=_MTKM?\ AHC_ *E?_P J'_VNC_AHC_J5_P#R
MH?\ VNC_ (:(_P"I7_\ *A_]KH).Z\)>,_\ A.?!FHZE]@^P^4\MOY?G>9G$
M:MG.T?WNF.U>5_ +_D?;W_L&2?\ HV*MK_AHC_J5_P#RH?\ VNC_ (:(_P"I
M7_\ *A_]KH F_:%_X\="_P"NDW\DK2_YMI_[AW_L]8__  T1_P!2O_Y4/_M=
M'_#1'_4K_P#E0_\ M= :$W[/7_'CKO\ UTA_D]<_\??^1]LO^P9'_P"C9:VO
M^&B/^I7_ /*A_P#:Z/\ AHC_ *E?_P J'_VN@-+$WQF\.:EJ?A[0]4L(9+B&
MS@*3I&"2@8*0V/3C!].*Q-*^(WB37?"47A#0]!62Z-L+,W,9.!'MVY*XPIV]
MR<>U:O\ PT1_U*__ )4/_M='_#1'_4K_ /E0_P#M= :&9\!YULO&FIV%S^[G
MDM2JJ>[(XR/KU_(UGZ[_ ,G%Q?\ 89M?_0HZZ/\ X:(_ZE?_ ,J'_P!KH_X:
M(_ZE?_RH?_:Z T.\^*W_ "2[6O\ KFG_ *,6N._9^57T'6E<!E:X0$$9!&TU
M4_X:(_ZE?_RH?_:Z/^&B/^I7_P#*A_\ :Z!W1ST^G:_\'O'$FI6=DUUIS!T2
M0@F.6$G.UF'W6&!U[C/(INN>)?$WQ6UVQBT33)K1+?<L8AD8A"V-S/)@8' _
MR:Z/_AHC_J5__*A_]KH_X:(_ZE?_ ,J'_P!KH%H;7Q&^'E[JO@/2HM/>6_U+
M1XPI+MN>X4@!^3WRH('ID5QFB_&#7?#/AU- NM'$MY;1^3;RS%D:,#@!DQ\V
M.G4=*V?^&B/^I7_\J'_VNC_AHC_J5_\ RH?_ &N@-#J_AAJOC;6;>6[\6+&E
MEMQ!YEN(Y96S][ P N/;G/'2O/OB#X<UOP5\06\6:-"TEK+<&Z695+"-SRZ.
M!T!R?J#ZBM;_ (:(_P"I7_\ *A_]KH_X:(_ZE?\ \J'_ -KH#0Q_$WQ%\0^/
M_"]Q8V&B?9+&*/SKZX1RZLJ?-C<0 HR!QR20.>M=)^SY_P @/6?^OB/_ -!-
M4_\ AHC_ *E?_P J'_VNC_AHC_J5_P#RH?\ VN@#VNBO%/\ AHC_ *E?_P J
M'_VNC_AHC_J5_P#RH?\ VN@=T86J?\G(I_V%8/Y+7T17BG_#1'_4K_\ E0_^
MUT?\-$?]2O\ ^5#_ .UT!H>UUY1\:? M]K\=KK>C0-<W-K&89X$&7:/)8%1W
MP2>.O-9?_#1'_4K_ /E0_P#M='_#1'_4K_\ E0_^UT!=&/)\8]=D\*MX>;2?
M^)DT/V8W6YMY&W;GR\?>QWSU[5V'PB\(:M9:'?7/B1[E(K^+R8K*:1OEC/5B
MIZ$]!WP/>L?_ (:(_P"I7_\ *A_]KH_X:(_ZE?\ \J'_ -KH%H<U GB+X-^,
M+BX^P-=6,@:(2,#Y=Q'G(.X?=8<?3GCFM^R^)GCOQAXCB3PKIT=M;$!6C>/S
M8TYY=Y"!Z]L?3-3?\-$?]2O_ .5#_P"UT?\ #1'_ %*__E0_^UT ;_QR#CX;
MP"8JTGVV+<5& 3L?.!S@5+\)_P#DCH_[>/YM7-_\-$?]2O\ ^5#_ .UT?\-$
M?]2O_P"5#_[70/0R_P!G_P#Y&_4O^O _^C$KW^O%/^&B/^I7_P#*A_\ :Z/^
M&B/^I7_\J'_VN@+HF_:%_P"/'0O^NDW\DKT+X>_\DYT+_KRC_E7F_P#PT1_U
M*_\ Y4/_ +71_P -$?\ 4K_^5#_[70&A[77E_P ??^1"LO\ L)Q_^BI:Q/\
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M_4K_ /E0_P#M='_#1'_4K_\ E0_^UT!H=/\ #S_D@\'_ %ZW?_HR6N$_9_\
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MB>:<>1/TV_1CQ]<>IJG\:/\ DJ=O_P!>\'_H35N_\-$?]2O_ .5#_P"UT?\
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MKPX=6TO31J2_:]7A\ZRC\M_WR8SG.,#CUQ0!T%%1W$\=K;2W$[;(HD+NV.@
MR37GQ^/GPU!Q_P )*G_@+-_\10!Z+16;H/B'2?$^EIJ.@WL=[:OTDC/\P>1^
M-:5 !116$?&OA\>(+S0SJ"C4;&#[3<0>6_R1_P![.,'KV- &[16+HWB_0M?\
M.MKNE:A'-IB[MUP59%&WK]X U2\+_$7PKXSO+BU\-:JM]-;KNE58G7:,XSEE
M /X4 =/1110 4453U35K#1-/>]U6ZCM;:/[TDC8'T]S0!<HK#OO&>@:;JVEZ
M9>Z@L5YJW_'E$48^=^(&!U'7%;E !1110 4444 %%%% !1110 4444 %%%%
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ML;.SUSC'ZT ;-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^\$6=MI%A%;3+)YL$=LBI)_O*!@_C7N=EIMCI5NT6F65O9Q9W&.WB6-2?7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML+:&U@3[L4$815^@' J>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@(9><Y05Z+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 <7\/?\ D*>-?^QBE_\ 1$-=I7%_#W_D
M*>-?^QBE_P#1$-=I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG@?X?R&^U"XU9]-M7D:ZN3^\F(!/S?RKE]:\.ZO<?M :%K<%A(^F6]C)'+=
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M110 4444 %%%% !1110 4444 %%,>:*+'FR(F>FY@,UF7GBG1K"Z-M<WR"8
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M_P"$3\/?] 2P_P# =?\ "CFK/[*^_P#X <U=[17W_P# %O/%.BV%P8+J_1)
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M%UA::7)XOL=-MHK6U@\0RK%!"H5$'D0\ #I7>4 %%%% !1110 4444 %%%%
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MT9+"359DG%^#OW$L., \8KV'X7^!Y/ ?A$:==W0NKN:5I[AT&%#L<D*/09H
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MO_,/JU/K=^K;_4PAX4@8@76I:G=P_P <%Q=%XY!Z,N.13_\ A#?#G_0&L_\
MOT*VJ*?L*7\J#ZM1_E7YE+3]&TW2?,_LVRAMO-QO\M,;L=,_G5S:/0?E2T5I
M&,8JT58VC&,5:*L@HHHJB@HHHH *" >HS110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %!HK#\87,-GX>>YNM<70X8IHWDO&.  '!*G_>Z?C0!X3X>
MD\6>"O$/B(V_PJN]6M[Z^>:*60X95S_>VG(/7\:]D^'FM:IK>E7,NL>$9/"\
MD<H5+>1MWFC&=WW1]*\COIX;K4+B>W_:%^SQ2R,Z0KR(P3D*/W@Z=*].^%'_
M "!+S'CL^,_WX_TH_P#+'Y1\GWC]: .\K@/BYXLN_#.@Z=;Z?(T%QJU_'9B9
M#AD4\MM/9BH('N17?US_ (R\)V_C#14LYI3;S03I<VTX7=Y4J,&4D=QD<C(H
M \PU7QO<Z1\.[&VTKQ'>:G<:CKHTK[9<1[+FU!D^9&.3\X4$;N_7%=5\*O%\
M^K:/X@M=8N9)3X>U&>S:ZG.6>)&;:S-W.T<FDB^#VGIX1N=,DO"^I7.H_P!J
MOJ BQ_I0;<'"9^[VVYZ=ZZ7P;X2@\(Z3-;+-]JN;NXDNKNX*;?-E=BS$+S@9
M/ R: ..UCQOX:\4^.O ]OX>UJUU":/5)9'CA;)5?LLPS],D?G7J5<3XV55\8
M^ ]J@?\ $XEZ#_ITFKMJ "BBB@ HHHH **** "BBB@ HHHH **** ,:YMYM'
MN9+_ $Z-I;>5BUU:(.<]Y$'][U'?U&.=6WN(;NVCN+:1989%#(ZG(8>M25C7
M-O-HUS)?Z=&TUO*Q:ZM$'.>\B#^]ZCOZC'.+3INZV_(YVG2=U\/Y>:_5&S14
M=O<0W=M'<6TBRPR*&1U.0P]:DK9.ZNC=--704444#"BBB@ J.XMXKNWD@N8U
MEBD4JZ,,A@>QJ2BAZZ,32:LS&LKB;2]2ATB\D>X2=6:TG8Y;"XW(_N,C![YZ
M#'.S5:_L(=2M3!<;@,AD=#AHV'1E/8CUJIHU_-.UQ97^!>6C[2<;?.3^&4+V
M!Y'?H:QC[DN1[/;_ ",(MTY<CV>W^7^1J4445L= 4444 %%%% !1102 .3B@
M#B;CX0>"KKQ!'JTFBP^8J,K6X4"&0G/S,F.6YZ_3TKM(HTAA2*)0D:*%55&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCKBM&BJC1IQ=TM1QP]*+NHZ_B   P!@>U%%%:FX4444 %%%% !1110 4444
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M7:UQ7C?_ )'+P'_V&)?_ $DFKM: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#&N-)FL[J2_T61Q(S;Y+-GQ#,3]XX_A8_WN?I6A87\.I6OGV^X8)5T<
M8:-AU5AV(]*LUEW]A-'=?VEI6!=@ 2Q,<+<J.BD]B.S<XR>.:Q<73=X[=O\
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M _: \-W'AJ:Y:*"SF2031F,;MK'IGGJ*SOB/X$O?#>I+XCFU[5[K7)[]'BU
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M2%^U2HO]XJF2%Z#/J1713PU>JN:$&UWMI]XG)+<UM>O]2TZP$^D:9%J,@?\
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M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[@8R%&W!Y&<UTGASPY8>%]*%CIBN5+M+++*VZ2:1CEG8\9)))K5HH XKQO\
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MS<X7;??L%>>:WX+U34?CAHOB9(+>32K.Q>"8NXW!CNQA2.>HKT.BO0/4//\
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M5Y=V +$GKS7V?^LE.63RH>RLTN3^[JG9]^FWXG/[%^TO<[6BBBOS\Z@HHHH
M**** "BBB@ HHHH **** "BBB@"G/I.G75TES<V-O+.GW9'C!8?C5SITHHH
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MP4HK[W_Z4VOP->7NSD/^$7\1ZI\^O>*[BUDC^6,:&@MT8>KB3S"3Z$$<4?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQWK/VL.;DOJ=GU'$NA]8Y'R=_P"NGF=-1116AQA1110 4444 %%%% !1110
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MQ+_\51Y?BK_GXTC_ +\2_P#Q5'/Y,/JZ_GC^/^1N45A^7XJ_Y^-(_P"_$O\
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MK6O4%U96U]"8KN%)4((^8<C/!P>H^HK'V;C_  W\NG_ _K0P]E*'\)_)[?\
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MQ<G'3C@5W7A_X9:+H5E?V\C3:A]N@2T=[DC*VZ+MCB& .%7 !Z\<FK'@_P
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M/3/AOI<7B&ZT=KV>ZN$L]UNJB4Y#, 6/)'R=/I7(_ ]53QE\2E10JC76 "C
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MW(Z$= 10%SZ/HKE?&7C2+PSX'_MR*/S);A46UC?H7<9&?H 2?I7E&C6?Q/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D'[0?\ R ]&
M_P"OB3_T$5J^'?\ DW&;_L$7G\I*O_%+P/J7C?3K"WTJ>UA>VE9W-R[*"",<
M;5-7=*\*7UC\)Y/#$TMN;UK&>V$BLWE[GWX.<9Q\PSQ0+J><_L]@?VMK1P,B
M"( _\":HOV@O^1BTG_KU;_T.NQ^%GP[U;P1>ZC-JUQ93+=1HJ"V=V(())SN4
M>M1_%'X<:OXVU6QN=*N;*%+>$QN+EW4DEL\;5- NAS_Q9AGD^$_A6X&6BC6$
M2'W:'@G\C^==O\(;F&X^%^EK P)A\R.0#^%O,8X/X$'\:V)/"]MJ7@>#P]K2
MB6-;2."1HST95 W*2.H(R#C\*\L;X*^*]+GGC\.>)8HK2;A\S2P,Z^C*@(/Y
MT#/0=/\ B=X=U+Q2V@6\EQ]M$[P*?*RCLN<D,I/'!Y->1?$N%;CXX"%_NR36
MJ'(SP505Z3\//A5!X-NVU*_NEO=2*E$9%(2$'KC/))]>.*S?%7POUK7/B8GB
M*TNK!+198'*2R.),(%SP$([''- 'J%VCR6<R1<2-&P7G'..*^7OAQHMUK/BN
M33K3Q!<^'[MH'VRP!MTF",Q\,I[9Z_PU]35Y/XR^##ZKKDNL^&-02PN9I#*\
M4N54/U+*R\KD\]#UH!E'6OA//=26]MXB^),DSG+017REB?4J'F^G2M7QAK]W
M\+?AWH^EZ5.EW>.##'=O'A0J\EMN3S\P &2*QK/X):YJFK)=>,_$"W:+@.8Y
MI)I'4?P[W Q^M=WXU^'UCXK\+V^E6["Q>Q ^QNJY6, 8VD?W2 /?@'V(!PFG
M>$->\6^$!K_BGQG=BTF@:?[+$V$"C/WCD*.G3;Q6)\ O^1]O?^P9)_Z-BK6T
MWX*>)M@T[5/$D<6C[]SV]K-*P;G^XP"@^_-;7@?X7ZSX-\>2ZE%=6,NENLL(
M02OYWE$Y3(V8SE5SSZT"$\>?#'1?$_B)KG3=;M;#5[DX>UD=6$S =0N=P.!S
M@'IG'6N$U;0_'WPQMTO5U5X[+S!$K6]T7C+<D QM]#VKN?&'P7.J:Y)K'AC4
M4T^XFD,KQ2 A0YY+*R\KSSC!K(;X,^,-8FB3Q-XHCGMT(P3<37#+] X 'YT
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M:I+H\L^JSB.]CSNB+,Q0C#*><@=1UKOM9^%>H/9+#XA^)ERUK*X4)?!MCMU
MP\V">,UM_$/X40>,+X:IIUTMEJ6T+)O7,<P' )QR"!QGG@#BN3'P5\6:K/!'
MXC\2PRVL/"8GEG9%[A0X 'YT".VTCPLGA#X4ZQIT6I+J4;V]S,LZQ[!@QXP!
MN;T]>]<-^SW_ ,A36_\ KC%_Z$U>K1>%[;3/ T_AW1E6-&M)((VD/5V4C<Q
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M'YWF?:79<[]F,;5/]T_I70:=X4C;X=VWAC7 DR"T6WG,+'!([J2!T(!!QVH
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M..*!GJ%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*/\ T.G_ )5;K_XFC_A6WQ1_Z'3_ ,JMU_\ $U[710%CQ3_A6WQ1_P"AT_\
M*K=?_$T?\*V^*/\ T.G_ )5;K_XFO:Z* L>*?\*V^*/_ $.G_E5NO_B:/^%;
M?%'_ *'3_P JMU_\37M=% 6/%/\ A6WQ1_Z'3_RJW7_Q-'_"MOBC_P!#I_Y5
M;K_XFO:Z* L>*?\ "MOBC_T.G_E5NO\ XFC_ (5M\4?^AT_\JMU_\37M=% 6
M/%/^%;?%'_H=/_*K=?\ Q-'_  K;XH_]#I_Y5;K_ .)KVNB@+'BG_"MOBC_T
M.G_E5NO_ (FC_A6WQ1_Z'3_RJW7_ ,37M=% 6/%/^%;?%'_H=/\ RJW7_P 3
M1_PK;XH_]#I_Y5;K_P")KVNB@+'BG_"MOBC_ -#I_P"56Z_^)H_X5M\4?^AT
M_P#*K=?_ !->UT4!8\4_X5M\4?\ H=/_ "JW7_Q-'_"MOBC_ -#I_P"56Z_^
M)KVNB@+'BG_"MOBC_P!#I_Y5;K_XFC_A6WQ1_P"AT_\ *K=?_$U[710%CQ3_
M (5M\4?^AT_\JMU_\31_PK;XH_\ 0Z?^56Z_^)KVNB@+'ST?@'XI)R=0T@G_
M *[2_P#QNM6U^%?Q)L;5+:R\616T$8PD4.I7**H]@$P*]PHH"QXI_P *V^*/
M_0Z?^56Z_P#B:/\ A6WQ1_Z'3_RJW7_Q->UT4!8\4_X5M\4?^AT_\JMU_P#$
MT?\ "MOBC_T.G_E5NO\ XFO:Z* L>*?\*V^*/_0Z?^56Z_\ B:/^%;?%'_H=
M/_*K=?\ Q->UT4!8\4_X5M\4?^AT_P#*K=?_ !-'_"MOBC_T.G_E5NO_ (FO
M:Z* L>*?\*V^*/\ T.G_ )5;K_XFC_A6WQ1_Z'3_ ,JMU_\ $U[710%CQ3_A
M6WQ1_P"AT_\ *K=?_$T?\*V^*/\ T.G_ )5;K_XFO:Z* L>*?\*V^*/_ $.G
M_E5NO_B:/^%;?%'_ *'3_P JMU_\37M=% 6/%/\ A6WQ1_Z'3_RJW7_Q-'_"
MMOBC_P!#I_Y5;K_XFO:Z* L>*?\ "MOBC_T.G_E5NO\ XFC_ (5M\4?^AT_\
MJMU_\37M=% 6/%/^%;?%'_H=/_*K=?\ Q-'_  K;XH_]#I_Y5;K_ .)KVNB@
M+'BG_"MOBC_T.G_E5NO_ (FC_A6WQ1_Z'3_RJW7_ ,37M=% 6/%/^%;?%'_H
M=/\ RJW7_P 31_PK;XH_]#I_Y5;K_P")KVNB@+'BG_"MOBC_ -#I_P"56Z_^
M)H_X5M\4?^AT_P#*K=?_ !->UT4!8\4_X5M\4?\ H=/_ "JW7_Q-'_"MOBC_
M -#I_P"56Z_^)KVNB@+'BG_"MOBC_P!#I_Y5;K_XFC_A6WQ1_P"AT_\ *K=?
M_$U[710%CQ3_ (5M\4?^AT_\JMU_\31_PK;XH_\ 0Z?^56Z_^)KVNB@+'BG_
M  K;XH_]#I_Y5;K_ .)H_P"%;?%'_H=/_*K=?_$U[710%CQ3_A6WQ1_Z'3_R
MJW7_ ,31_P *V^*/_0Z?^56Z_P#B:]KHH"QXI_PK;XH_]#I_Y5;K_P")H_X5
MM\4?^AT_\JMU_P#$U[710%CQ3_A6WQ1_Z'3_ ,JMU_\ $U>T7X?_ !'LM>T^
MZU'Q;]HM(+F.2>'^TKAO,C# LN"N#D C!XKUVB@+!1110,**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH "0.IQ0"#T--D7*TR+[
MQH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@?B]XYU+
MP!X3@U/1X+:::2[2$K<JQ7:W7H1S65\4_B1XA\(6GAT>'+.QN+O6'\LK=*VT
M-@8QAACKWK/_ &E_^2<VG_81B_K6%\>H;BX@\"0V-Q]FN9)PL4^,^6V%PV*
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M'B#0[#3+'4X[6R'V73M1F:.!QSSPRY/XT ?1BZO:7FBR:CI-U;WD(C9HY89
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZIIWARTAO%8LLHW'!/< G'Z5UU% !1110 4444 %%%% !1110 4444 %%%%
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M]U-'<SF=S<LK$,>PP!QS73T4 <CI'PYTK1O'^I>+K:XNWOM14K+'(ZF-<G/
MQG]:R/%WP3\,^+M;;5I)K_2[V0?OI=/F$9F_WL@UZ+10!RN@_#?PWX>\(S^'
M+.SWV-TI%R96R\^>I8^M<4G[-?@Y;:YMWO-7DBF!\M&N1MMSZH-N,_7->OT4
M <9J_P ,=(UGX=6G@VYN;U-/M @26-U$IV=,G;COZ5?UOP'H?B+PC'X=UBW-
MS9PH%C=CAT(& P([UTE% 'FOA;X%^&?"^OPZO]KU+5+FVYM_[0G$BPGU4!1S
M7I5%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHKYJU2_U./4=4>YOI&\7QZ]%;V.JQ%S96]NQ3
M]V[ ^6IY;*M\W/':@#Z5HKP3Q!?3^*/&GCN#4YIL^$]'6;3S%*R+'<B,N90
M1GG'#9'%=7HOQ?TC2/A3X:\0>-+J6"75(F0,D+2%W0D$G:..F?QH ]0HKD/!
MGQ0\+^/KRYMO#-Y+<2VL8DE$D#QX!.!]X<UU] !1110 4444 %%%% !1110
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MY8>;<N1C<Q4 9^@%=710!S'AKP+9>'=1FU*2^O-5U&6-8?ME\RETB7.V,;5
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M+F&SMI+B[FC@AB4L\DC!50#J23T%8OA#QGHOCG1GU3PY</<6B3- S/$T9#@
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M_7%/_015FJVG?\@NU_ZXI_Z"*LT %%%% !1110 4444 %%%% !1110 4444
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M52#=U_78G"Y/A\+556#=UW_X8****],]@**** "BBB@ HHHH **** "BBB@
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M@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI'3/O7KU%<D,HH1FIW=UK_6APPR/#0FJEVVG?I_D<W_PKWPK_P! >+_OM_\
M&JEY\-=%F=38/=:8H&&6TF(#^YSFNOHKN>$H-6Y%]QZ4L%AI*WLU]UCB/^%7
MV/\ T&=7_P# @?X4?\(MXO@_<V7BS;;1_+"LD 9@@Z G')QWKMZ*CZE17PIK
MT;7ZF?\ 9^'7PIKT;7ZG$?V-XZL?])BU^#47CY%K)"$67V)XQ^=+_:/Q$_Z
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M2:U$C1;WB:/+*<' 8#//>MBN8^'&C#0OAYI%EC#" 2-]7)8_^A5T] !1110
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MK;1V\";(HD"(H_A4# %25]-!<L4F?7TXN,%%] HHHJBPHHHH **** "BBB@
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MR1LKHP!5E.00>X- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;'2X8W==K$Y?(Z_Q$ULT5<,+1@[J-WW>K^]FE/!T*;YE&[[O5_>Q  JA5
MP .U+1172=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %(S!%+,< #)-<QXR^(WAKP#]E_X2>]>U^U[O)V0/)NVXS]T''45R<_[1
M/PWDMY$769\LA _T&;T_W: /0=!\1:9XFT]KW1;I;FW61HBZ@C##J*T74,O(
M!(Y''0UY+^S?(DOPSN)(CE&U*8@^QQ7KE 'S'X0\':Q;>"O#>N76E7\;^'_$
M\UW<6IMV$K0-Y19U3&YON< =>:UM2^&^J^+O#?Q UBUM+F%]=OHKK3[>=/*D
MD2'<1N5N5)+'@^E?0U% 'DGA?2[CQ+\9X_&<5E>VFGV.D)8#[9;M SRY;< K
M $@ CGH:\_\ C/X6^(>E?#^YN_%'C6+5M,^U1C[&EJJ$DL=IW 9XKZ;KR7]I
M;_DC-S_U^0?^A4 >HZ=_R"[7_KBG_H(JS5;3O^07:_\ 7%/_ $$59H ****
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M4 %%%% 'CO@#_DY3XB?]<K;_ -!6O8J\=\ ?\G*?$3_KE;?^@K7L5 !1110
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M-O!7AZ7151T$ZR(R^8<''7TYKTN@ HHHH *CG_X]Y/\ </\ *I*CG_X]Y/\
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M%%%%6:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%ITX4H*$%9(****LT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BO'W^+^LI(R_8+'Y6(Z/\ _%5N^#/B'J7B3Q$F
MGW=I:Q1-$SEH@V[(^IKS:>9X:I-0B]7Y'D4LXPE6HJ<6[O38]#HHK!\<ZA=:
M5X"UN_T^4PW5M9R212  [6"\'!XKTCUS>HKS/X>?$?3[_P"&6GW?B/Q3IO\
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M[9&#FH?#OCO7-/UKP7+K6J/J%OXRM7F,#Q*JV<@"LJQE0#M^8CYB>@K4\/\
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M_JY&0%D^AZB@#S_PA\%-!\*:^FLO?:EK%_$,02ZC-O,/^[@"O1J** "BBB@
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M]:KR7]I;_DC-S_U^0?\ H5 'J.G?\@NU_P"N*?\ H(JS5;3O^07:_P#7%/\
MT$59H **** "N?\ %GBV#PG!;2W%K)<"X9E C8#&!GO]:Z"O-?C+_P @_2O^
MNTG_ *"*X\;5G1P\JD-U_F<&8UIT,+.I3W7^9AZ5\0;33_%FKZN]C.\=^$"1
MAAE-H[UT=S\29M7LQ:^%M,N)K^9 "Q7*V[%L?-V]\].>>]>05[W\/8(D\#Z;
M*D2+(\9W.% +?.W4]Z\++J^(Q$I4N:RU>VNK_P""?-95B,5BIRH*=EJ]M=7K
M;[S,L/AVU[=?;O&%_)J<[')A#;8N5 Z#&"/; XKMH((K:W2"WC6.*,;511@
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M10 4452DUK2X96BFU*SCD0X9&G4%3Z$9I.2CNR92C'XG8NT5GG7]' ).JV7
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M+X<U2PL=+TJ2:"+3Y8=WG! <ONQD$8SR<9[4 >T^(?$&G>%M#N-7UJ<P65N
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MRHSY4L31,P_V0P&?PKL:^>]*AU#Q_P#%[0-:T?P5=>%['20QNIKF 0-)D'
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MJMIW_(+M?^N*?^@BK- !1110 5QGBBUC\4^([/0X[>&9+,K<W<[2?ZM"?]6
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M40QV@)56/.&*Y[GO6KJ'P%ME\(:=9:#J\UIK.G7)NX]2D4,9)3U+#'2O7Z*
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M  & !2T45!]"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=]NIZYJNN:;HEN9M3NXX% SM)RQ&<9"CD]>U<;+XPU_Q/(UOX/TYH8#UOIU
MX#XW+G@\=N37!6WPS^)?B*X:_P!7U*UT:XBDRB2,)_,YW;N"P SV_2NE3X=?
M$'44&G^(?':?V1)_KX]/MDADP.1M8(,?-C/MFN5Y5.H_WV*A!=5%N4OO4>7[
MG\SCDL7B':7N1\M_OZ?(Z32OAS;+<?;?$ES)JUX26(=B(U.[.5'7\.GM6VOB
M'POI\DL":OI%JZN5DC%S$A##@@C/6N"_X4/;=O&?B7_P*'^%;$7P1\!+!&MS
MHOVJ8*!)/+<R[Y6QRS8;&2>3712P.489:592](:_-R9TT</&BK4X)?G]Y\X_
M%B_\/WOCZ^_X16W@2T21O,N(F<_:)2<NQW$C[V0-N 16G\&O$GA7PWXDDO/%
ML,<;0H9;.]"RL\<GW=NU.""I8\CM5#QWX3NF\:ZBGA?PEJMGIL,OE11BVED!
M*_*6#8.0Q!(YZ&M[X,>')K3XC6P\2^%+^:*5&2"6XM76."3&=[9&", CGN17
MZU7GAO['<')M<G\RY]NKNU?ONNABN;VESV;_ (7Q\/?^@U)_X!S?_$T?\+X^
M'O\ T&I/_ .;_P")KL_^$<T3_H#Z?_X"I_A1_P (YHG_ $!]/_\  5/\*_+/
M:93_ ,^ZG_@<?_D#NM4[HXS_ (7Q\/?^@U)_X!S?_$T?\+X^'O\ T&I/_ .;
M_P")KL_^$<T3_H#Z?_X"I_A1_P (YHG_ $!]/_\  5/\*/:93_S[J?\ @<?_
M ) +5.Z.,_X7Q\/?^@U)_P" <W_Q-:.B_%WP1KUZUK8ZY$DBQF0FY1H%P"!]
MYP 3STZUT7_".:)_T!]/_P# 5/\ "J&L^ ?"NOV:VNIZ':21+() (T\HA@".
MJ8/<\4N?*7IR5%Y\T7^'*K_>@_>>19_X2_PU_P!##I7_ (&Q_P#Q5'_"7^&O
M^AATK_P-C_\ BJYO_A2?P]_Z%V/_ ,")O_BZ/^%)_#W_ *%V/_P(F_\ BZ.3
M*?YZG_@,?_D@_>>1TG_"7^&O^AATK_P-C_\ BJ/^$O\ #7_0PZ5_X&Q__%5S
M?_"D_A[_ -"['_X$3?\ Q='_  I/X>_]"['_ .!$W_Q=')E/\]3_ ,!C_P#)
M!^\\CI/^$O\ #7_0PZ5_X&Q__%4?\)?X:_Z&'2O_  -C_P#BJYO_ (4G\/?^
MA=C_ / B;_XNC_A2?P]_Z%V/_P ")O\ XNCDRG^>I_X#'_Y(/WGD=)_PE_AK
M_H8=*_\  V/_ .*H_P"$O\-?]##I7_@;'_\ %5S?_"D_A[_T+L?_ ($3?_%T
M?\*3^'O_ $+L?_@1-_\ %T<F4_SU/_ 8_P#R0?O/(\@^/GB"S;Q99S^&?$EQ
M-/);XNHK2Y/DQ@?<(*G!)RV1DXP/6N6^&'B21?B1HYU_6-0^RBX7!-WA ^>-
M^XXV>M:/QR\+>%_"GB:SL_#"O;S/#ONK3+,D8XV,&;));YLC)Q@>M<S\-M'T
MW7OB%I6GZU*B6DTZAHW5R)SGB/*\C/KP*_4<'2PW]B)J_+R/5I<UM>B_#RZ]
M3BDY>U/MG.>E%( %4 < # I:_%CT0HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ,;2O">B:)J&JWNF6"PW&L2^=?.79O.?GDAB0/O'@8'-0Z
M+X&\.^'M2FO](TU8+F;.7,CN$!ZA Q(0>R@"M^B@#GAX$\-KXC.NC2T^WEMV
M_P Q]F[^]Y>=F[_:QGWK=G_X]Y/]P_RJ2HY_^/>3_</\J /)OV:/^22M_P!A
M*?\ ]EKUN66.")I9G6.-!EG<X 'J37DG[-'_ "25O^PE/_[+7JUY9P:A92VE
MY'YD$RE)$)(W ]N*3O;04KVTW*_]NZ1_T%++_P "$_QJU;W5O>1>9:3QSQYQ
MOB<,,^F17F9\(Z&/BDND_8%^P_8/-\G>WW\]<YS70ZOJFD^ -)6PT6U#7=PY
M:WLT+.68\;CR3CI]>U<%/%3M*55)1B[;O?[CRZ6,J)2G7248MIZO=?(/%GBV
M>VNET+PVOVK6+CY?E&1 #W/;/UZ=ZU?#/ANWT'0$L6BA>5QFY<+D2L>I.>WM
M5/P5X730]-%S=Q,=4NAON9)&W,#_ '0?3_)KIZTHTYSE[:KN]EV7^?<UP]*<
MY?6*^[V7\J_S?7[BI_9.G?\ 0/M?^_*_X5+!9VUJ6-M;Q0EOO>6@7/Y5-174
MHQ6J1W*$4[I!1115%!1110 45!>7MKI]L;B_N8;6!2 99Y B@G@<GBN)\1?&
M;P;X>#H^IK>3JX7RK4%\],G<.,#/K6L*-6HTJ<7)OLF_/2QG.I"FKR9D>(/B
M?KGAK43::K9:9 YR4#39R,\9PW!QSBNB\ ^,;[Q<MS-<P6:6T8 C>WDR6/?C
M)X]Z^0=?UB;7-<N[^=W83S-(JLQ. 3QU]L5T/PZ'B:\U*XL?"EO<75W)&,*L
MQCCC4')+-D >W/6OHJW!6-PN#6+=?FFK-P=DM>G,_P"6]V_)GA0>*A-5.=R_
MNZ?G;H?8USJ5C9R!+R\M[=V&0LLJJ2/7!-85]\0?#UE<2VPO#<7,?"Q01L_F
M-CA58#!)Z=:\DM?#GQ)2,_VGX(T[5)<_+-=:B=RK_=&)1QU/XUN64OQ0TZ"*
M&R^'6@1I#RG^D*S+SG.XR9ZUXG]DXZ?_ "\I1_[B1;_-'=[3&3Z*/WM_HOQ.
MN'CG5M0_T;1_#%ZMXWW#>+LC&.3D\=O>@CQ_J_[MQ9Z&(_F\Q")?,_V<9./6
ML WOQDUS_B7OI6E>'5DY.I)*LIBQSC;N;.<8Z=Z3_A#_ (O?]%!LO_ )?_B*
M/[#?_+_&13[)_K"+_.X?5ZD_XE23]+1_X/XG0?\ ""ZKJ?[WQ#XDNWN%^6,V
M9$:A>O(QR<YYK2@^'OAF!XI/[-626,AO,>1R68=R,X/-<;_PA_Q>_P"B@V7_
M (!+_P#$4?\ "L?&6O\ [GQKX[N);:+YX!IB+ P?H=QVC(QVJHY'@(>]/$0?
M_@<G^,5^94<'06KIW?=Z_G<]/BT^R@E$D%I!'(.CI$H(_$"K%>4?\*(M_P#H
M=/$O_@4/\*/^%$6__0Z>)?\ P*'^%=2P>7+;$_\ DC_S.Q<RVB>DWVMZ5I<J
MQZGJ=G9R.NY4N+A(RP]0"1D55_X2[PW_ -#!I7_@;'_\57'Z?\#?"L<;_P!O
M&]\03$_)/?W+[HU_NC:1QG)_&K?_  I+X>_]"ZG_ ($S?_%T>SRJ.CJ3?FHJ
MWXRN.\^QTO\ PEWAO_H8-*_\#8__ (JL;6_BSX*\/W$4-_KL#/*F]?LP,XQG
M')0$#Z&J?_"DOA[_ -"ZG_@3-_\ %ULZ+\//"?A^"6'2]"M425M[^:IE).,=
M7R1]!1;*8ZWJ2\K1C^-Y?D'[SR.?_P"%[_#W_H-/_P" <W_Q-'_"]_A[_P!!
MI_\ P#F_^)KLO^$<T/\ Z VG_P#@*G^%'_".:'_T!M/_ / 5/\*?M,I_Y]U/
M_ X__(!:IW1\W_&CXH2>)KJRMO#-U?0Z,J%O.V-"MT_0D9 8@9*D'C/:O//"
M/B/4_#GB*QN=,OKBV"W"%UBRP89P<IT;@D=*^H_B3\)M.\<:+;Q6'EZ;?V61
M:R(N(@I.64H.,').0,Y_&O)OA!\*+76/%VIW&MW GM] O6M_(C)7SI5)PQ/4
M+QG'7I7WN69KE<,IFE&R@M8O5N[TUM9W_K0Y9TY^T/I>VG2ZM8KB(,$E0.N]
M"C8(R,J>0?8\U)117Y4[7T.X****0!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7DO[2W_)&;G_K\@_\ 0J]:KR7]I;_DC-S_ -?D'_H5
M 'J.G?\ (+M?^N*?^@BK-5M._P"07:_]<4_]!%>-?&OQ%+X?\00RK<W"(;9
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M;O:"=M.EGW;/$I5Y5ZRP[NM=[[V^2_0ZO0_ .F:7*MU>F34K[@F:Y8M@[<$
M="/KDUU*J%4*H  &  .E+17BTJ-.BK05CZBC0I4(\M.-@HHHK4V"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** *=UH^F7LWG7NG6EQ+C&^6
M!7;'IDBF0Z#I%O,DT&E644J'*NEN@93Z@@<5?HK3VM1*W,["L@HHHK,84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3]HKXDW$[;8H;>!W;&<*$4DU7NO%EUX?\/:MXD@G9M:UJ[^Q:?YL!V,HQ^\
M _A4D\\?+WYKYZB^)WB2/Q)J^M-=J\^L8%ZFP*LJC[J\8( P.G7'.:^AOAGH
MG_">:O%XIU.SNHM$LHUCT>SED!C4X_>' Y;YRQR?IVQ12I7KK$5+<M-72_FF
M](JW;J_*_4\O%0JRK0<=E>W^)_HE^9R%GIEI9Z;:[M6CEN;B5C=?N6#1EF)+
ML0,-UZ"O7?AE;>'[1;F/2[_[?J)3,\HC=%"9X"A@./UK7UK7_!'A]BFKW6D6
MTJRQQ-$WEF16<@+E1R!\P.2, <GBMS35TR6W6[T<6CPS#Y9K4*5< ]F7@\UY
M=/!U?K3Q-62E*3NW9[O=[V_#T.7"95*AB/;2:;]'?\_ZZ%VBBBO4/>"BH+R]
MM=.M'NM0N8;6WCP7FGD"(N3CECP.34L<B2QK)$ZNC@,K*<A@>A!H =1110 4
M444 %%%% !16+XE\7Z#X0T][SQ#J<%G&B[]C-F1QD#Y4'S-R1T!JSHNOZ5XB
MT]+W1-0M[V!U5MT,@8KN&0&'53@]#@T :-%%% !1110 4444 %%%% !1110
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MZO)"9%W*39S$$?4+U]J2^^,_@ZU\+RZW;7LUY"L1DCCBMI TI&<#E>,D8R<
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M!'(&<U1E9IV/N&BHK6YAO;.&ZM9!+!/&LD;CHRD9!_(U+0+;1A1110 4444
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M[O+9;W\_^&/8:*\>_P"$,^-G_11M._\  %?_ (W1_P (9\;/^BC:=_X K_\
M&Z9![#17CW_"&?&S_HHVG?\ @"O_ ,;H_P"$,^-G_11M._\  %?_ (W0![#1
M7CW_  AGQL_Z*-IW_@"O_P ;H_X0SXV?]%&T[_P!7_XW0![#17SM83?&&_\
MB9JG@Q/'EHMUIMHET]P;*/8X;9P!Y><_./RKJ/\ A#/C9_T4;3O_  !7_P"-
MT >PT5X]_P (9\;/^BC:=_X K_\ &Z/^$,^-G_11M._\ 5_^-T >PT5X]_PA
MGQL_Z*-IW_@"O_QNC_A#/C9_T4;3O_ %?_C= 'L-9?B;P_:>*O#5]HFHEUMK
MV/RY#&<,!D'C\J\R_P"$,^-G_11M._\  %?_ (W1_P (9\;/^BC:=_X K_\
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MUU#5M-=0\-K; -Y,F>6YY ([#C-;FI? S6M:F?4]1T&?1I9)%1H+>XBE5F)
M#  G R<?ADUK>&_ 'CSX?:BX\.>!K'55"X-S?W<9+L>I #CC'&".V:Z%4;T2
MU/,E@Z=->TE43CTL]7\NGG?;[K]'_P -.:=_T)VN?]\K0/VG-.S_ ,B?KO\
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M$K^./_0@Z/\ ^!J__': /8**\?\ ^$K^./\ T(.C_P#@:O\ \=H_X2OXX_\
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MJ+V[*HLX#G]XVXC=P"<+D\5-J_Q$L;.'2DT:TGUN^UB,S65G;,J-+&!EFRY
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MNL>-=.U2?5+FWM=16&SGU$N3+&ID&Y2W!R #QQTKK]&^(=E?#5(=9LI]$O\
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MWCM=/OO#B2W$,*;4+@OAR!QN. "3R: /9Z*** "BBB@ HHHH **** "BBB@
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M9[$J3^->EW.EZ?>V0L[RQMKBU7&()859!CI\I&*L1QI#$L<*+'&@PJJ, #T
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MT!FNBHH Y[5O ?AS7-8CU34].$MU'C+"5U63'3>JD*^/]H&N@50BA5 50,
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MU?4FA6VCNKH*K10+G;& @ P,GDC/-=710 4444 %%%% !1110 4444 %%%%
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ME[>/4$#1VFCF2R#] Q8AF'O@D4 =MX?\9Z%XG>6/2+TO/#_K+>:)X95'J8W
M;'OBMRL'Q/=VGAK0]4\21V$#WEO:LQD$8WO@<*6'.,XKQ_2/B?XBEM])UBWU
M+4-7FO9E%UHXT618((V.,I,(QG&0<EB.* /6=3^(7AG1[[4;/4=2\J?3(5GN
MD\ESY:,0 <@<\D=*WK*\@U"Q@O+-_,@N(UDC?!&Y2,@X/M7SI\1VW>-?B"PR
M ='MSS_OQUJ>)O&GBCPY9^&[:UN[G1M$;2(774H;(7$9EVKQ+E6VK],&@#WZ
MBLSPWJ!U3PW87KW=O>/-"K-<6H(CD..2H/(&>QK3H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KC?B;XX_P"$$\+M??V9>W_G*\8:U7/DG;P[GL/>NRKS/XZP
M>(;OP*EIX:G=/M=PMM<Q) 9#+&Y"]@< 9R3Z4 >4^#?B!>:AXD\&:0]AXA'V
M>:2:Z9W<_:/,+;6.>L8R.O'%?2'B'Q!IWA?0[C5]9N!;VENN7<@GZ  =R:\)
M\!>$/B0OQ,DN+O785CT>*&SDEDM"J7$'#>7'E!TR1GUKTOXS>&=1\5?#FZL]
M&C$UW%)'.D!.!+L8$K^0H R= ^/6AZQK=M87^DZIHT5X^RTN[Z';%.2> #[U
MYMK_ (IO?%_Q\33;AO$UC8VLB10V]A\I!##+N.AC/KZ&K^KZKK?Q6C\.>&;/
MP=J.DOIES%)=W5W%LCC5, ["?I79Z-I][#^TKJUPUM<_9?[)BC6X:-MCD #&
M[H3[4 >A>)?#_P#PD?AFXT<ZA=V'G*%^U6K[94P0<@_A7S]K/PUN=,^+6A^$
MXO&WB-[;4K:2:29KL[T*[L <XQQ7TS7E'BBQNY?VD/"=W%:3O;1V4HDG6)BB
M'#\%L8% %:7QY:_"6T3PVNF>*/$PLPSSZBT!<+D[L%R #@'MQ75W?Q0T:'X8
M'QQ:Q3W>GJH)BC 5\[MI'.!P:\P\:ZUXPO/&/B'P_K&AZUJ5G<1%=)AL&\J!
M?E^\\BD9[G!/M3(M)U!?V1KG3/[,O$OXW*/;>0WF%A/V7&2/>@#J(_VB]!^Q
MR75SH>LVT)C5K9Y+?"W3G'[M#W/Z<5I>'_C?I/B#Q5IGA]-&U2SO[]69DNXO
M+\C )YSUR!U&:X[XCVESIOPR\!ZN($;^QI()9K&9@C/\H&%0X);)Z 9J%/$U
MSXL_:!\&ZI<:%<:-%);2B&.[ $T@PWS$#H/3- 'HGC+XNZ9X3UK^Q[72M2UW
M444/-;Z;"9&A4C(+?I7&^./V@5M/"]A=^$K"X>>YF$=P9HB#:,#\T; _QG'%
M<I\3?">IZ-\6M2UJZC\3-INI1J89_#I_>;@ "K^@X-5[_P "W%G\(GU31=.\
M22>;JL-Y);:DL;3N%X+A4Y_/F@#Z*\(^(#XE\*VFKR65U8&9,M#=IMD7'&2/
M?K7D=K8Z]\:O%>N//XBO-$T+2+IK6VATV38\CC@LQ[C@UZWX0UO_ (23PG9Z
M@^GW6G^:FTV]XFV1<<<C\*\CM+_7O@MXMUV.?PW>ZWH>KW+7=M-IT>]XW)R5
M([#D]: .N^'7AWQ=X)OM6L_$>LKJ?AZ%?,M+FX<M,.YR?3&<Y[]*HO\ M :&
M-2*IHNL2:0)?+;65MC]F7G&<]<9XI?"NK^-_B#9^(GUC2AH^C7=LT6GPSKMF
M#$8R?;USWKP[3O"%S9P?\(SXAL?'9N?.,36^G%#9MSP1NXQWYH ]>M]9GO/C
MIXG^RZA/+8MX>$T"K,WEC**0RC. ?>J_@'XDVW@WX&Z?JWB"2\U*YN+R6&&(
M,9)IFW' !8^@JOX8\-7NB?%+6K86=^;:+PRD$<UQ%DLPC4;-RC:6XQQ5'0M*
MMX/V?=/C\3>$=7U00WLLGE68,5Q;'<<2 $AORSUH ]4\#_$B+QI<SVSZ!K&C
M7$2[PFH6K('7U#8Q^&<UVE>&?!N]\577C*Z2!=?C\)QP'":_@S+,2/ND\D=:
M]SH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ J.XN([2UEN+AMD4*%W;'10,DU
M)5>_:1=-N6AB2:01,4B?[KG!P#['I0!X3KO[0&F#Q+J[:3XB(TZ'32MC&+,D
M2W1(YR5R .>O'%>L_#S6G\0_#_2=3FOA?S3P S3B/8&?^(8P.AR*^5[V?Q'J
M<.H21>$-)":]JRP121A,I+$>8H^>%.PY/UYKZO\ !2:C%X0L8]:TFVTB\1"L
MEG:L#''@\8()'(YH K^*OB+X5\%/&GB35XK227[L85I'^I502!]:Q?&/Q4T7
M2?AG/XET74H+CSE\NR<*6#2GH",<'&3SCI7G>HZEX>\(_'S7]0^)5F&M+RW0
M6%U<6QGB VKE0,'G@]JQ-%TZ*Z^&OQ)UBULO)T"YD,NFQSQ8'WA^\0$<<'MZ
MT >E_ SQ+KGBO0KO4M<\36^M990(8K7RFM&(R4)VKG\,_6K7C[2/B6^HW>I>
M$_%UEIFE0P;Q:RVJN^57+<E#UQ6O\);6VM_A;H3VMO#$9;.-Y#$@7>=HY..I
M]ZZ+Q#_R+.I_]>DO_H!H \8^'&M_$+5-%L_&?B?QQ81^'8W<W=O-;(C%5R/O
M!!WQWKTCPU\5_!?B[5#IV@ZW'<7>,B)HWC+?3<!G\*\N\)>(V\,_LN)J46EP
M:MMN)%\BXC\R+!DY9AZ"N9TK5])USXT^"]1TR[62)\B8P:<MK##*5/[M2$4O
MWY.: /=]?^*W@SPOK$^EZ[K*6EY;HLDD31.< ],$+@]>@J%_C%X"CO+>V?Q'
M;"2YA$T>0V-I&1DXP#CL<&N#32]/U;]K#58]2M+>[6/2D9$G0.H;"C.#QWKD
MO#][X0\,WGC?0O&>CJ=8NKN4V<+6)<RI\VWR\*=H'!["@#Z&T3Q;HGB'P^=<
MTF_27306!N'!C4;3@_> K$TKXO>!=:UA]+T[Q!!)=(&.UD=%.WKAB #^!KRC
MPY87]_\ LB7MMI$<C3F24^7'RQ42#(]Z\_TB >(X-%TIO&VCQW$,L;1646AR
MK,C#C:TD<.3W!^;% 'OGA/XY>'_%?CN[\/V[&%0_EV4CHV;IAG)'&%''?%=!
M\2_''_"!^$FU&&V^UWDTJV]K#V:1LXS[<5Y=\-9]$T#XZ^*-*U=+:+4KJY7[
M HM>IY)V''R_IFNP^/&A7^J>"[2_TJV>[FTF]CNV@3)+(,YP.YYH YR__P"%
MY:)IL7B&34K'4TRLDNBPVZ[D4_P[MH)QTX)KU#4/&NE^'O"]MK'BV9=&$T:L
M\,QW.K$<J N22/:N U']HWPRN@Q-H,5SJ&MR[5&F>0X9'[ACC!Q[&N4^.KZQ
M/JW@[7KC&CVOE,9GN[?[1'9R-M/SH%8'\C0!Z/KWQ.TO6/A=KVM^!-9CFN;&
M LKB/#1MD<E'&?S%<\?'?B3[?\,(_P"T?DUR+=J(\E/WQP/;Y>O;%>66MF;[
M3/%>NVWBW3=7QI+17,=EIDMJF,KC_EFB9_6NQ9E_M/X+\CF#CGKPM 'J6L_&
M+P+X?UI])U77HX;R-@KH(G<(?0LJD#\Z[*VNH+VUCN;29)X)5#1R1L&5@>X(
MKYB\77WAGP?XIUJ[\-^);9[^:X:6YT?5]%:;S),_=21HB0#GKG%?0/@/4[C6
M/ NE7UYIJ:9+-;JS6D:;%B]@O8>U '0T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M60#Z9%/-A9FQ^Q&T@-J5V^08QLQZ;>F*L44 1P016T"0VT20Q(,+'&H55'H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>fig15.jpg
<TEXT>
begin 644 fig15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" (< \ # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M37^N_#Z'Q#<6D<EX\4S_ &>V!4.4=PJKN)Y.T=3U-2>!/$=_XH\-KJ6HZ?\
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M[UT%>2?!9O%26,;WQ"^&%M93:$^5Q)YO/3Y_^>G7C]*AO/B!XV\8ZE=0> ;
M"QMB%^TLB;V]\R':,XX&,X_0 ]AHKSGP5\0=7N?$<GA;Q=8)9ZIC="Z#:).,
MX(R1G&2".#_.E\0_'7B#PSX^L-/TMQ-;W%B"+,QJ1),[2(A)QN^\$. 1T]Z
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MQ!?RZ5X<U/48%1I;2TEGC5P2I94+ '&.,BN?^&?B[4/&?ARXU'48;:*6*[:
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M[$FNI\1>'[3Q+H%QHMX\L5M<; S0$*PVL&&,@CJH[4 <-X4_Y-YG_P"P;?\
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M'17GE#&$,,908QD=02#@T <O\./^2(>*O^WS_P!)DK9^ O\ R(]Y_P!A)_\
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M$>/JN[\A4?PX_P"2W^*O^WS_ -*4KT/P5X,L?!6C_8K5S--*=]Q<,,&1OIV
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ME-9\0>)KJ_N43:(DGD9#_O,QRP]L 5Z'0 4444 %%%% !1110 4444 %%%%
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M^@?<?]]1_P#Q56:*.27\S_#_ " K?:IO^@?<?]]1_P#Q5'VJ;_H'W'_?4?\
M\55FBCDE_,_P_P @*WVJ;_H'W'_?4?\ \51]JF_Z!]Q_WU'_ /%59HHY)?S/
M\/\ ("M]JF_Z!]Q_WU'_ /%4?:IO^@?<?]]1_P#Q56:*.27\S_#_ " K?:IO
M^@?<?]]1_P#Q5'VJ;_H'W'_?4?\ \55FBCDE_,_P_P @*WVJ;_H'W'_?4?\
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M(=S 0C&T'</N-U':C2O#FK6WQEUOQ!-:;=,NK%8H9_,0[F A&-H.X?<;J.U
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MV..96E$A.V.4 E@2"2H!Z]ZZ'Q3X7\#VWPUO+JVL-.2-+(M:7:*HD=]O[O\
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M ZKOEER=IXS\@YK/T#3[,Z;\3].>UADM-.>:2TBDC#"!U%PH9<]& 4#(YXH
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MN&.?XV^(H)XTECDTU5='7*L"L ((/45#W+6Q2\/^/8]4UC6[;4M4+VQE9].
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M0!9C\Q5% !R,8;CJ,<UJY%&10!Q&C?"+PGHNIKJ$=O<74L<GF1+<R[DC/;
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M5H1I:1$N TQ]?X1_C4J-&Y\L (6/5:J74I>5N>] #?,9R<FI%MWE(55+,>@
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M^3.V,N#G*GC'RD#&1T)HC\%>'(O#<GAR/3$32YFWR0+(X+MN#9+YW$Y4<YZ
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M*XD^#]+\7_$CQG!JQN6BB6SV1Q3%%#M!@28'5E .W.1\S9!S0!N?\*H\*_\
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M>KEB78L>01W[5Z=7G?PTTJW74]5U.*WS&&$4,QR,.>9E53T^8+D^HQVKT2@
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M^,XSM SC)_,U=HH *\0\)SNFE%0Q ^TS?^C#7M]>'^$XV?3"0/\ EYF_]#-
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MFMY/,1>2",,!_6O,/6(PB,?W5P0?1N#3G:>+Y9/G4]F&:K59M7SNBD.8R/\
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M)'IQ5B\^(OAO5=;GGAFEMDF"X,\6 6 QSC(_.M/S+>6$2,[2QR ;#$XPQ(Z
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M8_O&&,A8XP6.#W&/Y5W'G%HK*655FFMR3P&PV??U_"N1\+?\@4<Y_?R\_P#
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MQ"^SI8:5/=,IBBU.$O"[<2@Y7[O\1!(;'MGM2G+EBY=A%ZY\9Z.FEQW]C/\
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M&D  &3Q5 Y[U/9'%RI_N_-^5 #%=HI\KU!Q6AX'<K>>(/WHBB^W+N.>3F,8
M'^)K.EW&5G"GDYJWX#,QN==<7CPH;U08TC#%CL'0GH: .ID<V\(E/VA;>/(D
MMI'#JR]BK=0>AJK=&U:X(EL$A/EJR3Y/"#L3V)R1[U9G-S]H6**ZN[::93M@
MN4#HQQSAO7J:@:RN+<?\>Z; H)*2D[6VD;<'M0!"Q\RUERRC('S*^X?=&"._
MX'ZUVUH_F6<+[=NZ-3@GIQ7&3Y,$SC(8CJ4 (X]>XS_A7:6T9BM8HSU1 #^
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M<'.0<]>E<>Z.9)BS@9.8\GT'7/KZ?C7G8BK)3LG8^CR["4IT>::3O^!T\'Q
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M)%*<L%R#U&/7)J#_ (0GQ<ECX2>#5-.74?#T5PC2.K-&X8!8T "C*[%",>"
M21DT =;X:\5:;XIM9I;+SH9K:4Q7-I<ILF@8$C#KDXS@_D1U! VJYCPAX<U+
M2KK5-8UR]AN=6U>5&G%LN(8EC!6-4R 3A3U/MU()/3T %%%% !1110 4444
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M4D7$JC^ON*WM1CMY[817,]G;S7,*A%N!_JR!U4@_+UZ>W>N6683':L_E!05
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M!J6OJY$-R;U=@,3.0-@R!CN<?RK/#E.E:7@*5OM&O,9A%&;U=S9PQ.P8 _\
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M%D!&<#I_GMFDD-BTBI"+RWD.U8@20'4=3CH,^]++O6-W1&+B1"%D48X XXH
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M,4YY!'3./PK,O/B7I%I/8VPL-4N;G4=/CO[:"VMA(\B.?N@!OO !F/;"GG.
M<*^T'QEIG_"1Z'I.F6=_8>(;F2=;^2<1?9//^60.A.6PO0K]><[1M:-X7O\
M2/'%A<;?.L+/PW'IWVK*KOE20'&S)(RHSZ=LT 58OC!H-UIQO;'3-:O5B5GN
MDM[+<;11G!D.[: 0"003P#G%7=6^)V@Z8\26\5]JK/:"]D73X/,,$! 8/)DC
M8"&!YY QG&1FKI_AS5H/"OC:RDM-MQJM]?RV:>8A\U9$ 0YS@9/KC'?%9.FZ
M)XT\'2F\T?1K;56U+2[2&>%[A8FL[B"%8QDEL.O4_*>?48RP!U-_X_T:TCTJ
M2W2\U)-7BFDM#80>:7\M02NW.X-SC&.#G=MP2.CAD:6".1X7A9U#&-R"R$CH
M=I(R/8D>]<!H_@C5-#O? T(V746C+?&]G1@JHTRY4 $Y8;B1D#MD@9KT.@ H
MHHH **** "BBB@ HHHH **** "O/->!'B"_4Y?H<'GJHP*]#KSC6S_Q/=1R1
MQ(?O9P/E'?Z5U8;XF<F+^!>I3"SDL(59F()8F3;V'ISUI[)-!\K7!B61N/)3
M<SGU'_UZA>(LA3^'[V$7&0!R"3ZU+'/%%(S/(R'HD: LP&/:NT\\L8E)"I-+
M <\!U#$^_J*Y;P>H_L968Y/GR_C\YKIF>"%5CE9D3J Z$D'U!KE/"C[=&4#I
MYTO_ *&:QGNCHI_"_E^IU:RX'%12R9%0J_%#G(JDB&S6^%?,OB/_ +"(_P#0
M!7H->??"K_6>(_\ L(#_ - %>@UYTOB9ZD/A1PWQ0M-1N]*MO(BEET^-V:\2
M+KT^5B.I4')X]J\R217<,DRNZ+@ #'/H/J*]>\=^([G0-,ACL5'VN]9DCD."
M(P!DMCN<=/<UY+-+),\MQ-=&:2ZDW&1P 2^!R<?3VKS<5R\V^I]+E+J>S>BY
M>_4F34)HM+:U6*!HH\D,^0RJ<D@XZ]>O&/>K^CWEU?S/+=7S1_:>(O*AVK-M
M&"V><-]<<5DQ$/>Q )YV)T#Y7AV(X^7N.!GVK5LI?[9BWH_EWQ;.8B$,0"XV
MJ?[A!^O7O7.MM3T9))Z!J4EW>"*QDO=@&9IEVA694.0%8<-DC. .U=+;>-?$
M.EV\BW=O;W]O:+O:Y=C&\B?W1@$%L=^!6$5:2WDMIKM)&DRA6:(/M & Z8QN
M  QDCK3;NY2;356>7SX=A$A5<)*JD9V$^H![\8/-:0J2ALSFK8>G6^)'LL4@
MEB20 @.H8 C!&:?7+>!&U)]-G>YDG:P+@6(N0?." <YSSMSC;GG'7M5CQ+XO
MM?#DUM:&WENKR[_U4*$*.N,LQZ#)QWKTN96NSYCV<N?DCJ_(Z&L)O&6AIKS:
M,]WLN5.TLRD1[\9V;^F[':N/U'Q1K^H>8M]+#HUB%)Q:S!II..1N(X[]!GI7
M)MI>EO#Y4=Q.SSW&U&D<D$$$@L"#].F<CMFL)XA)VCJ>A1RV<E>IH>Z_:(2'
M/FIA!E_F'R_7TH@N(;J%9[>:.:)_NO&P93]"*^>[JTGTR9X)66*%_P!T[P*?
M+G( <*_<XXX]ZTM'\2:EX;/G6-U';12Y+6]QEH23WP,8;CJ*2Q,;V:*EE53E
M;C),]VKDO',7VB?1K6Z=_P"S+FZ:*ZB#;5E;:3&&/]W<N,=R16%HWQ/N&U1(
M]<%G%9R@CS8%?]RPZ$YSD']*9X@\3:;JOC+3C:7$&IVEK;N_D*^,2[U 90>&
M;!X_&BO53H2<7T9Y]:A4HNTU8CTWPY+:ZA<&&Z(2R+/:6D>4,#N "PR2""!T
M/&<UJQPV=I%8P3,8?(7SB<[(6<]2Q/4YR?QICQP20M:*CPV=W$56:)SE7SG#
MGJI_KD5/#%*\<T\DZW0BC54B9%Q$P7YLC'7G\J^5J5)SUF_ZV_S.2Y2_M*SO
M);JWN3);2A2/,5P1*#@%5XZ8Q[\\XJ_/9+)=&66.-HKF 6TMO/)E749(QVSR
M01CFJFG^7YEM#86EO%Y<6TI(2^V,\Y4CU/8]<>U336\]V(VBT^T$15) 9%;S
M%;/3''8=<^Q%3*R=EHA%9+/R+@Z?8>(=9186XM;>56\GG')8$A?0$]*KZA+J
MNEV%UK UO6)9K6,21"8)L('!5XP ",]6ZX/'2I]2NK]X#<::UI=7:R>8L1#I
MY@ P55^[<=.G45=T70KGQ-:V^IZMJ:3:?,%ECL;4$1OSG$C,,M@@#;P..<UZ
MF$^MUI*T]%:]V6KG9VTCRVL,D@4.Z*S;#E<D<X/<5XQX1B+:.S*<XN9LC_MH
M:]K P,"O%/!TNS3F'K<3?^AFOHBSK$PMNJ]^IITI\V!<#F/.?I42-NZU-%C.
M.S#% &3X+\XWGB$!K81#4<GS4+L#L'( _K71S333.8H)[:XW+D6UQ#LE7U(Q
MUQUP*YWP4\4-[XA,DL*RIJ)VK-)M &Q<G'0GBNCGE1D:,:C&UU#F2,SG:Z<9
MZD#C'2@"O(;N&(03P7'D$*>0LBC.<<\-G('Z5$Q"6DH)Y154MM(R-O<=NO/I
MFGO),96D5Y=K*-\4P*@R8SG/08 SQWIKKLMI P 4  9DW+TZ>H]>?K0!V]ON
M-O$6.6V#)]\5)4%D2;&W+,6)B7)/?BIZ "BBB@ HHHH @N[.UOX#!>6\5Q$3
MDI*@8?D:Y&_^&>GWNN?:TN3;V#LKRV,4>T%@,?*P(V@X&0!VKM:HZAK.F:4T
M2ZA?V]JTV?+$T@7=CKC-)Q3W+A.<'>+L<]XB\)2-IVG0Z);0/%IK,RV4KE5D
M)'WMW/S D]>N37G^M7NHVUZ]J]FL$J+G9NQ+!E?XG'!R,\#.!BNK\0_$U<BW
M\.QF8%@'O'CRJ\'A4)!8].>GUKSV226Z/VRX>>XO9B [^86>1NF.O(] .E<5
M>4.FY[F7TJ]O?TCOYLOIKTY$<,>E1+;.0%M+<EI9 >< @<\]<#.,UT/@SX?W
MUQ<6]YK=LL%C$?-CM'^8R,2<!AV4>AYZ5S.EF^T_7;#%JXO8KU##')@+)N[$
M]%^4GZ5[W3P]-27,R,QQ$Z;]G!Z-?,YKQ-X-M=82"YLH+6WU"V=6CD>/Y75<
M_(V.W/X8%<(\<FD2ZA:7EG:Q_8]OF1K(#%N9=RMEL8!SC'4<=:]AK.NM TF^
MU&/4+K3X)KJ(861UR1Z>QQVSTK>I24_4X,-C)T--T>3V*I>65O="V^TQ21B%
MK=D"J&SP>2?FSG/MBI]25Y+-FAO7>WMYL7*2-MSMYV@@9SG'>NB\0>"KY]=N
M;_3;*"[ANSYC1R7#1&*3&"1V.< _G6<? ?B:WB1H[?1YY(U"Y\V3+'&-V"N
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M6"CKTJO.A$IXJY:(6BP.I/% #;S$-HT6?3\*@^'\C++KW[T1)]M7>^[!/R#
M'K^=17EP&DE4-O 8\^M.\ B?[1KS"\\F$7BY01!R3L'KP* .J8M&BMFX%NA*
MR6TI$@9>Q4]<],55N&M?.V_8%AD,.89"VW,8X(;CCJ1[U9FDF:<1VVH7$,TB
MY6VN8\YQUP2.O?K5:6&[MQ^]LF\M@K,R2;L$\ %6]..* $F(>T?9)YJG 3YQ
MC&!Z5VT8 B4 8 4<>E<1,%596D4(H=&)*8'(&?Z?EBNY7&T8((QU% "T444
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M/+<.[W96(-F3)P26^8X &><<#'I5 !115+6=172-%O=2:,R"U@>78.K8&<4
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MC<J.3N/.F;3]'TNYC@GNIW18Q)YPMT"$LS#KN7L,XRPKO-+T^'2=+M=/M_\
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M)_$6YIQ&HCCX5> *JFY.>M%R3DU2).:T2,VRXT@D'/6FPPH7W'G':JVX@5-
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M8E_E0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZV'ITXII'%6\EP+,6HT:Z:-N+<B,)A@<A<'[H&2-Q]#4ZSZFMV6;1KAG5?\
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M2X2:YB!BDE!R$ST1CGC' !^A- %A+VZAUN22\%UJ :,;)!$"\F#_ ,M#P"P
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M42';D!0!QA1QTX!QD A]OX"TJVT+1M&2XO#;Z-?+>V[%UWLZLS ,=N"N7/0
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MX/..>1P"!BNJ:DNYR0<7V_ [;2+M;G1-/FO+E#,]M&[.^=^YE!/ ['-8'A)
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MG2\_\#-0];7+6G-;R_4ZR1#525#6LB+.FY?O ?,*K30>U5%F<D6?A3P_B/\
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M<I@,B;5_=C<9&/1<GA> /4\YJ.Q_M75VF.F:5<7KP^6) H(B8)G=NW<,V>
M3TK3T#3U\0>,(].U6X+VCP_:GL_+PI9&QM);DJ2<\?W><5ZY8V%IIEG'9V-O
M';V\8PD<:X H \^T?X9IJFE6M[KEWJ-K?L7<P13 "%2Q(4<''&/>H?$FBZKX
M,FTL^&?$$ME%JU_;V$XGMDN'9W+?O2[\G  &P8''7FO3ZYCQMI%_J_\ PC_V
M&#SOL>MVUU/\ZKLB3=N;DC.,C@<T 7;+6D@UR#PO=2S76IQZ:MW+=>4J1R@-
MY9. >&+<X P >M9E[\2=#T^QN+VZCO([>VU=M)E?RU.V11DO@-DI@=OF_P!F
MH?$>F>(=/\9VOBK0=/AU;-B;"YL7F$+A=YD#J[''WL C'X'.5Q8?!?B%-'TJ
M6YAAEO[CQ3'K5_%"P5+93G> 6;YL<=,]<#.,D TXOBUHTEU/8-I&NQ:G%MV:
M<]C_ *1-D9.U03C"_,=Q''3-6C\3M!71$U$Q7PG>[:R733!_I;3@@%!'GD@,
MI/..0/O'%6?[(O\ _A:?]M^1_H']B?9?.WK_ *WS]VW;G/W><XQ7)KX0\4:=
MJDOB&PL89[NS\07MU#8RRJOVJWN%1-RN&PK *<!OKVPP!TR_$G0V\,7^N^7>
M*--E$5Y9/&JW,#%P@#(6P.3Z]B.H('0:5J7]JVK7(LKRT02LB"[B\IY #C>%
M)W!3VW 'VZ5YSJ7A#Q1K'ACQ9?75C#%JVORVWE:;%*I\E(7 &Z0MM+%1DXXX
M]3M'J= !1110 5R7C#7]?T_7="T;P_'IS7&J_:,M?B0HOEJK=4.1P6['MTKK
M:X+X@>%U\5>*O#%E=6ES+IY6]6YFA!Q"3&NPE@,*=P&,\$C&#TH UM$\907'
MAW4-1ULPV+Z/<R6=^ZL3$9(\ M'GYBK9& 1NR<<\$Z'A_P 4Z)XI@FFT6_2[
M6!@L@"LC(2,C*L <'G!Q@X/H:\\U#0M<O?A=8Z=!I4T%]X;U(&2.T#6[7*Q;
MAYMNQ!)9@X;=CE@Q )P#/H'AJ35O[;N(;?Q2DUWI$NGPW7B29.K\[=@&\*"5
M(89!RXX(Y .LL_B/X0O]832;76X9+N24Q(H1PCMZ!R-ISCC!YXQG(J?5?'?A
M?1-872=2UB&WO&VYC*L0F[IN8#:GK\Q& 0>AS7.>$-:NK.TT+PW<>!=4@N;)
MO)EN#;*+>%E5U:99. 2V23C&=[8+' ;F-2\-ZI9Z_K]A=6?BN:/5+N6XM1HM
MR%LYUF)^68LN$/16)SQVP 6 /3=;\:^'/#EV;35]32UG$ GV-&Y+(6V C .3
MG/ YP"<8!-8OB?XD:=9> Y/$>@7EM>,\ZV]N)(W*M)G+*R\,IV!FYQV]1G N
M91X9^)&D-#H-]J4=AX8BC\F-4ENK=1(4#A0<,W(4[3T9CT!JEJFB:OJGA7QO
MK,/A^YLAKD]J;33_ "3]H812#>[1J."Q);U^\>1AB 7?%'B+2K347U">^"6=
M_%'+;,%8LX:,$$#&1P1VXR,XS5&36='BM+;49KQA;W# 02 G!<]\_P /0YSC
M'.:@\8"2R^(T^M)ILNHVWE&W;[.F^2)^N['IU7(/K]#@6^E:A'IUC(NF2PR3
M:VEZ((8\^1$1QGC Q].._H/0C.25CS90BVWYG3:AKDHT>*]T*QENIKQ@(T:(
M@*#T8@XPO?/3D<C.0W1M6U+^UI-*UF&!KGR?M0>WW;/+W;<$-@Y!YXXP?;E^
MOZEJ.AZ<\]K8?:9WD$: (9#N(/)Q_#QV[X'?C,\'B;[7---97PU6Y3S+F]U"
MT\M#R!Y:'/ Z<8&=O;  IOWDKDI+D;L,\--_HDQ/4W4Q_P#'S721C<.M<QX=
MS]EFR<G[5-DCO\YKHX3P*F&PZGQ,F:,U&"5;!J;/%1.AK0R'UIAS<6JR$ 'H
M<>U9*-QS6O8 &V9>^<U,BHE":(YJ$1X-:$R<G-56&*:8-##A1DU7.3\U32 L
M<4QU(4 4T25HF(8$&KH7S%]ZC@A5W!(QZXK26WAW.J.=R'E6'Y'Z5Y9[!0CB
MVDYXITMR(HR8W&5/(]J==*X)'(JB4/ERD^@YH NK*DJ$N@#8X('6J<G#4L+L
M8T)Z ;1_G\:D95DQQR* (H<K.CG.U6!)%/O[5HY2RG<IY!J98SP,?05(DT$^
MZV#?,OW2>C>PH R0=AR:O>!;N!+[7@9-EPUXNTB$N<;!D#'0G%,FM"2>@%3^
M RT5QKZ><(HQ?*';=@GY!@#_ /70!T5W):V\4EH\MQ:MRRF1&*ACSD')Y-5-
MC-*;A%,;[ C?,'5CMSN..3P,#\ZOL6BC5O\ 2! A*O:R,) R]BIZ@],54N7M
MO.P;!(7,&8I"Q7]V."&XXZD>] #&58HIA^[&W!8HI!'R]UZ#CTZ<UU^D,K:/
M9E 0OD)C(P>@KD+E@UA*8Y/,7;\GS C&T>G\JZ_28S%I-HC  B%<@=N* +E%
M%% !1110 4444 %%%)0 M%)2T %%%% !1110 4444 %%%% !1110 4444 %%
M%% !4%M96MGYOV6VA@\^4S2^5&%\QSU9L=6..2>:GHH *\TU1E;6=3*]!.^=
MX(P<8_S[5Z77FFH(T6O:DI^4^<Q!4^O/]:ZL+NSCQ?PHJ/$60I_!]["C;P!T
M)/K4L<\44C%G=6Z+&@+$#'M43M 0=\:SY( &[/S8[^GI^-6LEI<(&MR#F4H.
M6]AGMFNUG @9X(%$<I>-.H5HR2#Z@]*X_P )D+IP(Z>=)_Z&:[.-B@!7<ISN
M:-WR?KWKBO"[XTWD<^=+_P"AFL9_$C>'POY?J=S#R@=3@]B*NR1AHEWXWD<U
M0TL,\&2.#TJW>,5-24'PS&V]\3CTU+_V05WE<#\,3NNO$Q/_ $$O_9!7?5PR
MW9Z$?A04444BC)O_  OHFHO<2W.FP&>X3:\ZH!)[$-U!'K7FS6]YI.I7NCS2
M)+]CF'E7$DF"%8;D)XP3C.>G)KU^L/7?"EAKDJW#M);7:#:+B @,5_NL""&'
MU'':L:U+G6FYVX/%>PGKLSQS6EAFU:ZW7.Q7C0L4;:K,>X!Z\ <]ZKA7\B1;
ME'5X>#D8;H#T^G8_C7K$GPWTEYE?[7?;3CS@TH9I<>K$;EXX^4CBI-2^''A^
M_$1MX7T^2($"2UP"_P#O;@=WUZ^]<SPLNYZBS6DFO==CR!YA',1-*D@D3(0?
M*WK]!]:Z;X:QS2>-8YH_](6.WD6:3!(CZ8PW0D]/SKT;3?!/A[3++[,NF07&
M0/,EN(U=Y"#G))'J:V;>V@M(1#;0QPQKT2-0JC\!6M/#\DE)LY<3F7MH.FH[
M^9+11174>0%4M7U>PT'2YM3U.?R+2#;YDFQFVY8*.%!/4CM5VO/_ (AW5_J6
MN:1X<TS3O[6\O_B97U@)UA\V)&"QJS/\C(7)W+@D[1TZT =S97D&H6,%[:R>
M9;W,2RQ/@C<K#(.#R.#WJ>O&5U36=.\#2:%>7=YI!T35[>+4&BN-]Q;:=+\R
M'S5R&8%@HV#HH&T#(-S2=:UPV_C-O#6HZCK3VMM8G36OU9I-K1G<ZHP7+;<L
M/E^<A2=V>0#UJH+V\@T^QN+VZD\NWMHFEE?!.U5&2<#D\#M7F&F:O<'2O$O_
M  C^NZIJ^A0Z--*-1OG?SH+T*WR([*K8V -@ X.#D9YJV.I:S91WD;:]J-T+
MOP1_:9,\V3%.%V@QD %<#OU)Y))YH ]9LKR#4+&"]M9/,M[F)98GP1N5AD'!
MY'![U#I&KV&O:7#J>F3^?:3[O+DV,N[#%3PP!Z@]J\O\/W]QK/BS3--N/$>M
M3M<:#%NCLY7C%F[6PW/-E<.6\P.L@)(?:".E='\&K;R/AM8R>?-)]HEFDVR/
ME8_WA7:@[+\N<>K,>] '=52_LBP_MS^V_(_T_P"S?9?.WM_JMV[;MSC[W.<9
MJ[10 5XUX.,@T%C$-S?:9N/;S&KV6O&?!D@CT9F)Z7$W_HPT =/#=.D!<@*6
MX7U^M2B-YXEDW!<GYC_]:J46ZX?<QPHZFK3SA4"+PH[4 <"=.:\UG71%;+,W
MV[;'(74%6"@\YZ#KS^E2_P!CW?VNZCN=)0$)ATVJIW$?>7)Y'&>"/7UKI_!
M)U#Q"RQIN&HG,K*/D&Q<<GG/L*Z"8K(J&=_/ME)607$&V5/1@W?G'UH \Y&D
MZ['/&#HFPHNV5]P'F #(!;Z9]CTI@T6[:&X8Z/+L,A\DNJAHSG(#9.0.^>@Z
M#I7H$GV+S2D"W*R>4/+ ?Y95 P6'.,X/4]Q2789;2<GYCMZA0"1M[GO0!QMO
MX5UF[\RX.A"2!XP28PGS,W1DR3D>N",=?6H[GP'XG>XAC_L=HW1?FF@N]H8@
M?+D@]1SSCKP.*]CTA2FCV:L""(5X)Y'%7* .+^'7A:ZT2TGO]2!CO;L*AC'
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M:$MI=-M[JW4*" 51URK8( (. !C'.:3P1JU_J,>I6U]<-=_8;D11W+QA&<%
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M4XP!R2 "0 ;5%%% !1110 444E 'G.NC9XAU$L3D'=@\<;1CI5 [(R52%F;
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MX7/L17F&D>/X=-TRWMI=+^TS0H$,KR<$#I@8]*T#\4+:1@T^B^:P_B,@!^G
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M9&X5POCGP%<ZO?P^(_#MU]@UZU VN#A9P.@8^N.,G@C@\=.ZHH \N@^+6I:
MOV;QIX8OK6>/@SVR I)[@,0/Q#$4EW\<+.YC:+P]H.H7UR<A?-4*H]_E+$C\
MJ]2KS750W]K:CDY(F?DMC'X_E6U*G[1V,:U7V:O8Y.UTK6];UW_A(/$I:>]7
M'DVZ$!+<9^7'4<$G@9]<DUTNV: [&FCMP[':0F]F/?'J*C>-B"@R%R21$#EE
M[@_G4J3I$SO-/Y9SM12,LH^F#UKOC!05D>;.;F[LF_?,P,,WE\_\M8OF ^O^
M(KF?!D8DT90K!G\^7J>?OFNE9H4 264 IT\S/F#_ !%<CX3Q_92D# \Z7'M\
MYK.:U1K3^%_+]3K?->TU6/3/[/NW>92ZSJ8O+V J&;EPV 77/&?0&A+OSY4\
MFTNY+21@$O$5#&V> 0-V\KG^+;C'S9V_-5FTAFN=2L+O[T<-I<12,6&0S/"5
M&.O(1ORJ/2XM0T^"STK^SI95M8T@^U^;&(610!NQNW@[1]W;][C./FK'F:9K
MRQ:T*KWD:WTUL]O<B*&=+>2YPGEB1PA48W;^?,09VXR?0$UKP).'"N2T8.,G
MFLM]#G3Q!/J3)))$U\C& SGRWC\F-1)Y>[;N21<Y/. 2 2$Q)J=F\FN65REH
M)1'_ ,M3* (AG+8Z,AZ?=R'!*N -K!\S!PCT-*1I&3,<3Q_,PVL1G . >">#
MU'?!YP>*CBBN?,W%<@]1GK7,WICT^SB&JI'):M=7;O:RNBI+OF9D;<Q"$@'(
M1B,Y+=4 J32]&D>'3Y+ZUD2&*.]<@W#[E:2='CR20Y.T%@6 (8 G# 8.9[!R
M+>YTLNG2/RHS57[-$]Y-9*LGGPPQRMG&W#EP,>_[L_I5".VO[^ULI]0M/[1E
M^RQJT7FK%]GN<?-+D=.?XERR;?D!W'%OPY8WFFB'[3&(]NDV5L?F4XDC\W>O
M![;EYZ'/%'/*]@Y(VN7HM.D7EEP![U2U246EI<W4Z/Y%M"TK!,%B%&3CWXIN
MG:?>0WT;O%Y<T>?MM]O!_M#((7Y0<C!PWS8V8V)E236$-$OK30%TVW@97FT6
M2*Y0S!MUQL14&2>O+KD<8"CHJX%)AR1[FO+82"0B-25[$FF06TCNR@<KUJH\
M4D>L7P"-/86;?;FBA&6:8IQ$%Z$Y4RXX.^2,^YMZC837FG_9]F)9)K:258YB
M-H$J,^U_E/ !P1@\<<UHINQFZ:NB^FFS-C@?G4K6QMT)?T-9*VMTUM=6J1;[
M*"[!CL]P FM_+7,8.>!O+$*< A0APAXMVT,MOIK(Z^3&TA:"VR#]GCP,)D>^
M3@<+NVC*J#4\S;LQN,4KHS_#8_XI?3/^O9:TAG'%5?"D>_PII>5S_HRUH<>;
ML QS7">B0[F'<TJ2NC;@Q!'0YJPXMAP2V1U.*:($D4F)PV.W0T 7(Y/M,(+8
M\S\LU"T#=&0C\*9&"HQ5J)F ^\>.M %&2':>E1XQ5F&Y621EN/NN<JW]W_ZU
M+):.&X'% "VX(4'WI;BW2-@R ^6Q_(U(J&.(#IZTEP^+1SC(R /8T 5-ASQ4
MPB+ 'H:A0EV %67D,?RK@@=30 CV^1DBHGAPN0*47S(V-N?K4OVDN0'08/\
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M8S@Y46J* "BBB@ HHHH XGQUX';6W&K:4B?VDB[)(G;:MRO& >V1CC/'8^W
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MQCW^E33^(=0O+>1;WQ+>R[P!-%]HVJX)Z!1TSZ#GM7NKZ1IDA<OIUHQD&'S
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MY/WH&>O!J%XV0X-+#@2+GL: 'K&58@_PG%2*A)X%6%@#R\GACGCTIQF"-L4
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M)QR,]NG/Z4 >EV15K* KT\M<9^E3UR5C\0O!T-A;Q-X@LU9(U!&X\''TJ?\
MX6/X-_Z&&S_[Z/\ A0!TU%<S_P +'\&_]##9_P#?1_PH_P"%C^#?^AAL_P#O
MH_X4 =-17,_\+'\&_P#0PV?_ 'T?\*/^%C^#?^AAL_\ OH_X4 =-17,_\+'\
M&_\ 0PV?_?1_PH_X6/X-_P"AAL_^^C_A0!TU%<S_ ,+'\&_]##9_]]'_  H_
MX6/X-_Z&&S_[Z/\ A0!TU%<S_P +'\&_]##9_P#?1_PH_P"%C^#?^AAL_P#O
MH_X4 =-17,_\+'\&_P#0PV?_ 'T?\*/^%C^#?^AAL_\ OH_X4 =-17,_\+'\
M&_\ 0PV?_?1_PH_X6/X-_P"AAL_^^C_A0!TU%<S_ ,+'\&_]##9_]]'_  H_
MX6/X-_Z&&S_[Z/\ A0!TO48JM8Z;8Z8CI86<%JLC%W6&,(&8]SBL/_A8_@W_
M *&&S_[Z/^%'_"Q_!O\ T,-G_P!]'_"@#IJ*YG_A8_@W_H8;/_OH_P"%'_"Q
M_!O_ $,-G_WT?\* .FHKF?\ A8_@W_H8;/\ [Z/^%'_"Q_!O_0PV?_?1_P *
M .FHKF?^%C^#?^AAL_\ OH_X4?\ "Q_!O_0PV?\ WT?\* .FI*YK_A8_@W_H
M8;/_ +Z/^%'_  L?P;_T,-G_ -]'_"@# UHH^NZ@\))RX!(&3D  _KG\JI>8
MY9MMPL2=&9L9.#V/;']:IZAXG\/S:C?/%K-F8Y9&*$-C@]\57_X2+07+,=<@
MC4<A48 GGD?D/UKTXSBHK4\F4)N3T-A"9"LLQ0B,$(\N!SZXS].:E +H"9%)
M'_+7<%!^HK%.O^'!,I34[&0L<LTTA.T=N.Y_PJ1_$GAQW5I]4L9FZ[\X_ T^
M>/<7)/L4/!\*OITK*<I]KFQ[C>:ZZ)5C3TKD/"-PXTAGZ"2YE=2!P06/(]JZ
M)+AB.M803L;S:3+O!:GC"\DU6A8DYJ5U+)D&K,Q)KT(-L?7UJ*"]VOA_N-PW
M^-5Y8VJ Y%6DB7)W-6>WS\RX93T(Z&JPM3GI4$-S-#]R0@>G4?E4O]I7&/X
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MK039)&7'#1\D>U7%\'ZX&&;'_P BI_\ %5<M_"NK)+\]GA2I!_>)_C0!EJB
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MH.*OC0=3)P;; _ZZ+_C7G'JF:1FD8<"M5M!U(MQ;\?[Z_P"-(?#^HX_X]_\
MQ]?\: *,3XZ59CC^<;SC/..YJ5="U1,E;;)[?O%_QJ>+1-15<M#\[=3O'^-
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M@V0  L;< ?\ 3%?\*Z(0@#  P*/)'I0!SW]A67_/E;_]^5_PH_L*R_Y\K?\
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>fig16.jpg
<TEXT>
begin 644 fig16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1":17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0>.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UI
M;&QE<@    'J'  '   (#   "&H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MHHH **** "BBB@ HK$USQ?HOAZXMK;4;M1=74BQQ6T?S2,6( ..PYZG K;H
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MUBW\0:':ZK9I(D%TF]%E # 9QR 2.WK0!?HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M^<?CG_R48?\ 7E%_-J^CJ^<?CG_R48?]>47\VH$SH/!/P>\/^)/!NGZM?7FI
M1W%RC,ZPRQA1AR. 4)[>M9'Q%^$47A/1&UC2+Z:YM8G59HK@#<@8X#;@ #R0
M.@ZUK^"?C#X?\-^#=/TF^L]2DN+9&5VABC*G+D\$N#W]*Q_B)\74\6Z&='TF
MQEM;61PT\D[#<X4Y"X&0.0#U[4"TL:7P UNX&K:CH;N6MF@^U(I/",K*IQ]0
MP_[YK;^)&E_#Z[\6>9XNUW4+'4/LZ#RK="5V9.#Q$W/7O6/\ ="N1J&H:](A
M2V\C[)$2/]8Q96;'TVC\ZPOCG_R48?\ 7E%_-J Z'N7A1=*LO!=B-%N9+C2X
MH"89Y5.YD!)R1M'OV%4M*^)?A+6]2CL--U<2W,H8JC6\J#"J68[F4 8"D\GM
M5;P)_P D@T[_ *\'_P#9J^:]"T^YU;7K/3K&0QS7DH@#@] _RG/M@G/M0.Y]
M!ZE\;O"6GW[6T;7E\%.#-:Q*8\_5F&?J 175^&_%>C^++$W6B7:S!#B2,C:\
M9]&4\CZ]#VKCIO@;X7;0C:P"X2^"?+?&4DEL=2GW<9[ 9]Z\>\%:O=^#/B);
M^8S1A+G[)>1@\,A;:P]\'D>X% :GU2S!5+,0% R23TK@-7^-/A+2;MK=);K4
M&0X9K.(,H/\ O,R@_49K-^.GB2?2_#=KI-G(8WU)V\XJ>?*7&1[9+#Z@$5S/
MPF^&>D^(]%EUGQ#&]S$TK106ZR,BX'5B5(/4X SVH ])\-?$_P ,^*;I;2QN
MI+>[?[EO=)L9_H<D$^V<UU]?-'Q2\$P>!M?LY=&DF2TNU,D(9LM$Z$9 ;KQE
M2#UYKW+X>^()/$O@73M0N6W7)0Q3GU="5)/UP#^- 'S?X!_Y*'H/_7_%_P"A
M"OHOXC6V@7?A)HO%E]<6.G^<A,UNI+;N<#A6_E7SIX!_Y*'H/_7_ !?^A"O<
M?CA_R3>3_KZB_K0);$?PLT_P597NHGP7J][J$K1H+A;E"H09.",QK[^M=+KO
MQ \,^&M1^P:WJ?V:YV"39]GE?Y3T.54CM7EW[/?_ "%-;_ZXQ?\ H35B_'/_
M )*,/^O*+^;4!?0]CU_XE>&?#MK;RWEXTKW,2S100(6D9&&0Q!QMR/[V*S=#
M^,GA37+]+,27-A+(VU#>1JJL?3<K$#\<5ROPY^%NE:_X;AUWQ2)KZ:\!\J(R
ML@1%^5<D$$GCUQC%>=?$;PO;^$?&4^G6+NUJR+-$'.656[$]\$&@=V?5E<QX
MH^(?A[PC((-5NV:Z(#?9H%WR >I[#\2*S]+\3RV'P6M]?NCYD\&G @MSO<#:
MN?J<9^M>)^ _#DGQ"\=.FK7,KIM:[NY<_/(,@8SV)+#\,T!<]>T[XX>$;ZY6
M&8WUB&.!)<PC:/J49L5Z%#-%<0)-;R)+%(H9)$8,K ]"".HKQKXE?"?0])\)
MSZOX>BDM9;(*TD1E9UE0D GYB2",YZXZ\4[X!^(YYX[_ ,/W,C/' @N;8$YV
M#.' ]LE3^)]: /9J**IZMJ,6CZ->:C<<Q6D#S,,XR%!./QQB@9G^)/&6A^$X
M5?6[U87<9CA4%I''LH[>YXKCX_CQX4>?8UOJD:Y_UC0)M_1R?TKQ_2;34OB9
M\0$CO;EO/O9"\TQY$48&2 /0#@#Z5[+J'P0\*SZ.UM81SVMX%^2[,S.2W;<I
M.W'T H%J=OHNNZ9XAT];W1KR.Z@/!9#RI]"#R#[&N+^+/B_2+#PMJF@O?&/5
M;BW7RX!$YW*S#/S ;>@;O7CW@K7[[P%X^6*X9DB6X-K?P@_*0&VDX]5/(_\
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MVC_]M_\ T1)7IOPZ\9?\)'\-]1TZ]DW:AIMFZ-GK)%L(5O<CH?H/6O,O@_\
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M7T7H?B&WU7P=:Z](ZQPR6OGRGLF!\X_ @_E0"*.M?$7PKX>U233M7U46]W&
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M_EL_S$$@84$]C65#\1_"EQHUSJL.KH;.U8)([1.AW$9"JK*"QXZ &N<^._\
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MB*H[(.^!T _'UH%>YZI\#8)(?AP'<86:\E=#ZCY5_FIKPVT_Y*)!_P!A5?\
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M_'V;_@)_0^U>>?!__DJVC_\ ;?\ ]$24"ZG=?M#0.UIH-P/]7&\Z-]6"$?\
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MH2&0:KHLYSY30RH/3(92?YBO5_!>@CPSX.T[2\ 211 S$=Y&^9OU)'T K/\
MB/X-_P"$T\+M:P%4OK=O-M7;@;L8*D^A'ZX/:@=M#Q_P/\)4\:>&QJJ:]]D/
MFM$\/V3S-I&.^\=B#T[UT7_#._\ U-'_ )3_ /[97$:/KWB[X7:A<0_8WMQ(
M?WEO>0L8G(Z,"",_4'FGB3QK\2_$R7<"3M,5$8EA!BA@3/\ >[#DGJ2?>@6A
M[WX%\)'P7X=.E&_^W#SVE$GD^7C('&-Q]/7O7S=X!_Y*'H/_ %_Q?^A"OJ/P
M]I3Z)X?L]/FNYKR2",*\\SEF=NI.22<9Z#L,5\N> ?\ DH>@_P#7_%_Z$* 9
M]:T444%!7@'[0'_(WZ;_ -> _P#1CU[_ %X!^T!_R-^F_P#7@/\ T8] GL>@
M_!7_ ))C9_\ 7:;_ -#-=]7 _!7_ ))C9_\ 7:;_ -#-=]0,^2O /_)0]!_Z
M_P"+_P!"%?6M?)7@'_DH>@_]?\7_ *$*^M:!(^2O /\ R4/0?^O^+_T(5Z#^
MT)#(-5T6<Y\IH94'ID,I/\Q7GW@'_DH>@_\ 7_%_Z$*^B/B/X-_X33PNUK 5
M2^MV\VU=N!NQ@J3Z$?K@]J!+8\?\#_"5/&GAL:JFO?9#YK1/#]D\S:1COO'8
M@].]=%_PSO\ ]31_Y3__ +97$:/KWB[X7:A<0_8WMQ(?WEO>0L8G(Z,"",_4
M'FGB3QK\2_$R7<"3M,5$8EA!BA@3/][L.2>I)]Z T/;-!\)'P7\.]2THW_VX
M>7/*)/)\O&4Z8W'T]>]>$?#! _Q,T0,,CSR?Q"DBOHJ/2GT3X>S:?-=S7DD%
MC(KSS.69VVDDY))QGH.PQ7SM\+O^2G:+_P!=F_\ 0&H!GU37SC\2_'NL:[XL
MN]'TVZE@T^WG-LD,#E?.8':68C[V3T'3&/K7T=7S3\3O!&I^'O%=YJ=O;2OI
MUU.UQ%<1*2(BQW%21]T@YQ[?C0-G3:1^S_.\:2Z_K2PDC+PVL>XC_@;$#]#7
M > (D?XF:*B,2BWRE3Z@'(_E736OQ ^(/C+3ET'2X5E:1?*ENK> J[*>"7<G
M:OU %<OHROX/^)=G'J;*ITW452=EY&T/AF&>V,F@1[/\=_\ DGD7_7_'_P"@
MO7.?L]7<8EUVS.!*RPRK[J-X/Y9'YUT?QV.?AW$1R/MT?_H+UXYX+M?$D#7?
MB#PF'>;2C&)HXQN9D?=_#_$OR<CW![9 '4^@/BC-'!\,M:,K!0T(09[DL !7
MD/P(A>3X@RR*,K%8R%CZ99!_6LGQ)XX\5^/FATNXM^%<8L[*!AO?H"P)))_2
MO8/A-X$F\(:+-=:HH74[[:9$!!\E!T3/KR2?P':@-V>9?'/_ )*,/^O*+^;5
MVEW$\W[,:K$2&%G&QQZ+,"?T!KB_CG_R48?]>47\VKU[P!9P:A\)=+L[M!)!
M<6312(?XE8D$?D: ZG@/@+P?'XVUZ73'U(:>ZP&9&,/F;\$ KC<.QS^%>A_\
M,[_]31_Y3_\ [97&ZUX1\4?#?Q,M_IT=PT4$A:UOX8]RE3D8?' )'!4]>>HH
MUSXA>+?'MK%I7D*R;U)AT^!MTK#H3R3U[# X]J /5_ GPH;P1XA?5%UPW@>!
MH6B^R^7D$@YSO/=1VIGQ"\!^&O%.H+<RZS;:5J[8CW-(A\X]%#(2"3V!'/UJ
MW\*?"6K^'='EN?$-W</=7>-MH\Q=;=1[9QN.?P_.O-_B7\,M5TG7KC6-!M9;
MK3[B0S8MU+/;N3D@@<XSR".GMW!]"CJWP4\6Z;N:U@M]1C7G-M* V/\ =;!_
M 9JCX$\::UX2\2VUF9IC9M<"&YLI2=HRV#@'[K#VQTP:U8OC7XRMK,6,B6<E
MPH"^?+;MYV?IN"Y_X#3OA_\ #W6O$_B>/6M<@FM[))_M,LTZ%6N7W;L*#UR>
MIZ=>] O0^BZ***"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"MJ/_ ""[K_KB_P#Z":^6?AO_
M ,E(T/\ Z^E_K7U;)&LT3QR#*.I5AGJ#7*Z;\,?"&D:E!?Z=I'DW5N^^*3[3
M,VT^N"Y!_&@3.LHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-8[O<IDASD[<':WU(SQQTH FG^)MFFK7UA:>'O$.H26$[03265D)4# ^H?\
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MM7T6[L+X*;>XB9'W#@ CK^'7\*\82^GOO@]X+:Y;>T/B"&%6/=5,@7\AQ^%
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MF^&^GZ!=6!DN=,U:-HG\^/$ELI8A_O<8SC!YQBM3QYX,U?6/$]M<Z&H^RZE
MMCJS;U79")5?< 3DG (XYP/>O1J*!6..U'P_?/\ %'0-4M+4?V;8V<L,D@=0
M(R5(4;<Y/4=!78T44#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"3R3CVQ639^$]3T#Q9XAAT:P7^P=8L2T:Q/&BP7 4@*%R" <GH,<CTX]#HH
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M (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\
M"C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_
MPKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)
MX:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A
M<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJ
MHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y
M[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK
M_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[
M/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_W
MT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO
M_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_
M (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\
M"C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_
MPKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)
MX:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A
M<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJ
MHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y
M[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK
M_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[
M/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_W
MT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO
M_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_
M (7)X:_Y[K_WT?\ "C_A<GAK_GNO_?1_PKYJHH"[/I7_ (7)X:_Y[K_WT?\
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MK_WT?\*/^%R>&O\ GNO_ 'T?\*^:J* NSZ5_X7)X:_Y[K_WT?\*/^%R>&O\
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M5% 79]*_\+D\-?\ /=?^^C_A1_PN3PU_SW7_ +Z/^%?-5% 79]*_\+D\-?\
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MO6?V@?\ D:=+_P"O(_\ H9KR:@E[A1110 4444 %%%% !1110 4444 %%%%
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M9PP'&0>?:O6_B%:Q6_Q_\-R11JC7$EE)(5&-S>>5R?4X4#\!67\??^1]LO\
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MB9%K %,:S_+G=NZL,\<=Q7H(N+G4_A#XA76=;T_Q!<0VEQON+)5\M6$6X+D
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M+$HPL98C('MD$^V<5S7Q)^(_B*P\;WNE:==K;6%G-&5A2-1YC#;)EF^]RW4
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M#M3:=JJ2 3MR">.M=+IOAWQ'JOAO4M'^(-SINHK<+B"6V4AE)SR1L4 J=I!
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M%%% !1110 4444 %%%% 'I'Q>_YE;_L#15YO7I'Q>_YE;_L#15YO0#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "O1/@?_P E)C_Z]9?Y"O.Z]$^!_P#R4F/_ *]9?Y"@$>?S
M_P#'Q)_OG^=1U)/_ ,?$G^^?YU'0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z1JW_)NVA_
M]A=_Y35YO7I&K?\ )NVA_P#87?\ E-0!YO1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!L
M^#O^1YT+_L)6_P#Z-6M;XJ?\E0UK_KJG_HM:R?!W_(\Z%_V$K?\ ]&K6M\5/
M^2H:U_UU3_T6M =#D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-- LO@C>:!<W^S4Y8IU2#R9#DL25^8+M_6O)Z* N>H_\)AH7_#/O_"-?;O\
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M\"SVMZO[K2[EC%*P^4*PW=?4$L?H17B7BK6F\1>*]1U5^ES.60$8P@X0?@H
MKM-;^,#7GA:?0_#_ (?M=#@N%*2&"0$;6^\%4(H!/KSW^M>:4#85]#>(O&'P
MI\5_9_[?OOM?V7=Y/[FZ3;NQN^ZHS]T=?2OGFB@1[G>?$SP5X/\ #\]I\/K5
M9+J885EA=55L8#.S_,V,\#G\*YSX/>,M&\,W>LS>)-0:W:[$11VCDD,A!<L3
MM!_O#KZUY?10%SO/#%S\/[F]U(>,8KO?+.[P74;/L"D\?*OS ]^01]*[32O'
M'@7P!H=VGAG5M3UJ>4#RX+G>%4@' &455'/) )^O%>'T4!<]/\ ?$'2;7P_J
M'AKQFDCZ=>,[B9$)";OO*0O(&>01T)--U2/X2:?H=PNF2ZCJU\V3"=TD;*3T
M&655VCZ$_6O,J* N>M^"O&GA.;X:R^$?%\TUE'EAYL:,V\%]X(*@D$-ZC' Z
M\BM6V\:> ++P-J_A?1[V>SA>WDCAGN8)&-Q(Z$%SM4D<X'('L*\/HH"YWOA'
M_A6USH+VWBP7UGJ/(^U(SLN,\% H(!]F4_X=7?>/_"GAGP'>:'X4U'4-9GND
M>-)+L,?*WKM).]5& .BA<$]>I->+T4!<]7\*^.O#6I> 1X2\>&>*&'B&YC5F
M^4'*_=!(9<XZ$8K*\3CX86?ATP>&C?ZCJ9&$N69T /J^Y0"/95Y]1UKSVB@+
MGHOAQ?A=>^&XH?$#ZAIFJ+CS;A6=\D=TVJR@'T*Y'KW.YXJ^(?AVQ^'S^%_"
MEY>:JTZ&)KJ[#'8A.3DN 23T   'X 'QZB@+A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'I'Q>_YE;_L#15YO7I'Q
M>_YE;_L#15YO0#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "O1/@?_P E)C_Z]9?Y"O.Z]$^!
M_P#R4F/_ *]9?Y"@$>?S_P#'Q)_OG^=1U)/_ ,?$G^^?YU'0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5Z1JW_)NVA_]A=_Y35YO7I&K?\ )NVA_P#87?\ E-0!YO1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!L^#O^1YT+_L)6_P#Z-6M;XJ?\E0UK_KJG_HM:R?!W
M_(\Z%_V$K?\ ]&K6M\5/^2H:U_UU3_T6M =#D**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /4?@%_R/M[_P!@R3_T;%7T+7SU\ O^1]O?^P9)_P"C8J^A:"D>!?M _P#(
MTZ7_ ->1_P#0S7DU>L_M _\ (TZ7_P!>1_\ 0S7DU!+W"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /2/B]_S*W_8&BKS>O2/B]_S*W_8&BKS>
M@&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %>B? __DI,?_7K+_(5YW7HGP/_ .2DQ_\ 7K+_
M "% (\_G_P"/B3_?/\ZCJ2?_ (^)/]\_SJ.@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KTC
M5O\ DW;0_P#L+O\ RFKS>O2-6_Y-VT/_ +"[_P IJ /-Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** -GP=_R/.A?]A*W_ /1JUK?%3_DJ&M?]=4_]%K63X._Y'G0O^PE;
M_P#HU:UOBI_R5#6O^NJ?^BUH#H<A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ZC\ O\
MD?;W_L&2?^C8J^A:^>O@%_R/M[_V#)/_ $;%7T+04CD/&'P\T_QC?6]UJ#?/
M!%Y8P6'&2>Q'K7._\*,T+^\?^^G_ /BJ]1HH"R/+O^%&:%_>/_?3_P#Q5'_"
MC-"_O'_OI_\ XJO4:* LCR[_ (49H7]X_P#?3_\ Q5'_  HS0O[Q_P"^G_\
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M+O\ A1FA?WC_ -]/_P#%4?\ "C-"_O'_ +Z?_P"*KU&B@+(\N_X49H7]X_\
M?3__ !5'_"C-"_O'_OI__BJ]1HH"R/+O^%&:%_>/_?3_ /Q5'_"C-"_O'_OI
M_P#XJO4:* LCR[_A1FA?WC_WT_\ \51_PHS0O[Q_[Z?_ .*KU&B@+(\N_P"%
M&:%_>/\ WT__ ,51_P *,T+^\?\ OI__ (JO4:* LCR[_A1FA?WC_P!]/_\
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M+O\ A1FA?WC_ -]/_P#%4?\ "C-"_O'_ +Z?_P"*KU&B@+(\N_X49H7]X_\
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MD>7?\*,T+^\?^^G_ /BJ/^%&:%_>/_?3_P#Q5>HT4!9'EW_"C-"_O'_OI_\
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M_P#XJC_A1FA?WC_WT_\ \57J-% 61Y=_PHS0O[Q_[Z?_ .*H_P"%&:%_>/\
MWT__ ,57J-% 61Y=_P *,T+^\?\ OI__ (JC_A1FA?WC_P!]/_\ %5ZC10%D
M>7?\*,T+^\?^^G_^*H_X49H7]X_]]/\ _%5ZC10%D>7?\*,T+^\?^^G_ /BJ
M/^%&:%_>/_?3_P#Q5>HT4!9'&>$/AOIW@_5Y=0L&S)) 83DL>"RMW)[J*[.B
MB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M $']4_\  R3_ !IP\5^(O^@_JG_@9)_C6,*<*=D+GEW-C_A*_$7_ $'M3_\
M R3_ !IP\5^(?^@]J?\ X&2?XUCBG"BR%SR[FP/%7B'_ *#VI_\ @9)_C3AX
MI\0?]!W4_P#P,D_QK'%/%%D+GEW-<>*?$'_0=U+_ ,#)/\:</%'B#_H.:E_X
M%R?XUD"G"G9!SR[FM_PE&O\ _0<U+_P+D_QIP\4:_P#]!S4O_ N3_&LD4HHY
M4+GEW-<>)]?_ .@WJ7_@7)_C2CQ/KW_0;U'_ ,"Y/\:R13A1RH7/+N:W_"3:
M]_T&]1_\"Y/\:7_A)M>_Z#>H_P#@7)_C64*<*?*NPN>7<U1XEUW_ *#6H_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHID,T=Q"DT$B2Q2*&1T8%6!Z$$=13Z "BBB@ HHJK_:=E_:W]F"YC-]Y)G,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY[:[BC^T2+AG 5\9&3T&!^%>H2:5ITT;1RV%JZ,,%6A4@_ABO)_B5J.IZO\
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M9U <-L1F+*,CV(^G2KGC/Q0?"NC1W$%HU[>7,ZVUK;J<;Y&Z9/8?_6'>N?\
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M^STF<P&-;=)9YL$@O\W09'45SNB6_F_%_4[&TUN?6YCH\T#W4[@YD('R@C@
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MK&L?]L/_ $1'7&"NS^,'_)6-8_[8?^B(ZXP5VQ^%'C5?C?J;'A/_ )'/1/\
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MP=6AB"00&)U7EP6W97&<;NC8YJE\5/%.C^)(=%71;S[2;591-^Z=-N[R\?>
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M!:LMVFL70U&$077F$RQA0H4GG@#C%516AX@U;^W-?NM1$?EB9AM3T   S[X
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ME]&4I8L9G/D@J%(Z_-PH'S9Z5K44 %9UMH&FVFO7FM6]MLU"]14N)O,8[PH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#P;XD?#?Q7K_Q"U+4])TK[19S^5Y<GVF)=VV)
M%/#,#U![5S(^$'CG_H!_^3<'_P 77T_16JJR2L<TL-"3N[GS"/A#XY_Z ?\
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M4?#CQ7_T"O\ R8B_^*KW>BCV\A?4:?=_U\CPK_A7/BK_ *!?_DQ%_P#%4O\
MPKGQ5_T"_P#R8B_^*KW2BG]8D'U&EW?]?(\,'PZ\4_\ 0+_\F(O_ (JE_P"%
M=^*?^@7_ .3$7_Q5>Y44?6)!]0I=W_7R/#Q\//%'_0+_ /)B+_XJE'P]\4?]
M S_R8B_^*KV^BCZQ(/J%+N_Z^1XD/A[XG_Z!G_DQ%_\ %4H^'WB?_H&?^3$7
M_P 57ME%'UB0?4*7=_U\CQ0?#_Q/_P! S_R8B_\ BJ4?#_Q-_P! S_R8B_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;_Y$H U:*RO^*@_ZAO\ Y$H_XJ#_ *AO_D2@#5HK*_XJ#_J&_P#D2C_BH/\
MJ&_^1* -6BLK_BH/^H;_ .1*/^*@_P"H;_Y$H U:*RO^*@_ZAO\ Y$H_XJ#_
M *AO_D2@#5HK*_XJ#_J&_P#D2C_BH/\ J&_^1* -6BLK_BH/^H;_ .1*/^*@
M_P"H;_Y$H U:*RO^*@_ZAO\ Y$H_XJ#_ *AO_D2@#5HK*_XJ#_J&_P#D2C_B
MH/\ J&_^1* -6BLK_BH/^H;_ .1*/^*@_P"H;_Y$H U:*RO^*@_ZAO\ Y$H_
MXJ#_ *AO_D2@#5HK*_XJ#_J&_P#D2C_BH/\ J&_^1* -6BLK_BH/^H;_ .1*
M/^*@_P"H;_Y$H U:*RO^*@_ZAO\ Y$H_XJ#_ *AO_D2@#5HK*_XJ#_J&_P#D
M2C_BH/\ J&_^1* -6BLK_BH/^H;_ .1*/^*@_P"H;_Y$H U:*RO^*@_ZAO\
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M;_Y$H U:*RO^*@_ZAO\ Y$H_XJ#_ *AO_D2@#5HK*_XJ#_J&_P#D2C_BH/\
MJ&_^1* -6BLK_BH/^H;_ .1*/^*@_P"H;_Y$H U:*RO^*@_ZAO\ Y$H_XJ#_
M *AO_D2@#5HK*_XJ#_J&_P#D2C_BH/\ J&_^1* -6BLK_BH/^H;_ .1*/^*@
M_P"H;_Y$H U:*RO^*@_ZAO\ Y$H_XJ#_ *AO_D2@#5HK*_XJ#_J&_P#D2C_B
MH/\ J&_^1* -6BLK_BH/^H;_ .1*/^*@_P"H;_Y$H U:*RO^*@_ZAO\ Y$H_
MXJ#_ *AO_D2@#5HK*_XJ#_J&_P#D2C_BH/\ J&_^1* -6BLK_BH/^H;_ .1*
M/^*@_P"H;_Y$H U:*RO^*@_ZAO\ Y$H_XJ#_ *AO_D2@#5HK*_XJ#_J&_P#D
M2C_BH/\ J&_^1* -6BLK_BH/^H;_ .1*/^*@_P"H;_Y$H U:*RO^*@_ZAO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)<\5+N%%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-8AT^:[$\DC' V,0H7.T?* .F>M8GPR\"Z;XYTO4/$'BPS:A<SW+1KF9EVD
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MI7I=% PKC/BIH&I>)/!+V&BVWVFZ-Q&XC\Q4X&<G+$"NSHH Y_POHTMM\/\
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M"BBBH-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR?\ Q5'M(=T'L*W\K^YF+16W_P (=KO_ #X_^1D_^*H_X0[7?^?'_P C)_\
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M]^1_\<H_X7[;_P#/A+_WY'_QR@+H]EHKQK_A?MO_ ,^$O_?D?_'*/^%^V_\
MSX2_]^1_\<H"Z/9:*\:_X7[;_P#/A+_WY'_QRC_A?MO_ ,^$O_?D?_'* NCV
M6BO&O^%^V_\ SX2_]^1_\<H_X7[;_P#/A+_WY'_QR@+H]EHKQK_A?MO_ ,^$
MO_?D?_'*/^%^V_\ SX2_]^1_\<H"Z/9:*\:_X7[;_P#/A+_WY'_QRC_A?MO_
M ,^$O_?D?_'* NCV6BO&O^%^V_\ SX2_]^1_\<H_X7[;_P#/A+_WY'_QR@+H
M]EHKQK_A?MO_ ,^$O_?D?_'*/^%^V_\ SX2_]^1_\<H"Z/9:*\:_X7[;_P#/
MA+_WY'_QRC_A?MO_ ,^$O_?D?_'* NCV6BO&O^%^V_\ SX2_]^1_\<H_X7[;
M_P#/A+_WY'_QR@+H]EHKQK_A?MO_ ,^$O_?D?_'*/^%^V_\ SX2_]^1_\<H"
MZ/9:*\:_X7[;_P#/A+_WY'_QRC_A?MO_ ,^$O_?D?_'* NCV6BO&O^%^V_\
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M_?D?_'*/^%^V_P#SX2_]^1_\<H"Z/9:*\:_X7[;_ //A+_WY'_QRC_A?MO\
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M_P#SX2_]^1_\<H"Z/9:*\:_X7[;_ //A+_WY'_QRC_A?MO\ \^$O_?D?_'*
MNCV6BO&O^%^V_P#SX2_]^1_\<H_X7[;_ //A+_WY'_QR@+H]EHKQK_A?MO\
M\^$O_?D?_'*/^%^V_P#SX2_]^1_\<H"Z/9:*\:_X7[;_ //A+_WY'_QRC_A?
MMO\ \^$O_?D?_'* NCV6BO&O^%^V_P#SX2_]^1_\<H_X7[;_ //A+_WY'_QR
M@+H]EHKQK_A?MO\ \^$O_?D?_'*/^%^V_P#SX2_]^1_\<H"Z/9:*\:_X7[;_
M //A+_WY'_QRC_A?MO\ \^$O_?D?_'* NCV6BO&O^%^V_P#SX2_]^1_\<H_X
M7[;_ //A+_WY'_QR@+H]EHKQK_A?MO\ \^$O_?D?_'*/^%^V_P#SX2_]^1_\
M<H"Z/9:*\:_X7[;_ //A+_WY'_QRC_A?MO\ \^$O_?D?_'* NCV6BO&O^%^V
M_P#SX2_]^1_\<H_X7[;_ //A+_WY'_QR@+H]EHKQK_A?MO\ \^$O_?D?_'*/
M^%^V_P#SX2_]^1_\<H"Z/9:*\:_X7[;_ //A+_WY'_QRC_A?MO\ \^$O_?D?
M_'* NCV6BO(]-^-\>J:M::?;V3++=SI C/%A0S,%!.)#QDU8\0?&+_A'->NM
M)OK/S)[5@KM#%E3D \$N#W]* N>J45XU_P +]M_^?"7_ +\C_P".4?\ "_;?
M_GPE_P"_(_\ CE 71[+17C7_  OVW_Y\)?\ OR/_ (Y1_P +]M_^?"7_ +\C
M_P".4!='LM%>-?\ "_;?_GPE_P"_(_\ CE'_  OVW_Y\)?\ OR/_ (Y0%T>R
MT5XU_P +]M_^?"7_ +\C_P".4?\ "_;?_GPE_P"_(_\ CE 71[+17C7_  OV
MW_Y\)?\ OR/_ (Y1_P +]M_^?"7_ +\C_P".4!='LM%>-?\ "_;?_GPE_P"_
M(_\ CE'_  OVW_Y\)?\ OR/_ (Y0%T>RT5XU_P +]M_^?"7_ +\C_P".4?\
M"_;?_GPE_P"_(_\ CE 71[+17C7_  OVW_Y\)?\ OR/_ (Y1_P +]M_^?"7_
M +\C_P".4!='LM%>-?\ "_;?_GPE_P"_(_\ CE'_  OVW_Y\)?\ OR/_ (Y0
M%T>RT5XU_P +]M_^?"7_ +\C_P".4?\ "_;?_GPE_P"_(_\ CE 71[+17C7_
M  OVW_Y\)?\ OR/_ (Y1_P +]M_^?"7_ +\C_P".4!='LM%>-?\ "_;?_GPE
M_P"_(_\ CE'_  OVW_Y\)?\ OR/_ (Y0%T>RT5XU_P +]M_^?"7_ +\C_P".
M4?\ "_;?_GPE_P"_(_\ CE 71[+17C7_  OVW_Y\)?\ OR/_ (Y1_P +]M_^
M?"7_ +\C_P".4!='LM%>-?\ "_;?_GPE_P"_(_\ CE'_  OVW_Y\)?\ OR/_
M (Y0%T>RT5XU_P +]M_^?"7_ +\C_P".4?\ "_;?_GPE_P"_(_\ CE 71[+1
M7G_@3XG1^-->ETZ*V>(Q6S3EFC"Y 95Q]\_WJ] H&>!?M _\C3I?_7D?_0S7
MDU>L_M _\C3I?_7D?_0S7DU!#W"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML6@ HKT?X3_#VW\6W%QJ6M9_LNS;88PVWSGQD@D<@ $$_4>]=A-XS^$MK?\
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MB6Y>#0]/EO'09<I@*GU8X _$U=USP#XG\.6?VK6-(E@MP<&57615^I0G'XT
M<[16GH?AW5O$EX;71+&6[E498)@!1[L< ?B:VO\ A5_C+^U!IYT207#1&8 S
M1A2H(!P^[;G+#C.>: .2HKH5\">(WTJ^U)-.#6NGO)'=.MQ&3$T?WP5W9X]A
M[U2T#PWJWBB_>RT*T-U<)&963>J84$#.6('4B@#+HJQ?64^FZA/97B!+BWD,
M<JAPVU@<$9!(//I5>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M52@S@]CQUKS+X@?$>]\<W$47D"TTZW<M% &W%FZ;F/KC\LGK6IXB^(>DZO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]>D:M_R;MH?_ &%W_E-0!YO1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!L^#O^1YT+_L)
M6_\ Z-6M;XJ?\E0UK_KJG_HM:R?!W_(\Z%_V$K?_ -&K6M\5/^2H:U_UU3_T
M6M =#D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /4?@%_P C[>_]@R3_ -&Q5]"U\]?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#?J/\ ^)H"S/E6BOJK_A6GAG_GPC_[]1__ !-'_"M/#/\ SX1_]^H__B:
MLSY5HKZJ_P"%:>&?^?"/_OU'_P#$T?\ "M/#/_/A'_WZC_\ B: LSY5HKZJ_
MX5IX9_Y\(_\ OU'_ /$T?\*T\,_\^$?_ 'ZC_P#B: LSY5HKZJ_X5IX9_P"?
M"/\ []1__$T?\*T\,_\ /A'_ -^H_P#XF@+,^5:*^JO^%:>&?^?"/_OU'_\
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MO^%:>&?^?"/_ +]1_P#Q-'_"M/#/_/A'_P!^H_\ XF@+,^5:*^JO^%:>&?\
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MX1_]^H__ (F@+,^5:*^JO^%:>&?^?"/_ +]1_P#Q-'_"M/#/_/A'_P!^H_\
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M?\*T\,_\^$?_ 'ZC_P#B: LSY5HKZJ_X5IX9_P"?"/\ []1__$T?\*T\,_\
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M:>&?^?"/_OU'_P#$T?\ "M/#/_/A'_WZC_\ B: LSY5HKZJ_X5IX9_Y\(_\
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M\(_^_4?_ ,31_P *T\,_\^$?_?J/_P")H"S/E6BOJK_A6GAG_GPC_P"_4?\
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M]1__ !-'_"M/#/\ SX1_]^H__B: LSY5HKZJ_P"%:>&?^?"/_OU'_P#$T?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_@;'_P#%4O\ PEWAO_H8-+_\#8_\:^6!3Q1[%=P^N2['U)_PEOAS_H8-+_\
M V/_ !H_X2SPY_T']+_\#8_\:^713Q3]@NXOKLNQ]0?\)9X=_P"@_I?_ (&1
M_P"-'_"5^'?^@]IG_@9'_C7S$*<*/8+N+Z[+L?3?_"5>'O\ H/:9_P"!D?\
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ME?\ 03L__ A?\:/[:TK_ *"=G_X$+_C7D%%'U5=P_M*?\IZ__;6E?]!.S_\
M A?\:/[:TK_H)V?_ ($+_C7D%%'U5=P_M*?\I[3#/%<0K+;RI+&W1T8,#VZB
MGUB>#O\ D4[/_@?_ *&U;=<<E:31[%.7/!2[H****DL**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<*44@I10 X4X4T4X4Q"BG"FBG"@0HIPIHIPH 44M(*6@0M**2E%,!PI:04M
MA:6DI: %H%% H 6EI*6F(444"B@!:*** "E%)2B@!:*** "BBB@#U'P=_P B
MG9_\#_\ 0VK;K$\'?\BG9_\  _\ T-JVZ\FI\;]3ZJA_!CZ+\@HHHJ#8****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKC&X?WNN>U5]>T?4?A%XGL)-,UY;MG/F-'%F-L#&5DCR1AL\<\X/I5@>#/\
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MW&IDX:VL=R?[^W"C_OHBN'\3^&IK']GJ*QA5C-;0Q74ZCJ26WR9]<;B?^ T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^S;2PA,<5NMKY@R<<_?&. !T[5WM% 6/+8OA/XEAA2*'XDZK''&H5$1) %
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MP]3GZ\5T=% SD8O OE:UXGO_ .T<_P!OP>3Y?D?ZCY"N<[OFZY[5 ?AM:3>
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M:!10* %I:2EIB%%% HH 6BBB@ I124HH 6BBB@ HHHH ]1\'?\BG9_\  _\
MT-JVZQ/!W_(IV?\ P/\ ]#:MNO)J?&_4^JH?P8^B_(****@V"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#LZ/\ A57_ %&?_)7_ .SI^VI]Q?4Z_P#+^*//A3A7H'_"J_\ J,?^2O\
M]G2_\*L_ZC'_ )*__9T>VI]P^IU_Y?Q1Y^*<*[__ (5;_P!1C_R5_P#LZ/\
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MH*,7&G&+W204445)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 452O--6\=&-U=0[5QB&7:#]:K_V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U
M#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_
M  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0
M_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P
M(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT52L],6SF,@
MNKJ;*XVS2[A]<5=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_ V/_P"*I?\ A+?#G_0P:7_X&Q_XU\K+4JT>Q7<7UR78^I/^$L\.?]!_2_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R_\7_^
M2L:Q_P!L/_1$=<<M=C\7_P#DK&L?]L/_ $1'7'+7;'X4>-5^-^I,M2K42U*M
M68LF6I5J):E6F22K4HJ):E%,DE6I5J):E6F(D6I%J-:D6F22"I%J,5(M,DD6
MI!4:U(*"1XJ05&*D%,0X4\4P4\4Q#Q3Q3!3Q0(<*<*:*<*!#Q2BD%**8APIP
MIHIPH 44X4T4X4Q!2BDI10 M%%% 'J/@[_D4[/\ X'_Z&U;=8G@[_D4[/_@?
M_H;5MUY-3XWZGU5#^#'T7Y!1114&P4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<G\2/%LG@
M[P?+?6H4WDSB"WW<A7()W$=\ $_7%=97EWQ[LII_!-I<Q+N2VO%,F!]T,K '
M\\#\:!,Y+0_A1K_C?2X]=UW7FA>[7S81,C3.RGH3\PV@]1C/&*M^%-9\0?#O
MXAP>$_$-V;JPNV5(RSEE7><(Z$\@9X(Z=?2O2OA_XBT[6_!.G-:7$9DMK5(K
MB(N-T3(H4Y'8<9SZ5Y?XWU&W\6?&S0[31)$N1:O#"\L9W*2)"[8(Z@#^1H$1
M>(OB:I^+-M>22WYT?2YBC6@"@EU#*S!=V#ST)/3TJU\0M9M+GXE>"-;9C!9R
MPVEV6FP#'&9M^6QGH.M7-<_Y.9TS_=C_ /134SXKVL5]\7_"MI<KOAN/(BD7
MU5IR"/R- '7:5\9/"NK:Y'ID+W<+2N(XIYX@L;L>@SDD9]P*WO%?C71O!MK'
M-K,S!YB?*@B7=))CK@>@SU)%>:?':VAM]4\+RP1)'(3*FY!CY5,6T?0;CCZU
M0^)$FIR_&^Q33[2&_N8XHOLEK=X\ISACCD@=<GJ.10.YZ1X5^*/AWQ=?_8;!
M[BVNR"4AND"F3')VD$@\<XSFH_$'Q5T#PUXAN-'U.*]6>",.TB1JR-E0P ^;
M.3D#I^G-<%J/A[XCZ[XQTK7;_P -65G<64R%I;2>)=ZAP?FS*V<<_@:EU2RA
MU#]IZV@N45X_DD*L,@E+?>/U44 >I^%?%%GXOT4:GIL%S# 9&C N4"L2.I&"
M1C\:\Q_:"C\V?PS'G&]KA<XZ9,5>T5XO^T%'YL_AF/.-[7"YQTR8J >QB^*/
M@Y)X2T&?6(?$T;O;#<$>#R"WLK;S\WH*['P9\1?[/^$T>M>)?M5Y]FNC:%X@
M'D<<%2=Q&>N,Y[5DP_L\Q+(#/XE=T[JED%)_$N?Y5I?%'0K'PU\'(]+TJ,I;
MPW,>"QRS$DDLQ[DF@1OZ#\5M!\1Z_;Z1I<%_)//&) YA4(GR[B&.[((Z'C&>
MA-0:Y\9/"NAZE)9,UU?2Q-MD:SC5E4]QEF&?PS1X7A;3/@6CZ6FRX_LJ6X0H
M,$RE&8'ZYQ6'\!;+3G\*:A<B..2]>Z,<S, 6$>U=J_0Y;Z\T#._\,^+=(\76
M#76BW/FB,@2QNNUXB>@8?UZ5S>J_&;PII.L/I[O=7+1OLDGMH@T:$=>2P)Q[
M UP>B%M,^+GBZW\-C;;+971*1?=1@H(QZ8DX'ITK<^ 5G82^&M5G:..2\>Z\
MJ7<H)\K8-H^A)?ZXH [3P]\1-%\3^)+G1M)%Q));PF<W!5?*D4%1\I#9_C'4
M#O6%-\<?"]N;E9;?4A);R^48_)3=(<D$K\^,#;SDCJ*YCX70VEM\;O$D.FA!
M:1PW*Q!#E0HGCP![4?!:TAE\>^([J1%:6#*QL1]W=(<X_P"^: N>@:[\2]!\
M.Z78WFI?:@]]$)H;5(P9MA[D$@+^)_D:;X4^)_A[QA?FQT\W-O=[2RPW484N
M!UP5)''IFN?\3ZOI"?%2"VTCPT=:\4PQC;++=F*.'Y"PX)*DA3GH.O!S7,:,
M=0/[25JVL6]G;7KAVEBLV+(I-JW<]3C&?>@#N;SXR>&+#4-2LKQ+Z*;3YFA8
M&)3YS*Q4A,-[$Y..*+/XS^$;K2;B^>>XMC 0#;31 2OGIM )!Z>O'?%<A\.[
M&WNOCKXIFN(ED>VFNGBW#.QC<8W#WP2/QJ/PKIUF_P"T5J\;6\92!IY8T*C"
MOQR!_P "- :GHOA#XCZ%XTN);;2S<0W,2[S!<H%9ESC(P2#U'?O69K?QF\+:
M)JDUBWVR]EA<I(UK$I56'!&69<X]JY3P_$D/[2VII"BQIB4[5&!DQJ3^M)_P
MA7CSP'K%_=^#OLVHV=TQ9D94+E<D@,&P<C/\)Y_D >E^%/&VC>,K:671IGWP
MD"6&9=LB9Z''/'N*Z"O-_ACXU&LZEJ&AWNA6VCZE:@R2I:Q>6CX8*V5Z@AF]
M3UKTB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[C_F._\ DG_]G3A\'\?\QS_R4_\ LZ/;0[B^J5_Y?R/-UJ05Z,/A%C_F-_\
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M^%<_]13_ ,E__LJ7_A77_44_\E__ +*CV]/N'U'$?R_BCB:*[;_A77_44_\
M)?\ ^RH_X5U_U%/_ "7_ /LJ/;T^X?4<1_+^*-OP=_R*=G_P/_T-JVZI:/IW
M]DZ3#9>;YWE;OGV[<Y8GID^M7:\Z;3DVCZ"C%QIQB]TD%%%%2:!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 452O--6\=&-U=0[5QB&7:#]:K_V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I
M_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4 :M%97
M]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E?V"G_00U#_P(_P#K4?V"
MG_00U#_P(_\ K4 :M%97]@I_T$-0_P# C_ZU']@I_P!!#4/_  (_^M0!JT5E
M?V"G_00U#_P(_P#K4?V"G_00U#_P(_\ K4"-6BLK^P4_Z"&H?^!'_P!:C^P4
M_P"@AJ'_ ($?_6H U:*RO[!3_H(:A_X$?_6H_L%/^@AJ'_@1_P#6H&:M%97]
M@I_T$-0_\"/_ *U']@I_T$-0_P# C_ZU &K165_8*?\ 00U#_P "/_K4?V"G
M_00U#_P(_P#K4 :M%97]@I_T$-0_\"/_ *U']@I_T$-0_P# C_ZU &K165_8
M*?\ 00U#_P "/_K4?V"G_00U#_P(_P#K4 :M%97]@I_T$-0_\"/_ *U']@I_
MT$-0_P# C_ZU &K165_8*?\ 00U#_P "/_K4?V"G_00U#_P(_P#K4 :M%97]
M@I_T$-0_\"/_ *U']@I_T$-0_P# C_ZU &K15*STQ;.8R"ZNILKC;-+N'UQ5
MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R[SQ/H.G
MW;VNH:WIMK<1XWPSW<:.N1D9!.1P0?QJ'_A,_"__ $,FD?\ @=%_\57SS\7_
M /DK&L?]L/\ T1'7'+6ZI)JYPSQ4HR:L?7'_  F/AC_H8])_\#HO_BJ/^$P\
M,_\ 0Q:3_P"!T?\ \57R:M2K5>Q7<CZY+L?5W_"7^&_^AATK_P #8_\ XJE_
MX2WPY_T,&E_^!L?^-?*RU*M'L5W%]<EV/J3_ (2SPY_T']+_ / V/_&E_P"$
MK\._]![3/_ R/_&OE]:E%/V"[B^NR['TY_PE7A[_ *#NF?\ @9'_ (T?\)3X
M?_Z#NF_^!D?^-?-"U*M/V"[B^O2['TG_ ,)1H'_0<TW_ ,"X_P#&C_A)]!_Z
M#>G?^!<?^-?."U(M'U==R?K\NQ]&?\)-H7_0:T[_ ,"T_P :/^$ET+_H-:?_
M .!2?XU\[BI%I_5UW#Z_+^4^A?\ A)-#_P"@SI__ (%)_C1_PD>B?]!G3_\
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M +<TG_H*6?\ X$)_C1_;FD_]!.S_ / A/\:\:%.%'U9=P_M*?\I['_;>E?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !111F@ HI,TN: "BDS2YH **3<*0
MN!0*Z'4A-5KC4K2U!-Q/''CD[F K'N_&VBVW NA,WI$I;]>E7&G.6R,95Z4-
MY'09HS7"W?Q(A7_CSL9']Y6"_H,TQ_%6H16']IZY<P:1IR],)F2;V4'-:/#U
M$KLP6-I-VBSOLTM8_AO5)-9T2*_>!K>.;YH4D.7*=BWN>M;%8-6=CLB^97"B
MBB@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%&NU$4*H'8"IJYO5O'?A[0M2^P:IJ AN< ^7L8]>G05NM=1I!YSN%C"[BQX
M&,YKP7&74^EC.-K7)Z*Y*'XF^%;B]6TM]3$L[OL1$B<[CTP.*=<_$;P_:>)5
MT*>[*WA8(3L^16/\);L:?LY=A>UAW.KHIF\^U*&S4&ET.HI,T9H&+1110 44
M44 %%%% !1110 4444 %%%% !7*?$CQ9)X/\'RW]J%-W*X@M]PR [ G<1WP
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MI^G-<+-X=^(>L>/M(\0ZCX:LK*6TFC\U[2>-0Z!\DL#*Q)P2..<4^6RM[_\
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MA&VO;E=EY&3!=)C&V5.&^F>#^-)X#U[3_$/A2&[TK3UTV)':)[1%"K$X/(&
M!WST'6N?^%AVZIXRBB_X]DUN;R@/N_>/3\ M 'HE%%% SY?^+_\ R5C6/^V'
M_HB.N.6NQ^+_ /R5C6/^V'_HB.N.6NV/PH\:K\;]29:E6HEJ5:LQ9,M2K42U
M*M,DE6I142U**9)*M2K42U*M,1(M2+4:U(M,DD%2+48J1:9)(M2"HUJ04$CQ
M4@J,5(*8APIXI@IXIB'BGBF"GB@0X4X4T4X4"'BE%(*44Q#A3A313A0 HIPI
MHIPIB"E%)2B@!:*** /4?!W_ "*=G_P/_P!#:MNL3P=_R*=G_P #_P#0VK;K
MR:GQOU/JJ'\&/HOR"BBBH-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4XV2,9U)5'=FIX;T67Q#XBM--A!S-( Q ^ZHZG\J^J[&TAL;&&UMD"10H$0
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M=_VVV2W^S>5C9MV\[L\_=Z8'6NBHH \Q^(<EC_PG.DI=W4OAZ[6W9K/7T8%
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M4$CQ4@J,5(*8APIXI@IXIB'BGBF"GB@0X4X4T4X4"'BE%(*44Q#A3A313A0
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M#Q_K_BN&\>S6VT_[LJ3P;(0F>P/);_/2O9\#K2@ 5;Q+:LUJ3'!1C*Z8@&
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M_)?_ .RI?^%<_P#44_\ )?\ ^RI^WI]Q?4<1_+^*.(I17;?\*Y_ZBG_DO_\
M94O_  KK_J*?^2__ -E1[>GW#ZCB/Y?Q1Q-%=M_PKK_J*?\ DO\ _94?\*Z_
MZBG_ )+_ /V5'MZ?</J.(_E_%&WX._Y%.S_X'_Z&U;=4M'T[^R=)ALO-\[RM
MWS[=N<L3TR?6KM>=-IR;1]!1BXTXQ>Z2"BBBI- HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #28I:* $Q1BEHH 3%-9
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M]:@#5HK*_L%/^@AJ'_@1_P#6H_L%/^@AJ'_@1_\ 6H U:*RO[!3_ *"&H?\
M@1_]:C^P4_Z"&H?^!'_UJ -6BLK^P4_Z"&H?^!'_ -:C^P4_Z"&H?^!'_P!:
M@#5HK*_L%/\ H(:A_P"!'_UJ/[!3_H(:A_X$?_6H U:*RO[!3_H(:A_X$?\
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M&H?^!'_UJ -6BLK^P4_Z"&H?^!'_ -:C^P4_Z"&H?^!'_P!:@#5HK*_L%/\
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M'_UJ/[!3_H(:A_X$?_6H U:*RO[!3_H(:A_X$?\ UJ/[!3_H(:A_X$?_ %J
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M ($?_6H_L%/^@AJ'_@1_]:@#5HK*_L%/^@AJ'_@1_P#6H_L%/^@AJ'_@1_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779907232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 06, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alpine Immune Sciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALPN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001626199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,561,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778067984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,711<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">41,592<span></span>
</td>
<td class="nump">73,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">53,545<span></span>
</td>
<td class="nump">82,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">54,873<span></span>
</td>
<td class="nump">85,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,716<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">4,277<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent, current portion</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">2,048<span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,127<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, long-term portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">2,155<span></span>
</td>
<td class="nump">4,039<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,282<span></span>
</td>
<td class="nump">6,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, $0.001 par value per share; 10,000,000 shares authorized at December 31, 2018 and 2017; zero shares issued and outstanding at December 31, 2018 and 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value per share; 200,000,000 shares authorized at December 31, 2018 and 2017; 13,904,672 shares issued and 13,854,205 shares outstanding at December 31, 2018; 13,881,645 shares issued and 13,831,178 shares outstanding at December 31, 2017</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 50,467 shares at December 31, 2018 and 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">90,664<span></span>
</td>
<td class="nump">88,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(46,074)<span></span>
</td>
<td class="num">(9,384)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">44,591<span></span>
</td>
<td class="nump">78,917<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and stockholders&#8217; equity</a></td>
<td class="nump">$ 54,873<span></span>
</td>
<td class="nump">$ 85,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 305<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84242212&amp;loc=d3e2352-115587<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779974608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">13,904,672<span></span>
</td>
<td class="nump">13,881,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">13,854,205<span></span>
</td>
<td class="nump">13,831,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">50,467<span></span>
</td>
<td class="nump">50,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6767691552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">$ 1,731<span></span>
</td>
<td class="nump">$ 2,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">28,970<span></span>
</td>
<td class="nump">10,626<span></span>
</td>
<td class="nump">2,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,362<span></span>
</td>
<td class="nump">6,079<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Loss on sale of intangible asset</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">38,535<span></span>
</td>
<td class="nump">16,705<span></span>
</td>
<td class="nump">4,138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(37,830)<span></span>
</td>
<td class="num">(14,974)<span></span>
</td>
<td class="num">(1,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount', window );">Bargain purchase gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,601<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(319)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">542<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="num">(36,853)<span></span>
</td>
<td class="num">(7,983)<span></span>
</td>
<td class="num">(1,166)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Basic and diluted net loss attributable to common stockholders</a></td>
<td class="num">(36,487)<span></span>
</td>
<td class="num">(7,783)<span></span>
</td>
<td class="num">(1,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">46<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (36,441)<span></span>
</td>
<td class="num">$ (7,842)<span></span>
</td>
<td class="num">$ (1,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute basic and diluted net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">13,849,470<span></span>
</td>
<td class="nump">6,481,665<span></span>
</td>
<td class="nump">564,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (2.63)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6571-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6387-128476<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6396-128476<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6527-128477<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6393-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6781825408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance, convertible preferred stock, shares (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,212,436<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance, convertible preferred stock at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 610<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares issued (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2015</a></td>
<td class="num">$ (352)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,099,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple', window );">Net loss</a></td>
<td class="num">(1,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance, convertible preferred stock, shares (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,311,770<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance, convertible preferred stock at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,535<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares issued (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608,701<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2016</a></td>
<td class="num">(1,457)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,989,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,301,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (49,201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,301,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="nump">49,201<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination', window );">Common stock acquired in business combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,914,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_StockAcquiredDuringPeriodValueInBusinessCombination', window );">Common stock acquired in business combination</a></td>
<td class="nump">38,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_AdjustmentOfParValue', window );">Adjustment of par value from $0.0001 per share to $0.001 per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity', window );">Conversion of warrant liability to equity</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare', window );">Exercise of stock options and common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_ExerciseOfStockOptionsAndCommonStockWarrants', window );">Exercise of stock options and common stock warrants</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,467<span></span>
</td>
<td class="nump">50,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple', window );">Net loss</a></td>
<td class="num">$ (7,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance, convertible preferred stock, shares (in shares) at Dec. 31, 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance, convertible preferred stock at Dec. 31, 2017</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares issued (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,831,178<span></span>
</td>
<td class="nump">50,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">78,917<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">88,346<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(9,384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple', window );">Net loss</a></td>
<td class="num">$ (36,487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance, convertible preferred stock, shares (in shares) at Dec. 31, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance, convertible preferred stock at Dec. 31, 2018</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares issued (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,854,205<span></span>
</td>
<td class="nump">50,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 44,591<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 90,664<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="num">$ (46,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_AdjustmentOfParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment of par value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_AdjustmentOfParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital conversion of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_ExerciseOfStockOptionsAndCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of stock options and common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_ExerciseOfStockOptionsAndCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of stock options and common stock warrants share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_ExerciseOfStockOptionsAndCommonStockWarrantsShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_StockAcquiredDuringPeriodSharesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock acquired during period shares in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_StockAcquiredDuringPeriodSharesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_StockAcquiredDuringPeriodValueInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock acquired during period value in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_StockAcquiredDuringPeriodValueInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_TemporaryEquitySharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity shares conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_TemporaryEquitySharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_TemporaryEquityValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity value conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_TemporaryEquityValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income or Loss from continuing operations, net of taxes, including net Income or Loss from discontinued operations but before extraordinary items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933606192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6780135840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (36,487)<span></span>
</td>
<td class="num">$ (7,783)<span></span>
</td>
<td class="num">$ (1,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Loss on sale of intangible asset</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount', window );">Bargain purchase gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,601)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium/discount on investments</a></td>
<td class="num">(669)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax</a></td>
<td class="num">(305)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation and warrant expense</a></td>
<td class="nump">2,309<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">66<span></span>
</td>
<td class="num">(1,193)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,523<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(480)<span></span>
</td>
<td class="num">(1,731)<span></span>
</td>
<td class="num">(2,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">3,895<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities', window );">Deferred rent and other</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(28,416)<span></span>
</td>
<td class="num">(16,572)<span></span>
</td>
<td class="num">(3,797)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(495)<span></span>
</td>
<td class="num">(586)<span></span>
</td>
<td class="num">(782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible asset</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of short-term investments</a></td>
<td class="num">(72,863)<span></span>
</td>
<td class="num">(88,307)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Maturities of short-term investments</a></td>
<td class="nump">105,226<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from the sale of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,960<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash and cash equivalents acquired in connection with merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,130<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">32,118<span></span>
</td>
<td class="num">(29,803)<span></span>
</td>
<td class="num">(782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from sale of preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,666<span></span>
</td>
<td class="nump">10,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options and common stock warrants</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(991)<span></span>
</td>
<td class="nump">42,688<span></span>
</td>
<td class="nump">10,975<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="num">(3,687)<span></span>
</td>
<td class="nump">6,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">8,132<span></span>
</td>
<td class="nump">11,819<span></span>
</td>
<td class="nump">5,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, end of period</a></td>
<td class="nump">10,843<span></span>
</td>
<td class="nump">8,132<span></span>
</td>
<td class="nump">11,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Convertible preferred stock exchanged for common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">49,201<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_IssuanceOfDebtDiscount', window );">Discount in connection with issuance of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity', window );">Reclass of preferred stock warrant liability to equity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Deferred Rent And Other Operating Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_IncreaseDecreaseInDeferredRentAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_IssuanceOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of debt, discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_IssuanceOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of preferred stock warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_ReclassificationOfPreferredStockWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6571-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6387-128476<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6396-128476<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6527-128477<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6393-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6771012480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alpine Immune Sciences, Inc. (the &#8220;Company&#8221;, &#8220;Alpine&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, or &#8220;our&#8221;), together with its consolidated subsidiaries, is focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory disorders, and other diseases. Our proprietary scientific platform uses a process known as directed evolution, or an iterative scientific engineering process purposefully conducted to &#8220;evolve&#8221; a protein to create multi-targeted therapeutics potentially capable of modulating the human immune system. In our&#160;pre-clinical&#160;animal studies, our platform has proven capable of identifying novel molecules, including single domains capable of modulating multiple targets. We were incorporated under the laws of the State of Delaware and are headquartered in Seattle, Washington.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Merger and Subscription Agreement</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April&#160;18, 2017, we entered into a merger agreement with Nivalis Therapeutics, Inc. (&#8220;Nivalis&#8221;), a public biotechnology company, and one of its wholly-owned subsidiaries pursuant to which, the subsidiary merged with and into Alpine, with Alpine continuing as a wholly owned subsidiary of Nivalis and the surviving corporation of the merger (the &#8220;Merger Agreement&#8221;). Nivalis Therapeutics, Inc. was incorporated in Delaware in March 2007.&#160;Alpine Immune Sciences, Inc. (prior to its business combination with Nivalis Therapeutics, Inc.) was incorporated in Delaware on December 30, 2014.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. At the closing of the merger, each outstanding share of our capital stock (common stock and preferred stock) was converted into the right to receive shares of Nivalis common stock (subject to the payment of cash in lieu of fractional shares and after giving effect to a 1:4 reverse stock split of Nivalis common stock) such that, immediately following the effective time of the merger, preexisting Nivalis stockholders, optionholders, and warrantholders owned, or held rights to acquire, approximately </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;"> of the fully-diluted common stock of Nivalis, which changed its name to &#8220;Alpine Immune Sciences, Inc.&#8221; following the completion of the merger and Alpine&#8217;s preexisting stockholders, optionholders, and warrantholders owned, or held rights to acquire approximately </font><font style="font-family:inherit;font-size:10pt;">74%</font><font style="font-family:inherit;font-size:10pt;"> of the fully-diluted common stock of Nivalis. The issuance of the shares to our pre-existing stockholders was registered under the Securities Act of 1933, as amended, pursuant to a registration statement on Form S-4 (No. 333-218134) (the &#8220;Registration Statement&#8221;) declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on June 6, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contemporaneously with the execution and delivery of the Merger Agreement, certain of our pre-existing stockholders entered into a subscription agreement with us pursuant to which such stockholders purchased, immediately prior to the closing of the merger, </font><font style="font-family:inherit;font-size:10pt;">1,335,118</font><font style="font-family:inherit;font-size:10pt;"> shares of our capital stock at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$12.74</font><font style="font-family:inherit;font-size:10pt;"> per share for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$17.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The merger and the subscription described above were consummated on </font><font style="font-family:inherit;font-size:10pt;">July&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770833200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC and generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates inherent in the preparation of the accompanying consolidated financial statements include accruals for clinical trial activities and other accruals, and the estimated fair value of equity-based awards. We base our estimates and assumptions on historical experience when available and on various factors we believe to be reasonable under the circumstances. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include the financial position and results of operations of Alpine and our wholly owned operating company and subsidiaries, AIS Operating Co., Inc., and Alpine Immune Sciences Australia PTY LTD. On </font><font style="font-family:inherit;font-size:10pt;">July&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">, we closed the merger on the terms described in more detail in </font><a style="font-family:inherit;font-size:10pt;" href="#sD31BE121D5B120F8794C31F4AFBEEF04"><font style="font-family:inherit;font-size:10pt;">Note 1</font></a><font style="font-family:inherit;font-size:10pt;">. In connection with the merger, Nivalis effected a&#160;1:4&#160;reverse stock split of its common stock. Upon the closing of the merger, (1)&#160;a wholly-owned subsidiary of Nivalis merged with and into Alpine, with Alpine (renamed as &#8220;AIS Operating Co., Inc.&#8221;) remaining as the surviving entity; and (2)&#160;Nivalis was renamed as &#8220;Alpine Immune Sciences, Inc.&#8221;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segments</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate as&#160;</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#160;operating segment and use cash flow as the primary measure to manage our business.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted cash</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consider all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking and interest-bearing accounts, and highly liquid money market funds.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash represents cash drawn on a line of credit used to establish collateral to support the security deposit on our operating lease to rent office and laboratory space in Seattle, Washington.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Periodically, we maintain deposits in financial institutions in excess of government insured limits. We believe we are not exposed to significant credit risk as our deposits, which are held at financial institutions, are high credit quality securities such as money market funds, U.S. Treasury securities, and commercial paper. To date, we have not realized any losses on these deposits.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our short-term investments include funds invested in highly liquid money market funds, U.S. Treasury securities, commercial paper, and corporate debt securities with a final maturity of each security of less than one year. All investments are classified as available-for-sale securities and are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses excluded from earnings and reported in other comprehensive income (loss). Purchase premiums and discounts are recognized as interest income using the interest method over the terms of the securities. Realized gains and losses and declines in fair value deemed to be other than temporary are reflected in the </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;"> using the specific-identification method.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years, while leasehold improvements are amortized over the shorter of their estimated useful lives or the related lease term. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Maintenance and repairs are expensed as incurred. Major improvements are capitalized as additions to property and equipment.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Asset</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intangible asset is our indefinite-life S-nitrosoglutathione reductase (&#8220;GSNOR&#8221;) inhibitor in-process research and development asset (&#8220;IPR&amp;D&#8221;) acquired from Nivalis. The IPR&amp;D represents the processes, expertise, and technology employed in the development of GSNOR inhibitors and Nivalis&#8217; lead product candidate, cavosonstat. The IPR&amp;D represents the estimated fair value as of the acquisition date of substantive&#160;in-process&#160;projects that have not reached technological feasibility. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-lived Assets</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate our long-lived tangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If the carrying value exceeds the undiscounted future cash flows estimated to result from the use and eventual disposition of the asset, we write down the asset to its estimated fair value. Impairment is assessed by comparing the undiscounted cash flows expected to be generated by the asset to its carrying value. We did not record any impairments in the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate accruals for professional services and research and development expenses. This process involves reviewing contracts and vendor agreements and communicating with applicable personnel to identify services that have been performed on our behalf. We estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We estimate accrued liabilities as of each balance sheet date based on known facts and circumstances.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, we have not experienced any significant adjustments to our estimates.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases and Deferred Rent</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into lease agreements for office and laboratory space. These leases are classified as operating leases. Rent payments, rent-free periods and rent increases are recognized as rent expense on a straight-line basis over the lease term. The difference between rent expense recognized and rental payments is recorded as deferred rent in the accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We granted common stock warrants to certain&#160;non-employee&#160;professional advisers. We account for our warrants at fair value, with changes in fair value recognized in operating expenses. Common stock warrants are initially recorded at their issuance date fair value and are subsequently remeasured at each balance sheet date. These warrants are valued using the Black-Scholes option pricing model based on the estimated market value of the underlying common stock at the valuation measurement dates, the remaining contractual term of the warrant, risk-free interest rates, expected dividends, and expected volatility of the price of the underlying common stock.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative Financial Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate all of our financial instruments, including issued&#160;stock purchase warrants, to determine if such instruments are derivatives or contain&#160;features qualifying as embedded derivatives.&#160;For derivative financial instruments accounted for as liabilities, the derivative instrument&#160;is initially recorded at its fair value and is then re-valued at each reporting date, with changes in&#160;the fair value reported in the </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">. We use the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. We do not use derivative instruments to hedge exposures to cash flow, market, or&#160;foreign currency risks.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition (effective January 1, 2018)</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our steps for recognizing revenue consist of;&#160;(1) identifying the contract,&#160;(2) identifying the performance obligations as either distinct or bundled goods and services,&#160;(3) determining the transaction price associated with each performance obligation for which we expect to be entitled in exchange for transferring such goods and services,&#160;(4) allocating the transaction price to the performance obligations in the contract and&#160;(5) recognizing revenue upon satisfaction of performance obligations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our collaboration agreements principally contain multiple performance obligations, which may include (1)&#160;grants of, or options to obtain, intellectual property licenses; (2)&#160;research and development services; and/or (3) manufacturing or supply services. Payments typically received under these arrangements include one or more of the following: non-refundable upfront license fees, option exercise fees, payment for research and/or development efforts, amounts due upon the achievement of specified objectives, and/or royalties on future product sales. Our revenue is primarily derived from our License and Research Agreement (the &#8220;Collaboration Agreement&#8221;) with Kite Pharma, a Gilead company (&#8220;Kite&#8221;). See further discussion of the Collaboration Agreement in </font><a style="font-family:inherit;font-size:10pt;" href="#s8A49DD14B58EDD54C86131F4B9EFCB92"><font style="font-family:inherit;font-size:10pt;">Note 12</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We allocate revenue to each performance obligation based on its relative stand-alone selling price. We generally determine stand-alone selling prices at the inception of the contract based on our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;"> and recognized as revenue when the related revenue recognition criteria are met. We recognize revenue under the Collaboration Agreement based on employee hours contributed to each performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Collaboration Agreement provides for non-refundable milestone payments. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to us for such milestone (1)&#160;is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance; (2)&#160;relates solely to our past performance; and (3)&#160;is reasonable relative to all of the other deliverables and payments within the arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial, and other risks that must be overcome to achieve the milestone, the level of effort and investment required to achieve the milestone and whether any portion of the milestone consideration is related to future performance or deliverables.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We review the contributed employee hours for each performance obligation under the Collaboration Agreement and adjust the revenue recognized to reflect changes in assumptions relating to the estimated satisfaction of the performance obligation. We could accelerate revenue recognition in the event of early termination of programs or if our expectations change. Alternatively, we could decelerate revenue recognition if programs are extended or delayed. While such changes to our estimates have no impact on our reported cash flows, the timing of revenue recorded in future periods could be materially impacted.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 2 included in our Annual Report on </font><a style="font-family:inherit;font-size:10pt;" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-10k_20171231.htm"><font style="font-family:inherit;font-size:10pt;">Form 10-K for the year ended December 31, 2017</font></a><font style="font-family:inherit;font-size:10pt;"> for more discussion regarding the accounting policies that governed revenue recognition prior to January 1, 2018.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred. Research and development costs include personnel costs, clinical trials, external contract research and development expenses, raw materials, drug product manufacturing costs and allocated overhead &#8211; including depreciation, rent and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for all stock-based compensation granted to employees and&#160;non-employees&#160;using a fair value method. Stock-based compensation awarded to employees and&#160;non-employees&#160;is measured at the grant date fair value for stock option grants. We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. Stock-based compensation to employees is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis. Stock-based compensation awarded to&#160;non-employees&#160;is revalued over its vesting period using a Black-Scholes option pricing model. For performance-based awards where the vesting of the options may be accelerated upon the achievement of certain milestones, vesting and the related stock-based compensation is recognized as an expense when it is probable the milestone will be met. We recognize forfeiture of awards as they occur rather than estimating the expected forfeiture rate.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When awards are modified, we compare the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the consolidated financial statement and tax bases of assets and liabilities at the applicable enacted tax rates. We will establish a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefits or that future deductibility is uncertain.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize the tax benefit from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax position is measured based on the largest benefit that has a greater than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> likelihood of being realized upon ultimate settlement. We recognize interest and penalties related to income tax matters in income tax expense if incurred. In December 2017, the SEC issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118 to address the application of GAAP in situations in which a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Cuts and Jobs Act (the &#8220;Tax Reform Act&#8221;) which was signed into law on December 22, 2017. In March 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-05, which amended ASC 740 to incorporate the requirements of SAB 118. We recognized the provisional tax impacts of the Tax Reform Act in the fourth quarter of 2017. Our federal tax loss and research and development credit carryforwards have been updated from the amounts previously provisionally disclosed to reflect a change in position with respect to our 2017 federal research and development credit. The update is a result of additional time spent on modeling the potential use of our tax attributes, as impacted by the Tax Reform Act. Otherwise, during the year ended December 31, 2018, we did not receive any additional information regarding these provisional calculations, except as disclosed in </font><a style="font-family:inherit;font-size:10pt;" href="#s2FF5B04E48A0D29197CD31F4BBF8E887"><font style="font-family:inherit;font-size:10pt;">Note 14, Income Taxes</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) is comprised of net loss and certain changes in equity excluded from net loss. For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, other comprehensive loss consisted of unrealized losses on our short-term investments. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> difference between comprehensive loss and net loss for the year ended December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU&#160;No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606. This ASU clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. This ASU is effective for public companies for annual reporting periods and interim periods within those annual periods beginning after December 15, 2019. We are currently evaluating the effect, if any, that ASU 2018-18 will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In&#160;August 2018,&#160;the FASB issued ASU&#160;No.&#160;2018-13,&#160;Fair Value Measurement. ASU&#160;2018-13&#160;modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted for any eliminated or modified disclosures. We are evaluating the effect of adopting this new accounting guidance to determine the impact it may have on our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU No.&#160;2018-07, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. Upon transition, nonemployee awards will be required to be measured at fair value as of the adoption date with a cumulative-effect adjustment recognized in retained earnings as of the beginning of the annual period of adoption. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity&#8217;s adoption date of ASC 606. We are evaluating the effect the standard will have on our financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No.&#160;2016-02, Leases. ASU 2016-02 requires a lessee to separate the lease components from the non-lease components in a contract and recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. It also aligns lease accounting for lessors with the revenue recognition guidance in ASU 2014-09. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years, and is to be applied at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU 2018-11, related to another transition method in lease accounting. If elected, the transition method allows entities to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We plan to adopt ASU 2016-02 on January 1, 2019 and intend to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of the accumulated deficit in the period of adoption as permitted under ASU 2018-11. Based on our leases in place on January 1, 2019 and considering the practical expedients, we expect the adoption of the new standard will not have a material effect on our consolidated statements of operations, will result in a gross-up on our consolidated balance sheets of less than </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> relating to our office and laboratory leases, and will have no effect on our consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09, Revenue from Contracts with Customers, as amended (&#8220;new revenue standard&#8221; or &#8220;ASC 606&#8221;), which amends the guidance for revenue recognition to replace numerous industry specific requirements. ASC 606 implements a five-step process for customer contract revenue recognition focusing on transfer of control, as opposed to transfer of risk and rewards. ASC 606 also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include ensuring the time value of money is considered in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. ASC 606 is effective for reporting periods beginning after December&#160;15, 2017. On January 1, 2018, we adopted the new accounting standard and all of the related amendments using the modified retrospective method. We recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of our accumulated deficit. The cumulative effect of the changes related to the adoption of the new revenue standard increased our beginning balances in accumulated deficit and deferred revenue by </font><font style="font-family:inherit;font-size:10pt;">$203,000</font><font style="font-family:inherit;font-size:10pt;"> within our </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Collaboration Agreement with Kite is the only contract that was impacted by the adoption of the new revenue standard. Prior to the adoption of the new revenue standard, we recognized revenue under the Collaboration Agreement based upon the estimated performance periods related to the non-refundable upfront payments we received from Kite. Under the new standard, we recognize revenue based on employee hours contributed to each performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated financial statements as of and for the year ended December 31, 2018 is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance without Adoption of ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,074</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,277</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,487</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Statement of Cash Flows</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15 which provides new guidance on the classification of certain cash receipts and payments in the statement of cash flows. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We adopted this new standard effective January 1, 2018. The adoption of this standard did not impact our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09 to provide clarity and reduce both diversity in practice and cost and complexity when applying the guidance in Compensation - Stock Compensation (&#8220;Topic 718&#8221;) about a change to the terms and conditions of a share-based payment award. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this update are effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted and applied prospectively to modifications occurring on or after the adoption date. We adopted this this standard effective January 1, 2018. The adoption of this standard did not have an impact on our financial statements.&#160;For the year ended December 31, 2018, there were no modifications to the terms or conditions of a share-based payment award.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770873792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Combination</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">July&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">, we closed the merger on the terms described in more detail in </font><a style="font-family:inherit;font-size:10pt;" href="#sD31BE121D5B120F8794C31F4AFBEEF04"><font style="font-family:inherit;font-size:10pt;">Note 1</font></a><font style="font-family:inherit;font-size:10pt;">. In connection with the merger, Nivalis effected a </font><font style="font-family:inherit;font-size:10pt;">1:4 reverse stock split</font><font style="font-family:inherit;font-size:10pt;"> of its common stock. Upon the closing of the merger, (1) a wholly-owned subsidiary of Nivalis merged with and into Alpine, with Alpine (renamed as &#8220;AIS Operating Co., Inc.&#8221;) remaining as the surviving entity; and (2) Nivalis was renamed as &#8220;Alpine Immune Sciences, Inc.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Merger Agreement, Nivalis issued shares of its common stock to Alpine&#8217;s stockholders, at an exchange rate of </font><font style="font-family:inherit;font-size:10pt;">0.4969</font><font style="font-family:inherit;font-size:10pt;"> shares of Nivalis common stock, after taking into account the 1:4 reverse stock split, for each share of Alpine&#8217;s common stock and preferred stock outstanding immediately prior to the merger. The exchange rate was determined through arms-length negotiations between Nivalis and Alpine. Nivalis also assumed all of the stock options outstanding under Alpine&#8217;s Amended and Restated 2015 Stock Plan, as amended (the &#8220;Alpine Plan&#8221;), and stock warrants for Alpine&#8217;s capital stock outstanding immediately prior to the merger, with such stock options and warrants henceforth representing the right to purchase a number of shares of the Nivalis common stock equal to </font><font style="font-family:inherit;font-size:10pt;">0.4969</font><font style="font-family:inherit;font-size:10pt;"> multiplied by the number of shares of Alpine&#8217;s common stock or preferred stock previously represented by such options and warrants. Nivalis also assumed the Alpine Plan. Immediately after the merger, there were </font><font style="font-family:inherit;font-size:10pt;">13,881,645</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock outstanding. Immediately after the merger, Alpine&#8217;s former stockholders, warrantholders, and optionholders owned, or held rights to acquire, approximately </font><font style="font-family:inherit;font-size:10pt;">74%</font><font style="font-family:inherit;font-size:10pt;"> of the fully-diluted common stock of Nivalis, which for these purposes is defined as the outstanding common stock of Nivalis, plus &#8220;in the money&#8221; options and warrants to purchase shares of Nivalis&#8217; common stock, assuming all &#8220;in the money&#8221; options and warrants of Nivalis outstanding immediately prior to the merger are exercised on a cashless basis immediately prior to the closing of the merger, with Nivalis&#8217; stockholders, optionholders, and warrantholders immediately prior to the merger owning, or holding rights to acquire, approximately </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;"> of the fully diluted common stock of Nivalis. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The issuance of shares of Nivalis&#8217; common stock to our pre-existing stockholders was registered with the SEC pursuant to the Registration Statement. Immediately prior to the merger, we issued and sold an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$17.0 million</font><font style="font-family:inherit;font-size:10pt;"> of shares of our capital stock to certain existing stockholders. For accounting purposes, our historical financial statements were not adjusted to reflect the merger, other than adjustments to the capital structure to reflect the historical capital structure of Nivalis. No other adjustments to our historical assets and liabilities were made as a result of the merger.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the operating assets and liabilities of Nivalis, we also acquired Nivalis&#8217; tax attributes, which primarily consisted of net operating losses which begin to expire in 2032. Our ability to utilize the tax attributes of Nivalis may be limited under Section 382 of the U.S. Internal Revenue Service and as such, have been reserved. We recorded a deferred tax liability related to future tax benefits arising from IPR&amp;D acquired in the Merger. The combined organization is focusing on the development and commercialization of our innovative immunotherapies. Following the merger, the increased cash resources and increased access to capital of the combined organization will help to support the clinical development of our products.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consideration Transferred</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the consideration transferred was based on the most reliable measure, which was determined to be the market price of Nivalis shares of common stock as of the acquisition date. The fair value of the consideration transferred consisted of the following (in thousands except share and per share amounts):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Nivalis common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,914,058</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per share fair value of Nivalis common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Nivalis stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">421,992</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average per share fair value of Nivalis stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of consideration (in 000&#8217;s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,103</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Merger Agreement, unvested Nivalis stock options immediately vested as of the closing of the business combination and were adjusted to give effect to the recapitalization.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Price Allocation</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As Alpine was the accounting acquirer in the merger, we allocated the purchase price to the acquired tangible and intangible assets and assumed liabilities of Nivalis based on their estimated fair values as of the acquisition date. The excess of the estimated fair values of net assets acquired over the acquisition consideration paid was recorded as a bargain purchase gain in the </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">. The determination of the fair values of the assets acquired and liabilities assumed requires significant judgment, including third party valuation estimates relating to the value of the acquired IPR&amp;D. The allocation of the purchase consideration to the assets acquired and liabilities assumed in our financial statements was finalized as of December 31, 2017.&#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The final allocation of the purchase consideration is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,130</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,952</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,453</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,614</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(401</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(910</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bargain purchase gain</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,601</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,103</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We relied on significant Level 3 unobservable inputs to estimate the fair value of our acquired IPR&amp;D using management&#8217;s estimate of future royalties and expected earnings of the assets after taking into account an estimate of future expenses necessary to bring the products to completion. These projected cash flows were then discounted to their present values using a discount rate of </font><font style="font-family:inherit;font-size:10pt;">17%</font><font style="font-family:inherit;font-size:10pt;">, which was considered commensurate with the risks and stages of development of the IPR&amp;D.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The bargain purchase gain resulted from expenses incurred by Nivalis between the time the purchase price was negotiated and the close of the transaction, and changes in the Nivalis stock price during that period as the exchange ratio was fixed when the purchase price was negotiated.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognized acquisition-related costs of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2017. These costs are included within general and administrative expense in our </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pro Forma Financial Information</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following pro forma consolidated results of net loss for the year ended December 31, 2017 assume the business combination was completed as of January 1, 2017 (in thousands, except per share amounts):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,731</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,327</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.32</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of the pro forma disclosures above, the primary adjustments for the year ended December 31, 2017 includes the elimination of acquisition related costs and acceleration of stock compensation expense upon the change in control.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933597744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we considered our convertible preferred stock to be participating securities, and we computed net loss per share attributable to common stockholders using the two-class method required for participating securities. All participating securities are excluded from basic weighted-average common shares outstanding. In accordance with the two-class method, earnings allocated to these participating securities, which include participation rights in undistributed earnings, are subtracted from net income to determine total undistributed earnings to be allocated to common stockholders. Net loss is not allocated to participating securities as there is no contractual obligation to share in net losses. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net loss per share for the year ended December 31, 2017 includes the conversion of </font><font style="font-family:inherit;font-size:10pt;">9,301,433</font><font style="font-family:inherit;font-size:10pt;"> shares of our convertible preferred stock into common stock, and </font><font style="font-family:inherit;font-size:10pt;">3,914,058</font><font style="font-family:inherit;font-size:10pt;"> shares acquired in connection with the merger.&#160;&#160;The significant number of shares issued has affected the year-over-year comparability of our net loss per share calculations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share attributable to common stockholders calculation because their effect would have been antidilutive. Diluted net loss per share, therefore, does not differ from basic net loss per share for the periods presented:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,311,770</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,422</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,611,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,739</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,533,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,636,119</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,844,931</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6771006288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash Equivalents and Short-term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Equivalents and Short-Term Investments</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amortized cost and fair value of our cash equivalents and short-term investments are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br clear="none"/>unrealized<br clear="none"/>gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br clear="none"/>unrealized<br clear="none"/>losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair market<br clear="none"/>value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,405</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,405</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury bills</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities and commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,331</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair market</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,680</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,680</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury bills</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities and commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,979</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All short-term investments held as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> were classified as available-for-sale securities and had contractual maturities of less than </font><font style="font-family:inherit;font-size:10pt;">one year</font><font style="font-family:inherit;font-size:10pt;">. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> realized gains and losses on these securities for the periods presented.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -URI http://asc.fasb.org/topic&amp;trid=2122426<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933578080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, receivables, accounts payable and accrued liabilities, which are recorded at invoiced amount or cost, approximate fair value based on the short-term nature of these financial instruments. Fair value is defined as the exchange price received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, is as follows:</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:inherit;font-size:10pt;">: Quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2</font><font style="font-family:inherit;font-size:10pt;">: Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, quoted prices in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:inherit;font-size:10pt;">: Unobservable inputs supported by little or no market activity and significant to the fair value of the assets or liabilities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, cash of </font><font style="font-family:inherit;font-size:10pt;">$614,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, is excluded from the fair value table below. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets:</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,405</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,405</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury bills</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities and commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets:</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,680</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,680</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury bills</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities and commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,568</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,352</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Level 2 assets consist of commercial paper and corporate debt securities. We review trading activity and pricing for our available-for-sale securities as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770854192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following (in thousands):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,506</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General equipment and furniture</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,895</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,400</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(699</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(311</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,196</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,089</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense was </font><font style="font-family:inherit;font-size:10pt;">$388,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$241,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$69,000</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770951616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss on Sale of Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Loss on Sale of Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss on Sale of Intangible Asset</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, we entered into an Option License Agreement (&#8220;Option Agreement&#8221;) with Laurel Venture Capital Ltd. (&#8220;Laurel&#8221;), which granted Laurel a limited license to evaluate the indefinite-life GSNOR inhibitor IPR&amp;D asset acquired as part of the merger with Nivalis in 2017. The IPR&amp;D represents the processes, expertise, and technology employed in the development of GSNOR inhibitors and Nivalis&#8217; lead product candidate, cavosonstat. Under the Option Agreement, we received an upfront non-refundable payment of&#160;</font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;">, which was recognized as revenue in our accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, we entered into an Asset Purchase Agreement (&#8220;Purchase Agreement&#8221;) with Laurel and completed the sale of global rights to the GSNOR asset. As consideration under the Purchase Agreement, we received a non-refundable closing payment of&#160;</font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;">, which was accounted for as a purchase of our intangible asset. We are also eligible to receive an additional payment of approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$425,000</font><font style="font-family:inherit;font-size:10pt;">&#160;on the one-year anniversary of the sale completion date. In addition, we are eligible to receive milestone payments of up to&#160;</font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">, in the aggregate upon satisfaction by Laurel of certain regulatory approval milestones. We will also be eligible to receive royalty payments equal to a low single-digit percentage rate of worldwide net sales of any approved products. If Laurel transfers any part of the rights to the GSNOR assets within 12 months of the sale completion date, we will be eligible to receive one-fourth of any cash payments made to Laurel by a transferee within 18 months of the sale completion date and such transferee will remain obligated with respect to Laurel&#8217;s milestone and royalty obligations to us.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the sale of the GSNOR assets, we derecognized the full carrying value of the intangible asset of&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#160;on our accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;"> and recognized a loss on the sale of the intangible asset of&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#160;on the accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933495872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Consolidated Balance Sheets Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Additional Consolidated Balance Sheets Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Consolidated Balance Sheets Information</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets consists of the following (in thousands):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid insurance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,242</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities and other current liabilities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal and professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,277</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933580720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term Debt</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain a long-term financing arrangement with Silicon Valley Bank. On June 30, 2017, we drew down a term loan of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">. The loan had an interest-only period that expired on </font><font style="font-family:inherit;font-size:10pt;">July&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">, at which point we became obligated to make </font><font style="font-family:inherit;font-size:10pt;">thirty</font><font style="font-family:inherit;font-size:10pt;"> consecutive equal monthly payments of principal (each in an amount that will fully amortize the loan), plus accrued interest. Interest accrues at a floating per annum rate equal to the lender&#8217;s prime rate minus </font><font style="font-family:inherit;font-size:10pt;">1.75%</font><font style="font-family:inherit;font-size:10pt;">. As a condition to the loan, we agreed to pay a final payment fee of </font><font style="font-family:inherit;font-size:10pt;">7.5%</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">$375,000</font><font style="font-family:inherit;font-size:10pt;">, upon repayment of the loan. The final payment fee was recorded in long-term debt with an offsetting reduction in long-term debt and was accounted for as a debt discount.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the loan agreement we have pledged substantially all of our assets, excluding intellectual property, as collateral.&#160;The obligations under the loan agreement are subject to acceleration upon the occurrence of specified events of default, including a material adverse change in our business, operations, financial, or other condition. We assessed the likelihood of the lender accelerating payment of the loan due to a material adverse change in our business, operations, financial, or other condition as remote. As such, as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the classification of the loan is split between current and noncurrent based on the timing of payment obligations. The term loan agreement contains customary conditions to borrowings, events of default and negative covenants, including covenants that could limit our ability to, among other things, incur additional indebtedness, liens or other encumbrances; make dividends or other distributions; buy, sell or transfer assets; engage in any new line of business; and enter into certain transactions with affiliates. We were in compliance with our covenants as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also, in connection with the drawdown of the loan, we granted Silicon Valley Bank </font><font style="font-family:inherit;font-size:10pt;">7,069</font><font style="font-family:inherit;font-size:10pt;"> Series A</font><font style="font-family:inherit;font-size:10pt;">-1</font><font style="font-family:inherit;font-size:10pt;"> Preferred Stock warrants at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$12.38</font><font style="font-family:inherit;font-size:10pt;"> per share. The fair value of the warrants on the date of issuance was </font><font style="font-family:inherit;font-size:10pt;">$53,000</font><font style="font-family:inherit;font-size:10pt;">, determined using the Black-Scholes option-pricing model, and was recorded as a discount to the note and as a warrant liability on the accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">. In connection with the merger and conversion of all outstanding Series A-1 preferred stock, the warrants became exercisable for </font><font style="font-family:inherit;font-size:10pt;">7,069</font><font style="font-family:inherit;font-size:10pt;"> fully vested shares of our common stock. As a result of the change in the underlying shares, the warrants were equity-classified beginning on </font><font style="font-family:inherit;font-size:10pt;">July&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The debt discount is being amortized to interest expense using the effective interest method over the repayment term of the initial loan amount. Non-cash interest expense associated with the amortization of the discount was </font><font style="font-family:inherit;font-size:10pt;">$169,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$87,000</font><font style="font-family:inherit;font-size:10pt;">, for years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The unamortized discount was </font><font style="font-family:inherit;font-size:10pt;">$172,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future principal payments as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> under our loan based on contractual maturities are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year Ending December 31, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future principal payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770841248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Lease</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we entered into a non-cancelable operating lease to rent office and laboratory space in Seattle, Washington. In April 2016, we amended the agreement to lease additional premises adjacent to our existing leased premises. Under our lease agreements, we lease approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">11,158</font><font style="font-family:inherit;font-size:10pt;">&#160;square feet of office and laboratory space with an annual base rent of </font><font style="font-family:inherit;font-size:10pt;">$566,000</font><font style="font-family:inherit;font-size:10pt;"> in the first year, which will increase by </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> each year thereafter. The leases expire on </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and has </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> options to extend the lease term with each option enabling us to extend the lease term by </font><font style="font-family:inherit;font-size:10pt;">twelve months</font><font style="font-family:inherit;font-size:10pt;">. As required by the terms of the lease, in May 2017, we entered into a line of credit to establish collateral to support the security deposit in an amount of </font><font style="font-family:inherit;font-size:10pt;">$132,000</font><font style="font-family:inherit;font-size:10pt;">. This is recorded as restricted cash in the accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2018, we entered into a lease amendment for approximately </font><font style="font-family:inherit;font-size:10pt;">6,184</font><font style="font-family:inherit;font-size:10pt;"> square feet of additional office and laboratory space adjacent to our existing leased premises in Seattle, Washington. The lease expires on December&#160;31, 2019 and has </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> options to extend the lease term with each option enabling us to extend the lease term by </font><font style="font-family:inherit;font-size:10pt;">twelve months</font><font style="font-family:inherit;font-size:10pt;">. The annual base rent due under the lease is </font><font style="font-family:inherit;font-size:10pt;">$295,000</font><font style="font-family:inherit;font-size:10pt;"> for the first year and will increase by </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> each year thereafter. We recognize rent expense on a straight-line basis over the lease period and accrue for rent expense incurred but not paid. The lease also requires us to pay additional amounts for operating and maintenance expenses. Rent expense was </font><font style="font-family:inherit;font-size:10pt;">$811,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$529,000</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">$267,000</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease payments for&#160;our non-cancelable&#160;operating leases at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Minimum Lease Payments</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">930</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">949</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2019, we entered into a lease with ARE-Seattle No. 28, LLC (the &#8220;Landlord&#8221;) for </font><font style="font-family:inherit;font-size:10pt;">27,164</font><font style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space located at 188 East Blaine Street, Seattle, Washington. The term of the lease is </font><font style="font-family:inherit;font-size:10pt;">10.8 years</font><font style="font-family:inherit;font-size:10pt;"> with </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> option to extend the term by </font><font style="font-family:inherit;font-size:10pt;">5.0 years</font><font style="font-family:inherit;font-size:10pt;">. The target &#8220;Commencement Date&#8221; is May 1, 2019 and shall be the date that Landlord delivers the premises to us in substantially complete condition. The &#8220;Rent Commencement Date&#8221; shall be the date that is nine months after the Commencement Date. The annual base rent due under the lease is </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> for the first year and will increase by </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> each year thereafter. We will not be required to pay base rent from the Rent Commencement Date through the last day of the ninth month following the Rent Commencement Date. We will receive a maximum tenant improvement allowance of </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;">, which is included in our base rent, and a maximum additional tenant improvement allowance of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, which will result in additional rent amortized over the term of the lease at an annual rate of </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">. The lease also requires us to pay additional amounts for operating and maintenance expenses. In connection with the lease, we provided a&#160;</font><font style="font-family:inherit;font-size:10pt;">$254,000</font><font style="font-family:inherit;font-size:10pt;">&#160;letter of credit as a security deposit. Rent payments under our lease with ARE are not included in the table above.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770993904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration and License Agreement</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, we entered into a Collaboration Agreement with Kite to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. Under our agreement, we are to perform certain research services and grant to Kite an exclusive license to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> programs from our transmembrane immunomodulatory protein (&#8220;TIP&#8221;) technology, which Kite is planning to further engineer into chimeric antigen receptor (&#8220;CAR&#8221;) and T cell receptor (&#8220;TCR&#8221;) product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Collaboration Agreement, in 2015, Kite made upfront payments to us of </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;">, which were initially recorded as deferred revenue. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we are also eligible to receive milestone payments based upon the successful achievement of pre-specified research, clinical, and regulatory milestones totaling up to </font><font style="font-family:inherit;font-size:10pt;">$530.0 million</font><font style="font-family:inherit;font-size:10pt;"> plus royalty payments on product sales, if any. Kite will receive an exclusive, worldwide license to research, develop, and commercialize engineered autologous T cell therapies incorporating </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> programs coming from our platform.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, we entered into an amendment with Kite to extend the research term of the Collaboration Agreement. Under the amended agreement, we became eligible to receive an additional </font><font style="font-family:inherit;font-size:10pt;">$450,000</font><font style="font-family:inherit;font-size:10pt;"> in research support payments from Kite in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> tranches. In June 2018, we recognized one of the research support payments under the amended agreement. In October 2018, we entered into another amendment with Kite, which amended portions of the research plan. We have recorded revenue of </font><font style="font-family:inherit;font-size:10pt;">$630,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, under the Collaboration and Licensing Agreement. In the second quarter of 2018, based on the completion of our research and development efforts in connection with the performance period, we recognized the remaining balance in deferred revenue on our accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As further discussed in </font><a style="font-family:inherit;font-size:10pt;" href="#sFE10AB00D18A281B653831F4AFFB388C"><font style="font-family:inherit;font-size:10pt;">Note 2</font></a><font style="font-family:inherit;font-size:10pt;">, on January 1, 2018, we adopted the new revenue standard using the modified retrospective method. Prior to the adoption of the new revenue standard, we recognized revenue under the Collaboration Agreement based upon the estimated performance periods related to the non-refundable upfront payments we received from Kite. Under the new standard, we recognize revenue based on employee hours contributed to each performance obligation. We recognized </font><font style="font-family:inherit;font-size:10pt;">$203,000</font><font style="font-family:inherit;font-size:10pt;"> in higher revenue for the year ended December 31, 2018, as compared to what would have been recorded under previous accounting guidance.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933597744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Deficit</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; Deficit </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the closing of the merger in 2017, all outstanding shares of our convertible preferred stock converted into </font><font style="font-family:inherit;font-size:10pt;">9,301,433</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we did not have any convertible preferred stock outstanding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had </font><font style="font-family:inherit;font-size:10pt;">13,854,205</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">13,831,178</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. Shares of common stock reserved for future issuance were as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares to be issued upon exercise of outstanding stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,611,996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares to be issued upon conversion of common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for future stock grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">496,530</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">576,722</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares to be issued under employee stock purchase plan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,211</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,211</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares of common stock reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,075,714</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,258,052</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, we repurchased </font><font style="font-family:inherit;font-size:10pt;">50,467</font><font style="font-family:inherit;font-size:10pt;"> shares of unvested common stock issued to one of our former employees for the original purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.002</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Securities Offerings</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, we entered into a sales agreement (the &#8220;Cowen Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;) to sell shares of our common stock having aggregate sales proceeds of up to </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;">, from time to time, through an &#8220;at the market&#8221; equity offering program under which Cowen acted as our sales agent. In June 2018, we and Cowen agreed to terminate the Cowen Sales Agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, we entered into an equity distribution agreement, (&#8220;Equity Distribution Agreement&#8221;), with Piper Jaffray &amp; Co., (&#8220;Piper Jaffray&#8221;), pursuant to which we may sell shares of our common stock through an &#8220;at the market&#8221; equity offering program for up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">, in gross cash proceeds. Piper Jaffray will be entitled to compensation for its services of up to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross sales price per share of all shares sold through Piper Jaffray under the Equity Distribution Agreement. The Equity Distribution Agreement may be terminated by us upon written notice to Piper Jaffray for any reason or by Piper Jaffray upon written notice to us for any reason or at any time under certain circumstances, including but not limited to if we experience a material adverse change.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Equity Distribution Agreement, we will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. We have no obligation to sell any shares under the Equity Distribution Agreement and may at any time suspend solicitation and offers under the Equity Distribution Agreement. The shares will be issued pursuant to our effective shelf registration statement on Form S-3 (File No.&#160;333-212404), declared effective by the SEC on July&#160;14, 2016. We filed a prospectus supplement (the &#8220;Prospectus Supplement&#8221;), dated June 11, 2018, with the SEC in connection with the offer and sale of the shares pursuant to the Equity Distribution Agreement. The Prospectus Supplement relates to the offering of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of our common stock and we will be required to file an additional prospectus supplement in the event we seek to offer more than </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of our common stock in accordance with the Equity Distribution Agreement. As </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we have made no sales under the Equity Distribution Agreement. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2019, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with a limited number of accredited investors, pursuant to which we, in a private placement (the &#8220;Private Placement&#8221;), sold </font><font style="font-family:inherit;font-size:10pt;">$25.3 million</font><font style="font-family:inherit;font-size:10pt;"> units (the &#8220;Units&#8221;) for a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$5.37</font><font style="font-family:inherit;font-size:10pt;"> per Unit. Each Unit consists of one share of our common stock and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.39</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. Pursuant to the terms of the Purchase Agreement, we issued </font><font style="font-family:inherit;font-size:10pt;">4,706,700</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,835,610</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. The warrants have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$12.74</font><font style="font-family:inherit;font-size:10pt;"> and have a term of </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The securities being sold in the Private Placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. We have agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable in connection with the Private Placement and upon exercise of the warrants.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred legal, accounting and other direct costs related to our efforts to raise capital. These costs have been capitalized as deferred financing costs and are included within prepaid expenses and other current assets in our accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">. These costs are deferred until completion of an offering, at which time they will be reclassified to additional paid-in capital as a reduction of the proceeds. As </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we have incurred </font><font style="font-family:inherit;font-size:10pt;">$477,000</font><font style="font-family:inherit;font-size:10pt;"> of deferred financing costs. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:12px;padding-left:0px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued warrants in connection with the drawdown of our SVB loan, and to certain non-employee professional advisers. We also assumed warrants in connection with the merger. No additional warrants were issued or exercised during the year ended December 31, 2018. A summary of our warrant activity is presented below:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contract</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.62</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.86</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,153</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.76</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Incentive Plans</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, our board of directors adopted, and in June 2018 our stockholders approved, the 2018 Equity Incentive Plan (&#8220;2018 Plan&#8221;) under which </font><font style="font-family:inherit;font-size:10pt;">901,530</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of our common stock were initially reserved for issuance, and we ceased granting stock awards under the Nivalis Therapeutics, Inc. 2015 Equity Incentive Plan (the &#8220;2015 EIP&#8221;) and the Amended and Restated 2015 Stock Plan (the &#8220;2015 Plan&#8221;), collectively, the &#8220;Legacy Plans&#8221;. All shares of common stock subject to awards under the Legacy Plans that expire or terminate without having been exercised in full, or are forfeited to or repurchased by the company, will be added to the 2018 Plan up to a maximum of </font><font style="font-family:inherit;font-size:10pt;">1,972,784</font><font style="font-family:inherit;font-size:10pt;"> shares.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, our 2018 Plan provides for an annual increase in the number of shares reserved for insurance under our 2018 Plan equal to the lesser of (1) </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of the number of shares of common stock outstanding as of the last day of the preceding calendar year and (2) </font><font style="font-family:inherit;font-size:10pt;">1,500,000</font><font style="font-family:inherit;font-size:10pt;">. However, our board of directors may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for such year will be a lesser number of shares. On January 1, 2019, a total of </font><font style="font-family:inherit;font-size:10pt;">692,710</font><font style="font-family:inherit;font-size:10pt;"> additional shares were automatically added to the shares authorized under the 2018 Plan.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018 our board of directors approved an &#8220;inducement&#8221; option grant, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules, to purchase </font><font style="font-family:inherit;font-size:10pt;">150,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock to our President and Chief Operating Officer. The option grant was exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof as a transaction by an issuer not involving a public offering. The options granted vest within </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> years, subject to continued employment, and expire </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years after the date of grant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, in connection with the merger, we assumed Nivalis&#8217; Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) and the 2015 EIP. Upon assumption of the ESPP, there were </font><font style="font-family:inherit;font-size:10pt;">45,211</font><font style="font-family:inherit;font-size:10pt;"> shares available for issuance under the ESPP. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we have not activated the ESPP. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options granted under our equity plans generally vest within </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> years and vested options are exercisable from the grant date until </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;"> after the date of grant. Vesting of certain employee options may be accelerated in the event of a change in control of the Company. We grant stock options to employees with exercise prices equal to the fair value of our common stock on the date of grant. The term of incentive stock options may not exceed </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;"> from the date of grant. We utilize newly issued shares to satisfy option exercises.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, a total of </font><font style="font-family:inherit;font-size:10pt;">3,061,084</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were authorized for issuance under our 2018 Plan, 2015 Plan and 2015 EIP, and </font><font style="font-family:inherit;font-size:10pt;">496,530</font><font style="font-family:inherit;font-size:10pt;"> shares were available for future grants under our 2018 Plan. A summary of stock option activity under our plans is presented below:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contract</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,611,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">936,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,869</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.01</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest after December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,484,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">887,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$6.5 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized stock-based compensation expense related to nonvested stock options that is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.9 years</font><font style="font-family:inherit;font-size:10pt;">. The aggregate intrinsic value of stock options exercised during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$214,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$18,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$22,000</font><font style="font-family:inherit;font-size:10pt;">. The total fair value of shares vested during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$139,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$70,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes option pricing model requires us to make certain estimates and assumptions, including assumptions related to the expected price volatility of our stock, the period during which the options will be outstanding, the rate of return on risk-free investments, and the expected dividend yield of our stock. The fair values of stock options granted to employees were calculated using the following assumptions:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average estimated fair value at grant</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$5.43</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.69</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.42</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.27% - 3.07%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.90% - 2.26%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.14% - 2.24%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term of options (in years) (2)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50 &#8211; 7.00</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.69 &#8211; 6.32</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.22 &#8211; 7.00</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected stock price volatility (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70% - 77%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72% - 83%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72% - 79%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield (4)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that had terms consistent with the expected term of our stock option grants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We used the &#8220;simplified method&#8221; for options to determine the expected term of stock option granted to employees, since we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited time our shares have been publicly traded. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility is a measure of the amount by which a financial variable, such as share price, has fluctuated or is expected to fluctuate during a period. We analyzed the stock price volatility of companies at a similar stage of development to estimate expected volatility of our stock price.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each non-employee stock option is estimated at the date of grant using the Black-Scholes option pricing model is are remeasured over the vesting term, as earned. Assumptions used in valuing non-employee stock options are generally consistent with those used for employee stock options, with the exception that the expected term is over the contractual life of the option.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is classified in the </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;"> as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,385</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-Employee:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">838</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016 we extended the vesting period of </font><font style="font-family:inherit;font-size:10pt;">567,500</font><font style="font-family:inherit;font-size:10pt;"> unvested share options held by </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> employees. As a result of this modification, we recognized additional compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$4,000</font><font style="font-family:inherit;font-size:10pt;"> for the year ended December&#160;31, 2016.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933598992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the U.S. government enacted the Tax Act. The Tax Act incorporates broad and complex changes to the U.S. tax code. The main provision of the Tax Act that is applicable to us is the reduction of a maximum federal tax rate of 35% to a flat tax rate of 21%, effective January 1, 2018. We incorporated the change in federal tax rates in our annual tax provision for the annual period ended December 31, 2017. Additionally, SAB 118 was issued to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. December 22, 2018 marked the end of the measurement period for purposes of SAB 118. We have completed and recorded the adjustments necessary under SAB 118 related to the Tax Act. </font></div><div style="line-height:120%;padding-top:12px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our income (loss) before taxes is derived from domestic (United States) sources. The provision for income taxes is composed of the following (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. - Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. - State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. - Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(204</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. - State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(204</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total income tax benefit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(366</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes (net of federal benefit)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.8</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permanent differences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal research and development credit</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Benefit of a lower tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-deductible merger costs</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17.6</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bargain purchase gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax rate change</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recorded tax benefits of </font><font style="font-family:inherit;font-size:10pt;">$366,000</font><font style="font-family:inherit;font-size:10pt;"> and of </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> for the years ended December 31, 2018 and 2017, respectively, which represent effective tax rates of </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;"> for the years ended December 31, 2018 and 2017, respectively. The difference between the U.S. federal statutory tax rates of </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;"> and our effective tax rate in all periods is primarily due to a full valuation allowance related to our deferred tax assets, the generation and consumption of federal R&amp;D tax credits, as well as a refund of state taxes from a carryback of the 2018 net operating loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table represents the significant components of our deferred tax assets and liabilities for the periods presented (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,546</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset basis</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,774</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,722</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets, net of valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed asset basis</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset basis</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets and liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the merger with Nivalis, we identified </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> of acquired IPR&amp;D. IPR&amp;D acquired in a business combination is an indefinite-lived intangible asset until the completion or abandonment of the associated R&amp;D efforts. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2017, future reversal of the deferred tax liability resulting from IPR&amp;D costs could not be scheduled for tax purposes and therefore could not be considered as a source of future taxable income. A deferred tax liability of </font><font style="font-family:inherit;font-size:10pt;">$305,000</font><font style="font-family:inherit;font-size:10pt;"> was recorded in 2017 as a result of the acquired IPR&amp;D having a financial reporting basis of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and a tax basis of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">. In the year ended December 31, 2018, we sold the IPR&amp;D and reversed the deferred tax liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A valuation allowance is provided for deferred tax assets where the recoverability of the assets is uncertain. The determination to provide a valuation allowance is dependent upon the assessment of whether it is more likely than not that sufficient taxable income will be generated to utilize the deferred tax assets. Based on the weight of the available evidence, which includes our historical operating losses, uncertainty of future taxable income, and the accumulated deficit, we provided a full valuation allowance against our deferred tax assets. The valuation allowance increased by </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended December 31, 2018 and December 31, 2017, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have net operating loss carryforwards as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal (before January 1, 2018)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,094</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,784</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal (after January 1, 2018)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,417</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,756</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state net operating loss carryforwards created before January 1, 2018 begin to expire in 2037. Federal net operating loss carryforwards created after January 1, 2018 carryforward indefinitely. The State net operating loss carryforwards begin to expire in 2038. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have net research and development tax credit carryforwards as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal research and development tax credit carryforwards begin to expire in 2035.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current tax laws impose substantial restrictions on the utilization of R&amp;D credit and net operating loss carryforwards in the event of an ownership change, as defined by the Internal Revenue Code Section 382 and 383. Such an event may limit our ability to utilize net operating losses and R&amp;D tax credit carryforwards. Under Internal Revenue Code Section 382 and 383, the 2017 merger with Nivalis is likely considered an ownership change with respect to the potential limitation of the Nivalis federal tax credits and net operating losses. As such, it is likely that any future utilization of Nivalis federal tax credits and net operating losses is substantially limited. Therefore, as of December 31, 2018, all Nivalis tax credit and net operating loss carryforwards have been reduced to </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for uncertainty in income taxes in accordance with ASC 740. Tax positions are evaluated in a two-step process, whereby we first determine whether it is more likely than not that a tax position will be sustained upon examination by the tax authority, including resolutions of any related appeals or litigation processes, based on technical merit. If a tax position meets the more-likely-than-not recognition threshold it is then measured to determine the amount of benefit to recognize in the financial statements. The tax position is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarized the activity related to unrecognized tax benefits (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized benefits &#8211; beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross increases (decreases) &#8211; prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross increases &#8211; current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized benefit &#8211; end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">469</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the unrecognized tax benefits as of December 31, 2018 are accounted for as a reduction in our deferred tax assets. Due to our valuation allowance, none of the </font><font style="font-family:inherit;font-size:10pt;">$469,000</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized tax benefits would affect our effective tax rate, if recognized. We do not believe it is reasonably possible that our unrecognized tax benefits will significantly change in the next twelve months.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize interest and penalties related to unrecognized tax benefits as income tax expense. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> accrued interest or penalties related to unrecognized tax benefits for 2018 and 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not expect any significant change in our unrecognized tax benefits during the next twelve months.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our material income tax jurisdictions are the United States (federal), and California (state). We are subject to audit for tax years 2012 and forward for federal purposes, and 2015 and forward for California.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6771027728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2019, in connection with our Purchase Agreement we sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">935,753</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and issued warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">364,943</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> to certain of our </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> stockholders. See </font><a style="font-family:inherit;font-size:10pt;" href="#s5D1F7A0CEF73296F6BF731F4CC92B1EC"><font style="font-family:inherit;font-size:10pt;">Part III, Item 13 of this Form 10-K</font></a><font style="font-family:inherit;font-size:10pt;"> for additional information. </font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a shared services agreement with Alpine BioVentures GP, LLC, pursuant to which we incurred costs of </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$17,000</font><font style="font-family:inherit;font-size:10pt;"> for years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. We had an accrual of </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> related to the shared services agreement at December&#160;31, 2016, which was paid in April 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933569024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Retirement Plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">401(k) Retirement Plan</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have adopted a 401(k) plan. All employees are eligible to participate, provided they meet the requirements of the plan. To date, we have not matched employee contributions to the plan.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6780170432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC and generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates inherent in the preparation of the accompanying consolidated financial statements include accruals for clinical trial activities and other accruals, and the estimated fair value of equity-based awards. We base our estimates and assumptions on historical experience when available and on various factors we believe to be reasonable under the circumstances. Actual results could differ materially from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include the financial position and results of operations of Alpine and our wholly owned operating company and subsidiaries, AIS Operating Co., Inc., and Alpine Immune Sciences Australia PTY LTD. On </font><font style="font-family:inherit;font-size:10pt;">July&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">, we closed the merger on the terms described in more detail in </font><a style="font-family:inherit;font-size:10pt;" href="#sD31BE121D5B120F8794C31F4AFBEEF04"><font style="font-family:inherit;font-size:10pt;">Note 1</font></a><font style="font-family:inherit;font-size:10pt;">. In connection with the merger, Nivalis effected a&#160;1:4&#160;reverse stock split of its common stock. Upon the closing of the merger, (1)&#160;a wholly-owned subsidiary of Nivalis merged with and into Alpine, with Alpine (renamed as &#8220;AIS Operating Co., Inc.&#8221;) remaining as the surviving entity; and (2)&#160;Nivalis was renamed as &#8220;Alpine Immune Sciences, Inc.&#8221;</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segments</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate as&#160;</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#160;operating segment and use cash flow as the primary measure to manage our business.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted cash</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consider all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking and interest-bearing accounts, and highly liquid money market funds.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash represents cash drawn on a line of credit used to establish collateral to support the security deposit on our operating lease to rent office and laboratory space in Seattle, Washington.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Periodically, we maintain deposits in financial institutions in excess of government insured limits. We believe we are not exposed to significant credit risk as our deposits, which are held at financial institutions, are high credit quality securities such as money market funds, U.S. Treasury securities, and commercial paper. To date, we have not realized any losses on these deposits.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-Term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our short-term investments include funds invested in highly liquid money market funds, U.S. Treasury securities, commercial paper, and corporate debt securities with a final maturity of each security of less than one year. All investments are classified as available-for-sale securities and are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses excluded from earnings and reported in other comprehensive income (loss). Purchase premiums and discounts are recognized as interest income using the interest method over the terms of the securities. Realized gains and losses and declines in fair value deemed to be other than temporary are reflected in the </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;"> using the specific-identification method.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years, while leasehold improvements are amortized over the shorter of their estimated useful lives or the related lease term. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Maintenance and repairs are expensed as incurred. Major improvements are capitalized as additions to property and equipment.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Intangible Asset</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Asset</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intangible asset is our indefinite-life S-nitrosoglutathione reductase (&#8220;GSNOR&#8221;) inhibitor in-process research and development asset (&#8220;IPR&amp;D&#8221;) acquired from Nivalis. The IPR&amp;D represents the processes, expertise, and technology employed in the development of GSNOR inhibitors and Nivalis&#8217; lead product candidate, cavosonstat. The IPR&amp;D represents the estimated fair value as of the acquisition date of substantive&#160;in-process&#160;projects that have not reached technological feasibility. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-lived Assets</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate our long-lived tangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If the carrying value exceeds the undiscounted future cash flows estimated to result from the use and eventual disposition of the asset, we write down the asset to its estimated fair value. Impairment is assessed by comparing the undiscounted cash flows expected to be generated by the asset to its carrying value. We did not record any impairments in the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_AccruedLiabilitiesPolicyPolicyTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate accruals for professional services and research and development expenses. This process involves reviewing contracts and vendor agreements and communicating with applicable personnel to identify services that have been performed on our behalf. We estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We estimate accrued liabilities as of each balance sheet date based on known facts and circumstances.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, we have not experienced any significant adjustments to our estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases and Deferred Rent</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases and Deferred Rent</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into lease agreements for office and laboratory space. These leases are classified as operating leases. Rent payments, rent-free periods and rent increases are recognized as rent expense on a straight-line basis over the lease term. The difference between rent expense recognized and rental payments is recorded as deferred rent in the accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_CommonStockWarrantsPolicyTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We granted common stock warrants to certain&#160;non-employee&#160;professional advisers. We account for our warrants at fair value, with changes in fair value recognized in operating expenses. Common stock warrants are initially recorded at their issuance date fair value and are subsequently remeasured at each balance sheet date. These warrants are valued using the Black-Scholes option pricing model based on the estimated market value of the underlying common stock at the valuation measurement dates, the remaining contractual term of the warrant, risk-free interest rates, expected dividends, and expected volatility of the price of the underlying common stock.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative Financial Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate all of our financial instruments, including issued&#160;stock purchase warrants, to determine if such instruments are derivatives or contain&#160;features qualifying as embedded derivatives.&#160;For derivative financial instruments accounted for as liabilities, the derivative instrument&#160;is initially recorded at its fair value and is then re-valued at each reporting date, with changes in&#160;the fair value reported in the </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;">. We use the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. We do not use derivative instruments to hedge exposures to cash flow, market, or&#160;foreign currency risks.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition (effective January 1, 2018)</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our steps for recognizing revenue consist of;&#160;(1) identifying the contract,&#160;(2) identifying the performance obligations as either distinct or bundled goods and services,&#160;(3) determining the transaction price associated with each performance obligation for which we expect to be entitled in exchange for transferring such goods and services,&#160;(4) allocating the transaction price to the performance obligations in the contract and&#160;(5) recognizing revenue upon satisfaction of performance obligations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our collaboration agreements principally contain multiple performance obligations, which may include (1)&#160;grants of, or options to obtain, intellectual property licenses; (2)&#160;research and development services; and/or (3) manufacturing or supply services. Payments typically received under these arrangements include one or more of the following: non-refundable upfront license fees, option exercise fees, payment for research and/or development efforts, amounts due upon the achievement of specified objectives, and/or royalties on future product sales. Our revenue is primarily derived from our License and Research Agreement (the &#8220;Collaboration Agreement&#8221;) with Kite Pharma, a Gilead company (&#8220;Kite&#8221;). See further discussion of the Collaboration Agreement in </font><a style="font-family:inherit;font-size:10pt;" href="#s8A49DD14B58EDD54C86131F4B9EFCB92"><font style="font-family:inherit;font-size:10pt;">Note 12</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We allocate revenue to each performance obligation based on its relative stand-alone selling price. We generally determine stand-alone selling prices at the inception of the contract based on our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the accompanying </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;"> and recognized as revenue when the related revenue recognition criteria are met. We recognize revenue under the Collaboration Agreement based on employee hours contributed to each performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Collaboration Agreement provides for non-refundable milestone payments. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to us for such milestone (1)&#160;is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance; (2)&#160;relates solely to our past performance; and (3)&#160;is reasonable relative to all of the other deliverables and payments within the arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial, and other risks that must be overcome to achieve the milestone, the level of effort and investment required to achieve the milestone and whether any portion of the milestone consideration is related to future performance or deliverables.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We review the contributed employee hours for each performance obligation under the Collaboration Agreement and adjust the revenue recognized to reflect changes in assumptions relating to the estimated satisfaction of the performance obligation. We could accelerate revenue recognition in the event of early termination of programs or if our expectations change. Alternatively, we could decelerate revenue recognition if programs are extended or delayed. While such changes to our estimates have no impact on our reported cash flows, the timing of revenue recorded in future periods could be materially impacted.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred. Research and development costs include personnel costs, clinical trials, external contract research and development expenses, raw materials, drug product manufacturing costs and allocated overhead &#8211; including depreciation, rent and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for all stock-based compensation granted to employees and&#160;non-employees&#160;using a fair value method. Stock-based compensation awarded to employees and&#160;non-employees&#160;is measured at the grant date fair value for stock option grants. We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. Stock-based compensation to employees is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis. Stock-based compensation awarded to&#160;non-employees&#160;is revalued over its vesting period using a Black-Scholes option pricing model. For performance-based awards where the vesting of the options may be accelerated upon the achievement of certain milestones, vesting and the related stock-based compensation is recognized as an expense when it is probable the milestone will be met. We recognize forfeiture of awards as they occur rather than estimating the expected forfeiture rate.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When awards are modified, we compare the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the consolidated financial statement and tax bases of assets and liabilities at the applicable enacted tax rates. We will establish a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefits or that future deductibility is uncertain.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize the tax benefit from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax position is measured based on the largest benefit that has a greater than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> likelihood of being realized upon ultimate settlement. We recognize interest and penalties related to income tax matters in income tax expense if incurred. In December 2017, the SEC issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118 to address the application of GAAP in situations in which a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Cuts and Jobs Act (the &#8220;Tax Reform Act&#8221;) which was signed into law on December 22, 2017. In March 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-05, which amended ASC 740 to incorporate the requirements of SAB 118. We recognized the provisional tax impacts of the Tax Reform Act in the fourth quarter of 2017. Our federal tax loss and research and development credit carryforwards have been updated from the amounts previously provisionally disclosed to reflect a change in position with respect to our 2017 federal research and development credit. The update is a result of additional time spent on modeling the potential use of our tax attributes, as impacted by the Tax Reform Act. Otherwise, during the year ended December 31, 2018, we did not receive any additional information regarding these provisional calculations, except as disclosed in </font><a style="font-family:inherit;font-size:10pt;" href="#s2FF5B04E48A0D29197CD31F4BBF8E887"><font style="font-family:inherit;font-size:10pt;">Note 14, Income Taxes</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) is comprised of net loss and certain changes in equity excluded from net loss. For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, other comprehensive loss consisted of unrealized losses on our short-term investments. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> difference between comprehensive loss and net loss for the year ended December 31, 2016.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU&#160;No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606. This ASU clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. This ASU is effective for public companies for annual reporting periods and interim periods within those annual periods beginning after December 15, 2019. We are currently evaluating the effect, if any, that ASU 2018-18 will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In&#160;August 2018,&#160;the FASB issued ASU&#160;No.&#160;2018-13,&#160;Fair Value Measurement. ASU&#160;2018-13&#160;modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted for any eliminated or modified disclosures. We are evaluating the effect of adopting this new accounting guidance to determine the impact it may have on our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU No.&#160;2018-07, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. Upon transition, nonemployee awards will be required to be measured at fair value as of the adoption date with a cumulative-effect adjustment recognized in retained earnings as of the beginning of the annual period of adoption. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity&#8217;s adoption date of ASC 606. We are evaluating the effect the standard will have on our financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No.&#160;2016-02, Leases. ASU 2016-02 requires a lessee to separate the lease components from the non-lease components in a contract and recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. It also aligns lease accounting for lessors with the revenue recognition guidance in ASU 2014-09. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years, and is to be applied at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU 2018-11, related to another transition method in lease accounting. If elected, the transition method allows entities to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We plan to adopt ASU 2016-02 on January 1, 2019 and intend to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of the accumulated deficit in the period of adoption as permitted under ASU 2018-11. Based on our leases in place on January 1, 2019 and considering the practical expedients, we expect the adoption of the new standard will not have a material effect on our consolidated statements of operations, will result in a gross-up on our consolidated balance sheets of less than </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> relating to our office and laboratory leases, and will have no effect on our consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09, Revenue from Contracts with Customers, as amended (&#8220;new revenue standard&#8221; or &#8220;ASC 606&#8221;), which amends the guidance for revenue recognition to replace numerous industry specific requirements. ASC 606 implements a five-step process for customer contract revenue recognition focusing on transfer of control, as opposed to transfer of risk and rewards. ASC 606 also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include ensuring the time value of money is considered in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. ASC 606 is effective for reporting periods beginning after December&#160;15, 2017. On January 1, 2018, we adopted the new accounting standard and all of the related amendments using the modified retrospective method. We recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of our accumulated deficit. The cumulative effect of the changes related to the adoption of the new revenue standard increased our beginning balances in accumulated deficit and deferred revenue by </font><font style="font-family:inherit;font-size:10pt;">$203,000</font><font style="font-family:inherit;font-size:10pt;"> within our </font><a style="font-family:inherit;font-size:10pt;" href="#s5586C0A9B3D54801F78C31F4AB9529B3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a><font style="font-family:inherit;font-size:10pt;">. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Collaboration Agreement with Kite is the only contract that was impacted by the adoption of the new revenue standard. Prior to the adoption of the new revenue standard, we recognized revenue under the Collaboration Agreement based upon the estimated performance periods related to the non-refundable upfront payments we received from Kite. Under the new standard, we recognize revenue based on employee hours contributed to each performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated financial statements as of and for the year ended December 31, 2018 is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance without Adoption of ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,074</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,277</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,487</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Statement of Cash Flows</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15 which provides new guidance on the classification of certain cash receipts and payments in the statement of cash flows. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We adopted this new standard effective January 1, 2018. The adoption of this standard did not impact our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09 to provide clarity and reduce both diversity in practice and cost and complexity when applying the guidance in Compensation - Stock Compensation (&#8220;Topic 718&#8221;) about a change to the terms and conditions of a share-based payment award. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this update are effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted and applied prospectively to modifications occurring on or after the adoption date. We adopted this this standard effective January 1, 2018. The adoption of this standard did not have an impact on our financial statements.&#160;For the year ended December 31, 2018, there were no modifications to the terms or conditions of a share-based payment award.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we considered our convertible preferred stock to be participating securities, and we computed net loss per share attributable to common stockholders using the two-class method required for participating securities. All participating securities are excluded from basic weighted-average common shares outstanding. In accordance with the two-class method, earnings allocated to these participating securities, which include participation rights in undistributed earnings, are subtracted from net income to determine total undistributed earnings to be allocated to common stockholders. Net loss is not allocated to participating securities as there is no contractual obligation to share in net losses. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, receivables, accounts payable and accrued liabilities, which are recorded at invoiced amount or cost, approximate fair value based on the short-term nature of these financial instruments. Fair value is defined as the exchange price received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, is as follows:</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:inherit;font-size:10pt;">: Quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2</font><font style="font-family:inherit;font-size:10pt;">: Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, quoted prices in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:inherit;font-size:10pt;">: Unobservable inputs supported by little or no market activity and significant to the fair value of the assets or liabilities.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_AccruedLiabilitiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_AccruedLiabilitiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and use of estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_CommonStockWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_CommonStockWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770921536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of New Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated financial statements as of and for the year ended December 31, 2018 is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance without Adoption of ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,074</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,277</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,487</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22580-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e725-108305<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6592008416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock', window );">Schedule of Fair Value of Consideration Transferred</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the consideration transferred consisted of the following (in thousands except share and per share amounts):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Nivalis common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,914,058</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per share fair value of Nivalis common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Nivalis stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">421,992</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average per share fair value of Nivalis stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of consideration (in 000&#8217;s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,103</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Adjusted Allocation of Purchase Consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The final allocation of the purchase consideration is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,130</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,952</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,453</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,614</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(401</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(910</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bargain purchase gain</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,601</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,103</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro Forma Financial Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following pro forma consolidated results of net loss for the year ended December 31, 2017 assume the business combination was completed as of January 1, 2017 (in thousands, except per share amounts):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,731</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,327</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.32</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933562864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share Attributable to Common Stockholders Calculation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share attributable to common stockholders calculation because their effect would have been antidilutive. Diluted net loss per share, therefore, does not differ from basic net loss per share for the periods presented:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,311,770</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,422</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,611,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,739</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,533,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,636,119</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,844,931</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6648768528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Amortized Cost and Fair Value of Cash Equivalents and Short Term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amortized cost and fair value of our cash equivalents and short-term investments are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br clear="none"/>unrealized<br clear="none"/>gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br clear="none"/>unrealized<br clear="none"/>losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair market<br clear="none"/>value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,405</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,405</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury bills</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities and commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,331</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair market</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,680</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,680</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury bills</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities and commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,979</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770886560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets:</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,405</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,405</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury bills</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities and commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets:</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,680</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,680</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury bills</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities and commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,568</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,352</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770913536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following (in thousands):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,506</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General equipment and furniture</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,895</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,400</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(699</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(311</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,196</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,089</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770993904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Consolidated Balance Sheets Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets consists of the following (in thousands):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid insurance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,242</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities and other current liabilities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal and professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,277</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770883184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future principal payments as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> under our loan based on contractual maturities are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year Ending December 31, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future principal payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6647598400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Lease Payments for Non-cancelable Operating Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease payments for&#160;our non-cancelable&#160;operating leases at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Minimum Lease Payments</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">930</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">949</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6937939728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Shares of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares of common stock reserved for future issuance were as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares to be issued upon exercise of outstanding stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,611,996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares to be issued upon conversion of common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for future stock grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">496,530</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">576,722</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares to be issued under employee stock purchase plan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,211</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,211</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares of common stock reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,075,714</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,258,052</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;padding-left:0px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of our warrant activity is presented below:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contract</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.62</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.86</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,153</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.76</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of stock option activity under our plans is presented below:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contract</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,611,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">936,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,869</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.01</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest after December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,484,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">887,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Assumptions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair values of stock options granted to employees were calculated using the following assumptions:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average estimated fair value at grant</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$5.43</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.69</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.42</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.27% - 3.07%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.90% - 2.26%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.14% - 2.24%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term of options (in years) (2)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50 &#8211; 7.00</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.69 &#8211; 6.32</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.22 &#8211; 7.00</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected stock price volatility (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70% - 77%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72% - 83%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72% - 79%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield (4)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that had terms consistent with the expected term of our stock option grants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We used the &#8220;simplified method&#8221; for options to determine the expected term of stock option granted to employees, since we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited time our shares have been publicly traded. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility is a measure of the amount by which a financial variable, such as share price, has fluctuated or is expected to fluctuate during a period. We analyzed the stock price volatility of companies at a similar stage of development to estimate expected volatility of our stock price.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future.</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is classified in the </font><a style="font-family:inherit;font-size:10pt;" href="#s03C62274E02E2844700331F4AC9CCF8A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></a><font style="font-family:inherit;font-size:10pt;"> as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,385</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-Employee:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">838</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768024448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Provision for Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes is composed of the following (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. - Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. - State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. - Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(204</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. - State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(204</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total income tax benefit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(366</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes (net of federal benefit)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.8</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permanent differences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal research and development credit</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Benefit of a lower tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-deductible merger costs</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17.6</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bargain purchase gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax rate change</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents the significant components of our deferred tax assets and liabilities for the periods presented (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,546</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset basis</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,774</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,722</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets, net of valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed asset basis</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset basis</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets and liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of Net Operating Loss Carryforwards</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have net operating loss carryforwards as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal (before January 1, 2018)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,094</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,784</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal (after January 1, 2018)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,417</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,756</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock', window );">Summary of Net Research and Development Tax Credit Carryforwards</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have net research and development tax credit carryforwards as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Activity Related to Unrecognized Tax benefits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarized the activity related to unrecognized tax benefits (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized benefits &#8211; beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross increases (decreases) &#8211; prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross increases &#8211; current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized benefit &#8211; end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">469</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779733056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 24, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 24, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares) | shares</a></td>
<td class="nump">1,335,118<span></span>
</td>
<td class="nump">1,335,118<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, purchase price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.74<span></span>
</td>
<td class="nump">$ 12.74<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 37,666<span></span>
</td>
<td class="nump">$ 10,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember', window );">AIS Operating Co Inc Preexisting Stockholders, Optionholders, and Warrantholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation', window );">Ownership percentage immediately following merger consummation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember', window );">Nivalis Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation', window );">Ownership percentage immediately following merger consummation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership Percentage Immediately Following Effective Merger Consummation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768393536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies  - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 24, 2017</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">IPR&amp;D intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement', window );">Minimum percentage of income tax benefit realized upon ultimate settlement (greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Increase in accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Increase in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember', window );">Nivalis Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=alpn_OfficeAndLaboratoryLeasesMember', window );">Office And Laboratory Leases | Scenario, Forecast | Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member', window );">Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Increase in accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Increase in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of Income tax benefit realized on settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=alpn_OfficeAndLaboratoryLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=alpn_OfficeAndLaboratoryLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6767720320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of New Accounting Pronouncements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (46,074)<span></span>
</td>
<td class="num">$ (9,384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">$ 2,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,487)<span></span>
</td>
<td class="num">$ (7,783)<span></span>
</td>
<td class="num">$ (1,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member', window );">Adjustments | Accounting Standards Update 2014-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Balance without Adoption of ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(46,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (36,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6781922000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 24, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 24, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 25, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,854,205<span></span>
</td>
<td class="nump">13,831,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,881,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 37,666<span></span>
</td>
<td class="nump">$ 10,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount', window );">Bargain purchase gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,601<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Acquisition-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember', window );">Nivalis Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="nump">3,914,058<span></span>
</td>
<td class="nump">3,914,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation', window );">Ownership percentage immediately following merger consummation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount', window );">Bargain purchase gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_CashFlowProjectionsDiscountRate', window );">Percenatge of projected cash flows discounted to their present value using discount rate</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember', window );">Nivalis Therapeutics, Inc. | AIS Operating Co Inc Preexisting Stockholders, Optionholders, and Warrantholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_BusinessCombinationCommonStockIssuedExchangeRate', window );">Exchange rate of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation', window );">Ownership percentage immediately following merger consummation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_BusinessCombinationCommonStockIssuedExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Common Stock Issued, Exchange Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_BusinessCombinationCommonStockIssuedExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_CashFlowProjectionsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash flow projections discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_CashFlowProjectionsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership Percentage Immediately Following Effective Merger Consummation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_OwnershipPercentageImmediatelyFollowingEffectiveMergerConsummation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=82851474&amp;loc=d3e511914-122862<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(3)(ii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=82851474&amp;loc=d3e511914-122862<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6571-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6387-128476<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6396-128476<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6527-128477<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6393-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alpn_AISOperatingCoIncPreexistingStockholdersOptionholdersAndWarrantholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768201920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Schedule of Fair Value of Consideration Transferred (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 24, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 25, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Outstanding Nivalis common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,854,205<span></span>
</td>
<td class="nump">13,831,178<span></span>
</td>
<td class="nump">13,881,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember', window );">Nivalis Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Outstanding Nivalis common stock (in shares)</a></td>
<td class="nump">3,914,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Per share fair value of Nivalis common stock (in dollars per share)</a></td>
<td class="nump">$ 9.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Nivalis stock options (in shares)</a></td>
<td class="nump">421,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average per share fair value of Nivalis stock options (in dollars per share)</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total fair value of consideration</a></td>
<td class="nump">$ 38,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6780161872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Schedule of Adjusted Allocation of Purchase Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 24, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount', window );">Bargain purchase gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (6,601)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember', window );">Nivalis Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">12,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Other receivables</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">IPR&amp;D</a></td>
<td class="nump">1,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">45,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="num">(509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="num">(910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount', window );">Bargain purchase gain</a></td>
<td class="num">(6,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total</a></td>
<td class="nump">$ 38,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6571-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6387-128476<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6396-128476<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6527-128477<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6393-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768666480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Schedule of Pro Forma Financial Information (Details) - Nivalis Therapeutics, Inc.<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Pro forma revenues</a></td>
<td class="nump">$ 1,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Pro forma net loss</a></td>
<td class="num">$ (18,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted', window );">Pro forma basic and diluted net loss per share (in dollars per share) | $ / shares</a></td>
<td class="num">$ (1.32)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition pro forma earnings per share basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6767642608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock converted to common stock (in shares)</a></td>
<td class="nump">9,301,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alpn_NivalisTherapeuticsIncMember', window );">Nivalis Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock acquired in business combination (in shares)</a></td>
<td class="nump">3,914,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alpn_NivalisTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alpn_NivalisTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768246816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">2,533,973<span></span>
</td>
<td class="nump">1,636,119<span></span>
</td>
<td class="nump">4,844,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,311,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">24,123<span></span>
</td>
<td class="nump">24,123<span></span>
</td>
<td class="nump">12,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">2,509,850<span></span>
</td>
<td class="nump">1,611,996<span></span>
</td>
<td class="nump">520,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6781936032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short-Term Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 51,702,000<span></span>
</td>
<td class="nump">$ 78,979,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(13,000)<span></span>
</td>
<td class="num">(59,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">51,689,000<span></span>
</td>
<td class="nump">78,920,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Realized gains and losses on securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,405,000<span></span>
</td>
<td class="nump">5,680,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">6,405,000<span></span>
</td>
<td class="nump">5,680,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13,966,000<span></span>
</td>
<td class="nump">19,909,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(21,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">13,964,000<span></span>
</td>
<td class="nump">19,888,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alpn_CorporateDebtSecuritiesAndCommercialPaperMember', window );">Corporate debt securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">31,331,000<span></span>
</td>
<td class="nump">53,390,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(11,000)<span></span>
</td>
<td class="num">(38,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair market value</a></td>
<td class="nump">$ 31,320,000<span></span>
</td>
<td class="nump">$ 53,352,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=alpn_CorporateDebtSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=alpn_CorporateDebtSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779735984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 614<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6780788416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">$ 51,689<span></span>
</td>
<td class="nump">$ 78,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">6,405<span></span>
</td>
<td class="nump">5,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">13,964<span></span>
</td>
<td class="nump">19,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alpn_CorporateDebtSecuritiesAndCommercialPaperMember', window );">Corporate debt securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">31,320<span></span>
</td>
<td class="nump">53,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">20,369<span></span>
</td>
<td class="nump">25,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">6,405<span></span>
</td>
<td class="nump">5,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">13,964<span></span>
</td>
<td class="nump">19,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">31,320<span></span>
</td>
<td class="nump">53,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">31,320<span></span>
</td>
<td class="nump">53,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value assets disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=alpn_CorporateDebtSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=alpn_CorporateDebtSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6780756480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 1,895<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(699)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">1,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alpn_GeneralEquipmentAndFurnitureMember', window );">General equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alpn_GeneralEquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alpn_GeneralEquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768880944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss on Sale of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">$ 1,731<span></span>
</td>
<td class="nump">$ 2,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Loss on sale of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alpn_LaurelVentureCapitalLtd.Member', window );">Laurel Venture Capital Ltd. | GSNOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived', window );">Potential milestone payments eligible to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Loss on sale of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alpn_LaurelVentureCapitalLtd.Member', window );">Laurel Venture Capital Ltd. | GSNOR | Term Sheet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast | Laurel Venture Capital Ltd. | GSNOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived', window );">Potential milestone payments eligible to be received</a></td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Laurel Venture Capital Ltd. | GSNOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_IntangibleAssetsAmountDerecognizedUponSale', window );">Intangible assets, amount derecognized upon sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement Potential Milestone Payments Eligible to be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_AssetPurchaseAgreementPotentialMilestonePaymentsEligibletobeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_IntangibleAssetsAmountDerecognizedUponSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Amount Derecognized Upon Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_IntangibleAssetsAmountDerecognizedUponSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alpn_LaurelVentureCapitalLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alpn_LaurelVentureCapitalLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=alpn_GSNORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=alpn_GSNORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alpn_TermSheetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alpn_TermSheetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933490448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Additional Consolidated Balance Sheets Information - Prepaid Expense and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred financing costs</a></td>
<td class="nump">$ 477<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_PrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,242<span></span>
</td>
<td class="nump">$ 1,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6936340080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Additional Consolidated Balance Sheets Information - Accrued Liabilities and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_AccruedResearchAndDevelopmentCurrent', window );">Research and development services</a></td>
<td class="nump">$ 2,457<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal and professional fees</a></td>
<td class="nump">646<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 4,277<span></span>
</td>
<td class="nump">$ 382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768825248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt  - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>payment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 24, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Term loan drew down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_DebtInstrumentNumberOfEqualMonthlyPayment', window );">Number of equal monthly payments | payment</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable for shares of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alpn_SeriesAOnePreferredStockWarrantsMember', window );">Series A-1 Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants issued, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of warrant liability</a></td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable for shares of common stock (in shares) | shares</a></td>
<td class="nump">7,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alpn_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Term loan drew down</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_DebtInstrumentFinalPaymentPercentage', window );">Long-term debt final payment fee percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Long-term debt final payment fee</a></td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alpn_TermLoanMember', window );">Term Loan | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument variable interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_DebtInstrumentFinalPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument final payment percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_DebtInstrumentFinalPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_DebtInstrumentNumberOfEqualMonthlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument number of equal monthly payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_DebtInstrumentNumberOfEqualMonthlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109247956&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alpn_SeriesAOnePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alpn_SeriesAOnePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alpn_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alpn_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6937776960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Schedule of Maturities of Long-term Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2019</a></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2020</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total future principal payments</a></td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6777959376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 18, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>term</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>term</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>term</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease', window );">Office and laboratory space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Operating lease, annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage', window );">Operating lease, annual base rent increasing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_NumberOfOptionsToExtendTermLease', window );">Number of option to extend term lease | term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
<td class="nump">$ 529<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease', window );">Additional office and laboratory space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Operating lease, annual base rent</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage', window );">Operating lease, annual base rent increasing percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_NumberOfOptionsToExtendTermLease', window );">Number of option to extend term lease | term</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease', window );">Additional office and laboratory space | ft&#178;</a></td>
<td class="nump">27,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">10 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Maximum tenant improvement allowance</a></td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_PaymentsForProceedsFromAdditionalTenantAllowance', window );">Additional maximum tenant improvement allowance</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate', window );">Percentage of tenant improvement allowance</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional square feet area of office and laboratory space under lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_AdditionalSquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_NumberOfOptionsToExtendTermLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Extend Term Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_NumberOfOptionsToExtendTermLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Additional Maximum Tenant Improvement Allowance Amortization Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Annual Base Rent Increasing Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_OperatingLeaseAnnualBaseRentIncreasingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_PaymentsForProceedsFromAdditionalTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Additional Tenant Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_PaymentsForProceedsFromAdditionalTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Square Feet Area Of Office And Laboratory Space Under Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_SquareFeetAreaOfOfficeAndLaboratorySpaceUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888428&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888428&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77910348&amp;loc=d3e34039-112682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6936216000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Lease Payments for Non-cancelable Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">$ 930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">$ 949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769007472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">$ 1,731<span></span>
</td>
<td class="nump">$ 2,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alpn_KiteMember', window );">Kite | Collaboration and Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_NumberOfProgramsFromLicenseTechnology', window );">Number of programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_EligibleToReceiveAdditionalResearchSupportPayment', window );">Eligible to receive additional research support payment</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_NumberOfTranches', window );">Number of tranches | program</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 | Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Kite | Collaboration and Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable', window );">Potential future milestones receivable (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_EligibleToReceiveAdditionalResearchSupportPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible to receive additional research support payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_EligibleToReceiveAdditionalResearchSupportPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_NumberOfProgramsFromLicenseTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Programs From License Technology</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_NumberOfProgramsFromLicenseTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of tranches.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Future Revenue Recognition Milestone Method Milestones Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_PotentialFutureRevenueRecognitionMilestoneMethodMilestonesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alpn_KiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alpn_KiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6786126192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 11, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>employee </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 25, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 24, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock converted to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,301,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,301,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,831,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,854,205<span></span>
</td>
<td class="nump">13,831,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,881,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Repurchase of unvested common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,467<span></span>
</td>
<td class="nump">50,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Original purchase price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_MaximumAmountOfCommonStockEligibleToBeSold', window );">Maximum amount of common stock eligible to be sold | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred financing costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 477<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,258,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,075,714<span></span>
</td>
<td class="nump">2,258,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions', window );">Extended vesting period of number of unvested share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">567,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_AdditionalCompensationExpense', window );">Additional compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to nonvested stock options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which unrecognized compensation expense related to nonvested stock options is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alpn_TwoThousandAndEighteenPlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent', window );">Percentage of outstanding stock maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alpn_TwoThousandAndEighteenPlanMember', window );">2018 Plan | Common Stock Initial Reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">901,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alpn_TwoThousandAndEighteenPlanMember', window );">2018 Plan | Legacy Plan Cancellations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,972,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alpn_InducementGrantMember', window );">Inducement Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alpn_IncentiveStockOptionMember', window );">Incentive Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member', window );">Stock Plan 2018, Stock Plan 2015 And Equity Incentive Plan 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,061,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alpn_StockPlan2018Member', window );">Stock Plan 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock converted to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,301,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alpn_CowenandCompanyLLCMember', window );">Cowen and Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_MaximumAmountOfCommonStockEligibleToBeSold', window );">Maximum amount of common stock eligible to be sold | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alpn_PiperJaffrayCo.Member', window );">Piper Jaffray &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_MaximumAmountOfCommonStockEligibleToBeSold', window );">Maximum amount of common stock eligible to be sold | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices', window );">Percentage of compensation for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,706,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_PurchaseAgreementRatioOfCommonStockToWarrants', window );">Per unit, common stock to warrant ratio (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_PurchaseAgreementAggregatePurchasePricePerUnit', window );">Purchase price per unit (in dollars per unit) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,835,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants issued, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares authorized (in shares)</a></td>
<td class="nump">692,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">935,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_AdditionalCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_AdditionalCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended vesting period of number of unvested share options .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_ExtendedVestingPeriodOfNumberOfUnvestedShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_MaximumAmountOfCommonStockEligibleToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Of Common Stock Eligible To Be Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_MaximumAmountOfCommonStockEligibleToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_PurchaseAgreementAggregatePurchasePricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement Aggregate Purchase Price Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_PurchaseAgreementAggregatePurchasePricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_PurchaseAgreementRatioOfCommonStockToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement Ratio Of Common Stock To Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_PurchaseAgreementRatioOfCommonStockToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Percentage of Compensation for Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageofCompensationforServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share based Payment Award Annual Additional Shares Authorized Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alpn_TwoThousandAndEighteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alpn_TwoThousandAndEighteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alpn_CommonStockInitialReservesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alpn_CommonStockInitialReservesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alpn_LegacyPlanCancellationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alpn_LegacyPlanCancellationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alpn_InducementGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alpn_InducementGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alpn_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alpn_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alpn_StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alpn_StockPlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alpn_StockPlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alpn_CowenandCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alpn_CowenandCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alpn_PiperJaffrayCo.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alpn_PiperJaffrayCo.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933546112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Deficit - Schedule of Shares of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance (in shares)</a></td>
<td class="nump">3,075,714<span></span>
</td>
<td class="nump">2,258,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember', window );">Shares to be issued upon exercise of outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance (in shares)</a></td>
<td class="nump">2,509,850<span></span>
</td>
<td class="nump">1,611,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember', window );">Shares to be issued upon conversion of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance (in shares)</a></td>
<td class="nump">24,123<span></span>
</td>
<td class="nump">24,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alpn_SharesAvailableForFutureStockGrantsMember', window );">Shares available for future stock grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance (in shares)</a></td>
<td class="nump">496,530<span></span>
</td>
<td class="nump">576,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember', window );">Shares to be issued under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance (in shares)</a></td>
<td class="nump">45,211<span></span>
</td>
<td class="nump">45,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alpn_SharesToBeIssuedUponExerciseOfOutstandingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alpn_SharesToBeIssuedUponConversionOfCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alpn_SharesAvailableForFutureStockGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alpn_SharesAvailableForFutureStockGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alpn_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6937834608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Schedule of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">24,123<span></span>
</td>
<td class="nump">24,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_NumberOfWarrantsAvailableTobeExercised', window );">Warrants exercisable (in shares)</a></td>
<td class="nump">17,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding', window );">Weighted average, exercise price (in dollars per share)</a></td>
<td class="nump">$ 24.86<span></span>
</td>
<td class="nump">$ 24.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable', window );">Weighted average, exercisable (in dollars per share)</a></td>
<td class="nump">$ 32.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding', window );">Weighted- average Remaining Contract Term</a></td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
<td class="text">6 years 7 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable', window );">Weighted- average Remaining Contract Term, Exercisable</a></td>
<td class="text">5 years 9 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Weighted Average-Exercise Price Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_ClassofWarrantorRightWeightedAverageExercisePriceOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_ClassofWarrantorRightWeightedAveragePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Weighted-Average Price Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_ClassofWarrantorRightWeightedAveragePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Weighted-Average Remaining Contractual Term Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_ClassofWarrantorRightWeightedAverageRemainingContractualTermOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_NumberOfWarrantsAvailableTobeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Available To be Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_NumberOfWarrantsAvailableTobeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding, Weighted-Average Remaining Contractual Term Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_WarrantsandRightsOutstandingWeightedAverageRemainingContractualTermExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768253056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deflicit - Summary of Option Activity (Details) - Options to purchase common stock - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">1,611,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">936,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(23,027)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/Expired (in shares)</a></td>
<td class="num">(15,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending of period (in shares)</a></td>
<td class="nump">2,509,850<span></span>
</td>
<td class="nump">1,611,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">2,484,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">887,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">8.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/Expired (in dollars per share)</a></td>
<td class="nump">10.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending of period (in dollars per share)</a></td>
<td class="nump">5.82<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">5.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 4.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted- average Remaining Contract Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">8 years 1 month 11 days<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (in years)</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (in years)</a></td>
<td class="text">6 years 7 months 27 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Ending balance</a></td>
<td class="nump">2,548<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">2,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable</a></td>
<td class="nump">$ 1,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, weighted-average remaining contractual life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769091968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Schedule of Stock Option Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average estimated fair value at grant (in dollars per share)</a></td>
<td class="nump">$ 5.43<span></span>
</td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.27%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.14%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">3.07%<span></span>
</td>
<td class="nump">2.26%<span></span>
</td>
<td class="nump">2.24%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 8 months 9 days<span></span>
</td>
<td class="text">5 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">6 years 3 months 26 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6780017104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,309<span></span>
</td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=alpn_EmployeesMember', window );">Employee | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=alpn_EmployeesMember', window );">Employee | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,385<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=alpn_NonEmployeesMember', window );">Non-Employee | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=alpn_NonEmployeesMember', window );">Non-Employee | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=alpn_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=alpn_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=alpn_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=alpn_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6767291904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jul. 24, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="nump">$ 366,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="num">$ (66,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">469,000<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember', window );">Nivalis Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">IPR&amp;D acquired in business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,453,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent', window );">Deferred tax liability, IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis', window );">IPR&amp;D acquired in business combination, tax basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_TaxCreditAndNetOperatingLossCarryforwards', window );">Tax credit and net operating loss carryforwards</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed indefinite lived intangible assets on tax basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsOnTaxBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_TaxCreditAndNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit and net operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_TaxCreditAndNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=alpn_NivalisTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6780751440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. - Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">U.S. - State</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. - Federal</a></td>
<td class="num">(305)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">U.S. - State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(305)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit</a></td>
<td class="num">$ (366)<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933656432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effect of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Federal research and development credit</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(27.30%)<span></span>
</td>
<td class="num">(19.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate', window );">Benefit of a lower tax rate</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(2.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts', window );">Non-deductible merger costs</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(17.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain', window );">Bargain purchase gain</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">28.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(24.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, bargain purchase gain.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_EffectiveIncomeTaxRateReconciliationBargainPurchaseGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation benefit of lower tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_EffectiveIncomeTaxRateReconciliationBenefitOfLowerTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, non-deductible merger related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_EffectiveIncomeTaxRateReconciliationNonDeductibleMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to excess tax benefit for share-based compensation cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933531120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 10,546<span></span>
</td>
<td class="nump">$ 2,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">1,958<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets', window );">Intangible asset basis</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">1,382<span></span>
</td>
<td class="nump">810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">13,964<span></span>
</td>
<td class="nump">3,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(13,774)<span></span>
</td>
<td class="num">(3,722)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net of valuation allowance</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed asset basis</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets', window );">Intangible asset basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(190)<span></span>
</td>
<td class="num">(420)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets and liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (305)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets attributable to deductible and non-deductible goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities attributable to deductible and non-deductible goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_DeferredTaxLiabilitiesAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6780919616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Net Operating Loss Carryforwards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 16,756<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=alpn_BeforeJanuary12018Member', window );">Before January 1 2018 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,094<span></span>
</td>
<td class="nump">$ 11,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=alpn_AfterJanuary12018Member', window );">After January 1 2018 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 33,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=alpn_BeforeJanuary12018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=alpn_BeforeJanuary12018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=alpn_AfterJanuary12018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=alpn_AfterJanuary12018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6938133984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary Tax Credit Carryforwards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">$ 1,958<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">$ 2,456<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6936292400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized benefits &#8211; beginning of year</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases (decreases) &#8211; prior year tax positions</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases (decreases) &#8211; prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases &#8211; current year tax positions</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized benefit &#8211; end of year</a></td>
<td class="nump">$ 469<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769103232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alpn_AlpineBioVenturesGPLLCMember', window );">Alpine BioVentures GP, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses related to shared services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accrued expenses related to shared services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold (in shares)</a></td>
<td class="nump">4,706,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from exercise of stock options and common stock warrants</a></td>
<td class="nump">$ 25,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold (in shares)</a></td>
<td class="nump">935,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock', window );">Warrants issued to purchase shares of common stock (in shares)</a></td>
<td class="nump">364,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from exercise of stock options and common stock warrants</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owners</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Warrants Issued To Purchase Shares Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alpn_PurchaseAgreementWarrantsIssuedToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alpn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alpn_AlpineBioVenturesGPLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alpn_AlpineBioVenturesGPLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6648768528">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">$ (203,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>101
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*NQ[Z_;N'QM?!%4#O^Y"?0%02P,$%     @ 3X!R3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MO" I#:4&SS^!Z6;@/".8P'FF^!> PG0S_SQCF) *_@6@,-TL]U403!%0P;\
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M@;6=T+Y]?0HB:;3J#?8,W_\SXP/%*.2KZ@!T],8H5R7JM![6&*NZ T;40@S
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MZ=+,I3_C/M!B"-<73_^0Z@-02P,$%     @ 3X!R3L;L*CEL!0  !1T  !@
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MMOE=]@=S_45=7(9#Q]7UY'/S/U!+ P04    " !/@').1C:,%K !  #2 P
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M^]\8XP&E)#<X0AU^L-50T/AP?(=G.X_9;'@S+#^(K=^X_ 502P,$%     @
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M_\$60T'MPO'&G\TT9I/AL)]_$%N^<?$;4$L#!!0    ( $^ <DX=U8J;M $
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M@MJ'XT<\VVG,)L.;?OY!;/G&Q2]02P,$%     @ 3X!R3F#9]0NQ 0  T@,
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M:&5E=#(T+GAM;'56[6[;(!1]%<L/4!O\$:=*(C6=IDW:I*K3MM\T(8E5VWA
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M@2V.@MH'\QW:=EJSR?&FGU\06YYQ\1M02P,$%     @ 3X!R3E0^KA>S 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL;5-M;YLP$/XKEG]
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M-\6+(:"V?OO![?7TEB?#JGX>4[+\*XH_4$L#!!0    ( $^ <DY.'Z )MP$
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M!UL,!;4/QUL\VVG,)L.;?OY!;/G&Q6]02P,$%     @ 3X!R3C(CD@2V 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL;5-ACYP@$/TKA!]P
MJ&N[EXV:W%[3M$F;;*YI^YG54<D!8P'7Z[\OH&?MU2_ #//>O!F&8D+S;'L
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MC4#4$XA@@0@4B(Q W!.(G:RUF,1@:H-!490@Y&9N(&YYCW-S]PS1,Q6#IF+
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MJ%<BWYMVWFH7@M5FEO2Z@7;Y#U!+ P04    " !/@').<#<ZU-L"  !T"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6R-5NMNFS 4?A7$ Q0;;"Y5
M$FE-+YNT256G;;_=Q$E0 3-PDN[M9QN7!G-(\B=@Y_N^<_'QX<R.HGEK=YQ+
M[[TLJG;N[Z2L;X.@7>UXR=H;4?-*_;,13<FD6C;;H*T;SM:&5!9!B% <E"RO
M_,7,[#TWBYG8RR*O^'/CM?NR9,V_.UZ(X]S'_L?&2[[=2;T1+&8UV_*?7/ZJ
MGQNU"GJ5=5[RJLU%Y35\,_>_X-LGG&B"0?S.^;$]>?=T**]"O.G%M_7<1]HC
M7O"5U!),/0Y\R8M"*RD__EI1O[>IB:?O'^J/)G@5S"MK^5(4?_*UW,W]U/?6
M?,/VA7P1QZ_<!D1]ST;_G1]XH>#:$V5C)8K6_'JK?2M%:564*R5[[YYY99Y'
MJ_]!@PFA)80](3Q/B"PA^B0D9PG$$LBU!&H)]%I"; GQ)P&?)226D#A!!UUV
MS7'=,\D6LT8<O::KN)KIPL:WB2J(E=XTYV_^4R?6JMW#(DKP+#AH(8NYZS#A
M !,.,4L($PTQ]Q"&##$/$(8.,8\ )G+\>8)TXAX3J)STB0G!Q(1&(!H()+!
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M$Z6Q9;4PSVA[$I(UED6ETI"W_EVUYGVQ_->P<$!J ](A *)W S(;D'TT -D
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MV8'AHK4QM4W8_GU](93-DI?8,YPYYXSC<3H*^:(: !V\<M:I##5:]P>,5=$
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ME(T-C.(D2OK  :40I!0"E*(1I183]B*-N<PA!B0H2((").(1"6J%N$/$WA4
M%D[O2032B0 ZR8A.9,4)$8T3FY -E&52Y9R@%(.48IL2'D7:Q!^6:0XQ()&
M)!* Q,0113XL _[M1PA-* FZX1 94#]3&OBA71T &-)XNCH(U)X'A&\X1@8T
M5Z!9R) (+%&(W'"4#&B6R!QD2 26.@1IW?@0&= -9;*!\V6"Q0X!:H?QA M8
MJA#]CPZ&Y05!^F)UL*T;B"24 GL#()/$GQ8]!$L, C3&[N&/1686,B0"RPP"
M=,;NX<06>N"?) A#DUN#8=G"_@W-;$#CB@4V*0B9Q'$\30N60@Q((283+F#A
MPOCV=L:PY&!(<L;MC&T](8@0!&R.C0P)2:;/.H8%"$,"-&YG;.N*Q6<.,B0"
MBPZ&KECC=L;V#>H.0;L#X,A,X\ BAJ$+E]7/U+I@RI(-;RZ&E(V4)0NQ3<OK
MS0L%JX]ZM&J<'3^70MW,>ZO=^/: U;PQ6M_(L:X=PM[=M#/A][0^9F7C/',A
MIQD]<QPX%TP2]>_EOIWD&-I]Y.P@U&LDW^MV%FL_!*_,G.EUP^[Z'U!+ P04
M    " !/@').E+P H+(!  #1 P  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q]4^UNVR 4?17$ Q0;TG:-;$NKIVF3-BGJM.XWL:]C5#X\(''W]@/L
M6&Z:[8_A7LXYG(.A&(U]<3V 1Z]*:E?BWOMA2XAK>E#<W9@!=%CIC%7<A](>
MB!LL\#:1E"0TR^Z(XD+CJDB]G:T*<_12:-A9Y(Y*<?OG$:092YSC<^-)''H?
M&Z0J!GZ '^!_#CL;*K*HM$*!=L)H9*$K\<=\6[.(3X!G :-;S5%,LC?F)19?
MVQ)GT1!(:'Q4X&$X00U21J%@X_>LB9<M(W$]/ZM_3ME#ECUW4!OY2[2^+_$'
MC%KH^%'Z)S-^@3G/+49S^&]P AG@T4G8HS'2I2]JCLX;-:L$*XJ_3J/0:1QG
M_3/M.H'.!+H0\LU_"6PFL L"F9REJ)^XYU5AS8CL]+,&'N]$OF7A,)O83&>7
MUD):%[JG:D,W!3E%H1GS.&'H"D/?(NKW"/:P0$@PL+B@5UW0Q&<K?O[P#P%V
M58 E@<V;&+<7,2;,?<+HA+G++Z+6[S&49=F%$[(ZW'C9OW-[$-JAO?'A/Z73
M[(SQ$ 2SFW"#^O"^ED)"Y^/T/LSM=,NFPIMA?D!D><757U!+ P04    " !/
M@').R9&UO)\#  #B$P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6R5
MF&UOHS@4A?\*X@<,V->\54FDG:Y6N]*,5,UJ=S_3Q&G0 ,Z"V\S\^S$OC4(X
MIN9+ ^3XY-Z3/N:&S44UW]N3E-K[495UN_5/6I\?@J#=GV25MY_46=;FG:-J
MJER;T^8E:,^-S _]HJH,>!C&0947M;_;]->>FMU&O>JRJ.53X[6O594W/S_+
M4EVV/O/?+WPK7DZZNQ#L-N?\1?XM]3_GI\:<!5>70U')NBU4[37RN/5_8P^/
M(NT6](I_"WEI;XZ]KI5GI;YW)W\=MG[8521+N=>=16Y>WN2C+,O.R=3Q_VCJ
M7S^S6WA[_.[^1]^\:>8Y;^6C*O\K#OJT]5/?.\AC_EKJ;^KRIQP;BGQO[/Z+
M?).ED7>5F,_8J[+M_WK[UU:K:G0QI53YC^&UJ/O7R^C_O@POX.,"?EW Q.("
M&A?0W8)@J*QO]?=<Y[M-HRY>,WQ;Y[S[IV /9,+<=Q?[[/KW3+>MN?JV$SS>
M!&^=T:CY/&CXC89/%8]S!65726 *N%;!816\7T^3*A)L0-" >@,Q,4COVA@T
M2:^I>TW$XC2[:V6N2M*,A[@8 8L1H!B&#2)H$+G'$4.#V"&.01/=-!J+,+I+
M8RZ*XM021@)+24 I'!NDT"!U#R.#!IE#&-FL3T99+.[2 *HL35-<# LQ<"$H
MARP6%F:9>R0, \>X0RBCZ+9?8G3#P@C_7!81198OF6& &2+8LH<PC!T3*V+!
MX+'()99HUB\/*;[?2) L,O18"L(@,T R6?AC&$"6K(@%(\A2EUA2EPT%J.P[
M"L- ,T T6398CBGDH7LH'%/(F4,HH^BCC07)[#L+M]Q$ =-DH9!C"CFMB 53
MR-'=;Q:+F/5[OZLL2J:%8)8Y8)DL&RW']/%X11R8/H[N?[,X$J>-%L@6-EJ.
M6>: 91(6"\P?SU:,:Y@_0G?!V< 6?OA?LBB9%H(I)D Q118+S!VMF5XMXZO3
M_$H?Q[$DF1:"Z25 +\46"\P=K9A>"7-'+O,KS6=3! V0+4!#F&("%).M)\P=
MK9AC"7-'+I,LS8?4621+DNGO&TRO /22Y68E,'=BQ0PK,'?"9885\^'T/HY%
MR;003*\ ]-I^_PK+3\85LZO W F7V57,A])9'$N2:2&87@'H%38+S)M8,;,*
MS)MPF5E'4;(4QY)D*"2X>=C2/?WZFC<O1=UZSTIK5?5/5XY*:6GLPD\FUY/,
M#]>34AYU=YB8XV9XZC2<:'4>GZ@%U\=ZNU]02P,$%     @ 3X!R3D;]MMO&
M @  P@H  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N>&ULE59=;]L@%/TK
MEM]7&^//*HF4#TV;M$E5IV[/-"&)5=MX0)+NWP^PZR1P724OL<'G'LX]<,F=
MG!A_$WM*I?=>5XV8^GLIV\<@$.L]K8EX8"UMU)<MXS61:LAW@6@Y)1L35%=!
M%(9I4).R\6<3,_?$9Q-VD%79T"?NB4-=$_YO02MVFOK(_YAX+G=[J2>"V:0E
M._J+RI?VB:M1,+!LRIHVHF2-Q^EVZL_1XPH5.L @?I?T)"[>/9W**V-O>O!]
M,_5#K8A6="TU!5&/(UW2JM),2L??GM0?UM2!E^\?[%]-\BJ95R+HDE5_RHW<
M3_W<]S9T2PZ5?&:G;[1/*/&]/OL?]$@K!==*U!IK5@GSZZT/0K*Z9U%2:O+>
M/<O&/$_=ER3OP^" J ^(A@"4?AJ ^P!\#H@_#8C[@-@*"+I4C#<K(LELPMG)
MX]WVMD2?(O08*_?7>M*8;;XI>X2:/<[B&$V"HR;J,8L.$UU@SHA L0]+1- 2
MB\@)CZX76+H(7%Q#5BXDQ[ (#.:)33R^RC.""6*0(#8$\14!MHSJ,)G!-)U1
M>9%8R0*@. QA*0DH)0&DQ):4#I-<K/(E+2Q3EP (HY&]34$IJ2LEM92DSB((
M%19H"8#"O("59*"2###%LGZ1.:O@/+>4N)C(+HA5YFQA.J(U![7F@-84)BA
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MN(N.[?WA:N+DP8<IO2"ENR#V/BV=/1@GJ7WB/"+L'!FTN@7TK?R-\$O;B^#
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M)CZS/BC(4A_ %0J N##KHT&#SA;:-AS@.@9,QV:) -%Q8@V$"QD0(8-O!L)
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M7RG[QZ\Y5Z#]_ >=;:-?MF7!H%9FFNBYF.[WM%!\F)\NO+R?Q3]02P,$%
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MY_GZ)Q;K%V6V:G\^,MG^AN7X?U!+ P04    " !/@').QE'92%$"   K"
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MW9P]RM;=?C#ZCV#<#0CQDF#P/!B,()SF\AZL$P1&;VUSC'XCXES6TMMSI0\
M^YH^<:ZHI@R>-%FA3^YAP>A)F6FBYZ([OKJ%XDU_-(/A^V#S%U!+ P04
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M".KE1H(LVX.T@"!Q:[!]_)!6!B24 ?5#2X%L*T_+ A*R@/J)1?/:@&&0Z,>
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M\IWU+50_$+0=VD-G[%'7?P!02P,$%     @ 3X!R3OE':7F5 @  I0D  !D
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M6[.7PQ<W%%ITXV6"IQLM^P]02P,$%     @ 3X!R3H:GYD8H @  .@8  !D
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M#@3]V9XH%2 MKIYDERHYR,<-@9-0RUBNF1EG9B-H-TQJ-/Y=Y'\!4$L#!!0
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MD/T'9:L@I/\Z?GN$5*/K6$NCBK*]ZM]-49VN%M8^\/5P%_.^9_9UL.A[_O\
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M/W^C7&7X1O2/&0Y-X)^S1!YD]&\4FR$UG;1=AYV./NP"6P9N*5%$?$);A.I
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MZ\(C3L&DTD;KK=3+IMN0 SG)+X\ 0Y&I"A33#=E!ZO,GW5\4;UX)A1RPVM\
M\W0.JWS_'-P7.*-!4(KY*+-G*KJD[!&B=(>.&X<?Q&U/P;ZEY3R:>R-$&%--
M))7@@I^5P@H%TB(W]U*%OXN4\'?R;DY/!%;V)BBCQSZW!^W,NO_VYWT<>%&U
M\A!RH]^GK2H(<C *<H/I3 =CA<!PLB?;'_AQ5>_N34..[0S715G41\[Z>4"M
M50N0 Z?S"3<<A.#\Z*UX7@XNW()"6C*6K3[SI8G-OKXDF7939YYV3[)2B#.B
MR%:&;/'6.H#]=-,O'2ZG;U9S['-MUS]*ET' \-Y>*00*X6(,C3C0,^\JE!RV
M81A1*GDY/'0$$=!NEN,_2(I(7^.-_]+F/8/+C989.[J,+$@4-L6V0R :&Z8J
MH126LY/DN38V>SH8,CON)#I[7^?B,:9)HMK9 H/7HS^\M>P0=U<HJGUR,&3Z
M!=6NAEL #FG.&@DSU0 V34=M9^L-TGY\2!DA]^F])M68:_GAHMZR/ASI(@H6
MTC5HI(NOM K)#.9HBQ6<U7*)@B@+.:E"C6KC6=C&#5,3Z?U,Q5\R')I2!*PO
MT6].I^DC:=H^J^^A*G*[< 5H@JN"BYO-Z/2 _9I:([$&@I?R?Z=@.4^;# '+
M=NK.0:<K<_ 93%;S07]*@TVPX?#MP<$Z1QD==!7W:XS6AUQ%$M'U]I%.'*ZL
MANA:]X+1;J)7]_8?T)@(8^%TL2_DGI62TN3A+I^M*XZZM:6.DR<8U"<*:AP/
MW1I(S?#J2,6F,,HR/Q;G]D!Z$E](1DW,]Z'@"N6X="!KGJ!0QG33Z.:%TI=^
M,,(A,,3B[B J$+LP@4MO!)%#<,$$O4URK=1$E@Q\"6P'\&EIVRQ;J_C9UD[(
M02U&S(.T48>N3I:N/=R";JE*5#V/6M$AI*/#.$=%C%%$.?L13E$H1)?/'  $
MBL926* (#.B!=*Y^/*#BH6+!>30FT N!4AP\" RU15SZ5C<%[6]SY[3N=[XS
MB'4%P0)Q"5O?;($9^_+Y;W9KQ'\MS3-[<_V-.72Q#<*+.U28A^A_BRX5" WV
M>B?\XJ_5+;?&]EYQ?.(C7LX-_BDXPPT< G.U+%$*#).JIWW+B#ODH-W B&GX
M@9"XX [L!EVX)(6_H1;F>F[?7M^$@Y/3[GWMIT<21?K>]<U/]AI^^FR\L$(S
M;OJM.&E*EEK;9#JE0X+P33B\M^'!=5X0R#DV6J.-#MMHV0$5A@4P'T+++WBW
M,+[A\>NHAF%O(FDO^&+(YMP]B@BQ'$")TCRBSZ;:-:2CV HH/;'1&NG@2_%=
MHAV_B[$ I:/PA:W@P*29D_$,N1E< !AVP"U4CPH?*<GC0$JQA7(->7#76%=I
M8J];<4(QNKTZ$I0#QX<R8G#Q)ZH?.!*EE=1#EP>-(09RL_4CSB#+@).1D9N8
M:K2!)@<NN8T8A1CL)"PD-$^32/WI2Y8;RAAYP:.MQ).X+8PT;JD+*>3!\BBC
M4^4\SODF;=/CTCE]B<T;W>W#'1R2M+>XCO$5Q76^4D@R$5ZA1K,:K*,T1*X,
MV7E?0F3/!Q7GD7[X7;VT/N9+SL9[QYR-$ X$WL:#P=156:&^TIL3UAYD\$5D
MQC]@O9+(4>7'P&*-M=[\!(^,F&7B \X5"\N^=B'HKY+7H%^XQ H"(Q7WJ>[:
MI^JQ6":78SY!_NE\?"YI[_BU)0U2:"*ZZ60>!RN<@9^,\]H'>)\XD:B3)]:)
ML1TU)',GS8KQB1 (AT9!IUU9:)4@.8E( P+&P%C7/D7"S2)VO5ND4IMM'#<U
M40_CV2);"C-VVVVX%)1<1[VFL&^HZVM).\5]P-KY4TVHT2\V]CL+U%1-JX-8
MX\ 96SW*)PNZ$E>&[R9@BD#&DK]HMCM-E[+A@<&F3":X%*%1UKM)Y,D5/UC;
M06K)]>X> PG'W(-9FGR+UC+WE_\^Y)V.W$1F:C^S1KD*_>\B;8)PZ;S'SP9K
M4#Q1I6.!W9YIM&?ZIR"9H6XHUR.,WNP[W#MX#%;.O/7@6:2'C]</F&H^$X8T
M")2+O%<8V]C:E0.1F"-B0)E)":8Y&:(E"!'T'CWK SB\QOS*_,FKO/>[@H&E
M.KBK$JDH&(O9T\@@6?P584B.((KQA>F3:]"$!3?6I223.(SS(VVBY'9%6#9Q
MH5G0D[V)KL.V@LL<]:KK6\PYJ=K97%N3-J$M<!@R[4P] "VY\@4W+_,^BL5[
MQ^U,NHY=AK)!5EYP:&'/(#ZD>9M'_NO^LDFE.-(?!8% :HB!_L^$>$(922OQ
MOL[%2@]E_#9VA"E+'XL:(QI!HCEN'&!\\0<OX&64D#UT#0D>PT8=)6_C^U<T
MX0JF">C J,_@'2W4VD?W*$'T2(5KT]I*A' "TXC$]-Y[2>$7,<"Z7'@0HDS=
M 1$#@)OW;7Y;*];E^=[;=WXV!@/SO930R '@+X,7+R.D":Z2;QC83,O6,"?"
MM6<RTPC=^)V_$DYVE/+8@6T.3KD(.RZ 93F?HR+#\7?L[IZ$F=FSIQP'2VJ*
M251W9U162GY,JR\F0L$D)^J]0;DEO$I7?\"OJ'KJ2W_>P8+63:4,3*J=8E<"
M[B+!GQEF7T^$V9@38D7R:<S/QE?QT?Q7W(VNB-),?N(IY.4)G*ISR_F:--:+
M,[3?TH"-22_@'G6E@)SF2A8)LG[>(T%86YBDWBV6E8*G8:Q2,2)@6>USH?+E
MG$$V)-+>>2WCY@]TSPN.Y8?"AXP24-E9]23#VSU6AW'$$F*Z/\!F);&B I.]
MH+X_:XT$=UENG(45\=6?<^M@3K^,B*DJ6PGQ5Z:[E*O_158KCKEV5YKA-:,
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MHZR8.BCN>4 U(K:E@@[G"8L0"?SRK_IGG5<%L'4[-=#==M%Q9RG+.B_*2OT
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MBGQ,NJ0J7_*9044-0#A* 7V &TB_O4;/Q,9+UH!)X?0CV_J'20C37TQ4J1H
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M+BJN$-?\,!#-A_(BB_WNRYHSGQ+L:X^'5K>;[_S7.6E\#&D?J &$=5!)AR'
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M_F+ /;_;->\D0MC;#S@A%;,S;_]F%?T$4$L#!!0    ( $^ <DZ'"9J7C 4
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MPMFJ:N\*)]J;X W^I>11N487G0L;.;N7P#H>Y"-XX$9[/=.5;KZ-!^W_E1K
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MT,-\T ,]R*^!C&M^$L*:K[4'7'N^UQZ [?EB>T"VYYOM =J>K[8';'N^VQ[
M[?ER>T"WY]OM =Z>K[< O86OMP"]98%K;72QS==;@-["UUN WL+76X#>PM=;
M@-["UUN WL+76X#>PM=;@-["UUN!WLK76X'>RM=;@=ZZP%D).BSAZZU ;^7K
MK4!OY>NM0&_EZZU ;^7KK4!OY>NM0&_EZQV WH&O=P!Z![[> >@=^'H'H'=8
MX*P;'7;S]0Y [\#7.P"] U_O /0.?+T#T#OP]0Y [\#7.P*](U_O"/2.?+TC
MT#OR]8Y [\C7.P*]XP+W*M'-2K[>$>@=^7I'H'?DZQV!WI&O=P1Z1[[>!O0V
MOMX&]#:^W@;T-K[>!O0VOMX&]#:^W@;TM@6>-4$/F_#U-J"W\?4VH+?Q]3:@
MM_'UKH'>-5_O&NA=\_6N)WKG8S.DW8\RG-I#OG7)/\._K)G G<O'.=T^XSKU
MR_T3I<NX);GKZ\W_ENO4/Q%N6I&??@-02P,$%     @ 3X!R3FW:TR ( @
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ML^G?FQ?_ %!+ 0(4 Q0    ( $^ <DX?(\\#P    !,"   +
M  "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $^ <DXGZ(<.@@   +$
M   0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ 3X!R3C<L?*[O    *P(  !$              ( !F0$  &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ 3X!R3IE<G",0!@  G"<  !,
M     ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !/@').
M)4Z;R<H"  "4"P  &               @ 'X"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ 3X!R3IL*L@'; P  BA(  !@
M     ( !^ L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M $^ <D[$:'V16@(  $0(   8              "  0D0  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " !/@').%-(IPK0#   ?$   &
M            @ &9$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ 3X!R3DM"3X^7!0  PQX  !@              ( !@Q8  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( $^ <D[GYMS0QP$  $\$
M   8              "  5 <  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " !/@').QNPJ.6P%   %'0  &               @ %-'@
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 3X!R3D8VC!:P
M 0  T@,  !@              ( ![R,  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( $^ <DZP,!VOM0$  -(#   8              "
M =4E  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !/@').
M5YM"9K8!  #2 P  &0              @ ' )P  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( $^ <DYY['<@LP$  -(#   9
M      "  :TI  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ 3X!R3I<'[>JV 0  T@,  !D              ( !ERL  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !/@').,"(%YK8!  #2 P
M&0              @ &$+0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( $^ <DY%&9?=LP$  -(#   9              "  7$O  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 3X!R3GW=G]RU
M 0  T@,  !D              ( !6S$  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " !/@').Y0U\-[4!  #2 P  &0
M@ %',P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( $^
M<DZ)G$ ELP$  -(#   9              "  3,U  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ 3X!R3AW5BINT 0  T@,  !D
M         ( !'3<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " !/@').8-GU"[$!  #2 P  &0              @ $(.0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( $^ <DZZB1(9M@$  -(#
M   9              "  ? Z  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ 3X!R3A?M*0VT 0  T@,  !D              ( !W3P
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !/@').1,6%
M?+4!  #2 P  &0              @ '(/@  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( $^ <DYH,!IVM $  -(#   9
M  "  ;1   !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M3X!R3IG$/''* @  Y L  !D              ( !GT(  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " !/@').HSF$_K8!  #2 P  &0
M            @ &@10  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( $^ <DY.S[5(TP$  )P$   9              "  8U'  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 3X!R3F69X<2R 0
MT@,  !D              ( !ETD  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " !/@').5#ZN%[,!  #2 P  &0              @ &
M2P  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( $^ <DYK
MBI>OM $  -(#   9              "  6I-  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ 3X!R3L[>0Z*V 0  T@,  !D
M     ( !54\  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $^ <D[%]"N2] $  ,L%   9              "
M 3U9  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 3X!R
M3M<+X2YY @  "@D  !D              ( !:%L  'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " !/@').4-:[%.("  !(#   &0
M        @ $87@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( $^ <D[D3G2.W0(  -P*   9              "  3%A  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 3X!R3G W.M3; @  = L
M !D              ( !160  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " !/@').LO1PGT8"   V!P  &0              @ %79P
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( $^ <D[ XSW2
MGP(  )()   9              "  =1I  !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ 3X!R3IF$ZSWC 0  I 0  !D
M ( !JFP  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !/
M@').<T^]%^@!  ##!   &0              @ '$;@  >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( $^ <DZ^I6:=?P(  ),(   9
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M970T."YX;6Q02P$"% ,4    " !/@').PGWG0?8"  #K"P  &0
M    @ 'E?P  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M $^ <DY$QFIV'0(  'H&   9              "  1*#  !X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ 3X!R3ERMBY(, @  ] 4  !D
M             ( !9H4  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " !/@').-"+^==P"  "O"P  &0              @ &IAP  >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( $^ <DZ6.$NSX0$
M % %   9              "  ;R*  !X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ 3X!R3M>8L:MJ P  %P\  !D              ( !
MU(P  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !/@').
M'/R')N<!  !+!0  &0              @ %UD   >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( $^ <DZW6<G$T@(  -D*   9
M      "  9.2  !X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ 3X!R3H+H64;^!0  SR(  !D              ( !G)4  'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !/@').QE'92%$"   K"
M&0              @ '1FP  >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( $^ <DXT2--Z-0(  *\&   9              "  5F>  !X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ 3X!R3I:IVJ=4
M P  U@T  !D              ( !Q:   'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    " !/@').(&U;UK4"  "O"@  &0
M@ %0I   >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( $^
M<D[Y1VEYE0(  *4)   9              "  3RG  !X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ 3X!R3B63*1B\ @  W@D  !D
M         ( !"*H  'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
M    " !/@').$[-N'VT"  !5"   &0              @ '[K   >&PO=V]R
M:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( $^ <DZS9!ZRH (  !4*
M   9              "  9^O  !X;"]W;W)K<VAE971S+W-H965T-C4N>&UL
M4$L! A0#%     @ 3X!R3C.;6(KD @  M L  !D              ( !=K(
M 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " !/@').>*<"
M<@<"   -!@  &0              @ &1M0  >&PO=V]R:W-H965T<R]S:&5E
M=#8W+GAM;%!+ 0(4 Q0    ( $^ <DX]3(^RV $  -T$   9
M  "  <^W  !X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @
M3X!R3H:GYD8H @  .@8  !D              ( !WKD  'AL+W=O<FMS:&5E
M=',O<VAE970V.2YX;6Q02P$"% ,4    " !/@').!%.W3Z8"  !U"0  &0
M            @ $]O   >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4
M Q0    ( $^ <DXD=0[0L@$  -<#   9              "  1J_  !X;"]W
M;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ 3X!R3IYY)N^>E@
M$5(" !0              ( ! \$  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!
M A0#%     @ 3X!R3E)R+&=D @  9@T   T              ( !TU<! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " !/@').APF:EXP%  !*+P  #P
M        @ %B6@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 3X!R3IR4
M7O]1 @  JBH  !H              ( !&V ! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ 3X!R3FW:TR ( @  Q2D  !,
M     ( !I&(! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %  4 #B%0
&W60!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>202</ContextCount>
  <ElementCount>364</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0002000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/ConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/BusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Cash Equivalents and Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestments</Role>
      <ShortName>Cash Equivalents and Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Loss on Sale of Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssets</Role>
      <ShortName>Loss on Sale of Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Additional Consolidated Balance Sheets Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformation</Role>
      <ShortName>Additional Consolidated Balance Sheets Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/LongTermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreement</Role>
      <ShortName>Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - 401(k) Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/A401KRetirementPlan</Role>
      <ShortName>401(k) Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Business Combination (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/BusinessCombinationTables</Role>
      <ShortName>Business Combination (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/BusinessCombination</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash Equivalents and Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsTables</Role>
      <ShortName>Cash Equivalents and Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/PropertyAndEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Additional Consolidated Balance Sheets Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationTables</Role>
      <ShortName>Additional Consolidated Balance Sheets Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/LongTermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/LongTermDebt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/StockholdersDeficitTables</Role>
      <ShortName>Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/StockholdersDeficit</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/DescriptionOfBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/DescriptionOfBusiness</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies  - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies  - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Schedule of New Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNewAccountingPronouncementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of New Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Business Combination - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/BusinessCombinationAdditionalInformationDetails</Role>
      <ShortName>Business Combination - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Business Combination - Schedule of Fair Value of Consideration Transferred (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfFairValueOfConsiderationTransferredDetails</Role>
      <ShortName>Business Combination - Schedule of Fair Value of Consideration Transferred (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Business Combination - Schedule of Adjusted Allocation of Purchase Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfAdjustedAllocationOfPurchaseConsiderationDetails</Role>
      <ShortName>Business Combination - Schedule of Adjusted Allocation of Purchase Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Business Combination - Schedule of Pro Forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/BusinessCombinationScheduleOfProFormaFinancialInformationDetails</Role>
      <ShortName>Business Combination - Schedule of Pro Forma Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Net Loss Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/NetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Cash Equivalents and Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsDetails</Role>
      <ShortName>Cash Equivalents and Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/CashEquivalentsAndShortTermInvestmentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Loss on Sale of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssetsDetails</Role>
      <ShortName>Loss on Sale of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/LossOnSaleOfIntangibleAssets</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Additional Consolidated Balance Sheets Information - Prepaid Expense and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationPrepaidExpenseAndOtherCurrentAssetsDetails</Role>
      <ShortName>Additional Consolidated Balance Sheets Information - Prepaid Expense and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Additional Consolidated Balance Sheets Information - Accrued Liabilities and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/AdditionalConsolidatedBalanceSheetsInformationAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Additional Consolidated Balance Sheets Information - Accrued Liabilities and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Long-term Debt  - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/LongTermDebtNarrativeDetails</Role>
      <ShortName>Long-term Debt  - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Long-term Debt - Schedule of Maturities of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/LongTermDebtScheduleOfMaturitiesOfLongTermDebtDetails</Role>
      <ShortName>Long-term Debt - Schedule of Maturities of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments for Non-cancelable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForNonCancelableOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Lease Payments for Non-cancelable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2412401 - Disclosure - Collaboration and License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreementDetails</Role>
      <ShortName>Collaboration and License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/CollaborationAndLicenseAgreement</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Stockholders' Deficit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/StockholdersDeficitAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Deficit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Stockholders' Deficit - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Deficit - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Stockholders' Deficit - Schedule of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfWarrantsDetails</Role>
      <ShortName>Stockholders' Deficit - Schedule of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Stockholders' Deflicit - Summary of Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/StockholdersDeflicitSummaryOfOptionActivityDetails</Role>
      <ShortName>Stockholders' Deflicit - Summary of Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Stockholders' Deficit - Schedule of Stock Option Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockOptionAssumptionsDetails</Role>
      <ShortName>Stockholders' Deficit - Schedule of Stock Option Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Stockholders' Deficit - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/StockholdersDeficitScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Deficit - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Income Taxes - Summary of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Income Taxes - Summary of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Summary of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/IncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Income Taxes - Summary of Net Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfNetOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Summary of Net Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Income Taxes - Summary Tax Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryTaxCreditCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Summary Tax Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/IncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2415401 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alpineimmunesciences.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alpineimmunesciences.com/role/RelatedPartyTransactions</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="alpn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - alpn-20181231.xml</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - alpn-20181231.xml</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>alpn-20181231.xml</File>
    <File>alpn-20181231.xsd</File>
    <File>alpn-20181231_cal.xml</File>
    <File>alpn-20181231_def.xml</File>
    <File>alpn-20181231_lab.xml</File>
    <File>alpn-20181231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0001626199-19-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001626199-19-000010-xbrl.zip
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M3E[\O=.?0" S__'_ 5T[1??+_>OL:]9?X?3\F5<#B(E&Y0/DPMB]$\8+[F]
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MT[RM0+Z[BL7GH[OAJ-/_M1A.[LHL='Z3-]Q3M_+<])<,%JF]3Z"]&8[+'3(
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MN<[D-:9H42-FB36:2%$N;1:48[*A6AC31]U9.PUY'E:=8@AMO.66"4JT1UZ
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M%:V?IU\/I)L@J(B7KNM8DH"],X+:.\*"0])9SHU.5_!)YP0#+<F5IYO.8&X
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M$0VO7:1.&-^B(+^/*M7?9JYO*F&!?\L"1'"/9Y[PJ"RUL9U1UEM^($7>>RH
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ML'R%>-ZA!$+PFG'#J9)64D<H31G8QE)XIAQKMHOA1'&MODH<G986O0]&>Y.
M 0_BT7"E;!(1;35CC45&SXKH4(SNUF6HRZ<N!(J: &"[-(X/'@T&\-$W. <^
M7ZVIWT-79[CERP(M8D,_M8&J4&T4<%)PVC!-7A&RTG9^PM,\&])V:!4)3J!-
MB96!I5I8PXFK2TFT(4T'\94R&Z7=UX.T75,H P'#,-$.ER@!@X)!7QOPJ0.G
M:@U;:O&,6-NC'7\';P4EB;0\,!#[*<V PX0#WN(&;!#/F]-^UC+6UN[[M@8A
MX#Y:$):@G+@'CT1)E8GJ;@P8\,W9IJO.;9NP[J C 8QGI1)<L& HR\"NJPK1
M!/;,KJ.CX_&:CYM#'O>9K(4EJJDT&NY<>4T=5[0<IIY1QY)MD[56'GT05+O&
M77"XU"3C/+$)]9+"SUE]RYD6#?=?;<#;$9#M&I!*?!8\$=CSS9C.P-6G%636
M"KDMXK8=JB+OCG.?E_^>*69XYP/.*SR<HXW/O,BLTHJJ+'-:JJ2LUI929TUW
M0C>X9#M CX1^U_W+%/PAD26XSQ%4OO*AWFE#@LH:1GJ3;TX*_2[]8;RVTM"@
M)5 P923S]9@I;8-NMM +VM >CX2_F"YEDPXF'R%\0CDQH C10,5N!5.2C^;2
M\X:QQ<SN ZS ]/@S[!J_9T+@)%/6&NQ+%B$1]8XOH7VS#O\5%<]QBET1.1V"
MHEJE28I;GL ")J(F)BI#0Q0R;43+IT#S9;^]3_N0%B:=$HM;!*1PAH6$I,FL
MCV1Y4W9U+?% 6T^T%<)6#[<K]LM,!I:C=AG)$BE3GX9*/2C/1+-C_A51C)S-
MX7;E:8Q0RH-):"F6'H!P%A4IRBP1K,E0?*=6><39JK:TE698\';C0(PCTX*<
M@[P@7CEK?!) ^VB;U7)/J>8\'[I+\>P#Y2G.N8-.P7T& \8X2U.;@8!DH($J
M.LT 20VSCQ"S2T4]UTEW=6,Y[X-VUJ%<!#)UW(=:"S!-UBQU:/]*MV;ZLM^O
M!U-<Q?B7T:CWI3\8'%8] WP'5D9&&2XN9*E/'/@;Y?G2#/[2N$G><%4/ Z_=
MHVT=/Y)1PE5*" ^:&.$)2ZOLMI*I58VL06N'*AWM^D;7#5K;9TT5>'EI\*DE
M3&;6X' ,6\:K;(IAA88H64UXK(/B&#AW)1[ Z@$U;*4T4A%A9$CK18A!ZN;.
M#<%/!>@.3G;<".XX:%="L4: <%M1N@K@K#9E%C6KK+POI,>FK6/"'1D06%$X
M@,H3&>,HAB=I0K:M)EMY]$%0[8J9H' '5%B5<"TX.-=I'3.11O$FXL3Z&SX&
MM!UWZI.$*04\(G$*"IB$*3/U\E+I9".<P\BJB;X3-/2U&_/H]KG+A!J5NL %
MQQT04N*F=8R,I%0%D$A[W&7UZ(.@VG&70$W4<>%3ER;2>>/2NKA XO2IYN#)
M56%_/&0[KA+WD5)C C'@:R59"L*D,BFD\FESRLMJQ<86T'[*Q^-1,1\CAWKX
MEWR8?^D.<#7(VC[?17^<,JI)QHQ6F??@%E(W6VKC049_]^?WA+Z=0[+C<<="
M-M\_QLCBC0I,1WI*9.!4"? ?G%$XA$^CUE#Z::%[VRV(GF>]IA_'^?],,>WU
M&9>NK%8@KOR]4>E) [$,-'4:)#!-AK2H>2 *!#CF&!,XF_A[\C;QK1T/W_/N
MIG8K3G]"\&"Q)Y(+:W0*9.6#PA."M.49_$_A[25_-V^)WG'&9<"7CGGLF!AF
M,ZT-L* 3A#!!.$E9/5,ZH4TC7Z[.B=D0(3AZ(@SA#-P-9S6(UB18QD'X5R)"
M9K(9D2$)71F-M1LB4.ZQEO1V-.CEQ;A,UQZ&-]"/N.T@!KHPTR#2F=VI?6C.
M]-2"THU@KH7G<;!O';KC#+@UDH:$&\\4DU[6[H[%S79-:TXKU@;L1Y7^<R=
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MWV76"^T(+MZESDL09B[!R2#Q!&!WD6WIF#9@?U_T/W<G.5AB9=WQ.A?[? 8
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M,Z#6C'Q9F *ZI<UBT7:A7%+O&35")D8(;^5L+0:QF0,,J380M/,LYX>Q#5N
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MMSCK*IY5$,+LNFLEF 7CB_FMXP^+I9\_5!;(3_WNQ_X@#H![/QKTKQ_*?WZ
MT[@!N&)[;(;D*DB>I&FB+9&:6!;FH]S _P-.^[?!Y,=>_W-G/'D8Y/_QW0U\
MY:N;[EU_\/##A_Y=/N[\G'_I_#*ZZPY_C'\;@_KX@23WDQ^_^[=/DQ]7/C[H
M#_-7M_'T/Q":_.N/]]T>GO359'0/+]S_OO%+\/5U0/2'MZ"%)JN?*W_%M_^
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M&>JO^\7U] Z%$&#M]4MAA\'D=C3]=(O([8TB:O.XFBA>;8VF,5+&Q[R#/Q?
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M5W6+ZUM@O>(SW$W)EY^ S"?X]@@VR+G\]^O!= P<T!E4%PA_;$4L3+ZT)%X
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M)R@"1P!:)9GFRJD_O*YJUQ&[9ZH1X&0(W4PQ@.R>H!9\*9)RV?A0:XP/,*Z
M5'I->P/ @M<C9\U4??0RMTO;VH[ M\1O1C)8LB<^YM?PA[5,CM  >O ;P75J
MA]>X2*Z2I!F0.8HPENR>Z3V0[X(*B512:OF6_+O6"!H-FFMPE%YW@"+^BF8@
MBNYX':A"/@VC>X72M;K=S:><;K[>^.T+]*;7T5NT3]<17:WBZJ_%QP(AC!L@
MH0'UNO.W''SMS_E<!59JKST=+EE[E'/5$DSDM6I7;[06=_D#?6W:!:UVY#'"
M,>Z41/$RC)DS"V2U&5N3+:$(N!DL,@R-#,!#F@N538X_JF&[)&BBS0?,#V_Y
MGVFWF*#S>E.)G=(TK Q#4.+W@SQ^'[P!U?A,E"SXTE$8Y3= =!,T3C D,T0
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M!<HWJ=)600K?#SM)%1^2:W,VWHVUCBL?06 HP@8!&@-(J_SUM[MG\!))B:1
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M'(%I_ 8CXZ1A(X2G [L,DCJP":A''WYFK8X0*5GI/D?,+8@,31U$DLG&WI1
M*3QZ<Y3#K=+JZ4$L@G$+"<O,8DDSBSQ):)*,<%I#\:L@XL@D?/+<WX7G+H+
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M^@-SV&> )3[<>5N7@A48*[":9#E8B[$68RW&6NRXB:#NV_E@!R5\:L%X7%#
MNHUU6]5T&X:8Q^IW=:[.V=X8OLF___J76%[>6=;J^ZF81;=I=<3HWG(]'.@F
M"&\M3WS%?W\%"HR]P/[][__[/W_-WIN+,!0.@J')B;5R(P47\R44*\MU1K[S
M.8*%CZ04D9RZTO8"&8?96$!U'TG[LYC_[;N;::O1'/RK\Y^OT^\,UX%?6'9T
M.9B.QMU.MSML=L;]R:@U;MRT.C?-QFAXTQL-6Y/O_OYDJ_)D?P'6=]-.OXQJ
MG$<H[B#\<)G,H"EGB&\KX4M=J1(@$0W8GA"^:5A$322==('L1C WX._&//#
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M>/"!&,X7($X UT5QM,OD@^Y5I]_NW]Z,AC?MVTZW/^F9$S'YH-/K776/-/E
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MFL2@2]XN1-M!>^P/QK$!Y@.?<?4\\2 >V@6WHST97'7'_=YP/.@,KFZZD\'
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M>'<JP@PLAJ'J$]'PBZ E(>HXK N]?P8O/$V-YTL56&:9\LM47H;[Q,U>YHH
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ME(7G/OB<1XLP'>1;E[N^,[K2^3A.BA8GFUE1<8PMUWY^.)U-U-OJUNR^%&1
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M3N>R;;:[K2Z8,(<A?A$KHKV <..J[VXF^"3T2_-[S2XU0?>)QE,75;65P=&
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M-*M[YPI&WH^DX7^HLH]5&W!MI[4.."D=8 ZE8=>JLH]:!V@=H'7 +CJ@JU7
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M[+_^]Y_?XW/<#_C??_W_4$L#!!0    ( $^ <DZJ8Q?J0A8  ,+O   1
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M4(J2H40 $VK!/S  NW<=#E+UCRU@?4-[4IWU3:K6H6KKV_OF:5 RQB10\%$
M#8"T9#2"RV$=3$,KC>YP1XGYL06K%SQ/%LB\6<*?Q6E,.T]8][2L(JSXUB6:
MBR3D?;- P'>5#DG#4DS /C5=[F?"/Y(0]8_E?OFQD\OI2BH(W<A$_F2+/-_-
MT[BV[&Y+A>Y4.AU[K*SEB3&C$ $&P8<A&%'O&6*4*9D\U=AUN=3\A]B_+H]Q
M*=V4]T3S9OS;Z8MZ?CF;KR*DWJ8#[FYMV4,5B3/1<(*H41J4M+=(8*^0M$9Z
M :8 )1WBB,B/M9D]'*@EBP?$U2"M+XNR:PZ G;7/ ?,%'-N+>GDQWW)]Y@.5
M!0[OL(*)IQD%3R;2%/+VKD,B8HZBCTQ'91WN<N,\83^4V!7#N.")[C;<UL1W
MC#K8TDE%M10B,HZX,2E?O9*0%SPA$2(V!@?L98>SX#)AMX\_ZJ"?D2EWPK,N
M^_YQMKD8^\&B>SM/?MIV4LF@3:(4Z(C@>S/I*$K>PKRUW$<BL4RRGQR"$RC$
MSB/_W9'0@+ 6$[!FYF,,\U> 8JX.?)!YM[]QY4,@RCB"E-4>,>,%(E(E% UU
M@AMA2!Q]Y=12\C0$FB=35+O+3A^BK7;W5 DKP;3E+-\D*Q #>P-)HB@26@!2
MC&OI.@3SG=:&&UQE]8[MJ?06J-O?[2+3_O5M>IBK Y19RQXKSZW%"HA,Q"FD
MN29(,TT1)3(9'CGQNE65SA$&40RMX8:#^'3+Y_%Z[\"N*L9\$$'2=75EI6@.
M,* <*8VQ)=@FUJ5HWDFC,X9?6GO'MEC><':RULH[9'96OZ_W@/:D&SS0JO+>
M!TRQ0<0'C9S$#$4F0-VSR. K'@7O$$@J?R0YZA?&$V]TO*JG=NH[;G1LZ:0"
M9X>H"+,%RQ#@!P[(4H-1Y%1ZI?,%C*._1>/Q;W3T,S*G6$A?S^?+G#:X(^6M
MY3K:HJ=*>6H9L1:%J&&V!@5F!LQ8I(+"P4?#N!]],M!0(K!C&1T&VM.*V]TR
M: =+V-W&E<36$6PD<DDP6%HDN.S2!<0928"%2AZ/OL[@286J(YKE<N0O-RYU
M:^EYJ$GE$VA[Q242AF+DF5O9#H"D"C'"ZQ-@^5@W,OH6FAY!/(FKF-7CV\N,
MY_SEE]CX>AY#2XVSM6VE $0P,[.630*12/)AKU3(8ZJHYEA%]UA3.894.'V!
M><(:"W<3[#=GOO#MJ@3?ULHC]PDOF7O_/3TM2M+L: 6376(16 YLA]&A"2MD
M)<QX!5:TY)I@;%J%C?QOQG#/SE-?8_9(4X1OB<PZ9ET*<PD*['9Z/HMIUL2;
M<,,(RF?16!@DT'7-U]> [CS7X<TATK,)T/>I18+?@&^M>-!.!F+ -159Z8)-
M3[$"C4@PT]@%BL-C<)*.E9[O8XY'A'0IJ;X)*&JEU;8\70FO#18*@W&&.5(Y
M+(W) #^$,S+XQ(4=_<4_HQG[V1!X%Y>E3:!U*TFZ?K:R-'&? "?!+4,^GTT:
MQP.BS"D),SG2+CF#A:)4.@_80P+0 :9R;O,\PKOR)NJ+>!4GLU68S(;PG;[S
MCG85(=X$%07R0D84E;;(1N40448;JXFBN$O&0Q'UTG$4O[^PMU>\BD6>QRG
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M2.\181HC"O\A+[%=U8%4F%!/?8<5L$S6;(\B-R:@3Z;O[M>E/42_W6]989B
MGE*8@R(&%)0&GA-3*&JF./%,$=]AF2QSDE)"GW6&[91+XS>W0&0MW%S%["&O
M2F+;R0U[[W<7C.O>>14#3@ 512Y@\'X4!>\G&HH(MMAZC8E('9(9RQ0G*;2
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M5!P9H2(*P1N'/0F2=MA3**N*BHE5?V#VL5-ZA[0RVZ7]OK#R3..0T])@),
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M]\[4C=&5?SC0TG__R_\ 4$L#!!0    ( $^ <D[WJ^[EC6(   / !  5
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M<28H!X%6"ZZX/V-M@A^(/E9?X/4&B=602F<#>SX,.*(,A++DT!A=W_%ON49
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M"VPY9H+IDCLIW0!K%K:K!ZW TI?0-P<T4INN?[Z;_;@A]S&?3GU>?!L5AVK
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M?^NW?+8\_W0%46]90G$W>3-=QNEM[< ?<DGVM$BXH%9A"+"WWB)NJ*&DY$_
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MYK&R&P2EEW* ^=H=:MN94#W[C/4A/:1KAYHE!C ,(= (,X;BAJ%WO.04<3O
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MX)XAU\>,'K)%2?@FBW;B\\(OXR7K98B_6@)0M;X2Z#"3FB-JJ*>>!!G!<G/
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MSZ6EBLRJZ*OI("U,<XV[=TJ'[?"HJLT?=^*[OY1;06O-_G6?[Q[>E[ML/R#
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M\L(X88/1>8<**QZ5]MJ?QH#1#%)E;[AL!ZE_9O+?V0:)_#']O =P5>7K['@
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M*-&<BFVCXGF(PP(JN^D3JZ^G)J*T:%TUXJ":OIKC4OW"XT-7^0VM_W6?5YF
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M?D8-)4+00)Q8#Q5(.S\U-T;Y,K3/J$?/I_"&V=+>5GA!69,@C /./)^(G"B
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M/_5OGW0)4,("#:Z!"UT:K.FM!=HA;,QZX)1<#5L8M,/9HA8']RXJ+!#JT[$
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MJ>8V6546\C8?O;RYO&N>;RT^OROKFJ15]2#R3_E,]M'K$L2)6,(2!T6!SY(
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M^XPD-(R]*.Q<@+X3(;U:S8N";CWEZ1&"7?I]KV0/\\WWQP=[^LG_-%%>TDK
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M]2._C%1O)M\M'.H<&@'540I]3?.M/#C*R^IC>OPRTN/!<Q6%B1]$,(8N=MT
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M6)"1AGY5](;_Q0HRSPG2U ]AA*GCQ"%V#ZN?<8A"64U0^E#+8G!8NQ=@Y$5
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M3_EC68EG$S[OLMV^7B40I5R3'#>-B.?Y:>RSP[%=SP^DKE4?;62BB59W0O2
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MW_+V:#'^4=2KF&'B)*Z3$(>;2*E+(MA;\]Q4JB!EK W+6G.$!1I<S=EV\)>
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MI\2A:&TDJ1"\# $RY(OTEI$Z0U+K;'B];A[\R38:N_EN"$GLA2$?2,4II7Y
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MBV7=/7@ 'H\/P!=''\!=[P1X:, +=3Z@5WD\?(*P20S4%Q8Q-=T^!NN('IS
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M=]X3?E-0$$W6)(37/F%JJGN!*QW9U21-07/MDZ<GN-HDRBGNJVY?DMMQ'"U
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M8;\1PY'F72)N\;'*O^;;NOB6M_5O[\M:5+U=W]UD/U8P#3P$*?&<E&+F,Q3
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MLVN>YSX6V[J)6L.CDMGWT^]TQ7W\QW+7OHBV"!DFQ(<)0#@(@(_"/*$))8@
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MK#Z?&?#9P^8@TH]/U:ZY1?:)7/W*S1?/;_/I _^5#]M]P1'N%SY#29P#EE)
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M["?U-CA9:C(IELGT8QI_2V>A73)7V?3SXB8IS+(H@A >?6.319S.YNURHL$
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MO5S>!6V[2NT]K&]JM8\@XYAQI[UC&FADF-..>(@\DH@[*X?3- ^#C6>/A?-
MU[R.=CFFFX@;IC"3T%'A&>?&:"X"-P"RPGL$W% :I1LETC)"\MX8/W*5T;C
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MAT5R>Z2SN6T620,L <8ZHCB6@B%&J\EM JM1 ^2-/2]N2(_S5 'TMO/VXJ[
M3_DB67UZ>3=+%^M[!LMS45]*L<,]\#NVJT@YCZ64BD%HD)0KYE0<L4B<V4']
M=L#Q/+#6+<]/7IA?B2(^*AY;UHI-IN[GY";.KI/REII=B^^Q_422AL7$:RRL
MTLQI&E86OJ5/HR;I36-W)UH%6!_<[TO'/1KSII+Q<C%?Q-DT6 Q[]-F^9A'P
MC!B@@.'"< ^A-DA4E$I4K^3*&UU..U%D+3+[9*7U^4<6.'F3WETDQ:04S'7R
MX?8VF:8!VK-[G\]F^8\PG.W-7'\DQ752E*ER95G)Q^D"S]58\YXCA;50G&A$
M$<724&3TE@=>@2;VV]BSS]M7;+W+H[_\X7R2)-/5;7!51?8]ET7OS24^JJ?(
M2DA6;'#$JF ^ PNV_"#:-<'GT3GL=WF)DN]O%:+]B*!O9_:1$:'CXCKX_Q?+
M(M@.\^0OX><OV\L?U6U9CO>X?(8:'48&:X 4\ 8CQ;0,4]3Z!^[4RWYJ*_$]
M"/!;_F95:*^".'DUK^Z*#[/HOY/-A2GI?%7K>9_'<:!9I"BC##J$B<-><N(=
MWTXRZAKMW/-WMPZWR^S^BF1LZ3]T]OWYHY&S.GC=SM,RVXZ&B2"YJ2B"@C3Q
M3\5[@D]+#!Y#KN&C!.KI?R_GBZ H9RO!A^\^7U6JM#0^T^DJ[GV>F8B&21I$
MI<.?,N$<<4>(,5)J0"G!J)9B/;],1">\X)XX:*P-TP "X,":*PR6U8#/>,.H
M';0TS40\3@!O+Q/1Z["F6D@])TH+:9R'N**/ M+D5/O8 =8=%FIF(A['^_/(
M1$1>6 V"8><YM\9*[9BN: [^ZGO,1*P-@Z,S$8]C]G@R$0F4D'D%@1)6J&#1
MB:#2-^.6E+R'_/L6A%H[$_$X=K_E+ BOC$*.2*"]@1!(A6'%.^0D;K)M,_;M
MP2%7NU,%,&",\B%L]6$:N)M>I?'V5O?-A"R/6S^N#U]>C!D^7#]RDC?4TDLC
MHR'54&AFJ#046B.XJ+@<=/<[TY\GH.]PI',84;W%"5$&^38W@X<U*#2MH[V[
M>7$$'4226,TXU<"&U2X K.*V(K[))L!;F1A#8KC#:=58V&]R:CVNB_M'7/PC
M690M+Y/)LE@]U]=,.S2.B'/HD>62(P<#7SCS<@L1 OTYE^X\]XG7LNS?_#Q\
M5&]NB.GWZ/411TQ;08FPQH5_#/18;CB/@61-BBR_E2RU]S#K3A?Y6YQL'[)I
M<I5FZ2+YF'XO?UW$V76Z;=O3G#LPBLAA!#CWF& <O&=*$9%53 5S_B[R]<YT
MZK4K^;<X WN=:!NN8DZE(%HP:2UP%#%*MWH-,FO[S"_LN6[IF<^GDP3\%J?-
MXT_Z#0^^\N9(*Z6]AQ8Y*ZT4S'A<A7<Q=J[)%8AOQ2,;;8RPN;S:/+EU^LQ^
M41#RB'->+;XU\M !9 VG !".K*94P8IW L%^XN%RC?4LN5Y=8O@FEX]&P#QP
MM&PX@;_%Q:2J!/PU_OGHRT]Y-CE8)K[/840:,0L#.JS SDC+!.)L(PF" >\G
M\/?OJ?=F$/ 6Y^+^!:[C-T8>:>(TP9H$"YYB212H;'C"..\GR/=TAGU]NP[2
M6*?9Z1)_;P>]B.,.&:.,98PXQ: .PJJX$[S=(>;#>?HW[4MC0*P^.6"QJI2U
MEO.^DB?'=!,YAHS2AGMNE$("0Z0KQE/';1,]?71$N#HA^[=1'41L$9IMB6%<
M!X1\G!9_BV?+]3'@5PD\RZ-!TBF P\*F/<5.64J@),Z4 F/6UKNNX_R.!G$J
ME:% XL >[JCTR."**]Z3P<HG#7XTJ"Y:FAX-.DX ;^]HD-58*^0-*)/ ,76
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MKB_)]R1;'KDS\;QUI$$YITJ.PC#3E.3&@XINC'63^O=O<*4[ 0^'0=:0YV/
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MG*%38X96/0Q:B3 !6@BL D21H !X2B$BTIIZI1>Z-M[5]R"BTOX*Z]]E_+B
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M*:!D8>H9 ;&KQBWT<'YAN[ Y45;/)7T2S[J4]1_QS_1V>;M7VD^>B:@D2FI
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M]5AC&-2 51-FGUP.X%-9["N=?[U)BO@N62[2R3SXJ'\D9>ABUU*WKTT$N(4
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M+S=EIWJ:.'O'$#%,H19: N*4",C04)FM^E*B25!EY!?SCG;:M"FPDYVD'O7
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M.? QL?7CAMLI%6N^+>57 [YG#1\,LYRQ>)H((*$5W K,!!+>:ZX$Z*\*U3_
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MH3+OFOQ=P?)IV>GCP? G:H2__G+0+"JIQ"JO"4W=6IVC/JY:0 R!)S:G@>T
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MP*IO43U,0M%><]Q,Z9?* *TP0(@*M3$P:M=8>>Q5_,F4!)30D!Q #MTU-31
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M@_#^:*,Z)\YSZ$7,KVU39?!U6.%S9:&]:PV8(RDV/3*$$"LEX\(#Z+>\(9Q
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ML/!*Y^RNP0?$7^[N:IW15[;]^M]SJ4<A!Q!(:JFBQC)JY/[XLXQUVFC^TAU
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M>-T2U^>-$[JS(VR__L\I(&VTN%W^]G@;)8'X/ /H)*8JO1^DXA9 :5F\$H!
MP&.W)R3S+">5;X @RV/_RW.J!0(/ 5P$R"QP[=\/(CDIHEB@A"*>2 P<W:]=
M<M-IX]4K E== G<%+KU>3F;%<JG&_UE/*CFU#[P12)0@F!/:884<C']ZZ'?K
M,TJB'//U4 OPM"U=-4/J/J&4?EP4IRW:)]\-7"$CG$.IK@A"U,9]Y,HU2\ZN
ML<A,8S"H *L<8M>V=7^8?!M-)\LO7XO%Z+%8KR;CY;O9^+BA^]@[02GG)*7
M*:.8@1"E5E.;>7.H<+>IF0, 24VFSMLA=\US:+E8/3F#XG^]/'_B7X5/R=)_
MX.)Z]OO@.73&.4"LPU(1*JA@Y9PM$3DQO$/-JV_KFLHA;.M@.'B*O'@BQ),3
M"\^23*:4A!&Y")7S-MA<XYE1DW$OV5Z+@&TR_M?);/*P?CC*^F?/!(,$10P
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MW2_2O_X8+8O__W_]/U!+ 0(4 Q0    ( $^ <D[<)$>.[X4!  1V%  1
M          "  0    !A;'!N+3(P,3@Q,C,Q+GAM;%!+ 0(4 Q0    ( $^
M<DZJ8Q?J0A8  ,+O   1              "  1Z& 0!A;'!N+3(P,3@Q,C,Q
M+GAS9%!+ 0(4 Q0    ( $^ <DYJL"^ QB0  )J7 0 5              "
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8;6Q02P4&      8 !@"* 0  G[4#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
